"Epitope_ID","Epitope_Name","Variant_ID","Subtype","Epitope_Subtype","Variant_Subtype","Protein","HXB2_start","HXB2_end","Subprotein","HXB2_DNA_Contig","HLA","Epitope","Variant_Epitope","Mutation_epitope","Mutation_protein","Mutation_Type_Code","Mutation_Type_Description","Methods","Note","References"
"54532","AI14","1016","B","B","A, M-group","Gag","5","19","p17(5-19)","802..846","","ASVLSGGELDRWEKI","ASVLSGGkLDaWEKI","R11A, E8K","R15A, E12K","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy","No cross-recognition of this variant was seen across clades or intra-clade central sequences.","Malhotra2007"
"54532","AI14","1017","B","B","C","Gag","5","19","p17(5-19)","802..846","","ASVLSGGELDRWEKI","ASiLrGGkLDkWEKI","R11K, V3I, S5R, E8K","R15K, V7I, S9R, E12K","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy","No cross-recognition of this variant was seen across clades or intra-clade central sequences.","Malhotra2007"
"54532","AI14","1018","B","B","B","Gag","5","19","p17(5-19)","802..846","","ASVLSGGELDRWEKI","ASVLSGGkLDkWEKI","R11K, E8K","R15K, E12K","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy","No cross-recognition of this variant was seen across clades or intra-clade central sequences.","Malhotra2007"
"54532","AI14","1019","B","B","B","Gag","5","19","p17(5-19)","802..846","","ASVLSGGELDRWEKI","ASVLSGGELDkWEKI","R11K","R15K","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy","No cross-recognition of this variant was seen across clades or intra-clade central sequences.","Malhotra2007"
"53591","Gag 1.2","54","","B","CRF02_AG","Gag","8","18","p17(8-18)","811..843","","LSGGELDRWEK","LSGGkLDaWEK","E5K, R8A","E12K, R15A","SNSF","subtype-specific non-susceptible form","Intracellular cytokine staining, T-cell Elispot","CRF02 form, LSGGkLDaWEK, does not cross-react with the B clade LSGGELDRWEK elicited response.","Amara2005a"
"53844","GI9","1569","B","","","Gag","11","19","p17(11-19)","820..846","B40","GELDRWEKI","GELDRWkKI","E7K","E17K","DR, LE","diminished response, literature escape","CD8 T-cell Elispot - IFNy, Sequence","This variant from the HXB2 sequence was present in the restricting HLA-B40-carrying mother, M-1002, but was never detected in her non-HLA-B40-carrying infant, P-1031. Decreased recognition of the E17K variant relative to the index epitope was seen in the mother.","Sanchez-Merino2005"
"56027","GI9(p17)","1903","B","B","B","Gag","11","19","p17(11-19)","820..846","","GQLDRWEKI","GeLDRWEKI","Q2E","Q12E","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B40 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"55632",,"11","A, CRF02_AG, CRF01_AE","A, AG","AE","Gag","11","22","p17(11-22)","820..855","","GKLDSWEKIRLR","GKLDaWEKIRLR","S5A","S15A","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","1 subject responded to peptide GKLDSWEKIRLR from subtypes CRF02_AG and A, and to peptide GKLDaWEKIRLR from subtype CRF01_AE.","Aidoo2008"
"54629","GAG-03","1957","B","B","C","Gag","17","34","p17(17-34)","838..891","","EKIRLRPGGKKKYRLKHL","EKIRLRPGGKKhYmLKHL","K12H, R14M","K28H, R30M","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 2 amino acids (11.1%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"53201","KK9","31","B","","","Gag","18","26","p17(18-26)","841..867","A3","KIRLRPGGK","KIRLRPGGq","K9Q","K26Q","E, P","escape documented in this paper, processing","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay","Variant inhibits processing, resulting in rapid decline in the KK9 specific CD8+ T-cell response.","Allen2004"
"55770","KK9","153","B","","","Gag","18","26","p17(18-26)","841..867","A3","KIRLRPGGK","KIRLRPGGr","K9R","K26R","SF","susceptible form","Flow cytometric T-cell cytokine assay","KIRLRPGGK was recognized by 3 patients. The autologous sequence in one patient was KIRLRPGGr which induced high frequency response.","Daucher2008"
"55233",,"790","B, CRF01_AE","","B","Gag","18","26","p17(18-26)","841..867","A3","KIRLRPGGK","KIRLRPGGr","K9R","K26R","IE","inferred escape","Sequence","Patient was superinfected with three strains, B1, B2 and CRF01_AE. This variant developed in B1 to include 42% of the viruses within 4 years.","Kozaczynska2007"
"53818",,"1300","A","","","Gag","18","26","p17(18-26)","841..867","A*0301","KIRLRPGGK","KIRLRPGGr","K9R","K26R","DHB","diminished HLA binding or increased off-rate","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","This variant was seen in Donor1 and Recipient1.  It was not recognized by either subject and showed diminished binding to HLA.  The restricting HLA-A*0301 was only carried in the Donor.","Milicic2005"
"53838","KR9","1570","B","","","Gag","18","26","p17(18-26)","841..867","A3","KIRLRPGGK","KIRLRPGGr","K9R","K26R","LE, OV","literature escape, observed variant","Sequence","This variant from the HXB2 sequence was present in the restricting HLA-A3 allele carrying mother, M-1001, as well as her HLA-A*31-carrying infant, P-1024.  Infant P-1024 had lost this variant by 15 months of age.","Sanchez-Merino2005"
"5",,"1838","","","","Gag","18","26","p17(18-26)","841..867","A3","KIRLRPGGK","KIRLRPGGr","K9R","K26R","E","escape documented in this paper","Chromium-release assay","This escape was not recognized by HIV-transmitting mothers","Wilson1999a"
"5",,"1839","","","","Gag","18","26","p17(18-26)","841..867","A3","KIRLRPGGK","rIRLRPGGr","K1R, K9R","K18R, K26R","E","escape documented in this paper","Chromium-release assay","This escape was not recognized by HIV-transmitting mothers","Wilson1999a"
"52827","A3-KK9 Gag","2281","B","","","Gag","18","26","p17(18-26)","841..867","B7","KIRLRPGGK{*R}","KIRLRPGGK{*t}","R+2T","R28T","E, P","escape documented in this paper, processing","CD8 T-cell Elispot - IFNy","Response declined over time; authors suggested that the decline was due to a downstream Arg -> Thr substitution at C+2 that may impair processing.","Altfeld2002a"
"55233",,"2325","B, CRF01_AE","","B","Gag","18","26","p17(18-26)","841..867","A3","KIRLRPGGK{KS}","KIRLRPGGK{Kr}","S+2R","S28R","OV","observed variant","Sequence","Patient was superinfected with three strains, B1, B2 and CRF01_AE. This was the infecting variant  in B2.","Kozaczynska2007"
"53629",,"113","","","","Gag","19","27","p17(19-27)","844..870","B27","IRLRPGGKK","IRLRPGGrK","K8R","K26R","SF","susceptible form","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining","The dominant viral sequence was irlrpggRk, found in 12/15 clones, while the screening sequence IRLRPGGKK was found in 3/15 clones. The least frequent variant stimulated the strongest response.","Casazza2005a"
"1819","IK9","385","","","","Gag","19","27","p17(19-27)","844..870","B27","IRLRPGGKK","IRLRPGrKK","G7R","G25R","OV","observed variant","","Variant found in one B27 positive child in 4/11 clones, but not in its B27 positive mother","Goulder2001c"
"1819","IK9","386","","","","Gag","19","27","p17(19-27)","844..870","B27","IRLRPGGKK","IRLRPrrKK","G6R, G7R","G24R, G25R","OV","observed variant","","Variant found in one B27 positive child in 1/11 clones, but not in its B27 positive mother","Goulder2001c"
"1819","IK9","387","","","","Gag","19","27","p17(19-27)","844..870","B27","IRLRPGGKK","IRkRPGGKK","L3K","L21K","OV","observed variant","","Variant found in one B27 positive child in 1/19 clones, but not in its B27 positive mother","Goulder2001c"
"1819","IK9","388","","","","Gag","19","27","p17(19-27)","844..870","B27","IRLRPGGKK","IRLgPGGsK","R4G, K8S","R22G, K26S","IE","inferred escape","","Author tabulates this variant found in one B27 positive child in 1/8 clones, and in its B27 positive mother in 1/10 clones as an escape variant.","Goulder2001c"
"1819","IK9","389","","","","Gag","19","27","p17(19-27)","844..870","B27","IRLRPGGKK","IRLRPGGsK","K8S","K26S","IE","inferred escape","","Variant found in one B27 positive child in 7/8 clones, and in its B27 positive mother in 9/10 clones.","Goulder2001c"
"53202","RK9","32","B","","","Gag","20","28","p17(20-28)","847..873","A3","RLRPGGKKK","RLRPGGKqK","K8Q","K27Q","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay","Variant abrogates the response.","Allen2004"
"52824","A3-RK9 Ga9","43","B","","","Gag","20","28","p17(20-28)","847..873","A3","RLRPGGKKK","RLRPGGKKt","K9T","K28T","DR","diminished response","CD8 T-cell Elispot - IFNy","Superinfection. The second infecting strain had the variant rlrpggkkT. The CTL response declined over time, and the response to the second variant was lower than to the first one","Altfeld2002a"
"53602","RK9","59","B","","","Gag","20","28","p17(20-28)","847..873","A*0301","RLRPGGKKK","RLRPGGKKq","K9Q","K28Q","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Chromium-release assay, Intracellular cytokine staining","Drastically reduced avidity. The response to this peptide was not apparent until month 20, by month 32 the escape variant was present.","Bansal2005a"
"23",,"98","","A, B, D","C","Gag","20","28","p17(20-28)","847..873","A3","RLRPGGKKK","RLRPGGKKh","K9H","K28H","SSF","subtype-specific susceptible form","Chromium-release assay","The consensus peptide of C clade viruses is RLRPGGKKh and is equally reactive.","Cao1997a"
"53633",,"114","","","","Gag","20","28","p17(20-28)","847..873","A3, A30, B42, B62","RLRPGGKKK","RLRPGGKKq","K9Q","K28Q","DR, SF","diminished response, susceptible form","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining","The majority of viral sequences prior to therapy were rlrpggkkQ. At week 14 of therapy a major change in the viral quasispecies occurred: the variants present were found to be rlrpggkkK (14/16 clones) and rlrpggkkR (2/16 clones), both well recognized by HIV-specific CD8 T cells. At week 19, the quasispecies reverted back to the less well-recognized rlrpggkkQ variant.","Casazza2005a"
"53633",,"115","","","","Gag","20","28","p17(20-28)","847..873","A3, A30, B42, B62","RLRPGGKKK","RLRPGGKKr","K9R","K28R","SF","susceptible form","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining","The majority of viral sequences prior to therapy were rlrpggkkQ. At week 14 of therapy a major change in the viral quasispecies occurred: the variants present were found to be rlrpggkkK (14/16 clones) and rlrpggkkR (2/16 clones), both well recognized by HIV-specific CD8 T cells. At week 19, the quasispecies reverted back to the less well-recognized rlrpggkkQ variant.","Casazza2005a"
"56296","RK9","154","B","","","Gag","20","28","p17(20-28)","847..873","A3, B7","RLRPGGKKK","RLRPGGrKr","K7R, K9R","K26R, K28R","SF","susceptible form","Flow cytometric T-cell cytokine assay","RLRPGGKKK was recognized by 3 patients. One patient had variants RLRPGGrKr and RLRPGGKKr, which were well recognized within longer peptides.","Daucher2008"
"56296","RK9","155","B","","","Gag","20","28","p17(20-28)","847..873","A3, B7","RLRPGGKKK","RLRPGGKKr","K9R","K28R","SF","susceptible form","Flow cytometric T-cell cytokine assay","RLRPGGKKK was recognized by 3 patients. One patient had variants RLRPGGrKr and RLRPGGKKr, which were well recognized within longer peptides.","Daucher2008"
"52994",,"305","","","","Gag","20","28","p17(20-28)","847..873","A3","RLRPGGKKK","RLRPGGKKr","K9R","K28R","SF","susceptible form","","The variant became fixed in the viral population at 20 months post-seroconversion. CTL responses to both wild type and variant peptides were detectable and decreased over time, then increased after mutation fixation.","Geels2003"
"18",,"357","","","","Gag","20","28","p17(20-28)","847..873","A*03","RLRPGGKKK","RLRPGGKKc","K9C","K28C","E","escape documented in this paper","Chromium-release assay","HLA-identical siblings infected with the same batch. One responded to RLRPGGKKK, the non-responder carried RLRPGGKKc. There was no CTL response to this variant and the variant was not recognized by CTLs.","Goulder1997, Goulder1997e"
"54533","RK9","1020","B","B","C","Gag","20","28","p17(20-28)","847..873","A3","RLRPGGKKK","RLRPGGKKh","K9H","K28H","DR","diminished response","CD8 T-cell Elispot - IFNy","Cross-recognition of the variant is seen with both C- and A-clades.  The C-clade variant contains a change at position 9 to RLRPGGKKh.  Typically, magnitude and avidity of binding for T-cell responses were much lower to the C-clade variant.","Malhotra2007"
"53817",,"1301","A","","","Gag","20","28","p17(20-28)","847..873","A*0301","RLRPGGKKK","RLRPGGrKK","K7R","K26R","OV","observed variant","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","This K26R variant was found in both Donor1 and Recipient1.  The restricting HLA-A*0301 was only carried in the Donor.","Milicic2005"
"53817",,"1302","A","","","Gag","20","28","p17(20-28)","847..873","A*0301","RLRPGGKKK","RLRPGGrKt","K7R, K9T","K26R, K28T","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","Donor1 who carried the restricting HLA-A*0301 generated this mutation which rose to fixation and was not recognized.  It was not found in Recipient1 as the mutation arose after transmission of virus between the pair.","Milicic2005"
"53817",,"1303","A","","","Gag","20","28","p17(20-28)","847..873","A*0301","RLRPGGKKK","RLRPGGKKq","K9Q","K28Q","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","This K28Q variant was seen in Donor2 and Recipient2, where only the donor carried the restricting allele.  It was not recognized and binding to HLA was abrogated in the Donor.","Milicic2005"
"58244",,"2835","B","B","B","Gag","20","28","p17(20-28)","847..873","A*0301","{KWEKI}RLRPGGKKK","{rWEKI}RLRPGGKKK","K-5R","K15R","IE","inferred escape","Sequence","3/16 and 1/11 sequences of peptide {KWEKI}RLRPGGKKK varied at 639 and 821 DFOSx to {rWEKI}RLRPGGKKK.  Position 15 in the peptide is marked as being under selection to vary.","Ferrari2011"
"53748","RY10","752","B","","","Gag","20","29","p17(20-29)","847..876","B62","RLRPGGKKKY","RLRPGGrKKY","K7R","K26R","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","Variant was detected over a 5 year time period in a patient. The variant was better recognized than the wt epitope by patient CTLs.","Koibuchi2005a"
"53839","RY10","1571","","","","Gag","20","29","p17(20-29)","847..876","A30","RLRPGGKKKY","RLRPGGKKqY","K9Q","K28Q","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence","This variant from the HXB2 sequence was present in the restricting HLA-A30 allele carrying mother, M-1003, as well as her non-HLA-A30-carrying infant, P-1189. Decreased recognition of the variant was seen relative to index epitope. This variant was still detected at 12 months of age in Infant P-1189.","Sanchez-Merino2005"
"53839","RY10","1572","","","","Gag","20","29","p17(20-29)","847..876","A30","RLRPGGKKKY","RLRPGGKKrY","K9R","K28R","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence","This variant from the HXB2 sequence was present in the restricting HLA-A30 allele carrying mother, M-1002, as well as her  HLA-A30-carrying infant, P-1031. Decreased recognition of the variant was seen relative to index epitope in the mother. The variant was detected at decreasing frequencies by 11 months of age in infant P-1031, but recognition was equivalent to index epitope recognition in the infant.","Sanchez-Merino2005"
"57682","EnvRY10","2678","A, B, C, D","A, B, C, D","B, C","Gag","20","29","p17(20-29)","847..876","A3","RLRPGGKKKY","RLRPGGKKhY","K9H","K28H","SF, SSF","susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Variant RLRPGGKKhY was found at frequencies of 2 and 48 in clades B and C respectively.","Koup2010"
"57682","EnvRY10","2679","A, B, C, D","A, B, C, D","B, C","Gag","20","29","p17(20-29)","847..876","A3","RLRPGGKKKY","RLRPGGKKrY","K9R","K28R","SF, SSF","susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Variant RLRPGGKKrY was found at frequencies of 9 and 14 in clades B and C respectively.","Koup2010"
"57682","EnvRY10","2680","A, B, C, D","A, B, C, D","A, B, C, D","Gag","20","29","p17(20-29)","847..876","A3","RLRPGGKKKY","RLRPGGKKqY","K9Q","K28Q","SF, SSF","susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Variant RLRPGGKKqY was found at frequencies of 5, 11, 8 and 5 in clades A, B, C and D respectively.","Koup2010"
"57682","EnvRY10","2681","A, B, C, D","A, B, C, D","D","Gag","20","29","p17(20-29)","847..876","A3","RLRPGGKKKY","qLRPGGKKrY","R1Q, K9R","R20Q, K28R","SF, SSF","susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Variant qLRPGGKKrY was found at a frequency of 23 in clade D.","Koup2010"
"57875",,"2944","C","C","C","Gag","20","29","p17(20-29)","847..876","B*4201","RLRPGGKKHY","kLRPGGKKHY","R1K","R20K","IE","inferred escape","Sequence","Subject CAP 274 carried this escape in 9/9 sequences 2.4 months post-infection (Mo.PI) and in 7/7 sequences 5.1 Mo.PI.","Chopera2011"
"57875",,"2945","C","C","C","Gag","20","29","p17(20-29)","847..876","B*4201","RLRPGGKKHY","kLRPGGKKrY","R1K, H9R","R20K, H28R","IE","inferred escape","Sequence","Subject CAP 274 carried this escape in 19/19 sequences 13.9 months post-infection.","Chopera2011"
"57875",,"2946","C","C","C","Gag","20","29","p17(20-29)","847..876","B*4201","RLRPGGKKHY","RLRPGGKKrY","H9R","H28R","IE","inferred escape","Sequence","Subject CAP 239 carried this escape in 4/9 sequences 18.2 months post-infection.","Chopera2011"
"57875",,"2947","C","C","C","Gag","20","29","p17(20-29)","847..876","B*4201","RLRPGGKKHY","RLRPGGKKqY","H9Q","H28Q","IE","inferred escape","Sequence","Subject CAP 239 carried this escape in 5/9 sequences 18.2 months post-infection.","Chopera2011"
"55629",,"12","A, CRF02_AG, CRF01_AE","AG","A, AE","Gag","20","31","p17(20-31)","847..882","","RLRPGGKKRYRL","RLRPGGKKkYRL","R9K","R28K","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","1 subject responded to peptide RLRPGGKKRYRL from subtype CRF02_AG and to peptide RLRPGGKKkYRL from subtypes A and CRF01_AE.","Aidoo2008"
"53611",,"63","A, D","","","Gag","21","35","p17(21-35)","850..894","","LRPGGKKKYRLKHLV","LRPGGKKKYkLKHLV","R10K","R30K","OV","observed variant","CD8 T-cell Elispot - IFNy","The sequence contains a known B8 epitope, but the subjects recognizing it were B8-negative. The autologous viral sequence was lrpggkkkyKlkhlv, and the index peptide was recognized.","Barugahare2005"
"57700",,"2594","","","","Gag","21","35","p17(21-35)","850..894","B*08","LRPGGKKKYKLKHIV","LRPGGKKqYKLKHIV","K8Q","K28Q","SF","susceptible form","CD8 T-cell Elispot - IFNy","CTL response to variant LRPGGKKqYKLKHIV was also detected 48 weeks after TI began.","Schweighardt2010"
"57722",,"2620","","","","Gag","21","35","p17(21-35)","850..894","","LRPGGKKKYKLKHIV","LRPGGKKrYKLKHIV","K8R","K28R","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Variant LRPGGKKrYKLKHIV is seen in patient I04.","Vollbrecht2010"
"57722",,"2621","","","","Gag","21","35","p17(21-35)","850..894","","LRPGGKKKYKLKHIV","LRPGGKKKYrLKHlV","I14L, K6R","I34L, K26R","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Variant LRPGGrKKYKLKHlV is seen in patient I04.","Vollbrecht2010"
"57722",,"2622","","","","Gag","21","35","p17(21-35)","850..894","","LRPGGKKKYKLKHIV","LRPGGKKKYrLKHIV","K10R","K30R","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Variant LRPGGKKKYrLKHIV is seen in patient C06.","Vollbrecht2010"
"36",,"170","A","A","B","Gag","21","40","p17(21-40)","850..909","Cw4","LRPGGKKKYRLKHLVWASRE","LRPGGKKKYkLKHiVWASRE","R10K, L14I","R30K, L34I","SNSF","subtype-specific non-susceptible form","","CTL responses in three individuals with non-clade B infections were studied, 2 with subtype A infections, 1 with subtype C -- their infections all originated in East Africa. This epitope was defined in an A subtype infection -- the B clade variant (LRPGGKKKYKLKHIVWASRE) has two mutations relative to the A subtype form, and the CTLs from this patient were not A-B cross-reactive.","Dorrell1999"
"54602",,"337","A, C, D","C","D","Gag","22","29","p17(22-29)","853..876","B42, B7","RPGGKKHY","RPGGKKkY","H7K","H28K","DR","diminished response","","The wild type epitope sequence was a subtype C peptide, the variant found in subtype D. CTL response in 56 individuals from Tanzania was strongest for subtype D peptide, and lower for subtype C, due to point mutation effect.","Geldmacher2007"
"54602",,"338","A, C, D","C","A","Gag","22","29","p17(22-29)","853..876","B42, B7","RPGGKKHY","RPGGKKqY","H7Q","H28Q","DR","diminished response","","The wild type epitope sequence was a subtype C peptide, the variant found in subtype A. CTL response in 56 individuals from Tanzania was strongest for subtype D peptide, and lower for subtype A, due to point mutation effect.","Geldmacher2007"
"56297",,"156","B","","","Gag","22","30","p17(22-30)","853..879","B7","RPGGKKKKYK","RPGGrKKrYK","K5R, K8R","K26R, K29R","SF","susceptible form","Flow cytometric T-cell cytokine assay","RPGGKKKKYK was recognized by 3 patients. One patient had variants RPGGrKKrYK, RPGGKKKrYK, RPGGKKKKYr which were well recognized. Variant RPGGKKKKYr  was also present and recognized in other 2 patients","Daucher2008"
"56297",,"157","B","","","Gag","22","30","p17(22-30)","853..879","B7","RPGGKKKKYK","RPGGKKKrYK","K8R","K29R","SF","susceptible form","Flow cytometric T-cell cytokine assay","RPGGKKKKYK was recognized by 3 patients. One patient had variants RPGGrKKrYK, RPGGKKKrYK, RPGGKKKKYr which were well recognized. Variant RPGGKKKKYr  was also present and recognized in other 2 patients","Daucher2008"
"56297",,"158","B","","","Gag","22","30","p17(22-30)","853..879","B7","RPGGKKKKYK","RPGGKKKKYr","K10R","K31R","SF","susceptible form","Flow cytometric T-cell cytokine assay","RPGGKKKKYK was recognized by 3 patients. One patient had variants RPGGrKKrYK, RPGGKKKrYK, RPGGKKKKYr which were well recognized. Variant RPGGKKKKYr  was also present and recognized in other 2 patients","Daucher2008"
"58700","p17-RM9","3110","C","C","C","Gag","22","30","p17(22-30)","853..879","B*4201, B*4202","RPGGKKHYM","RPGGKKrYM","H7R","H28R","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","p17-RM9 mutation, RPGGKKrYM, is selected in 13% HLA-B*4201 (8% have wt RM9), 10% HLA-B*4202 (31% have wt RM9) and 8% on-HLA-B*42 (46% have wt RM9) subjects.  The authors designate this variant as an escape when presented by HLAs-B*4201 and -B*4202.","Kloverpris2012a"
"58700","p17-RM9","3111","C","C","C","Gag","22","30","p17(22-30)","853..879","B*4201, B*4202","RPGGKKHYM","RPGGKKHYk","M9K","M30K","OV","observed variant","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","p17-RM9 mutation, RPGGKKHYk, is selected in 9% HLA-B*4201 (8% have wt RM9), 5% HLA-B*4202 (31% have wt RM9) and 2% on-HLA-B*42 (46% have wt RM9) subjects.","Kloverpris2012a"
"58700","p17-RM9","3112","C","C","C","Gag","22","30","p17(22-30)","853..879","B*4201, B*4202","RPGGKKHYM","RPGGKKHYr","M9R","M30R","OV","observed variant","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","p17-RM9 mutation, RPGGKKHYr, is selected in 4% HLA-B*4201 (8% have wt RM9), 0% HLA-B*4202 (31% have wt RM9) and 1% on-HLA-B*42 (46% have wt RM9) subjects.","Kloverpris2012a"
"59012","RM9-p17","3219","C","C","B","Gag","22","30","p17(22-30)","853..879","B*0702","RPGGKKHYM","RPGGKKkYk","H7K, M9K","H28K, M30K","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Epitope RK9, RPGGKKkYk, the B-clade consensus epitope differs at H7K and M9K, and is not recognized by HLA-B*0702.  RK9 is unstable in complex with HLA-B*0702; and its binding affinity is K<sub>d</sub> = >20,000 nM.  RK9 is contained within OLP3, EKIRLRPGGKKkYkLKHI.","Kloverpris2014"
"53687",,"326","B, D","","","Gag","22","31","p17(22-31)","853..882","Cw4","RPGGKKKYKL","RPGGnKKYKL","K5N","K26N","OV","observed variant","","Cross-clade T cell responses are frequently induced in individuals infected with different HIV-1 clades. There was an inverse correlation between the height of responses and epitope sequence divergence. For Gag epitopes, the magnitude of the response was directly linked to the homology between HLA anchor residues.","Geels2005"
"55633",,"13","A, CRF02_AG","AG","A","Gag","23","34","p17(23-34)","856..891","","PGGKKRYRLKHL","PGGKKkYRLKHL","R6K","R28K","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","1 subject responded to peptide PGGKKRYRLKHL from subtype CRF02_AG and to peptide PGGKKkYRLKHL from subtype A.","Aidoo2008"
"53683",,"327","B, D","","","Gag","24","31","p17(24-31)","859..882","B8","GGKKKYKL","GGKKKYKm","L8M","L31M","OV","observed variant","","Cross-clade T cell responses are frequently induced in individuals infected with different HIV-1 clades. There was an inverse correlation between the height of responses and epitope sequence divergence. For Gag epitopes, the magnitude of the response was directly linked to the homology between HLA anchor residues.","Geels2005"
"54627","GL8","954","B","","","Gag","24","31","p17(24-31)","859..882","B8","GGKKKYKL","GGKKKYKf","L8F","L31F","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Presumed escape variant was transmitted from a B8 positive donor to a B8 negative recipient. The variant was not recognized by CTLs.","Liu2006"
"38",,"1104","","B","","Gag","24","31","p17(24-31)","859..882","B8","GGKKKYKL","GGKKKYrL","K7R","K30R","SNSF","subtype-specific non-susceptible form","Chromium-release assay","This circulating Ugandan variant was not recognized by a CTL clone from a patient infected with Clade B virus.","McAdam1998"
"38",,"1105","","B","","Gag","24","31","p17(24-31)","859..882","B8","GGKKKYKL","GGnKrYrL","K3N, K5R, K7R","K26N, K28R, K30R","SNSF","subtype-specific non-susceptible form","Chromium-release assay","A peptide containing this circulating Ugandan variant was not recognized by a CTL clone from a  Clade B-infected  patient.","McAdam1998"
"38",,"1106","","B","","Gag","24","31","p17(24-31)","859..882","B8","GGKKKYKL","GGKKKYqL","K7Q","K30Q","SNSF","subtype-specific non-susceptible form","Chromium-release assay","A peptide containing this circulating Ugandan variant was not recognized by a CTL clone from a  Clade B-infected  patient.","McAdam1998"
"38",,"1107","","B","","Gag","24","31","p17(24-31)","859..882","B8","GGKKKYKL","GGKKKYrm","K7R, L8M","K30R, L31M","SNSF","subtype-specific non-susceptible form","Chromium-release assay","A peptide containing this circulating Ugandan variant was not recognized by a CTL clone from a  Clade B-infected  patient.","McAdam1998"
"38",,"1108","","B","","Gag","24","31","p17(24-31)","859..882","B8","GGKKKYKL","GGsKKYKL","K3S","K26S","SNSF","subtype-specific non-susceptible form","Chromium-release assay","A peptide containing this circulating Ugandan variant was not recognized by a CTL clone from a  Clade B-infected  patient.","McAdam1998"
"38",,"1109","","B","","Gag","24","31","p17(24-31)","859..882","B8","GGKKKYKL","GGKKtYqL","K5T, K7Q","K28T, K30Q","SNSF","subtype-specific non-susceptible form","Chromium-release assay","A peptide containing this circulating Ugandan variant was not recognized by a CTL clone from a  Clade B-infected  patient.","McAdam1998"
"53819","GL8","1304","A","","","Gag","24","31","p17(24-31)","859..882","B*0801","GGKKKYKL","GGrKKYKL","K3R","K26R","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","This variant was seen in Donor1 and Recipient1, where only the donor carried the restricting HLA-B*0801 allele.  It was not recognized by either subject.","Milicic2005"
"53819","GL8","1305","A","","","Gag","24","31","p17(24-31)","859..882","B*0801","GGKKKYKL","GGKKqYrL","K5Q, K7R","K28Q, K30R","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","This anchor residue variant was seen in Donor2 and Recipient2, both of whom carried the restricting HLA-B*0801 allele.  It was not recognized and binding to HLA was greatly reduced.","Milicic2005"
"40",,"1440","B","B","B","Gag","24","31","p17(24-31)","859..882","B8","GGKKKYKL","GGKKqYKL","K5Q","K28Q","E","escape documented in this paper","Chromium-release assay, HLA binding","This variant from the index was seen from the earliest recorded time point.  It is either an escape that became fixed or infection occurred with the virus bearing variant Q5.  Diminished recognition by index epitope-specific CTL was measured.","Price1997"
"40",,"1441","B","B","B","Gag","24","31","p17(24-31)","859..882","B8","GGKKKYKL","erKKqYKL","G1E, G2R, K5Q","G24E, G25R, K28Q","OV","observed variant","","This variant from the index epitope was seen at the earliest recorded time point but was later lost.","Price1997"
"53840","GL8","1573","B","","","Gag","24","31","p17(24-31)","859..882","B8","GGKKKYKL","GGrKKYKL","K3R","K26R","R","reversion","CD8 T-cell Elispot - IFNy, Sequence","This variant from the HXB2 sequence was present in the restricting HLA-B8 allele carrying mother, M-1001, as well as her non-HLA-B8-carrying infant, P-1024.  Infant P-1024 had lost this variant by 15 months of age.","Sanchez-Merino2005"
"46",,"1344","","","","Gag","24","32","p17(24-32)","859..885","B8","GGKKKYKLK","GGrKKYKLK","K3R","K26R","E, SF","escape documented in this paper, susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, HLA binding, Longitudinal study","Both K and R variants bind HLA-B8.  The predominant variant shifts from K to R, back to K.  R variant is never recognized; but the K variant is initially recognized, loses recognition and begins to gain recognition by CTL again.","Nowak1995"
"49",,"373","","","","Gag","24","35","p17(24-35)","859..894","B8","GGKKKYKLKHIV","GGKKKYKLKHIi","V12I","V35I","SF","susceptible form","","This variant was recognized as efficiently as the wt epitope by patient CTLs.","Goulder1997e, Phillips1991"
"49",,"374","","","","Gag","24","35","p17(24-35)","859..894","B8","GGKKKYKLKHIV","GrKKKYKLKHIV","G2R","G25R","E","escape documented in this paper","","This variant failed to be recognized by CTLs and failed to induce target specific lysis.","Goulder1997e, Phillips1991"
"49",,"375","","","","Gag","24","35","p17(24-35)","859..894","B8","GGKKKYKLKHIV","GrKKKYKfKHIV","G2R, L8F","G25R, L31F","E","escape documented in this paper","","This variant failed to be recognized by CTLs and failed to induce target specific lysis.","Goulder1997e, Phillips1991"
"49",,"376","","","","Gag","24","35","p17(24-35)","859..894","B8","GGKKKYKLKHIV","rGKKrYKLKHIV","G1R, K5R","G24R, K28R","OV","observed variant","","Previously published variants of this epitope.","Goulder1997e, Phillips1991"
"49",,"377","","","","Gag","24","35","p17(24-35)","859..894","B8","GGKKKYKLKHIV","GGKKqYrLKHIV","K5Q, K7R","K28Q, K30R","OV","observed variant","","Previously published variants of this epitope.","Goulder1997e, Phillips1991"
"49",,"378","","","","Gag","24","35","p17(24-35)","859..894","B8","GGKKKYKLKHIV","GGKKKYqLKHIV","K7Q","K30Q","OV","observed variant","","Previously published variants of this epitope.","Goulder1997e, Phillips1991"
"49",,"379","","","","Gag","24","35","p17(24-35)","859..894","B8","GGKKKYKLKHIV","GGKKKYaLKHli","I11L, V12I, K7A","I34L, V35I, K30A","OV","observed variant","","Previously published variants of this epitope.","Goulder1997e, Phillips1991"
"58382","Peptide 7","2899","C","C","C","Gag","26","40","p17(26-40)","865..909","","KKHYMLKHIVWASRE","KKHYMLKHlVWASRE","I9L","I34L","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Chinese Clade-C peptide 7, KKHYMLKHlVWASRE, cross reacted to elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"58382","Peptide 7","2900","C","C","B","Gag","26","40","p17(26-40)","865..909","","xKKHYMLKHIVWASRE","gKKkYkLKHlVWASR","x1G, I10L, H4K, M6K","x26G, I35L, H29K, M31K","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-B peptide 7, gKKkYkLKHlVWASR, did not cross react to elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"58382","Peptide 7","2903","C","C","A","Gag","26","40","p17(26-40)","865..909","","KKHYMLKHIVWASRE","KKkYrLKHlVWASRE","H3K, M5R, I9L","H28K, M30R, I34L","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-A peptide 7, KKkYrLKHlVWASRE, did not cross react to elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"58382","Peptide 7","2904","C","C","D","Gag","26","40","p17(26-40)","865..909","","KKHYMLKHIVWASRE","KKkYrLKHlVWASRE","H3K, M5R, I9L","H28K, M30R, I34L","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-D peptide 7, KKkYrLKHlVWASRE, did not cross react to elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"1756",,"87","CRF01_AE","B","CRF01_AE","Gag","28","36","p17(28-36)","871..897","A*24","KYKLKHIVW","KYKmKHlVW","L4M, I7L","L31M, I34L","SNSF","subtype-specific non-susceptible form","Chromium-release assay, HLA binding","The HLA-A24 subjects tested did not recognize the E clade version KYKmKHlVW, which differs from the previously defined B clade version KYKLKHIVW by two amino acids.","Bond2001"
"54596",,"339","A, C","C","D","Gag","28","36","p17(28-36)","871..897","A*2301","HYMLKHIVW","kYrLKHlVW","H1K, M3R, I7L","H28K, M30R, I34L","DR","diminished response","","The wild type epitope sequence was a subtype C peptide, the variant found in subtype D. CTL response in 56 individuals from Tanzania was strongest for subtype C peptide, and lower for subtype D, due to point mutation effect.","Geldmacher2007"
"54596",,"340","A, C","C","A","Gag","28","36","p17(28-36)","871..897","A*2301","HYMLKHIVW","qYrmKHlVW","H1Q, M3R, L4M, I7L","H28Q, M30R, L31M, I34L","DR","diminished response","","The wild type epitope sequence was a subtype C peptide, the variant found in subtype A. CTL response in 56 individuals from Tanzania was strongest for subtype C peptide, and lower for subtype A, due to point mutation effect.","Geldmacher2007"
"53841","QW9","1574","","","","Gag","28","36","p17(28-36)","871..897","A24","KYKLKHIVW","qYKLKHIVW","K1Q","K28Q","E, LE","escape documented in this paper, literature escape","CD8 T-cell Elispot - IFNy, Sequence","This variant from the HXB2 sequence was present in the restricting HLA-A24 allele carrying mother, M-1003, as well as her HLA-A24-carrying infant, P-1189.   Decreased recognition of the variant was seen relative to wild type index epitope.  This variant was still detected at 12 months of age in infant P-1189.  While the mother could recognize index epitope QW9, but not this variant,  infant P-1189 could not recognize either index or variant.","Sanchez-Merino2005"
"53158",,"1877","","","","Gag","28","36","p17(28-36)","871..897","A24","KYKLKHIVW","KYrLKHlVW","K3R, I7L","K30R, I34L","E, P, SF","escape documented in this paper, processing, susceptible form","Chromium-release assay","This 3R variant escaped from killing by Gag-epitope-specific CTL clonal lines when presented as an endogenously expressed sequence on transformed cells, but was recognized when exogenously loaded as synthetic peptide. A processing or epitope presentation mutation is assumed. Only 1/8 screened A24-positive individuals had CTL activity against this mutant.","Yokomaku2004"
"53158",,"1879","","","","Gag","28","36","p17(28-36)","871..897","A24","KYKLKHIVW","qYKLKHIVW","K1Q","K28Q","E, P, SF","escape documented in this paper, processing, susceptible form","Chromium-release assay","This variant escaped from killing by Gag-epitope-specific CTL clonal lines when presented as an endogenously expressed sequence on transformed cells, but was recognized when exogenously loaded as synthetic peptide.  A processing or epitope presentation mutation is assumed.","Yokomaku2004"
"53158",,"1880","","","","Gag","28","36","p17(28-36)","871..897","A24","KYKLKHIVW","rYrLKHlVW","K1R, K3R, I7L","K28R, K30R, I34L","E, P, SF","escape documented in this paper, processing, susceptible form","Chromium-release assay","This variant escaped from killing by Gag-epitope-specific CTL clonal lines when presented as an endogenously expressed sequence on transformed cells, but was recognized when exogenously loaded as synthetic peptide.  A processing or epitope presentation mutation is assumed.","Yokomaku2004"
"55928","KW9(p17)","1904","B","B","B","Gag","28","36","p17(28-36)","871..897","","KYRLKHLVW","KYkLKHLVW","R3K","R30K","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-A24 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"57701",,"2595","","","","Gag","28","36","p17(28-36)","871..897","A*23","KYKLKHIVW","qYKLKHIVW","K1Q","K28Q","SF","susceptible form","CD8 T-cell Elispot - IFNy","Gag variant qYKLKHIVW also elicited CTL response 48 weeks after start of TI in Patient 311.","Schweighardt2010"
"58187","Gag28-36","2782","B","B","B","Gag","28","36","p17(28-36)","871..897","A*2402","KYKLKHIVW","KYrLKHIVW","K3R","K30R","EL, LE","epitope loss, literature escape","CD8 T-cell Elispot - IFNy, Chromium-release assay, Intracellular cytokine staining, Relative replication capacity assay, Tetramer binding","This K3R mutant was used for studies comparing CTL specific for mutants and  WT KYKLKHIVW.  The 3R mutant was unable to revert to WT in HLA-A*2402 minus subjects.","Akahoshi2012"
"58383","Peptide 11","2905","C","C","B","Gag","42","56","p17(42-56)","913..957","","xERFALNPGLLETSE","lERFAvNPGLLETSE","x1L, L6V","x42L, L47V","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-B peptide 11, lERFAvNPGLLETSE, did not cross react to elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"58383","Peptide 11","2906","C","C","A","Gag","42","56","p17(42-56)","913..957","","ERFALNPGLLETSEG","ERFALNPsLLETaEG","S13A, G8S","S54A, G49S","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-A peptide 11, ERFALNPsLLETaEG, did not cross react to elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"59036","OLP8","3218","C","C","C","Gag","49","64","p17(49-64)","934..981","A*6802","GLLETSEGCKQIMKQL","GLLETaEGCKQIMKQL","S6A","S54A","OV","observed variant","Sequence","Observed variant GLLETaEGCKQIMKQL contains an S54A substitution within the predicted epitope.","Kloverpris2013c"
"58384","Peptide 15","2907","C","C","C","Gag","58","72","p17(58-72)","961..1005","","KQIMKQLQPALQTGT","KQIiKQLQPALQTGT","M4I","M61I","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Chinese Clade-C peptide 15, KQIiKQLQPALQTGT, did not cross react to elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"58384","Peptide 15","2908","C","C","B","Gag","58","72","p17(58-72)","961..1005","","xKQIMKQLQPALQTGT","crQIlgQLQPALQTGT","x1C, K2R, M5L, K6G","x58C, K59R, M62L, K63G","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-B peptide 15, crQIlgQLQPALQTGT, cross reacted to elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"58384","Peptide 15","2909","C","C","D","Gag","58","72","p17(58-72)","961..1005","","KQIMKQLQPALQTGT","KQIigQLQPAiQTGs","L11I, T15S, M4I, K5G","L68I, T72S, M61I, K62G","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-D peptide 15, KQIigQLQPAiQTGs, did not cross react to elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"58384","Peptide 15","2910","C","C","A","Gag","58","72","p17(58-72)","961..1005","","xKQIMKQLQPALQTGT","cqQImeQLQsALkTse","x1C, P10S, Q13K, G15S, T16E, K2Q, K6E","x58C, P67S, Q70K, G72S, T73E, K59Q, K63E","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-A peptide 15, cqQImeQLQsALkTse, did not cross react to elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"53684",,"328","B","","","Gag","71","79","p17(71-79)","1000..1026","A1","GSEELRSLY","GtEgikSLh","S2T, E4G, L5I, R6K, Y9H","S72T, E74G, L75I, R76K, Y79H","OV","observed variant","","Cross-clade T cell responses are frequently induced in individuals infected with different HIV-1 clades. There was an inverse correlation between the height of responses and epitope sequence divergence. For Gag epitopes, the magnitude of the response was directly linked to the homology between HLA anchor residues.","Geels2005"
"54577","GY9","627","B","","","Gag","71","79","p17(71-79)","1000..1026","A*01","GSEELRSLY","GSEELRSLf","Y9F","Y79F","E","escape documented in this paper","","The variant was present in most of the clones by week 139 and was not recognized by the CTLs.","Karlsson2007"
"54577","GY9","628","B","","","Gag","71","79","p17(71-79)","1000..1026","A*01","GSEELRSLY","GSEELRSLc","Y9C","Y79C","IE","inferred escape","","Author tabulates this minor variant (1/12) found in patient OP428 at week 63 as viral escape. No CTL response.","Karlsson2007"
"53821",,"1306","B","","","Gag","71","79","p17(71-79)","1000..1026","A*0101","GSEELRSLY","GSEEikSLY","L5I, R6K","L75I, R76K","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","This variant was seen in Donor2 and Recipient2, both of whom carried the restricting HLA-A*0101 allele.  It was not recognized and binding to HLA was reduced.","Milicic2005"
"53820",,"1307","A","","","Gag","71","79","p17(71-79)","1000..1026","A*0101","GTEELRSLY","GTEELRSLf","Y9F","Y79F","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","This Y79F variant was seen in Donor1 and Recipient1, where only the donor carried the restricting HLA-A*0101 allele.  It was not recognized and showed loss of binding to HLA.","Milicic2005"
"57703",,"2597","","","","Gag","71","79","p17(71-79)","1000..1026","A*01","GSEELKSLY","GSEELrSLY","K6R","K76R","SF","susceptible form","CD8 T-cell Elispot - IFNy","Gag variant GSEELrSLY also elicited CTL responses all through TI in Patient 311.","Schweighardt2010"
"53685",,"329","B","","","Gag","74","82","p17(74-82)","1009..1035","B8","ELRSLYNTV","gikSLhNTV","E1G, L2I, R3K, Y6H","E74G, L75I, R76K, Y79H","OV","observed variant","","Cross-clade T cell responses are frequently induced in individuals infected with different HIV-1 clades. There was an inverse correlation between the height of responses and epitope sequence divergence. For Gag epitopes, the magnitude of the response was directly linked to the homology between HLA anchor residues.","Geels2005"
"54580","EV9","629","B","","","Gag","74","82","p17(74-82)","1009..1035","B*08","ELRSLYNTV","ELRSLYNTi","V9I","V82I","OV","observed variant","","A major variant found in one of the patients throughout study period.","Karlsson2007"
"54580","EV9","630","B","","","Gag","74","82","p17(74-82)","1009..1035","B*08","ELRSLYNTV","ELRSLfNTi","Y6F, V9I","Y79F, V82I","OV","observed variant","","A major variant found in one of the patients throughout study period.","Karlsson2007"
"54580","EV9","631","B","","","Gag","74","82","p17(74-82)","1009..1035","B*08","ELRSLYNTV","ELRSLcNTi","Y6C, V9I","Y79C, V82I","OV","observed variant","","Minor variant found in one of the patients at week 63.","Karlsson2007"
"54580","EV9","632","B","","","Gag","74","82","p17(74-82)","1009..1035","B*08","ELRSLYNTV","ELRSLYNai","T8A, V9I","T81A, V82I","OV","observed variant","","Minor variant found in one of the patients at week 39.","Karlsson2007"
"55238",,"791","B, CRF01_AE","","B, CRF01_AE","Gag","74","82","p17(74-82)","1009..1035","B8","ELRSLYNTV","ELkSLYNTV","R3K","R76K","OV","observed variant","Sequence","Patient was superinfected with three strains, B1, B2 and CRF01_AE. This was the infecting variant  in CRF01_AE and it did not change over time. It was also the infecting variant in B1.","Kozaczynska2007"
"55238",,"792","B, CRF01_AE","","B","Gag","74","82","p17(74-82)","1009..1035","B8","ELRSLYNTV","ELkSLYNTi","R3K, V9I","R76K, V82I","IE","inferred escape","Sequence","Patient was superinfected with three strains, B1, B2 and CRF01_AE. This variant developed in B1 to include 50% of the viruses within 4 years.","Kozaczynska2007"
"55238",,"793","B, CRF01_AE","","B","Gag","74","82","p17(74-82)","1009..1035","B8","ELRSLYNTV","ELkSLfNTV","R3K, Y6F","R76K, Y79F","OV","observed variant","Sequence","Patient was superinfected with three strains, B1, B2 and CRF01_AE. This was the infecting variant  in B2.","Kozaczynska2007"
"55238",,"2257","B, CRF01_AE","B","B","Gag","74","82","p17(74-82)","1009..1035","B8","ELKSLFNTV","ELKSLyNTV","F6Y","F79Y","R","reversion","Sequence","Patient was superinfected with three strains, B1, B2 and CRF01_AE. The B2 variant is epitope ELKSLFNTV and reversion variant ELKSLyNTV developed in B2 to include 67% of the viruses within 3 years.","Kozaczynska2007"
"57702",,"2601","","","","Gag","74","82","p17(74-82)","1009..1035","B*08","ELKSLYNTV","ELrSLYNTV","K3R","K76R","SF","susceptible form","CD8 T-cell Elispot - IFNy","Gag variant ELrSLYNTV also was recognized through TI in Patient 311.","Schweighardt2010"
"58385","Peptide 19","2911","C","C","C","Gag","74","88","p17(74-88)","1009..1053","","ELKSLYNTVATLYCV","ELrSLfNTVATLYCV","K3R, Y6F","K76R, Y79F","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Chinese Clade-C peptide 19, ELrSLfNTVATLYCV, cross reacted to elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"58385","Peptide 19","2912","C","C","B","Gag","74","88","p17(74-88)","1009..1053","","xELKSLYNTVATLYCV","eELrSLYNTVATLYCV","x1E, K4R","x74E, K77R","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-B peptide 19, eELrSLYNTVATLYCV, cross reacted to elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"58385","Peptide 19","2913","C","C","D","Gag","74","88","p17(74-88)","1009..1053","","ELKSLYNTVATLYCV","ELrSLYNTVATLYCV","K3R","K76R","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-D peptide 19, ELrSLYNTVATLYCV, cross reacted to elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"58385","Peptide 19","2914","C","C","A","Gag","74","88","p17(74-88)","1009..1053","","LKSLYNTVATLYCVx","LKSLfNTVATLYCVH","x15H, Y5F","x88H, Y78F","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-A peptide 19, LKSLfNTVATLYCVH, cross reacted to elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"55946","RY11(p17)","1905","B","B","B","Gag","76","86","p17(76-86)","1015..1047","","RSLFNTVATLY","RSLyNTVATLY","F4Y","F79Y","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"57877",,"2948","C","C","C","Gag","76","86","p17(76-86)","1015..1047","A*3002","RSLYNTVATLY","kSLYNTVATLY","R1K","R76K","IE","inferred escape","Sequence","Subject CAP270 carried mutation kSLYNTVATLY in 6/6 sequences 1.8 months post-infection (Mo.PI), 7/7 sequences 2.9 Mo.PI, 9/9 sequences 6.6 Mo.PI, 17/29 sequences 13.3 Mo.PI.","Chopera2011"
"57877",,"2949","C","C","C","Gag","76","86","p17(76-86)","1015..1047","A*3002","RSLYNTVATLY","kSLYNTVAvLY","R1K, T9V","R76K, T84V","IE","inferred escape","Sequence","Subject CAP270 carried mutation kSLYNTVAvLY in 12/29 sequences 13.3 months post-infection.","Chopera2011"
"57300","RY11","2973","B","B","B","Gag","76","86","p17(76-86)","1015..1047","A*0201, A*3002","RSLYNTVATLY","RSLYNTiATLY","V7I","V82I","DR, E","diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding","Variant RSLYNTiATLY had a large increase in binding to HLA-A*02 in vitro, but it showed a significant decrease in ex-vivo EliSpot responses in 3/3 chronically-infected, untreated patients as compared to wt RY11.  The authors designate V82I mutation-containing peptides to be escapes.","Tenzer2009"
"57300","RY11","2974","B","B","B","Gag","76","86","p17(76-86)","1015..1047","A*0201, A*3002","RSLYNTVATLY","RSLYNTVAvLY","T9V","T84V","DR, E","diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding","Variant RSLYNTVAvLY bound at the same Kd to HLA-A*02 as to the WT sequence, but EliSpot response in 2/3 chronically-infected, untreated patients was abolished.  Slightly diminished response was seen in one patient.  The authors designate T84V mutation-containing peptides as escapes.","Tenzer2009"
"57300","RY11","2975","B","B","B","Gag","76","86","p17(76-86)","1015..1047","A*0201, A*3002","RSLYNTVATLY","RSLYNTiAvLY","V7I, T9V","V82I, T84V","DHB, DR, E","diminished HLA binding or increased off-rate, diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding","Variant RSLYNTiAvLY did not bind to HLA-A*02 in vitro, and it showed complete abrogation of ex-vivo EliSpot responses in 1/3 chronically-infected, untreated patients; diminished response in another patient; and no change in the third as compared to WT RY11.  The authors designate both V82I and T84V mutation-containing peptides to be escapes.","Tenzer2009"
"57300","RY11","2976","B","B","B","Gag","76","86","p17(76-86)","1015..1047","A*0201, A*3002","RSLYNTVATLY","RSLfNTiATLY","Y4F, V7I","Y79F, V82I","DHB, DR, E","diminished HLA binding or increased off-rate, diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding","Variant RSLfNTiATLY did not bind to HLA-A*02, and it showed a significant decrease in ex-vivo EliSpot response in 2 chronically-infected, untreated patients, with no changes in 1 patient as compared to WT RY11.  The authors designate Y79F or V82I mutation-containing peptides as escapes.","Tenzer2009"
"57300","RY11","2977","B","B","B","Gag","76","86","p17(76-86)","1015..1047","A*0201, A*3002","RSLYNTVATLY","RSLfNTVATLY","Y4F","Y79F","DHB, DR, E","diminished HLA binding or increased off-rate, diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding","Variant RSLfNTVATLY did not bind to HLA-A*02 in vitro, and it showed a decrease in ex-vivo EliSpot response in 2/3 chronically-infected, untreated patients as compared to wt RY11.  The authors designate Y79F mutation-containing peptides to be escapes.","Tenzer2009"
"57300","RY11","2978","B","B","B","Gag","76","86","p17(76-86)","1015..1047","A*0201, A*3002","RSLYNTVATLY","RSLfNTVAvLY","Y4F, T9V","Y79F, T84V","DHB, DR, E","diminished HLA binding or increased off-rate, diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding","Variant RSLfNTVAvLY did not bind to HLA-A*02 in vitro, and it showed a significant decrease in ex-vivo EliSpot response in 1 chronically-infected, untreated patient; abrogation of CTL response in another such patient; with no changes in the third patient when compared to wt RY11.  The authors designate Y79F and T84V mutation-containing peptides to be escapes.","Tenzer2009"
"57300","RY11","2979","B","B","B","Gag","76","86","p17(76-86)","1015..1047","A*0201, A*3002","RSLYNTVATLY","RSLfNTiAvLY","Y4F, V7I, T9V","Y79F, V82I, T84V","DHB, DR, E","diminished HLA binding or increased off-rate, diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding","Variant RSLfNTiAvLY did not bind to HLA-A*02 in vitro, and it showed a decrease in ex-vivo EliSpot response in 1/3 chronically-infected, untreated patients; with abrogation of CTL response in 1 other patient; and a slight increase for the last patient as compared with WT RY11.  The authors designate Y79F, V82I or T84V mutation-containing peptides to be escapes.","Tenzer2009"
"57300","RY11","2980","B","B","B","Gag","76","86","p17(76-86)","1015..1047","A*0201, A*3002","RSLYNTVATLY","kSLYNTVATLY","R1K","R76K","DHB, DR","diminished HLA binding or increased off-rate, diminished response","CD8 T-cell Elispot - IFNy, HLA binding","Variant kSLfNTiATLY did not bind to HLA-A*02 in vitro, but it showed a decrease in ex-vivo EliSpot response in 2/3 chronically-infected, untreated patients as compared to WT RY11.","Tenzer2009"
"57300","RY11","2981","B","B","B","Gag","76","86","p17(76-86)","1015..1047","A*0201, A*3002","RSLYNTVATLY","kSLYNTVAvLY","R1K, T9V","R76K, T84V","DHB, DR, E","diminished HLA binding or increased off-rate, diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding","Variant kSLYNTVAvLY had loss of binding to HLA-A*02 in vitro; and it showed a significant decrease in ex-vivo EliSpot response in 1 chronically-infected, untreated patient, and abrogation of CTL responses in the other 2.","Tenzer2009"
"57300","RY11","2982","B","B","B","Gag","76","86","p17(76-86)","1015..1047","A*0201, A*3002","RSLYNTVATLY","kSLYNTiATLY","R1K, V7I","R76K, V82I","DR, E","diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding","Variant kSLYNTiATLY had an increase in binding to HLA-A*02 in vitro; but it showed a significant decrease in EliSpot response in 1 chronically-infected, untreated patient; abrogation of CTL responses in the second patient; and no change in the third when compared to wt RY11.  The authors designate V82I mutation-containing peptides to be escapes.","Tenzer2009"
"57300","RY11","2983","B","B","B","Gag","76","86","p17(76-86)","1015..1047","A*0201, A*3002","RSLYNTVATLY","kSLYNTiAvLY","R1K, V7I, T9V","R76K, V82I, T84V","DHB, DR, E","diminished HLA binding or increased off-rate, diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding","Variant kSLYNTiAvLY lost binding to HLA-A*02 in vitro; and it showed a significant decrease in ex-vivo EliSpot response in 2 chronically-infected, untreated patients and abrogation of CTL response in the third.  The authors designate V82I or T84V mutation-containing peptides as escapes.","Tenzer2009"
"57300","RY11","2984","B","B","B","Gag","76","86","p17(76-86)","1015..1047","A*0201, A*3002","RSLYNTVATLY","kSLfNTVATLY","R1K, Y4F","R76K, Y79F","DHB, DR, E","diminished HLA binding or increased off-rate, diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding","Variant kSLfNTVATLY lost binding to HLA-A*02 in vitro; and it showed a significant decrease in ex-vivo EliSpot response in 3/3 chronically-infected, untreated patients.  The authors designate Y79F mutation-containing peptides as escapes.","Tenzer2009"
"57300","RY11","2985","B","B","B","Gag","76","86","p17(76-86)","1015..1047","A*0201, A*3002","RSLYNTVATLY","kSLfNTiATLY","R1K, Y4F, V7I","R76K, Y79F, V82I","DHB, DR, E","diminished HLA binding or increased off-rate, diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding","Variant kSLfNTiATLY lost binding to HLA-A*02 in vitro; and it showed a significant decrease in ex-vivo EliSpot responses in 3/3 chronically-infected, untreated patients as compared to wt RY11.  The authors designate Y79F or V82I mutation-containing peptides as escapes.","Tenzer2009"
"57300","RY11","2986","B","B","B","Gag","76","86","p17(76-86)","1015..1047","A*0201, A*3002","RSLYNTVATLY","kSLfNTVAvLY","R1K, Y4F, T9V","R76K, Y79F, T84V","DHB, DR, E","diminished HLA binding or increased off-rate, diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding","Variant kSLfNTVAvLY lost binding to HLA-A*02 in vitro; and it showed a significant decrease in EliSpot response in 2 chronically-infected, untreated patients; and abrogation of CTL response in the third.  The authors designate Y79F or T84V mutation-containing peptides as escapes.","Tenzer2009"
"57300","RY11","2987","B","B","B","Gag","76","86","p17(76-86)","1015..1047","A*0201, A*3002","RSLYNTVATLY","kSLfNTiAvLY","R1K, Y4F, V7I, T9V","R76K, Y79F, V82I, T84V","DHB, DR, E","diminished HLA binding or increased off-rate, diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding","Variant kSLfNTiAvLY did not bind to HLA-A*02 in vitro, and it showed a decrease in ex-vivo EliSpot response in 1/3 chronically-infected, untreated patients, with abrogation of CTL response in the other 2 patients as compared to WT RY11.  The authors designate Y79F, V82I or T84V mutation-containing peptides to be escapes.","Tenzer2009"
"58604","GagRY11","3056","","","","Gag","76","86","p17(76-86)","1015..1047","A*3002","RSLYNTVATLY","RSLYNTVATLc","Y11C","Y86C","E","escape documented in this paper","Cytokine production, Sequence, Tetramer binding","5/5 (100%) sequenced variants showed this escape, RSLYNTVATLc, in subject 0406; 13/15 (86.7%) in subject 2401; and 8/16 (50%) in subject 3902.","Mahlokozera2011"
"58604","GagRY11","3057","","","","Gag","76","86","p17(76-86)","1015..1047","A*3002","RSLYNTVATLY","kSLfNTVATLc","R1K, Y11C, Y4F","R76K, Y86C, Y79F","E","escape documented in this paper","Cytokine production, Sequence, Tetramer binding","1/22 (4.5%) sequenced variants showed this escape, kSLfNTVATLc, in subject 2007; 1/4 (25%) in subject 5506.","Mahlokozera2011"
"58604","GagRY11","3058","","","","Gag","76","86","p17(76-86)","1015..1047","A*3002","RSLYNTVATLY","RSLfNTiATLf","Y11F, Y4F, V7I","Y86F, Y79F, V82I","E","escape documented in this paper","Cytokine production, Sequence, Tetramer binding","12/18 (66.7%) sequenced variants showed this escape, RSLfNTiATLf, in subject 3706.","Mahlokozera2011"
"53603","SL9","60","B","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTIATL","SLYNTIAvL","T8V","T84V","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, Intracellular cytokine staining","The response to this peptide was not apparent until month 20, by month 32 a T to V change was dominant, but the slyntiaVl mutant showed comparable avidity.","Bansal2005a"
"55518","SL9","69","A, B, C, D, F, G, K","B","A, F","Gag","77","85","p17(77-85)","1018..1044","A*02","SLYNTVATL","SLYNTVAvL","T8V","T84V","SSF","subtype-specific susceptible form","Chromium-release assay","SL9 epitope variants used were SLYNTVATL for clades B/A1/C/D, SLYNTVAVL for clades A2/F1, and SLFNTVATL for clades G/K. Clade B-elicited CTLs recognized epitopes from all other clades when tested by Cr-release.","Bennett2008"
"55518","SL9","70","A, B, C, D, F, G, K","B","G, K","Gag","77","85","p17(77-85)","1018..1044","A*02","SLYNTVATL","SLfNTVATL","Y3F","Y79F","SSF","subtype-specific susceptible form","Chromium-release assay","SL9 epitope variants used were SLYNTVATL for clades B/A1/C/D, SLYNTVAVL for clades A2/F1, and SLFNTVATL for clades G/K. Clade B-elicited CTLs recognized epitopes from all other clades when tested by Cr-release.","Bennett2008"
"55763","SL9","76","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVATL","Y3F","Y79F","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","To identify immunogenically optimized epitopes for use in vaccines, mutants of SL9 were tested in transgenic mice. SLYNTVATL and most common mutant, SLfNTVATL, were weakly immunogenic or cross-reactive. 3 mutants, SLYNlVATL, SLfNlVATL and SiYNlVATL were highly immunogenic. Peptide SiYNlVATL with the additional L2I change allowed great cross-reactivity to the consensus.","Blondelle2008"
"55763","SL9","77","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNlVATL","T5L","T81L","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","To identify immunogenically optimized epitopes for use in vaccines, mutants of SL9 were tested in transgenic mice. SLYNTVATL and most common mutant, SLfNTVATL, were weakly immunogenic or cross-reactive. 3 mutants, SLYNlVATL, SLfNlVATL and SiYNlVATL were highly immunogenic. Peptide SiYNlVATL with the additional L2I change allowed great cross-reactivity to the consensus.","Blondelle2008"
"55763","SL9","78","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNlVATL","Y3F, T5L","Y79F, T81L","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","To identify immunogenically optimized epitopes for use in vaccines, mutants of SL9 were tested in transgenic mice. SLYNTVATL and most common mutant, SLfNTVATL, were weakly immunogenic or cross-reactive. 3 mutants, SLYNlVATL, SLfNlVATL and SiYNlVATL were highly immunogenic. Peptide SiYNlVATL with the additional L2I change allowed great cross-reactivity to the consensus.","Blondelle2008"
"55763","SL9","79","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SiYNlVATL","L2I, T5L","L78I, T81L","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","To identify immunogenically optimized epitopes for use in vaccines, mutants of SL9 were tested in transgenic mice. SLYNTVATL and most common mutant, SLfNTVATL, were weakly immunogenic or cross-reactive. 3 mutants, SLYNlVATL, SLfNlVATL and SiYNlVATL were highly immunogenic. Peptide SiYNlVATL with the additional L2I change allowed great cross-reactivity to the consensus.","Blondelle2008"
"64","SL9","97","B","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLfNTVATL","Y3F","Y79F","E, SF","escape documented in this paper, susceptible form","","The substitution Y79F was an escape mutation because it interfered with CTL recognition by one CTL clone from an A*0201 infected individual, clone 13010.B17, but it was still recognized by another CTL clone, 115.D4.","Brander1999a"
"96","SL9","99","","B, C, D","A, C","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVATL","Y3F","Y79F","SSF","subtype-specific susceptible form","Chromium-release assay","The consensus peptides of B and D clade viruses and some Cs have the sequence SLYNTVATL. The consensus peptide of A, and some C strains is SLFNTVATL, a form that is cross-reactive.","Cao1997a"
"55051",,"142","","A, C","A, D","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLfNTiATL","Y3F, V6I","Y79F, V82I","SNSF, SSF","subtype-specific non-susceptible form, subtype-specific susceptible form","","SLYNTVATL within peptide SLYNTVATLYC from A consensus and C isolate was recognized by 5/9 HLA A*0201 carriers from subtype A Kenyan cohort. The variant SLfNTiATL within peptide  SLfNTiATLYC from A isolate and peptide SLfNTiATLWC from D isolate was recognized by 3 out 5 subjects that recognized SLYNTVATL and not recognized by 2 subjects.","Currier2006"
"102","SL9","171","A","A, C","B","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLFNTVATL","SLyNTVATL","F3Y","F79Y","SNSF","subtype-specific non-susceptible form","","CTL responses in three individuals with non-clade B infections were studied, 2 with subtype A infections, 1 with subtype C -- their infections all originated in East Africa. This epitope is most commonly SLYNTVATL in B subtype, and CTL from the C subtype infection did not recognize B clade gag or the 3Y form of the epitope, but did recognize the predominant A and C clade form, SLFNTVATL.","Dorrell1999"
"52187","SL9","178","B","","","Gag","77","85","p17(77-85)","1018..1044","","SLYNTVATL","SLYNTVAvL","T8V","T84V","SF","susceptible form","","SLYNTVATL was the only form of the epitope found initially, but three alternate forms eventually appeared: SLYNTVAVL, SLYNTIATL, and most commonly SLYNTIAVL. These distinct forms bind A2, but have distinct abilities to stimulate different T-cell clonotypes. In subject TX7, the observed mutations of SL9 failed to escape overall CTL recognition, presumably because the six T-cell clonotypes allowed a more flexible response. The BV17 T-cell clone recognized SL9 but not SLYNTIAVL, and BV17 became undetectable at week 20 when SLYNTIAVL predominated. Subsequently BV17 became the second most common clone.","Douek2002"
"52187","SL9","179","B","","","Gag","77","85","p17(77-85)","1018..1044","","SLYNTVATL","SLYNTiATL","V6I","V82I","E, SF","escape documented in this paper, susceptible form","","SLYNTVATL was the only form of the epitope found initially, but three alternate forms eventually appeared: SLYNTVAVL, SLYNTIATL, and most commonly SLYNTIAVL. These distinct forms bind A2, but have distinct abilities to stimulate different T-cell clonotypes. In subject TX7, the observed mutations of SL9 failed to escape overall CTL recognition, presumably because the six T-cell clonotypes allowed a more flexible response. The BV17 T-cell clone recognized SL9 but not SLYNTIAVL, and BV17 became undetectable at week 20 when SLYNTIAVL predominated. Subsequently BV17 became the second most common clone.","Douek2002"
"52187","SL9","180","B","","","Gag","77","85","p17(77-85)","1018..1044","","SLYNTVATL","SLYNTiAvL","V6I, T8V","V82I, T84V","SF","susceptible form","","SLYNTVATL was the only form of the epitope found initially, but three alternate forms eventually appeared: SLYNTVAVL, SLYNTIATL, and most commonly SLYNTIAVL. These distinct forms bind A2, but have distinct abilities to stimulate different T-cell clonotypes. In subject TX7, the observed mutations of SL9 failed to escape overall CTL recognition, presumably because the six T-cell clonotypes allowed a more flexible response. The BV17 T-cell clone recognized SL9 but not SLYNTIAVL, and BV17 became undetectable at week 20 when SLYNTIAVL predominated. Subsequently BV17 became the second most common clone.","Douek2002"
"55064","SL9","183","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTVAvL","T8V","T84V","DR","diminished response","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Immune responses were examined in monozygotic male twins infected simultaneously with the same virus. SLYNTVAvL variant arose in one twin and not the other. Response to the variant was diminished.","Draenert2006"
"54597",,"341","A, C, D","C","A, D","Gag","77","85","p17(77-85)","1018..1044","A2, A68","SLYNTVATL","SLfNTiATL","Y3F, V6I","Y79F, V82I","DR","diminished response","","The wild type epitope sequence was a subtype C peptide, the variant common to subtypes A and D. CTL response in 56 individuals from Tanzania was strongest for subtype C peptide, and lower for subtypes A and D, due to point mutation effect.","Geldmacher2007"
"97","SL9","358","","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLhNaVAvL","Y3H, T5A, T8V","Y79H, T81A, T84V","E","escape documented in this paper","Chromium-release assay","HLA-identical siblings infected with the same batch. One responded to SLYNTVATL, the non-responder carried SLhNaVAvL. There was no CTL response to this variant.","Goulder1997, Goulder1997e"
"97","SL9","359","","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLfNTVATL","Y3F","Y79F","E","escape documented in this paper","Chromium-release assay","A subject went to SLYNTVATL responder to non-responder which coincided with a switch to the variant epitope. The variant had poor CTL recognition and there was no peptide-specific CTLs generated upon stimulation of PBMCs.","Goulder1997, Goulder1997e"
"97","SL9","360","","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLYNTiAvL","V6I, T8V","V82I, T84V","SF","susceptible form","Chromium-release assay","Variant was recognized by CTLs to a similar level as the wt.","Goulder1997, Goulder1997e"
"97","SL9","361","","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLhNTVATL","Y3H","Y79H","E","escape documented in this paper","Chromium-release assay","Variant was not recognized by CTLs.","Goulder1997, Goulder1997e"
"97","SL9","362","","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLlNTVATL","Y3L","Y79L","OV","observed variant","","Variant was found in one epitope responder in 6% of the clones.","Goulder1997, Goulder1997e"
"97","SL9","363","","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLYNTVAvL","T8V","T84V","OV","observed variant","","Variant was found in one epitope responder in 10% of the clones.","Goulder1997, Goulder1997e"
"97","SL9","364","","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLYNTiATL","V6I","V82I","OV","observed variant","","Variant was found in one epitope responder in 9% of the clones.","Goulder1997, Goulder1997e"
"97","SL9","365","","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLsNTiATL","Y3S, V6I","Y79S, V82I","OV","observed variant","","Variant was found in one epitope non-responder in 10% of the clones.","Goulder1997, Goulder1997e"
"97","SL9","366","","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLfNTVAvL","Y3F, T8V","Y79F, T84V","OV","observed variant","","Variant was found in two epitope non-responders in 25% and 38% of the clones, respectively.","Goulder1997, Goulder1997e"
"1822","SL9","383","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVATL","Y3F","Y79F","E","escape documented in this paper","","The variant was not recognized by autologous CTL in an infected mother. The variant was transmitted both vertically and horizontally.","Goulder2001b"
"1822","SL9","384","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTVAvL","T8V","T84V","E","escape documented in this paper","","A variant found in an infected mother that was vertically transmitted. The wt epitope was not recognized by children's CTLs.","Goulder2001b"
"104","SL9","408","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVATL","Y3F","Y79F","SF","susceptible form","Chromium-release assay","No variants were found in the patient, but this synthetic variant was tested against patient CTLs. The variant was recognized by CTLs and induced target specific lysis.","Harrer1998"
"104","SL9","409","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTiATL","V6I","V82I","SF","susceptible form","Chromium-release assay","No variants were found in the patient, but this synthetic variant was tested against patient CTLs. The variant was recognized by CTLs and induced target specific lysis.","Harrer1998"
"104","SL9","410","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTVAvL","T8V","T84V","SF","susceptible form","Chromium-release assay","No variants were found in the patient, but this synthetic variant was tested against patient CTLs. The variant was recognized by CTLs and induced target specific lysis.","Harrer1998"
"104","SL9","411","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNaVATL","T5A","T81A","SF","susceptible form","Chromium-release assay","No variants were found in the patient, but this synthetic variant was tested against patient CTLs. The variant was recognized by CTLs and induced target specific lysis.","Harrer1998"
"54498","SL9","467","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTiATL","V6I","V82I","NSF, SF","non-susceptible form, susceptible form","","Variant present in 8% of 76 A2+ patients.  Bound strongly to HLA-A2 (binding affinity was 94 nM). Was recognized by some A2+ patient's PBMCs and not recognized by others.","Iversen2006"
"54498","SL9","468","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTVAvL","T8V","T84V","OV","observed variant","","Variant present in 4% of A2+ patients. Bound strongly to HLA-A2 (binding affinity was 20 nM). Was not present in the patients tested for EliSpot responses.","Iversen2006"
"54498","SL9","469","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVAvL","Y3F, T8V","Y79F, T84V","E","escape documented in this paper","","Positively selected transition variant present in 5% of A2+ patients. HLA-binding affinity was sufficient to elicit CTL responses. Not well recognized by patient PBMCs.","Iversen2006"
"54498","SL9","470","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVATL","Y3F","Y79F","DHB, SF","diminished HLA binding or increased off-rate, susceptible form","","Positively selected transition variant present in 16% of A2+ patients. HLA-binding affinity was sufficient to elicit CTL responses but was somewhat weaker compared to other variants. Recognized by patient PBMCs.","Iversen2006"
"54498","SL9","471","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTiATL","Y3F, V6I","Y79F, V82I","DR","diminished response","","Transition variant present in 7% of A2+ patients. Intermediate recognition by patient PBMCs.","Iversen2006"
"54498","SL9","472","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTiAvL","Y3F, V6I, T8V","Y79F, V82I, T84V","E, TCR","escape documented in this paper, TCR related mutation","","Positively selected escape variant present in 7% of A2+ patients. HLA-binding affinity was sufficient to elicit CTL responses but the responses were usually weaker than to other variants. Assumed to impair TCR binding.","Iversen2006"
"54498","SL9","473","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLhNaVAvL","Y3H, T5A, T8V","Y79H, T81A, T84V","SF","susceptible form","","A minor variant found in one patient. HLA-binding affinity was sufficient to elicit CTL responses.","Iversen2006"
"54498","SL9","474","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTiAvL","V6I, T8V","V82I, T84V","DR","diminished response","","Positively selected transition variant present in 11% of A2+ patients. HLA-binding affinity was sufficient to elicit CTL responses. Not well recognized by patient PBMCs.","Iversen2006"
"54498","SL9","475","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTiAiL","V6I, T8I","V82I, T84I","OV","observed variant","","A minor variant found in one patient.","Iversen2006"
"54498","SL9","476","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVATv","Y3F, L9V","Y79F, L85V","SF","susceptible form","","A minor variant found in one patient. HLA-binding affinity was sufficient to elicit CTL responses.","Iversen2006"
"54498","SL9","477","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNaVATL","T5A","T81A","SF","susceptible form","","A minor variant found in one patient. HLA-binding affinity was sufficient to elicit CTL responses.","Iversen2006"
"54498","SL9","478","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNlVAvL","T5L, T8V","T81L, T84V","DHB","diminished HLA binding or increased off-rate","","A minor variant found in one patient. HLA-binding affinity was not sufficient to elicit CTL responses.","Iversen2006"
"54498","SL9","479","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTVAif","T8I, L9F","T84I, L85F","DHB","diminished HLA binding or increased off-rate","","A minor variant found in one patient. HLA-binding affinity was not sufficient to elicit CTL responses.","Iversen2006"
"54498","SL9","480","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNaVATL","Y3F, T5A","Y79F, T81A","R, SF","reversion, susceptible form","","An unusual variant resulting in strong response. This is suggested to be a transient reversion variant. HLA-binding affinity was sufficient to elicit CTL responses.","Iversen2006"
"54498","SL9","481","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNaVAvL","Y3F, T5A, T8V","Y79F, T81A, T84V","SF","susceptible form","","A minor variant found in one patient. HLA-binding affinity was sufficient to elicit CTL responses.","Iversen2006"
"54498","SL9","482","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNmVATL","Y3F, T5M","Y79F, T81M","SF","susceptible form","","A minor variant found in one patient. HLA-binding affinity was sufficient to elicit CTL responses.","Iversen2006"
"54498","SL9","483","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTVsTL","A7S","A83S","SF","susceptible form","","Variant described before. HLA-binding affinity was sufficient to elicit CTL responses.","Iversen2006"
"54498","SL9","484","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTitvL","V6I, A7T, T8V","V82I, A83T, T84V","SF","susceptible form","","Variant described before. HLA-binding affinity was sufficient to elicit CTL responses.","Iversen2006"
"54498","SL9","485","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTisvL","V6I, A7S, T8V","V82I, A83S, T84V","SF","susceptible form","","Variant described before. HLA-binding affinity was sufficient to elicit CTL responses.","Iversen2006"
"53008","SL9","486","B","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLfNTVATL","Y3F","Y79F","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","","This variant was found in one patient and elicited <50% the response to the wt while it elicited strong response in another patient. Likely mechanism of escape was loss of HLA binding.","Jamieson2003"
"53008","SL9","487","B","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLfNTVAvL","Y3F, T8V","Y79F, T84V","E, TCR","escape documented in this paper, TCR related mutation","","This variant was found in two patients and elicited <50% the response to the wt in both patients. Likely mechanism of escape was loss of T cell recognition.","Jamieson2003"
"53008","SL9","488","B","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLYNTVvTL","A7V","A83V","IE","inferred escape","","Variant found in one patient. Decline of CTL responses.","Jamieson2003"
"53008","SL9","489","B","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLfNTiATL","Y3F, V6I","Y79F, V82I","IE","inferred escape","","Variant found in one patient.  Decline of CTL responses.","Jamieson2003"
"53008","SL9","490","B","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLYNTiAvL","V6I, T8V","V82I, T84V","E, TCR","escape documented in this paper, TCR related mutation","","This variant was found in two patients and elicited <50% the response to the index peptide in both patients. The likely mechanism of escape was loss of T cell recognition.","Jamieson2003"
"53008","SL9","491","B","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLhNTVAvL","Y3H, T8V","Y79H, T84V","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","","This variant was found in one patient and elicited <25% the response to the wt in two patients. Likely mechanism of escape was loss of HLA binding.","Jamieson2003"
"53008","SL9","492","B","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLYNTVAvL","T8V","T84V","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","","This variant was found in three patients and elicited <50% the response to the wt in two patients. Likely mechanism of escape was loss of HLA binding.","Jamieson2003"
"53742",,"500","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVATL","Y3F","Y79F","OV","observed variant","","Two of the subjects carried this variant of the epitope","Jansen2005a"
"53742",,"501","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTiATL","V6I","V82I","OV","observed variant","","One of the subjects carried this variant of the epitope.","Jansen2005a"
"54497","SL9","596","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTVAaL","T8A","T84A","SF","susceptible form","","This synthesized variant was recognized by CTLs from 8/9 individuals. The variant was more immunogenic than the wt, reduced IL-2-mediated activation induced cell death that the wt CTLs were susceptible to, and induced broad response to several SL9 variants.","Kan-Mitchell2006"
"54497","SL9","597","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","lLYNTVATL","S1L","S77L","SF","susceptible form","","74 synthesized SL9 variants were tested for recognition by CTLs from 9 HLA-A2+ donors. This variant was one of the 22 recognized by CTLs. It was recognized by CTLs from 6/8 donors.","Kan-Mitchell2006"
"54497","SL9","598","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTVAsL","T8S","T84S","SF","susceptible form","","74 synthesized SL9 variants were tested for recognition by CTLs from 9 HLA-A2+ donors. This variant was one of the 22 recognized by CTLs. It was recognized by CTLs from 7/8 donors.","Kan-Mitchell2006"
"54497","SL9","599","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTpATL","V6P","V82P","SF","susceptible form","","74 synthesized SL9 variants were tested for recognition by CTLs from 9 HLA-A2+ donors. This variant was one of the 22 recognized by CTLs. It was recognized by CTLs from 1/8 donors.","Kan-Mitchell2006"
"54497","SL9","600","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","lLYNTVAaL","S1L, T8A","S77L, T84A","SF","susceptible form","","74 synthesized SL9 variants were tested for recognition by CTLs from 9 HLA-A2+ donors. This variant was one of the 22 recognized by CTLs. It was recognized by CTLs from 5/8 donors.","Kan-Mitchell2006"
"54497","SL9","601","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","lLYNTVAsL","S1L, T8S","S77L, T84S","SF","susceptible form","","74 synthesized SL9 variants were tested for recognition by CTLs from 9 HLA-A2+ donors. This variant was one of the 22 recognized by CTLs. It was recognized by CTLs from 6/8 donors.","Kan-Mitchell2006"
"54497","SL9","602","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","lLYNTVlTL","S1L, A7L","S77L, A83L","SF","susceptible form","","74 synthesized SL9 variants were tested for recognition by CTLs from 9 HLA-A2+ donors. This variant was one of the 22 recognized by CTLs. It was recognized by CTLs from 2/8 donors.","Kan-Mitchell2006"
"54497","SL9","603","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTsAaL","V6S, T8A","V82S, T84A","SF","susceptible form","","74 synthesized SL9 variants were tested for recognition by CTLs from 9 HLA-A2+ donors. This variant was one of the 22 recognized by CTLs. It was recognized by CTLs from 3/8 donors.","Kan-Mitchell2006"
"54497","SL9","604","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","lLYNTpATL","S1L, V6P","S77L, V82P","SF","susceptible form","","74 synthesized SL9 variants were tested for recognition by CTLs from 9 HLA-A2+ donors. This variant was one of the 22 recognized by CTLs. It was recognized by CTLs from 3/8 donors.","Kan-Mitchell2006"
"54497","SL9","605","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTpAaL","V6P, T8A","V82P, T84A","SF","susceptible form","","74 synthesized SL9 variants were tested for recognition by CTLs from 9 HLA-A2+ donors. This variant was one of the 22 recognized by CTLs. It was recognized by CTLs from 1/8 donors.","Kan-Mitchell2006"
"54497","SL9","606","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTpAsL","V6P, T8S","V82P, T84S","SF","susceptible form","","74 synthesized SL9 variants were tested for recognition by CTLs from 9 HLA-A2+ donors. This variant was one of the 22 recognized by CTLs. It was recognized by CTLs from 2/8 donors.","Kan-Mitchell2006"
"54497","SL9","607","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLhNwslaL","Y3H, T5W, V6S, A7L, T8A","Y79H, T81W, V82S, A83L, T84A","SF","susceptible form","","74 synthesized SL9 variants were tested for recognition by CTLs from 9 HLA-A2+ donors. This variant was one of the 22 recognized by CTLs. It was recognized by CTLs from 1/8 donors.","Kan-Mitchell2006"
"54497","SL9","608","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLwNwplaL","Y3W, T5W, V6P, A7L, T8A","Y79W, T81W, V82P, A83L, T84A","SF","susceptible form","","74 synthesized SL9 variants were tested for recognition by CTLs from 9 HLA-A2+ donors. This variant was one of the 22 recognized by CTLs. It was recognized by CTLs from 3/8 donors.","Kan-Mitchell2006"
"54497","SL9","609","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLwNwplsL","Y3W, T5W, V6P, A7L, T8S","Y79W, T81W, V82P, A83L, T84S","SF","susceptible form","","74 synthesized SL9 variants were tested for recognition by CTLs from 9 HLA-A2+ donors. This variant was one of the 22 recognized by CTLs. It was recognized by CTLs from 3/8 donors.","Kan-Mitchell2006"
"54497","SL9","610","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLhNwplaL","Y3H, T5W, V6P, A7L, T8A","Y79H, T81W, V82P, A83L, T84A","SF","susceptible form","","74 synthesized SL9 variants were tested for recognition by CTLs from 9 HLA-A2+ donors. This variant was one of the 22 recognized by CTLs. It was recognized by CTLs from 3/8 donors.","Kan-Mitchell2006"
"54497","SL9","611","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLhNwplsL","Y3H, T5W, V6P, A7L, T8S","Y79H, T81W, V82P, A83L, T84S","SF","susceptible form","","74 synthesized SL9 variants were tested for recognition by CTLs from 9 HLA-A2+ donors. This variant was one of the 22 recognized by CTLs. It was recognized by CTLs from 3/8 donors.","Kan-Mitchell2006"
"54497","SL9","612","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","lLwNTslaL","S1L, Y3W, V6S, A7L, T8A","S77L, Y79W, V82S, A83L, T84A","SF","susceptible form","","74 synthesized SL9 variants were tested for recognition by CTLs from 9 HLA-A2+ donors. This variant was one of the 22 recognized by CTLs. It was recognized by CTLs from 3/8 donors.","Kan-Mitchell2006"
"54497","SL9","613","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","lLwNwslaL","S1L, Y3W, T5W, V6S, A7L, T8A","S77L, Y79W, T81W, V82S, A83L, T84A","SF","susceptible form","","74 synthesized SL9 variants were tested for recognition by CTLs from 9 HLA-A2+ donors. This variant was one of the 22 recognized by CTLs. It was recognized by CTLs from 2/8 donors.","Kan-Mitchell2006"
"54497","SL9","614","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","lLwNwslsL","S1L, Y3W, T5W, V6S, A7L, T8S","S77L, Y79W, T81W, V82S, A83L, T84S","SF","susceptible form","","74 synthesized SL9 variants were tested for recognition by CTLs from 9 HLA-A2+ donors. This variant was one of the 22 recognized by CTLs. It was recognized by CTLs from 1/8 donors.","Kan-Mitchell2006"
"54497","SL9","615","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","lLwNwplaL","S1L, Y3W, T5W, V6P, A7L, T8A","S77L, Y79W, T81W, V82P, A83L, T84A","SF","susceptible form","","74 synthesized SL9 variants were tested for recognition by CTLs from 9 HLA-A2+ donors. This variant was one of the 22 recognized by CTLs. It was recognized by CTLs from 1/8 donors.","Kan-Mitchell2006"
"54497","SL9","616","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","lLhNwslaL","S1L, Y3H, T5W, V6S, A7L, T8A","S77L, Y79H, T81W, V82S, A83L, T84A","SF","susceptible form","","74 synthesized SL9 variants were tested for recognition by CTLs from 9 HLA-A2+ donors. This variant was one of the 22 recognized by CTLs. It was recognized by CTLs from 1/8 donors.","Kan-Mitchell2006"
"54497","SL9","617","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","lLhNwplsL","S1L, Y3H, T5W, V6P, A7L, T8S","S77L, Y79H, T81W, V82P, A83L, T84S","SF","susceptible form","","74 synthesized SL9 variants were tested for recognition by CTLs from 9 HLA-A2+ donors. This variant was one of the 22 recognized by CTLs. It was recognized by CTLs from 1/8 donors.","Kan-Mitchell2006"
"54497","SL9","618","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVATL","Y3F","Y79F","E, SF","escape documented in this paper, susceptible form","","This variant was not recognized by SL9-CTLs from one patient while it was recognized by the T/A-variant CTLs from this patient and by SL9- and T/A-CTLs derived from sister cells from another patient.","Kan-Mitchell2006"
"54497","SL9","619","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVAvL","Y3F, T8V","Y79F, T84V","DR, E","diminished response, escape documented in this paper","","This variant was not recognized by SL9-CTLs from one patient while it was recognized by the T/A-variant CTLs from this patient and by SL9- and T/A-CTLs derived from sister cells from another patient. It was recognized to a lesser extent than the wt.","Kan-Mitchell2006"
"54497","SL9","620","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTiAvL","Y3F, V6I, T8V","Y79F, V82I, T84V","E, SF","escape documented in this paper, susceptible form","","This variant was not recognized by SL9-CTLs from one patient while it was recognized by the T/A-variant CTLs from this patient and by SL9- and T/A-CTLs derived from sister cells from another patient.","Kan-Mitchell2006"
"54497","SL9","621","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTiATL","V6I","V82I","DR, SF","diminished response, susceptible form","","This variant was recognized by SL9-CTLs from one patient while it was recognized to a lesser extent by the T/A-variant CTLs from this patient. It was recognized by SL9- and T/A-CTLs derived from sister cells from another patient.","Kan-Mitchell2006"
"54497","SL9","622","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTiAvL","V6I, T8V","V82I, T84V","DR, SF","diminished response, susceptible form","","This variant was recognized by SL9-CTLs from one patient while it was recognized to a lesser extent by the T/A-variant CTLs from this patient. It was recognized by SL9- and T/A-CTLs derived from sister cells from another patient.","Kan-Mitchell2006"
"54497","SL9","623","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SvYNTVATL","L2V","L78V","DR, SF","diminished response, susceptible form","","This variant was recognized by both SL9-CTLs and by the T/A-variant CTLs from this patient, but to somewhat lesser extent than the wt epitope. It was also recognized by SL9- and T/A-CTLs derived from sister cells from another patient.","Kan-Mitchell2006"
"54556","SL9","633","B","","","Gag","77","85","p17(77-85)","1018..1044","A*02","SLYNTVATL","SLYNTiATL","V6I","V82I","SF","susceptible form","CD8 T-cell Elispot - IFNy","A major variant detected by week 39 in one of the patients that induced a CTL response.","Karlsson2007"
"54556","SL9","634","B","","","Gag","77","85","p17(77-85)","1018..1044","A*02","SLYNTVATL","SLfNTiATL","Y3F, V6I","Y79F, V82I","DR, E","diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy","Variant detected by week 63. Lower magnitude responses than wt and V/I mutant. Positive selection. Seen with upstream changes E62G/V/A, where the 62A mutation persisted and is suggested to reduce fitness cost of the Y/F escape mutation.","Karlsson2007"
"54556","SL9","635","B","","","Gag","77","85","p17(77-85)","1018..1044","A*02","SLYNTVATL","SLYNaiATL","T5A, V6I","T81A, V82I","IE","inferred escape","CD8 T-cell Elispot - IFNy","Author tabulates this variant detected in 1/14 clones at week 39 in patients. OP428 as viral escape. No CTL response detected.","Karlsson2007"
"54556","SL9","636","B","","","Gag","77","85","p17(77-85)","1018..1044","A*02","SLYNTVATL","SLcNTiATL","Y3C, V6I","Y79C, V82I","IE","inferred escape","CD8 T-cell Elispot - IFNy","Author tabulates this variant as a viral escape, detected in 1/12 clones at week 63 in patient OP428. No CTL response detected.","Karlsson2007"
"1649",,"670","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLFNTVATL","SLyNTVATL","F3Y","F79Y","SF","susceptible form","CD8 T-cell Elispot - IFNy","This epitope and the variant were recognized by 22/26 HLA-A2+ infected women but only by 1/10 HIV-exposed, persistently seronegative women (HEPS). Responses to the epitope and the variant were much higher after HIV-1 seroconversion in previous HEPS.","Kaul2001a"
"53755","SL9","753","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTiATL","Y3F, V6I","Y79F, V82I","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Chromium-release assay","Variant was found in the beginning and at the end of a 7 year period in a patient. It was not recognized by patient CTLs.","Koibuchi2005a"
"53755","SL9","754","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTiAaL","Y3F, V6I, T8A","Y79F, V82I, T84A","OV","observed variant","","Variant was found in 1/22 clones at the beginning  of a 7 year period in a patient.","Koibuchi2005a"
"53755","SL9","755","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVAvL","Y3F, T8V","Y79F, T84V","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Chromium-release assay","Variant dominated in the middle of a 7 year period in a patient. It was not recognized by patient CTLs.","Koibuchi2005a"
"53755","SL9","756","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfsTVAvL","Y3F, N4S, T8V","Y79F, N80S, T84V","OV","observed variant","","Variant was found in 1/28 clones at the middle of a 7 year period in a patient.","Koibuchi2005a"
"53755","SL9","757","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVAvp","Y3F, T8V, L9P","Y79F, T84V, L85P","OV","observed variant","","Variant was found in 1/28 clones at the middle of a 7 year period in a patient.","Koibuchi2005a"
"53755","SL9","758","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTiAvL","Y3F, V6I, T8V","Y79F, V82I, T84V","OV","observed variant","","Variant was found at the end of a 7 year period in a patient.","Koibuchi2005a"
"53386","gag 77-85","1004","B","B","HIV-2","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVcvi","Y3F, A7C, T8V, L9I","Y79F, A83C, T84V, L85I","DR, E, SNSF, TCR","diminished response, escape documented in this paper, subtype-specific non-susceptible form, TCR related mutation","CD8 T-cell Elispot - IFNy","Naturally-occurring HIV-2 variant. It was not recognized well by CTLs from four A2+ HIV infected asymptomatic individuals. The variant bound to HLA-A2 with higher affinity than the wt epitope, indicating that the poor CTL recognition was due to inhibition of TCR recognition.","Lopes2003"
"53386","gag 77-85","1005","B","B","A","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVATL","Y3F","Y79F","DR, E, SNSF, TCR","diminished response, escape documented in this paper, subtype-specific non-susceptible form, TCR related mutation","CD8 T-cell Elispot - IFNy","Naturally-occurring clade A variant. It was poorly recognized by CTLs from some of the A2+ HIV infected asymptomatic individuals. The variant bound to HLA-A2 with higher affinity than the wt epitope, indicating that the poor CTL recognition was due to inhibition of TCR recognition.","Lopes2003"
"53386","gag 77-85","1006","B","B","G","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNaVATL","Y3F, T5A","Y79F, T81A","DR, E, SNSF, TCR","diminished response, escape documented in this paper, subtype-specific non-susceptible form, TCR related mutation","CD8 T-cell Elispot - IFNy","Naturally-occurring clade G variant. It was poorly recognized by CTLs from some of the A2+ HIV infected asymptomatic individuals. The variant bound to HLA-A2 with higher affinity than the wt epitope, indicating that the poor CTL recognition was due to inhibition of TCR recognition.","Lopes2003"
"53386","gag 77-85","1007","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLaNTVATL","Y3A","Y79A","DR, E, TCR","diminished response, escape documented in this paper, TCR related mutation","CD8 T-cell Elispot - IFNy","Artificially synthesized variant. It was poorly recognized by CTLs from some of the A2+ HIV infected asymptomatic individuals. The variant bound to HLA-A2 with higher affinity than the wt epitope, indicating that the poor CTL recognition was due to inhibition of TCR recognition.","Lopes2003"
"53386","gag 77-85","1008","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYaTVATL","N4A","N80A","DR, E, TCR","diminished response, escape documented in this paper, TCR related mutation","CD8 T-cell Elispot - IFNy","Artificially synthesized variant. It was poorly recognized by CTLs from some of the A2+ HIV infected asymptomatic individuals. The variant bound to HLA-A2 with higher affinity than the wt epitope, indicating that the poor CTL recognition was due to inhibition of TCR recognition.","Lopes2003"
"53386","gag 77-85","1009","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNaVATL","T5A","T81A","DR, E, TCR","diminished response, escape documented in this paper, TCR related mutation","CD8 T-cell Elispot - IFNy","Artificially synthesized variant. It was poorly recognized by CTLs from some of the A2+ HIV infected asymptomatic individuals. The variant bound to HLA-A2 with higher affinity than the wt epitope, indicating that the poor CTL recognition was due to inhibition of TCR recognition.","Lopes2003"
"53386","gag 77-85","1010","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTaATL","V6A","V82A","SF","susceptible form","CD8 T-cell Elispot - IFNy","The only artificially synthesized variant that did not abrogate recognition by CTLs from some of the A2+ HIV infected asymptomatic individuals. The variant bound to HLA-A2 with slightly reduced affinity than the wt epitope.","Lopes2003"
"53386","gag 77-85","1011","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTVAaL","T8A","T84A","DR, E, TCR","diminished response, escape documented in this paper, TCR related mutation","CD8 T-cell Elispot - IFNy","Artificially synthesized variant. It was poorly recognized by CTLs from some of the A2+ HIV infected asymptomatic individuals. The variant bound to HLA-A2 with higher affinity than the wt epitope, indicating that the poor CTL recognition was due to inhibition of TCR recognition.","Lopes2003"
"54495","SL9","1052","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTiATL","V6I","V82I","SF","susceptible form","Chromium-release assay, Sequence","This natural variant when tested in the presence of D3 TCR, Gag-specific CTL was susceptible.","Martinez-Hackert2006"
"54495","SL9","1053","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTiAvL","V6I, T8V","V82I, T84V","SF","susceptible form","Chromium-release assay, Sequence","This natural variant when tested in the presence of D3 TCR, Gag-specific CTL was susceptible.","Martinez-Hackert2006"
"54495","SL9","1054","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTVAvL","T8V","T84V","SF","susceptible form","Chromium-release assay, Sequence","This natural variant when tested in the presence of D3 TCR, Gag-specific CTL was susceptible.","Martinez-Hackert2006"
"54495","SL9","1055","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVATL","Y3F","Y79F","SF","susceptible form","Chromium-release assay, Sequence","This natural variant when tested in the presence of D3 TCR, Gag-specific CTL was susceptible and only very slightly less active than wild type SL9.","Martinez-Hackert2006"
"54495","SL9","1056","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTiAvL","Y3F, V6I, T8V","Y79F, V82I, T84V","SF","susceptible form","Chromium-release assay, Sequence","This natural variant when tested in the presence of D3 TCR, Gag-specific CTL was susceptible.","Martinez-Hackert2006"
"54495","SL9","1057","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVAvL","Y3F, T8V","Y79F, T84V","SF","susceptible form","Chromium-release assay, Sequence","This natural variant when tested in the presence of D3 TCR, Gag-specific CTL was susceptible.","Martinez-Hackert2006"
"54495","SL9","1058","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTiATL","Y3F, V6I","Y79F, V82I","SF","susceptible form","Chromium-release assay, Sequence","This natural variant when tested in the presence of D3 TCR, Gag-specific CTL was susceptible.","Martinez-Hackert2006"
"54495","SL9","1059","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNsVATL","T5S","T81S","SF","susceptible form","Chromium-release assay, Sequence","This natural variant when tested in the presence of D3 TCR, Gag-specific CTL was susceptible.","Martinez-Hackert2006"
"54495","SL9","1060","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYqTVATL","N4Q","N80Q","SF","susceptible form","Chromium-release assay, Sequence","This synthetic variant when tested in the presence of D3 TCR, Gag-specific CTL was susceptible.","Martinez-Hackert2006"
"54495","SL9","1061","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYlTVATL","N4L","N80L","SF","susceptible form","Chromium-release assay, Sequence","This synthetic variant when tested in the presence of D3 TCR, Gag-specific CTL was susceptible.","Martinez-Hackert2006"
"54495","SL9","1062","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","aLYNTVATL","S1A","S77A","SF","susceptible form","Chromium-release assay, Sequence","This synthetic variant when tested in the presence of D3 TCR, Gag-specific CTL was susceptible, indistinguishable from the wild type SL9.","Martinez-Hackert2006"
"54495","SL9","1063","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLaNTVATL","Y3A","Y79A","NSF","non-susceptible form","Chromium-release assay, Sequence","This synthetic variant when tested in the presence of D3 TCR, Gag-specific CTL elicited no response.","Martinez-Hackert2006"
"54495","SL9","1064","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYaTVATL","N4A","N80A","NSF","non-susceptible form","Chromium-release assay, Sequence","This synthetic variant when tested in the presence of D3 TCR, Gag-specific CTL elicited no response.","Martinez-Hackert2006"
"54495","SL9","1065","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTaATL","V6A","V82A","DR","diminished response","Chromium-release assay, Sequence","This synthetic variant when tested in the presence of D3 TCR, Gag-specific CTL has very low activity.","Martinez-Hackert2006"
"54495","SL9","1066","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTVAaL","T8A","T84A","DR","diminished response","Chromium-release assay, Sequence","This synthetic variant when tested in the presence of D3 TCR, Gag-specific CTL was less active.","Martinez-Hackert2006"
"54495","SL9","1067","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","aLYNTaAaL","S1A, V6A, T8A","S77A, V82A, T84A","NSF","non-susceptible form","Chromium-release assay, Sequence","This synthetic variant when tested in the presence of D3 TCR, Gag-specific CTL elicited no response.","Martinez-Hackert2006"
"54495","SL9","1068","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNvVATL","T5V","T81V","NSF","non-susceptible form","Chromium-release assay, Sequence","This synthetic variant when tested in the presence of D3 TCR, Gag-specific CTL elicited no response.","Martinez-Hackert2006"
"74","SL9","1111","","B","A","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLfNaiAvL","Y3F, T5A, V6I, T8V","Y79F, T81A, V82I, T84V","SNSF","subtype-specific non-susceptible form","Chromium-release assay","Recombinant vaccinia virus containing this Clade A circulating Ugandan variant was not recognized by a CTL clone from a  Clade B-infected  patient.","McAdam1998"
"74","SL9","1112","","B","A","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLfNTVATL","Y3F","Y79F","SNSF","subtype-specific non-susceptible form","Chromium-release assay","Recombinant vaccinia virus containing this Clade A circulating Ugandan variant was not recognized by a CTL clone from a  Clade B-infected  patient.","McAdam1998"
"74","SL9","1113","","B","D","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLYNTiATL","V6I","V82I","SSF","subtype-specific susceptible form","Chromium-release assay","Recombinant vaccinia virus containing this Clade D circulating Ugandan variant was well recognized by a CTL clone from a  Clade B-infected  patient.  A natural variant with the same substitution was found in the same Clade B carrying patient.","McAdam1998"
"53411","SLF","1349","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLFNTVATL","SLyNTVATL","F3Y","F79Y","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Positive selection on this epitope resulted in an escape by phylogenetic analysis. The variant peptide was less potent at inducing production of IFN-gamma than the index peptide.","Oxenius2004"
"53411","SLF","1350","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLFNTVATL","SLyNaVATL","F3Y, T5A","F79Y, T81A","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Positive selection on this epitope resulted in an escape by phylogenetic analysis. The variant peptide was less potent at inducing production of IFN-gamma than the index peptide.","Oxenius2004"
"101","SL9","1542","","B","A","Gag","77","85","p17(77-85)","1018..1044","A*0202, A2","SLYNTVATL","SLfNTVATL","Y3F","Y79F","SF","susceptible form","Chromium-release assay","Two HEPS Kenyan subjects cross-reacted to this B clade epitope and one of them elicited a stronger reaction to the A clade form, SLfNTVATL","Rowland-Jones1998"
"83","SL9","1555","","B, D","A","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVATL","Y3F","Y79F","OV","observed variant","Chromium-release assay","5/6 Kenyan HEPS subjects recognized this clade B epitope which differed from the clade A variant, SLfNTVATL.","RowlandJones1998b"
"82","SL9","1622","","B","B","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTVAvL","T8V","T84V","SF","susceptible form","Chromium-release assay","This naturally occurring, strain MANC variant, was recognized by a Patient LWF CTL clone.","Sipsas1997"
"82","SL9","1623","","B","B","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVAvL","Y3F, T8V","Y79F, T84V","SF","susceptible form","Chromium-release assay","This naturally occurring, strain NY5CG variant, was recognized by a Patient LWF CTL clone.","Sipsas1997"
"55395","Gag 77","1658","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVATL","Y3F","Y79F","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subjects Pt15, Pt18 carried this variant epitope, but cross-recognized the  challenge HXB2 sequence SLYNTVATL.  Subject Pt30 who carried the challenge epitope too did not recognize that HXB2 sequence.","Thorn2007"
"55395","Gag 77","1660","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTVAvL","T8V","T84V","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject P43 carried this variant epitope, but cross-recognized the challenge HXB2 sequence SLYNTVATL.  Subject Pt21 who also carried the variant epitope did not recognize HXB2  sequence.","Thorn2007"
"55395","Gag 77","1661","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTVATi","L9I","L85I","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt23 carried this variant epitope, and recognized the challenge HXB2 sequence SLYNTVATL.","Thorn2007"
"55395","Gag 77","1662","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVATi","Y3F, L9I","Y79F, L85I","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt41 carried this variant epitope, and recognized the challenge HXB2 sequence SLYNTVATL.","Thorn2007"
"55395","Gag 77","1663","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLnNaiAvL","Y3N, T5A, V6I, T8V","Y79N, T81A, V82I, T84V","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt17 carried this variant epitope, and did not recognize the challenge HXB2 sequence SLYNTVATL.","Thorn2007"
"55700","SL9","1830","","","","Gag","77","85","p17(77-85)","1018..1044","A*02","SLYNTVATL","SLYNTiATL","V6I","V82I","SF","susceptible form","Sequence, TCR binding","This natural variant was found in 1/12 proviruses of patient 868 and bound isolated wild type TCR with high affinity. High-affinity, mutated a11b6 TCR also bound this variant.","Varela-Rohena2008"
"55700","SL9","1831","","","","Gag","77","85","p17(77-85)","1018..1044","A*02","SLYNTVATL","SLfNTVATL","Y3F","Y79F","SF","susceptible form","Intracellular cytokine staining, Sequence, TCR binding","This naturally occurring variant was recognized by a CTL line from patient 868. Wild type 868 TCR also bound this variant. Binding to high-affinity TCR (a11b6) increased the magnitude of cytokine response.","Varela-Rohena2008"
"55700","SL9","1832","","","","Gag","77","85","p17(77-85)","1018..1044","A*02","SLYNTVATL","SLfNTVAvL","Y3F, T8V","Y79F, T84V","SF","susceptible form","Intracellular cytokine staining, Sequence, TCR binding","This naturally occurring variant was recognized by a CTL line from patient 868. Wild type 868 TCR also bound this variant. Binding to high-affinity TCR (a11b6) increased the magnitude of cytokine response, though this binding was the weakest of all variants tested.","Varela-Rohena2008"
"55700","SL9","1833","","","","Gag","77","85","p17(77-85)","1018..1044","A*02","SLYNTVATL","SLfNTiAvL","Y3F, V6I, T8V","Y79F, V82I, T84V","SF","susceptible form","Intracellular cytokine staining, Sequence, TCR binding","This naturally occurring variant was recognized by a CTL line from patient 868 and found in 11/12 sequenced proviruses.   Wild type 868 TCR also bound this variant.  Binding to high-affinity TCR (a11b6) increased the magnitude of cytokine response.","Varela-Rohena2008"
"55700","SL9","1834","","","","Gag","77","85","p17(77-85)","1018..1044","A*02","SLYNTVATL","SLhNTVATL","Y3H","Y79H","E, TCR","escape documented in this paper, TCR related mutation","Sequence, Surface Plasmon Resonance, TCR binding","This unusual SL9 escape variant was recognized poorly by patient 868 CTL, suggesting that viruses with this mutation would escape wild type TCR recognition.  High affinity a11b6 TCR, however, did bind this variant well enough by surface plasmon resonance to predict recognition.","Varela-Rohena2008"
"52791","SL9","1856","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVATL","Y3F","Y79F","E, SF, TCR","escape documented in this paper, susceptible form, TCR related mutation","Chromium-release assay, Relative replication capacity assay, Sequence","CTL Clone 161JxA14 recognizes this variant but Clone 18030D23 from a different subject does not. Both clones recognize SL9 index sequence similarly.","Yang2003"
"52791","SL9","1857","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTiATL","V6I","V82I","E","escape documented in this paper","Chromium-release assay, Sequence","After 2 weeks of selective pressure by culturing with 1 of 4 SL9-specific clones i.e. 161JxA14, this variant arose and was not recognized.","Yang2003"
"52791","SL9","1858","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTiAvL","V6I, T8V","V82I, T84V","E, NSF, SF, TCR","escape documented in this paper, non-susceptible form, susceptible form, TCR related mutation","Chromium-release assay, Relative replication capacity assay, Sequence","CTL Clone 18030D23 recognizes this variant but Clone 161JxA14 from a different subject does not. Both clones recognize SL9 Clade B index sequence similarly.  Since the clones are from different HIV-1 infected subjects, with different TCR sequences, TCR is seen to contribute to escape differentially in this instance.","Yang2003"
"52791","SL9","1859","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTiATL","Y3F, V6I","Y79F, V82I","E, NSF, SF, TCR","escape documented in this paper, non-susceptible form, susceptible form, TCR related mutation","Chromium-release assay, Relative replication capacity assay, Sequence","CTL Clone 18030D23 recognizes this variant but Clone 161JxA14 from a different subject does not. Both clones recognize SL9 index sequence similarly.  Since the clones are from different HIV-1 infected subjects, with different TCR sequences, TCR is seen to contribute to escape differentially in this instance.","Yang2003"
"52791","SL9","1860","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNlVAvL","T5L, T8V","T81L, T84V","E, NSF, TCR","escape documented in this paper, non-susceptible form, TCR related mutation","Chromium-release assay, Relative replication capacity assay, Sequence","CTL Clones 18030D23 and  161JxA14 from different subjects do not recognize this variant. Both clones recognize SL9 index sequence similarly.  Since the clones are from different HIV-1 infected subjects, with different TCR sequences, TCR is seen to contribute to escape differentially in this instance.","Yang2003"
"52791","SL9","1861","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTVAaL","T8A","T84A","OV","observed variant","Chromium-release assay, Sequence","This minority epitope variant was seen after 2 weeks of selection by SL9-specific clone 18030D23.","Yang2003"
"53157",,"1878","","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLYNTiATL","V6I","V82I","E, P, SF","escape documented in this paper, processing, susceptible form","Chromium-release assay","Index epitope SL9 and this variant escaped from killing by Gag-epitope-specific CTL clonal lines when presented as endogenously expressed sequences on transformed cells, but were recognized when exogenously loaded as synthetic peptide.  A processing or epitope presentation mutation is assumed.","Yokomaku2004"
"53157",,"1881","","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SvYNTVATL","L2V","L78V","E, P, SF","escape documented in this paper, processing, susceptible form","Chromium-release assay","This variant escaped from killing by Gag-epitope-specific CTL clonal lines when presented as an endogenously expressed sequence on transformed cells, but was recognized when exogenously loaded as synthetic peptide.  A processing or epitope presentation mutation is assumed.","Yokomaku2004"
"53157",,"1882","","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLYNlVATL","T5L","T81L","E, P, SF","escape documented in this paper, processing, susceptible form","Chromium-release assay","This variant escaped from killing by Gag-epitope-specific CTL clonal lines when presented as an endogenously expressed sequence on transformed cells, but was recognized when exogenously loaded as synthetic peptide.  A processing or epitope presentation mutation is assumed.","Yokomaku2004"
"53157",,"1883","","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLfNTVAvL","Y3F, T8V","Y79F, T84V","E, P, SF","escape documented in this paper, processing, susceptible form","Chromium-release assay","This variant escaped from killing by Gag-epitope-specific CTL clonal lines when presented as an endogenously expressed sequence on transformed cells, but was recognized when exogenously loaded as synthetic peptide.  A processing or epitope presentation mutation is assumed.","Yokomaku2004"
"54495","SL9","2224","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNlVAvL","T5L, T8V","T81L, T84V","E, TCR","escape documented in this paper, TCR related mutation","Chromium-release assay, Sequence","This natural variant when tested in the presence of D3 TCR, Gag-specific CTL abolished CTL recognition, but was still able to bind HLA-A2.","Martinez-Hackert2006"
"54495","SL9","2248","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNlVAvL","T5L, T8V","T81L, T84V","E, TCR","escape documented in this paper, TCR related mutation","Chromium-release assay, Sequence","This natural variant when tested in the presence of D3 TCR, Gag-specific CTL abolished CTL recognition, but was still able to bind HLA-A2.","Martinez-Hackert2006"
"54495","SL9","2250","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNaVATL","T5A","T81A","E, TCR","escape documented in this paper, TCR related mutation","Chromium-release assay, Sequence","This natural variant when tested in the presence of D3 TCR, Gag-specific CTL abolished CTL recognition, but was still able to bind HLA-A2.","Martinez-Hackert2006"
"54495","SL9","2251","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNaiATL","T5A, V6I","T81A, V82I","E, TCR","escape documented in this paper, TCR related mutation","Chromium-release assay, Sequence","This natural variant when tested in the presence of D3 TCR, Gag-specific CTL abolished CTL recognition, but was still able to bind HLA-A2.","Martinez-Hackert2006"
"54495","SL9","2252","B","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNlVAvL","T5L, T8V","T81L, T84V","E, TCR","escape documented in this paper, TCR related mutation","Chromium-release assay, Sequence","This natural variant when tested in the presence of D3 TCR, Gag-specific CTL abolished CTL recognition, but was still able to bind HLA-A2.","Martinez-Hackert2006"
"54497","SL9","2256","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTVAvL","T8V","T84V","DR, SF","diminished response, susceptible form","","This variant was recognized by both SL9-CTLs and by the T/A-variant CTLs from two patients, but to somewhat lesser extent than the wt epitope in one of the patients.","Kan-Mitchell2006"
"55395","Gag 77","2264","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SvYNTVATL","L2V","L78V","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt33 carried this variant, and did not recognize the challenge HXB2  SLYNTVATL.","Thorn2007"
"55700","SL9","2279","","","","Gag","77","85","p17(77-85)","1018..1044","A*02","SLYNTVATL","SLYaaaAaL","N4A, T5A, V6A, T8A","N80A, T81A, V82A, T84A","SF","susceptible form","TCR binding","A patient 868 CTL line showed some recognition of this multiply substituted peptide.","Varela-Rohena2008"
"57381","SL9","2340","B","B","B","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLYNTiAvL","V6I, T8V","V82I, T84V","LE","literature escape","CD8 T-cell Elispot - IFNy, Chromium-release assay","SL9 variant V82I/T84V, SLYNTiAvL, was recognized by different TCR mutants with differing functional avidities.","Bennett2010"
"57381","SL9","2341","B","B","B","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLfNTVATL","Y3F","Y79F","LE","literature escape","CD8 T-cell Elispot - IFNy, Chromium-release assay","SL9 variant Y79F, SLfNTVATL, was recognized by different TCR mutants with differing functional avidities.","Bennett2010"
"57381","SL9","2342","B","B","B","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLYNTiATL","V6I","V82I","LE","literature escape","CD8 T-cell Elispot - IFNy, Chromium-release assay","SL9 variant V82I, SLYNTiATL, was recognized by different TCR mutants with differing functional avidities.","Bennett2010"
"57719",,"2617","","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLfNTVATL","Y3F","Y79F","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Variant SLfNTVATL was seen in patient I09.","Vollbrecht2010"
"57719",,"2618","","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLYNTiATL","V6I","V82I","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Variant SLYNTiAL was seen in patients I11, I07 and C06.","Vollbrecht2010"
"57719",,"2619","","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLfNTiATL","Y3F, V6I","Y79F, V82I","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Variant SLfNTiATL was seen in patients I07.","Vollbrecht2010"
"57959","SL9","2690","B","B","B","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVVTL","SLYNTVaTL","V7A","V83A","SF","susceptible form","CD8 T-cell Elispot - IFNy","SLYNTVVTL underwent adaptation to neo-epitope SLYNTVaTL. 4 subjects had higher EliSpot responses to the neo-epitope than to the non-adapted form.","Keane2012"
"58010","SL9","2705","B","B","B","Gag","77","85","p17(77-85)","1018..1044","A*02","SLYNTVATL","SLYNTVAvL","T8V","T84V","A, P","HLA association, processing","","A2-SL9 has known HLA-associated mutants (T8V, Y3F, V6I, V6I/T8V, Y3F/V6I). All 5 mutants displayed severely reduced half-lives.","Lazaro2011"
"58010","SL9","2706","B","B","B","Gag","77","85","p17(77-85)","1018..1044","A*02","SLYNTVATL","SLfNTVATL","Y3F","Y79F","A, P","HLA association, processing","","A2-SL9 has known HLA-associated mutants (T8V, Y3F, V6I, V6I/T8V, Y3F/V6I). All 5 mutants displayed severely reduced half-lives.","Lazaro2011"
"58010","SL9","2707","B","B","B","Gag","77","85","p17(77-85)","1018..1044","A*02","SLYNTVATL","SLYNTiATL","V6I","V82I","A, P","HLA association, processing","","A2-SL9 has known HLA-associated mutants (T8V, Y3F, V6I, V6I/T8V, Y3F/V6I). All 5 mutants displayed severely reduced half-lives.","Lazaro2011"
"58010","SL9","2708","B","B","B","Gag","77","85","p17(77-85)","1018..1044","A*02","SLYNTVATL","SLYNTiAvL","V6I, T8V","V82I, T84V","A, P","HLA association, processing","","A2-SL9 has known HLA-associated mutants (T8V, Y3F, V6I, V6I/T8V, Y3F/V6I). All 5 mutants displayed severely reduced half-lives.","Lazaro2011"
"58010","SL9","2709","B","B","B","Gag","77","85","p17(77-85)","1018..1044","A*02","SLYNTVATL","SLfNTiATL","Y3F, V6I","Y79F, V82I","A, P","HLA association, processing","","A2-SL9 has known HLA-associated mutants (T8V, Y3F, V6I, V6I/T8V, Y3F/V6I). All 5 mutants displayed severely reduced half-lives.","Lazaro2011"
"57182","SL9","2963","B","B","B","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLYNTVAvL","T9V","T85V","DHB, E, LE, SF","diminished HLA binding or increased off-rate, escape documented in this paper, literature escape, susceptible form","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","CTL selection at TCR contact residues is predicted to drive SL9 (SLYNTVATL) to SLYNTVAvL, reversion to SL9 is predicted to result from selection for optimal viral growth.  This variant did not bind HLA-A*02 in vitro; and could not elicit response in 2/3 chronically-infected, untreated patients, but showed a complete EliSpot response in the other patient when compared to that elicited by wt peptide SL9.  The authors designate all T84V-mutation containing peptides to be escapes.","Tenzer2009"
"57182","SL9","2965","B","B","B","Gag","77","85","p17(77-85)","1018..1044","A*0201","{r}SLYNTVATL","{k}SLfNTVAvL","-1K, Y4F, T9V","-77K, Y80F, T85V","LE","literature escape","Sequence","CTL selection at TCR contact residues is predicted to drive {k}SLYNTVAvL (SL9-V) to {k}SLfNTVAvL (SL9-KFV); reversion to SL9-V is predicted to result from selection for optimal viral growth.","Tenzer2009"
"57182","SL9","2966","B","B","B","Gag","77","85","p17(77-85)","1018..1044","A*0201","{r}SLYNTVATL","{k}SLfNTiAvL","-1K, Y4F, V7I, T9V","-77K, Y80F, V83I, T85V","LE","literature escape","Sequence","CTL selection at TCR contact residues is predicted to drive {k}SLfNTVAvL (SL9-KFV) or {k}SLfNTiATL(SL9-KFI) or {r}SLFNTiAvL(SL9-IV) to {k}SLfNTiAvL (SL9-KFIV), reversion to SL9-KFV is predicted to result from selection for optimal viral growth.","Tenzer2009"
"57182","SL9","2967","B","B","B","Gag","77","85","p17(77-85)","1018..1044","A*0201","{r}SLYNTVATL","{k}SLYNTVATL","-1K","-77K","LE","literature escape","Sequence","Epitope rSLYNTVATL is seen to vary to {k}SLYNTVATL (SL9-K).","Tenzer2009"
"57182","SL9","2968","B","B","B","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLfNTVATL","Y3F","Y79F","E, LE, SF","escape documented in this paper, literature escape, susceptible form","CD8 T-cell Elispot - IFNy, HLA binding, Longitudinal study","CTL selection at TCR contact residues is predicted to drive SL9 (SLYNTVATL) to SLfNTVATL (SL9-F); reversion to SL9 is predicted to result from selection for optimal viral growth.  This variant showed a slight increase in EliSpot responses in 2/3 chronically-infected, untreated patients when compared to SL9.","Tenzer2009"
"57182","SL9","2969","B","B","B","Gag","77","85","p17(77-85)","1018..1044","A*0201","{r}SLYNTVATL","{k}SLfNTiATL","-1K, Y4F, V7I","-77K, Y80F, V83I","LE","literature escape","Sequence","CTL selection at TCR contact residues is predicted to drive SL9-KF {k}SLfNTVATL to {k}SLfNTiATL (SL9-KFI), reversion to SL9-KF is predicted to result from selection for optimal viral growth.","Tenzer2009"
"57182","SL9","2970","B","B","B","Gag","77","85","p17(77-85)","1018..1044","A*0201","{r}SLYNTVATL","{k}SLfNTVATL","-1K, Y4F","-77K, Y80F","LE","literature escape","Sequence","CTL selection at TCR contact residues is predicted to drive epitope {k}SLYNTVATL (SL9) to variant, {k}SLfNTVATL (SL9-KF).","Tenzer2009"
"57182","SL9","2971","B","B","B","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLYNTiATL","V6I","V82I","DHB, DR, E, LE, SF","diminished HLA binding or increased off-rate, diminished response, escape documented in this paper, literature escape, susceptible form","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","CTL selection at TCR contact residues is predicted to drive SL9 (SLYNTVATL) to SLYNTiATL (SL9-I); reversion to SL9 is predicted to result from selection for optimal viral growth.  This variant shows a loss of binding to HLA-A*02 in vitro; and is unable to generate a CTL response in 1 chronically-infected, untreated patient, with slight decrease in EliSpot in 2 others as compared to wt peptide SL9.  The authors refer to all V82I mutation-containing peptides as escapes.","Tenzer2009"
"57182","SL9","2972","B","B","B","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLYNTiAvL","V6I, T8V","V82I, T84V","DHB, E, LE, SF","diminished HLA binding or increased off-rate, escape documented in this paper, literature escape, susceptible form","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","CTL selection at TCR contact residues is predicted to drive SL9-I (SLYNTiATL) to SLYNTiAvL (SL9-IV); reversion to SL9-I is predicted to result from selection for optimal viral growth.  This variant could not bind HLA-A*02 in vitro; and did not elicit EliSpot responses in 2/3 chronically-infected, untreated patients, but it showed an increased CTL response in the third patient as compared to WT SL9. The authors designate all V82I and T84V mutation-containing peptides as escapes.","Tenzer2009"
"85","SL9","3233","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVATL","Y3F","Y79F","OV","observed variant","Chromium-release assay, HLA binding","Natural 3F variant SLfNTVATL, was found in patients 001 and 008.  Variant peptide bound HLA-A*02 at a relative binding of 109% compared to SL9 index peptide.  Lysis is abrogated in CTL line 9300868 at lower concentrations, but occurs in CTL line 003.","Sewell1997"
"85","SL9","3234","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTVAvL","Y3F, T8V","Y79F, T84V","DHB","diminished HLA binding or increased off-rate","Chromium-release assay, HLA binding","Natural 3F,8V variant SLfNTVAvL, was found in patients 001 and 008.  Variant peptide bound HLA-A*02 at a relative binding of 72% compared to SL9 index peptide.  Lysis is abrogated in CTL line 9300868 at lower concentrations, but occurs in CTL line 003.","Sewell1997"
"85","SL9","3235","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLsNTVATL","Y3S","Y79S","DHB","diminished HLA binding or increased off-rate","Chromium-release assay, HLA binding","Natural 3S variant SLsNTVATL, was found in patient 008.  Variant peptide bound HLA-A*02 at a relative binding of 84% compared to SL9 index peptide.  Lysis is abrogated in CTL lines 9300868 and 003 at lower concentrations.","Sewell1997"
"85","SL9","3236","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SsfNTVATL","L2S, Y3F","L78S, Y79F","OV","observed variant","Chromium-release assay, HLA binding","Natural 2S,3F variant SsfNTVATL, was found in patient 008.","Sewell1997"
"85","SL9","3237","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLlNTVATL","Y3L","Y79L","DHB","diminished HLA binding or increased off-rate","Chromium-release assay, HLA binding","Natural 3L variant SLlNTVATL, was found in patients 003 and 008.  Variant peptide bound HLA-A*02 at a relative binding of 76% compared to SL9 index peptide.  Lysis is abrogated in CTL lines 9300868 and 003 at lower concentrations.","Sewell1997"
"85","SL9","3238","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLcNTVATL","Y3C","Y79C","DHB","diminished HLA binding or increased off-rate","Chromium-release assay, HLA binding","Variant peptide SLcNTVATL bound HLA-A*02 at a relative binding of 86% compared to SL9 index peptide.  Lysis is abrogated in CTL lines 9300868 and 003 at lower concentrations.","Sewell1997"
"85","SL9","3239","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTiATL","V6I","V82I","OV","observed variant","Chromium-release assay, HLA binding","Natural 6I variant SLYNTiATL, was found in patients 9300868 and 241.  Variant peptide bound HLA-A*02 at a relative binding of 114% compared to SL9 index peptide.  Lysis of CTL lines occurs at all concentrations of peptide tested.","Sewell1997"
"85","SL9","3240","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNaVATL","Y3F, T5A","Y79F, T81A","DHB","diminished HLA binding or increased off-rate","Chromium-release assay, HLA binding","3F, 5A variant peptide SLfNaVATL bound HLA-A*02 at a relative binding of 80% compared to SL9 index peptide, but is a strict antagonist.  Lysis is abrogated in CTL lines 9300868 and 003 at all concentrations tested.","Sewell1997"
"85","SL9","3241","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTiAvL","Y3F, V6I, T8V","Y79F, V82I, T84V","DHB","diminished HLA binding or increased off-rate","Chromium-release assay, HLA binding","3F, 6I, 8V variant peptide SLfNTiAvL bound HLA-A*02 at a relative binding of 48% compared to SL9 index peptide.  Lysis is abrogated in CTL line 9300868 but occurs in CTL line 003.","Sewell1997"
"85","SL9","3242","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLfNTiATL","Y3F, V6I","Y79F, V82I","OV","observed variant","Chromium-release assay, HLA binding","3F, 6I variant peptide SLfNTiATL bound HLA-A*02 at a relative binding of 100% compared to SL9 index peptide.  Lysis occurs in both CTL lines 9300868 and 003.","Sewell1997"
"85","SL9","3243","","","","Gag","77","85","p17(77-85)","1018..1044","A2","SLYNTVATL","SLYNTiAvL","V6I, T8V","V82I, T84V","DHB","diminished HLA binding or increased off-rate","Chromium-release assay, HLA binding","6I, 8V variant peptide SLYNTiAvL was found in patient 9300868 and bound HLA-A*02 at a relative binding of 58% compared to SL9 index peptide.  Lysis occurs in both CTL lines 9300868 and 003.","Sewell1997"
"52308",,"3244","","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLfNTVATL","Y3F","Y79F","SF","susceptible form","","SLfNTVATL was a recognized variant.","Schoenbach2002, Sewell1997"
"52308",,"3245","","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLYNTiATL","V6I","V82I","SF","susceptible form","","SLYNTiATL was a recognized variant.","Schoenbach2002, Sewell1997"
"52308",,"3246","","","","Gag","77","85","p17(77-85)","1018..1044","A*0201","SLYNTVATL","SLYNTVAvL","T8V","T84V","SF","susceptible form","","SLYNTVAvL was a recognized variant.","Schoenbach2002, Sewell1997"
"59229",,"3368","B","B","B","Gag","77","85","p17(77-85)",,"A*0201","SLFNTVATL","SLFNTVAAL","T8A","T84A","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence","First variant to arise; seen only in early post-seroconversion period; Elispot response <100 SFC/10<sup>6</sup>PBMC.","Melhem2014"
"59229",,"3369","B","B","B","Gag","77","85","p17(77-85)",,"A*0201","SLFNTVATL","SLFNTVATP","L9P","L85P","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence","Second variant to arise; seen only in early post-seroconversion period; Elispot response <50 SFC/10<sup>6</sup>PBMC.","Melhem2014"
"59229",,"3370","B","B","B","Gag","77","85","p17(77-85)",,"A*0201","SLFNTVATL","SLFSTVATL","N4S","N80S","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Third variant to arise; seen only in early post-seroconversion period; zero Elispot response.","Melhem2014"
"59229",,"3371","B","B","B","Gag","77","85","p17(77-85)",,"A*0201","SLFNTVATL","SLFNTIATL","V6I","V82I","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Fourth variant to arise; seen only in late post-seroconversion period; Elispot response <100 SFC/10<sup>6</sup>PBMC.","Melhem2014"
"59229",,"3372","B","B","B","Gag","77","85","p17(77-85)",,"A*0201","SLFNTVATL","SLYNTVATL","F3Y","F79Y","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Fifth variant to arise; seen only in late post-seroconversion period; positive Elispot response <50 SFC/10<sup>6</sup>PBMC.","Melhem2014"
"57298","SY10","2988","B","B","B","Gag","77","86","p17(77-86)","1018..1047","A*02","SLYNTVATLY","SLYNTVAvLY","T8V","T84V","DHB, E, SF","diminished HLA binding or increased off-rate, escape documented in this paper, susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Variant SLYNTVAvLY could not bind HLA-A*02 in vivo; but did elicit ex-vivo EliSpot responses in at least 1 of 3 chronically-infected, untreated patients.  The authors refer to all T84V mutation-containing peptides as escapes.","Tenzer2009"
"57298","SY10","2989","B","B","B","Gag","77","86","p17(77-86)","1018..1047","A*02","SLYNTVATLY","SLYNTiATLY","V6I","V82I","DHB, E, SF","diminished HLA binding or increased off-rate, escape documented in this paper, susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Variant SLYNTiATLY could not bind HLA-A*02 in vivo; but did elicit ex-vivo EliSpot responses in at least 2 of 3 chronically-infected, untreated patients.  The authors refer to all V82I mutation-containing peptides as escapes.","Tenzer2009"
"57298","SY10","2990","B","B","B","Gag","77","86","p17(77-86)","1018..1047","A*02","SLYNTVATLY","SLYNTiAvLY","V6I, T8V","V82I, T84V","DHB, E, SF","diminished HLA binding or increased off-rate, escape documented in this paper, susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Variant SLYNTiAvLY could not bind HLA-A*02 in vivo; but did elicit ex-vivo EliSpot responses in at least 1 of 3 chronically-infected, untreated patients.  The authors refer to all V82I and T84V mutation-containing peptides as escapes.","Tenzer2009"
"57298","SY10","2991","B","B","B","Gag","77","86","p17(77-86)","1018..1047","A*02","SLYNTVATLY","SLfNTVATLY","Y3F","Y79F","DHB, E, SF","diminished HLA binding or increased off-rate, escape documented in this paper, susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Variant SLfNTVATLY could not bind HLA-A*02 in vitro; but did elicit ex-vivo EliSpot responses in at least 2 of 3 chronically-infected, untreated patients.  The authors refer to all Y79F mutation-containing peptides as escapes.","Tenzer2009"
"57298","SY10","2992","B","B","B","Gag","77","86","p17(77-86)","1018..1047","A*02","SLYNTVATLY","SLfNTiAvLY","Y3F, V6I, T8V","Y79F, V82I, T84V","DHB, E, SF","diminished HLA binding or increased off-rate, escape documented in this paper, susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Variant SLfNTiAvLY could not bind HLA-A*02 in vitro; but did elicit ex-vivo EliSpot responses in at least 2 of 3 chronically-infected, untreated patients.  The authors refer to all Y79F, V82I and T84V mutation-containing peptides as escapes.","Tenzer2009"
"57298","SY10","2993","B","B","B","Gag","77","86","p17(77-86)","1018..1047","A*02","SLYNTVATLY","SLfNTVAvLY","Y3F, T8V","Y79F, T84V","DHB, E, SF","diminished HLA binding or increased off-rate, escape documented in this paper, susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Variant SLfNTVAvLY could not bind HLA-A*02 in vitro; but did elicit ex-vivo EliSpot responses in at least 1 of 3 chronically-infected, untreated patients.  The authors refer to all Y79F mutation-containing peptides as escapes.","Tenzer2009"
"57298","SY10","2994","B","B","B","Gag","77","86","p17(77-86)","1018..1047","A*02","SLYNTVATLY","SLfNTiATLY","Y3F, V6I","Y79F, V82I","DHB, E, SF","diminished HLA binding or increased off-rate, escape documented in this paper, susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Variant SLfNTiATLY could not bind HLA-A*02 in vitro; but did elicit ex-vivo EliSpot responses in at least 2 of 3 chronically-infected, untreated patients.  The authors refer to all Y79F mutation-containing peptides as escapes.","Tenzer2009"
"53612",,"64","A, D","","","Gag","77","91","p17(77-91)","1018..1062","A*0201, A*3002","SLYNTVATLYCVHQR","SLfNTVATLYCVHQR","Y3F","Y79F","SF","susceptible form","CD8 T-cell Elispot - IFNy","The sequence contains a known A2 epitope and a known A*3002 epitope, and the subjects recognizing it each carry an HLA with a previously-defined restriction. The viral sequence isolated from the subjects was slFntvatlycvhqr, and was reactive.","Barugahare2005"
"55939","LY9(p17)","1906","B","B","B","Gag","78","86","p17(78-86)","1021..1047","","LFNTVATLY","LyNTVATLY","F2Y","F79Y","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-A29 restricted and possibly HLA-B44 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"55634",,"14","CRF02_AG, CRF01_AE","AG","AE","Gag","79","90","p17(79-90)","1024..1059","","YNIVATLWCVHQ","YNtVATLWCVHQ","I3T","I81T","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","1 subject responded to peptide YNIVATLWCVHQ from subtype CRF02_AG and to peptide YNtVATLWCVHQ from subtype CRF01_AE.","Aidoo2008"
"55367","Gag 80","1664","","","","Gag","80","88","p17(80-88)","1027..1053","A2","NTVATLYCV","NaiAvLYCV","T2A, V3I, T5V","T81A, V82I, T84V","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subjects Pt15, Pt16, Pt18, Pt30, Pt33 and Pt35 carried this HXB2  epitope.  All of the above were unable to recognize it however, except for Pt15 who did recognize the HXB2 sequence.  Only Pt17 carried the variant NaiAvLYCV and was unable to cross-recognize the challenge HXB2 sequence.","Thorn2007"
"55367","Gag 80","1665","","","","Gag","80","88","p17(80-88)","1027..1053","A2","NTVATLYCV","NTVAvLYCV","T5V","T84V","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subjects Pt21 and Pt43 carried this variant and were unable to recognize the challenge HXB2 form, NTVATLYCV.","Thorn2007"
"55367","Gag 80","1666","","","","Gag","80","88","p17(80-88)","1027..1053","A2","NTVATLYCV","NTVATiYCV","L6I","L85I","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subjects Pt23 and Pt41 carried this variant and were unable to recognize the challenge HXB2 form, NTVATLYCV.","Thorn2007"
"55367","Gag 80","1667","","","","Gag","80","88","p17(80-88)","1027..1053","A2","NTVATLYCV","NTVATLYCV","","","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt21 carried this variant and was unable to recognize the challenge HXB2 form, NTVATLYCV.","Thorn2007"
"57304","IR10","2964","B","B","B","Gag","82","91","p17(82-91)","1033..1062","A*11","IAVLYCVHQR","IvVLYCVHQR","A2V","A83V","OV","observed variant","CD8 T-cell Elispot - IFNy, HLA binding","Variant A11-VR10, IvVLYCVHQR, may also be present and is restricted by the same HLA, A*11.","Tenzer2009"
"57708",,"2600","","","","Gag","82","92","p17(82-92)","1033..1065","A*11","VATLYCVHQRI","VvTLYCVHQRI","A2V","A83V","SF","susceptible form","CD8 T-cell Elispot - IFNy","Gag variant at anchor position 2, VvTLYCVHQRI, also elicited CTL response but from week 24 after TI began in Patient 313.","Schweighardt2010"
"55635",,"15","CRF02_AG, CRF01_AE","AG","AE","Gag","83","94","p17(83-94)","1036..1071","","ATLWCVHQRIDI","ATLWCVHQRIev","D11E, I12V","D93E, I94V","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","1 subject responded to peptide ATLWCVHQRIDI from subtype CRF02_AG and to peptide ATLWCVHQRIev from subtype CRF01_AE.","Aidoo2008"
"52106",,"290","B","B","B","Gag","84","91","p17(84-91)","1039..1062","A*1101","TLYCVHQR","TLYCVHQk","R8K","R91K","SF","susceptible form","Chromium-release assay","Variant predominantly found in clade B. There was some CTL activity in PBMC from clade B patients stimulated with this epitope variant.","Fukada2002"
"52106",,"291","B","B","CRF01_AE","Gag","84","91","p17(84-91)","1039..1062","A*1101","TLYCVHQR","TLwCVHQR","Y3W","Y86W","OV","observed variant","","Variant predominantly found in clade E.","Fukada2002"
"52106",,"292","B","B","D","Gag","84","91","p17(84-91)","1039..1062","A*1101","TLYCVHQR","TLYCVHeR","Q7E","Q90E","OV","observed variant","","Variant predominantly found in clade D.","Fukada2002"
"107",,"412","","","","Gag","84","91","p17(84-91)","1039..1062","A11","TLYCVHQR","TLYCVHQk","R8K","R91K","SF","susceptible form","Chromium-release assay","Variant found in patient. It was recognized by patient CTLs and induced target specific lysis.","Harrer1998"
"107",,"413","","","","Gag","84","91","p17(84-91)","1039..1062","A11","TLYCVHQR","TLYCVHQq","R8Q","R91Q","DR","diminished response","Chromium-release assay","Variant found in patient. It was recognized by patient CTLs but less than the R/K variant, and only induced target specific lysis at high concentrations. This mutation did not abrogate virus replication.","Harrer1998"
"107",,"414","","","","Gag","84","91","p17(84-91)","1039..1062","A11","TLYCVHQR","TLYCVHeR","Q7E","Q90E","E","escape documented in this paper","Chromium-release assay","Variant found in patient. It was not able to induce target specific lysis. This mutation did not abrogate virus replication.","Harrer1998"
"54579","EL9","637","B","","","Gag","93","101","p17(93-101)","1066..1092","B*08","EVKDTKEAL","dVKDTKEAL","E1D","E93D","DR","diminished response","CD8 T-cell Elispot - IFNy","Variant found in one patient at week 63. A minor response to this variant, but the variant was eliminated by CTLs. R91G upstream mutation affects processing.","Karlsson2007"
"54579","EL9","638","B","","","Gag","93","101","p17(93-101)","1066..1092","B*08","EVKDTKEAL","EiKDTKEAL","V2I","V94I","IE","inferred escape","CD8 T-cell Elispot - IFNy","Author tabulates this variant detected in 9/14 clones at week 39 in patient OP428 as viral escape. No CTL response detected.","Karlsson2007"
"54579","EL9","639","B","","","Gag","93","101","p17(93-101)","1066..1092","B*08","EVKDTKEAL","kVKDTKEAL","E1K","E93K","IE","inferred escape","CD8 T-cell Elispot - IFNy","Author tabulates this variant detected in 1/11 clones at week 139 in patient  OP428 as viral escape. No CTL response detected.","Karlsson2007"
"54579","EL9","640","B","","","Gag","93","101","p17(93-101)","1066..1092","B*08","EVKDTKEAL","EVKDTKgAL","E7G","E99G","IE","inferred escape","CD8 T-cell Elispot - IFNy","Author tabulates this variant detected in 1/16 clones at week 15 in patient OP428 as viral escape. No CTL response detected.","Karlsson2007"
"55237",,"795","B, CRF01_AE","","B","Gag","93","101","p17(93-101)","1066..1092","B8","EIKDTKEAL","EvKDTKEAL","I2V","I94V","OV","observed variant","Sequence","Patient was superinfected with three strains, B1, B2 and CRF01_AE. This was the infecting variant  in B1.","Kozaczynska2007"
"55237",,"797","B, CRF01_AE","","B","Gag","93","101","p17(93-101)","1066..1092","B8","EIKDTKEAL","dvKDTKEAL","E1D, I2V","E93D, I94V","OV","observed variant","Sequence","Patient was superinfected with three strains, B1, B2 and CRF01_AE. This was the infecting variant  in B2 and it did not change over time.","Kozaczynska2007"
"55237",,"798","B, CRF01_AE","","CRF01_AE","Gag","93","101","p17(93-101)","1066..1092","B8","EIKDTKEAL","EIlDTKEAL","K3L","K95L","OV","observed variant","Sequence","Patient was superinfected with three strains, B1, B2 and CRF01_AE. This was the infecting variant  in CRF01_AE and it did not change over time.","Kozaczynska2007"
"53822",,"1308","B","","","Gag","93","101","p17(93-101)","1066..1092","B*0801","EVKDTKEAL","dVKgTKEAL","E1D, D4G","E93D, D96G","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","This variant was found in Donor2 but not transmitted to Recipient2.  The variant was not recognized by CTL.  Both donor and recipient carried the restricting HLA-B*0801 allele","Milicic2005"
"53822",,"1309","B","","","Gag","93","101","p17(93-101)","1066..1092","B*0801","EVKDTKEAL","dVKDTKEAL","E1D","E93D","E, SF","escape documented in this paper, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant was found in Donor2 and Recipient2  both of whom were restricting HLA-B*0801 carriers.  The variant was not recognized by CTL in Donor2, but was recognized in Recipient2 from whom it was driven out de novo in time.","Milicic2005"
"55237",,"2258","B, CRF01_AE","","B","Gag","93","101","p17(93-101)","1066..1092","B8","EIKDTKEAL","dIKDTKEAL","E1D","E93D","R","reversion","Sequence","Patient was superinfected with three strains, B1, B2 and CRF01_AE. This reversion variant developed in B1 to include 83% of the viruses within 4 years.","Kozaczynska2007"
"57704",,"2598","","","","Gag","93","101","p17(93-101)","1066..1092","B*08","EIKDTKEAL","EvKDTKEAL","I2V","I94V","SF","susceptible form","CD8 T-cell Elispot - IFNy","Gag variant EvKDTKEAL was recognized by CTL 48 weeks into TI, in Patient 311.","Schweighardt2010"
"57704",,"2599","","","","Gag","93","101","p17(93-101)","1066..1092","B*08","EIKDTKEAL","dvKDTKEAL","E1D, I2V","E93D, I94V","SF","susceptible form","CD8 T-cell Elispot - IFNy","Gag variant dvKDTKEAL was recognized by CTL 48 weeks into TI, in Patient 311.","Schweighardt2010"
"53223","Gag AQ9","507","B","","","Gag","119","127","p17(119-127)","1144..1170","","AADTGNSSQ","AADTGNgSQ","S7G","S125G","E","escape documented in this paper","","Variant dramatically reduced CTL recognition.","Jones2004"
"53223","Gag AQ9","508","B","","","Gag","119","127","p17(119-127)","1144..1170","","AADTGNSSQ","eADTGNSSQ","A1E","A119E","E","escape documented in this paper","","Variant dramatically reduced CTL recognition.","Jones2004"
"53223","Gag AQ9","509","B","","","Gag","119","127","p17(119-127)","1144..1170","","AADTGNSSQ","AADTkNSSQ","G5K","G123K","E","escape documented in this paper","","Variant dramatically reduced CTL recognition.","Jones2004"
"53223","Gag AQ9","510","B","","","Gag","119","127","p17(119-127)","1144..1170","","AADTGNSSQ","AADTrNSSQ","G5R","G123R","E","escape documented in this paper","","Variant dramatically reduced CTL recognition.","Jones2004"
"53223","Gag AQ9","511","B","","","Gag","119","127","p17(119-127)","1144..1170","","AADTGNSSQ","eADTGkSSQ","A1E, N6K","A119E, N124K","E","escape documented in this paper","","Variant dramatically reduced CTL recognition.","Jones2004"
"53223","Gag AQ9","512","B","","","Gag","119","127","p17(119-127)","1144..1170","","AADTGNSSQ","AADTGNSSk","Q9K","Q127K","E","escape documented in this paper","","Variant dramatically reduced CTL recognition.","Jones2004"
"53223","Gag AQ9","513","B","","","Gag","119","127","p17(119-127)","1144..1170","","AADTGNSSQ","AADTGsSSQ","N6S","N124S","E","escape documented in this paper","","Variant dramatically reduced CTL recognition.","Jones2004"
"53223","Gag AQ9","514","B","","","Gag","119","127","p17(119-127)","1144..1170","","AADTGNSSQ","tADTGNSns","A1T, S8N, Q9S","A119T, S126N, Q127S","E","escape documented in this paper","","Variant dramatically reduced CTL recognition.","Jones2004"
"53223","Gag AQ9","515","B","","","Gag","119","127","p17(119-127)","1144..1170","","AADTGNSSQ","AADTGNnnQ","S7N, S8N","S125N, S126N","E","escape documented in this paper","","Variant dramatically reduced CTL recognition.","Jones2004"
"53223","Gag AQ9","516","B","","","Gag","119","127","p17(119-127)","1144..1170","","AADTGNSSQ","A-DTGNSSQ","A2-","A120-","OV","observed variant","","1/15 clones at time point 35.","Jones2004"
"53223","Gag AQ9","517","B","","","Gag","119","127","p17(119-127)","1144..1170","","AADTGNSSQ","AAgTGNSSQ","D3G","D121G","OV","observed variant","","1/15 clones at time point 55.","Jones2004"
"53223","Gag AQ9","518","B","","","Gag","119","127","p17(119-127)","1144..1170","","AADTGNSSQ","AADTeNSSQ","G5E","G123E","OV","observed variant","","2/15 clones at time point 55 and 1/15 clones at time point 65.","Jones2004"
"53223","Gag AQ9","2285","B","","","Gag","119","127","p17(119-127)","1144..1170","","AADTGNSSQ","AADTGN-S-(ss)","S7-, Q9-, -(9.1)S, -(9.2)S","S125-, Q127-, -(127.1)S, -(127.2)S","E","escape documented in this paper","","Variant dramatically reduced CTL recognition.","Jones2004"
"53223","Gag AQ9","2287","B","","","Gag","119","127","p17(119-127)","1144..1170","","AADTGNSSQ","tADTGN-Sn(s)","A1T, S7-, Q9N, -(9.1)S","A119T, S125-, Q127N, -(127.1)S","E","escape documented in this paper","","Variant dramatically reduced CTL recognition.","Jones2004"
"53223","Gag AQ9","2288","B","","","Gag","119","127","p17(119-127)","1144..1170","","AADTGNSSQ","AADTGNnS(ns)Q","S7N, -(8.1)N, -(8.2)S","S125N, -(126.1)N, -(126.2)S","OV","observed variant","","1/15 clones at time point 556.","Jones2004"
"53223","Gag AQ9","2299","B","","","Gag","119","127","p17(119-127)","1144..1170","","AADTGNSSQ","AADTGN-S(ss)Q","S7-, -(8.1)S, -(8.2)S","S125-, -(126.1)S, -(126.2)S","E","escape documented in this paper","","Variant dramatically reduced CTL recognition.","Jones2004"
"56010","NY9(p17)","1907","B","B","B","Gag","124","132","p17(124-132)","1159..1185","","NSSQVSQNY","NSSkVSQNY","Q4K","Q127K","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B35 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"53224","Gag NP10","519","B","","","Gag","124","133","p17(124)-p24(1)","1159..1188","","NSSQVSQNYP","NgSQVSQNYP","S2G","S125G","DR","diminished response","","Confirmed some degree of escape by diminishing CTL response.","Jones2004"
"53224","Gag NP10","520","B","","","Gag","124","133","p17(124)-p24(1)","1159..1188","","NSSQVSQNYP","NSSQaSQNYP","V5A","V128A","DR","diminished response","","Confirmed some degree of escape by diminishing CTL response.","Jones2004"
"53224","Gag NP10","521","B","","","Gag","124","133","p17(124)-p24(1)","1159..1188","","NSSQVSQNYP","sSSQVSQNYP","N1S","N124S","DR","diminished response","","Confirmed some degree of escape by diminishing CTL response.","Jones2004"
"53224","Gag NP10","522","B","","","Gag","124","133","p17(124)-p24(1)","1159..1188","","NSSQVSQNYP","NSSQdSQNYP","V5D","V128D","DR","diminished response","","Confirmed some degree of escape by diminishing CTL response.","Jones2004"
"53224","Gag NP10","523","B","","","Gag","124","133","p17(124)-p24(1)","1159..1188","","NSSQVSQNYP","NSSQgSQNYP","V5G","V128G","DR","diminished response","","Confirmed some degree of escape by diminishing CTL response.","Jones2004"
"53224","Gag NP10","524","B","","","Gag","124","133","p17(124)-p24(1)","1159..1188","","NSSQVSQNYP","kSSQVSQNYP","N1K","N124K","DR","diminished response","","Confirmed some degree of escape by diminishing CTL response.","Jones2004"
"53224","Gag NP10","525","B","","","Gag","124","133","p17(124)-p24(1)","1159..1188","","NSSQVSQNYP","NSSkVSQNYP","Q4K","Q127K","DR","diminished response","","Confirmed some degree of escape by diminishing CTL response.","Jones2004"
"53224","Gag NP10","526","B","","","Gag","124","133","p17(124)-p24(1)","1159..1188","","NSSQVSQNYP","NmnQVSQNYP","S2M, S3N","S125M, S126N","DR","diminished response","","Confirmed some degree of escape by diminishing CTL response.","Jones2004"
"53224","Gag NP10","2289","B","","","Gag","124","133","p17(124)-p24(1)","1159..1188","","NSSQVSQNYP","NSS(s)QVSQNYP","-(3.1)S","-(126.1)S","DR","diminished response","","Confirmed some degree of escape by diminishing CTL response.","Jones2004"
"53224","Gag NP10","2290","B","","","Gag","124","133","p17(124)-p24(1)","1159..1188","","NSSQVSQNYP","NS(n)SQVSQNYP","-(2.1)N","-(125.1)N","DR","diminished response","","Confirmed some degree of escape by diminishing CTL response.","Jones2004"
"53224","Gag NP10","2291","B","","","Gag","124","133","p17(124)-p24(1)","1159..1188","","NSSQVSQNYP","NnS(ns)QVSQNYP","S2N, -(3.1)N, -(3.2)S","S125N, -(126.1)N, -(126.2)S","DR","diminished response","","Confirmed some degree of escape by diminishing CTL response.","Jones2004"
"54628","GAG-18","2269","B","B","C","Gag","126","143","p17(126)-p24(11)","1165..1218","","SQVSQNYPIVQNLQGQMV","-kVSQNYPIVQNLQGQMV","S1-, Q2K","S126-, Q127K","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 2 amino acids (11.1%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"53592","Gag 7.3","55","","B","CRF02_AG","Gag","129","139","p17(129)-p24(7)","1174..1206","","SQNYPIVQNIQ","SQNYPIVQNaQ","I10A","I138A","SNSF","subtype-specific non-susceptible form","Intracellular cytokine staining, T-cell Elispot","The response elicited to the B clade epitope SQNYPIVQNIQ does not cross-react with the CRF02 form SQNYPIVQNaQ","Amara2005a"
"58386","Peptide 32","2915","C","C","D","Gag","129","143","p17(129)-p24(11)","1174..1218","","xxxSQNYPIVQNLQG","sqvSQNYPIVQNLQG","x1S, x2Q, x3V","x129S, x130Q, x131V","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-D peptide 32, sqvSQNYPIVQNLQG, cross reacted to elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"58386","Peptide 32","2916","C","C","A","Gag","129","143","p17(129)-p24(11)","1174..1218","","xxSQNYPIVQNLQGM","kvSQNYalkhrayel","x1K, Q10H, N11R, L12A, Q13Y, G14E, M15L, x2V, P7A, I8L, V9K","x129K, Q138H, N139R, L140A, Q141Y, G142E, M143L, x130V, P135A, I136L, V137K","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-A peptide 32, kvSQNYalkhrayel, did not elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"58174","GI8","2781","","","","Gag","140","147","p24(8-15)","1207..1230","B*4801","GQMVHQAI","GQMVHQpI","A7P","A146P","A, E","HLA association, escape documented in this paper","Intracellular cytokine staining","Variant GQMVHQpI, A146P, was shown to be an escape  and was strongly associated with HLA allele  B*4801 among HIV-1 infected Japanese.","Naruto2011, Kawashima2009"
"55234",,"799","B, CRF01_AE","","B","Gag","140","153","p24(8-21)","1207..1248","A3, Cw3","GQMVHQAISPRTLN","GQMVHQpISPRTLN","A7P","A146P","OV","observed variant","Sequence","Patient was superinfected with three strains, B1, B2 and CRF01_AE. This was the infecting variant  in B1 and B2, and it did not change over time.","Kozaczynska2007"
"55234",,"800","B, CRF01_AE","","CRF01_AE","Gag","140","153","p24(8-21)","1207..1248","A3, Cw3","GQMVHQAISPRTLN","GQMVHQpvSPRTLN","A7P, I8V","A146P, I147V","OV","observed variant","Sequence","Patient was superinfected with three strains, B1, B2 and CRF01_AE. This was the infecting variant  in CRF01_AE and it did not change over time.","Kozaczynska2007"
"53613",,"65","A, D","","","Gag","141","155","p24(9-23)","1210..1254","","QMVHQSLSPRTLNAW","QMtHQnLSPRTLNAW","V3T, S6N","V143T, S146N","OV","observed variant","CD8 T-cell Elispot - IFNy","The sequence contains a known B7/B8 epitope, but the subjects recognizing it are B7- and B8-negative. The viral sequences isolated from the subjects were qmThqNlsprtlnaw and qmvhqAlsprtlnaw, and the index peptide was recognized.","Barugahare2005"
"53613",,"66","A, D","","","Gag","141","155","p24(9-23)","1210..1254","","QMVHQSLSPRTLNAW","QMVHQaLSPRTLNAW","S6A","S146A","OV","observed variant","CD8 T-cell Elispot - IFNy","The sequence contains a known B7/B8 epitope, but the subjects recognizing it are B7- and B8-negative. The viral sequences isolated from the subjects were qmThqNlsprtlnaw and qmvhqAlsprtlnaw, and the index peptide was recognized.","Barugahare2005"
"55639",,"16","A, CRF02_AG","AG","A","Gag","142","155","p24(10-23)","1213..1254","","MVHQSMSPRTLNAW","MVHQplSPRTLNAW","S5P, M6L","S146P, M147L","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","2 subjects responded to peptide MVHQSMSPRTLNAW from subtype CRF02_AG, and 1 of the 2 responded to peptide MVHQplSPRTLNAW from subtype A.","Aidoo2008"
"55992","HL9(p24)","1908","B","B","B","Gag","144","152","p24(12-20)","1219..1245","","HQPISPRTL","HQaISPRTL","P3A","P146A","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope. This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B15 restricted.","Zhai2008"
"54145","QW11","955","B","","","Gag","145","155","p24(13-23)","1222..1254","A*2501","QAISPRTLNAW","QAlSPRTLNAW","I3L","I147L","DR","diminished response","CD8 T-cell Elispot - IFNy","Amino acid site in the third position potentially experienced positive selection. Wt form of the epitope was 2.4 times better recognized than the variant.","Liu2006"
"58160","QW11","2747","B","B","B","Gag","145","155","p24(13-23)","1222..1254","A*2501","QAISPRTLNAW","QAlSPRTLNAW","I3L","I147L","SF","susceptible form","CD8 T-cell Elispot - IFNy, Longitudinal study","Major variant QAlSPRTLNAW replaced the wild type sequence by 800 days post-infection. It did not abrogate EliSpot response to the epitope.","Liu2011a"
"58812","ISW9","3172","B","B","B","Gag","146","155","p24(14-23)","1225..1254","B*5701","{A}ISPRTLNAW","{s}lSPRTLNAW","I1L, A-1S","I146L, A145S","OV","observed variant","Sequence","Flanking and epitope mutations, {s}lSPRTLNAW{V}, were seen for ISW9 by 13 weeks post-infection in patient 1 (P1) who carried HLA alleles A*0101, A*0301, B*2705, B*5701.","Norstrom2012"
"58812","ISW9","3173","B","B","B","Gag","146","155","p24(14-23)","1225..1254","B*5701","{A}ISPRTLNAW","{p}lSPRTLNAW","I1L, A-1P","I146L, A145P","OV","observed variant","Sequence","Flanking and epitope mutations, {p}lSPRTLNAW{V}, were seen for ISW9 by 104 weeks post-infection in patient 1 (P1) who carried HLA alleles A*0101, A*0301, B*2705, B*5701 and at 179 weeks post-infection in patient 3 (P3) who carried HLA alleles A*2402 , A*3201, B*4002, B*5701.","Norstrom2012"
"58812","ISW9","3174","B","B","B","Gag","146","155","p24(14-23)","1225..1254","B*5701","ISPRTLNAW","lSPRTLNAW","I1L","I146L","OV","observed variant","Sequence","Epitope mutation, A|lSPRTLNAW|V, was seen for ISW9 by 271 weeks post-infection in patient 1 (P1) who carried HLA alleles A*0101, A*0301, B*2705, B*5701; at 45 weeks post-infection in patient 3 (P3) who carried HLA alleles A*2402 , A*3201, B*4002, B*5701; from 144 weeks post-infection in patient 5 (P5) who carried alleles A*0101,A*0101,B*0801,B*5701 and from 17 weeks post-infection in patient 6 (P6) who carried alleles A*0301,A*2402,B*3501,B*5701.","Norstrom2012"
"58812","ISW9","3175","B","B","B","Gag","146","155","p24(14-23)","1225..1254","B*5701","{A}ISPRTLNAW","{p}ISPRTLNAW","A-1P","A145P","OV","observed variant","Sequence","Flanking mutation, {p}ISPRTLNAW{V}, was seen for ISW9 from 75 weeks post-infection in patient 3 (P3) who carried HLA alleles A*2402 , A*3201, B*4002, B*5701; from 60 weeks post-infection in P4 who carried HLA alleles A*0101,A*0201,B*5101,B*5701; and from 10 weeks post-infection in P6 who carried HLA alleles  A*0301,A*2402,B*3501,B*5701.","Norstrom2012"
"58812","ISW9","3176","B","B","B","Gag","146","155","p24(14-23)","1225..1254","B*5701","{A}ISPRTLNAW","{p}IaPRTLNAW","A-1P, S2A","A145P, S147A","OV","observed variant","Sequence","Flanking and epitope mutations, {p}IaPRTLNAW{V}, were seen for ISW9 by 274 weeks post-infection in P3 who carried HLA alleles A*2402 , A*3201, B*4002, B*5701.","Norstrom2012"
"58812","ISW9","3177","B","B","B","Gag","146","155","p24(14-23)","1225..1254","B*5701","{A}ISPRTLNAW","{p}ItPRTLNAW","A-1P, S2T","A145P, S147T","OV","observed variant","Sequence","Flanking and epitope mutations, {p}ItPRTLNAW{V}, were seen for ISW9 by 11 weeks post-infection in P4 who carried HLA alleles A*0101,A*0201,B*5101,B*5701.","Norstrom2012"
"58812","ISW9","3178","B","B","B","Gag","146","155","p24(14-23)","1225..1254","B*5701","{A}ISPRTLNAW","{p}ltPRTLNAW","I1L, A-1P, S2T","I146L, A145P, S147T","OV","observed variant","Sequence","Epitope mutation, {A}ItPRTLNAW{V}, was seen for ISW9 by 11 weeks post-infection in P4 who carried HLA alleles A*0101,A*0201,B*5101,B*5701.","Norstrom2012"
"58812","ISW9","3179","B","B","B","Gag","146","155","p24(14-23)","1225..1254","B*5701","ISPRTLNAW","ItPRTLNAW","S2T","S147T","OV","observed variant","Sequence","Flanking and epitope mutations, A|ItPRTLNAW|V, were seen for ISW9 by 316 weeks post-infection in P4 who carried HLA alleles A*0101,A*0201,B*5101,B*5701.","Norstrom2012"
"58812","ISW9","3180","B","B","B","Gag","146","155","p24(14-23)","1225..1254","B*5701","ISPRTLNAW","IlPRTLNAW","S2L","S147L","OV","observed variant","Sequence","Flanking and epitope mutations including IlPRTLNAW, were seen for ISW9 by 45 weeks post-infection in P3 who carried HLA alleles A*2402,A*3201,B*4002,B*5701.","Norstrom2012"
"57412","IW9","2353","B","B","B","Gag","146","156","p24(14-24)","1225..1257","B*57","AISPRTLNAWV","pISPRTLNAWV","A1P","A146P","OV","observed variant","Sequence","One HLA-B*5703 positive patient with low viral load carried this variant from month 6 after enrollment.","Durand2010"
"57412","IW9","2355","B","B","B","Gag","146","156","p24(14-24)","1225..1257","B*57","AISPRTLNAWV","plSPRTLNAWV","A1P, I2L","A146P, I147L","OV","observed variant","Sequence","One HLA-B*5703 positive patient with increased viral load carried this variant from month 10 after enrollment onwards.","Durand2010"
"57412","IW9","2356","B","B","B","Gag","146","156","p24(14-24)","1225..1257","B*57","AISPRTLNAWV","pISaRTLNAWV","A1P, P4A","A146P, P149A","OV","observed variant","Sequence","One HLA-B*5701 positive patient with increased viral load carried this variant from enrollment onwards.","Durand2010"
"57412","IW9","2357","B","B","B","Gag","146","156","p24(14-24)","1225..1257","B*57","AISPRTLNAWV","AlSPRTLNAWV","I2L","I147L","OV","observed variant","Sequence","One HLA-B*5701 positive patient with low viral load carried this variant, AlSPRTLNAWV, at month 28 after enrollment; One HLA-B*5702 positive patient with low viral load carried it at month 13; and one HLA-B*5703 positive patient with increased viral load carried it from 7 months post-enrollment on.","Durand2010"
"53636","IW9","138","C","","","Gag","147","155","p24(15-23)","1228..1254","B57","ISPRTLNAW","lSPRTLNAW","I1L","I147L","OV","observed variant","CD8 T-cell Elispot - IFNy","ISPRTLNAW had a variant lSPRTLNAW in 7/10 B57+ subjects, and 4/9 B57- subjects; 2 other variants were observed, but there was no apparent sequence selection in this epitope.","Currier2005"
"52917","ISW9","181","B, C","","","Gag","147","155","p24(15-23)","1228..1254","B57","ISPRTLNAW","pSPRTLNAW","I1P","I147P","E, P","escape documented in this paper, processing","CD8 T-cell Elispot - IFNy, Chromium-release assay","The A146P mutation flanking the ISW9 epitope, {p}ISPRTLNAW, is positively selected in HLA-B57+ persons and it prevents trimming of the optimal epitope by the endoplasmic reticulum aminopeptidase I. The A146P processing escape mutation does not influence replicative capacity of the virus in vitro and is accumulated over time in the human population.","Draenert2004a"
"53648","ISW9","196","","","","Gag","147","155","p24(15-23)","1228..1254","B57, B*5801","ISPRTLNAW","lSPRTLNAW","I1L","I147L","IE","inferred escape","Sequence","ISPRTLNAW was recognized more often in children than in adults, and was the most frequently recognized B57 epitope in children. Longitudinal sequencing of 2 HLA B57-positive children born to HLA B57-negative mothers and HIV-negative fathers showed variants of this epitope: p|lSPRTLNAW, and lSPRTLNAW. In both cases the mother carried A|ISPRTLNAW, confirming that the mutations arose under selective pressure in the children following vertical transmission. Response to the variants was not studied.","Feeney2005a"
"53675",,"330","B, D","","","Gag","147","155","p24(15-23)","1228..1254","B58","ISPRTLNAW","lSPRTLNAW","I1L","I147L","OV","observed variant","","Cross-clade T cell responses are frequently induced in individuals infected with different HIV-1 clades. There was an inverse correlation between the height of responses and epitope sequence divergence. For Gag epitopes, the magnitude of the response was directly linked to the homology between HLA anchor residues.","Geels2005"
"54598",,"342","A, C","C","A, D","Gag","147","155","p24(15-23)","1228..1254","B57, B58","ISPRTLNAW","lSPRTLNAW","I1L","I147L","DR","diminished response","","The wild type epitope sequence was a subtype C peptide, the variant common to subtypes A and D. CTL response in 56 individuals from Tanzania was strongest for subtypes A and D peptides, and much lower for subtype C, due to point mutation and/or frame-of-epitope effect.","Geldmacher2007"
"54576","IW9","641","B","","","Gag","147","155","p24(15-23)","1228..1254","B*57","ISPRTLNAW","lSPRTLNAW","I1L","I147L","OV","observed variant","","Variant detected at week 106 in one of the patients, but not in association with antigen processing altering mutation A146P.","Karlsson2007"
"54534","IW9","1021","B","B","A","Gag","147","155","p24(15-23)","1228..1254","B57","ISPRTLNAW","lSPRTLNAW","I1L","I147L","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","Cross-recognition of this variant is seen with both C- and A-clades.  Anchor residues are at positions 2 and 9; while the A-clade variant contains a change at position 1 to lSPRTLNAW.","Malhotra2007"
"52758",,"1280","B","","","Gag","147","155","p24(15-23)","1228..1254","B*5701","ISPRTLNAW","lSPRTLNAW","I1L","I147L","OV","observed variant","Sequence","This variant was seen in 6/10 nonprogressors, 11/12 untreated progressors and 3/5 treated progressors.","Migueles2003"
"52758",,"1281","B","","","Gag","147","155","p24(15-23)","1228..1254","B*5701","ISPRTLNAW","ISaRTLNAW","P3A","P149A","OV","observed variant","Sequence","This variant was seen in 1/5 treated progressors.","Migueles2003"
"52758",,"1282","B","","","Gag","147","155","p24(15-23)","1228..1254","B*5701","ISPRTLNAW","ISPRTLNAx","W9X","W155X","OV","observed variant","Sequence","This variant was seen in 1/10 nonprogressors.","Migueles2003"
"52758",,"1283","B","","","Gag","147","155","p24(15-23)","1228..1254","B*5701","ISPRTLNAW","ISPkTLNAW","R4K","R150K","OV","observed variant","Sequence","This variant was seen in 1/10 nonprogressors.","Migueles2003"
"52758",,"1284","B","","","Gag","147","155","p24(15-23)","1228..1254","B*5701","ISPRTLNAW","IaPRTLNAW","S2A","S148A","OV","observed variant","Sequence","This variant was seen in 1/12 untreated progressors.","Migueles2003"
"52758",,"1285","B","","","Gag","147","155","p24(15-23)","1228..1254","B*5701","ISPRTLNAW","mSPRTLNAW","I1M","I147M","OV","observed variant","Sequence","This variant was seen in 1/12 untreated progressors.","Migueles2003"
"52758",,"1286","B","","","Gag","147","155","p24(15-23)","1228..1254","B*5701","ISPRTLNAW","mSaRTLNAW","I1M, P3A","I147M, P149A","OV","observed variant","Sequence","This variant was seen in 1/12 untreated progressors.","Migueles2003"
"52758",,"1287","B","","","Gag","147","155","p24(15-23)","1228..1254","B*5701","ISPRTLNAW","kSaRTLNAW","I1K, P3A","I147K, P149A","OV","observed variant","Sequence","This variant was seen in 1/12 untreated progressors.","Migueles2003"
"52758",,"1288","B","","","Gag","147","155","p24(15-23)","1228..1254","B*5701","ISPRTLNAW","lSPRTfNAW","I1L, L6F","I147L, L152F","OV","observed variant","Sequence","This variant was seen in 1/12 untreated progressors.","Migueles2003"
"53832",,"1413","C","","","Gag","147","155","p24(15-23)","1228..1254","B57","ISPRTLNAW","mSPRTLNAW","I1M","I147M","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","This is de novo variant seen in infant by week 33 of age. The index peptide was recognized, but not the variant.","Pillay2005"
"53832",,"1414","C","","","Gag","147","155","p24(15-23)","1228..1254","B57","ISPRTLNAW","lSPRTLNAW","I1L","I147L","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence","This is de novo variant seen in infant by week 33 of age. Both index peptide and the variant were recognized, but response to the variant was diminished.","Pillay2005"
"55002","ISP","1789","","","","Gag","147","155","p24(15-23)","1228..1254","B*5701","ISPRTLNAW","raPRTLNAW","I1R, S2A","I147R, S148A","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","None of the patients tested recognized the variant.","Turnbull2006"
"55002","ISP","1790","","","","Gag","147","155","p24(15-23)","1228..1254","B*5701","ISPRTLNAW","mSPRTLNAW","I1M","I147M","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","Some patients recognized the variant, some did not.","Turnbull2006"
"55002","ISP","1791","","","","Gag","147","155","p24(15-23)","1228..1254","B*5701","ISPRTLNAW","vSPRTLNAW","I1V","I147V","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","Some patients recognized the variant, some did not.","Turnbull2006"
"55002","ISP","1792","","","","Gag","147","155","p24(15-23)","1228..1254","B*5701","ISPRTLNAW","ltPRTLNAW","I1L, S2T","I147L, S148T","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","Some patients recognized the variant, some did not.","Turnbull2006"
"55002","ISP","1793","","","","Gag","147","155","p24(15-23)","1228..1254","B*5701","ISPRTLNAW","vtPRTLNAW","I1V, S2T","I147V, S148T","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","Some patients recognized the variant, some did not.","Turnbull2006"
"55002","ISP","1794","","","","Gag","147","155","p24(15-23)","1228..1254","B*5701","ISPRTLNAW","ISaRTLNAW","P3A","P149A","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","Some patients recognized the variant, some did not.","Turnbull2006"
"55002","ISP","1795","","","","Gag","147","155","p24(15-23)","1228..1254","B*5701","ISPRTLNAW","IaPRTLNAr","S2A, W9R","S148A, W155R","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","None of the patients tested recognized the variant.","Turnbull2006"
"55002","ISP","1796","","","","Gag","147","155","p24(15-23)","1228..1254","B*5701","ISPRTLNAW","lSPRTLNAW","I1L","I147L","DR, SF","diminished response, susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","Some patients recognized the variant at the level of the index peptide, some had diminished response.","Turnbull2006"
"56630","IW9","1980","","","","Gag","147","155","p24(15-23)","1228..1254","B*5701","ISPRTLNAW","lSPRTLNAW","I1L","I147L","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","A simple but atypical pattern of escape was seen with this variant in one patient, CH77 where the variant completely replaced the index epitope. In patient CH58, no significant change with respect to selection in this epitope was detected. For CH58, positive ELISpot from the full proteome scan but with not statistical evidence for selection for change was seen.  For CH77, known T cell response from the full proteome scan with evidence for variation and escape by positive ELISpot was seen.","Goonetilleke2009"
"53832",,"2304","C","","","Gag","147","155","p24(15-23)","1228..1254","B57","{A}ISPRTLNAW","{p}lSPRTLNAW","I1L, --1P","I147L, -146P","OV","observed variant","Sequence","A substitution proximal to the epitope and variant within the epitope was seen in infant I5 by week 33.","Pillay2005"
"53648","ISW9","2324","","","","Gag","147","155","p24(15-23)","1228..1254","B57, B*5801","{A}ISPRTLNAW","{p}lSPRTLNAW","I1L, A-1P","I147L, A146P","IE, P","inferred escape, processing","Sequence","ISPRTLNAW was recognized more often in children than in adults, and was the most frequently recognized B57 epitope in children. Longitudinal sequencing of 2 HLA B57 children born to HLA B57-negative mothers and HIV-negative fathers showed variants of this epitope: {p}lSPRTLNAW, and lSPRTLNAW. In both cases the mother carried {A}ISPRTLNAW, confirming that the mutations arose under selection pressure in the children following vertical transmission. Response to the variants was not studied, but a processing escape was assumed.","Feeney2005a"
"57415","ISW9","2360","B","B","B","Gag","147","155","p24(15-23)","1228..1254","B*57","ISPRTLNAW","lSPRTLNAW","I2L","I147L","LE","literature escape","CD8 T-cell Elispot - IFNy, Sequence","This 147L mutation was more common in progressors than controllers.","Tang2010"
"57415","ISW9","2361","B","B","B","Gag","147","155","p24(15-23)","1228..1254","B*57","{A}ISPRTLNAW","{p}lSPRTLNAW","A1P, I2L","A146P, I147L","OV","observed variant","Sequence","This double mutation was seen in one progressor, CH-01 and one controller, CH-04.","Tang2010"
"57415","ISW9","2362","B","B","B","Gag","147","155","p24(15-23)","1228..1254","B*57","{A}ISPRTLNAW","{p}ISPRTLNAW","A1P","A146P","LE, P","literature escape, processing","Sequence","This antigen processing escape, 146P, was more common in controllers than progressors.","Tang2010"
"57258","IW9","2552","D, A1","A1","D","Gag","147","155","p24(15-23)","1228..1254","B*57","ISPRTLNAW","lSPRTLNAW","I1L","I147L","SF","susceptible form","CD8 T-cell Elispot - IFNy","Previously-documented Clade D ISPRTLNAW escape variant I147L was not selected against among B*57+ clade A1 subjects. These subjects responded similarly to 147I and 147L.","McKinnon2009"
"57649","ISW9","2567","","","","Gag","147","155","p24(15-23)","1228..1254","B*57","ISPRTLNAW","lSPRTLNAW","I1L","I147L","E","escape documented in this paper","Relative replication capacity assay","Of 2 HLA-B57-positive early controllers both had, at the earliest time point tested, signature B57 mutations in Gag that impaired viral replication capacity: T242N in TSTLQEQIGW (TSnLQEQIGW) and I147L in ISPRTLNAW (lSPRTLNAW).","Miura2010"
"58232",,"2799","B","B","B","Gag","147","155","p24(15-23)","1228..1254","B*5701","ISPRTLNAW","lSPRTLNAW","I1L","I147L","IE","inferred escape","Sequence","1/3 or 2/3 sequences of epitope ISPRTLNAW varied at 350 DFOSx to lSPRTLNAW and xSPRTLNAW, where X = l or s.  Position 15 in the epitope is marked as being under selection to vary.","Ferrari2011"
"58232",,"2800","B","B","B","Gag","147","155","p24(15-23)","1228..1254","B*5701","ISPRTLNAW","xSPRTLNAW","I1X","I147X","IE","inferred escape","Sequence","1/3 or 2/3 sequences of epitope ISPRTLNAW varied at 350 DFOSx to xSPRTLNAW, since x = l or s, and another variant, lSPRTLNAW is found.  Position 15 in the epitope is marked as being under selection to vary.","Ferrari2011"
"58674","ISW9","3093","C","C","C","Gag","147","155","p24(15-23)","1228..1254","B*5701, B*5702, B*5703, B*5801","{A}ISPRTLNAW","{x}ISPRTLNAW","A-1X","A146X","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","ISW9 escapes at A146X, {x}ISPRTLNAW, are seen in &tilde;100% of HLA-B*5703 and -B*5702 positive subjects.","Kloverpris2012"
"58674","ISW9","3094","C","C","C","Gag","147","155","p24(15-23)","1228..1254","B*5701, B*5702, B*5703, B*5801","ISPRTLNAW","xSPRTLNAW","I2X","I148X","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","ISW9 escapes at I147X, xSPRTLNAW, are seen in >75% of HLA-B*5703 and -B*5702 positive subjects.","Kloverpris2012"
"58743",,"3131","","","","Gag","147","155","p24(15-23)","1228..1254","B*57","ISPRTLNAW","lSPRTLNAW","I1L","I147L","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Mutant epitope lSPRTLNAW is recognized only by subject ES38 as seen by EliSpot; though it is found in both ES38 and CP2 HIV-1.","Buckheit2012"
"59137","IW9","3302","B","B","B","Gag","147","155","p24(15-23)",,"B*57","ISPRTLNAW","plPRTLNAW","I1P, S2L","I147P, S148L","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","B*57-restricted variant lpPRTLNAW in the 1999 Berlin patient found circulating 15 years post-end of ART.","Jessen2014"
"59207","ISW9","3339","B","B","B","Gag","147","155","p24(15-23)",,"B*5701","ISPRTLNAW","lSPRTLNAW","I1L","I147L","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant lSPRTLNAW, was seen in 2/3 HRPs and 2/3 LRPs. lSPRTLNAW was the only analogous ISW9 in patient P1 and was found in the major viral population in patients P5 and P6 at latter time points.","Buggert2014"
"59207","ISW9","3340","B","B","B","Gag","147","155","p24(15-23)",,"B*5701","ISPRTLNAW","ltPRTLNAW","I1L, S2T","I147L, S148T","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant ltPRTLNAW, was seen in 0/3 HRPs and 1/3 LRPs (patient P4) at the last sampling point.","Buggert2014"
"59207","ISW9","3341","B","B","B","Gag","147","155","p24(15-23)",,"B*5701","ISPRTLNAW","ItPRTLNAW","S2T","S148T","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant ItPRTLNAW, was seen in 0/3 HRPs and 1/3 LRPs. It was the predominant variant in subject P4.","Buggert2014"
"59207","ISW9","3342","B","B","B","Gag","147","155","p24(15-23)",,"B*5701","ISPRTLNAW","IaPRTLNAW","S2A","S148A","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant ItPRTLNAW, was seen in 1/3 HRPs and 0/3 LRPs. It was the predominant variant in subject P4.","Buggert2014"
"59207","ISW9","3343","B","B","B","Gag","147","155","p24(15-23)",,"B*5701","ISPRTLNAW","IlPRTLNAW","S2L","S148L","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant IlPRTLNAW, was seen in 1/3 HRPs and 0/3 LRPs. It was an early variant in Gag that was later lost in subject P3.","Buggert2014"
"59015","CE1","3207","B, C, M","B, C, M","A","Gag","147","158","p24(15-26)","1228..1263","","ISPRTLNAWVKV","lSPRTLNAWVKV","I1L","I147L","SSF","subtype-specific susceptible form","Intracellular cytokine staining","lSPRTLNAWVKV is the Clade-A variant of CE1.  It was used in the p24CE2 vaccine form in this study, eliciting a strong T-helper response from the vaccinated mouse.","Kulkarni2013"
"59230",,"3373","B","B","B","Gag","148","156","p24(16-24)",,"B*0702","SPRTLNAWV","SPRTLDAWV","N6D","N153D","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","First variant to arise; seen only in early post-seroconversion period; positive Elispot response <100 SFC/10<sup>6</sup>PBMC.","Melhem2014"
"59230",,"3374","B","B","B","Gag","148","156","p24(16-24)",,"B*0702","SPRTLNAWV","SPRALNAWV","T4A","T151A","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Second variant to arise; seen in early post-seroconversion period; positive Elispot response <100 SFC/10<sup>6</sup>PBMC.","Melhem2014"
"59230",,"3375","B","B","B","Gag","148","156","p24(16-24)",,"B*0702","SPRTLNAWV","PPRTLNAWV","S1P","S148P","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Third variant to arise; seen in late post-seroconversion period; zero Elispot response.","Melhem2014"
"59230",,"3376","B","B","B","Gag","148","156","p24(16-24)",,"B*0702","SPRTLNAWV","SPRPLNAWV","T4P","T151P","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Fourth variant to arise; seen in early ART period; positive Elispot response >300 SFC/10<sup>6</sup>PBMC.","Melhem2014"
"59230",,"3377","B","B","B","Gag","148","156","p24(16-24)",,"B*0702","SPRTLNAWV","SPRTLSAWV","N6S","N153S","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Fifth variant to arise; seen in early and late ART period; positive Elispot result in early ART >200 SFC/10<sup>6</sup>PBMC, but no response in late ART.","Melhem2014"
"58746",,"3135","","","","Gag","149","160","p24(17-28)","1234..1269","","EKIRLRPGGKKKYKL","EKIRLRPGGKKKYqL","K14Q","K162Q","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Variant EKIRLRPGGKKKYqL was detected in CP2 and ES2 HIV-1 sequences, but is only recognized by CTL from subject CP2.","Buckheit2012"
"56141","TV9","80","B","","","Gag","151","159","p24(19-27)","1240..1266","A2","TLNAWVKVV","TLNAWVKVi","V9I","V159I","DR","diminished response","CD8 T-cell Elispot - IFNy, Chromium-release assay","To identify immunogenically optimized epitopes for use in vaccines, mutants of TV9 were tested in transgenic mice. Natural TV9 mutants tested in transgenic HLA-A*02 mice showed the following responses - the common mutant V9I, TLNAWVKVi was less immunogenic and had low cross-reactivity. TLNAWVKaV (most cross-reactive) and TLNAWVKai were highly immunogenic and cross-reactive to the consensus.","Blondelle2008"
"56141","TV9","81","B","","","Gag","151","159","p24(19-27)","1240..1266","A2","TLNAWVKVV","TLNAWVKaV","V8A","V158A","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","To identify immunogenically optimized epitopes for use in vaccines, mutants of TV9 were tested in transgenic mice. Natural TV9 mutants tested in transgenic HLA-A*02 mice showed the following responses - the common mutant V9I, TLNAWVKVi was less immunogenic and had low cross-reactivity. TLNAWVKaV (most cross-reactive) and TLNAWVKai were highly immunogenic and cross-reactive to the consensus.","Blondelle2008"
"56141","TV9","82","B","","","Gag","151","159","p24(19-27)","1240..1266","A2","TLNAWVKVV","TLNAWVKai","V8A, V9I","V158A, V159I","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","To identify immunogenically optimized epitopes for use in vaccines, mutants of TV9 were tested in transgenic mice. Natural TV9 mutants tested in transgenic HLA-A*02 mice showed the following responses - the common mutant V9I, TLNAWVKVi was less immunogenic and had low cross-reactivity. TLNAWVKaV (most cross-reactive) and TLNAWVKai were highly immunogenic and cross-reactive to the consensus.","Blondelle2008"
"55357","8L","1589","","","","Gag","151","159","p24(19-27)","1240..1266","A*0201","TLNAWVKLV","TLNAWVKLi","V9I","V159I","OV","observed variant","","9I is the one known variant of epitope TV9.","Schaubert2007"
"57650","TV9","2569","","","","Gag","151","159","p24(19-27)","1240..1266","A*0201","TLNAWVKVV","kINAWiKVV","T1K, L2I, V6I","T151K, L152I, V156I","SF","susceptible form","Flow cytometric T-cell cytokine assay, HLA binding, TCR binding, Tetramer binding","This is a mimic peptide shown to consistently activate cross-reactive and equally functional CTLs as measured by cytotoxicity, cytokine production and suppression of HIV replication in vitro.","Schaubert2010"
"59244",,"3378","B","B","B","Gag","151","159","p24(19-27)",,"A*0201","TLNAWVKVV","TLDAWVKVV","N3D","N153D","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","First variant to arise; seen in early and late post-seroconversion periods; positive Elispot <100 SFC/10<sup>6</sup>PBMC in early post-SC, and <50 SFC/10<sup>6</sup>PBMC in late post-SC period.","Melhem2014"
"59244",,"3379","B","B","B","Gag","151","159","p24(19-27)",,"A*0201","TLNAWVKVV","ALNAWVKVV","T1A","T151A","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Second variant to arise; seen in early and late post-seroconversion periods; positive Elispot response <100 SFC/10<sup>6</sup>PBMC in early period, but negative in late period.","Melhem2014"
"59244",,"3380","B","B","B","Gag","151","159","p24(19-27)",,"A*0201","TLNAWVKVV","PLNAWVKVV","T1P","T151P","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Third variant to arise; seen in early and late ART periods; positive Elispot >600 SFC/10<sup>6</sup>PBMC in early ART, and 100-200 SFC/10<sup>6</sup>PBMC in late ART period.","Melhem2014"
"59244",,"3381","B","B","B","Gag","151","159","p24(19-27)",,"A*0201","TLNAWVKVV","TLSAWVKVV","N3S","N153S","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Fourth variant to arise; seen in early and late ART periods; positive Elispot about 300 SFC/10<sup>6</sup>PBMC in early ART, and 100-200 SFC/10<sup>6</sup>PBMC in late ART period.","Melhem2014"
"53593","Gag 8.4","56","","B","CRF02_AG","Gag","153","163","p24(21-31)","1246..1278","","NAWVKVVEEKA","NAWVKViEEKA","V7I","V159I","DR, SSF","diminished response, subtype-specific susceptible form","Intracellular cytokine staining, T-cell Elispot","The B clade immune response to NAWVKVVEEKA gives a diminished response to the CRF02 variant NAWVKViEEKA, but does cross-react.","Amara2005a"
"58387","Peptide 38","2917","C","C","B","Gag","154","168","p24(22-36)","1249..1293","","xAWVKVIEEKAFSPE","nAWVKVvEEKAFSPE","x1N, I7V","x154N, I160V","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-B peptide 38, xAWVKVIEEKAFSPE, did not elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"55068",,"213","B, C","B","C","Gag","156","164","p24(24-32)","1255..1281","B*1503","VKVVEEKAF","VKViEEKAF","V4I","V159I","SSF","subtype-specific susceptible form","","VKVVEEKAF epitope is found in subtype B, while the variant is found in subtype C. Both are frequently targeted by B*1503 positive individuals.","Frahm2006"
"55648",,"17","A, CRF02_AG, CRF01_AE","A, AG","AE","Gag","158","172","p24(26-40)","1261..1305","","VIEEKAFSPEVIPMF","VvEEKgFnPEVIPMF","I2V, A6G, S8N","I159V, A163G, S165N","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","1 subject responded to peptide VIEEKAFSPEVIPMF from subtypes A and CRF02_AG; and to peptide VvEEKgFnPEVIPMF from subtype CRF01_AE.","Aidoo2008"
"58840","KF11","3181","B","B","B","Gag","161","173","p24(29-41)","1270..1308","B*5701","KAFSPEVIPMF","KAFSPEVIPMs","F11S","F171S","OV","observed variant","Flow cytometric T-cell cytokine assay","Epitope mutation, E|KAFSPEVIPMs|S, was seen for KF11 by 104 weeks post-infection in P1 who carried HLA alleles A*0101,A*0301,B*2705,B*5701.","Norstrom2012"
"58840","KF11","3182","B","B","B","Gag","161","173","p24(29-41)","1270..1308","B*5701","KAFSPEVIPMF","KAFSPEVIPMt","F11T","F171T","OV","observed variant","Flow cytometric T-cell cytokine assay","Epitope mutation, E|KAFSPEVIPMt|S, was seen for KF11 by 168 weeks post-infection in P1 who carried HLA alleles A*0101,A*0301,B*2705,B*5701 and by 377 weeks post-infection in P6 who carried HLA alleles A*0301,A*2402,B*3501,B*5701.","Norstrom2012"
"58840","KF11","3183","B","B","B","Gag","161","173","p24(29-41)","1270..1308","B*5701","KAFSPEVIPMF","KAFSPEiIPMF","V7I","V167I","OV","observed variant","Flow cytometric T-cell cytokine assay","Epitope mutation, E|KAFSPEiIPMF|S, was seen for KF11 by 168 weeks post-infection in P1 who carried HLA alleles A*0101,A*0301,B*2705,B*5701 and by 301 weeks post-infection in P6 who carried HLA alleles A*0301,A*2402,B*3501,B*5701.","Norstrom2012"
"58840","KF11","3184","B","B","B","Gag","161","173","p24(29-41)","1270..1308","B*5701","KAFSPEVIPMF","KAsSPEVIPMF","F3S","F163S","OV","observed variant","Flow cytometric T-cell cytokine assay","Epitope mutation, E|KAFSPEVIPMF|S, was seen for KF11 by 301 weeks post-infection in P6 who carried HLA alleles A*0301,A*2402,B*3501,B*5701.","Norstrom2012"
"53635","KF11","139","C","","","Gag","162","172","p24(30-40)","1273..1305","B*5703","KAFSPEVIPMF","KnFSPEVIPMF","A2N","A163N","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","5 variants of the epitope were observed: KAFSPEVIPMF, KnFSPEVIPMF, rAFSPEVIPMF, and KgFnPEVIPMF. Depending on the subject, different versions of these variants were more or less susceptible to their CD8+ T cells, i.e., one person's escape form was another person's susceptible form. Responses against KnFSPEVIPMF were strong but subdominant in subjects carrying KAFSPEVIPMF and  KnFSPEVIPMF and there was little or no response in subjects carrying KgFnPEVIPMF.","Currier2005"
"53635","KF11","140","C","","","Gag","162","172","p24(30-40)","1273..1305","B*5703","KAFSPEVIPMF","rAFSPEVIPMF","K1R","K162R","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","5 variants of the epitope were observed: KAFSPEVIPMF, KnFSPEVIPMF, rAFSPEVIPMF, and KgFnPEVIPMF. Depending on the subject, different versions of these variants were more or less susceptible to their CD8+ T cells, i.e., one person's escape form was another person's susceptible form. Responses against rAFSPEVIPMF were among maximal in subjects carrying KAFSPEVIPMF, KnFSPEVIPMF and rAFSPEVIPMF but there was little or no response in subjects carrying KgFnPEVIPMF.","Currier2005"
"53635","KF11","141","C","","","Gag","162","172","p24(30-40)","1273..1305","B*5703","KAFSPEVIPMF","KgFnPEVIPMF","A2G, S4N","A163G, S165N","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","5 variants of the epitope were observed: KAFSPEVIPMF, KnFSPEVIPMF, rAFSPEVIPMF, and KgFnPEVIPMF. Depending on the subject, different versions of these variants were more or less susceptible to their CD8+ T cells, i.e., one person's escape form was another person's susceptible form. Responses against KgFnPEVIPMF were strong but subdominant in subjects carrying KAFSPEVIPMF and  KnFSPEVIPMF. In subjects carrying KgFnPEVIPMF there was a strong response against the index peptide but little or no response against other peptides. Subject carrying provirus with rAFSPEVIPMF showed dramatic nonrecognition of KgFnPEVIPMF.","Currier2005"
"55053",,"143","","A, C, D","A","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KgFnPEVIPMF","A2G, S4N","A163G, S165N","SNSF, SSF","subtype-specific non-susceptible form, subtype-specific susceptible form","","KAFSPEVIPMF within peptide EKAFSPEVIPMFSAL from A consensus, C isolate and D isolate was recognized by 5/5 HLA B*5701/B*5703 carriers from subtype A Kenyan cohort. The variant KgFnPEVIPMF within peptide EKgFnPEVIPMFSAL from A isolate was recognized by 3 out 5 subjects that recognized KAFSPEVIPMF and not recognized by 2 subjects.","Currier2006"
"54625","KF11","219","C","C","","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KgFnPEVIPMF","A2G, S4N","A163G, S165N","OV","observed variant","","Epitope highly variant in African cohort when restricted by B*5703 but highly conserved in B*5701 European cohort.","Frater2007"
"54625","KF11","220","C","C","","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KnFSPEVIPMF","A2N","A163N","OV","observed variant","","Epitope highly variant in African cohort when restricted by B*5703 but highly conserved in B*5701 European cohort.","Frater2007"
"54625","KF11","221","C","C","","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KsFSPEVIPMF","A2S","A163S","OV","observed variant","","Epitope highly variant in African cohort when restricted by B*5703 but highly conserved in B*5701 European cohort.","Frater2007"
"54625","KF11","222","C","C","","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KgFSPEVIPMF","A2G","A163G","OV","observed variant","","Epitope highly variant in African cohort when restricted by B*5703 but highly conserved in B*5701 European cohort.","Frater2007"
"54625","KF11","223","C","C","","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KgFkPEVIPMF","A2G, S4K","A163G, S165K","OV","observed variant","","Epitope highly variant in African cohort when restricted by B*5703 but highly conserved in B*5701 European cohort.","Frater2007"
"54625","KF11","224","C","C","","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KsFSPEtIPMF","A2S, V7T","A163S, V168T","OV","observed variant","","Epitope highly variant in African cohort when restricted by B*5703 but highly conserved in B*5701 European cohort.","Frater2007"
"52191","KAFS","347","A, B","B","A, AC","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KgFnPEVIPMF","A2G, S4N","A163G, S165N","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, Tetramer binding","Variant found in clades A and AC. B*5701 CTL clones recognized this variant and displayed similar levels of lytic activity as against the wt at time 0 but 50% of activity at 24h later. This variant was presented more efficiently by B*5703 than by B*5701. The variant reacted with 100% of CTLs but failed to induce significant IFN-gamma secretion in 2 of the patients, indicating that this variant is unable to activate all downstream effector functions. However, it induced IFN-gamma in some patients' PBMCs.","Gillespie2002"
"52191","KAFS","348","A, B","B","A","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KAlSPEVIPMF","F3L","F164L","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, Tetramer binding","Variant found in clade A. It was  recognized by CTLs and induced lysis of peptide-pulsed targets. The variant induced IFN-gamma secretion in PBMCs from 5 patients and did not induce secretion in PBMCs from 1 patient.","Gillespie2002"
"52191","KAFS","349","A, B","B","A","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KAFSPEVIPvF","M10V","M171V","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, Tetramer binding","Variant found in clade A. It was  recognized by CTLs and induced lysis of peptide-pulsed targets. The variant induced IFN-gamma secretion in PBMCs from all patients.","Gillespie2002"
"52191","KAFS","350","A, B","B","O","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KAFnPEiIPMF","S4N, V7I","S165N, V168I","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, Tetramer binding","Variant found in group O. It was recognized by CTLs and induced lysis of peptide-pulsed targets. The variant induced IFN-gamma secretion in PBMCs from 4 patients and did not induce secretion in PBMCs from 2 patients.","Gillespie2002"
"52191","KAFS","351","A, B","B","AC","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KAFSPEiIPMF","V7I","V168I","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, Tetramer binding","Variant found in clade A/C.  It was  recognized by CTLs and induced lysis of peptide-pulsed targets. The variant induced IFN-gamma secretion in PBMCs from all patients.","Gillespie2002"
"52191","KAFS","352","A, B","B","AC","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KAFSqEVIPMF","P5Q","P166Q","DR, SSF","diminished response, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, Tetramer binding","Variant found in clade A /C. It induced IFN-gamma production in 3/6 patients&#39; PBMC but it demonstrated a diminished capacity to sensitize target cells for lysis. This variant was a weak ligand.","Gillespie2002"
"52191","KAFS","353","A, B","","","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","rgFSPEVIPMF","K1R, A2G","K162R, A163G","OV","observed variant","","Variant found in one patient in 10/11 clones.","Gillespie2002"
"52191","KAFS","354","A, B","","","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","rgsSPEVIPMF","K1R, A2G, F3S","K162R, A163G, F164S","OV","observed variant","","Variant found in one patient in 1/11 clones.","Gillespie2002"
"53741","KAF","502","","","","Gag","162","172","p24(30-40)","1273..1305","B57","KAFSPEVIPMF","KvFSPEVIPMF","A2V","A163V","OV","observed variant","","Variant was found in 2/5 B57+ individuals, but was always in a minor form. The frequency of the epitope mutation did not correlate with the percentage of IFN-gamma producing CTLs.","Jansen2005a"
"53741","KAF","503","","","","Gag","162","172","p24(30-40)","1273..1305","B57","KAFSPEVIPMF","eAFSPEVIPMF","K1E","K162E","OV","observed variant","","Variant was found in 1/5 B57+ individuals, but was always in a minor form. The frequency of the epitope mutation did not correlate with the percentage of IFN-gamma producing CTLs.","Jansen2005a"
"53741","KAF","504","","","","Gag","162","172","p24(30-40)","1273..1305","B57","KAFSPEVIPMF","KtFSPEVIPMF","A2T","A163T","OV","observed variant","","Variant was found in 1/5 B57+ individuals, but was always in a minor form. The frequency of the epitope mutation did not correlate with the percentage of IFN-gamma producing CTLs.","Jansen2005a"
"53776","KF11","913","B, C","","","Gag","162","172","p24(30-40)","1273..1305","B*57","KAFSPEVIPMF","KgFSPEVIPMF","A2G","A163G","A, E, NSF","HLA association, escape documented in this paper, non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Mutation A163G is suggested to be a result of selection pressure from the HLA-B*57 allele, and can be transmitted and stable in the absence of HLA-B*57. Experimental evidence indicated that the mechanism of escape was an increased off-rate; CTL recognition of KgFSPEVIPMF was ablated.  3% of HLA-B*57-positive subjects, 2% of HLA-B*5801-positive subjects carried this variant.","Leslie2005a"
"52760","KAF11","1289","B","","","Gag","162","172","p24(30-40)","1273..1305","B*5701","KAFSPEVIPMF","KsFSPEVIPMF","A2S","A163S","OV","observed variant","Sequence","This variant was seen only in one non-progressor and one treated progressor.  Index epitope KAF11 is immunodominant in several subjects and highly conserved.","Migueles2003"
"52760","KAF11","1290","B","","","Gag","162","172","p24(30-40)","1273..1305","B*5701","KAFSPEVIPMF","KgFnPEVIPMF","A2G, S4N","A163G, S165N","OV","observed variant","Sequence","This variant was seen only in one untreated progressor.","Migueles2003"
"55001","KAF","1797","B","","","Gag","162","172","p24(30-40)","1273..1305","B*5701","KAFSPEVIPMF","rAFSPEVIPMF","K1R","K162R","SF","susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","This natural variant was recognized in all patients tested.","Turnbull2006"
"55001","KAF","1798","B","","","Gag","162","172","p24(30-40)","1273..1305","B*5701","KAFSPEVIPMF","KnFSPEVIPMF","A2N","A163N","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","About half of patients tested recognized the variant, other patients had reduced or no response.","Turnbull2006"
"55001","KAF","1799","B","","","Gag","162","172","p24(30-40)","1273..1305","B*5701","KAFSPEVIPMF","KgFSPEVIPMF","A2G","A163G","SF","susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","All patients recognized the variant at >60% of the response to the index peptide.","Turnbull2006"
"55001","KAF","1800","B","","","Gag","162","172","p24(30-40)","1273..1305","B*5701","KAFSPEVIPMF","KAFSPEiIPMF","V7I","V168I","SF","susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","All patients recognized the variant at >60% of the response to the index peptide.","Turnbull2006"
"55001","KAF","1801","B","","","Gag","162","172","p24(30-40)","1273..1305","B*5701","KAFSPEVIPMF","KAFnPEVIPMF","S4N","S165N","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","About half of patients tested recognized the variant, other patients had reduced or no response.","Turnbull2006"
"55001","KAF","1802","B","","","Gag","162","172","p24(30-40)","1273..1305","B*5701","KAFSPEVIPMF","KgFnPEVIPMF","A2G, S4N","A163G, S165N","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","2 patients had response about 80% of the response to the index peptide.  Most patients had reduced or no  response.","Turnbull2006"
"55001","KAF","1803","B","","","Gag","162","172","p24(30-40)","1273..1305","B*5701","KAFSPEVIPMF","KAFnPEiIPMF","S4N, V7I","S165N, V168I","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","1 patient had response comparable to the response to the index peptide.  Most patients had reduced or no  response.","Turnbull2006"
"55001","KAF","1804","B","","","Gag","162","172","p24(30-40)","1273..1305","B*5701","KAFSPEVIPMF","KAFSPgVIPMF","E6G","E167G","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","None of the patients tested responded to this variant.","Turnbull2006"
"55092","KF11","1885","B, C","B, C","B, C","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KgFSPEVIPMF","A2G","A163G","SNSF, SSF","subtype-specific non-susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, Intracellular cytokine staining, Sequence, Tetramer binding","This variant is seen in both Clades B and C and binds HLA-B*5703.  A162G variant in Clade C is detected significantly more frequently than in Clade B and is preferentially selected in context of HLA-B*5703.  This A2G variant was recognized by HLA-B*5701- and -B*5703-expressing subjects.","Yu2007a"
"55092","KF11","1886","B, C","B, C","B, C","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KnFSPEVIPMF","A2N","A163N","SNSF, SSF","subtype-specific non-susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, Intracellular cytokine staining, Sequence, Tetramer binding","This variant is seen in both Clades B and C and binds HLA-B*5703 and -B*5701.  A162N variant in Clade C is detected significantly more frequently than in Clade B and is preferentially selected in context of HLA-B*5703.  This A2N variant was recognized by HLA-B*5701- and -B*5703-expressing subjects.","Yu2007a"
"55092","KF11","1887","B, C","B, C","B, C","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KsFSPEVIPMF","A2S","A163S","OV","observed variant","Sequence","This variant is seen in both Clades B and C and binds HLA-B*5703.  A162S variant in Clade C is detected significantly more frequently than in Clade B and is preferentially selected in context of HLA-B*5703.","Yu2007a"
"55092","KF11","1889","B, C","B, C","C","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KgFnPEVIPMF","A2G, S4N","A163G, S165N","DHB, SNSF, SSF","diminished HLA binding or increased off-rate, subtype-specific non-susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, Intracellular cytokine staining, Sequence, Tetramer binding","This variant is seen only in Clade C and binds HLA-B*5703.  S164N variant is seen most frequently and is preferentially selected in context of HLA-B*5703.  This A2G-S4N variant was recognized by HLA-B*5701- but not by -B*5703-expressing subjects, though avidity of recognition was reduced.","Yu2007a"
"55092","KF11","1890","B, C","B, C","C","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KgFkPEVIPMF","A2G, S4K","A163G, S165K","DHB, SNSF, SSF","diminished HLA binding or increased off-rate, subtype-specific non-susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, Intracellular cytokine staining, Sequence, Tetramer binding","This variant is seen only in Clade C and binds HLA-B*5703.  S164K variant is seen most frequently and is preferentially selected in context of HLA-B*5703.  This A2G-S4K variant was recognized by HLA-B*5701- but not by -B*5703-expressing subjects, though avidity of recognition was reduced.","Yu2007a"
"55092","KF11","1892","B, C","B, C","C","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KsFSPEtIPMF","A2S, V7T","A163S, V168T","OV","observed variant","Sequence","This variant is seen only in Clade C and binds HLA-B*5703.","Yu2007a"
"55092","KF11","1893","B, C","B, C","C","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KAFSPEiIPMF","V7I","V168I","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, Intracellular cytokine staining, Sequence, Tetramer binding","This variant is seen only in Clade C and binds HLA-B*5701.  The V7I variant was recognized by HLA-B*5701- and -B*5703-expressing subjects.","Yu2007a"
"55092","KF11","1894","B, C","B, C","B","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KsFSPEiIPMF","A2S, V7I","A163S, V168I","OV","observed variant","Sequence","This variant is seen only in Clade B and binds HLA-B*5703.","Yu2007a"
"55092","KF11","1895","B, C","B, C","B, C","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KAFnPEVIPMF","S4N","S165N","OV","observed variant","Sequence","This variant was seen only in non-HLA-B57 carriers, in both Clades B and C sequences.","Yu2007a"
"55092","KF11","1896","B, C","B, C","C","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KAFnPEiIPMF","S4N, V7I","S165N, V168I","OV","observed variant","Sequence","This variant was seen only in non-HLA-B57 carriers, and only in their Clade C sequences.","Yu2007a"
"55092","KF11","1897","B, C","B, C","B, C","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","rAFSPEVIPMF","K1R","K162R","OV","observed variant","Sequence","This variant was seen only in non-HLA-B57 carriers, in both Clades B and C sequences.","Yu2007a"
"55092","KF11","1898","B, C","B","C","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KAFSPkVIPMF","E6K","E167K","OV","observed variant","Sequence","This variant was seen only in non-HLA-B57 carriers, and only in Clade C sequences.","Yu2007a"
"55092","KF11","1900","B, C","","","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KAlSPEVIPMF","F3L","F164L","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","The F3L variant was recognized by HLA-B*5701- and -B*5703-expressing subjects.","Yu2007a"
"55092","KF11","1901","B, C","","","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KAFSPEVIPvF","M10V","M171V","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","The M10V variant was recognized by HLA-B*5701- and -B*5703-expressing subjects.","Yu2007a"
"55092","KF11","1902","B, C","","","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KAFSqEVIPMF","P5Q","P166Q","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","The P5Q variant was not recognized by HLA-B*5701- and -B*5703-expressing subjects.","Yu2007a"
"55092","KF11","2268","B, C","C","B","Gag","162","172","p24(30-40)","1273..1305","B*5701, B*5703","KAFSPEVIPMF","KAFSPEaIPMF","V7A","V168A","OV","observed variant","Sequence","This variant was seen only in non-HLA-B57 carriers, and only in Clade B sequences.","Yu2007a"
"57416","KF11","2363","B","B","B","Gag","162","172","p24(30-40)","1273..1305","B*57","KAFSPEVIPMF","KnFSPEVIPMF","A2N","A163N","DHB, LE","diminished HLA binding or increased off-rate, literature escape","CD8 T-cell Elispot - IFNy, Sequence","Controller subject CH-22 had the A163X escape that has a fitness cost.  CH-22 lacked the partially compensating mutation S165X, however.  Variant A163N was recognized with a lower avidity than wild type KF11.","Tang2010"
"57416","KF11","2364","B","B","B","Gag","162","172","p24(30-40)","1273..1305","B*57","KAFSPEVIPMF","rAFSPEiIPMF","K1R, V7I","K162R, V168I","DHB, LE","diminished HLA binding or increased off-rate, literature escape","CD8 T-cell Elispot - IFNy, Sequence","This rare escape was seen in subject CH-13, a controller.  CH-13 also displayed a rare substitution in epitope TW10 (TSTLQEQIGW), suggesting that the two rare mutational pathways may be inter-dependent.  Avidity of this variant, rAFSPEiIPMF, was much lower than that of wild type KF11.","Tang2010"
"53776","KF11","3067","B, C","","","Gag","162","172","p24(30-40)","1273..1305","B*57","KAFSPEVIPMF","KnFSPEVIPMF","A2N","A163N","A, E, NSF","HLA association, escape documented in this paper, non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Variant KnFSPEVIPMF (A163N) did not elicit response in EliSpot assays.  8% of HLA-B*57-positive subjects, 2% of HLA-B*5801-positive subjects, and 1% of HLA-B&amp;57/5801-negative subjects carried this variant.","Leslie2005a"
"53776","KF11","3068","B, C","","","Gag","162","172","p24(30-40)","1273..1305","B*57","KAFSPEVIPMF","KgFnPEVIPMF","A2G, S4N","A163G, S165N","A, E, NSF","HLA association, escape documented in this paper, non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","For mutation A163G, S165N CTL recognition of KgFnPEVIPMF was ablated.  14% of HLA-B*57-positive subjects, 6% of HLA-B*5801-positive subjects, and 5% of HLA-B*57/5801-negative subjects carried this variant.","Leslie2005a"
"53776","KF11","3069","B, C","","","Gag","162","172","p24(30-40)","1273..1305","B*57","KAFSPEVIPMF","KgFkPEVIPMF","A2G, S4K","A163G, S165K","A, DHB, E, NSF","HLA association, diminished HLA binding or increased off-rate, escape documented in this paper, non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","For mutation A163G, S165K CTL recognition of KgFkPEVIPMF was ablated.  8% of HLA-B*57-positive subjects carried this variant.","Leslie2005a"
"53776","KF11","3070","B, C","","","Gag","162","172","p24(30-40)","1273..1305","B*57","KAFSPEVIPMF","KsFSPEtIPMF","A2S, V7T","A163S, V168T","OV","observed variant","Sequence","Variant KsFSPEtIPMF (A163S, S168T) was found in 3% of HLA-B*57-positive subjects.","Leslie2005a"
"53776","KF11","3071","B, C","","","Gag","162","172","p24(30-40)","1273..1305","B*57","KAFSPEVIPMF","KAFSPEiIPMF","V7I","V168I","OV","observed variant","Sequence","Variant KAFSPEiIPMF (V168I) was found in 4% of HLA-B*57-positive, and 7% of HLA-B*57/5802-negative subjects.","Leslie2005a"
"53776","KF11","3072","B, C","","","Gag","162","172","p24(30-40)","1273..1305","B*57","KAFSPEVIPMF","KAFnPEVIPMF","S4N","S165N","OV","observed variant","Sequence","Mutation S165N was found in 7% of HLA-B*57/5801-negative subjects.","Leslie2005a"
"58684","KF11","3100","C","C","C","Gag","162","172","p24(30-40)","1273..1305","B*5703","KAFSPEVIPMF","KxFSPEVIPMF","A2X","A163X","OV","observed variant","Sequence","Mutation KxFSPEVIPMF was seen in &gt; 50% of HLA-B*5703-positive subjects.","Kloverpris2012"
"58684","KF11","3101","C","C","C","Gag","162","172","p24(30-40)","1273..1305","B*5703","KAFSPEVIPMF","KAFxPEVIPMF","S4X","S165X","OV","observed variant","Sequence","Mutation KAFxPEVIPMF was seen in &gt; 30% of HLA-B*5703-positive subjects.","Kloverpris2012"
"58741","KF11","3130","","","","Gag","162","172","p24(30-40)","1273..1305","B*57","KAFSPEVIPMF{S}","KAFSPEVIPMF{t}","S+1T","S173T","LE, NSF, SF","literature escape, non-susceptible form, susceptible form","CD4 T-cell Elispot - IFNy, Sequence","The S173T mutation to epitope KF11 is seen and recognized in HLA-B*57 individuals like ES38, but in this case was present in both ES38 as well as non-B*57-subject, CP2.","Buckheit2012"
"59208","KF11","3344","B","B","B","Gag","162","172","p24(30-40)",,"B*5701","KAFSPEVIPMF","KAFSPEVIPMs","F11S","F172S","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant KAFSPEVIPMs was seen in 1/3 HRP subjects (patient P1).","Buggert2014"
"59208","KF11","3345","B","B","B","Gag","162","172","p24(30-40)",,"B*5701","KAFSPEVIPMF","KAFSPEVIPMt","F11T","F172T","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant KAFSPEVIPMt was seen in 1/3 HRP (patient P1) and 1/3 LRP (patient P6) subjects.","Buggert2014"
"59208","KF11","3346","B","B","B","Gag","162","172","p24(30-40)",,"B*5701","KAFSPEVIPMF","KAFSPEiIPMF","V7I","V168I","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant KAFSPEiIPMF was seen in 1/3 HRP (patient P1) and 1/3 LRP (patient P6) subjects.","Buggert2014"
"59208","KF11","3347","B","B","B","Gag","162","172","p24(30-40)",,"B*5701","KAFSPEVIPMF","KAsSPEVIPMF","F3S","F164S","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant KAsSPEVIPMF was seen in 1/3 LRP (patient P6) subjects.","Buggert2014"
"54631","GAG-23","1956","B","B","C","Gag","163","179","p24(31-47)","1276..1326","","AFSPEVIPMFSALSEGA","AFSPEVIPMFtALSEGA","S11T","S173T","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 1 amino acid (5.9%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"57652",,"2571","","","","Gag","164","172","p24(32-40)","1279..1305","Mamu A*01","FSPEVIPMF","FnPEVIPMF","S2N","S165N","SF","susceptible form","CD8 T-cell Elispot - IFNy","T cells specific for FSPEVIPMF recognized equally strongly all tested epitope variants: FnPEVIPMF, FSPEiIPMF, qSPEVIPMF, FnPEiIPMF, FSPqVIPMF in rhesus macaques vaccinated with HIVconsv.","Rosario2010"
"57652",,"2572","","","","Gag","164","172","p24(32-40)","1279..1305","Mamu A*01","FSPEVIPMF","FSPEiIPMF","V5I","V168I","SF","susceptible form","CD8 T-cell Elispot - IFNy","T cells specific for FSPEVIPMF recognized equally strongly all tested epitope variants: FnPEVIPMF, FSPEiIPMF, qSPEVIPMF, FnPEiIPMF, FSPqVIPMF in rhesus macaques vaccinated with HIVconsv.","Rosario2010"
"57652",,"2573","","","","Gag","164","172","p24(32-40)","1279..1305","Mamu A*01","FSPEVIPMF","qSPEVIPMF","F1Q","F164Q","SF","susceptible form","CD8 T-cell Elispot - IFNy","T cells specific for FSPEVIPMF recognized equally strongly all tested epitope variants: FnPEVIPMF, FSPEiIPMF, qSPEVIPMF, FnPEiIPMF, FSPqVIPMF in rhesus macaques vaccinated with HIVconsv.","Rosario2010"
"57652",,"2574","","","","Gag","164","172","p24(32-40)","1279..1305","Mamu A*01","FSPEVIPMF","FnPEiIPMF","S2N, V5I","S165N, V168I","SF","susceptible form","CD8 T-cell Elispot - IFNy","T cells specific for FSPEVIPMF recognized equally strongly all tested epitope variants: FnPEVIPMF, FSPEiIPMF, qSPEVIPMF, FnPEiIPMF, FSPqVIPMF in rhesus macaques vaccinated with HIVconsv.","Rosario2010"
"57652",,"2575","","","","Gag","164","172","p24(32-40)","1279..1305","Mamu A*01","FSPEVIPMF","FnPEiIPMF","S2N, V5I","S165N, V168I","SF","susceptible form","CD8 T-cell Elispot - IFNy","T cells specific for FSPEVIPMF recognized equally strongly all tested epitope variants: FnPEVIPMF, FSPEiIPMF, qSPEVIPMF, FnPEiIPMF, FSPqVIPMF in rhesus macaques vaccinated with HIVconsv.","Rosario2010"
"57652",,"2576","","","","Gag","164","172","p24(32-40)","1279..1305","Mamu A*01","FSPEVIPMF","FSPqVIPMF","E4Q","E167Q","SF","susceptible form","CD8 T-cell Elispot - IFNy","T cells specific for FSPEVIPMF recognized equally strongly all tested epitope variants: FnPEVIPMF, FSPEiIPMF, qSPEVIPMF, FnPEiIPMF, FSPqVIPMF in rhesus macaques vaccinated with HIVconsv.","Rosario2010"
"169",,"355","B","","","Gag","167","175","p24(35-43)","1288..1314","A*2601","EVIPMFSAL","EVIPMFaAL","S7A","S173A","OV","observed variant","","14 of 70 sequences had a conservative change at this position, either to A or to T. Only one subtype B sequence had this epitope variant.","Goulder1996b"
"169",,"356","B","","","Gag","167","175","p24(35-43)","1288..1314","A*2601","EVIPMFSAL","EVIPMFtAL","S7T","S173T","OV","observed variant","","14 of 70 sequences had a conservative change at this position, either to A or to T.","Goulder1996b"
"53745",,"683","A, B, C, CRF01_AE, D","","","Gag","167","175","p24(35-43)","1288..1314","A*2601, A*2603","EVIPMFSAL","EVIPMFaAL","S7A","S173A","E, TCR","escape documented in this paper, TCR related mutation","CD8 T-cell Elispot - IFNy","Variant bound to A*2603 with equal affinity as the consensus form but could not be recognized by an EVIPMFSAL-specific T-cell clone, so it may mediate TCR escape","Kawashima2005"
"53745",,"684","A, B, C, CRF01_AE, D","A, B, CRF01_AE, D","C","Gag","167","175","p24(35-43)","1288..1314","A*2601, A*2603","EVIPMFSAL","EVIPMFtAL","S7T","S173T","E, TCR","escape documented in this paper, TCR related mutation","CD8 T-cell Elispot - IFNy","Variant bound to A*2603 with equal affinity as the consensus form but could not be recognized by an EVIPMFSAL-specific T-cell clone, so it may mediate TCR escape","Kawashima2005"
"53745",,"685","A, B, C, CRF01_AE, D","","","Gag","167","175","p24(35-43)","1288..1314","A*2601, A*2603","EVIPMFSAL","kVIPMFSAL","E1K","E167K","DHB","diminished HLA binding or increased off-rate","CD8 T-cell Elispot - IFNy","Variant did not bind to A*2603.","Kawashima2005"
"53745",,"686","A, B, C, CRF01_AE, D","","A","Gag","167","175","p24(35-43)","1288..1314","A*2601, A*2603","EVIPMFSAL","EiIPMFSAL","V2I","V168I","OV","observed variant","","Variant found in clade A from HIV sequence database.","Kawashima2005"
"53745",,"687","A, B, C, CRF01_AE, D","","A","Gag","167","175","p24(35-43)","1288..1314","A*2601, A*2603","EVIPMFSAL","EVIPvFSAL","M5V","M171V","OV","observed variant","","Variant found in clade A from HIV sequence database.","Kawashima2005"
"53745",,"688","A, B, C, CRF01_AE, D","","A","Gag","167","175","p24(35-43)","1288..1314","A*2601, A*2603","EVIPMFSAL","gVIPMFSAL","E1G","E167G","OV","observed variant","","Variant found in clade A from HIV sequence database.","Kawashima2005"
"53745",,"689","A, B, C, CRF01_AE, D","","B","Gag","167","175","p24(35-43)","1288..1314","A*2601, A*2603","EVIPMFSAL","EgIPMFSAL","V2G","V168G","OV","observed variant","","Variant found in clade B from HIV sequence database.","Kawashima2005"
"53745",,"690","A, B, C, CRF01_AE, D","","CRF01_AE","Gag","167","175","p24(35-43)","1288..1314","A*2601, A*2603","EVIPMFSAL","EVIPMFpAL","S7P","S173P","OV","observed variant","","Variant found in clade E from HIV sequence database.","Kawashima2005"
"53745",,"691","A, B, C, CRF01_AE, D","","B","Gag","167","175","p24(35-43)","1288..1314","A*2601, A*2603","EVIPMFSAL","EiIPMFaAL","V2I, S7A","V168I, S173A","OV","observed variant","","Variant found in clade B from HIV sequence database.","Kawashima2005"
"53745",,"692","A, B, C, CRF01_AE, D","","B","Gag","167","175","p24(35-43)","1288..1314","A*2601, A*2603","EVIPMFSAL","EmIPMFaAL","V2M, S7A","V168M, S173A","OV","observed variant","","Variant found in clade B from HIV sequence database.","Kawashima2005"
"53745",,"693","A, B, C, CRF01_AE, D","","B","Gag","167","175","p24(35-43)","1288..1314","A*2601, A*2603","EVIPMFSAL","EVIPMFttL","S7T, A8T","S173T, A174T","OV","observed variant","","Variant found in clade B from HIV sequence database.","Kawashima2005"
"53745",,"694","A, B, C, CRF01_AE, D","","C","Gag","167","175","p24(35-43)","1288..1314","A*2601, A*2603","EVIPMFSAL","EiIPMFtAL","V2I, S7T","V168I, S173T","OV","observed variant","","Variant found in clade C from HIV sequence database.","Kawashima2005"
"53745",,"695","A, B, C, CRF01_AE, D","","C","Gag","167","175","p24(35-43)","1288..1314","A*2601, A*2603","EVIPMFSAL","EeIPMFtAL","V2E, S7T","V168E, S173T","OV","observed variant","","Variant found in clade C from HIV sequence database.","Kawashima2005"
"53745",,"696","A, B, C, CRF01_AE, D","","C","Gag","167","175","p24(35-43)","1288..1314","A*2601, A*2603","EVIPMFSAL","EVIPiFtAL","M5I, S7T","M171I, S173T","OV","observed variant","","Variant found in clade C from HIV sequence database.","Kawashima2005"
"53745",,"697","A, B, C, CRF01_AE, D","","A","Gag","167","175","p24(35-43)","1288..1314","A*2601, A*2603","EVIPMFSAL","EVIPvFtAL","M5V, S7T","M171V, S173T","OV","observed variant","","Variant found in clade A from HIV sequence database.","Kawashima2005"
"53745",,"698","A, B, C, CRF01_AE, D","","C","Gag","167","175","p24(35-43)","1288..1314","A*2601, A*2603","EVIPMFSAL","EiIPiFtAL","V2I, M5I, S7T","V168I, M171I, S173T","OV","observed variant","","Variant found in clade C from HIV sequence database.","Kawashima2005"
"58694","VL8","3107","B","B","B","Gag","168","175","p24(36-43)","1291..1314","Cw*0102","VIPMSFAL","VIPMtFAL","S5T","S172T","A, DR, E","HLA association, diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","C-mut VIPMtFAL was the result of an S173T substitution in Gag epitope VIPMSFAL (VL8).  A peptide containing VIPMtFAL escape was less well recognized than wt VL8 as proved by testing for &gamma;-IFN and TNF-&alpha; production with intracellular cytokine staining (ICS) of a VL8-specific CTL cell line and its HLA-Cw*0102-transfected APC.","Blais2012"
"59019","CE2","3206","A, B, M","A, B, M","C","Gag","168","185","p24(36-53)","1291..1344","","VIPMFSALSEGATPQDLN","VIPMFtALSEGATPQDLN","S6T","S173T","SSF","subtype-specific susceptible form","Intracellular cytokine staining","VIPMFtALSEGATPQDLN is the Clade-C variant of CE2.  It was used in the p24CE2 vaccine form in this study, eliciting a robust CTL response from the vaccinated mouse.","Kulkarni2013"
"54630","GAG-24","1958","B","B","C","Gag","170","187","p24(38-55)","1297..1350","","PMFSALSEGATPQDLNTM","PMFtALSEGATPQDLNTM","S4T","S173T","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 1 amino acid (5.6%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"178",,"172","A","A","B, C, D","Gag","173","192","p24(41-60)","1306..1365","B*8101","SALSEGATPQDLNMMLNIVG","SALSEGATPQDLNtMLNtVG","M14T, I18T","M186T, I190T","OV","observed variant","","CTL responses in three individuals with non-clade B infections were studied, 2 with subtype A infections, 1 with subtype C -- their infections all originated in East Africa. This epitope is distinct in subtype A relative to subtypes B, C, and D which share the dominant sequence: SALSEGATPQDLNTMLNTVG.","Dorrell1999"
"55229",,"801","B, CRF01_AE","","CRF01_AE","Gag","173","192","p24(41-60)","1306..1365","","SALSEGATPQDLNTMLNTVG","SALSEGATPQDLNmMLNiVG","T14M, T18I","T186M, T190I","OV","observed variant","Sequence","Patient was superinfected with three strains, B1, B2 and CRF01_AE. This was the infecting variant  in CRF01_AE and it did not change over time.","Kozaczynska2007"
"55229",,"802","B, CRF01_AE","","B","Gag","173","192","p24(41-60)","1306..1365","","SALSEGATPQDLNTMLNTVG","tALSEGATPQDLNTMLNTVG","S1T","S173T","IE","inferred escape","Sequence","Patient was superinfected with three strains, B1, B2 and CRF01_AE. This variant developed in B1 to include 92% of the viruses within 4 years, and in B2 to include 96% of the viruses within 3 years.","Kozaczynska2007"
"55054",,"144","","","","Gag","180","188","p24(48-56)","1327..1353","B*4202","TPQDLNMML","TPQDLNtML","M7T","M186T","SNSF, SSF","subtype-specific non-susceptible form, subtype-specific susceptible form","","TPQDLNMML within peptide EGATPQDLNMMLNIV from A consensus and A isolate was recognized by 4 HLA B*4202 carriers from subtype A Kenyan cohort. The variant TPQDLNtML  within peptide  EGATPQDLNtMLNtV from C and D isolates was recognized by only 1 out 4 subjects that recognized TPQDLNMML.","Currier2006"
"1712",,"176","A","A","B, C, D","Gag","180","188","p24(48-56)","1327..1353","B53","TPQDLNMML","TPQDLNtML","M7T","M186T","SNSF, TCR","subtype-specific non-susceptible form, TCR related mutation","CD8 T-cell Elispot - IFNy, Cytotoxicity assay, Tetramer binding","TPQDLNMML was subtype A-specific with no cross-recognition of the subtype B, C, and D variant, TPQDLNTML, although the B/C/D variant bound more efficiently to B53 in vitro. Position 7 shows great positional variation in crystal structures of two HLA-B53 complexes, suggesting that variation here might significantly alter the position of the peptide in the binding groove and thus affect TCR interactions.","Dorrell2001"
"54622","TL9","225","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*8101","TPQDLNTML","TPeDLNTML","Q3E","Q182E","OV","observed variant","","Found in African cohort","Frater2007"
"54622","TL9","226","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*8101","TPQDLNTML","TPsDLNsML","Q3S, T7S","Q182S, T186S","OV","observed variant","","Found in African cohort","Frater2007"
"54622","TL9","227","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*8101","TPQDLNTML","TPQDLNmML","T7M","T186M","OV","observed variant","","Found in African cohort","Frater2007"
"54622","TL9","228","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*8101","TPQDLNTML","TPsDLNTMf","Q3S, L9F","Q182S, L188F","OV","observed variant","","Found in African cohort","Frater2007"
"54622","TL9","229","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*8101","TPQDLNTML","TPQDLNaML","T7A","T186A","OV","observed variant","","Found in African cohort","Frater2007"
"54622","TL9","230","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*8101","TPQDLNTML","TPrDLNmML","Q3R, T7M","Q182R, T186M","OV","observed variant","","Found in African cohort","Frater2007"
"54622","TL9","231","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*8101","TPQDLNTML","TPaDLNTML","Q3A","Q182A","OV","observed variant","","Found in African cohort","Frater2007"
"54622","TL9","232","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*8101","TPQDLNTML","TPrDLNTML","Q3R","Q182R","OV","observed variant","","Found in African cohort","Frater2007"
"54622","TL9","233","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*8101","TPQDLNTML","TPgDLNTML","Q3G","Q182G","OV","observed variant","","Found in African cohort","Frater2007"
"54622","TL9","234","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*8101","TPQDLNTML","TPQDLNTfL","M8F","M187F","OV","observed variant","","Found in African cohort","Frater2007"
"54594",,"343","A, C, D","C, D","A","Gag","180","188","p24(48-56)","1327..1353","B42, B7, B81","TPQDLNTML","TPQDLNmML","T7M","T186M","DR","diminished response","","The wild type epitope sequence was common to subtypes C and D, the variant to subtype A. CTL response in 56 individuals from Tanzania was strongest for subtype C peptide, and much lower for subtype A, due to point mutation effect. The response was also lower for subtype D, due to frame-of-epitope effect.","Geldmacher2007"
"54192","TL9","916","C","","","Gag","180","188","p24(48-56)","1327..1353","","TPQDLNTML","TPQDLNsML","T7S","T186S","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Most common variant for B*4201, B*8101 and B*3910. The variant was less well recognized than the wt, or not recognized at all, by CTLs from B*8101 and B*4201 positive individuals.","Leslie2006"
"54192","TL9","917","C","","","Gag","180","188","p24(48-56)","1327..1353","","TPQDLNTML","TPtDLNTML","Q3T","Q182T","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Variant found in B*8101, B*4201 and B*0702 positive patients. The variant was less well recognized than the wt, or not recognized at all, by CTLs from B*8101 and B*4201 positive individuals.","Leslie2006"
"54192","TL9","918","C","","","Gag","180","188","p24(48-56)","1327..1353","","TPQDLNTML","TPsDLNTML","Q3S","Q182S","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Variant found in B*8101 positive patients. The variant was less well recognized than the wt, or not recognized at all, by CTLs from B*8101 and B*4201 positive individuals.","Leslie2006"
"54192","TL9","919","C","","","Gag","180","188","p24(48-56)","1327..1353","","TPQDLNTML","TPpDLNTML","Q3P","Q182P","OV","observed variant","","Variant found in B*4201 positive patients.","Leslie2006"
"54192","TL9","920","C","","","Gag","180","188","p24(48-56)","1327..1353","","TPQDLNTML","TPaDLNTML","Q3A","Q182A","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Variant found in B*8101 and B*4201 positive patients. The variant was less well recognized than the wt, or not recognized at all, by CTLs from B*8101 and B*4201 positive individuals.","Leslie2006"
"54192","TL9","921","C","","","Gag","180","188","p24(48-56)","1327..1353","","TPQDLNTML","TPvDLNTML","Q3V","Q182V","OV","observed variant","","Variant found in B*4201 positive patients.","Leslie2006"
"54192","TL9","922","C","","","Gag","180","188","p24(48-56)","1327..1353","","TPQDLNTML","TPhDLNTML","Q3H","Q182H","OV","observed variant","","Variant found in B*4201 positive patients.","Leslie2006"
"54192","TL9","923","C","","","Gag","180","188","p24(48-56)","1327..1353","","TPQDLNTML","TPQDLNmML","T7M","T186M","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Variant found in B*8101 and B*4201 positive patients. The variant was not recognized by CTLs from B*8101 and B*4201 positive individuals.","Leslie2006"
"54192","TL9","924","C","","","Gag","180","188","p24(48-56)","1327..1353","","TPQDLNTML","TsQDLNTML","P2S","P181S","OV","observed variant","","Variant found in B*8101 and B*4201 positive patients.","Leslie2006"
"54192","TL9","925","C","","","Gag","180","188","p24(48-56)","1327..1353","","TPQDLNTML","TPeDLNTML","Q3E","Q182E","OV","observed variant","","Variant found in 8% of B*4201 positive patients.","Leslie2006"
"54192","TL9","926","C","","","Gag","180","188","p24(48-56)","1327..1353","","TPQDLNTML","TPsDLNsML","Q3S, T7S","Q182S, T186S","OV","observed variant","","Variant found in 6% of B*4201 positive patients.","Leslie2006"
"54192","TL9","927","C","","","Gag","180","188","p24(48-56)","1327..1353","","TPQDLNTML","TPgDLNTML","Q3G","Q182G","OV","observed variant","","Variant found in 2% of B*4201 positive patients.","Leslie2006"
"54192","TL9","928","C","","","Gag","180","188","p24(48-56)","1327..1353","","TPQDLNTML","aPQDLNTMv","T1A, L9V","T180A, L188V","OV","observed variant","","Variant found in 2% of B*4201 positive patients.","Leslie2006"
"54192","TL9","929","C","","","Gag","180","188","p24(48-56)","1327..1353","","TPQDLNTML","nPQDLNTML","T1N","T180N","OV","observed variant","","Variant found in 2% of B*4201 positive patients.","Leslie2006"
"54192","TL9","930","C","","","Gag","180","188","p24(48-56)","1327..1353","","TPQDLNTML","TPsDLNTMf","Q3S, L9F","Q182S, L188F","OV","observed variant","","Variant found in 2% of B*4201 positive patients.","Leslie2006"
"54192","TL9","931","C","","","Gag","180","188","p24(48-56)","1327..1353","","TPQDLNTML","TPQDLyTML","N6Y","N185Y","OV","observed variant","","Variant found in 2% of B*4201 positive patients.","Leslie2006"
"54192","TL9","932","C","","","Gag","180","188","p24(48-56)","1327..1353","","TPQDLNTML","TPQDLNTfL","M8F","M187F","OV","observed variant","","Variant found in 2% of B*4201, and 2% of B*0702 positive patients.","Leslie2006"
"54192","TL9","933","C","","","Gag","180","188","p24(48-56)","1327..1353","","TPQDLNTML","TPQDLNTvL","M8V","M187V","OV","observed variant","","Variant found in 2% of B*0702 positive patients.","Leslie2006"
"54192","TL9","934","C","","","Gag","180","188","p24(48-56)","1327..1353","","TPQDLNTML","TqQDLNpML","P2Q, T7P","P181Q, T186P","OV","observed variant","","Variant found in 6% of B*3910 positive patients.","Leslie2006"
"54192","TL9","935","C","","","Gag","180","188","p24(48-56)","1327..1353","","TPQDLNTML","aPQDLNTML","T1A","T180A","OV","observed variant","","Variant found in 6% of B*3910 positive patients.","Leslie2006"
"55736",,"1523","C","","","Gag","180","188","p24(48-56)","1327..1353","B*81","TPQDLNTML","TPQDmNTML","L5M","L184M","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","Variants TPQDmNTML, TPQDyNTML, TPQDsNTML were resistant to CTL response, but associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"55736",,"1524","C","","","Gag","180","188","p24(48-56)","1327..1353","B*81","TPQDLNTML","TPQDsNTML","L5S","L184S","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","Variants TPQDmNTML, TPQDyNTML, TPQDsNTML were resistant to CTL response, but associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"55736",,"1525","C","","","Gag","180","188","p24(48-56)","1327..1353","B*81","TPQDLNTML","TPQDyNTML","L5Y","L184Y","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","Variants TPQDmNTML, TPQDyNTML, TPQDsNTML were resistant to CTL response, but associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"58675","Gag-TL9","3113","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*4201","TPQDLNTML","TPxDLNTML","Q3X","Q182X","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","p24-TL9 mutation, TPxDLNTML, is selected in 21% HLA-B*4201 (75% have wt TL9), 15% HLA-B*4202 (82% have wt TL9) and 5% HLA-B*42-negative (89% have wt TL9) subjects.  Mutant TPlDLNTML is designated as an escape by the authors when presented by HLA-B*4201.","Kloverpris2012a"
"58813","TL9","3155","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*3910, B*8101","TPQDLNTML{...I...A}","TPtDLNTML{...h...t}","Q3T, I+35H, A+60T","Q182T, I223H, A248T","OV","observed variant","Sequence","A mutation within TL9, Q182T had developed by 2 weeks post-infection , and putative compensatory mutations I223H and A248T had also developed by then in a B*8101-positive subject [Donor HLA = A*2601, A*8001, B*1801, B*8101, Cw*0202, Cw*0401; relatively high VL with CD4+ cell count increasing between years 3-4 post-infection]","Ntale2012"
"58813","TL9","3156","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*3910, B*8101","TPQDLNTML{...I...A}","TPsDLNTML{...h...t}","Q3S, I+35H, A+60T","Q182S, I223H, A248T","OV","observed variant","Sequence","A mutation within TL9, Q182S had developed by 32 weeks post-infection , and putative compensatory mutations I223H and A248T had also developed by then in a B*8101-positive subject [Donor HLA = A*2601, A*8001, B*1801, B*8101, Cw*0202, Cw*0401; relatively high VL with CD4+ cell count increasing between years 3-4 post-infection]","Ntale2012"
"58813","TL9","3157","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*3910, B*8101","TPQDLNTML{...I}","TPQDLNTML{...a}","I+35A","I223A","OV","observed variant","Sequence","A mutation outside TL9, I223A had developed by 56 weeks post-infection in a B*8101-positive subject [Donor HLA = A*3001, A*3303, B*5301, B*8101, Cw*0401, Cw*0401; after an initial 18-24 months of control, this subject had an increased VL and decreased CD4+ T cell counts]","Ntale2012"
"58813","TL9","3158","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*3910, B*8101","TPQDLNTML{...I...I}","TPsDLNTML{...a...v}","Q3S, I+35A, I+68V","Q182S, I223A, I256V","OV","observed variant","Sequence","A mutation within TL9, Q182S, had developed by 83 weeks post-infection, and putative compensatory mutations I223A and I26V had also developed by then in a B*8101-positive subject [Donor HLA = A*3001, A*3303, B*5301, B*8101, Cw*0401, Cw*0401; after an initial 18-24 months of control, this subject had an increased VL and decreased CD4+ T cell counts]","Ntale2012"
"58813","TL9","3159","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*3910, B*8101","{E...}TPQDLNTML{...I}","{d...}aPsDLNsML{...a}","T1A, Q3S, E-3D, I+35A, T7S","T180A, Q182S, E177D, I223A, T186S","OV","observed variant","Sequence","Mutations within TL9, E177D, T180A, Q182S had developed by 108 weeks post-infection, and putative compensatory mutations I223A had also developed by then in a B*8101-positive subject [Donor HLA = A*3001, A*3303, B*5301, B*8101, Cw*0401, Cw*0401; after an initial 18-24 months of control, this subject had an increased VL and decreased CD4+ T cell counts]","Ntale2012"
"58813","TL9","3160","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*3910, B*8101","{E...}TPQDLNTML{...I}","{d...}TPsDLNsML{...v}","Q3S, E-3D, I+35V, T7S","Q182S, E177D, I223V, T186S","OV","observed variant","Sequence","Mutations within TL9, E177D, Q182S had developed by 108 weeks post-infection, and putative compensatory mutations I223V had also developed by then in a B*8101-positive subject [Donor HLA = A*3001, A*3303, B*5301, B*8101, Cw*0401, Cw*0401; after an initial 18-24 months of control, this subject had an increased VL and decreased CD4+ T cell counts].  The very same set of mutations developed in a B*3910-positive subject too, by 9 weeks post-infection [Donor HLA = A*3001, A*4301, B*3901, B*4202, Cw*1203, Cw*1701; a controller of infection]","Ntale2012"
"58813","TL9","3161","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*3910, B*8101","{E...}TPQDLNTML{...H...I}","{d...}TPsDLNsML{...q...v}","Q3S, E-3D, H+31Q, I+35V, T7S","Q182S, E177D, H219Q, I223V, T186S","OV","observed variant","Sequence","Mutations within TL9, E177D, Q182S had developed by 108 weeks post-infection, and putative compensatory mutations H219Q, I223V had also developed by then in a B*3910-positive subject, by 85 weeks post-infection [Donor HLA = A*3001, A*4301, B*3901, B*4202, Cw*1203, Cw*1701; a controller of infection]","Ntale2012"
"58813","TL9","3162","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*3910, B*8101","TPQDLNTML{...I...I}","TPaDLNTML{...v...v}","Q3A, I+35V, I+68V","Q182A, I223V, I256V","OV","observed variant","Sequence","A mutation within TL9, Q182A had developed by 8 weeks post-infection, and putative compensatory mutations I223V and !256V had also developed by then in a B*3910-positive subject, weeks post-infection [Donor HLA = A*3001, A*4301, B*3901, B*4202, Cw*1203, Cw*1701; a controller of infection]","Ntale2012"
"58813","TL9","3163","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*3910, B*8101","TPQDLNTML{...I...I}","TPgDLNTML{...v...v}","Q3G, I+35V, I+68V","Q182G, I223V, I256V","OV","observed variant","Sequence","A mutation within TL9, Q182G had developed by 28 weeks post-infection, and putative compensatory mutations I223V and I256V had also developed by then in a B*3910-positive subject [Donor HLA = A*3001, A*4301, B*3901, B*4202, Cw*1203, Cw*1701; a controller of infection]","Ntale2012"
"58813","TL9","3164","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*3910, B*8101","TPQDLNTML{...M}","TPhDLNTML{...i}","Q3H, M+62I","Q182H, M250I","OV","observed variant","Sequence","A mutation within TL9, Q182H, had developed by 50 weeks post-infection, and a putative compensatory mutation,  M250I, had also developed by then in a B*8101-positive subject [Donor HLA = A*3009, A*4301, B*5802, B*8101, Cw*0401, Cw*0401; this subject was a controller for the first 18-24 months and thereafter became a progressor].","Ntale2012"
"58813","TL9","3165","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*3910, B*8101","TPQDLNTML{...M}","TPtDLNTML{...i}","Q3T, M+62I","Q182T, M250I","OV","observed variant","Sequence","A mutation within TL9, Q182T, had developed by 54 weeks post-infection, and a putative compensatory mutation,  M250I, had also developed by then in a B*8101-positive subject [Donor HLA = A*3009, A*4301, B*5802, B*8101, Cw*0401, Cw*0401; this subject was a controller for the first 18-24 months and thereafter became a progressor].","Ntale2012"
"58813","TL9","3166","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*3910, B*8101","TPQDLNTML{...M}","TPaDLNTML{...i}","Q3A, M+62I","Q182A, M250I","OV","observed variant","Sequence","A mutation within TL9, Q182A, had developed by 71 weeks post-infection, and a putative compensatory mutation,  M250I, had also developed by then in a B*8101-positive subject [Donor HLA = A*3009, A*4301, B*5802, B*8101, Cw*0401, Cw*0401; this subject was a controller for the first 18-24 months and thereafter became a progressor].","Ntale2012"
"58813","TL9","3167","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*3910, B*8101","TPQDLNTML{...M}","TPsDLNTML{...i}","Q3S, M+62I","Q182S, M250I","OV","observed variant","Sequence","A mutation within TL9, Q182S, had developed by 84 weeks post-infection, and a putative compensatory mutation,  M250I, had also developed by then in a B*8101-positive subject [Donor HLA = A*3009, A*4301, B*5802, B*8101, Cw*0401, Cw*0401; this subject was a controller for the first 18-24 months and thereafter became a progressor].","Ntale2012"
"58813","TL9","3168","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*3910, B*8101","TPQDLNTML","TPsDLNsML","Q3S, T7S","Q182S, T186S","OV","observed variant","Sequence","Mutations within TL9, Q182S and T186S had developed by 97 weeks post-infection in a B*8101-positive subject [Donor HLA = A*3009, A*4301, B*5802, B*8101, Cw*0401, Cw*0401; this subject was a controller for the first 18-24 months and thereafter became a progressor].","Ntale2012"
"58813","TL9","3169","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*3910, B*8101","TPQDLNTML{...A}","TPsDLNsML{...t}","Q3S, A+60T, T7S","Q182S, A248T, T186S","OV","observed variant","Sequence","Mutations within TL9, Q182S and T186S had developed by 110 weeks post-infection, as well as a putative compensatory mutation at A248T in a B*8101-positive subject [Donor HLA = A*3009, A*4301, B*5802, B*8101, Cw*0401, Cw*0401; this subject was a controller for the first 18-24 months and thereafter became a progressor].","Ntale2012"
"58813","TL9","3170","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*3910, B*8101","TPQDLNTML{...I}","TPtDLNTML{...v}","Q3T, I+68V","Q182T, I256V","OV","observed variant","Sequence","A mutation within TL9, Q182T, had developed by 53 weeks post-infection, and putative compensatory mutation I256V had also developed by then in a B*4201-positive subject.","Ntale2012"
"58813","TL9","3171","C","C","C","Gag","180","188","p24(48-56)","1327..1353","B*3910, B*8101","TPQDLNTML{...H...I...M}","TPQDLNTMf{...q...v...i}","H31Q, I35V, M62I, L9F","H219Q, I223V, M250I, L188F","OV","observed variant","Sequence","A mutation within TL9, L188F had developed by 76 weeks post-infection, and putative compensatory mutations H219Q, I223V and M250I had also developed by then in a B*4201, Cw*0802-positive subject","Ntale2012"
"53705",,"331","B, G","","","Gag","180","191","p24(48-59)","1327..1362","B58","TPQDLNQMLNTV","TPQDLNtMLNTV","Q7T","Q186T","OV","observed variant","","Cross-clade T cell responses are frequently induced in individuals infected with different HIV-1 clades. There was an inverse correlation between the height of responses and epitope sequence divergence. For Gag epitopes, the magnitude of the response was directly linked to the homology between HLA anchor residues.","Geels2005"
"1676",,"677","","","","Gag","183","191","p24(51-59)","1336..1362","B14","DLNMMLNIV","DLNMtLNvV","M5T, I8V","M187T, I190V","SF","susceptible form","CD8 T-cell Elispot - IFNy","This epitope and the variant were recognized by 3/7 HIV infected women and by 4/4 HIV-exposed, persistently seronegative women.","Kaul2001a"
"196",,"1543","B","B","A","Gag","183","191","p24(51-59)","1336..1362","B*1402, Cw8","DLNTMLNTV","DLNnMLNiV","T4N, T8I","T186N, T190I","SF","susceptible form","Chromium-release assay","One HEPS Kenyan subject cross-reacted to this B clade epitope but elicited a stronger reaction to  the  A clade form, DLNnMLNiV.","Rowland-Jones1998"
"195",,"1556","","B","D","Gag","183","191","p24(51-59)","1336..1362","B14, Cw8","DLNTMLNTV","DLNmMLNiV","T4M, T8I","T186M, T190I","OV","observed variant","Chromium-release assay","5/6 Kenyan HEPS subjects recognized this clade B epitope which differed from the clade D variant, DLNmMLNiV.","RowlandJones1998b"
"59020","CE3","3205","B","B","A, C, M","Gag","191","214","p24(59-82)","1360..1431","","VGGHQAAMQMLKETINEEAAEWDR","VGGHQAAMQMLKdTINEEAAEWDR","E13D","E203D","SSF","subtype-specific susceptible form","Intracellular cytokine staining","VGGHQAAMQMLKdTINEEAAEWDR is the Clades-A, -C and -M variant of CE3.  It was used in the p24CE1 vaccine form in this study, eliciting a small CTL response.","Kulkarni2013"
"54632","GAG-27","1959","B","B","C","Gag","193","210","p24(61-78)","1366..1419","","GHQAAMQMLKETINEEAA","GHQAAMQMLKdTINEEAA","E11D","E203D","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 1 amino acid (5.6%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"53188",,"121","C","C","B","Gag","197","205","p24(65-73)","1378..1404","H-2<sup>d</sup>","ANQMLKDTI","ANQMLKeTI","D7E","D203E","SSF","subtype-specific susceptible form","CD4 T-cell Elispot - IFNy, CD8 T-cell Elispot - IFNy, Cytokine production, Cytolytic LDH release assay","A cross-clade response to the C clade epitope ANQMLKDTI was observed to the B clade version of this epitope, aNqmlkEti. 66% lysis was observed to the peptide carrying the C clade epitope, only 33% to the B clade variant.","Chugh2004"
"55324","G","805","A, B, C","A, C","B","Gag","197","205","p24(65-73)","1378..1404","H-2K<sup>d</sup>","AMQMLKDTI","AMQMLKeTI","D7E","D203E","DR","diminished response","CD8 T-cell Elispot - IFNy","After immunization with Clades A or C vaccines, both containing the wt epitope, T cells responded well to the index epitope, but poorly to this variant.","Larke2007"
"55324","G","806","A, B, C","A, C","B","Gag","197","205","p24(65-73)","1378..1404","H-2K<sup>d</sup>","AMQMLKDTI","AMQiLKDTI","M4I","M200I","DR","diminished response","CD8 T-cell Elispot - IFNy","After immunization with Clades A or C vaccines, both containing the wt epitope, T cells responded well to the index epitope, and intermediately to this variant.","Larke2007"
"57936","G1","2665","A","A","A","Gag","197","205","p24(65-73)","1378..1404","H-2K<sup>d</sup>","AMQMLKDTI","AMefLKDTa","Q3E, M4F, I9A","Q199E, M200F, I205A","DHB","diminished HLA binding or increased off-rate","HLA binding","Artificially-produced mutant AMefLKDTa was created to abrogate the anchor residues of epitope AMQMLKDTI. Loss of HLA binding was confirmed.","Im2011"
"55640",,"18","A, CRF01_AE","A","AE","Gag","198","211","p24(66-79)","1381..1422","","MQMLKDTINEEAAE","MQMLKeTINEEAAE","D6E","D203E","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","2 subjects responded to peptide MQMLKDTINEEAAE from subtype A and 1 of the 2 responded to peptide MQMLKeTINEEAAE of subtype CRF01_AE.","Aidoo2008"
"54633","GAG-28","1960","B","B","C","Gag","201","218","p24(69-86)","1390..1443","","LKETINEEAAEWDRLHPV","LKdTINEEAAEWDRLHPV","E3D","E203D","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 1 amino acid (5.6%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"56301","EW10","159","B","","","Gag","203","212","p24(71-80)","1396..1425","A25","ETINEEAAEW","ETINdEAAEW","E5D","E207D","SF","susceptible form","Flow cytometric T-cell cytokine assay","ETINEEAAEW, elicited a response in 1 patient with low viremia who also targeted Nef epitopes with high frequency.  Patient had both the index epitope and the variant ETINdEAAEW which was recognized.","Daucher2008"
"53681",,"332","A, B, D","","","Gag","203","212","p24(71-80)","1396..1425","B53, B58","ETINEEAAEW","dTINEEAAEW","E1D","E203D","OV","observed variant","","Cross-clade T cell responses are frequently induced in individuals infected with different HIV-1 clades. There was an inverse correlation between the height of responses and epitope sequence divergence. For Gag epitopes, the magnitude of the response was directly linked to the homology between HLA anchor residues.","Geels2005"
"209",,"738","","","","Gag","203","212","p24(71-80)","1396..1425","A*2501","ETINEEAAEW","dTINEEAAEW","E1D","E203D","OV","observed variant","","ETINEEAAEW is found in most B, D, and E subtype isolates while the variant is found in A and some D subtype sequences.","Klenerman1996"
"54147","EW10","956","B","","","Gag","203","212","p24(71-80)","1396..1425","A*2501","ETINEEAAEW","ETINdEAAEW","E5D","E207D","DR","diminished response","CD8 T-cell Elispot - IFNy","Amino acid site in the 5th position potentially experienced positive selection. Wt form of the epitope was 27 times better recognized than the variant, making the variant a partial escape.","Liu2006"
"1713",,"2210","A","A","B, C, D","Gag","203","212","p24(71-80)","1396..1425","B53","DTINEEAAEW","eTINEEAAEW","D1E","D203E","DR, SSF","diminished response, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Cytotoxicity assay, Tetramer binding","DTINEEAAEW was not subtype A-specific and there was cross-recognition, although diminished, of the subtype B, C, and D variant, ETINEEAAEW.","Dorrell2001"
"59074",,"3247","B","B","B","Gag","203","212","p24(71-80)",,"A*2501","ETINEEAAEW","ETINdEAAEW","E5D","E207D","DR","diminished response","Peptide titration","Ratio of EliSpot peptide titration of this mutant to original epitope EC<sub>50</sub>ratio = 27, suggesting partial escape.","Liu2007a"
"53871",,"1870","B","B","A, B","Gag","207","215","p24(75-83)","1408..1434","B*40","EEAAEWDRV","EEAAEWDRl","V9L","V215L","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Autologous variant differed from the Strain B consensus, but was recognized.","Yang2005"
"58783","p24Gag209-218","3146","B","B","B","Gag","209","218","p24(77-86)","1414..1443","","AAEWDRLHPV","AAEWDRmHPV","L7M","L215M","A, DHB","HLA association, diminished HLA binding or increased off-rate","HLA binding","Gag209-218-M, AAEWDRmHPV, binds HLA-Cw*0102 but at a decreased level.  2.9% sequences carried this variation.","Fadda2012"
"58783","p24Gag209-218","3147","B","B","B","Gag","209","218","p24(77-86)","1414..1443","","AAEWDRLHPV","AAEWDRaHPV","L7A","L215A","A","HLA association","HLA binding","Gag209-218-A, AAEWDRaHPV, showed a significant increase in binding to HLA-Cw*0102.  0.9% of sequences carried this variant.","Fadda2012"
"58783","p24Gag209-218","3148","B","B","B","Gag","209","218","p24(77-86)","1414..1443","","AAEWDRLHPV","AAEWDRqHPV","L7Q","L215Q","A, DHB","HLA association, diminished HLA binding or increased off-rate","HLA binding","Gag209-218-Q, AAEWDRqHPV, showed a slight decrease in binding to HLA-Cw*0102.  0.1% of sequences carried this variant.","Fadda2012"
"58783","p24Gag209-218","3149","B","B","B","Gag","209","218","p24(77-86)","1414..1443","","AAEWDRLHPV","AAEWDRsHPV","L7S","L215S","A","HLA association","HLA binding","Gag209-218-S, AAEWDRsHPV, showed an increase in binding to HLA-Cw*0102.  0.1% of sequences carried this variant.","Fadda2012"
"58783","p24Gag209-218","3150","B","B","B","Gag","209","218","p24(77-86)","1414..1443","","AAEWDRLHPV","AAEWDRtHPV","L7T","L215T","A","HLA association","HLA binding","Gag209-218-T, AAEWDRtHPV, showed a significant increase in binding to HLA-Cw*0102.  5.2% of sequences carried this variant.","Fadda2012"
"58783","p24Gag209-218","3151","B","B","B","Gag","209","218","p24(77-86)","1414..1443","","AAEWDRLHPV","AAEWDRvHPV","L7V","L215V","A","HLA association","HLA binding","Gag209-218-V, AAEWDRvHPV, showed a significant increase in binding to HLA-Cw*0102.  16.3% of sequences carried this variant.","Fadda2012"
"58783","p24Gag209-218","3152","B","B","B","Gag","209","218","p24(77-86)","1414..1443","","AAEWDRLHPV","AAEWDRiHPV","L7I","L215I","A","HLA association","HLA binding","Gag209-218-I, AAEWDRiHPV, showed an increase in binding to HLA-Cw*0102.  3.6% of sequences carried this variant.","Fadda2012"
"58783","p24Gag209-218","3153","B","B","B","Gag","209","218","p24(77-86)","1414..1443","","AAEWDRLHPV","-AEWDRxHPV","A1-, L7X","A209-, L215X","A, DHB","HLA association, diminished HLA binding or increased off-rate","HLA binding","All sequences with mutations at position 7 and without the N-terminal Alanine were able to bind Cw*0102, but at reduced levels.","Fadda2012"
"58783","p24Gag209-218","3154","B","B","B","Gag","209","218","p24(77-86)","1414..1443","","AAEWDRLHPV","AAEWDRxHP-","V10-, L7X","V218-, L215X","A, DHB","HLA association, diminished HLA binding or increased off-rate","HLA binding","All sequences with mutations at position 7 and without the C-terminal Valine were unable to bind Cw*0102.","Fadda2012"
"53421","AEW","1351","","","","Gag","210","218","p24(78-86)","1417..1443","A2","AEWDRLHPV","AEWgRLHPV","D4G","D213G","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/18 viral clones contained this variant sequence at the first time point tested after infection.","Oxenius2004"
"53421","AEW","1352","","","","Gag","210","218","p24(78-86)","1417..1443","A2","AEWDRLHPV","AdWDRvHPV","E2D, L6V","E211D, L215V","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/18 viral clones contained this variant sequence at the first time point tested after infection.","Oxenius2004"
"53870",,"1871","B","B","A, B","Gag","210","218","p24(78-86)","1417..1443","B*40","AEWDRVHPV","AEWDRlHPV","V6L","V215L","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Autologous variant differed from the Strain B consensus, but was recognized.","Yang2005"
"53421","AEW","2302","","","","Gag","210","218","p24(78-86)","1417..1443","A2","AEWDRLHPV","AE*DRLHPV","W3*","W212*","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","This index epitope sequence had variants at position 3 that were not specified in the paper.  Only 2/18 viral clones contained variant sequences at the first time-point tested after infection.","Oxenius2004"
"58728","DQ15","3128","","","","Gag","213","227","p24(81-95)","1426..1470","","DRLHPVHAGPIAPGQ","DRvHPVHAGPIAPGQ","L3V","L215V","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Epitope DQ15 was seen to mutate to DRvHPVHAGPIAPGQ in subject CP1 but not in the controller, VC1.  Subject CP1 recognizes DRvHPVHAGPIAPGQ as shown by EliSpot.","Buckheit2012"
"53414","DRL","1353","","","","Gag","213","232","p24(81-100)","1426..1485","","DRLHPVHAGPAAPGQMREPR","DRLHPVHAGPiAPGQMREPR","A11I","A223I","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Diminished response at higher peptide concentration, similar response at lower peptide  concentration.","Oxenius2004"
"214",,"1624","","B","B","Gag","215","224","p24(83-92)","1432..1461","B55","VHPVHAGPIA","lHPVHAGPvA","V1L, I9V","V215L, I223V","SF","susceptible form","Chromium-release assay","This naturally occurring, strain PH136 variant, was recognized by a Patient LWR CTL clone.","Sipsas1997"
"214",,"1625","","B","B","Gag","215","224","p24(83-92)","1432..1461","B55","VHPVHAGPIA","lHPVHAGPIA","V1L","V215L","SF","susceptible form","Chromium-release assay","This naturally occurring, strain RF variant, was recognized by a Patient LWR CTL clone.","Sipsas1997"
"214",,"1626","","B","B","Gag","215","224","p24(83-92)","1432..1461","B55","VHPVHAGPIA","lHPVHAGPIt","V1L, A10T","V215L, A224T","SF","susceptible form","Chromium-release assay","This naturally occurring, strain MN variant, was recognized by a Patient LWR CTL clone.","Sipsas1997"
"214",,"1627","","B","B","Gag","215","224","p24(83-92)","1432..1461","B55","VHPVHAGPIA","lHPaqAGPIA","V1L, V4A, H5Q","V215L, V218A, H219Q","SF","susceptible form","Chromium-release assay","This naturally occurring, strain JH3 variant, was very poorly recognized by a Patient LWR CTL clone.","Sipsas1997"
"57432","HA9","2472","C, D, A1","A1, C, D","C, D","Gag","216","224","p24(84-92)","1435..1461","B7 supertype","HPVHAGPVA","HPVqAGPVA","H4Q","H219Q","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVqAGPVA, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).","Hoof2010"
"57432","HA9","2473","C, D, A1","A1, C, D","C, D","Gag","216","224","p24(84-92)","1435..1461","B7 supertype","HPVHAGPVA","HPVHAGPiA","V8I","V223I","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVHAGPiA, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).","Hoof2010"
"57432","HA9","2474","C, D, A1","A1, C, D","C, D","Gag","216","224","p24(84-92)","1435..1461","B7 supertype","HPVHAGPVA","HPVHAGPip","V8I, A9P","V223I, A224P","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVHAGPip, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).","Hoof2010"
"57432","HA9","2475","C, D, A1","A1, C, D","C, D","Gag","216","224","p24(84-92)","1435..1461","B7 supertype","HPVHAGPVA","HPVHAGPVp","A9P","A224P","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVHAGPVp, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).","Hoof2010"
"57432","HA9","2476","C, D, A1","A1, C, D","C, D","Gag","216","224","p24(84-92)","1435..1461","B7 supertype","HPVHAGPVA","HPaHAGPVA","V3A","V218A","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPaHAGPVA, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).","Hoof2010"
"57432","HA9","2477","C, D, A1","A1, C, D","D","Gag","216","224","p24(84-92)","1435..1461","B7 supertype","HPVHAGPVA","HPVaAGPVA","H4A","H219A","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","Patient 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVaAGPVA, but cells encountering this variant were not susceptible in patients 2632 (African female, experienced some treatment, autologous virus Clade A1) and 2295 (Caucasian female, experienced some treatment, autologous virus Clade C).","Hoof2010"
"57432","HA9","2478","C, D, A1","A1, C, D","C, D","Gag","216","224","p24(84-92)","1435..1461","B7 supertype","HPVHAGPVA","HPVHvGPVA","A5V","A220V","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVHvGPVA, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).","Hoof2010"
"57432","HA9","2479","C, D, A1","A1, C, D","C, D","Gag","216","224","p24(84-92)","1435..1461","B7 supertype","HPVHAGPVA","HPVHAaPVA","G6A","G221A","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) and 2840 (African female, treated, autologous virus Clade D) continued to elicit response to variant HPVHAaPVA, but cells encountering this variant were not susceptible in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).","Hoof2010"
"59142","HA9","3305","B","B","B","Gag","216","224","p24(84-92)",,"B*07","HPVHAGPIA","HPVHAGPvA","I8V","I223V","OV","observed variant","Sequence","B*07-restricted variant HPVHAGPvA in the 1999 Berlin patient found circulating 15 years post-end of ART.","Jessen2014"
"55285",,"1506","B","","","Gag","219","233","p24(87-101)","1444..1488","A2","HAGPIAPGQMREPRG","qAGPIAPGQMRdPRG","H1Q, E12D","H219Q, E230D","OV","observed variant","Sequence","This index epitope was conserved in the mother's viral strain but mutated in the daughter's isolate.","Reinis2007"
"59021","CE4","3203","A, C, M","B","A","Gag","231","249","p24(99-117)","1480..1536","","PRGSDIAGTTSTLQEQIGW","PRGSDIAGTTSTpQEQIGW","L13P","L243P","SSF","subtype-specific susceptible form","Intracellular cytokine staining","PRGSDIAGTTSTpQEQIGW is the Clade-A variant of CE4.  It was not used in any vaccine form in this study.","Kulkarni2013"
"59021","CE4","3204","A, C, M","B","C, M","Gag","231","249","p24(99-117)","1480..1536","","PRGSDIAGTTSTLQEQIGW","PRGSDIAGTTSTLQEQIaW","G18A","G248A","SSF","subtype-specific susceptible form","Intracellular cytokine staining","PRGSDIAGTTSTLQEQIaW is the Clades-C and -M variant of CE4.  It was used in the p24CE2 vaccine form in this study, eliciting no response.","Kulkarni2013"
"58388","Peptide 59","2919","C","C","C","Gag","238","252","p24(106-120)","1501..1545","","GTTSTLQEQIAWMTS","GTTSTLQgQIAWMTS","E8G","E245G","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Chinese Clade-C peptide 59, GTTSTLQgQIAWMTS, did not elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"58388","Peptide 59","2920","C","C","B","Gag","238","252","p24(106-120)","1501..1545","","xGTTSTLQEQIAWMT","aGTTSTLQEQIgWMT","x1A, A12G","x238A, A249G","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-B peptide 59, aGTTSTLQEQIgWMT, did not elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"58388","Peptide 59","2921","C","C","A","Gag","238","252","p24(106-120)","1501..1545","","GTTSTLQEQIAWMTS","GTTSTLQEQIgWMTS","A11G","A248G","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-A peptide 59, GTTSTLQEQIgWMTS, did not elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"59011","Gag-TA10","3213","C","C","C","Gag","239","248","p24(107-116)","1504..1533","A*6802","TTSTLQEQIA","TTSTLQEQvA","I9V","I247V","OV","observed variant","Sequence","The I247V variant of Gag TA10, TTSTLQEQvA was observed in 4/278 HLA-A*6802-expressing subjects.","Kloverpris2013c"
"58842","TW10","3188","B","B","B","Gag","239","250","p24(107-118)","1504..1539","B*5701","TSTLQEQIGW","TSTLrEQIGW","Q5R","Q243R","OV","observed variant","Sequence","Epitope mutation, T|TSTLrEQIGW|M, was seen for TW10 by the first sampling 13 weeks post-infection in P1 who carried HLA alleles A*0101,A*0301,B*2705,B*5701.","Norstrom2012"
"58842","TW10","3189","B","B","B","Gag","239","250","p24(107-118)","1504..1539","B*5701","TSTLQEQIGW","TSTLQEQIeW","G9E","G247E","OV","observed variant","Sequence","Epitope mutation, T|TSTLQEQIeW|M, was seen for TW10 by the first sampling 13 weeks post-infection in P1 who carried HLA alleles A*0101,A*0301,B*2705,B*5701 and at 13 weeks post-infection in P5 who carried HLA alleles A*0101,A*0101,B*0801,B*5701.","Norstrom2012"
"58842","TW10","3190","B","B","B","Gag","239","250","p24(107-118)","1504..1539","B*5701","TSTLQEQIGW","TSnLQEQIGW","T3N","T241N","OV","observed variant","Sequence","Most common epitope mutation, T|TSnLQEQIGW|M, was seen for TW10 by the first sampling 13 weeks post-infection in P1 who carried HLA alleles A*0101,A*0301,B*2705,B*5701; by 18 weeks post-infection in P2 who carried HLA alleles A*0101,A*0301,B*2705,B*5701; by 13 weeks post-infection in P3 who carried HLA alleles A*2402,A*3201,B*4002,B*5701; by 11 weeks post-infection in P4 who carried HLA alleles A*0101,A*0201,B*5101,B*5701 and by 10 weeks post-infection in P6 who carried HLA alleles  A*0301,A*2402,B*3501,B*5701.","Norstrom2012"
"58842","TW10","3192","B","B","B","Gag","239","250","p24(107-118)","1504..1539","B*5701","TSTLQEQIGW","TSsLQEQIGW","T3S","T241S","OV","observed variant","Sequence","Epitope mutation, T|TSsLQEQIGW|M, was seen for TW10 by the first sampling 18 weeks post-infection in P2 who carried HLA alleles A*0101,A*0301,B*2705,B*570.","Norstrom2012"
"58842","TW10","3193","B","B","B","Gag","239","250","p24(107-118)","1504..1539","B*5701","TSTLQEQIGW","TSnLQEQIrW","T3N, G9R","T241N, G247R","OV","observed variant","Sequence","Most common epitope mutation, T|TSnLQEQIrW|M, was seen for TW10 by 109 weeks post-infection in P2 who carried HLA alleles A*0101,A*0301,B*2705,B*5701.","Norstrom2012"
"58842","TW10","3194","B","B","B","Gag","239","250","p24(107-118)","1504..1539","B*5701","TSTLQEQIGW","TSnLQEQIaW","T3N, G9A","T241N, G247A","OV","observed variant","Sequence","Most common epitope mutation, T|TSnLQEQIaW|M, was seen for TW10 by 45 weeks post-infection in P3 who carried HLA alleles A*2402,A*3201,B*4002,B*5701; by 11 weeks post-infection in P4 who carried the HLA alleles A*0101,A*0201,B*5101,B*5701; and by 144 weeks post-infection in P5 who carried the HLA alleles A*0101,A*0101,B*0801,B*5701.","Norstrom2012"
"58842","TW10","3195","B","B","B","Gag","239","250","p24(107-118)","1504..1539","B*5701","TSTLQEQIGW","TSnLQEQItW","T3N, G9R","T241N, G247R","OV","observed variant","Sequence","Most common epitope mutation, T|TSnLQEQIrW|M, was seen for TW10 by 195 weeks post-infection in P2 who carried HLA alleles A*0101,A*0301,B*2705,B*5701.","Norstrom2012"
"58842","TW10","3196","B","B","B","Gag","239","250","p24(107-118)","1504..1539","B*5701","TSTLQEQIGW","TSTLQEQIaW","G9A","G247A","OV","observed variant","Sequence","Most common epitope mutation, T|TSTLQEQIaW|M, was seen for TW10 by 13 weeks post-infection in P3 who carried HLA alleles A*2402,A*3201,B*4002,B*5701.","Norstrom2012"
"53203","TW10","33","B","","","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIGW","TSnLQEQIGW","T3N","T242N","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay","The acute immunodominant response was to TSTLQEQIGW. The response declined following viral escape to TSnLQEQIGW by day 64.","Allen2004"
"53640","TW10","197","","","","Gag","240","249","p24(108-117)","1507..1536","B57, B*5801","TSTLQEQIGW","TSnLQEQIaW","T3N, G9A","T242N, G248A","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","TW10 was found to be more frequently recognized by HLA B57-positive adults than by HLA B57-positive children.  All 14 children carried mutations of this epitope which are usually escape mutations in adults. However, majority of children (9/13) exhibited a robust response to autologous variants, while recognizing wild type epitope weakly or not at all. TSnLQEQIaW was the most common autologous variant (recognized by children), other recognized autologous variants included TSTLQEQIaW, TSnLQEQItW, TSnLaEQIaW.","Feeney2005a"
"53640","TW10","198","","","","Gag","240","249","p24(108-117)","1507..1536","B57, B*5801","TSTLQEQIGW","TSTLQEQIaW","G9A","G248A","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","TW10 was found to be more frequently recognized by HLA B57-positive adults than by HLA B57-positive children.  All 14 children carried mutations of this epitope which are usually escape mutations in adults. However, majority of children (9/13) exhibited a robust response to autologous variants, while recognizing wild type epitope weakly or not at all. TSnLQEQIaW was the most common autologous variant (recognized by children), other recognized autologous variants included TSTLQEQIaW, TSnLQEQItW, TSnLaEQIaW.","Feeney2005a"
"53640","TW10","199","","","","Gag","240","249","p24(108-117)","1507..1536","B57, B*5801","TSTLQEQIGW","TSnLQEQItW","T3N, G9T","T242N, G248T","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","TW10 was found to be more frequently recognized by HLA B57-positive adults than by HLA B57-positive children.  All 14 children carried mutations of this epitope which are usually escape mutations in adults. However, majority of children (9/13) exhibited a robust response to autologous variants, while recognizing wild type epitope weakly or not at all. TSnLQEQIaW was the most common autologous variant (recognized by children), other recognized autologous variants included TSTLQEQIaW, TSnLQEQItW, TSnLaEQIaW.","Feeney2005a"
"53640","TW10","200","","","","Gag","240","249","p24(108-117)","1507..1536","B57, B*5801","TSTLQEQIGW","TSnLaEQIaW","T3N, Q5A, G9A","T242N, Q244A, G248A","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","TW10 was found to be more frequently recognized by HLA B57-positive adults than by HLA B57-positive children.  All 14 children carried mutations of this epitope which are usually escape mutations in adults. However, majority of children (9/13) exhibited a robust response to autologous variants, while recognizing wild type epitope weakly or not at all. TSnLQEQIaW was the most common autologous variant (recognized by children), other recognized autologous variants included TSTLQEQIaW, TSnLQEQItW, TSnLaEQIaW.","Feeney2005a"
"54619","TW10","235","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*58","TSTLQEQIGW","TSnLQEQIGW","T3N","T242N","CE","calculated escape","","The variant was more often found in HLA-matched than in HLA-unmatched patients, indicating that some favorable HLA alleles induce strong pressure, resulting in escape variants with high fitness cost and low viral loads.","Frater2007"
"54619","TW10","236","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*58","TSTLQEQIGW","TSnLQEQIaW","T3N, G9A","T242N, G248A","CE","calculated escape","","The variant was more often found in HLA-matched than in HLA-unmatched patients, indicating that some favorable HLA alleles induce strong pressure, resulting in escape variants with high fitness cost and low viral loads.","Frater2007"
"54619","TW10","237","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*58","TSTLQEQIGW","TSTpQEQIGW","L4P","L243P","OV","observed variant","","Found in European cohort.","Frater2007"
"54619","TW10","238","B","","","Gag","240","249","p24(108-117)","1507..1536","B*57, B*58","TSTLQEQIGW","TSnLQEQIrW","T3N, G9R","T242N, G248R","CE","calculated escape","","This variant was more often found in HLA-B*5703 and HLA-B*5801 patients.","Frater2007"
"54621","TW10","239","C","","","Gag","240","249","p24(108-117)","1507..1536","B*5703, B*5801","TSTLQEQIAW","TSnLQEQInW","T3N, A9N","T242N, A248N","OV","observed variant","","Found in African and European cohort","Frater2007"
"54621","TW10","240","C","","","Gag","240","249","p24(108-117)","1507..1536","B*5703, B*5801","TSTLQEQIAW","TSnLQEQIAW","T3N","T242N","CE","calculated escape","","This variant was more often found in HLA-B*5703 and HLA-B*5801 patients.","Frater2007"
"54621","TW10","241","C","","","Gag","240","249","p24(108-117)","1507..1536","B*5703, B*5801","TSTLQEQIAW","TSnLQEQItW","T3N, A9T","T242N, A248T","CE","calculated escape","","This variant was more often found in HLA-B*5703 and HLA-B*5801 patients.","Frater2007"
"54621","TW10","243","C","","","Gag","240","249","p24(108-117)","1507..1536","B*5703, B*5801","TSTLQEQIAW","TSnLQEQvAW","T3N, I8V","T242N, I247V","CE","calculated escape","","This variant was more often found in HLA-B*5703 patients.","Frater2007"
"54621","TW10","244","C","","","Gag","240","249","p24(108-117)","1507..1536","B*5703, B*5801","TSTLQEQIAW","TSnLaEQIAW","T3N, Q5A","T242N, Q244A","CE","calculated escape","","This variant was more often found in HLA-B*5703 patients.","Frater2007"
"54621","TW10","245","C","","","Gag","240","249","p24(108-117)","1507..1536","B*5703, B*5801","TSTLQEQIAW","TSnLQEQIgW","T3N, A9G","T242N, A248G","CE","calculated escape","","This variant was more often found in HLA-B*5703 and HLA-B*5801 patients.","Frater2007"
"54621","TW10","246","C","","","Gag","240","249","p24(108-117)","1507..1536","B*5703, B*5801","TSTLQEQIAW","TSnLgEQIAW","T3N, Q5G","T242N, Q244G","CE","calculated escape","","This variant was more often found in HLA-B*5703 patients.","Frater2007"
"54621","TW10","247","C","","","Gag","240","249","p24(108-117)","1507..1536","B*5703, B*5801","TSTLQEQIAW","TSTpQEQIAW","L4P","L243P","OV","observed variant","","Found in African B*5801 cohort","Frater2007"
"54621","TW10","248","C","","","Gag","240","249","p24(108-117)","1507..1536","B*5703, B*5801","TSTLQEQIAW","TSTtQEQIAW","L4T","L243T","OV","observed variant","","Found in African cohort","Frater2007"
"54621","TW10","249","C","","","Gag","240","249","p24(108-117)","1507..1536","B*5703, B*5801","TSTLQEQIAW","TSsLQEQIAW","T3S","T242S","OV","observed variant","","Found in African cohort","Frater2007"
"54621","TW10","250","C","","","Gag","240","249","p24(108-117)","1507..1536","B*5703, B*5801","TSTLQEQIAW","TSTLQEQIrW","A9R","A248R","OV","observed variant","","Found in European cohort","Frater2007"
"54621","TW10","251","C","","","Gag","240","249","p24(108-117)","1507..1536","B*5703, B*5801","TSTLQEQIAW","TSTLaEQIAW","Q5A","Q244A","OV","observed variant","","Found in African cohort","Frater2007"
"54621","TW10","252","C","","","Gag","240","249","p24(108-117)","1507..1536","B*5703, B*5801","TSTLQEQIAW","TSTLQEQvAW","I8V","I247V","OV","observed variant","","Found in African cohort","Frater2007"
"54621","TW10","253","C","","","Gag","240","249","p24(108-117)","1507..1536","B*5703, B*5801","TSTLQEQIAW","TSTLQEQmAW","I8M","I247M","OV","observed variant","","Found in African B*5703 cohort","Frater2007"
"53214","TW10","395","","","","Gag","240","249","p24(108-117)","1507..1536","B57, B*5801","TSTLQEQIGW","TSnLQEQIGW","T3N","T242N","E","escape documented in this paper","","This escape variant occurs early in 75% of HLA-B*5801 and B57 positive individuals. Transmission of the variant to B*5801 and B57 negative individuals results in reversion to wt.","Goulder2004"
"53214","TW10","396","","","","Gag","240","249","p24(108-117)","1507..1536","B57, B*5801","TSTLQEQIGW","TSTLQEQIaW","G9A","G248A","E","escape documented in this paper","","This variant occurs in one third of HLA-B*5801 and B57 positive individuals. Transmission of the variant to B*5801 and B57 negative individuals does not result in reversion to wt, indicating little fitness cost of the escape mutation.","Goulder2004"
"53214","TW10","397","","","","Gag","240","249","p24(108-117)","1507..1536","B57, B*5801","TSTLQEQIGW","TSnLQEQIaW","T3N, G9A","T242N, G248A","E","escape documented in this paper","","This variant occurs in one third of HLA-B*5801 and B57 positive individuals. Transmission of the variant to B*5801 and B57 negative individuals results in reversion to wt at position 3 but not in position 9.","Goulder2004"
"53047","TW10","886","B, C","C","B, C","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSnLQEQIAW","T3N","T242N","DHB, DR, E","diminished HLA binding or increased off-rate, diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy","Variant shown to be an escape mutant correlated with HLA-B57 and HLA-B5801 alleles, and is never found in HLA-B57 and HLA-B5801 negative individuals. Variant was recognized to a lesser extent by CTLs than the wt epitope in clade C but the opposite is true in clade B. The variant can be transmitted to HLA-B57/B5801 negative individuals, but reverts to wild-type in those. Site under positive selection pressure.","Leslie2004"
"53047","TW10","887","B, C","C","B, C","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSTLQEQIgW","A9G","A248G","DR, SF","diminished response, susceptible form","CD8 T-cell Elispot - IFNy","The most common form of the epitope in the B clade. Here, the variant is recognized by CTLs. In clade-C patients, this variant is weakly associated with HLA-B57 and is recognized to a lesser extent than the clade-C wt epitope, which has an A in this position.","Leslie2004"
"53047","TW10","888","B, C","C","B, C","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSnLQEQIgW","T3N, A9G","T242N, A248G","DR, E","diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy","This variant is either not recognized at all, or recognized to a lesser extent, by CTLs of patients infected with either clade B or clade C. The second A/G escape mutation is maintained after transmission.","Leslie2004"
"53047","TW10","889","B, C","C","B, C","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSnLaEQIAW","T3N, Q5A","T242N, Q244A","OV","observed variant","","Variant found in HLA-B57 positive individuals in both clades B and C.","Leslie2004"
"53047","TW10","890","B, C","C","B, C","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSnLQEQItW","T3N, A9T","T242N, A248T","OV","observed variant","","Variant found in HLA-B57 and HLA-B5801 positive individuals in both clades B and C.","Leslie2004"
"53047","TW10","891","B, C","C","C","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSnLQEQvAW","T3N, I8V","T242N, I247V","OV","observed variant","","Variant found in HLA-B57 positive individuals in clade C.","Leslie2004"
"53047","TW10","892","B, C","C","C","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSTLQEQmAW","I8M","I247M","OV","observed variant","","Variant found in HLA-B57 positive individuals in clade C.","Leslie2004"
"53047","TW10","893","B, C","C","C","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSTLQEQmtW","I8M, A9T","I247M, A248T","OV","observed variant","","Variant found in HLA-B57 positive individuals in clade C.","Leslie2004"
"53047","TW10","894","B, C","C","B, C","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSTLQEQItW","A9T","A248T","OV","observed variant","","Variant found in HLA-B57, HLA-B5801, and other alleles, positive individuals in both clades B and C.","Leslie2004"
"53047","TW10","895","B, C","C","C","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSTLQEQIiW","A9I","A248I","OV","observed variant","","Variant found in HLA-B57 positive individuals in clade C.","Leslie2004"
"53047","TW10","896","B, C","C","C","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSTLQEQIqW","A9Q","A248Q","OV","observed variant","","Variant found in HLA-B57 and HLA-B5801 positive individuals in clade C.","Leslie2004"
"53047","TW10","897","B, C","C","C","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSTLQEQvAW","I8V","I247V","OV","observed variant","","Variant found in HLA-B57 positive individuals in clade C and in individuals with other alleles in clade C.","Leslie2004"
"53047","TW10","898","B, C","C","B","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSTpQEQIgW","L4P, A9G","L243P, A248G","OV","observed variant","","Variant found in HLA-B5801 positive individuals in clade C and  in individuals with other alleles in clade B.","Leslie2004"
"53047","TW10","899","B, C","C","B, C","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSsLQEQIAW","T3S","T242S","OV","observed variant","","Variant found in HLA-B5801 positive individuals in clade C and in individuals with other alleles in both clades B and C.","Leslie2004"
"53047","TW10","900","B, C","C","C","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSTLaEQIAW","Q5A","Q244A","OV","observed variant","","Variant found in HLA-B57 and HLA-B5801 positive individuals in clade C.","Leslie2004"
"53047","TW10","901","B, C","C","C","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSnLQEQInW","T3N, A9N","T242N, A248N","OV","observed variant","","Variant found in HLA-B5801 positive individuals in clade C.","Leslie2004"
"53047","TW10","902","B, C","C","B","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSnLQEQIqW","T3N, A9Q","T242N, A248Q","OV","observed variant","","Variant found in HLA-B57 positive individuals in clade B.","Leslie2004"
"53047","TW10","903","B, C","C","B","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSnLaEQIgW","T3N, Q5A, A9G","T242N, Q244A, A248G","OV","observed variant","","Variant found in HLA-B57 positive individuals in clade B.","Leslie2004"
"53047","TW10","904","B, C","C","B","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSTLQEQIdW","A9D","A248D","OV","observed variant","","Variant found in HLA-B57 positive individuals in clade B.","Leslie2004"
"53047","TW10","905","B, C","C","B","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSThQEQIgW","L4H, A9G","L243H, A248G","OV","observed variant","","Variant found in HLA-B57 positive individuals in clade B.","Leslie2004"
"53047","TW10","906","B, C","C","C","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSTLQEQvdW","I8V, A9D","I247V, A248D","OV","observed variant","","Variant found in individuals with other alleles than HLA-B57 and HLA-B5801 in clade C.","Leslie2004"
"53047","TW10","907","B, C","C","B, C","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSTLQEQvtW","I8V, A9T","I247V, A248T","OV","observed variant","","Variant found in individuals with other alleles than HLA-B57 and HLA-B5801 in both clades B and C.","Leslie2004"
"53047","TW10","908","B, C","C","C","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSTLQdQIAW","E6D","E245D","OV","observed variant","","Variant found in individuals with other alleles than HLA-B57 and HLA-B5801 in clade C.","Leslie2004"
"53047","TW10","909","B, C","C","B","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSTLQEQIeW","A9E","A248E","OV","observed variant","","Variant found in individuals with other alleles than HLA-B57 and HLA-B5801 in clade B.","Leslie2004"
"53047","TW10","910","B, C","C","B","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSTaQEQIgW","L4A, A9G","L243A, A248G","OV","observed variant","","Variant found in individuals with other alleles than HLA-B57 and HLA-B5801 in clade B.","Leslie2004"
"53047","TW10","911","B, C","C","C","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSnLQEQIeW","T3N, A9E","T242N, A248E","OV","observed variant","","Variant found in clade C.","Leslie2004"
"53047","TW10","912","B, C","C","C","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSnLQEQmAW","T3N, I8M","T242N, I247M","OV","observed variant","","Variant found in clade C.","Leslie2004"
"53387","gag 240-9","1012","","B","HIV-2","Gag","240","249","p24(108-117)","1507..1536","B57, B58","TSTLQEQIGW","TSTveEQIqW","L4V, Q5E, G9Q","L243V, Q244E, G248Q","SNSF, SSF","subtype-specific non-susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","The HIV-2 variant of this epitope. 5/6 HIV-2 infected individuals could recognize both the HIV-1 and HIV-2 peptides, while 0/5 HIV-1 infected patients that could react with the HIV-1 peptide could also react with the HIV-2 peptide.","Lopes2003"
"53387","gag 240-9","1013","","B","A","Gag","240","249","p24(108-117)","1507..1536","B57, B58","TSTLQEQIGW","TSTLQEQIaW","G9A","G248A","DR, SNSF, SSF","diminished response, subtype-specific non-susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","The clade A variant of this epitope. The variant resulted in significant reduction of CTL recognition in HIV-1 individuals, but was recognized by CTLs from HIV-2 infected patients.","Lopes2003"
"54535","TW10","1022","B","B","A","Gag","240","249","p24(108-117)","1507..1536","B57, B58","TSTLQEQIGW","TSTpQEQIGW","L4P","L243P","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy","No cross-recognition is seen with this A-clade variant.   This A-clade variant contains a non-conservative change at position 4 to TSTpQEQIGW.","Malhotra2007"
"54535","TW10","1023","B","B","C","Gag","240","249","p24(108-117)","1507..1536","B57, B58","TSTLQEQIGW","TSTLQEQIaW","G9A","G248A","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","Cross-recognition is seen only to the C-clade variant.  This C-clade variant has a semi-conservative substitution at position 9 to TSTLQEQIaW.  Reduced avidity was seen with this variant.","Malhotra2007"
"54216","TW10","1070","","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW","TSnLaEQIaW","T3N, Q5A, G9A","T242N, Q244A, G248A","OV","observed variant","Sequence","This triple variant was found in 1/80 HLA-B*57/58 subjects infected by Clade B HIV-1, and in 0/239 HLA-B*57/5801 negative subjects.","Martinez-Picado2006"
"54216","TW10","1071","","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW","TSnLQEQIaW","T3N, G9A","T242N, G248A","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Previously reported in the literature, Sequence","This previously suggested escape, a double variant was found in 30/80 HLA-B*57/58 subjects infected by Clade B HIV-1, but only in 1/239 HLA-B*57/5801 negative subjects.  It abrogates recognition completely at low peptide concentrations.","Martinez-Picado2006"
"54216","TW10","1072","","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW","TSnLQEQItW","T3N, G9T","T242N, G248T","OV","observed variant","Sequence","This double variant was found in 4/80 HLA-B*57/58 subjects, but in none of 107 HLA-B*57/5801 negative subjects infected with Clade B HIV-1.","Martinez-Picado2006"
"54216","TW10","1073","","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW","TSnLQEQIqW","T3N, G9Q","T242N, G248Q","OV","observed variant","Sequence","This double variant was found in 3/80 HLA-B*57/58 subjects infected with Clade B HIV-1, but in no HLA-B*57/5801 negative subjects.","Martinez-Picado2006"
"54216","TW10","1074","","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW","TSnLsEQIaW","T3N, Q5S, G9A","T242N, Q244S, G248A","OV","observed variant","Sequence","This triple variant was found in 1/80 HLA-B*57/58 subjects infected with Clade B HIV-1, and in no HLA-B*57/5801 negative subjects.","Martinez-Picado2006"
"54216","TW10","1075","","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW","TSnLQEQvaW","T3N, I8V, G9A","T242N, I247V, G248A","OV","observed variant","Sequence","This triple variant was found in 1/80 HLA-B*57/58 subjects infected with Clade B HIV-1, and in no HLA-B*57/5801 negative subjects.","Martinez-Picado2006"
"54216","TW10","1076","","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW","TtnLQEQIaW","S2T, T3N, G9A","S241T, T242N, G248A","OV","observed variant","Sequence","This triple variant was found in 1/80 HLA-B*57/58 subjects infected with Clade B HIV-1, and in no HLA-B*57/5801 negative subjects.","Martinez-Picado2006"
"54216","TW10","1077","","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW","TSThQEQIaW","L4H, G9A","L243H, G248A","OV","observed variant","Sequence","This double variant was found in 1/80 HLA-B*57/58 subjects infected with Clade B HIV-1, and in no HLA-B*57/5801 negative subjects.","Martinez-Picado2006"
"54216","TW10","1078","","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW","TSTLQEQIaW","G9A","G248A","DR","diminished response","CD8 T-cell Elispot - IFNy, Previously reported in the literature, Sequence","This variant was found in 6/80 HLA-B*57/58 subjects, but only in 17/107 HLA-B*57/5801 negative subjects infected with Clade B HIV-1.  It arises commonly and at no cost to the virus and is readily transmitted to persistence in restricting HLA negative subjects, is not correlated with compensations and increases viral infectivity.  It is however, relatively ineffective as an escape with only partial loss of recognition.","Martinez-Picado2006"
"54216","TW10","1079","","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW","TSTLQEQIdW","G9D","G248D","OV","observed variant","Sequence","This variant was found in 1/68 HLA-B*57 subjects, and in 0/107 HLA-B*57/5801 negative subjects infected with Clade B HIV-1.","Martinez-Picado2006"
"54216","TW10","1080","","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW","TSTLpEQIGW","Q5P","Q244P","OV","observed variant","Sequence","This variant was found in 1/80 HLA-B*57/58 subjects, and in no HLA-B*57/5801 negative subjects infected with Clade B HIV-1.","Martinez-Picado2006"
"54216","TW10","1081","","B, C","B, C","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW","TSnLQEQIGW","T3N","T242N","E, R, RCR","escape documented in this paper, reversion, replicative capacity reduced","","This T242N variant from Clade B consensus was found in 24/80 HLA-B*57/5801 subjects, but only in 1/107 HLA-B*57/5801 negative subject infected with Clade B HIV-1. T242N from Clade C consensus was found in 68/126 HLA-B*57/5801 subjects, but only in 2/132 HLA-B*57/5801 negative subjects infected with Clade C HIV-1.  It was thought to revert quickly to TSTLQEQIAW in HLA-B*57/5801 negative subjects since viral replication is affected in these mutants.  Amino acid T at position Gag242 is the helix stabilizing residue in p24 Gag.","Martinez-Picado2006"
"52759",,"1291","B","","","Gag","240","249","p24(108-117)","1507..1536","B*5701","TSTLQEQIGN","TSnLQEQIGN","T3N","T242N","OV","observed variant","Sequence","This variant is seen in 4/10 nonprogressors, 4/12 untreated progressors and 3/5 treated progressors.","Migueles2003"
"52759",,"1292","B","","","Gag","240","249","p24(108-117)","1507..1536","B*5701","TSTLQEQIGN","TtnLQEQIaN","S2T, T3N, G9A","S241T, T242N, G248A","OV","observed variant","Sequence","This variant is seen in 1/12 untreated progressors.","Migueles2003"
"52759",,"1293","B","","","Gag","240","249","p24(108-117)","1507..1536","B*5701","TSTLQEQIGN","TSnLQEQIaN","T3N, G9A","T242N, G248A","OV","observed variant","Sequence","This variant is seen in 2/10 nonprogressors, 5/12 untreated progressors and 2/5 treated progressors.","Migueles2003"
"52759",,"1294","B","","","Gag","240","249","p24(108-117)","1507..1536","B*5701","TSTLQEQIGN","TSnLQEQvaN","T3N, I8V, G9A","T242N, I247V, G248A","OV","observed variant","Sequence","This variant is seen in 1/12 untreated progressor.","Migueles2003"
"52759",,"1295","B","","","Gag","240","249","p24(108-117)","1507..1536","B*5701","TSTLQEQIGN","TSnLQEQIqN","T3N, G9Q","T242N, G248Q","OV","observed variant","Sequence","This variant is seen in 1/12 untreated progressor.","Migueles2003"
"53833",,"1415","C","","","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSTLQEQItW","A9T","A248T","OV","observed variant","Sequence","This variant was the autologous form seen in this non-HLA-B57 carrying mother, M5.  The variant was transmitted to her infant, I5.","Pillay2005"
"53833",,"1416","C","","","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TSnLQEQIAW","T3N","T242N","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","This variant was a dominant, escape form (complete abrogation of response) that arose by week 33 in infant I5 who carried the restricting HLA allele, B57.","Pillay2005"
"56143",,"1526","C","","","Gag","240","249","p24(108-117)","1507..1536","B57, B*5801","TSTLQEQIGW","TSnLQEQIGW","T3N","T242N","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"56143",,"1527","C","","","Gag","240","249","p24(108-117)","1507..1536","B57, B*5801","TSTLQEQIGW","TSsLQEQIGW","T3S","T242S","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"55104","TW10","1645","B","","","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIGW","TSnLQEQIGW","T3N","T242N","LE","literature escape","Previously reported in the literature","This TW10 immunodominant epitope is an early CTL response target in HLA-B57+ LTNPs.  After the acute phase of infection most subjects developed this escape variant which rapidly reverted to index sequence if transmitted to an HLA-B57- individual.","Streeck2007a"
"56633","TW10","1987","","","","Gag","240","249","p24(108-117)","1507..1536","B*5701","TSTLQEQVGW","TSTLQEQiGW","V8I","V247I","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","In patient 77 at day 159, the transmitted epitope disappeared and was substituted by two variants, TSTLQEQiGW (89%) and TSTLQEQVeW (11%). At the same time, response was high.","Goonetilleke2009"
"56633","TW10","1988","","","","Gag","240","249","p24(108-117)","1507..1536","B*5701","TSTLQEQVGW","TSTLQEQVeW","G9E","G248E","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","In patient 77 at day 159, the transmitted epitope disappeared and was substituted by two variants, TSTLQEQiGW (89%) and TSTLQEQVeW (11%). At the same time, response was high.","Goonetilleke2009"
"56673",,"2128","","","","Gag","240","249","p24(108-117)","1507..1536","B*5701","TSTLQEQIGW","TnTLQEQIGW","S2N","S241N","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Patient CH58 carried this mutant. By day 85, two mutants, TnTLQEQIGW (22%) and TSTLQEQIeW (67%) dominated; pooled mutants were reactive to the same extent as the transmitted form.","Goonetilleke2009"
"56673",,"2129","","","","Gag","240","249","p24(108-117)","1507..1536","B*5701","TSTLQEQIGW","TSTLQEQIeW","G9E","G248E","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Patient CH58 carried this mutant. By day 85, two mutants, TnTLQEQIGW (22%) and TSTLQEQIeW (67%) dominated; pooled mutants were reactive to the same extent as the transmitted form.","Goonetilleke2009"
"57353","TW10","2225","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW","TSnLQEQIGW","T3N","T242N","E, LE","escape documented in this paper, literature escape","CD8 T-cell Elispot - IFNy, Sequence","This mutation TSnLQEQIGW, is the dominant, earliest mutation found in the sample group.  It is present in lower, though not statistically significant, numbers in EC as compared to viremic subjects (CP, chronic progressors and VC, viremic controllers).  It confers a fitness cost, and WT virus out competes it in culture.  Compensatory mutations, H219Q, I223V and M228I are seen, correlating with increase in plasma VL (viral load).","Miura2009a"
"57353","TW10","2226","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","{H...}TSTLQEQIGW","{q...}TSnLQEQIGW","H-21Q, T3N","H219Q, T242N","CM","compensatory mutation","CD8 T-cell Elispot - IFNy, Sequence","H219Q, compensatory mutation to T242N is seen in greater numbers in subjects with increasing plasma VL.  This compensatory mutation alone cannot account for VL differences between HLA-B57/B*5801-positive persons.","Miura2009a"
"57353","TW10","2228","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","{M...}TSTLQEQIGW","{i...}TSnLQEQIGW","M-12I, T3N","M228I, T242N","CM","compensatory mutation","CD8 T-cell Elispot - IFNy, Sequence","M228I, compensatory mutation to T242N, is seen in increasing numbers in subjects with increasing plasma VL.  This compensatory mutation alone cannot account for VL differences between HLA-B57/B*5801-positive persons.","Miura2009a"
"57353","TW10","2253","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW{MTN}","TSTLQEQIdW{MTh}","N+3H, G9D","N252H, G248D","CM, RCR, SF","compensatory mutation, replicative capacity reduced, susceptible form","CD8 T-cell Elispot - IFNy, Relative replication capacity assay, Sequence","This G248D rare mutation was seen in only 2 EC and 2 VC B*57/B*5801 + subjects in this cohort, and 1 non-HLA B*57/B*5801 subject from a different Canadian cohort. It was associated with mutations at N252H/R. Author protein location for these double mutants is G248D/N252H. The mutation most likely did not arise from a common ancestor but through in vivo selection after transmission.  This double mutant had 54% VRC (viral replicative capacity) of the wild type NL4-3.  Since the single mutant TSTLQEQIdW (not seen in vivo) has 24% VRC in vitro, the authors suggest the 252H variation is a compensatory mutation.  The double mutation is never linked in vivo with T242N, but in vitro it is severely defective.  Authors suggest the G248D and T242N pathways of escape are mutually exclusive and incompatible in vivo.  The double mutant also affects VL by CTL response which is stronger than response to the wild type in subjects with autologous double mutant sequence.","Miura2009a"
"57353","TW10","2254","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW{MTN}","TSTLQEQIdW{MTr}","N+3R, G9D","N252R, G248D","CM, RCR, SF","compensatory mutation, replicative capacity reduced, susceptible form","CD8 T-cell Elispot - IFNy, Relative replication capacity assay","This G248D rare mutation was seen in only 2 EC and 2 VC B*57/B*5801 + subjects in this cohort, and 1 non-HLA B*57/B*5801 subject from a different Canadian cohort. It was associated with mutations at N252H/R. Author protein location for these double mutants is G248D/N252R. The mutation most likely did not arise from a common ancestor but through in vivo selection after transmission. This double mutant had 74% VRC (viral replicative capacity) of the wild type NL4-3. Since the single mutant TSTLQEQIdW (not seen in vivo) has 24% VRC in vitro, the authors suggest the 252R variation is a compensatory mutation. The double mutation is never linked in vivo with T242N, but in vitro it is severely defective.  Authors suggest the G248D and T242N pathways of escape are mutually exclusive and incompatible in vivo. The double mutant also affects VL by CTL response which is stronger than response to the wild type in subjects with autologous double mutant sequence.","Miura2009a"
"52918","TW10","2284","C","","","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIAW","TS*LQEQIAW","T3*","T242*","OV","observed variant","","174 people who have C clade infections were studied -- those who carried B57 have 2 positions in which their HIV Gag consensus is different than the C consensus. One mutation is within this epitope, TW10, at position 3, and is believed to be a TCR contact residue. The mutation is not specified in the study.","Draenert2004a"
"56633","TW10","2332","","","","Gag","240","249","p24(108-117)","1507..1536","B*5701","TSTLQEQVGW","TSnLQEQiaW","T3N, V8I, G9A","T242N, V247I, G248A","IE","inferred escape","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","In patient CH77 at 592 days, this variant predominated and the authors infer escape.","Goonetilleke2009"
"57379","TW10 wt","2339","","","","Gag","240","249","p24(108-117)","1507..1536","B*5701","TSTLQEQIGW","TSTLQEQIaW","G9A","G248A","LE","literature escape","Tetramer binding","Natural variant TSTLQEQIaW had no change in binding over wild type TW10 to inhibitory receptor ILT4 on CD14+ monocytes.","Yang2010"
"57382","TW10","2343","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSTLQEQIaW","G9A","G248A","OV","observed variant","","One HLA-B*5703 positive patient with low viral load carried this mutation at enrollment.","Durand2010"
"57382","TW10","2344","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSTLQdQvaW","E6D, I8V, G9A","E245D, I247V, G248A","OV","observed variant","Sequence","One HLA-B*5701 positive patient with low viral load carried this mutation at enrollment.","Durand2010"
"57382","TW10","2345","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSnLQEQIaW","T3N, G9A","T242N, G248A","OV","observed variant","Sequence","One HLA-B*5703 positive patient with low viral load carried this mutation by month 6; one HLA-B*5701 positive patient with low viral load carried it by month 28.","Durand2010"
"57382","TW10","2346","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSTLQEQItW","G9T","G248T","OV","observed variant","Sequence","One HLA-B*5703 positive patient with low viral load carried this mutation at enrollment.","Durand2010"
"57382","TW10","2347","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSTLQEQIeW","G9E","G248E","OV","observed variant","Sequence","One HLA-B*5702 positive patient with low viral load carried this mutation at enrollment.","Durand2010"
"57382","TW10","2348","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSTLeEQIdW","Q5E, G9D","Q244E, G248D","OV","observed variant","Sequence","One HLA-B*5702 positive patient with low viral load carried this mutation at month 13 after enrollment.","Durand2010"
"57382","TW10","2349","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSnLQEQvaW","T3N, I8V, G9A","T242N, I247V, G248A","OV","observed variant","Sequence","One HLA-B*5701 positive patient with low viral load carried this variant from month 10 onwards.","Durand2010"
"57382","TW10","2350","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSTLQEQIdW","G9D","G248D","OV","observed variant","Sequence","One HLA-B*5702 positive patient with low viral load carried this mutation a month after enrollment; one HLA-B*5701 positive patient with increased viral load also carried this variant from enrollment on.","Durand2010"
"57382","TW10","2351","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSTLQEQInW","G9N","G248N","OV","observed variant","Sequence","One HLA-B*5703 positive patient with increased viral load carried this mutation at enrollment.","Durand2010"
"57382","TW10","2352","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSnLQEQInW","T3N, G9N","T242N, G248N","OV","observed variant","Sequence","One HLA-B*5703 positive patient carried this mutation from enrollment on.","Durand2010"
"57418","TW10","2368","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSnLQEQIGW","T3N","T242N","LE","literature escape","Sequence","The T242N mutation in p24-Gag was seen in all subjects except for one controller, CH-13.  Controllers CH-04 and CH-03 who carried this particular variant, TSnLQEQIGW, did not carry any compensatory mutations known.","Tang2010"
"57418","TW10","2369","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSnLQEQIqW","T3N, G9Q","T242N, G248Q","CM, LE","compensatory mutation, literature escape","Sequence","This T242N carrying variant, TSnLQEQIqW, is accompanied by compensatory mutations H219Q and M228I (but not I223V) in progressor CH-12.","Tang2010"
"57418","TW10","2370","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSnLQEQIaW","T3N, G9A","T242N, G248A","CM, LE","compensatory mutation, literature escape","Sequence","This T242N mutation carrying variant, TSnLQEQIaW, was accompanied by compensatory mutations H219Q and M228I (but not I223V) in progressor CH-01.  In controller CH-22, however, this same variant of TW10 was not accompanied by an compensatory mutations studied.","Tang2010"
"57418","TW10","2371","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSTLQEQIdW","G9D","G248D","LE","literature escape","Sequence","This rare mutant, TSTLQEQIdW, found only in controller CH-13, did not carry the usual T242N mutation and likely represents an alternative escape pathway from epitope TW10.","Tang2010"
"57418","TW10","2372","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSnLQEQItW","T3N, G9T","T242N, G248T","CM, LE","compensatory mutation, literature escape","Sequence","This T242N carrying variant, TSnLQEQItW, is accompanied by compensatory mutations H219Q, I223V and M228I in subject CH-08.","Tang2010"
"57418","TW10","2373","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSnLaEQIaW","T3N, Q5A, G9A","T242N, Q244A, G248A","CM, LE","compensatory mutation, literature escape","Sequence","This T242N carrying variant, TSnLaEQIaW, was accompanied by compensatory mutations H219Q, I223V and M228L in progressor CH-11.","Tang2010"
"57555",,"2527","B","B","B","Gag","240","249","p24(108-117)","1507..1536","","TSTLQEQIGW","TSnLQEQIGW","T3N","T242N","E","escape documented in this paper","CD4 T-cell Elispot - IFNy","The variant TSnLQEQIGW evolved to dominate the quasispecies, and was not recognized compared to the index peptide TSTLQEQIGW by the PBMC from time points around the time of response decline, indicating escape.","Turnbull2009"
"57261","TW10","2548","A1","A1","A1","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTPQEQIGW","TSTPtEQIGW","Q5T","Q244T","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","The majority of A1-infected B*57+ subjects who responded to TW10 did not respond to P243T TSTPtEQIGW or I247L TSTPQEQlGW variants, supporting previous findings that these represent escape mutations in clade A1.","McKinnon2009"
"57261","TW10","2549","A1","A1","A1","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTPQEQIGW","TSTPQEQlGW","I8L","I247L","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","The majority of A1-infected B*57+ subjects who responded to TW10 did not respond to P243T TSTPtEQIGW or I247L TSTPQEQlGW variants, supporting previous findings that these represent escape mutations in clade A1.","McKinnon2009"
"57261","TW10","2550","A1","A1","B, D","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTPQEQIGW","TSTlQEQIGW","P4L","P243L","DR","diminished response","CD8 T-cell Elispot - IFNy","In clade A1-infected patients the recognition of the B/D consensus TSTlQEQIGW was diminished compared to that of clade A1 TSTPQEQIGW. The mutant T242N TSnlQEQIGW was previously documented for clades B and D as escape. However, despite the presumed absence of this variant in these subjects' autologous sequences, the clade B/D escape variant TSnlQEQIGW was recognized at a magnitude similar to that of consensus clade A1 TSTPQEQIGW.","McKinnon2009"
"57261","TW10","2551","A1","A1","B, D","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTPQEQIGW","TSnlQEQIGW","T3N, P4L","T242N, P243L","SF","susceptible form","CD8 T-cell Elispot - IFNy","In clade A1-infected patients the recognition of the B/D consensus TSTlQEQIGW was diminished compared to that of clade A1 TSTPQEQIGW. The mutant T242N TSnlQEQIGW was previously documented for clades B and D as escape. However, despite the presumed absence of this variant in these subjects' autologous sequences, the clade B/D escape variant TSnlQEQIGW was recognized at a magnitude similar to that of consensus clade A1 TSTPQEQIGW.","McKinnon2009"
"57648","TW10","2566","","","","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSnLQEQIGW","T3N","T242N","E","escape documented in this paper","Relative replication capacity assay","Of 2 HLA-B57-positive early controllers both had, at the earliest time point tested, signature B57 mutations in Gag that impaired viral replication capacity: T242N in TSTLQEQIGW (TSnLQEQIGW) and I147L in ISPRTLNAW (lSPRTLNAW).","Miura2010"
"57846","TW10","2649","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*5703","TSTLQEQIGW","TSTLQEQIeW","G9E","G248E","E, SF","escape documented in this paper, susceptible form","CD8 T-cell Elispot - IFNy, Longitudinal study","Variant arose during early infection in 2 B*57-positive patients. The variant failed to evade TW10-specific T cells, but severely reduced interaction between KIR3DL1 and HLA-B*5703.","Brackenridge2011"
"57846","TW10","2650","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*5703","TSTLQEQIGW","TSnLQEQIGW","T3N","T242N","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Longitudinal study","Variant arose during early infection in 2 B*57-positive patients, but disappeared by day 350. The T3N change abrogated T cell recognition of the TW10 epitope, but was not associated with loss of KIR binding to HLA-B*57.","Brackenridge2011"
"57676",,"2672","B","A, B, C, D","B, D","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIGW","TSnLQEQIGW","T3N","T242N","SF, SSF","susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Variant TSnLQEQIGW was found at a frequency of 3 and 5 in clades B and D respectively.","Koup2010"
"57676",,"2673","B","A, B, C, D","A, B, C, D","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIGW","TSTLQEQIaW","G9A","G248A","SF, SSF","susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Variant TSTLQEQIaW was found at frequencies of 5, 8, 63 and 36 in clades A, B, C and D respectively.","Koup2010"
"57676",,"2674","B","A, B, C, D","A, B, C, D","Gag","240","249","p24(108-117)","1507..1536","B57","TSTLQEQIGW","TSTpQEQIGW","L4P","L243P","SF, SSF","susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Variant TSTpQEQIGW was found at a frequency of 42 in clade A.","Koup2010"
"58008","TW10","2696","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSnLQEQIGW","T3N","T242N","LE, P","literature escape, processing","","B57-TW10 was selected for analysis based on having known early mutants (T3N and T3N-G9A or T3N-G9D) that were predicted to have reduced intracellular stability. Mutant T3N was stable, while T3N-G9A or T3N-G9D severely reduced half-life. Single mutants G9A and G9D also displayed decreased half-lives.","Lazaro2011"
"58008","TW10","2697","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSnLQEQIaW","T3N, G9A","T242N, G248A","LE, P","literature escape, processing","","B57-TW10 was selected for analysis based on having known early mutants (T3N and T3N-G9A or T3N-G9D) that were predicted to have reduced intracellular stability. Mutant T3N was stable, while T3N-G9A or T3N-G9D severely reduced half-life. Single mutants G9A and G9D also displayed decreased half-lives.","Lazaro2011"
"58008","TW10","2698","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSnLQEQIdW","T3N, G9D","T242N, G248D","LE, P","literature escape, processing","","B57-TW10 was selected for analysis based on having known early mutants (T3N and T3N-G9A or T3N-G9D) that were predicted to have reduced intracellular stability. Mutant T3N was stable, while T3N-G9A or T3N-G9D severely reduced half-life. Single mutants G9A and G9D also displayed decreased half-lives.","Lazaro2011"
"58008","TW10","2699","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSTLQEQIaW","G9A","G248A","A, P","HLA association, processing","","B57-TW10 was selected for analysis based on having known early mutants (T3N and T3N-G9A or T3N-G9D) that were predicted to have reduced intracellular stability. Mutant T3N was stable, while T3N-G9A or T3N-G9D severely reduced half-life. Single mutants G9A and G9D also displayed decreased half-lives.","Lazaro2011"
"58008","TW10","2700","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSTLQEQIdW","G9D","G248D","A, P","HLA association, processing","","B57-TW10 was selected for analysis based on having known early mutants (T3N and T3N-G9A or T3N-G9D) that were predicted to have reduced intracellular stability. Mutant T3N was stable, while T3N-G9A or T3N-G9D severely reduced half-life. Single mutants G9A and G9D also displayed decreased half-lives.","Lazaro2011"
"57873","TW10","2714","C","C","C","Gag","240","249","p24(108-117)","1507..1536","B*5801","TSTLQEQIAW","TSTLpEQIAW","Q5P","Q244P","?","unclear","Sequence","4/18 and 4/12 sampled viral sequences in subject CAP217 carried this variant, TSTLpEQIAW, 3.4 and 3.8 months post infection.","Chopera2011"
"57873","TW10","2715","C","C","C","Gag","240","249","p24(108-117)","1507..1536","B*5801","TSTLQEQIAW","TSTLQEeIAW","Q7E","Q246E","?","unclear","Sequence","1/18 sampled viral sequences in subject CAP217 carried this variant, TSTLQEeIAW, 3.4 months post infection.","Chopera2011"
"57873","TW10","2716","C","C","C","Gag","240","249","p24(108-117)","1507..1536","B*5801","TSTLQEQIAW","TSTLQEQIAW|i","M+1I","M250I","OV, SF","observed variant, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","All sampled viral sequences in subject CAP268 carried this flanking mutation, TSTLQEQIAW|i, 1.8, 5.5, 12.3, 19.8 and 31.4 months post infection.  While this subject responded to TW10, not surprisingly no epitopic escapes were found as the M250I mutation here has been previously associated with reduced frequency of escape in TW10.","Chopera2011"
"57873","TW10","2717","C","C","C","Gag","240","249","p24(108-117)","1507..1536","B*5801","TSTLQEQIAW","TSTLQEQItW","A9T","A248T","?","unclear","Sequence","2/10 sampled viral sequences in subject CAP229 carried this variant, TSTLQEQItW, 1.8 months post infection.","Chopera2011"
"57873","TW10","2718","C","C","C","Gag","240","249","p24(108-117)","1507..1536","B*5801","TSTLQEQIAW","TSnLQEQItW","T3N, A9T","T242N, A248T","OV, SF","observed variant, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","2/10, 6/6, 3/3, 23/23, 15/15, 24/24, 15/15 and 16/16 sampled viral sequences in subject CAP229 carried this variant, TSTLQEQItW, 1.8, 2.1, 4.8, 5.8, 18.4, 21.2, 24.2 and 28.1 months post infection.  At 2.1 months post-infection, CTL response was reduced.","Chopera2011"
"57873","TW10","2719","C","C","C","Gag","240","249","p24(108-117)","1507..1536","B*5801","TSTLQEQIAW","TSnLQEQvAW","T3N, I8V","T242N, I247V","OV, SF","observed variant, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","9/9 and 9/9 sampled viral sequences in subject CAP239 carried this variant, TSnLQEQvAW, 5.1 and 18.2 months post infection.  At 5.1 months post-infection, CTL response was reduced.","Chopera2011"
"57873","TW10","2720","C","C","C","Gag","240","249","p24(108-117)","1507..1536","B*5801","TSTLQEQIAW","TSTLQEQvAW","I8V","I247V","OV","observed variant","Sequence","20/21 sampled viral sequences in subject CAP239 carried this variant, TSTLQEQvAW, 0.5 months post infection.","Chopera2011"
"57873","TW10","2721","C","C","C","Gag","240","249","p24(108-117)","1507..1536","B*5801","TSTLQEQIAW","TSTiQEQvtW","L4I, I8V, A9T","L243I, I247V, A248T","?","unclear","Sequence","1/21 sampled viral sequences in subject CAP239 carried this variant, TSTiQEQvtW, 0.5 months post infection.","Chopera2011"
"57873","TW10","2722","C","C","C","Gag","240","249","p24(108-117)","1507..1536","B*5801","TSTLQEQIAW","TSnLQEQvtW","T3N, I8V, A9T","T242N, I247V, A248T","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","27/27 and 19/19 sampled viral sequences in subject CAP239 carried this variant, TSnLQEQvtW, 1.2 and 1.4 months post infection and CTL response when tested, was reduced.","Chopera2011"
"57873","TW10","2723","C","C","C","Gag","240","249","p24(108-117)","1507..1536","B*5801","TSTLQEQIAW","TSTLhEQvqW","Q5H, I8V, A9Q","Q244H, I247V, A248Q","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","2/9 sampled viral sequences in subject CAP274 carried this variant, TSTLhEQvqW, 2.4 months post infection.","Chopera2011"
"57873","TW10","2724","C","C","C","Gag","240","249","p24(108-117)","1507..1536","B*5801","TSTLQEQIAW","TSnLQEQvqW","T3N, I8V, A9Q","T242N, I247V, A248Q","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","All viral sequences sampled in subject CAP274 carried this variant, TSnLQEQvqW, 2.4, 5.1 and 13.9 months post infection.","Chopera2011"
"57873","TW10","2725","C","C","C","Gag","240","249","p24(108-117)","1507..1536","B*5801","TSTLQEQIAW","TSTLtEQIAW","Q5T","Q244T","?","unclear","Sequence","1/9 sampled viral sequences in subject CAP217 carried this variant, TSTLtEQIAW, 5.2 months post infection.","Chopera2011"
"57873","TW10","2726","C","C","C","Gag","240","249","p24(108-117)","1507..1536","B*5801","TSTLQEQIAW","TSnLQEQIAW","T3N","T242N","?, OV, SF","unclear, observed variant, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant at position 3, TSnLQEQIAW, was seen in subject CAP217.  6/12, 12/12, 7/9, 10/10 and 14/14 sequences carried the variant at 3.8, 4.3, 5.2, 6.2 and 13.8 months post-infection.  At 4.3 months post-infection, CTL response was reduced.","Chopera2011"
"58229",,"2796","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*5701","TSTLQEQIGW","TSnLQEQIGW","T3N","T242N","IE","inferred escape","Sequence","1/9, 2/9, 1/2 and 3/3 sequences of epitope TSTLQEQIGW varied at 45, 85, 154 and 350 DFOSx to TSnLQEQIGW.  Position 110 in the epitope is marked as being under selection to vary.","Ferrari2011"
"58229",,"2798","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*5701","TSTLQEQIGW","TSTLQEQIeW","G9E","G248E","IE","inferred escape","Sequence","1/2, 6/9 and 1/2 sequences of epitope TSTLQEQIGW varied at 45, 85 and 154 DFOSx to TSTLQEQIeW.  Position 116 in the epitope is marked as being under selection to vary.","Ferrari2011"
"58236",,"2806","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*5701","TSTLQEQVGW","TSTLQEQiGW","V8I","V247I","IE","inferred escape","Sequence","8/9 sequences of epitope TSTLQEQVGW  varied at 159 DFOSx to ITSTLQEQiGW.  Position 115 in the peptide is marked as being under selection to vary.","Ferrari2011"
"58236",,"2808","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*5701","TSTLQEQVGW","TSTLQEQVeW","G9E","G248E","OV","observed variant","Sequence","1/9 sequences of epitope TSTLQEQVGW  varied at 159 DFOSx to TSTLQEQVeW.  Position 116 in the peptide is marked as being under selection to vary.","Ferrari2011"
"58236",,"2809","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*5701","TSTLQEQVGW","TSnLQEQiaW","T3N, V8I, G9A","T242N, V247I, G248A","OV","observed variant","Sequence","8/8 sequences of epitope TSTLQEQVGW  varied at 592 DFOSx to TSnLQEQiaW.","Ferrari2011"
"57913",,"2827","","","","Gag","240","249","p24(108-117)","1507..1536","B*5701","TSTLQEQIGW","TSnLQEQIaW","T3N, G9A","T242N, G248A","E","escape documented in this paper","Tetramer binding",,"Fadda2011"
"57913",,"2829","","","","Gag","240","249","p24(108-117)","1507..1536","B*5701","TSTLQEQIGW","TSnLQEQIaW","T3N, G9A","T242N, G248A","E","escape documented in this paper","Tetramer binding",,"Fadda2011"
"57913",,"2830","","","","Gag","240","249","p24(108-117)","1507..1536","B*5701","TSTLQEQIGW","TSTLQEQIdW","G9D","G248D","E","escape documented in this paper","Tetramer binding",,"Fadda2011"
"58356","TW10","2890","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSTLtEQvaW","Q5T, I8V, G9A","Q244T, I247V, G248A","DR","diminished response","CD8 T-cell Elispot - IFNy, CTL suppression of replication","Variant TSTLtEQvaW elicited a highly diminished CTL response and when present in a virus, greatly reduced its replicative capacity.","OConnell2011"
"58356","TW10","2891","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSTLaEQvaW","Q5A, I8V, G9A","Q244A, I247V, G248A","DR","diminished response","CD8 T-cell Elispot - IFNy, CTL suppression of replication","Variant TSTLaEQvaW elicited a highly diminished CTL response and when present in virus, greatly reduced its replicative capacity.","OConnell2011"
"58356","TW10","2892","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSTLsEQvaW","Q5S, I8V, G9A","Q244S, I247V, G248A","DR","diminished response","CD8 T-cell Elispot - IFNy, CTL suppression of replication","Variant TSTLsEQvaW elicited a highly diminished CTL response and when present in virus, greatly reduced its replicative capacity.","OConnell2011"
"58356","TW10","2893","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSTLsEQIaW","Q5S, G9A","Q244S, G248A","DR","diminished response","CD8 T-cell Elispot - IFNy, CTL suppression of replication","Variant TSTLsEQIaW elicited a highly diminished CTL response and when present in virus, greatly reduced its replicative capacity.","OConnell2011"
"58356","TW10","2894","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSTLvEQIaW","Q5V, G9A","Q244V, G248A","DR","diminished response","CD8 T-cell Elispot - IFNy, CTL suppression of replication","Variant TSTLvEQIaW elicited a highly diminished CTL response and when present in virus, greatly reduced its replicative capacity.","OConnell2011"
"58356","TW10","2895","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSTLtEQIaW","Q5T, G9A","Q244T, G248A","DR","diminished response","CD8 T-cell Elispot - IFNy, CTL suppression of replication","Variant TSTLtEQIaW elicited a highly diminished CTL response and when present in virus, greatly reduced its replicative capacity.","OConnell2011"
"58356","TW10","2896","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSTLaEQIaW","Q5A, G9A","Q244A, G248A","DR","diminished response","CD8 T-cell Elispot - IFNy, CTL suppression of replication","Variant TSTLaEQIaW elicited a highly diminished CTL response and when present in virus, greatly reduced its replicative capacity.","OConnell2011"
"57353","TW10","2996","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","{I...}TSTLQEQIGW","{v...}TSnLQEQIGW","I-17V, T3N","I223V, T242N","CM","compensatory mutation","Sequence","I223V, compensatory mutation to T242N, is seen in increasing numbers in subjects with increasing plasma VL.  This compensatory mutation alone cannot account for VL differences between HLA-B57/B*5801-positive persons.","Miura2009a"
"57353","TW10","2999","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW{M}","TSTLQEQmtW{i}","M+1I, I8M, G9T","M250I, I247M, G248T","RCR","replicative capacity reduced","CD8 T-cell Elispot - IFNy, Relative replication capacity assay, Sequence","Variant TSTLQEQmtW{i} (author designation I247M/G248T/M250I/252N) displayed a lower replication capacity than variant G248D (TSTLQEQIdW) and was found in one elite controller.","Miura2009a"
"57353","TW10","3000","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW{MTN}","TSTLQEQmaW{iTh}","M+1I, N+3H, I8M, G9A","M250I, N252H, I247M, G248A","CM, RCR","compensatory mutation, replicative capacity reduced","CD8 T-cell Elispot - IFNy, Relative replication capacity assay, Sequence","Variant TSTLQEQmaW{iTh} (author designation I247M/G248A/M250I/N252H) was found in 2 elite controllers.  It displayed an improved replication capacity (VRC) over variant TSTLQEQmaW{iTN}, but had a slightly lower VRC (91%) than wild type virus, supporting the compensatory effect of N252H mutation.","Miura2009a"
"57353","TW10","3001","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW{M}","TSTLQEQmaW{i}","M+1I, I8M, G9A","M250I, I247M, G248A","E, RCR","escape documented in this paper, replicative capacity reduced","CD8 T-cell Elispot - IFNy, Relative replication capacity assay, Sequence","Variant TSTLQEQmaW{i} (author designation I247M/G248A/M250I/252N) displayed a reduced replication capacity at 71% of wild type virus. It was found in one elite controller, BEC33, who also carried 3 other rare variants.  Thus the M250I mutation likely induces a considerable fitness defect, while the I247M/G248A mutations are escapes [see variant TSTLQEQmaW].","Miura2009a"
"57353","TW10","3002","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW{M}","TSTLQEQmaW{v}","M+1V, I8M, G9A","M250V, I247M, G248A","E, RCR","escape documented in this paper, replicative capacity reduced","CD8 T-cell Elispot - IFNy, Relative replication capacity assay, Sequence","Variant TSTLQEQmaW{v} (author designation I247M/G248A/M250V/252N) was extremely attenuated, producing almost no live virus. It was found in one elite controller, BEC33, who also carried 3 other rare variants. The variant peptide was also not able to elicit CTL response.","Miura2009a"
"57353","TW10","3003","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW{M}","TSTLQEQIaW{i}","M+1I, G9A","M250I, G248A","RCR, SF","replicative capacity reduced, susceptible form","CD8 T-cell Elispot - IFNy, Relative replication capacity assay, Sequence","Variant TSTLQEQIaW{i} (author designation G248A/M250I/252N) displayed a reduced replication capacity at 62% of wild type virus'. This peptide was able to elicit a CTL response.  It was found in one elite controller, BEC33, who also carried 3 other rare variants.","Miura2009a"
"57353","TW10","3004","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW{MTN}","TSTLQEQlnW{iTN}","M+1I, I8L, G9N","M250I, I247L, G248N","?, RCR","unclear, replicative capacity reduced","Relative replication capacity assay, Sequence","Variant TSTLQEQlnW|iTN (author designation I247L/G248N/M250I/252N) displayed reduced viral replication at 79% of wild type.  Peptide  TSTLQEQlnW elicited CTL response greater than that of TW10.","Miura2009a"
"57353","TW10","3006","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW{M}","TSnLQEQIaW{i}","M+1I, T3N, G9A","M250I, T242N, G248A","RCR","replicative capacity reduced","CD8 T-cell Elispot - IFNy, Relative replication capacity assay, Sequence","Variant TSnLQEQIaW{i} (author designation T242N/G248A/M250I/252N) was extremely attenuated, producing no live virus.","Miura2009a"
"57353","TW10","3007","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW","TSTLQEQIaW","G9A","G248A","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Variant TSTLQEQIaW (author designation G248A) elicited a stronger CTL response in a controlling subject than wild type TW10 did. It was an autologous sequence in this patient.","Miura2009a"
"57353","TW10","3008","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW","TSTLQEQmaW","I8M, G9A","I247M, G248A","E, RCR","escape documented in this paper, replicative capacity reduced","CD8 T-cell Elispot - IFNy, Relative replication capacity assay, Sequence","Variant peptide TSTLQEQmaW (author designation I247M/G248A/252N) was unable to elicit CTL response in one subject, suggesting they represent mutations leading to escape. This peptide elicited low response, less than to WT TW10, when it was the autologous sequence in another subject. The variant virus showed reduced viral replication.","Miura2009a"
"57353","TW10","3009","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW","TSTLQEQlnW","I8L, G9N","I247L, G248N","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Variant peptide TSTLQEQlnW (author designation I247L/G248N) elicited CTL response greater than that of TW10 in a controller where it was the autologous sequence.  When combined with a downstream mutation at M250I, however (author designation I247L/G248N/M250I/252N), variant TSTLQEQlnW|iTN has a reduced viral replication capacity.","Miura2009a"
"57353","TW10","3010","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW{M}","TSnLQEQlnW{i}","M+1I, T3N, I8L, G9N","M250I, T242N, I247L, G248N","RCR","replicative capacity reduced","Relative replication capacity assay, Sequence","Variant TSnLQEQlnW{i} (author designation T242N/I247L/G248N/M250I/252N) displayed defective viral replication resulting in insufficient titers to obtain virus for tests.","Miura2009a"
"57353","TW10","3011","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW{M}","TSnLQEQInW{i}","M+1I, T3N, G9N","M250I, T242N, G248N","RCR","replicative capacity reduced","Relative replication capacity assay, Sequence","Variant TSnLQEQInW{i} (author designation T242N/G248N/M250I/252N) displayed defective viral replication resulting in insufficient titers to obtain virus for tests.","Miura2009a"
"57353","TW10","3013","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW{MTN}","TSnLQEQInW{MTg}","T3N, N+3G, G9N","T242N, N252G, G248N","RCR","replicative capacity reduced","Relative replication capacity assay, Sequence","Variant TSnLQEQInW{MTg} (author designation T242N/G248N/N252G) displayed reduced replication capacity, 85% of wild type virus.","Miura2009a"
"57353","TW10","3015","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW{MTN}","TSTLQEQInW{MTg}","N+3G, G9N","N252G, G248N","RCR","replicative capacity reduced","Relative replication capacity assay, Sequence","Variant TSnLQEQInW{MTg} (author designation G248N/N252G) displayed slightly reduced replication capacity, 89% of wild type virus.","Miura2009a"
"57353","TW10","3016","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW{MTN}","TSnLQEQIGW{MTg}","T3N, N+3G","T242N, N252G","RCR","replicative capacity reduced","Relative replication capacity assay, Sequence","Variant TSnLQEQIGW{MTg} (author designation N252G) displayed slightly reduced replication capacity, 72% of wild type virus.","Miura2009a"
"57353","TW10","3017","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW","TSnLQEQItW","T3N, G9T","T242N, G248T","NSF, RCR, SF","non-susceptible form, replicative capacity reduced, susceptible form","Relative replication capacity assay, Sequence","Variant TSnLQEQItW (author designation T242N/G248N) displayed very slightly reduced replication capacity at 92% of wild type virus.  The subject carrying this autologous virus was able to recognize the variant peptide even more strongly than wild type TW10. All subjects tested who recognized the T242N variant of TW10, whether they were controllers or not, were also able to recognize variant peptides of the T242N/G248X pattern (including this peptide, TSnLQEQItW).  The variant, however, was not recognized by any subject where it was a non-autologous sequence.","Miura2009a"
"57353","TW10","3018","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW","TSnLQEQItr","W10R, T3N, G9T","W249R, T242N, G248T","E","escape documented in this paper","Relative replication capacity assay","Variant TSnLQEQItr [author designation T242N/G248T/W249R] was found in only 1 viremic controller subject.  An in vitro synthesized mutant proviral NL4-3 was unable to generate enough virus for experimentation.  Position 249 is the anchor position of TW10.","Miura2009a"
"57353","TW10","3019","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW","TSnLQEQIaW","T3N, G9A","T242N, G248A","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","Variant peptide TSnLQEQIaW was not able to elicit CTL response in 7/8 subjects queried.  One subject elicited low IFN-&gamma; at higher peptide concentrations.","Miura2009a"
"57353","TW10","3020","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW","TSTLQEQIdW","G9D","G248D","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Variant peptide TSTLQEQIdW elicited CTL response in 6/8 controllers queried, where 4 of the subjects carried it as an autologous sequence.  The 2 non-responders did not carry this variant as autologous.","Miura2009a"
"57353","TW10","3021","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW","TSnLQEQInW","T3N, G9N","T242N, G248N","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Variant peptide TSnLQEQInW elicited low CTL response, and in only 1/8 controllers queried in whom it was the autologous sequence.","Miura2009a"
"58688","TW10","3102","C","C","C","Gag","240","249","p24(108-117)","1507..1536","B*5702, B*5703, B*5801","TSTLQEQIAW","TSxLQEQIAW","T3X","T242X","OV","observed variant","Sequence","Mutation TSxLQEQIAW was seen in >75% of both HLA-B*5703 and -B*5702 positive subjects, and in just under 75% of HLA-B*5801 carrying subjects.","Kloverpris2012"
"58688","TW10","3103","C","C","C","Gag","240","249","p24(108-117)","1507..1536","B*5702, B*5703, B*5801","TSTLQEQIAW","TSTLQEQxAW","I8X","I247X","OV","observed variant","Sequence","Mutation TSTLQEQxAW was seen in &#152;25% of HLA-B*5703-positive subjects, and in very few HLA-B*5801 or -B*5702 carrying subjects.","Kloverpris2012"
"58744",,"3132","","","","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSTLQEQIaW","G9A","G248A","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Mutant TSTLQEQIaW was seen in and recognized by subject ES38.","Buckheit2012"
"58744",,"3133","","","","Gag","240","249","p24(108-117)","1507..1536","B*57","TSTLQEQIGW","TSTLQEQvaW","I8V, G9A","I247V, G248A","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Mutant TSTLQEQvaW was seen in CP2 Gag sequences even though CP2 does not carry the HLA-B*57 allele.  Subject CP2 was not able to recognize this sequence by EliSpot.","Buckheit2012"
"58777","TW10","3142","B, C","B, C","B, C","Gag","240","249","p24(108-117)","1507..1536","","TSTLQEQIAW{M}","TSTLaEQIAW{i}","M+1I, Q5A","M250I, Q244A","DR","diminished response","Relative replication capacity assay","One of the subtype C variants.","Chopera2012"
"58777","TW10","3143","B, C","B, C","C","Gag","240","249","p24(108-117)","1507..1536","","TSTLQEQIAW{M}","TSTLQEQmAW{i}","M+1I, I8M","M250I, I247M","DR","diminished response","Relative replication capacity assay","One of the subtype C mutants.","Chopera2012"
"58777","TW10","3144","B, C","B, C","B, C","Gag","240","249","p24(108-117)","1507..1536","","TSTLQEQIAW{M}","TSTLQEQvAW{i}","M+1I, Q5A","M250I, Q244A","DR","diminished response","Relative replication capacity assay","TSTLQEQIAW{i} is the M250I mutation under study.","Chopera2012"
"57353","TW10","3200","B","B","B","Gag","240","249","p24(108-117)","1507..1536","B*57, B*5801","TSTLQEQIGW{M}","TSTLQEQlnW{i}","M+1I, I8L, G9N","M250I, I247L, G248N","?, RCR","unclear, replicative capacity reduced","Relative replication capacity assay, Sequence","Variant TSTLQEQlnW{i} (author designation I247L/G248N/M250I/252N) displayed reduced viral replication at 79% of wild type.  Peptide  TSTLQEQlnW elicited CTL response greater than that of TW10.","Miura2009a"
"59143","TW10","3306","B","B","B","Gag","240","249","p24(108-117)",,"B*57","TSTLQEQIGW","TnTLQEQIGW","S2N","S241N","OV","observed variant","Sequence","B*57-restricted variant TnTLQEQIGW in the 1999 Berlin patient found circulating 15 years post-end of ART.","Jessen2014"
"59194","TW10","3314","B","B","B","Gag","240","249","p24(108-117)",,"B*5701, B*58","TSTLQEQIGW","TSnLQEQIGW","T3N","T242N","DR, OV, RCR","diminished response, observed variant, replicative capacity reduced","Relative replication capacity assay, Sequence","Mutant TSnLQEQIGW, T242N, was detected in HLA-B*57 subject CH58 at 45 days post infection (dpi), and was fixed by 350 dpi.  This mutation is known to significantly reduce CTL response.  T242N mutation when introduced into the T/F backbones of CH58, CH470 and CH40 replicated as well as the T/F virus.  Relative fitness studies with both the introduced and T/F viruses in the same culture was greater for the T/F virus than its corresponding T242N mutant.","Liu2014a"
"59194","TW10","3315","B","B","B","Gag","240","249","p24(108-117)",,"B*5701, B*58","TSTLQEQIGW","TSTLQEQIeW","G9E","G248E","DR, OV","diminished response, observed variant","Relative replication capacity assay, Sequence","Mutant TSTLQEQIeW, G248E, was detected in HLA-B*57 subject CH58 at 45 days post infection (dpi), but disappeared after 154 dpi.  This mutation is known to modestly reduce CTL response.","Liu2014a"
"59194","TW10","3316","B","B","B","Gag","240","249","p24(108-117)",,"B*5701, B*58","TSTLQEQIGW","TiTLQEQIGW","S2I","S241I","OV","observed variant","Sequence","Variant TiTLQEQIGW was seen in subject CH131 175 dpi, transiently.","Liu2014a"
"59210","TW10","3348","B","B","B","Gag","240","249","p24(108-117)",,"B*5701","TSTLQEQIGW","TSTLrEQIGW","Q5R","Q244R","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant TSTLrEQIGW was seen in 1/3 HRP (patient P1) subjects.","Buggert2014"
"59210","TW10","3349","B","B","B","Gag","240","249","p24(108-117)",,"B*5701","TSTLQEQIGW","TSTLQEQIeW","Q5R, G9E","Q244R, G248E","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant TSTLQEQIeW was seen in 1/3 HRP (patient P1) and 1/3 LRP (patient 5) subjects.","Buggert2014"
"59210","TW10","3350","B","B","B","Gag","240","249","p24(108-117)",,"B*5701","TSTLQEQIGW","TSsLQEQIGW","T3S","T242S","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant TSTLrEQIeW was seen in 1/3 HRP (patient P2) subjects.","Buggert2014"
"59210","TW10","3351","B","B","B","Gag","240","249","p24(108-117)",,"B*5701","TSTLQEQIGW","TSnLQEQIGW","T3N","T242N","E, OV","escape documented in this paper, observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant TSnLQEQIGW, TW10-3N was seen in all 6 HRP and LRP subjects.","Buggert2014"
"59210","TW10","3352","B","B","B","Gag","240","249","p24(108-117)",,"B*5701","TSTLQEQIGW","TSnLQEQIrW","T3N, G9R","T242N, G248R","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant TSnLQEQIrW was seen in all 1/3 HRP (patient P2) subjects.","Buggert2014"
"59210","TW10","3353","B","B","B","Gag","240","249","p24(108-117)",,"B*5701","TSTLQEQIGW","TSnLQEQItW","T3N, G9T","T242N, G248T","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant TSnLQEQItW was seen in all 1/3 HRP (patient P2) subjects.","Buggert2014"
"59210","TW10","3354","B","B","B","Gag","240","249","p24(108-117)",,"B*5701","TSTLQEQIGW","TSnLQEQIaW","T3N, G9A","T242N, G248A","E, OV","escape documented in this paper, observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant TSnLQEQIaW, TW10-3N-9A, was seen in 1/3 HRP (patient P3) and 1/3 LRP (patient 5) subjects.  It was the analogous epitope of the major viral population at the last time point in patient P1, the earliest time point in patients P2 and P3, and the only variant in LRP patients P4 and P6.","Buggert2014"
"59210","TW10","3355","B","B","B","Gag","240","249","p24(108-117)",,"B*5701","TSTLQEQIGW","TSTLQEQIaW","G9A","G248A","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant TSTLQEQIaW was seen in 1/3 LRP (patient 5) subjects.","Buggert2014"
"53676",,"333","B, D","","","Gag","241","249","p24(109-117)","1510..1536","B58","STLQEQIGW","STLQEQIaW","G8A","G248A","OV","observed variant","","Cross-clade T cell responses are frequently induced in individuals infected with different HIV-1 clades. There was an inverse correlation between the height of responses and epitope sequence divergence. For Gag epitopes, the magnitude of the response was directly linked to the homology between HLA anchor residues.","Geels2005"
"56057","Gag242","202","","","","Gag","242","250","p24(110-118)","1513..1539","A2","TLQEQIGWM","sLQEQIGWM","T1S","T242S","OV","observed variant","","One HLA-A2 patient did not respond to the TLQEQIGWM epitope but the variant peptide was observed in the patient.","Fomsgaard2008"
"55368","Gag 242","1668","","","","Gag","242","250","p24(110-118)","1513..1539","A2","TLQEQIGWM","TLQEQIaWM","G7A","G248A","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subjects Pt15 and Pt33 carried this variant and were unable to recognize the challenge HXB2 form.  Subjects Pt35 and Pt41 carried the HXB2 sequence and were able to recognize it; all others Pt16, Pt17, Pt18, Pt21, Pt23 and Pt35 did carry the HXB2 epitope, but could not recognize it.","Thorn2007"
"55368","Gag 242","1669","","","","Gag","242","250","p24(110-118)","1513..1539","A2","TLQEQIGWM","nLQEQIGWM","T1N","T242N","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt30 carried this variant and was unable to recognize the challenge HXB2 form, NTVATLYCV.","Thorn2007"
"58747",,"3136","","","","Gag","249","263","p24(117-131)","1534..1578","","WMTNNPPIPVGEIYK","WMTsNPPvPVGEIYK","N4S, I8V","N252S, I256V","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, CTL suppression of replication, Intracellular cytokine staining","WMTsNPPvPVGEIYK  was a variant found in both CP2 and ES38 HIV-1 sequences even though it was recognized by subject CP2 and not ES38.","Buckheit2012"
"53072","Gag 271","1114","M","B, C","C","Gag","250","258","p24(118-126)","1537..1563","A*0201","MTSNPPIPV","MTnNPPIPV","S3N","S252N","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Mice immunized with subtype C epitope MTSNPPIPV, induced CTL that were able to recognize variant peptide MTnNPPIPV; and mice immunized with subtype B epitope form MTnNPPIPV induced CTL that also recognized self peptide, MTnNPPIPV.","McKinney2004"
"53072","Gag 271","1115","M","B, C","C","Gag","250","258","p24(118-126)","1537..1563","A*0201","MTSNPPIPV","MTSNPPvPV","I7V","I256V","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Mice immunized with subtype C epitope MTSNPPIPV induced CTL that were able to recognize variant MTSNPPvPV; but mice immunized with subtype B form MTnNPPIPV induced CTL that were unable to recognize the same subtype C variant, MTSNPPvPV.","McKinney2004"
"53072","Gag 271","1116","M","B, C","C","Gag","250","258","p24(118-126)","1537..1563","A*0201","MTSNPPIPV","MTSdPPvPV","N4D, I7V","N253D, I256V","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Mice immunized with subtype C epitope MTSNPPIPV induced CTL that were able to recognize variant MTSdPPvPV; but mice immunized with subtype B form MTnNPPIPV induced CTL that were unable to recognize the same subtype C variant, MTSdPPvPV.","McKinney2004"
"53072","Gag 271","1117","M","B, C","C","Gag","250","258","p24(118-126)","1537..1563","A*0201","MTSNPPIPV","MTSNPaIPV","P6A","P255A","DHB, NSF, SF","diminished HLA binding or increased off-rate, non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Mice immunized with subtype C epitope MTSNPPIPV induced CTL that were able to recognize variant MTSNPaIPV; but mice immunized with subtype B form  MTnNPPIPV induced CTL that were unable to recognize the same subtype C variant, MTSNPaIPV. Binding of variant MTSNPaIPV to HLA-A2 was extremely weak.","McKinney2004"
"53072","Gag 271","1118","M","B, C","C","Gag","250","258","p24(118-126)","1537..1563","A*0201","MTSNPPIPV","MTgNPPIPV","S3G","S252G","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Mice immunized with subtype C epitope MTSNPPIPV induced CTL that were able to recognize variant MTgNPPIPV; but mice immunized with subtype B form MTnNPPIPV induced CTL that were unable to recognize the same subtype C variant, MTgNPPIPV.","McKinney2004"
"53072","Gag 271","1119","M","B, C","C","Gag","250","258","p24(118-126)","1537..1563","A*0201","MTSNPPIPV","MTgNPsIPV","S3G, P6S","S252G, P255S","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Mice immunized with subtype C epitope MTSNPPIPV, induced CTL that were unable to recognize variant MTgNPsIPV; and mice immunized with subtype B form MTnNPPIPV induced CTL that were also unable to recognize the same subtype C variant.","McKinney2004"
"53072","Gag 271","1120","M","B, C","C","Gag","250","258","p24(118-126)","1537..1563","A*0201","MTSNPPIPV","MTgNPaIPV","S3G, P6A","S252G, P255A","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Mice immunized with subtype C epitope MTSNPPIPV, induced CTL that were unable to recognize variant MTgNPaIPV; and mice immunized with subtype B form MTnNPPIPV induced CTL that were also unable to recognize the same subtype C variant.","McKinney2004"
"53072","Gag 271","1121","M","B, C","C","Gag","250","258","p24(118-126)","1537..1563","A*0201","MTSNPPIPV","MTgNPPvPV","S3G, I7V","S252G, I256V","DHB, NSF, SF","diminished HLA binding or increased off-rate, non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Mice immunized with subtype C epitope MTSNPPIPV induced CTL that were able to recognize variant MTgNPPvPV; but mice immunized with subtype B form MTnNPPIPV, induced CTL that were unable to recognize the same subtype C variant, MTgNPPvPV.  Binding of variant MTgNPPvPV to HLA-A2 was extremely weak.","McKinney2004"
"53072","Gag 271","1122","M","B, C","C","Gag","250","258","p24(118-126)","1537..1563","A*0201","MTSNPPIPV","MTaNPPIPV","S3A","S252A","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Mice immunized with subtype C epitope MTSNPPIPV induced CTL that were able to recognize variant MTaNPPIPV; but mice immunized with subtype B form MTnNPPIPV, induced CTL that were unable to recognize the same subtype C variant, MTaNPPIPV.","McKinney2004"
"53072","Gag 271","1123","M","B, C","C","Gag","250","258","p24(118-126)","1537..1563","A*0201","MTSNPPIPV","MTaNPPvPV","S3A, I7V","S252A, I256V","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Mice immunized with subtype C epitope MTSNPPIPV induced CTL that were able to recognize variant MTaNPPvPV; but mice immunized with subtype B form MTnNPPIPV, induced CTL that were unable to recognize the same subtype C variant, MTaNPPvPV.","McKinney2004"
"53072","Gag 271","1125","M","B, C","C","Gag","250","258","p24(118-126)","1537..1563","A*0201","MTSNPPIPV","MThNPPIPV","S3H","S252H","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Mice immunized with subtype C epitope MTSNPPIPV induced CTL that were able to recognize variant MThNPPIPV; but mice immunized with subtype B form MTnNPPIPV, induced CTL that were barely able to recognize the same subtype C variant, MThNPPIPV.","McKinney2004"
"53842","MV9","1575","","","","Gag","250","258","p24(118-126)","1537..1563","A2","MTNNPPIPV","MThNPPIPV","N3H","N252H","OV","observed variant","Sequence","This variant from the HXB2 sequence was present in the non-HLA-A2 allele carrying mother, M-1004, as well as her restricting-HLA-A2-carrying infant, P-1115.   This variant was still detected at 12 months of age in infant P-1115.","Sanchez-Merino2005"
"59119","NY10","3292","CRF01_AE","CRF01_AE","CRF01_AE","Gag","252","262","p24(120-130)",,"B*3501, B*3505","nNPPIPVGDIY","nNPPIPVGeIY","D9E","D260E","DHB, IE, OV","diminished HLA binding or increased off-rate, inferred escape, observed variant","Sequence","Variant NPPIPVGeIY (D260E) is associated with B*3501 positive subjects, being present in 3/5 -B*3501+ but in only 3/211 -B*3501- subjects.  It is not associated with B*3505 positive subjects, being present in 0/4 -B*3505+ but in 6/212 -B*3505- subjects.  It has previously been seen to cause epitope-HLA binding instability.","Mori2014"
"59119","NY10","3293","CRF01_AE","CRF01_AE","CRF01_AE","Gag","252","262","p24(120-130)",,"B*3501, B*3505","nNPPIPVGDIY","nNPPIPVGDxY","I10X","I261X","IE, OV","inferred escape, observed variant","Sequence","Variant NPPIPVGDxY (I261X) is associated with B*3501 positive subjects, being present in 2/5 -B*3501+ but in only 2/209 -B*3501- subjects.  It is not associated with B*3505 positive subjectsIt is not associated with B*3505 positive subjects, being present in 0/4 -B*3505+ but in 6/212 -B*3505- subjects..","Mori2014"
"59119","NY10","3294","CRF01_AE","CRF01_AE","CRF01_AE","Gag","252","262","p24(120-130)",,"B*3501, B*3505","nNPPIPVGDIY","sNPPIPVGDIY","n1S","n252S","OV","observed variant","Sequence","Flanking mutation, sNPPIPVGDIY (n252s) is seen in B-3505+ patients P1013 and P1497 as well as in B-3501+ patient P453 of the Lampang cohort, but with no mutations within the NY10 epitope.","Mori2014"
"59119","NY10","3295","CRF01_AE","CRF01_AE","CRF01_AE","Gag","252","262","p24(120-130)",,"B*3501, B*3505","nNPPIPVGDIY","xNPPIPVGDIY","n1X","n252X","IE, OV","inferred escape, observed variant","Sequence","Flanking mutations, xNPPIPVGDIY (n252x), is associated with B*3501 positive subjects, being present in 5/5 -B*3501+ but in 94/209 -B*3501- subjects.  It is not associated with B*3505 positive subjects, being present in 2/4 -B*3505+ but in 97/212 -B*3505- subjects.","Mori2014"
"59119","NY10","3296","CRF01_AE","CRF01_AE","CRF01_AE","Gag","252","262","p24(120-130)",,"B*3501, B*3505","nNPPIPVGDIY","sNPPIPVGeIY","n1S, D9E","n252S, D260E","OV","observed variant","Sequence","Flanking and epitope mutations, sNPPIPVGeIY seen in B-3501+ patient P2097 of the Lampang cohort.","Mori2014"
"59119","NY10","3297","CRF01_AE","CRF01_AE","CRF01_AE","Gag","252","262","p24(120-130)",,"B*3501, B*3505","nNPPIPVGDIY","sNPPIPVGefY","n1S, I10F, D9E","n252S, I261F, D260E","OV","observed variant","Sequence","Flanking and epitope mutations, sNPPIPVGefY seen in B-3501+ patient P1349 of the Lampang cohort.","Mori2014"
"59119","NY10","3298","CRF01_AE","CRF01_AE","CRF01_AE","Gag","252","262","p24(120-130)",,"B*3501, B*3505","nNPPIPVGDIY","sNPPIPVGDlY","n1S, I10L","n252S, I261L","OV","observed variant","Sequence","Flanking and epitope mutations, sNPPIPVGDlY seen in B-3501+ patient P381 of the Lampang cohort.","Mori2014"
"59119","NY10","3299","CRF01_AE","CRF01_AE","CRF01_AE","Gag","252","262","p24(120-130)",,"B*3501, B*3505","nNPPIPVGDIY","dNPPvPVGeIY","n1D, I5V, D9E","n252D, I256V, D260E","OV","observed variant","Sequence","Flanking and epitope mutations, sNPPvPVGeIY seen in B-3501+ patient P206 of the Lampang cohort.","Mori2014"
"58600","NY10, NY10-260D","3081","C","C","C","Gag","253","262","p24(121-130)","1546..1575","B*3501","NPPIPVGDIY","NPPIPVGeIY","D8E","D260E","DHB, DR, E, SNSF","diminished HLA binding or increased off-rate, diminished response, escape documented in this paper, subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding, Intracellular cytokine staining, Sequence, Tetramer binding","The C clade variant, NPPIPVGeIY, is also the major B clade form of epitope NY10.  This NY10-260E variant binds to HLA-B*3105 10x less well than the wt and is 3x less stable.","Matthews2012"
"58651","NY10, NY10-260E","3082","B","B","B","Gag","253","262","p24(121-130)","1546..1575","B*3501","NPPIPVGEIY","NPPIPVGdIY","E8D","E260D","SF, SSF","susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, HLA binding, Intracellular cytokine staining, Tetramer binding","The B clade variant, NPPIPVGdIY, is also the major C clade form of epitope NY10.  This NY10-260D variant binds to HLA-B*3105 10x better than the Clade B wt and is 3x more stable.","Matthews2012"
"230",,"380","","","","Gag","253","267","p24(121-135)","1546..1590","B8","NPPIPVGEIYKRWII","NPPIPVGdIYKRWII","E8D","E260D","SF","susceptible form","","This variant was recognized by patient CTLs, but the wt epitope was not recognized, indicating that the CTLs tested were of different population than those raised against the wt epitope.","Goulder1997e, Phillips1991"
"57725",,"2626","","","","Gag","253","272","p24(121-140)","1546..1605","","NPPIPVGEIYKRWIILGLNK","NPPIPVGEIYKRWIImGLNK","L16M","L268M","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Variant NPPIPVGEIYKRWIImGLNK was seen in patient C07.","Vollbrecht2010"
"242",,"1544","B","B","A","Gag","254","262","p24(122-130)","1549..1575","B35","PPIPVGEIY","PPIPVGdIY","E7D","E260D","SF","susceptible form","Chromium-release assay","One HEPS Kenyan subject cross-reacted to this B clade epitope but elicited a stronger reaction to  the  A clade form, PPIPVGdIY.","Rowland-Jones1998"
"56011","PY9(p24)","1909","B","B","B","Gag","254","262","p24(122-130)","1549..1575","","PPIPVGEIY","PPIPVGdIY","E7D","E260D","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B35 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"56011","PY9(p24)","1910","B","B","B","Gag","254","262","p24(122-130)","1549..1575","","PPIPVGEIY","NPVPVGNIY","P1N, I3V, E7N","P254N, I256V, E260N","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at 3 residues. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"58389","Peptide 63","2922","C","C","C","Gag","254","268","p24(122-136)","1549..1593","","PPIPVGDIYKRWIIL","PPvPVGeIYKRWIIL","I3V, D7E","I256V, D260E","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Chinese Clade-C peptide 63, PPvPVGeIYKRWIIL, cross reacted to elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"58389","Peptide 63","2923","C","C","C","Gag","254","268","p24(122-136)","1549..1593","","xPPIPVGDIYKRWII","nPPIPVGeIYKRWII","x1N, D8E","x254N, D261E","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-B peptide 63, nPPIPVGeIYKRWII, cross reacted to elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"58389","Peptide 63","2924","C","C","D","Gag","254","268","p24(122-136)","1549..1593","","PPIPVGDIYKRWIIL","PPIPVGeIYKRWIIL","D7E","D260E","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Chinese Clade-D peptide 63, PPIPVGeIYKRWIIL, cross reacted to elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"254",,"1110","","B","","Gag","259","267","p24(127-135)","1564..1590","B*0801","GDIYKRWII","GeIYKRWII","D2E","D260E","SSF","subtype-specific susceptible form","Chromium-release assay","A peptide containing this circulating Ugandan variant was recognized as well by a CTL clone from a  Clade B-infected  patient.","McAdam1998"
"252",,"1345","","","","Gag","259","267","p24(127-135)","1564..1590","B8","GEIYKRWII","GdIYKRWII","E2D","E260D","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Chromium-release assay, HLA binding, Longitudinal study","Both E index epitope and D variant bind HLA-B8 similarly.  The E index loses recognition by CTL coincident with its emergence as the only detectable form, though later it is recognized again.  This appears to be an example of escape from CTL response when the circulating CTL clones fail to recognize the form they are specific for.   The latter return of recognition of the E form is thought to be a cross-reactive response.","Nowak1995"
"55007","GEI","1805","","","","Gag","259","267","p24(127-135)","1564..1590","B*0801","GEIYKRWII","GdIYrRWII","E2D, K5R","E260D, K263R","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","None of the patients tested responded to this variant.","Turnbull2006"
"55007","GEI","1806","","","","Gag","259","267","p24(127-135)","1564..1590","B*0801","GEIYKRWII","rkIYKRWII","G1R, E2K","G259R, E260K","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","None of the patients tested responded to this variant.","Turnbull2006"
"55007","GEI","1807","","","","Gag","259","267","p24(127-135)","1564..1590","B*0801","GEIYKRWII","GdIYrkWIv","E2D, K5R, R6K, I9V","E260D, K263R, R264K, I267V","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","None of the patients tested responded well to this variant.","Turnbull2006"
"55007","GEI","1808","","","","Gag","259","267","p24(127-135)","1564..1590","B*0801","GEIYKRWII","GnIYrRWIq","E2N, K5R, I9Q","E260N, K263R, I267Q","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","None of the patients tested responded to this variant.","Turnbull2006"
"55007","GEI","1809","","","","Gag","259","267","p24(127-135)","1564..1590","B*0801","GEIYKRWII","GEIYKRWIv","I9V","I267V","DR, SF","diminished response, susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","Some patients had response at the level of the response to the index peptide. 2 patients had about 50% of the original response.","Turnbull2006"
"55007","GEI","1810","","","","Gag","259","267","p24(127-135)","1564..1590","B*0801","GEIYKRWII","GdIYKRWII","E2D","E260D","DR, SF","diminished response, susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","Some patients had response at the level of the response to the index peptide. 2 patients had about 50% of the original response.","Turnbull2006"
"55007","GEI","1811","","","","Gag","259","267","p24(127-135)","1564..1590","B*0801","GEIYKRWII","GdIYKRWIv","E2D, I9V","E260D, I267V","DR, NSF, SF","diminished response, non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","One patient responded at 80% of original response, 2 at 60%, 1 at 40% and 1 at 10%.","Turnbull2006"
"57493","GI9","2480","B","B","B","Gag","259","267","p24(127-135)","1564..1590","","GEIYKRWII","GdIYKRWII","E2D","E260D","SF","susceptible form","CD8 T-cell Elispot - IFNy","Patients 2275 (Latin male, experienced some treatment, autologous virus Clade B); 2792 (Caucasian female, treatment naive, autologous virus Clade B); 2902 (Caucasian male, treated, autologous virus Clade B) all continued to elicit CTL response to variant GdIYKRWII.","Hoof2010"
"57493","GI9","2481","B","B","B","Gag","259","267","p24(127-135)","1564..1590","","GEIYKRWII","GEIYKRWIv","I9V","I267V","SF","susceptible form","CD8 T-cell Elispot - IFNy","Patients 2275 (Latin male, experienced some treatment, autologous virus Clade B); 2792 (Caucasian female, treatment naive, autologous virus Clade B); 2902 (Caucasian male, treated, autologous virus Clade B) all continued to elicit CTL response to variant GEIYKRWIv.","Hoof2010"
"57493","GI9","2482","B","B","B","Gag","259","267","p24(127-135)","1564..1590","","GEIYKRWII","GEIYKaWII","R6A","R264A","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","Patients 2275 (Latin male, experienced some treatment, autologous virus Clade B); 2792 (Caucasian female, treatment naive, autologous virus Clade B) both continued to elicit CTL response to variant GEIYKaWII, but patient 2902 (Caucasian male, treated, autologous virus Clade B) did not elicit a response upon encountering this variant.","Hoof2010"
"57493","GI9","2483","B","B","B","Gag","259","267","p24(127-135)","1564..1590","","GEIYKRWII","GEIYaRWII","K5A","K263A","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","All 3 patients, 2275 (Latin male, experienced some treatment, autologous virus Clade B); 2792 (Caucasian female, treatment naive, autologous virus Clade B); 2902 (Caucasian male, treated, autologous virus Clade B) did not  elicit CTL responses to variant GEIYaRWII.","Hoof2010"
"57493","GI9","2484","B","B","B","Gag","259","267","p24(127-135)","1564..1590","","GEIYKRWII","GEIaKRWII","Y4A","Y262A","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","Patient 2792 (Caucasian female, treatment naive, autologous virus Clade B) both continued to elicit CTL response to variant GEIaKRWII, but patients 2902 (Caucasian male, treated, autologous virus Clade B) and 2275 (Latin male, experienced some treatment, autologous virus Clade B)did not elicit a response upon encountering this variant.","Hoof2010"
"57493","GI9","2485","B","B","B","Gag","259","267","p24(127-135)","1564..1590","","GEIYKRWII","GEIYrRWII","K5R","K263R","SF","susceptible form","CD8 T-cell Elispot - IFNy","Patients 2275 (Latin male, experienced some treatment, autologous virus Clade B); 2792 (Caucasian female, treatment naive, autologous virus Clade B); 2902 (Caucasian male, treated, autologous virus Clade B) all continued to elicit CTL response to variant GEIYrRWII.","Hoof2010"
"53630",,"116","B","","","Gag","260","267","p24(128-135)","1567..1590","B8","EIYKRWII","dIYKRWII","E1D","E260D","NSF","non-susceptible form","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining","Diykrwii sequence was found in 12/17 clones after the initiation of therapy, while eVykrwii sequence was found in 5/17, and the peptide used to initially detect the response was not found, EIYKRWII. The less frequent clone was most often recognized. No dramatic shift towards escape was observed after the initiation of therapy.","Casazza2005a"
"53630",,"117","B","","","Gag","260","267","p24(128-135)","1567..1590","B8","EIYKRWII","EvYKRWII","I2V","I261V","SF","susceptible form","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining","Diykrwii sequence was found in 12/17 clones after the initiation of therapy, while eVykrwii sequence was found in 5/17, and the peptide used to initially detect the response was not found, EIYKRWII. The less frequent clone was most often recognized. No dramatic shift towards escape was observed after the initiation of therapy.","Casazza2005a"
"52925","E18","182","B","","","Gag","260","267","p24(128-135)","1567..1590","B8","EIYKRWII","dIYKRWII","E1D","E260D","SF","susceptible form","","3 subjects recognized this epitope with intermediate functional avidity. Autologous sequence revealed one substitution, Diyrkwil, in 1 of the 3; this version of the epitope also had intermediate functional avidity with the donor's cells.","Draenert2004b"
"53743",,"505","","","","Gag","260","267","p24(128-135)","1567..1590","B8","EIYRKWII","EfYRKWII","I2F","I261F","OV","observed variant","","Variant was found in 1/5 B57+ individuals, but was always in a minor form. The frequency of the epitope mutation did not correlate with the percentage of IFN-gamma producing CTLs.","Jansen2005a"
"53743",,"506","","","","Gag","260","267","p24(128-135)","1567..1590","B8","EIYRKWII","rIYRKWII","E1R","E260R","OV","observed variant","","Variant was found in 1/5 B57+ individuals, but was always in a minor form. The frequency of the epitope mutation did not correlate with the percentage of IFN-gamma producing CTLs.","Jansen2005a"
"53749","EI8","759","B","","","Gag","260","267","p24(128-135)","1567..1590","B8","EIYKRWII","dIYKRWII","E1D","E260D","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","This variant was the only form of the epitope detected over a 5 year time period in a patient. The variant was equally well recognized by patient CTLs as the wt consensus B epitope.","Koibuchi2005a"
"54536","EI8","1024","B","B","A, C","Gag","260","267","p24(128-135)","1567..1590","B8","EIYKRWII","dIYKRWII","E1D","E260D","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","Cross-recognition is seen to both A- and C-clade variants.  Both variants contain a change at position 1 to dIYKRWII.","Malhotra2007"
"58193","EI8","2857","","B","B","Gag","260","267","p24(128-135)","1567..1590","B*08","EIYKRWII","dIYKRWII","E1D","E260D","LE","literature escape","Intracellular cytokine staining","dIYKRWII was one of 2 EI8 sequence variants cross-recognized by subdominant clonotypes.","Conrad2011"
"58193","EI8","2858","","B","B","Gag","260","267","p24(128-135)","1567..1590","B*08","EIYKRWII","EIYKRWIv","I8V","I267V","LE","literature escape","Intracellular cytokine staining","EIYKRWIv was one of 2 EI8 sequence variants cross-recognized by subdominant clonotypes.","Conrad2011"
"53925",,"57","","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIILGLNK","KkWIImGLNK","R2K, L6M","R264K, L268M","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding","Previously reported escape (R2K) variant, confirmed here by lack of EliSpot response in 4 individuals and 348-fold decrease in binding to HLA B27.","Ammaranond2005"
"53925",,"58","","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIILGLNK","KqWIImGLNK","R2Q, L6M","R264Q, L268M","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding","Novel escape variant (R2Q), confirmed by lack of EliSpot response in 4 individuals and 30-fold decrease in binding to HLA B27. The escape mutation is R2Q, since HLA binding to KRWIImGLNK is comparable to KRWIILGLNK binding.","Ammaranond2005"
"53619","KK10","75","B","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KgWIILGLNK","R2G","R264G","E","escape documented in this paper","Chromium-release assay","The infecting virus escaped the vaccine-induced T-cell response with an R264G substitution, KgWIILGLNK, which diminishes binding to B27, between the second and third year of infection.","Betts2005"
"52329",,"133","CRF01_AE","B, C, D, F, G","A","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIILGLNK","KRWmILGLNK","I4M","I266M","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","Subject AIHP-6 (Thai, CDF01-AE infected) recognized this epitope. This subject showed cross-subtype CTL responses to gag constructs derived from subtypes A, B, C, D, F, G, and H, and this epitope was perfectly preserved in all of these but subtype A which had the sequence KRWMILGLNK. This subject didn't respond to a Gag CRF01 sequence which had a R->K mutation in position 2.","Currier2002b"
"52329",,"134","CRF01_AE","B, C, D, F, G","CRF01_AE","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIILGLNK","KkWIILGLNK","R2K","R264K","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy","Subject AIHP-6 (Thai, CDF01-AE infected) recognized this epitope. This subject showed cross-subtype CTL responses to gag constructs derived from subtypes A, B, C, D, F, G, and H, and this epitope was perfectly preserved in all of these but subtype A which had the sequence KRWMILGLNK. This subject didn't respond to a Gag CRF01 sequence which had a R->K mutation in position 2.","Currier2002b"
"56266",,"194","B","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIILGLNK","KgWIILGLNK","R2G","R264G","LE","literature escape","","Mutation of the peptide sequence EIYKRWIILGLNK to dIYKgWIILGLNK was seen only in 1 subject who exhibited delayed progression to viremia and who initiated ART, but succumbed to non-AIDS death at age 83. This is escape mutant was characterized previously.","Dyer2008"
"52932","KK10","195","","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIILGLNK","KtWIILGLNK","R2T","R264T","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Viral load in a perinatally infected child remained low until emergence of an escape variant (kTwiilglnk) in the immunodominant CTL epitope KRWIILGLNK when the child was 7.4 years old. The emergence of this escape mutation was followed by an increase in viremia and an increase in the number of targeted CTL epitopes, measured again when the child was 9.2 years old. The timing suggests that the loss of recognition of this epitope may have resulted in the subsequent loss of immune control.","Feeney2004"
"54618","KK10","254","B","","","Gag","263","272","p24(131-140)","1576..1605","B*27","KRWIILGLNK","KkWIILGLNK","R2K","R264K","CE","calculated escape","","The variant was more often found in HLA-matched than in HLA-unmatched patients, indicating that some favourable HLA alleles induce strong pressure, resulting in escape variants with high fitness cost and low viral loads.","Frater2007"
"54618","KK10","255","B","","","Gag","263","272","p24(131-140)","1576..1605","B*27","KRWIILGLNK","KRWIImGLNK","L6M","L268M","CE","calculated escape","","The variant was more often found in HLA-matched than in HLA-unmatched patients, indicating that some favourable HLA alleles induce strong pressure, resulting in escape variants with high fitness cost and low viral loads. Leucine at position 6 was under strong positive selection pressure.","Frater2007"
"54618","KK10","256","B","","","Gag","263","272","p24(131-140)","1576..1605","B*27","KRWIILGLNK","KRWvImGLNK","I4V, L6M","I266V, L268M","OV","observed variant","","Found in European cohort","Frater2007"
"54618","KK10","257","B","","","Gag","263","272","p24(131-140)","1576..1605","B*27","KRWIILGLNK","KkWIImGLNK","R2K, L6M","R264K, L268M","OV","observed variant","","Found in European cohort","Frater2007"
"54618","KK10","258","B","","","Gag","263","272","p24(131-140)","1576..1605","B*27","KRWIILGLNK","KRWIIiGLNK","L6I","L268I","CE","calculated escape","","The variant was more often found in HLA-matched than in HLA-unmatched patients, indicating that some favourable HLA alleles induce strong pressure, resulting in escape variants with high fitness cost and low viral loads. Leucine at position 6 was under strong positive selection pressure.","Frater2007"
"283",,"367","","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIIMGLNK","KkWIIMGLNK","R2K","R264K","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","Chromium-release assay, HLA binding","Two patients switched to this epitope form during a rapid decline to AIDS. The switch results in severely diminished binding to the B27 and abrogated recognition by CTLs. The switch coincided with rapid CD4 count decline and a rapid rise in viral load. This escape variant is not found in B*2705 negative patients.","Goulder1997b, Goulder1997e"
"283",,"368","","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIIMGLNK","KRWIIiGLNK","M6I","M268I","E","escape documented in this paper","Chromium-release assay","Variant found in one patient. It was not recognized by CTLs. The escape variant disappeared after initiation of ART.","Goulder1997b, Goulder1997e"
"283",,"369","","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIIMGLNK","KRWIIlGLNK","M6L","M268L","SF","susceptible form","Chromium-release assay, HLA binding","Variant bound to B*2705 with similar efficiency as the wt epitope.","Goulder1997b, Goulder1997e"
"283",,"370","","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIIMGLNK","KkWIIlGLNK","R2K, M6L","R264K, M268L","E","escape documented in this paper","Chromium-release assay, HLA binding","Variant had severely diminished binding to B*2705 comparable to the R/K escape variant.","Goulder1997b, Goulder1997e"
"271",,"371","B","","","Gag","263","272","p24(131-140)","1576..1605","B27, B*2705","KRWIILGLNK","KkWIILGLNK","R2K","R264K","E","escape documented in this paper","","Variant is not recognized by CTLs.","Goulder1997d, Goulder1997e"
"271",,"372","B","","","Gag","263","272","p24(131-140)","1576..1605","B27, B*2705","KRWIILGLNK","KRWIImGLNK","L6M","L268M","OV","observed variant","","Variant observed in 2/32 clade B sequences in the HIV database.","Goulder1997d, Goulder1997e"
"279",,"381","","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIILGLNK","KRWIImGLNK","L6M","L268M","SF","susceptible form","","This variant was recognized more efficiently than the wt epitope by patient CTLs.","Goulder1997e, Phillips1991"
"1818","KK10","390","","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIILGLNK","KRWIImGLNK","L6M","L268M","CM","compensatory mutation","HLA binding","Assumed compensatory mutation. Variant found in one B27 positive child but not in its B27 negative mother. Variant bound to B27 as well as the wt.","Goulder2001c"
"1818","KK10","391","","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIILGLNK","KkWIILGLNK","R2K","R264K","DHB","diminished HLA binding or increased off-rate","HLA binding","Variant bound to B27 poorly compared to the wt.","Goulder2001c"
"1818","KK10","392","","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIILGLNK","KkWIImGLNK","R2K, L6M","R264K, L268M","DHB","diminished HLA binding or increased off-rate","HLA binding","Variant bound to B27 poorly compared to the wt.","Goulder2001c"
"1818","KK10","393","","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIILGLNK","KtWIILGLNK","R2T","R264T","DHB","diminished HLA binding or increased off-rate","CD8 T-cell Elispot - IFNy","The variant was found in mothers and their infected children. There was no CTL response to the wt or the variant in mothers or in children. The variant failed to bind B27. Variant was replication competent.","Goulder2001c"
"1818","KK10","394","","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIILGLNK","KtWIImGLNK","R2T, L6M","R264T, L268M","CM, DHB","compensatory mutation, diminished HLA binding or increased off-rate","CD8 T-cell Elispot - IFNy","The variant was found in mothers and their infected children. There was no CTL response to the wt or the variant in mothers or in children. The variant failed to bind B27. The variant had presumed compensatory L/M mutation","Goulder2001c"
"1681",,"675","","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIILGLNK","KRWIImGLNK","L6M","L268M","SF","susceptible form","CD8 T-cell Elispot - IFNy","Responses to the epitope and the variant were much higher after HIV-1 seroconversion of previous HEPS.","Kaul2001a"
"1352",,"729","","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KkWIILGLNK","R2K","R264K","OV","observed variant","Tetramer binding","This variant was found in only 2/329 sequences, as R/K mutation was strongly associated with L/M mutation. This mutation occurs rarely in clade B viruses. Position under positive selection pressure.","Kelleher2001"
"1352",,"730","","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KRWIImGLNK","L6M","L268M","CM","compensatory mutation","Tetramer binding","Variant was present in 1/25 of the viral sequences 52 weeks after infection in one of the patients. Mutation occurs relatively early in the infection. L/M may be a compensatory mutation.","Kelleher2001"
"1352",,"731","","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KiWIImGLNK","R2I, L6M","R264I, L268M","OV","observed variant","","This variant was found in one of the patients in 4% of the sequences 1 year after initial infection.","Kelleher2001"
"1352",,"732","","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KkWIImGLNK","R2K, L6M","R264K, L268M","DHB, IE","diminished HLA binding or increased off-rate, inferred escape","Tetramer binding","Variant was present in 96% of the viral sequences 52 weeks after infection in one of the patients, and after 12 weeks in another, following L/M variant. The two mutations are strongly linked. Substitution reduced binding to B27 and occurred in conjunction with high viral loads.","Kelleher2001"
"55103","KK10","949","B","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KRWIImGLNK","L6M","L268M","DR, E, TCR","diminished response, escape documented in this paper, TCR related mutation","CD8 T-cell Elispot - IFNy","Mutation does not affect binding to HLA, peptide processing, or viral fitness. Variant was very poorly recognized by KK10-specific CTLs, but it recruited an alternative TCRalpha and beta during chronic infection, being immunogenic enough to elicit a de novo CTL response. Also, enhanced binding of HLA-B*2705-KK10-L6M complex to Immunoglobulin-like transcript-4 (ILT4) occurred, resulting in an impairment of DC maturation and function as measured by the markers HLA-DR, CD83, CD40, CD180 and CD86.","Lichterfeld2007a"
"55103","KK10","950","B","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KkWIILGLNK","R2K","R264K","DR","diminished response","CD8 T-cell Elispot - IFNy","Variant was recognized by CTLs, but the avidity of recognition decreased by &#152;10-fold.","Lichterfeld2007a"
"55103","KK10","951","B","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KtWIILGLNK","R2T","R264T","DR","diminished response","CD8 T-cell Elispot - IFNy","Variant was recognized by CTLs, but the avidity of recognition decreased by &#152;10-fold.","Lichterfeld2007a"
"55103","KK10","952","B","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KkWIImGLNK","R2K, L6M","R264K, L268M","DR, E","diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy","Variant was very poorly recognized by CTLs.","Lichterfeld2007a"
"55103","KK10","953","B","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KtWIImGLNK","R2T, L6M","R264T, L268M","DR, E","diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy","Variant was very poorly recognized by CTLs.","Lichterfeld2007a"
"281",,"1346","","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIIMGNK","KRWIIlGNK","M6L","M268L","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, HLA binding, Longitudinal study","The M variant is the predominant form, but both M and L forms are recognized by patient CTL.","Nowak1995"
"53834",,"1417","B","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIILGLNK","KqWIIiGLNK","R2Q, L6I","R264Q, L268I","LE","literature escape","Sequence","This variant was seen in an  HLA-B27 carrying father, and it was passed on to the non-B27-mother.","Pillay2005"
"53834",,"1418","B","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIILGLNK","KqWvImGLNK","R2Q, I4V, L6M","R264Q, I266V, L268M","OV","observed variant","Sequence","This variant arose in a non-B27 mother and it was transmitted to the infant who did carry the restricting HLA allele, B27.","Pillay2005"
"55101","KK10","1593","B","","","Gag","263","272","p24(131-140)","1576..1605","","KRWIILGLNK","KkWIILGLNK","R2K","R264K","RCR","replicative capacity reduced","Relative replication capacity assay","This R264K mutation abrogates replicative capacity of the virus.  Decreased replication is seen under the influence of Cyclophilin A, while increased replication is seen when treated with Cyclosporin A.","Schneidewind2007"
"55101","KK10","1594","B","","","Gag","263","272","p24(131-140)","1576..1605","","KRWIILGLNK","KRWIImGLNK","L6M","L268M","RCOK","replicative capacity is not abrogated","Relative replication capacity assay","This L268M mutation does not affect replicative capacity of the virus.","Schneidewind2007"
"55101","KK10","1595","B","","","Gag","263","272","p24(131-140)","1576..1605","","KRWIILGLNK","KkWIImGLNK","R2K, L6M","R264K, L268M","RCR","replicative capacity reduced","Relative replication capacity assay","This R264K, L268M mutation abrogates replicative capacity of the virus.  Increased replication is seen when treated with Cyclosporin A.","Schneidewind2007"
"55745","KK10","1596","B","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KkWIILGLNK","R2K","R264K","DHB, RCR","diminished HLA binding or increased off-rate, replicative capacity reduced","HLA binding, Relative replication capacity assay","This R264K mutation, which is not seen in vivo, abrogates replicative capacity of the virus.  Decreased HLA-B27 binding results.  Increased infectivity is seen when treated with Cyclosporin A.","Schneidewind2008"
"55745","KK10","1597","B","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KRWIImGLNK","L6M","L268M","RCOK","replicative capacity is not abrogated","HLA binding, Relative replication capacity assay","This natural L268M mutation does not affect replicative capacity of the virus  or binding to HLA-B27. A decrease in the influence of Cyclosporin A is seen on infectivity.","Schneidewind2008"
"55745","KK10","1598","B","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KkWIImGLNK","R2K, L6M","R264K, L268M","DHB, RCR","diminished HLA binding or increased off-rate, replicative capacity reduced","HLA binding, Relative replication capacity assay","This natural R264K, L268M mutation abrogates replicative capacity of the virus.  Decreased HLA-B27 binding results.  Increased infectivity is seen when treated with Cyclosporin A.","Schneidewind2008"
"55745","KK10","1599","B","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KtWIILGLNK","R2T","R264T","DHB, RCOK","diminished HLA binding or increased off-rate, replicative capacity is not abrogated","HLA binding, Relative replication capacity assay","This natural R264T mutation does not affect replicative capacity.  Severely decreased HLA-B27 binding results.  Decreased infectivity is seen when treated with Cyclosporin A.","Schneidewind2008"
"55745","KK10","1600","B","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KtWIImGLNK","R2T, L6M","R264T, L268M","DHB, RCOK","diminished HLA binding or increased off-rate, replicative capacity is not abrogated","HLA binding, Relative replication capacity assay","This natural R264T, L268M double mutation does not affect replicative capacity.  Severely decreased HLA-B27 binding results.  Decreased infectivity is seen when treated with Cyclosporin A.","Schneidewind2008"
"55745","KK10","1601","B","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KqWIILGLNK","R2Q","R264Q","DHB, RCOK","diminished HLA binding or increased off-rate, replicative capacity is not abrogated","HLA binding, Relative replication capacity assay","This R264Q variant is not seen in vivo, and does not affect replicative capacity.  Severely decreased HLA-B27 binding does, however, result with decrease in infectivity when treated with Cyclosporin A.","Schneidewind2008"
"55745","KK10","1602","B","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KqWIImGLNK","R2Q, L6M","R264Q, L268M","DHB, RCOK","diminished HLA binding or increased off-rate, replicative capacity is not abrogated","HLA binding, Relative replication capacity assay","This natural R264Q, L268M double mutation does not affect replicative capacity.  Severely decreased HLA-B27 binding results.  Decreased infectivity is seen when treated with Cyclosporin A.","Schneidewind2008"
"55745","KK10","1603","B","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KgWIILGLNK","R2G","R264G","RCOK","replicative capacity is not abrogated","HLA binding, Relative replication capacity assay","This natural R264G mutation does not affect replicative capacity.  Severely decreased HLA-B27 binding results.  Decreased infectivity is seen when treated with Cyclosporin A.","Schneidewind2008"
"55440","KK10","1649","B","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIILGLNK","KkWIILGLNK","R2K","R264K","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","This Gag R264K stereotypical escape was the first variant detected in a longitudinal study of one subject and coincided with a rise in viral load.   It abrogates binding to HLA-B27.  After an interim recombination-generated counter-mutation (L268M); a second recombination event in this subject recovered the R264K mutation, declining CTL response yet again.","Streeck2008a"
"55440","KK10","1650","B","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIILGLNK","KRWIImGLNK","L6M","L268M","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","This L268M mutation in response to variant R264K was detected and found to generate a CTL response polyfunctional in cytokine production.  Upon superinfection with another HIV-1 strain in this subject, the L268M mutation reverted to wild type index sequence by recombination of the two viral strains, facilitating escape from the now dominant L268M variant-specific response.","Streeck2008a"
"55440","KK10","1651","B","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIILGLNK","KkWIImGLNK","R2K, L6M","R264K, L268M","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","This double mutant was seen in the subject at the last two time points tested.  It was accompanied by the distinct, flanking mutations T239V and N252S.","Streeck2008a"
"55440","KK10","1652","B","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIILGLNK","KRWvILGLNK","I4V","I266V","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","This mutation was detected in the subject studied at one time point.","Streeck2008a"
"283",,"2211","","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIIMGLNK","KRWIIMGmNK","L8M","L270M","OV","observed variant","","Variant observed early on, but coincided with relatively stable CD4 count, viral load, and stable CTL response.","Goulder1997b, Goulder1997e"
"1352",,"2292","","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","{E**}KRWIILGLNK","{d**}KgWIILGLNK","R2G, E-3D","R264G, E260D","DHB, IE","diminished HLA binding or increased off-rate, inferred escape","Tetramer binding","Substitution reduced binding to B27 and occurred in conjunction with high viral loads. The two mutations are strongly linked. E/D may be compensatory mutation. No CTL responses.","Kelleher2001"
"55101","KK10","2305","B","","","Gag","263","272","p24(131-140)","1576..1605","","{S...}KRWIILGLNK","{a...}KRWIILGLNK","S-90A","S173A","RCOK","replicative capacity is not abrogated","Relative replication capacity assay","This upstream S173A mutation does not affect replicative capacity of the virus.","Schneidewind2007"
"55101","KK10","2306","B","","","Gag","263","272","p24(131-140)","1576..1605","","{S...}KRWIILGLNK","{a...}KkWIILGLNK","R2K, S-90A","R264K, S173A","RCOK","replicative capacity is not abrogated","Relative replication capacity assay","This S173A, R264K mutation does not affect replicative capacity of the virus.","Schneidewind2007"
"54865","KK10 (263-272)","2308","B","","","Gag","263","272","p24(131-140)","1576..1605","","KRWIILGLNK{...A}","KkWIImGLNK{...s}","R2K, A+33S, L6M","R264K, A305S, L268M","E","escape documented in this paper","","The L268M mutation accompanies R264K.  While L268M faces the TCR, L268M is involved in HLA-B27 binding.  Residue A173S lies outside the KK10 epitope, but clusters with the other two amino acids in the 3D structure of p24.  The R264K mutation comes with a fitness cost and rapidly reverts when transmitted to HLA-B27- subjects.    A173S is a compensatory mutation for R264K.  Since this triple mutation is rare, it could account for delayed escape from CTL response to KK10.","McMichael2007"
"55101","KK10","2309","B","","","Gag","263","272","p24(131-140)","1576..1605","","{S...}KRWIILGLNK","{a...}KkWIImGLNK","R2K, L6M, S-90A","R264K, L268M, S173A","RCOK","replicative capacity is not abrogated","Relative replication capacity assay","This triple S173A, R264K , L268M mutation does not affect replicative capacity of the virus, and brings its activity back to that of wild type.  Increased replication is seen under the influence of Cyclophilin A, while decreased replication is seen when treated with Cyclosporin A.","Schneidewind2007"
"55101","KK10","2310","B","","","Gag","263","272","p24(131-140)","1576..1605","","{S...}KRWIILGLNK","{t...}KkWIImGLNK","R2K, L6M, S-90T","R264K, L268M, S173T","RCOK, RCR","replicative capacity is not abrogated, replicative capacity reduced","Relative replication capacity assay","This triple A237T, R264K , L268M mutation does not affect replicative capacity of the virus.  Decreased replication is seen when treated with Cyclosporin A.","Schneidewind2007"
"55745","KK10","2311","B","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","{S...}KRWIILGLNK","{a...}KkWIImGLNK","R2K, L6M, S-90A","R264K, L268M, S173A","DHB, RCOK","diminished HLA binding or increased off-rate, replicative capacity is not abrogated","HLA binding, Relative replication capacity assay","This triple S173A, R264K , L268M natural mutation does not affect replicative capacity of the virus, and brings its activity back to that of wild type.  Decreased HLA-B27 binding results.  Decreased infectivity is seen when treated with Cyclosporin A.","Schneidewind2008"
"55745","KK10","2312","B","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","{S...}KRWIILGLNK","{t...}KtWIImGLNK","R2T, L6M, S-90T","R264T, L268M, S173T","DHB, RCOK","diminished HLA binding or increased off-rate, replicative capacity is not abrogated","HLA binding, Relative replication capacity assay","This natural S173T, R264T, L268M triple mutation does not affect replicative capacity.  Severely decreased HLA-B27 binding results.","Schneidewind2008"
"55745","KK10","2313","B","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","{E**}KRWIILGLNK","{d**}KRWIILGLNK","E-3D","E260D","RCOK","replicative capacity is not abrogated","HLA binding, Relative replication capacity assay","This natural, upstream E260D mutation increases replicative capacity and retains binding to HLA-B27.  Decreased infectivity is seen when treated with Cyclosporin A.","Schneidewind2008"
"55745","KK10","2314","B","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","{E**}KRWIILGLNK","{d**}KgWIILGLNK","R2G, E-3D","R264G, E260D","DHB, RCR","diminished HLA binding or increased off-rate, replicative capacity reduced","HLA binding, Relative replication capacity assay","This natural E260D, R264G double mutation does not affect replicative capacity.  Severely decreased HLA-B27 binding results.  Decreased infectivity is seen when treated with Cyclosporin A.","Schneidewind2008"
"55745","KK10","2315","B","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","{E**}KRWIILGLNK","{d**}KgWIImGLNK","R2G, E-3D, L6M","R264G, E260D, L268M","RCR","replicative capacity reduced","HLA binding, Relative replication capacity assay","This E260D, R264G, L268M triple mutation greatly affects replicative capacity.  It is not seen in vivo.","Schneidewind2008"
"55745","KK10","2316","B","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","{E**}KRWIILGLNK","{d**}KkWIILGLNK","R2K, E-3D","R264K, E260D","DHB, RCR","diminished HLA binding or increased off-rate, replicative capacity reduced","HLA binding, Relative replication capacity assay","This E260D, R264K double mutation is not found in vivo and  greatly affects replicative capacity.  Decreased HLA-B27 binding results.","Schneidewind2008"
"57716","KK10","2602","B","B","B","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KRWIImGLNK","L6M","L268M","LE","literature escape","Longitudinal study","L268M variant KRWIImGLNK was the dominant sequence carried by 5/7 patients - LTS5, LTS10, LTS13, LTS22, LTS57 - at the earliest time point sampled.","vanBockel2011"
"57716","KK10","2603","B","B","B","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KkWIILGLNK","R2K","R264K","LE","literature escape","Longitudinal study","R264K variant KkWIILGLNK, was observed in 4/7 patients - LTS5, LTS22, LTS57, LTS66.","vanBockel2011"
"57716","KK10","2604","B","B","B","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KgWIILGLNK","R2G","R264G","LE","literature escape","Longitudinal study","R264G variant KgWIILGLNK, was observed in 4/7 patients - LTS5, LTS22, LTS57, LTS66.","vanBockel2011"
"57716","KK10","2605","B","B","B","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KRWIILGLsK","N9S","N271S","OV","observed variant","Longitudinal study","Solvent-exposed N271S variant KRWIILGLsK, was transiently observed in 1/7 patients - LTS5.","vanBockel2011"
"57716","KK10","2606","B","B","B","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KRWIILGLhK","N9H","N271H","OV","observed variant","Longitudinal study","Solvent-exposed N271H variant KRWIILGLhK, was transiently observed in 1/7 patients - LTS12.","vanBockel2011"
"57716","KK10","2607","B","B","B","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","rRWIILGLNK","K1R","K263R","OV","observed variant","Longitudinal study","Solvent-exposed K263R variant rRWIILGLNK, was transiently observed in 1/7 patients - LTS13.","vanBockel2011"
"57716","KK10","2608","B","B","B","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KRWIILGLtK","N9T","N271T","OV","observed variant","Longitudinal study","Solvent-exposed N271T variant KRWIILGLtK, was transiently observed in 1/7 patients - LTS12.","vanBockel2011"
"57787","KK10","2641","","","","Gag","263","272","p24(131-140)","1576..1605","B27","KRWIILGLNK","KRWIImGLNK","L6M","L268M","LE","literature escape","Cytotoxicity assay","Authors state that this is a previously-documented escape mutant.","Aldy2011"
"57821","KK10","2642","B","B","B","Gag","263","272","p24(131-140)","1576..1605","B*27","KRWIILGLNK","KkWIILGLNK","R2K","R264K","E, LE","escape documented in this paper, literature escape","CD8 T-cell Elispot - IFNy, Sequence","Previously-documented escape mutant documented in B*27-positive patients.  No response in B*27 individuals was seen in this study.","Ammaranond2011"
"57821","KK10","2643","B","B","B","Gag","263","272","p24(131-140)","1576..1605","B*27","KRWIILGLNK","KkWIvLGLNK","R2K, I5V","R264K, I267V","E, LE","escape documented in this paper, literature escape","CD8 T-cell Elispot - IFNy, Sequence","Previously-documented escape mutant documented in B*27-positive patients.  No response in B*27 individuals was seen in this study. Escape mutation is R2K.","Ammaranond2011"
"57821","KK10","2644","B","B","B","Gag","263","272","p24(131-140)","1576..1605","B*27","KRWIILGLNK","KgWIILGLNK","R2G","R264G","E, IE","escape documented in this paper, inferred escape","CD8 T-cell Elispot - IFNy, Sequence","Previously-documented escape mutant documented in B*27-positive patients.  No response in B*27 individuals was seen in this study.","Ammaranond2011"
"57821","KK10","2645","B","B","B","Gag","263","272","p24(131-140)","1576..1605","B*27","KRWIILGLNK","KqWIILGLNK","R2Q","R264Q","E, LE","escape documented in this paper, literature escape","CD8 T-cell Elispot - IFNy, Sequence","Previously-documented escape mutant documented in B*27-positive patients.  No response in B*27 individuals was seen in this study.","Ammaranond2011"
"57821","KK10","2648","B","B","B","Gag","263","272","p24(131-140)","1576..1605","B*27","KRWIILGLNK","KRWIImGLNK","L6M","L268M","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","A common susceptible variant. Substantial IFN-&gamma; responses were measured from PBMCs stimulated with WT or L268M variant at pre-escape time points.","Ammaranond2011"
"57953","KK10","2668","","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KRWIIMGLNK","L6M","L268M","E, TCR","escape documented in this paper, TCR related mutation","CD8 T-cell Elispot - IFNy, TCR binding","The L6M mutant was associated with lower antigen sensitivity. The early-arising L6M mutation enables the virus to avoid recognition by effective CD8+ T-cell clonotypes.","Iglesias2011"
"58009","KK10","2701","B","B","B","Gag","263","272","p24(131-140)","1576..1605","B*27","KRWIILGLNK","KgWIILGLNK","R2G","R264G","A, P","HLA association, processing","","B27-KK10 has known HLA-associated mutants (R2G, R2K/L6M, L6M, R2K/L6M/N8H). All 4 mutants displayed severely reduced half-lives.","Lazaro2011"
"58009","KK10","2702","B","B","B","Gag","263","272","p24(131-140)","1576..1605","B*27","KRWIILGLNK","KkWIImGLNK","R2K, L6M","R264K, L268M","A, P","HLA association, processing","","B27-KK10 has known HLA-associated mutants (R2G, R2K/L6M, L6M, R2K/L6M/N8H). All 4 mutants displayed severely reduced half-lives.","Lazaro2011"
"58009","KK10","2703","B","B","B","Gag","263","272","p24(131-140)","1576..1605","B*27","KRWIILGLNK","KRWIImGLNK","L6M","L268M","A, P","HLA association, processing","","B27-KK10 has known HLA-associated mutants (R2G, R2K/L6M, L6M, R2K/L6M/N8H). All 4 mutants displayed severely reduced half-lives.","Lazaro2011"
"58009","KK10","2704","B","B","B","Gag","263","272","p24(131-140)","1576..1605","B*27","KRWIILGLNK","KkWIImGLhK","R2K, L6M, N9H","R264K, L268M, N271H","A, P","HLA association, processing","","B27-KK10 has known HLA-associated mutants (R2G, R2K/L6M, L6M, R2K/L6M/N8H). All 4 mutants displayed severely reduced half-lives.","Lazaro2011"
"58280","KK10","2861","B","B","B","Gag","263","272","p24(131-140)","1576..1605","B*27","KRWIILGLNK","KRWIImGLNK","L6M","L268M","LE","literature escape","Intracellular cytokine staining","KRWIImGLNK was one of 2 KK10 sequence variants cross-recognized by subdominant clonotypes.  This variant had similar results as those with consensus stimulation.","Conrad2011"
"58280","KK10","2862","B","B","B","Gag","263","272","p24(131-140)","1576..1605","B*27","KRWIILGLNK","KRWIvLGLNK","I5V","I267V","LE","literature escape","Intracellular cytokine staining","KRWIvLGLNK was one of 2 KK10 sequence variants cross-recognized by subdominant clonotypes.  This variant stimulated the dominant clonotype, TRBV12, to reach lower cytokine production than that by subdominant clonotypes which upon recognizing this variant peptide produced their highest levels of cytokine TNF-alpha and IFN-gamma.","Conrad2011"
"57768","KK10","3054","B","B","B","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KxWIILGLNK","R2X","R264X","LE","literature escape","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Intracellular cytokine staining","Variant KxWIILGLNK, the KK10 R264X mutation has been linked to accelerated progression to AIDS.  This mutation usually arises late and is typically followed by the KY9 G908E variant&#39;s emergence.","Payne2010"
"57768","KK10","3055","B","B","B","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KRWIIxGLNK","L6X","L268X","LE","literature escape","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Intracellular cytokine staining","Variant KRWIIxGLNK, the KK10 L268X mutation has a high escape rate with all subjects showing variation by 2 years post-infection.","Payne2010"
"59014","KK10","3211","","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KRWIImGLNK","L6M","L268M","SF","susceptible form","Chromium-release assay","Variant KRWIImGLNK was recognized equally well by KK10-specific CTL.  Structurally the TCR-KK10 and TCR-Leu268Met variant were identical.","Ladell2013"
"59014","KK10","3212","","","","Gag","263","272","p24(131-140)","1576..1605","B*2705","KRWIILGLNK","KkWIILGLNK","R2K","R264K","E, LE, NSF","escape documented in this paper, literature escape, non-susceptible form","Chromium-release assay","Variant KkWIILGLNK was not recognized by KK10-specific CTL and therefore an escape.  This epitope variation was more slowly acquired.","Ladell2013"
"59123","KK10","3301","B","B","B","Gag","263","272","p24(131-140)",,"B*27","KRWIILGLNK","KRWIImGLNK","L6M","L268M","DHB, E, OV","diminished HLA binding or increased off-rate, escape documented in this paper, observed variant","CTL suppression of replication, HLA binding, Sequence","Strain DH12-specific variant of epitope KK10, KRWIImGLNK, was poorly recognized by a strain LAI KK10-specific CTL clone and is an escape variant, that impairs TCR recognition. Suppression of replication of all DH12 viruses was poor.","Lissina2014"
"57726",,"2627","","","","Gag","263","282","p24(131-150)","1576..1635","","KRWIILGLNKIVRMYSPTSI","KRWIILGLNKIVRMYSPvSI","T18V","T280V","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Variant KRWIILGLNKIVRMYSPvSI is seen in patient I08.","Vollbrecht2010"
"59023","CE5","3208","B","B","A, C, M","Gag","263","282","p24(131-150)","1576..1635","","KRWIILGLNKIVRMYSPTSI","KRWIILGLNKIVRMYSPvSI","T18V","T280V","SSF","subtype-specific susceptible form","Intracellular cytokine staining","KRWIILGLNKIVRMYSPvSI is the Clades-A, -C and -M variant of CE5.  It was used in the p24CE2 vaccine form in this study, eliciting no response.","Kulkarni2013"
"56298",,"160","B","","","Gag","266","273","p24(134-141)","1585..1608","A2, A3","IILGLNKI","ImLGLNKI","I2M","I267M","OV","observed variant","Flow cytometric T-cell cytokine assay","IILGLNKI, elicited a response in 1 patient. The patient autologous sequence was ImLGLNKI.","Daucher2008"
"53763",,"839","B, CRF01_AE","B","CRF01_AE","Gag","267","274","p24(135-142)","1588..1611","A*02, A*03","ILGLNKIV","ILGLNKlg","I7L, V8G","I273L, V274G","OV","observed variant","","Variant found in 1/28 patients infected with CRF01_AE.","Lazaro2005"
"53763",,"840","B, CRF01_AE","B","CRF01_AE","Gag","267","274","p24(135-142)","1588..1611","A*02, A*03","ILGLNKIV","ILGLtKIV","N5T","N271T","OV","observed variant","","Variant found in 1/28 patients infected with CRF01_AE.","Lazaro2005"
"52952",,"302","B","","","Gag","267","277","p24(135-145)","1588..1620","B7 supertype","ILGLNKIVRMY","IvGLNKIVRMY","L2V","L268V","SF","susceptible form","CD8 T-cell Elispot - IFNy","After vaccination with a lipopeptide vaccine and a boost, both the variant and the wild type epitope were recognized.","Gahery-Segard2003"
"53758","RI8","760","B","","","Gag","275","282","p24(143-150)","1612..1635","B52","RMYSPTSI","RMYSPvSI","T6V","T280V","DR","diminished response","CD8 T-cell Elispot - IFNy, Chromium-release assay","Variant dominated in the beginning of a 7 year period in a patient and reverted to wt later on. The variant was less well recognized by patient CTLs compared to the wt form.","Koibuchi2005a"
"53758","RI8","761","B","","","Gag","275","282","p24(143-150)","1612..1635","B52","RMYSPTSI","RMYSPvgI","T6V, S7G","T280V, S281G","OV","observed variant","","Variant was found in 1/8 clones at the beginning of a 7 year period in a patient.","Koibuchi2005a"
"53758","RI8","762","B","","","Gag","275","282","p24(143-150)","1612..1635","B52","RMYSPTSI","RMYSPvSt","T6V, I8T","T280V, I282T","OV","observed variant","","Variant was found in 1/15 clones at the middle of a 7 year period in a patient.","Koibuchi2005a"
"53758","RI8","763","B","","","Gag","275","282","p24(143-150)","1612..1635","B52","RMYSPTSI","RMYSPsSI","T6S","T280S","OV","observed variant","","Variant was found in 3/15 clones at the middle of a 7 year period in a patient.","Koibuchi2005a"
"53758","RI8","764","B","","","Gag","275","282","p24(143-150)","1612..1635","B52","RMYSPTSI","RvYSPTSI","M2V","M276V","OV","observed variant","","Variant was found in 1/13 clones at the middle of a 7 year period in a patient.","Koibuchi2005a"
"53765",,"841","B, CRF01_AE","B","CRF01_AE","Gag","275","283","p24(143-151)","1612..1638","A*02","RMYSPTSIL","RMYSPvSIL","T6V","T280V","OV","observed variant","Computer prediction","This was the most common variant in CRF01 (13/28 patients). It had a higher binding score to HLA than the wt epitope.","Lazaro2005"
"53765",,"842","B, CRF01_AE","B","CRF01_AE","Gag","275","283","p24(143-151)","1612..1638","A*02","RMYSPTSIL","lMYSPvSIL","R1L, T6V","R275L, T280V","OV","observed variant","","Variant found in 1/28 patients infected with CRF01_AE.","Lazaro2005"
"53765",,"843","B, CRF01_AE","B","CRF01_AE","Gag","275","283","p24(143-151)","1612..1638","A*02","RMYSPTSIL","RMYSPvSIi","T6V, L9I","T280V, L283I","OV","observed variant","","Variant found in 1/28 patients infected with CRF01_AE.","Lazaro2005"
"53765",,"844","B, CRF01_AE","B","CRF01_AE","Gag","275","283","p24(143-151)","1612..1638","A*02","RMYSPTSIL","RMYSrvSIL","P5R, T6V","P279R, T280V","OV","observed variant","","Variant found in 1/28 patients infected with CRF01_AE.","Lazaro2005"
"53765",,"845","B, CRF01_AE","B","CRF01_AE","Gag","275","283","p24(143-151)","1612..1638","A*02","RMYSPTSIL","RMYSPvgIL","T6V, S7G","T280V, S281G","OV","observed variant","","Variant found in 1/28 patients infected with CRF01_AE.","Lazaro2005"
"53765",,"846","B, CRF01_AE","B","CRF01_AE","Gag","275","283","p24(143-151)","1612..1638","A*02","RMYSPTSIL","RMYSPgSIL","T6G","T280G","OV","observed variant","","Variant found in 1/28 patients infected with CRF01_AE.","Lazaro2005"
"53765",,"2212","B, CRF01_AE","B","CRF01_AE","Gag","275","283","p24(143-151)","1612..1638","A*02","RMYSPTSIL","RMYSPvSIw","T6V, L9W","T280V, L283W","CHB, OV","calculated diminished HLA binding, observed variant","Computer prediction","This rare variant was found in 2/28 patients infected with CRF01_AE. It was predicted not to bind to A2.","Lazaro2005"
"57691","YI9","2580","CRF01_AE","CRF01_AE","CRF01_AE","Gag","277","285","p24(145-153)","1618..1644","Cw*0102","YSPVSILDI","YSPVgILDI","S5G","S281G","A, DR, SSF","HLA association, diminished response, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","5/17(15.2%) Cw*0102+ patients carried this S281G mutation, while 8/56(11.9%) Cw*0102- patients did.  This variation at P5 reduced ELISpot response rate to 50% and diminished average magnitude of ELISpot from 1,832 to 1,493 SFC/million PBMC.","Buranapraditkun2011"
"57691","YI9","2581","CRF01_AE","CRF01_AE","CRF01_AE","Gag","277","285","p24(145-153)","1618..1644","Cw*0102","YSPVSILDI","YkPVgILDI","S2K, S5G","S278K, S281G","A, E, SNSF","HLA association, escape documented in this paper, subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","1/17(3%) Cw*0102+ patients carried this double S278K, S281G mutation, while no Cw*0102- patients did.  These variations abrogated ELISpot response.","Buranapraditkun2011"
"57691","YI9","2582","CRF01_AE","CRF01_AE","CRF01_AE","Gag","277","285","p24(145-153)","1618..1644","Cw*0102","YSPVSILDI","YSPtSILDI","V4T","V280T","A, DR, SSF","HLA association, diminished response, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","6/17(18.2%) Cw*0102+ patients carried this V280T mutation, while 1/56(1.5%) Cw*0102- patients did.  This was the most frequent variation.  This mutation reduced ELISpot response rate to 71.4% and diminished average magnitude from 1,832 to 682 SFC/million PBMC.","Buranapraditkun2011"
"57691","YI9","2583","CRF01_AE","CRF01_AE","CRF01_AE","Gag","277","285","p24(145-153)","1618..1644","Cw*0102","YSPVSILDI","YSPiSILDI","V4I","V280I","A, DR, SSF","HLA association, diminished response, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","1/17(3%) Cw*0102+ patients carried this V280I mutation, while no Cw*0102- patients did.  Variations at P4 (V280X) are most frequent and reduced ELISpot response rate to 71.4%, diminishing the average magnitude of ELISpot from 1,832 to 682 SFC/million PBMC.","Buranapraditkun2011"
"57691","YI9","2584","CRF01_AE","CRF01_AE","CRF01_AE","Gag","277","285","p24(145-153)","1618..1644","Cw*0102","YSPVSILDI","YkPVSILDI","S2K","S278K","A, E, SNSF","HLA association, escape documented in this paper, subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","2/17(6.1%) Cw*0102+ patients carried this S278K mutation, while no Cw*0102- patients did.  This variation at P2 abrogated ELISpot responses.","Buranapraditkun2011"
"57691","YI9","2585","CRF01_AE","CRF01_AE","CRF01_AE","Gag","277","285","p24(145-153)","1618..1644","Cw*0102","YSPVSILDI","YrPVSILDI","S2R","S278R","A, E, SNSF","HLA association, escape documented in this paper, subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","1/17(3%) Cw*0102+ patients carried this S278K mutation, while 1/56(1.5%) Cw*0102- patients did.  This variation at P2 abrogated ELISpot responses.","Buranapraditkun2011"
"57691","YI9","2586","CRF01_AE","CRF01_AE","CRF01_AE","Gag","277","285","p24(145-153)","1618..1644","Cw*0102","YSPVSILDI","YcPVSILDI","S2C","S278C","E, SNSF","escape documented in this paper, subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","No Cw*0102+ patients carried this S278C mutation, while 1/56(1.5%) Cw*0102- patients did.  This variation at P2 abrogated ELISpot responses.","Buranapraditkun2011"
"57691","YI9","2587","CRF01_AE","CRF01_AE","CRF01_AE","Gag","277","285","p24(145-153)","1618..1644","Cw*0102","YSPVSILDI","YSPaSILDI","V4A","V280A","OV","observed variant","CD8 T-cell Elispot - IFNy, Chromium-release assay","Patient 5043 who was Cw*0102+ carried this variant of YI9, V280A.","Buranapraditkun2011"
"58696",,"3109","B","B","B","Gag","277","285","p24(145-153)","1618..1644","Cw*12","YSPTSILDI","YSPvSILDI","T4V","T280V","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","C-mut YSPvSILDI that is a variant of Gag YSPTSILDI is restricted by HLA-Cw*12.  It is shown to be an escape by EliSpot.","Blais2012"
"54634","GAG-40","1961","B","B","C","Gag","288","305","p24(156-173)","1651..1704","","GPKEPFRDYVDRFYKTLR","GPKEPFRDYVDRFfKTLR","Y14F","Y301F","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 1 amino acid (5.6%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"54600",,"344","A, C, D","A, C","D","Gag","291","301","p24(159-169)","1660..1692","B81","EPFRDYVDRFF","EPFRDYVDRFy","F11Y","F301Y","DR","diminished response","","The wild type  epitope sequence was common to subtypes C and A, the variant to subtype D. CTL response in 56 individuals from Tanzania was strongest for subtypes C and A peptides, and much lower for subtype D, due to point mutation effect.","Geldmacher2007"
"1680",,"679","","","","Gag","293","302","p24(161-170)","1666..1695","B18","FRDYVDRFYK","FRDYVDRFfK","Y9F","Y301F","SF","susceptible form","CD8 T-cell Elispot - IFNy","This epitope and the variant were recognized by 1/9 HIV infected women and by 3/4 HIV-exposed, persistently seronegative women.","Kaul2001a"
"53615",,"67","A, D","","","Gag","293","307","p24(161-175)","1666..1710","","FRDYVDRFYKTLRAE","FRDYVDRFYKvLRAE","T11V","T303V","OV","observed variant","CD8 T-cell Elispot - IFNy","The sequence contains a known epitope (FRDYVDRFYKTL), but the subject recognizing it does not carry HLAs of the previously-defined restriction. The isolated viral sequence was frdyvdrfykVlrae, from the patient that could recognize the peptide.","Barugahare2005"
"57727",,"2628","","","","Gag","293","312","p24(161-180)","1666..1725","","FRDYVDRFYKTLRAEQASQE","FRDYVDRFfKTLRAEQAtQE","S18T, Y9F","S310T, Y301F","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Variant FRDYVDRFfKTLRAEQAtQE was seen in patient I08.","Vollbrecht2010"
"57727",,"2629","","","","Gag","293","312","p24(161-180)","1666..1725","","FRDYVDRFYKTLRAEQASQE","FRDYVDqFYKTLRAEQASQE","R7Q","R299Q","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Escape variant FRDYVDqFYKTLRAEQASQE was seen in patient I07, and suppression of this antigen led to a decline in CD38/PD-1 co-expression on CTL.","Vollbrecht2010"
"55936","RL11(p24)","1911","B","B","B","Gag","294","304","p24(162-172)","1669..1701","","RDYVDRFYKTL","RDYVDRFfKTL","Y8F","Y301F","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-A24, -A26 and -B35 restricted.  Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"316",,"2209","A","A","B","Gag","294","304","p24(162-172)","1669..1701","A*2402","RDYVDRFFKTL","RDYVDRyFKTL","F7Y","F300Y","DR, SSF","diminished response, subtype-specific susceptible form","","CTL responses in three individuals with non-clade B infections were studied, 2 with subtype A infections, 1 with subtype C -- their infections all originated in East Africa. This epitope is similar to the A24 DYVDRYFKT epitope found for B subtype, but CTL from this A subtype infection required the additional Arg -- the B clade sequence change from F to Y diminished CTL reactivity.","Dorrell1999"
"52330",,"135","B","B, D","A, C, CRF01_AE, F, G, H","Gag","296","304","p24(164-172)","1675..1701","A*0207","YVDRFYKTL","YVDRFfKTL","Y6F","Y301F","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","The Thai subject VAIP-4 demonstrated broad CTL cross-reactivity towards gag constructs derived from subtypes A, B, C, D, F, G, H, and CRF-01_AE. Sequence alignments of this epitope showed conservation for clades B and D, and Y->F substitutions at position 6 for subtypes A, C, CDR01-AE, F, G, and H. YVDRFYKTL and the variant epitope YVDRFFKTL are recognized equally well.","Currier2002b"
"318",,"173","A","A, C","B","Gag","296","304","p24(164-172)","1675..1701","A26, B70","YVDRFFKTL","YVDRFyKTL","F6Y","F301Y","SSF","subtype-specific susceptible form","","CTL responses in three individuals with non-clade B infections were studied, 2 with subtype A infections, 1 with subtype C -- their infections all originated in East Africa. This CTL epitope is conserved in A and C subtype, and B clade sequences tend to have a change from F to Y, YVDRFYKTL -- both variants showed strong CTL reactivity.","Dorrell1999"
"54595",,"345","A, C, D","A, C","D","Gag","296","304","p24(164-172)","1675..1701","B*1510","YVDRFFKTL","YVDRFyKTL","F6Y","F301Y","DR","diminished response","","The wild type epitope sequence was common to subtypes C and A, the variant to subtype D. CTL response in 56 individuals from Tanzania was strongest for subtype C  peptide, and much lower for subtype D, due to point mutation effect. The response was somewhat lower for subtype A peptide due to frame-of-epitope effect.","Geldmacher2007"
"1275","YL9","1337","C","","","Gag","296","304","p24(164-172)","1675..1701","B*1510, B70","YVDRFFKRL","YVDRFyKRL","F6Y","F301Y","LE, SF","literature escape, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Index epitope YVDRFFKRL is restricted by HLA-B*1510 which is serologically equivalent to B70.  The variant YVDRFyKRL previously described as an escape, is suggested to be restricted by HLA-A26 or -B70 and was recognized by an HIV-1A infected patient.","Novitsky2001"
"55899","YL9(p24)","1912","B","B","B","Gag","296","304","p24(164-172)","1675..1701","","YVDRFYKTL","YVDRFfKTL","Y6F","Y301F","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-A2 and -B15 restricted.  Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"57606","YL9","2559","C","C","C","Gag","296","304","p24(164-172)","1675..1701","Cw*03","YVDRFFKTL","YVDRFFKvL","T8V","T303V","R","reversion","CD8 T-cell Elispot - IFNy, Relative replication capacity assay","Selection of the Val-303 variant, via intracodon variation from Ile-303 (I303V) or Ala-303 (A303V), restored both viral fitness and CTL recognition.","Honeyborne2010"
"57606","YL9","2560","C","C","C","Gag","296","304","p24(164-172)","1675..1701","Cw*03","YVDRFFKTL","YVDRFFKiL","T8I","T303I","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Relative replication capacity assay","T303I had reduced CTL recognition and reduced viral replicative capacity.","Honeyborne2010"
"57606","YL9","2561","C","C","C","Gag","296","304","p24(164-172)","1675..1701","Cw*03","YVDRFFKTL","YVDRFFKaL","T8A","T303A","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Relative replication capacity assay","T303A had reduced CTL recognition and reduced viral replicative capacity.","Honeyborne2010"
"59022","CE6","3209","B","B","A, C, M","Gag","296","309","p24(164-177)","1675..1716","","YVDRFYKTLRAEQA","YVDRFfKTLRAEQA","Y6F","Y301F","SSF","subtype-specific susceptible form","Intracellular cytokine staining","YVDRFfKTLRAEQA is the Clades-A, -C and -M variant of CE6.  It was used in the p24CE2 vaccine form in this study, eliciting a low helper T-cell response.","Kulkarni2013"
"54635","GAG-41","1962","B","B","C","Gag","296","313","p24(164-181)","1675..1728","","YVDRFYKTLRAEQASQEV","YVDRFfKTLRAEQAtQdV","S15T, E17D, Y6F","S310T, E312D, Y301F","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 3 amino acids (16.7%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"54538","VS14","1025","B","B","A, C","Gag","297","310","p24(165-178)","1678..1719","","VDRFYKLTRAEQAS","VDRFYKLTRAEQAt","S14T","S310T","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","Cross-recognition is seen to both A- and C-clade variants.","Malhotra2007"
"320",,"110","","B, D","A, C","Gag","298","306","p24(166-174)","1681..1707","B14","DRFYKTLRA","DRFfKTLRA","Y4F","Y301F","SSF","subtype-specific susceptible form","Chromium-release assay","The consensus peptide for clades B and D is DRFYKTLRA. The consensus peptide for clades A and C is DRFFKTLRA and it is equally reactive.","Cao1997a"
"1675",,"676","","","","Gag","298","306","p24(166-174)","1681..1707","B14","DRFFKTLRA","DRFwKTLRA","F4W","F301W","SF","susceptible form","CD8 T-cell Elispot - IFNy","This epitope and the variant were recognized by 6/7 HIV infected women but not by HIV-exposed, persistently seronegative women.","Kaul2001a"
"53759","DA9","765","B","","","Gag","298","306","p24(166-174)","1681..1707","B14","DRFYKTLRA","DRFYrTLRA","K5R","K302R","DR","diminished response","CD8 T-cell Elispot - IFNy, Chromium-release assay","Variant dominated in the beginning of a 7 year period in a patient and reverted to wt later on. The variant was less well recognized by patient CTLs compared to the wt form.","Koibuchi2005a"
"53759","DA9","766","B","","","Gag","298","306","p24(166-174)","1681..1707","B14","DRFYKTLRA","DRFYrTpRA","K5R, L7P","K302R, L304P","OV","observed variant","","Variant was found in 2/8 clones at the beginning of a 7 year period in a patient.","Koibuchi2005a"
"53759","DA9","767","B","","","Gag","298","306","p24(166-174)","1681..1707","B14","DRFYKTLRA","kRFYKTLRA","D1K","D298K","OV","observed variant","","Variant was found in 1/13 clones at the middle of a 7 year period in a patient.","Koibuchi2005a"
"53759","DA9","768","B","","","Gag","298","306","p24(166-174)","1681..1707","B14","DRFYKTLRA","DRFcKTLRA","Y4C","Y301C","OV","observed variant","","Variant was found in 5/13 clones at the middle of a 7 year period in a patient.","Koibuchi2005a"
"53759","DA9","769","B","","","Gag","298","306","p24(166-174)","1681..1707","B14","DRFYKTLRA","DRFYKTLgA","R8G","R305G","OV","observed variant","","Variant was found in 1/13 clones at the middle of a 7 year period in a patient.","Koibuchi2005a"
"54537","DA9","1026","B","B","A, C","Gag","298","306","p24(166-174)","1681..1707","B14","DRFYKLTRA","DRFfKLTRA","Y4F","Y301F","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","Cross-recognition is seen to both A- and C-clade variants.  Both A- and C- variants contain a change at position 4 to DRFfKLTRA.","Malhotra2007"
"328",,"1545","B","B","A","Gag","298","306","p24(166-174)","1681..1707","B14, B*1402","DRFYKTLRA","DRFfKTLRA","Y4F","Y301F","SF","susceptible form","Chromium-release assay","Two HEPS Kenyan subjects cross-reacted to this B clade epitope and one of them elicited a stronger reaction to the A clade form, DTVLEdiNL.","Rowland-Jones1998"
"322",,"1557","","B","A","Gag","298","306","p24(166-174)","1681..1707","B14","DRFWKTLRA","DRFfKTLRA","W4F","W301F","OV","observed variant","Chromium-release assay","5/6 Kenyan HEPS subjects recognized this clade B epitope which differed from the clade A variant, DRFfKTLRA.","RowlandJones1998b"
"330",,"1840","","","","Gag","298","306","p24(166-174)","1681..1707","B14","DRFYKTLRA","DRFYKiLRA","T6I","T303I","E","escape documented in this paper","Chromium-release assay","This escape was not recognized by an HIV-transmitting mother.","Wilson1999a"
"57784","DE-10-1","2640","","","","Gag","298","307","p24(166-175)","1681..1710","B14","DRFYKTLRAE","DRFYKILRAE","T6I","T303I","LE","literature escape","Cytotoxicity assay","This escape variant is also called DE-10-2. Authors state that this is a previously-documented escape mutant.","Aldy2011"
"54636","GAG-42","1963","B","B","C","Gag","304","321","p24(172-189)","1699..1752","","LRAEQASQEVKNWMTETL","LRAEQAtQdVKNWMTdTL","E16D, S7T, E9D","E319D, S310T, E312D","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 3 amino acids (16.7%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"53756","RV9","770","B","","","Gag","305","313","p24(173-181)","1702..1728","Cw8","RAEQASQEV","RAEQAtQEV","S6T","S310T","DR","diminished response","CD8 T-cell Elispot - IFNy, Chromium-release assay","Variant dominated in the middle of a 7 year period in a patient. The variant was less well recognized by patient CTLs compared to the wt form.","Koibuchi2005a"
"53756","RV9","771","B","","","Gag","305","313","p24(173-181)","1702..1728","Cw8","RAEQASQEV","RAEQASQdV","E8D","E312D","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Chromium-release assay","Variant dominated in the beginning of a 7 year period in a patient. The variant was not recognized by patient CTLs.","Koibuchi2005a"
"53756","RV9","772","B","","","Gag","305","313","p24(173-181)","1702..1728","Cw8","RAEQASQEV","RAEQAtQdV","S6T, E8D","S310T, E312D","OV","observed variant","","Variant was found at the middle of a 7 year period in a patient.","Koibuchi2005a"
"53756","RV9","773","B","","","Gag","305","313","p24(173-181)","1702..1728","Cw8","RAEQASQEV","RAEQAShdV","Q7H, E8D","Q311H, E312D","OV","observed variant","","Variant was found in 1/15 clones at the middle of a 7 year period in a patient.","Koibuchi2005a"
"53756","RV9","774","B","","","Gag","305","313","p24(173-181)","1702..1728","Cw8","RAEQASQEV","RAErAtQEV","Q4R, S6T","Q308R, S310T","OV","observed variant","","Variant was found in 2/16 clones at the middle of a 7 year period in a patient.","Koibuchi2005a"
"53756","RV9","775","B","","","Gag","305","313","p24(173-181)","1702..1728","Cw8","RAEQASQEV","gAEQASQdV","R1G, E8D","R305G, E312D","OV","observed variant","","Variant was found in 1/13 clones at the middle of a 7 year period in a patient.","Koibuchi2005a"
"53756","RV9","776","B","","","Gag","305","313","p24(173-181)","1702..1728","Cw8","RAEQASQEV","RAEhASQdV","Q4H, E8D","Q308H, E312D","OV","observed variant","","Variant was found in 1/13 clones at the middle of a 7 year period in a patient.","Koibuchi2005a"
"53756","RV9","777","B","","","Gag","305","313","p24(173-181)","1702..1728","Cw8","RAEQASQEV","RAEQAlQdV","S6L, E8D","S310L, E312D","OV","observed variant","","Variant was found in 1/13 clones at the end of a 7 year period in a patient.","Koibuchi2005a"
"333",,"1558","","B","A","Gag","305","313","p24(173-181)","1702..1728","Cw8","RAEQASQEV","RAEQAtQEV","S6T","S310T","OV","observed variant","Chromium-release assay","5/6 Kenyan HEPS subjects recognized this clade B epitope which differed from the clade A variant, RAEQAtQEV.","RowlandJones1998b"
"333",,"2263","","B","D","Gag","305","313","p24(173-181)","1702..1728","Cw8","RAEQASQEV","RAEQ-SQdV","A5-, E8D","A309-, E312D","OV","observed variant","Chromium-release assay","5/6 Kenyan HEPS subjects recognized this clade B epitope which differed from the clade A variant, RAEQsQdV.","RowlandJones1998b"
"55630",,"20","A, CRF01_AE","AE, AG","A","Gag","305","319","p24(173-187)","1702..1746","","RAEQATQEVKNWMTE","RAEQATQdVKNWMTd","E15D, E8D","E319D, E312D","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","3 subjects responded to peptide RAEQATQEVKNWMTE from subtypes CRF01_AE and CRF02_AG; 1 of the 3 subjects also responded to peptide RAEQATQdVKNWMTd from subtype A.","Aidoo2008"
"53688",,"334","B, D","","","Gag","306","316","p24(174-184)","1705..1737","B44","AEQASQDVKNW","AEQASQeVKNW","D7E","D312E","OV","observed variant","","Cross-clade T cell responses are frequently induced in individuals infected with different HIV-1 clades. There was an inverse correlation between the height of responses and epitope sequence divergence. For Gag epitopes, the magnitude of the response was directly linked to the homology between HLA anchor residues.","Geels2005"
"56042","AW11(p24)","1913","B","B","B","Gag","306","316","p24(174-184)","1705..1737","B44","AEQASQEVKNW","AEQASQdVKNW","E7D","E312D","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"58841","QW9","3185","B","B","B","Gag","307","317","p24(175-185)","1708..1740","B*5701","QASQEVKNW","QASQdVKNW","E5D","E311D","OV","observed variant","Flow cytometric T-cell cytokine assay","Epitope mutation, E|QASQdVKNW|M, was seen for QW9 by the first sampling 13 weeks post-infection in P1 who carried HLA alleles A*0101,A*0301,B*2705,B*5701; and by 75 weeks post-infection in P3 who carried HLA alleles A*2402,A*3201,B*4002,B*5701.","Norstrom2012"
"58841","QW9","3186","B","B","B","Gag","307","317","p24(175-185)","1708..1740","B*5701","QASQEVKNW","QASQtVKNW","E5T","E311T","OV","observed variant","Flow cytometric T-cell cytokine assay","Epitope mutation E312T, E|QASQtVKNW|M, was seen for QW9 by the first sampling 18 weeks post-infection in P2 who carried HLA alleles A*0101,A*2402,B*4002,B*5701.","Norstrom2012"
"58841","QW9","3187","B","B","B","Gag","307","317","p24(175-185)","1708..1740","B*5701","QASQEVKNW","QASkEVKNW","Q4K","Q310K","OV","observed variant","Flow cytometric T-cell cytokine assay","Minor (4.5%) epitope variation E312K, E|QASkEVKNW|M, was seen for QW9 at 60 weeks post-infection in P4 who carried HLA alleles A*0101,A*0201,B*5101,B*5701.","Norstrom2012"
"1714",,"177","A","A","B","Gag","308","316","p24(176-184)","1711..1737","B53","QATQEVKNM","QAsQdVKNw","T3S, E5D, M9W","T310S, E312D, M316W","OV","observed variant","CD8 T-cell Elispot - IFNy, Cytotoxicity assay, Tetramer binding","Cross-recognition of QATQEVKNM was not studied here, but it was noted that both the subtype A version (QATQEVKNM) and subtype B version (QASQDVKNW) of this epitope are also presented by HLA-B57 and B58, common HLA alleles in Africans.","Dorrell2001"
"53674",,"335","B, D","","","Gag","308","316","p24(176-184)","1711..1737","B53, Cw4","QASQEVKNW","QASQdVKNW","E5D","E312D","OV","observed variant","","Cross-clade T cell responses are frequently induced in individuals infected with different HIV-1 clades. There was an inverse correlation between the height of responses and epitope sequence divergence. For Gag epitopes, the magnitude of the response was directly linked to the homology between HLA anchor residues.","Geels2005"
"52761","QW9","1296","B","","","Gag","308","316","p24(176-184)","1711..1737","B*5701","QASQEVKNW","QASQdVKNW","E5D","E312D","NSF, SF","non-susceptible form, susceptible form","HLA binding, Intracellular cytokine staining, Sequence","The E312D variant is more common in progressors (8/17) than controllers (1/10) of infection.  This variant  does not reliably confer loss of binding to HLA.  2/4 carriers of this variant and not the consensus, recognized it, but 2/4 did not.","Migueles2003"
"52761","QW9","1297","B","","","Gag","308","316","p24(176-184)","1711..1737","B*5701","QASQEVKNW","QAtQEVKNW","S3T","S310T","OV","observed variant","Sequence","This variant is found in 1/10 nonprogressors and 1/12 untreated progressors.","Migueles2003"
"52761","QW9","1298","B","","","Gag","308","316","p24(176-184)","1711..1737","B*5701","QASQEVKNW","QAtQdVKNW","S3T, E5D","S310T, E312D","OV","observed variant","Sequence","This variant is found in 1/10 nonprogressors.","Migueles2003"
"52761","QW9","1299","B","","","Gag","308","316","p24(176-184)","1711..1737","B*5701","QASQEVKNW","QASQdVKNx","E5D, W9X","E312D, W316X","OV","observed variant","Sequence","This variant is found in 1/10 nonprogressors.","Migueles2003"
"57413","QW9","2358","B","B","B","Gag","308","316","p24(176-184)","1711..1737","B*57","QASQEVKNW","QAStEVKNW","Q4T","Q311T","OV","observed variant","Sequence","Two patients, both with low viral load, positive for HLAs B*5703 and B*5701 respectively, carried variant QAStEVKNW from enrollment on.","Durand2010"
"57413","QW9","2359","B","B","B","Gag","308","316","p24(176-184)","1711..1737","B*57","QASQEVKNW","QASQdVKNW","E5D","E312D","OV","observed variant","Sequence","One HLA-B*5702 positive patient with low viral carried this variant from enrollment on; one HLA-B*5701 positive patient with increased viremia also carried it from enrollment.","Durand2010"
"57417","QW9","2365","B","B","B","Gag","308","316","p24(176-184)","1711..1737","B*57","QASQEVKNW","QASQEVKsW","N8S","N315S","OV","observed variant","Sequence","This variant, QASQEVKsW, was present in only 1 progressor, CH-02.","Tang2010"
"57417","QW9","2366","B","B","B","Gag","308","316","p24(176-184)","1711..1737","B*57","QASQEVKNW","QAtQEVKNW","S3T","S310T","OV","observed variant","Sequence","This variant, QAtQEVKNW, was present in only 1 progressor, CH-01.","Tang2010"
"57417","QW9","2367","B","B","B","Gag","308","316","p24(176-184)","1711..1737","B*57","QASQEVKNW","QASQdVKNW","E5D","E312D","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This variation to QASQdVKNW was present in 2 progressors and 3/4 controllers.","Tang2010"
"58284","QW9","2863","B","B","B","Gag","308","316","p24(176-184)","1711..1737","B*57","QASQEVKNW","QAtQdVKNW","S3T, E5D","S310T, E312D","LE","literature escape","Intracellular cytokine staining","QAtQdVKNW was one of 2 QW9 sequence variants cross-recognized by subdominant clonotypes.","Conrad2011"
"58284","QW9","2864","B","B","B","Gag","308","316","p24(176-184)","1711..1737","B*57","QASQEVKNW","QAtQEVKNW","S3T","S310T","","","Intracellular cytokine staining","QAtQEVKNW was one of 2 QW9 sequence variants cross-recognized by subdominant clonotypes.","Conrad2011"
"58690","QW9","3104","C","C","C","Gag","308","316","p24(176-184)","1711..1737","B*5702, B*5703, B*5801","QATQDVKNW","QAsQDVKNW","T3S","T310S","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","Mutant QAsQDVKNW was observed and recognized only in HLA-B*5801-positive subjects.  Only 10-15% of such B*5801 subjects, however, carried the P3 mutation.","Kloverpris2012"
"58690","QW9","3105","C","C","C","Gag","308","316","p24(176-184)","1711..1737","B*5702, B*5703, B*5801","QATQDVKNW","QAsQeVKNW","T3S, D5E","T310S, D312E","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","Mutant QAsQeVKNW was observed and recognized only in HLA-B*5801-positive subjects.  Only &tilde;5% of such B*5801 subjects, however, carried the P3/P5 mutation.","Kloverpris2012"
"58690","QW9","3106","C","C","C","Gag","308","316","p24(176-184)","1711..1737","B*5702, B*5703, B*5801","QATQDVKNW","QATQeVKNW","D5E","D312E","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","Mutant QATQeVKNW was observed and recognized only in HLA-B*5801-positive subjects.","Kloverpris2012"
"58745",,"3134","","","","Gag","308","316","p24(176-184)","1711..1737","B*57","QASQEVKNW","QASQdVKNW","E5D","E312D","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Variant QASQdVKNW is seen in both ES38 and CP2 HIV-1 sequences even though CP2 does not carry HLA-B*57 allele.  Neither subject can recognize this variant.","Buckheit2012"
"59209","QW9","3356","B","B","B","Gag","308","316","p24(176-184)",,"B*5701","QASQEVKNW","QASQdVKNW","E5D","E312D","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant QASQdVKNW was seen in 2/3 HRP and no LRP subjects.  It was the analogous epitope of the major viral population at the last time points in patient P3, the earliest time point in patient P1.","Buggert2014"
"59209","QW9","3357","B","B","B","Gag","308","316","p24(176-184)",,"B*5701","QASQEVKNW","QASQtVKNW","E5T","E312T","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant QASQtVKNW was seen in 1/3 HRP and no LRP subjects.  It was the only analogous epitope of the major viral population patient P2.","Buggert2014"
"1689",,"2190","","","","Gag","309","317","p24(177-185)","1714..1740","B53","ATQEVKNWM","AsQEVKNWM","T2S","T310S","SF","susceptible form","CD8 T-cell Elispot - IFNy","This epitope and the variant were recognized by 5/9 HIV infected women and by 1/2 HIV-exposed, persistently seronegative women.","Kaul2001a"
"54540","VV11","1027","B","B","C","Gag","313","323","p24(181-191)","1726..1758","","VKNWMTETLLV","VKNWMTdTLLV","E7D","E319D","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","Cross-recognition is seen only to the A-clade variant. The C-clade variant contains a semi-conservative change at position 7 to VKNWMTdTLLV.","Malhotra2007"
"58390","Peptide 80","2925","C","C","B","Gag","322","336","p24(190-204)","1753..1797","","xLVQNANPDCKTILRA","lLVQNANPDCKTILRk","x1L, A16K","x322L, A337K","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-B peptide 80, lLVQNANPDCKTILRk, cross reacted to elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"58390","Peptide 80","2926","C","C","A","Gag","322","336","p24(190-204)","1753..1797","","LVQNANPDCKTILRA","LVQNANPDCKsILRA","T11S","T332S","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-A peptide 80, LVQNANPDCKsILRA, cross reacted to elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"58390","Peptide 80","2927","C","C","D","Gag","322","336","p24(190-204)","1753..1797","","LVQNANPDCKTILRA","LVQNANPDCKTILkA","R14K","R335K","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-D peptide 80, LVQNANPDCKTILkA, cross reacted to elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"345",,"382","","","","Gag","323","337","p24(191-205)","1756..1800","B8","VQNANPDCKTILKAL","VQNANPDCrTILKAL","K9R","K331R","E","escape documented in this paper","","This variant failed to be recognized by CTLs and failed to induce target specific lysis.","Goulder1997e, Phillips1991"
"349",,"1764","","","","Gag","325","333","p24(193-201)","1762..1788","B*5101","NANPDCKTI","NsNPDCKTI","A2S","A326S","OV","observed variant","Chromium-release assay, HLA binding","2/32 Clade B strain sequences carried this 2S variant.  Challenge epitope elicited CTL response in 2 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with medium strength.  Variant not tested.","Tomiyama1999"
"53159",,"1884","","","","Gag","325","333","p24(193-201)","1762..1788","B*5101","NANPDCKTI","NsNPDCKnI","A2S, T8N","A326S, T332N","E, P, SF","escape documented in this paper, processing, susceptible form","Chromium-release assay","Index epitope and this variant escaped from killing by Gag-epitope-specific CTL clonal lines when presented as endogenously expressed sequences on transformed cells, but were recognized by CTL when exogenously loaded as synthetic peptide.  A processing or epitope presentation mutation is assumed.","Yokomaku2004"
"58394","NI9","2937","B","B","B","Gag","325","333","p24(193-201)","1762..1788","B*51","NANPDCKTI","NsNPDCKTI","A2S","A326S","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, CTL suppression of replication","This mutation, A328S, NsNPDCKTI, was found in 7/22 HLA-B51+ subjects (SM cohort IDs 350, 455, 47, 14, 342, 63 and 353) and in 3/126 HLA-B51- subjects.  The A2<i><b>S</i></b> mutant is significantly associated with HLA-B51 and also with low CD4+ cell counts.  It is not recognized by NI9-specific CTL clones.","Zhang2011"
"58729","NP15","3129","","","","Gag","325","339","p24(193-207)","1762..1806","","NANPDCKTILKALGP","NsNPDCKTILKALGP","A2S","A326S","IE, NSF, SF","inferred escape, non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Subject VC1, the controller, carried a mutation in NP15, NsNPDCKTILKALGP, that the authors predict to be an escape though it was recognized by VC1 by EliSpot.  CP2 also carried the mutation but did not recognize it.","Buckheit2012"
"53420","ANP","1354","","","","Gag","326","334","p24(194-202)","1765..1791","B7","ANPDCKTIL","sNPDCKTIL","A1S","A326S","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/18 viral clones contained this variant sequence at the first time point tested after infection.","Oxenius2004"
"53420","ANP","1355","","","","Gag","326","334","p24(194-202)","1765..1791","B7","ANPDCKTIL","ANPDCKTIs","L9S","L334S","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/18 viral clones contained this variant sequence at the first time point tested after infection.","Oxenius2004"
"354",,"1347","","","","Gag","329","337","p24(197-205)","1774..1800","B8","DCKTILKAL","DCrTILKAL","K3R","K331R","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Chromium-release assay, HLA binding, Longitudinal study","Both K and R variants bind HLA-B8.  Initial  recognition of the K variant is soon lost.  The predominant R variant is never recognized by patient CTL.","Nowak1995"
"56144",,"1528","C","","","Gag","335","343","p24(203-211)","1792..1818","","RALGPGATL","RALGaGATL","P5A","P339A","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"56144",,"1529","C","","","Gag","335","343","p24(203-211)","1792..1818","","RALGPGATL","RALGqGATL","P5Q","P339Q","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"56144",,"1530","C","","","Gag","335","343","p24(203-211)","1792..1818","","RALGPGATL","RALGsGATL","P5S","P339S","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"56144",,"1531","C","","","Gag","335","343","p24(203-211)","1792..1818","","RALGPGATL","RALGtGATL","P5T","P339T","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"56144",,"1532","C","","","Gag","335","343","p24(203-211)","1792..1818","","RALGPGATL","RALGvGATL","P5V","P339V","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"58681",,"3083","C","C","C","Gag","335","343","p24(203-211)","1792..1818","","RALGPGATM","RALGtGATM","P5T","P339T","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"58681",,"3084","C","C","C","Gag","335","343","p24(203-211)","1792..1818","","RALGPGATM","RALGvGATM","P5V","P339V","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"58681",,"3085","C","C","C","Gag","335","343","p24(203-211)","1792..1818","","RALGPGATM","RALGsGATM","P5S","P339S","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"58681",,"3086","C","C","C","Gag","335","343","p24(203-211)","1792..1818","","RALGPGATM","RALGqGATM","P5Q","P339Q","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"58681",,"3087","C","C","C","Gag","335","343","p24(203-211)","1792..1818","","RALGPGATM","RALGaGATM","P5A","P339A","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"54637","GAG-47","1964","B","B","C","Gag","340","358","p24(208-226)","1807..1863","","AATLEEMMTACQGVGGPSH","gAsLEEMMTACQGVGGPSH","A1G, T3S","A340G, T342S","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 2 amino acids (10.5%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"59024","CE7","3210","A, B, M","A, B, M","C","Gag","343","359","p24(211-227)","1816..1866","","LEEMMTACQGVGGPGHK","LEEMMTACQGVGGPsHK","G15S","G357S","SSF","subtype-specific susceptible form","Intracellular cytokine staining","LEEMMTACQGVGGPsHK is the Clade-C variant of CE7.  It was used in the p24CE2 vaccine form in this study, eliciting no T-cell response.","Kulkarni2013"
"53474","AK11","34","B","","","Gag","349","359","p24(217-227)","1834..1866","A11","ACQGVGGPGHK","ACQGVGGPsHK","G9S","G357S","SF","susceptible form","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Intracellular cytokine staining","A novel CD8 T-cell response was generated against ACQGVGGPsHK, which utilized a distinct T-cell receptor and did not exhibit any cross-reactivity against the wild type. Most individuals expressing HLA-A11 targeted ACQGVGGPsHK.","Allen2005"
"52104",,"293","B, CRF01_AE","B","C, CRF01_AE, D","Gag","349","359","p24(217-227)","1834..1866","A*1101","ACQGVGGPGHK","ACQGVGGPsHK","G9S","G357S","SNSF","subtype-specific non-susceptible form","Chromium-release assay, HLA binding","Variant predominantly found in clades C, D and E. CTLs from subtype B did not recognize this variant while its binding affinity to A*1101 was same as wt.","Fukada2002"
"54539","AK11","1028","B","B","C","Gag","349","359","p24(217-227)","1834..1866","A11","ACQGVGGPGHK","ACQGVGGPsHK","G9S","G357S","SNSF, SSF","subtype-specific non-susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","Cross-recognition is seen only to the A-clade variant.  The C-clade variant contains a semi-conservative change at position 9 to ACQGVGGPsHK.","Malhotra2007"
"360",,"1628","","B","B","Gag","349","359","p24(217-227)","1834..1866","A11","ACQGVGGPGHK","ACQGVGGPsHK","G9S","G357S","SF","susceptible form","Chromium-release assay","This naturally occurring, strain RF variant, was recognized by a Patient LWF CTL clone.","Sipsas1997"
"55919","AK11(p24)","1914","B","B","B","Gag","349","359","p24(217-227)","1834..1866","","ACQGVGGPSHK","ACQGVGGPgHK","S9G","S357G","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope. This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-A11 restricted.","Zhai2008"
"57377","AK11 wt","2337","","","","Gag","349","359","p24(217-227)","1834..1866","A*1101","ACQGVGGPGHK","ACQGVGGPsHK","G9S","G357S","LE","literature escape","Tetramer binding","Frequent natural variant ACQGVGGPsHK had increased binding over wild type AK11 to inhibitory receptor ILT4 on CD14+ monocytes.  In line with prior studies, this was assumed to induce inhibition of antigen presenting and cytokine secretion of myelomonocytic cells.","Yang2010"
"55627",,"19","A, CRF01_AE","A","AE","Gag","349","363","p24(217-231)","1834..1878","","ACQGVGGPSHKARIL","ACQGVGGPSHKARvL","I14V","I362V","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","1 subject responded to peptide ACQGVGGPSHKARIL from subtype A and to peptide ACQGVGGPSHKARvL from subtype CRF01_AE.","Aidoo2008"
"55918","GK8(p24)","1915","B","B","B","Gag","352","359","p24(220-227)","1843..1866","","GVGGPSHK","GVGGPgHK","S6G","S357G","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position.  It is predicted to be  HLA-A11 restricted.  No recognition was seen by CTL from HLA-A3 carriers.","Zhai2008"
"54601",,"346","A, C, D","D","A, C","Gag","355","363","p24(223-231)","1852..1878","B42, B7, B81","GPSHKARVL","GPgHKARVL","S3G","S357G","DR","diminished response","","The wild type epitope sequence was a subtype D peptide, the variant common to subtypes C and A. CTL response in 56 individuals from Tanzania was strongest for subtype D peptide, and much lower for subtypes C and A, due to point mutation and/or frame-of-epitope effect.","Geldmacher2007"
"55972","GL9(p24)","1916","B","B","B","Gag","355","363","p24(223-231)","1852..1878","","GPSHKARVL","GPgHKARVL","S3G","S357G","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope. This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B7 restricted.","Zhai2008"
"57960","GL9","2691","B","B","B","Gag","355","363","p24(223-231)","1852..1878","B*0702","GPSHKARVL","GPgHKARVL","S3G","S357G","SF","susceptible form","CD8 T-cell Elispot - IFNy","GPSHKARVL underwent adaptation to neo-epitope GPgHKARVL. 5 subjects had higher EliSpot responses to the neo-epitope than to the non-adapted form.","Keane2012"
"59039","GL9-p24","3220","C","C","B","Gag","355","363","p24(223-231)","1852..1878","B*0702","GPSHKARVL","GPgHKARVL","S3G","S24G","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","GL9-3G, GPgHKARVL, (3G), a B-clade Gag variant of C-clade GPSHKARVL was cross-recognized to equal extents as its C-clade variant, (3S), at 55% and 29% in C- or B-clade infected cohorts.  The B-clade consensus epitope differs at S3G and its binding affinity to B*0702 was K<sub>d</sub> = 342 nM.  GL9-3G is contained within OLP48, ACQGVGGPgHKARVLAEA.","Kloverpris2014"
"58391","Peptide 89","2928","C","C","D","Gag","358","373","p24(226)-p2p7p1p6(10)","1861..1908","","HKARVLAEAMSQTNS","HKARVLAEAMSQ(a)TN","-(12.1)A","-(369.1)A","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-D peptide 89, HKARVLAEAMSQ(a)TN, which carries an insertion, cross reacted to elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"58391","Peptide 89","2929","C","C","A","Gag","358","373","p24(226)-p2p7p1p6(10)","1861..1908","","HKARVLAEAMSQTNS","HKARVLgtgarasvl","M10A, S11R, Q12A, T13S, N14V, S15L, A7G, E8T, A9G","M367A, S368R, Q369A, T370S, N371V, S372L, A364G, E365T, A366G","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-A peptide 89, HKARVLgtgarasvl, did not elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"58391","Peptide 89","2930","C","C","B","Gag","358","373","p24(226)-p2p7p1p6(10)","1861..1908","","HKARVLAEAMSQTNS","{g}HKARVLAEAMSQ(v)T","-(15.1)V, x2G","-(372.1)V, x359G","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Consensus Clade-B peptide 89, {g}HKARVLAEAMSQ(v)T, did not elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"58391","Peptide 89","2931","C","C","C","Gag","358","373","p24(226)-p2p7p1p6(10)","1861..1908","","HKARVLAEAMSQTNS","HKARVLAEAMSQaNg","T13A, S15G","T370A, S372G","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Chinese Clade-C peptide 89, HKARVLAEAMSQaNg, did not elicit a response from South African subjects carrying clade-C virus.","Zembe2011"
"52666","Gag362(9L)","122","","","","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A2","VLAEAMSQV","VLAEAMSQa","V9A","V370A","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, Flow cytometric T-cell cytokine assay","This peptide was a good A2 binder that induced CTL and CD8+ T-cell IFN gamma responses in mice. Responses were detected in 1/17 HIV+ HLA-A2 subjects. The variant vlaeamsqA was also immunogenic in A2 transgenic mice, eliciting a CD8+ T-cell response, as was recognized in 3/17 HIV+ people, including the person that recognized the vlaeamsqV variant.","Corbet2003"
"56059","Gag362(9V)","203","","","","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A2","VLAEAMSQV","VLAEAMSQa","V9A","V370A","OV","observed variant","","One HLA-A2 patient did not respond to the VLAEAMSQV epitope but the variant peptide was observed in the patient.","Fomsgaard2008"
"53071","Gag 386","1168","M","B, C","B, C","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A*0201","VLAEAMSQV","VLAEAMSQa","V9A","V370A","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This anchor position variant elicited a CTL response with cells from mice immunized with the index form.","McKinney2004"
"53071","Gag 386","1169","M","B, C","C","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A*0201","VLAEAMSQV","VLAEAMSQt","V9T","V370T","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This anchor position variant elicited a CTL response with cells from mice immunized with the index form.","McKinney2004"
"53071","Gag 386","1170","M","B, C","B","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A*0201","VLAEAMSQV","VLAEAMSQi","V9I","V370I","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This anchor position variant elicited a CTL response with cells from mice immunized with the index form.","McKinney2004"
"53071","Gag 386","1171","M","B, C","B","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A*0201","VLAEAMSQV","iLAEAMSQV","V1I","V362I","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant elicited a CTL response with cells from mice immunized with the index form.","McKinney2004"
"53071","Gag 386","1172","M","B, C","C","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A*0201","VLAEAMSQV","VLAEAMgQV","S7G","S368G","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant did not elicit a CTL response with cells from mice immunized with the index form.","McKinney2004"
"53071","Gag 386","1173","M","B, C","B","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A*0201","VLAEAMSQV","VLAEAMSrV","Q8R","Q369R","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant elicited a CTL response with cells from mice immunized with the index form.","McKinney2004"
"53071","Gag 386","1174","M","B, C","C","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A*0201","VLAEAMSQV","VLAEAMSkV","Q8K","Q369K","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant elicited a CTL response with cells from mice immunized with the index form.","McKinney2004"
"53071","Gag 386","1175","M","B, C","","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A*0201","VLAEAMSQV","VLAEAMShV","Q8H","Q369H","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant elicited a weak CTL response with cells from mice immunized with the index form.","McKinney2004"
"53071","Gag 386","1176","M","B, C","C","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A*0201","VLAEAMSQV","aLAEAMSQa","V1A, V9A","V362A, V370A","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant did not elicit CTL response with cells from mice immunized with the index form.","McKinney2004"
"53071","Gag 386","1177","M","B, C","C","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A*0201","VLAEAMSQV","iLAEAMSQa","V1I, V9A","V362I, V370A","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited a CTL response with cells from mice immunized with the index form.","McKinney2004"
"53071","Gag 386","1178","M","B, C","C","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A*0201","VLAEAMSQV","VLgEAMSQa","A3G, V9A","A364G, V370A","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant did not elicit CTL response with cells from mice immunized with the index form.","McKinney2004"
"53071","Gag 386","1179","M","B, C","C","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A*0201","VLAEAMSQV","VLAEAMSka","Q8K, V9A","Q369K, V370A","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant did not elicit CTL response with cells from mice immunized with the index form.","McKinney2004"
"53071","Gag 386","1180","M","B, C","","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A*0201","VLAEAMSQV","VLAEAMSra","Q8R, V9A","Q369R, V370A","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant did not elicit CTL response with cells from mice immunized with the index form.","McKinney2004"
"53071","Gag 386","1181","M","B, C","C","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A*0201","VLAEAMSQV","VLAEAMSha","Q8H, V9A","Q369H, V370A","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant did not elicit CTL response with cells from mice immunized with the index form.","McKinney2004"
"53071","Gag 386","1182","M","B, C","C","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A*0201","VLAEAMSQV","VLAEAMSht","Q8H, V9T","Q369H, V370T","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant did not elicit CTL response with cells from mice immunized with the index form.","McKinney2004"
"53071","Gag 386","1183","M","B, C","","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A*0201","VLAEAMSQV","VLAEAMSaa","Q8A, V9A","Q369A, V370A","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited CTL response with cells from mice immunized with the index form.","McKinney2004"
"53071","Gag 386","1184","M","B, C","","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A*0201","VLAEAMSQV","VLAEAMata","S7A, Q8T, V9A","S368A, Q369T, V370A","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited CTL response with cells from mice immunized with the index form.","McKinney2004"
"53071","Gag 386","1185","M","B, C","","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A*0201","VLAEAMSQV","VLAEAMaaa","S7A, Q8A, V9A","S368A, Q369A, V370A","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited CTL response with cells from mice immunized with the index form.","McKinney2004"
"53071","Gag 386","1186","M","B, C","C","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A*0201","VLAEAMSQV","iLAEAMSka","V1I, Q8K, V9A","V362I, Q369K, V370A","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited CTL response with cells from mice immunized with the index form.","McKinney2004"
"53071","Gag 386","1187","M","B, C","","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A*0201","VLAEAMSQV","iLAEAMasa","V1I, S7A, Q8S, V9A","V362I, S368A, Q369S, V370A","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited CTL response with cells from mice immunized with the index form.","McKinney2004"
"53843","VV9","1576","","","","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A2","VLAEAMSQV","VLAEAMShV","Q8H","Q369H","OV","observed variant","Sequence","This variant from the HXB2 sequence was present in the restricting HLA-A2 allele carrying mother, M-1005, as well as her non-HLA-A2-carrying infant, P-1026.  This variant was still detected at 15 months of age in infant P-1026.","Sanchez-Merino2005"
"55371","Gag 362(9V)","1690","","","","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A2","VLAEAMSQV","VLAEAMSQa","V9A","V370A","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt15 carried this variant and was unable to recognize either variant or the challenge HXB2 form, VLAEAMSQV.","Thorn2007"
"55371","Gag 362(9V)","1691","","","","Gag","362","370","p24(230)-p2p7p1p6(7)","1873..1899","A2","VLAEAMSQV","VLAEAMSQm","V9M","V370M","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt17 carried this variant and was unable to recognize either variant or the challenge HXB2 form, VLAEAMSQV.","Thorn2007"
"56638",,"2004","","","","Gag","395","403","p2p7p1p6(32-40)","1972..1998","A*3101","CGKEGHIAR","CGKEGHIAk","R9K","R403K","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","CGKEGHIAR was strongly recognized by T cells, whereas CGKEGHIAk was not.","Goonetilleke2009"
"56638",,"2005","","","","Gag","395","403","p2p7p1p6(32-40)","1972..1998","A*3101","CGKEGHIAR","CGKEGHlAR","I7L","I401L","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","CGKEGHIAR was strongly recognized by T cells, whereas the mutant was not.","Goonetilleke2009"
"53682",,"2280","B, G","","","Gag","421","432","p2p7p1p6(58-69)","2050..2085","A2","HQMKDCNERQAN","HQMKDCNtR(qg)QAN","E8T, -(9.1)Q, -(9.2)G","E428T, -(429.1)Q, -(429.2)G","OV","observed variant","","Cross-clade T cell responses are frequently induced in individuals infected with different HIV-1 clades. There was an inverse correlation between the height of responses and epitope sequence divergence. For Gag epitopes, the magnitude of the response was directly linked to the homology between HLA anchor residues.","Geels2005"
"57179","RI9","2957","C","C","C","Gag","429","437","p2p7p1p6(66-74)","2074..2100","B*13","RQANFLGKI","RQANFLGKv","I9V","I437V","A, E","HLA association, escape documented in this paper","CD8 T-cell Elispot - IFNy, Relative replication capacity assay","Variant I437V, RQANFLGKv, is one of 5 variants studied at position 437, such 437-position variants being found in 30% of B*13-positive and 3% of B*13-negative subjects.  I437V was not significantly less well recognized than WT, but previous studies show that no subject carrying I437V-autologous virus can respond to WT RI9.  No significant difference from the WT was seen in p24 production for replication assays or in I437V infectivity, and therefore no significant decrease in viral growth rate was noted.","Prado2009"
"57179","RI9","2958","C","C","C","Gag","429","437","p2p7p1p6(66-74)","2074..2100","B*13","RQANFLGKI","RQANFLGrI","K8R","K436R","A","HLA association","CD8 T-cell Elispot - IFNy, Relative replication capacity assay","Variant I436R, RQANFLGrI was not significantly less well recognized than WT.  No significant difference from the WT was seen in p24 production for replication assays or in I436R infectivity, and therefore no significant decrease in viral growth rate was noted.","Prado2009"
"57179","RI9","2959","C","C","C","Gag","429","437","p2p7p1p6(66-74)","2074..2100","B*13","RQANFLGKI","RQANFLGKm","I9M","I437M","A, E","HLA association, escape documented in this paper","CD8 T-cell Elispot - IFNy, Relative replication capacity assay","Variant I437M, RQANFLGKm, is one of 5 variants studied at position 437, such 437-position variants being found in 30% of B*13-positive and 3% of B*13-negative subjects.  I437M was significantly less well recognized than WT.  Significant differences from the WT were seen in p24 production for replication assays and in I437M infectivity, and therefore significant decrease in viral growth rate was noted.  A significant accumulation of unprocessed p55 Gag was seen that was related to ribosomal frameshifting inefficiency, reducing frameshifts as compared to WT by as much as 58-74%.","Prado2009"
"57179","RI9","2960","C","C","C","Gag","429","437","p2p7p1p6(66-74)","2074..2100","B*13","RQANFLGKI","RQANFLGKl","I9L","I437L","A, E","HLA association, escape documented in this paper","CD8 T-cell Elispot - IFNy, Relative replication capacity assay","Variant I437L, RQANFLGKl, is one of 5 variants studied at position 437, such 437-position variants being found in 30% of B*13-positive and 3% of B*13-negative subjects.  I437L was significantly less well recognized than WT.  Significant differences from the WT were seen in p24 production for replication assays and in I437M infectivity, and therefore significant decrease in viral growth rate was noted.  A significant accumulation of unprocessed p55 Gag was also seen, increasing the p55/p24 ratio.","Prado2009"
"57179","RI9","2961","C","C","C","Gag","429","437","p2p7p1p6(66-74)","2074..2100","B*13","RQANFLGKI","RQANFLGrl","K8R, I9L","K436R, I437L","A, E","HLA association, escape documented in this paper","CD8 T-cell Elispot - IFNy, Relative replication capacity assay","Double variant K436R/I437L, RQANFLGrl, is one of 5 variants studied at positions 436 and 437, such 437-position variants being found in 30% of B*13-positive and 3% of B*13-negative subjects.  K436R/I437L was significantly less well recognized than WT with a 1-log decrease in peptide avidity.","Prado2009"
"57179","RI9","2962","C","C","C","Gag","429","437","p2p7p1p6(66-74)","2074..2100","B*13","RQANFLGKI","RQANFLGrm","K8R, I9M","K436R, I437M","A, E","HLA association, escape documented in this paper","CD8 T-cell Elispot - IFNy, Relative replication capacity assay","Double variant K436R/I437M, RQANFLGrm, is one of 5 variants studied at positions 436 and 437, such 437-position variants being found in 30% of B*13-positive and 3% of B*13-negative subjects.  K436R/I437M was significantly less well recognized than WT with a 1-log decrease in peptide avidity.","Prado2009"
"55372","Gag 433","1692","","","","Gag","433","440","p2p7p1p6(70-77)","2086..2109","A2","FLGKIWPS","FLGKIWsS","P7S","P439S","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt16 carried this variant and was able to cross-recognize the challenge HXB2 epitope, FLGKIWPS.  Of the 9 subjects that did carry the HXB2 epitope sequence, only 3, Pt30, Pt33 and Pt41 were able to recognize it.","Thorn2007"
"55372","Gag 433","1693","","","","Gag","433","440","p2p7p1p6(70-77)","2086..2109","A2","FLGKIWPS","FLGrIWPS","K4R","K436R","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt43 carried this variant and was able to cross-recognize the challenge HXB2 epitope, FLGKIWPS.","Thorn2007"
"54639","GAG-65","1965","B","B","C","Gag","474","490","p2p7p1p6(111-127)","2209..2259","","QKQEPIDKELYPLASLK","pKQEPkDrE--PLtSLK","Q1P, L10-, Y11-, A14T, I6K, K8R","Q474P, L483-, Y484-, A487T, I479K, K481R","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 6 amino acids (35.3%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"53845","KL9","1577","","","","Gag","481","489","p2p7p1p6(118-126)","2230..2256","B40","KELYPLTSL","KEmYPLaSL","L3M, T7A","L483M, T487A","OV","observed variant","Sequence","This variant from the HXB2 sequence was present in the restricting HLA-B40 allele carrying mother, M-1005, as well as her non-HLA-B40-carrying infant, P-1026.  This variant was still detected at 15 months of age in infant P-1026.","Sanchez-Merino2005"
"53873",,"1872","B","B","B","Gag","481","489","p2p7p1p6(118-126)","2230..2256","B*40","KELYPLTSL","KELYPLaSL","T7A","T487A","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Autologous variant differed from the Strain B consensus, but was recognized.","Yang2005"
"56034","KL9(p2p7p1p6)","1917","B","B","B","Gag","481","489","p2p7p1p6(118-126)","2230..2256","","KELYPLTSL","KELYPLaSL","T7A","T487A","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B40 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"54641","GAG-66","1966","B","B","C","Gag","481","498","p2p7p1p6(118-135)","2230..2283","","KELYPLASLKSLFGNDPS","rE--PL-SLKSLFGsDPl","K1R, N15S, S18L, L3-, Y4-, A7-","K481R, N495S, S498L, L483-, Y484-, A487-","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 5 amino acids (33.3%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"56654",,"2081","","","","Gag","481","498","p2p7p1p6(118-135)","2230..2283","","KELYPLASLRSLFGNDPS","qELYPLASLRSLFGNDPS","K1Q","K481Q","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This variant in Patient CH40 gave a positive ELISpot from the full proteome scan but was not associated with statistical evidence of positive selection.","Goonetilleke2009"
"54149","NL8","957","B","","","Pol","24","31","Gag/Pol-TF(24-31)","2154..2177","Cw*0102","NSPTRREL","tSPTRREL","N1T","N24T","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Position 4 in the epitope had potentially experienced positive selection.  The variant was full escape, as it was not recognized by CTLs.","Liu2006"
"55761","NL8","2282","B","","","Pol","24","31","Gag/Pol-TF(24-31)","2154..2177","Cw*0102","NSPTRREL","NSPT(spt)RREL","-(4.1)S, -(4.2)P, -(4.3)T","-(27.1)S, -(27.2)P, -(27.3)T","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Chromium-release assay","Epitope NSPTRREL escapes to NSPT(SPT)RREL (through insertion of a 3-amino-acid repeat) in subject PIC1362. Addition of an N-terminal Alanine to NL8 (aNSPTRREL) does not affect in vitro MHC I binding. Deletion of the C-terminal L as in peptide aNSPTRRE (AE8), however, shows that Leu is necessary for MHC I binding.","Cao2008"
"59082",,"3248","B","B","B","Pol","24","31","Gag/Pol-TF(24-31)",,"Cw*0102","NSPTRREL","NSPTsptRREL","-(4.1)S, -(4.2)P, -(4.3)T","-(27.1)S, -(27.2)P, -(27.3)T","E, I","escape documented in this paper, insertion","Peptide titration","EliSpot peptide titration indicated full escape.","Liu2007a"
"59082",,"3249","B","B","B","Pol","24","31","Gag/Pol-TF(24-31)",,"Cw*0102","NSPTRREL","tSPTRREL","N1T","N24T","E","escape documented in this paper","Peptide titration","EliSpot peptide titration indicated full escape.","Liu2007a"
"55374","Pol 59","1670","","","","Pol","59","67","Protease(3-11)","2259..2285","A2","ITLWQRPLV","ITLWQRPiV","L8I","L66I","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt21 carried this variant and was unable to recognize the challenge HXB2 epitope form, ITLWQRPLV.","Thorn2007"
"55374","Pol 59","1671","","","","Pol","59","67","Protease(3-11)","2259..2285","A2","ITLWQRPLV","ITLWQRPfV","L8F","L66F","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt41 carried this variant and was unable to recognize the challenge HXB2 epitope form, ITLWQRPLV.","Thorn2007"
"53866","QI9","1640","","","","Pol","63","71","Protease(7-15)","2271..2297","A*0101","QRPLVTIKI","QRPiVTIKI","L4I","L66I","DI, SF","drug induced, susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This ART induced-L10I variant and the index epitope were both recognized by CTL specific for each epitope.  The restricting HLA for the variant was found to be HLA-A*0101.","Stratov2005"
"54662","QG10","1319","B","","","Pol","63","72","Protease(7-16)","2271..2300","B51","QRPLVTVKIG","QRPiVTVKIG","L4I","L66I","DI, E","drug induced, escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","This is a drug-induced polymorphism that results in impaired CTL responses.","Mueller2007"
"54662","QG10","1320","B","","","Pol","63","72","Protease(7-16)","2271..2300","B51","QRPLVTVKIG","QRPLVTVrIG","K8R","K70R","A, DI","HLA association, drug induced","CD8 T-cell Elispot - IFNy, Sequence","This atazanavir-induced minor mutation, K14R, is associated with the broad antigen HLA-B5.","Mueller2007"
"53068","Pol 98","1188","M","B, C","B","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VaIKIGGQLK","T2A","T68A","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This anchor position variant did not elicit a CTL response with cells from mice immunized with the index form.  It was not recognized by CTL lines derived from HIV-1 uninfected donors either.","McKinney2004"
"53068","Pol 98","1189","M","B, C","","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VTIKIGGQLr","K10R","K76R","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This anchor position variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53068","Pol 98","1190","M","B, C","B","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VTvKIGGQLK","I3V","I69V","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53068","Pol 98","1191","M","B, C","B","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VTIrIGGQLK","K4R","K70R","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53068","Pol 98","1192","M","B, C","B","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VTIKvGGQLK","I5V","I71V","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53068","Pol 98","1193","M","B, C","B","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VTIKIeGQLK","G6E","G72E","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant did not elicit CTL response with cells from mice immunized with the index form.  It was not recognized by CTL lines derived from HIV-1 uninfected donors either.","McKinney2004"
"53068","Pol 98","1194","M","B, C","","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VTIKIGGQiK","L9I","L75I","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53068","Pol 98","1195","M","B, C","","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VTvKIGGQLr","K10R, I3V","K76R, I69V","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53068","Pol 98","1196","M","B, C","","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VTvKIGGeLK","I3V, Q8E","I69V, Q74E","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited a CTL response with cells from mice immunized with the index form.  It was however, not recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53068","Pol 98","1197","M","B, C","","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VTvKIeGQLK","I3V, G6E","I69V, G72E","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited a weak CTL response with cells from mice immunized with the index form.  It was barely recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53068","Pol 98","1198","M","B, C","","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VTvKvGGQLK","I3V, I5V","I69V, I71V","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited a weak CTL response with cells from mice immunized with the index form.  It was weakly recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53068","Pol 98","1199","M","B, C","","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VTvrIGGQLK","I3V, K4R","I69V, K70R","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited a CTL response with cells from mice immunized with the index form.  It was recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53068","Pol 98","1200","M","B, C","","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VTIrIGGQLr","K10R, K4R","K76R, K70R","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited a weak CTL response with cells from mice immunized with the index form.  It was well recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53068","Pol 98","1201","M","B, C","","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VTIrvGGQLK","K4R, I5V","K70R, I71V","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited no CTL response with cells from mice immunized with the index form.  It was well recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53068","Pol 98","1202","M","B, C","B","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VaIKIGGQiK","T2A, L9I","T68A, L75I","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited no CTL response with cells from mice immunized with the index form.  It was well recognized by CTL lines derived from HIV-1 uninfected donors.  Binding to HLA is at a very low level.","McKinney2004"
"53068","Pol 98","1203","M","B, C","C","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VnIKvGGQLK","T2N, I5V","T68N, I71V","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited no CTL response with cells from mice immunized with the index form.  It was not recognized by CTL lines derived from HIV-1 uninfected donors.   Binding to HLA is at a very low level.","McKinney2004"
"53068","Pol 98","1204","M","B, C","","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VTIKIGGQir","K10R, L9I","K76R, L75I","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited weak CTL response with cells from mice immunized with the index form.  It was not recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53068","Pol 98","1205","M","B, C","","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VTIKlGGQir","K10R, I5L, L9I","K76R, I71L, L75I","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited no CTL response with cells from mice immunized with the index form.  It was recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53068","Pol 98","1206","M","B, C","","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VTvKIeGQLr","K10R, I3V, G6E","K76R, I69V, G72E","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited no CTL response with cells from mice immunized with the index form.  It was not recognized by CTL lines derived from HIV-1 uninfected donors either.","McKinney2004"
"53068","Pol 98","1207","M","B, C","","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VTvKvGGQLr","K10R, I3V, I5V","K76R, I69V, I71V","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited CTL response with cells from mice immunized with the index form.  It was recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53068","Pol 98","1208","M","B, C","","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VTIrvGGQLr","K10R, K4R, I5V","K76R, K70R, I71V","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant did not elicit CTL responses with cells from mice immunized with the index form.  It was recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53068","Pol 98","1209","M","B, C","C","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VsIKvGGQiK","T2S, I5V, L9I","T68S, I71V, L75I","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited CTL responses with cells from mice immunized with the  index form.  It was recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53068","Pol 98","1210","M","B, C","","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VTvrvGGQLK","I3V, K4R, I5V","I69V, K70R, I71V","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited no CTL responses with cells from mice immunized with the index form.  It was recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53068","Pol 98","1211","M","B, C","","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VTIrvaGQvK","K4R, I5V, G6A, L9V","K70R, I71V, G72A, L75V","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited no CTL responses with cells from mice immunized with the index form.  It was not recognized by CTL lines derived from HIV-1 uninfected donors either.","McKinney2004"
"53068","Pol 98","1212","M","B, C","","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VsIrvGGQtK","T2S, K4R, I5V, L9T","T68S, K70R, I71V, L75T","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited no CTL responses with cells from mice immunized with the index form.  It was not recognized by CTL lines derived from HIV-1 uninfected donors either.","McKinney2004"
"53068","Pol 98","1213","M","B, C","C","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VsIrvGGQiK","T2S, K4R, I5V, L9I","T68S, K70R, I71V, L75I","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited no CTL responses with cells from mice immunized with the index form.  It was not recognized by CTL lines derived from HIV-1 uninfected donors either.","McKinney2004"
"53068","Pol 98","1214","M","B, C","C","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VsIKvGGQir","K10R, T2S, I5V, L9I","K76R, T68S, I71V, L75I","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited no CTL responses with cells from mice immunized with the index form.  It was not recognized by CTL lines derived from HIV-1 uninfected donors either.   Binding to HLA is at a very low level.","McKinney2004"
"53068","Pol 98","1215","M","B, C","","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VTvrIGGmqK","I3V, K4R, Q8M, L9Q","I69V, K70R, Q74M, L75Q","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited no CTL responses with cells from mice immunized with the index form.  It was weakly recognized by CTL lines derived from HIV-1 uninfected donors either.","McKinney2004"
"53068","Pol 98","1216","M","B, C","C","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","VsIrvGGQtr","K10R, T2S, K4R, I5V, L9T","K76R, T68S, K70R, I71V, L75T","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited no CTL responses with cells from mice immunized with the index form.  It was not recognized by CTL lines derived from HIV-1 uninfected donors either.","McKinney2004"
"53068","Pol 98","1217","M","B, C","","Pol","67","76","Protease(11-20)","2283..2312","A*1101","VTIKIGGQLK","iTvKIGkevr","V1I, K10R, I3V, G7K, Q8E, L9V","V67I, K76R, I69V, G73K, Q74E, L75V","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited no CTL responses with cells from mice immunized with the index form.  It was weakly recognized by CTL lines derived from HIV-1 uninfected donors either.   Binding to HLA is almost abrogated.","McKinney2004"
"54661","LL11","1321","B","","","Pol","79","89","Protease(23-33)","2319..2351","A2","LLDTGADDTVL","LLDTGADDTVx","L11X","L89X","CE, DI","calculated escape, drug induced","CD8 T-cell Elispot - IFNy, Sequence","This major mutation can be tipranavir-, atazanavir-, or darunavir-induced.","Mueller2007"
"56639",,"2330","","","","Pol","81","98","Protease(25-42)","2325..2378","","{KEALL}DTGADDTVLEEMNLPGRW","{rEALL}DTGADDTVLEEMNLPGRW","K-5R","K76R","CE, P","calculated escape, processing","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","The mutation seen proximal to DTGADDTVLEEMNLPGRW was {GQLrEAL}DTGADDTVLEEMNLPGRW where K/R, and it was predicted to be a processing escape.","Goonetilleke2009"
"398",,"1546","B","B","A","Pol","86","94","Protease(30-38)","2340..2366","A*6802","DTVLEEMNL","DTVLEdiNL","E6D, M7I","E91D, M92I","OV","observed variant","Chromium-release assay","Two HEPS Kenyan subjects cross-reacted to this B clade epitope though it differed from the A clade form, DTVLEdiNL.","Rowland-Jones1998"
"55968","DL9(Protease)","1918","B","B","B","Pol","86","94","Protease(30-38)","2340..2366","","DTVLEDMNL","DTVLEewNL","D6E, M7W","D91E, M92W","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at two positions. It is predicted to be HLA-A68 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"54656","EW9","1322","B","","","Pol","90","98","Protease(34-42)","2352..2378","B18, B40, B44","EEMNLPGRW","EEiNLPGRW","M3I","M92I","DI, SF","drug induced, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","PBMC from HLA-B44-positive patients were stimulated with the index peptide EEMNLPGRW and the tipranavir-induced variants EEiNLPGRW, EEMdLPGRW, EdiNLPGRW, EdMNLPGRW,  and tested for reactivity by IFN-? ELISPOT analysis. Outgrowing CD8+-T-cell lines were analyzed for cross-reactivity with the index peptide and the variants. Several patients responded to both the index peptide and this variant.","Mueller2007"
"54656","EW9","1323","B","","","Pol","90","98","Protease(34-42)","2352..2378","B18, B40, B44","EEMNLPGRW","EEMdLPGRW","N4D","N93D","DI, SF","drug induced, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","PBMC from HLA-B44-positive patients were stimulated with the index peptide EEMNLPGRW and the tipranavir-induced variants EEiNLPGRW, EEMdLPGRW, EdiNLPGRW, EdMNLPGRW,  and tested for reactivity by IFN-? ELISPOT analysis. Outgrowing CD8+-T-cell lines were analyzed for cross-reactivity with the index peptide and the variants. Several patients responded to both the index peptide and this variant.","Mueller2007"
"54656","EW9","1324","B","","","Pol","90","98","Protease(34-42)","2352..2378","B18, B40, B44","EEMNLPGRW","EdMNLPGRW","E2D","E91D","DI, E, SF","drug induced, escape documented in this paper, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","PBMC from HLA-B44-positive patients were stimulated with the index peptide EEMNLPGRW and the tipranavir-induced variants EEiNLPGRW, EEMdLPGRW, EdiNLPGRW, EdMNLPGRW,  and tested for reactivity by IFN-? ELISPOT analysis. Outgrowing CD8+-T-cell lines were analyzed for cross-reactivity with the index peptide and the variants. The E35D mutation induced a strong decrease in T-cell recognition in cell samples from 56% of patients; however, there were patient samples that could mount specific CD8+-T-cell responses to peptides containing the E35D mutation","Mueller2007"
"54656","EW9","1325","B","","","Pol","90","98","Protease(34-42)","2352..2378","B18, B40, B44","EEMNLPGRW","EdiNLPGRW","E2D, M3I","E91D, M92I","DI, SF","drug induced, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","PBMC from HLA-B44-positive patients were stimulated with the index peptide EEMNLPGRW and the tipranavir-induced variants EEiNLPGRW, EEMdLPGRW, EdiNLPGRW, EdMNLPGRW,  and tested for reactivity by IFN-? ELISPOT analysis. Outgrowing CD8+-T-cell lines were analyzed for cross-reactivity with the index peptide and the variants. Several patients responded to both the index peptide and this variant.","Mueller2007"
"56043","EW9(Protease)","1919","B","B","B","Pol","90","98","Protease(34-42)","2352..2378","","EDMNLPGRW","EeMNLPGRW","D2E","D91E","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope. This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B44 restricted.","Zhai2008"
"58240",,"2828","B","B","B","Pol","90","98","Protease(34-42)","2352..2378","B*4402","EEMNLPGRW","EdMNLPGRW","E2D","E91D","IE","inferred escape","Sequence","Epitope EEMNLPGRW varied from 96 DFOSx to EdMNLPGRW.","Ferrari2011"
"54668","LI10","1326","B","","","Pol","94","103","Protease(38-47)","2364..2393","Cw3","LPGRWKPKMI","LPGRWrPKMI","K6R","K99R","DI, NSF, SF","drug induced, non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This tipranavir-induced minor mutation, K43R is associated with HLA-B15.","Mueller2007"
"54655","WI9","1327","B","","","Pol","98","106","Protease(42-50)","2376..2402","Cw3","WKPKMIGGI","WxPKMIGGI","K2X","K99X","DI, NSF, SF","drug induced, non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This is a tipranavir-induced minor mutation in Protease.","Mueller2007"
"58286","KF9","2881","B","B","B","Pol","101","109","Protease(45-53)","2385..2411","B*1501","KMIGGIGGF","KlIGGIGGF","M2L","M102L","DI, SF","drug induced, susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","Recognition of PI-induced (indinavir/ lopinavir/ atazanavir/ fosamprenavir/ nelfinavir/ tipranavir) M46L variant, KlIGGIGGF, was good and unchanged by KF9-specific CTL.","Mueller2011"
"58286","KF9","2883","B","B","B","Pol","101","109","Protease(45-53)","2385..2411","B*1501","KMIGGIGGF","KMIvGIGGF","G4V","G104V","DI, E","drug induced, escape documented in this paper","CD8 T-cell Elispot - IFNy, Chromium-release assay","This PI (saquinavir or atazanavir) mutation completely abrogated or strongly reduced KF9-CTL recognition, and is an escape.","Mueller2011"
"58286","KF9","2884","B","B","B","Pol","101","109","Protease(45-53)","2385..2411","B*1501","KMIGGIGGF","KMIGGvGGF","I6V","I106V","DI, DR, SF","drug induced, diminished response, susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","Recognition of this PI-induced (darunavir, fosamprenavir, lopinavir) KF9 variant, KMIGGvGGF, was unchanged except for 2 samples where the functional avidity was reduced in comparison with wild type.","Mueller2011"
"58286","KF9","2885","B","B","B","Pol","101","109","Protease(45-53)","2385..2411","B*1501","KMIGGIGGF","KMaGGIGGF","I3A","I103A","DI, DR, E","drug induced, diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, Chromium-release assay","Recognition of PI-induced (lopinavir), I47A variant, KMaGGIGGF, was either moderately or strongly attenuated or lost.","Mueller2011"
"58286","KF9","2886","B","B","B","Pol","101","109","Protease(45-53)","2385..2411","B*1501","KMIGGIGGF","KiIGGIGGF","M2I","M102I","DI, DR, E, SF","drug induced, diminished response, escape documented in this paper, susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","Recognition of PI-induced (indinavir/ lopinavir/ atazanavir/ fosamprenavir/ nelfinavir) M46L variant, KlIGGIGGF, was either unchanged, lost, strongly reduced or attenuated.","Mueller2011"
"58286","KF9","2887","B","B","B","Pol","101","109","Protease(45-53)","2385..2411","B*1501","KMIGGIGGF","KMvGGIGGF","I3V","I103V","DI, DR, SF","drug induced, diminished response, susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","Recognition of PI-induced (lopinavir, darunavir, fosamprenavir, tipranavir) I47V, KMvGGIGGF, was comparable to that of the wild type in most cases except 4 where it was reduced.","Mueller2011"
"54657","KI10","1328","B","","","Pol","101","110","Protease(45-54)","2385..2414","A2, B62","KMIGGIGGFI","KiIGGIGGFI","M2I","M102I","DI, E, SF","drug induced, escape documented in this paper, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","PBMC from HLA-A2 and HLA-B62-positive patients  were stimulated with the index peptide KMIGGIGGFI and the tipranavir and atazanavir induced variants  KiIGGIGGFI and KMIGGIGGFv, and  evaluated for cross recognition. In samples from some A2-positive patients CD8+-T-cell recognition was abolished by these mutations, whereas in samples from other A2-positive patients a CD8+-T-cell response was induced only by the mutant peptides.","Mueller2007"
"54657","KI10","1329","B","","","Pol","101","110","Protease(45-54)","2385..2414","A2, B62","KMIGGIGGFI","KMIGGIGGFv","I10V","I110V","DI, E, SF","drug induced, escape documented in this paper, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","PBMC from HLA-A2 and HLA-B62-positive patients  were stimulated with the index peptide KMIGGIGGFI and the tipranavir and atazanavir induced variants  KiIGGIGGFI and KMIGGIGGFv, and  evaluated for cross recognition. In samples from some A2-positive patients CD8+-T-cell recognition was abolished by these mutations, whereas in samples from other A2-positive patients a CD8+-T-cell response was induced only by the mutant peptides.","Mueller2007"
"53441","pol45-54","1610","B","B","B","Pol","101","110","Protease(45-54)","2385..2414","A*0201","KMIGGIGGFI","KvIGGIGGFI","M2V","M102V","DI, SF","drug induced, susceptible form","Intracellular cytokine staining","This drug-induced Protease peptide-epitope variant was used to stimulate splenocytes from mice immunized with one of 3 kinds of vaccine: wildtype gag-pol plasmid or codon-optimized gag-pol plasmid or an expression library vaccine (ELI) re-engineered to express gag and pol fragments fused to ubiquitin for proteasome targeting.    Priming with plasmids did allow cross-recognition of the variant, but boosting drastically attenuated such a response.  In contrast, the variant was recognized more strongly by ELI vaccine with second immunization boosting this response.","Singh2004"
"55989","RI10(Protease)","1920","B","B","B","Pol","113","122","Protease(57-66)","2421..2450","","RQYDQIPIEI","RQYDQIlIEI","P7L","P119L","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B13 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"53864","QI9","2208","","","","Pol","114","122","Protease(58-66)","2424..2450","Cw*0401","QYDQIPIEI","QYDQIlIEI","P6L","P119L","DI, SF","drug induced, susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This L63P antiretroviral drug-induced mutation converted an index sequence that is not an epitope into one that was recognized by CTL as an epitope.","Stratov2005"
"56000","GL9(Protease)","1921","B","B","B","Pol","124","132","Protease(68-76)","2454..2480","","GKKAIGTVL","GhKAIGTVL","K2H","K125H","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B15 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"53442","pol75-84","1611","B","B","B","Pol","131","140","Protease(75-84)","2475..2504","A*0201","VLVGPTPVNI","VLVGPTPtNv","I10V, V8T","I140V, V138T","DI, SF","drug induced, susceptible form","Intracellular cytokine staining","This drug-induced Protease peptide-epitope variant was used to stimulate splenocytes from mice immunized with one of 3 kinds of vaccine: wildtype gag-pol plasmid or codon-optimized gag-pol plasmid or an expression library vaccine (ELI) re-engineered to express gag and pol fragments fused to ubiquitin for proteasome targeting.    Priming with plasmids did allow cross-recognition of the variant, but boosting drastically attenuated such a response.  In contrast, the variant was recognized more strongly by ELI vaccine with second immunization boosting this response.","Singh2004"
"58875",,"3202","B","B","B","Pol","131","140","Protease(75-84)","2475..2504","A*0201","VLVGPTPVNI","iLVGPTPVNI","V1I","V131I","DHB","diminished HLA binding or increased off-rate","Chromium-release assay, HLA binding","Variant iLVGPTPVNI bound HLA*0201 about half as strong as peptide VLVGPTPVNI.","Konya1997"
"52727","PR82V","625","","","","Pol","132","140","Protease(76-84)","2478..2504","A2","LVGPTPVNI","LVGPTPaNI","V7A","V138A","DR, E","diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, Chromium-release assay","The variant was generally not recognized by wt CTL response, and when recognized, it was of low to moderate avidity. The emergence of the variant could not inhibit the wt CTL response, suggesting that the mutation did not affect recognition.","Karlsson2003"
"52727","PR82V","626","","","","Pol","132","140","Protease(76-84)","2478..2504","A2","LVGPTPVNI","LVGPTPVNv","I9V","I140V","OV","observed variant","","The emergence of the variant could not inhibit the wt CTL response, suggesting that the mutation did not affect recognition.","Karlsson2003"
"53051",,"1082","B","","","Pol","132","140","Protease(76-84)","2478..2504","A2","LVGPTPVNI","LVGPTPVNv","I9V","I140V","DI, SF","drug induced, susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","This I84V ART-drug induced variant and its wild type epitope elicited cross-reactive CTL recognition of each other in 5 subjects.","Mason2004"
"53867",,"1641","","","","Pol","132","140","Protease(76-84)","2478..2504","A*0205","LVGPTPANI","LVGPTPvNI","A7V","A138V","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","A response against the peptide harboring the protease drug resistance mutation V82A, LVGPTPANI, was detected in one individual, but the wildtype epitope was not recognized, lvgptpVni.  Other drug resistant variants were not recognized: V82T and I84V.","Stratov2005"
"53867",,"1642","","","","Pol","132","140","Protease(76-84)","2478..2504","A*0205","LVGPTPANI","LVGPTPtNI","A7T","A138T","DI, NSF","drug induced, non-susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","A response against the peptide harboring the protease drug resistance mutation V82A, LVGPTPANI, was detected in one individual, but the wildtype epitope was not recognized, lvgptpVni.  Other drug resistant variants were not recognized: V82T and I84V.","Stratov2005"
"53867",,"1643","","","","Pol","132","140","Protease(76-84)","2478..2504","A*0205","LVGPTPANI","LVGPTPANv","I9V","I140V","DI, NSF","drug induced, non-susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","A response against the peptide harboring the protease drug resistance mutation V82A, LVGPTPANI, was detected in one individual, but the wildtype epitope was not recognized, lvgptpVni.  Other drug resistant variants were not recognized: V82T and I84V.","Stratov2005"
"55330","V","807","B","","","Pol","133","141","Protease(77-85)","2481..2507","H-2D<sup>d</sup>","VGPTPVNII","VGPTPiNII","V6I","V138I","SF","susceptible form","CD8 T-cell Elispot - IFNy","After immunization with clade B vaccine containing the wt epitope, T cells responded well both to the index epitope and to this variant.","Larke2007"
"57778",,"2638","","","","Pol","133","141","Protease(77-85)","2481..2507","","VGPTPVNII","VGPTPfNvI","V6F, I8V","V138F, I140V","E","escape documented in this paper","CD4 T-cell Elispot - IFNy, CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, T-cell Elispot","Response against the protease gene variants was reduced when the cells were stimulated with peptides carrying the V82F/I84V mutations, located in previously described VGPTPvNiI epitope. the 82/84 mutations destroyed the dominant VGPTPvNiI epitope","Hallengard2011"
"55070",,"214","B","B","C","Pol","147","155","Protease(91-99)","2523..2549","B*1503","TQIGCTLNF","TQlGCTLNF","I3L","I149L","SNSF","subtype-specific non-susceptible form","","TQIGCTLNF epitope is found in subtype B, while the variant is found in subtype C. Only subtype B epitope is frequently recognized by B*1503 positive individuals.","Frahm2006"
"57605","FV9","2558","","","","Pol","155","163","Protease(99)-RT(8)","2547..2573","B*5401","FPISPIETV","FPISPIdTV","E7D","E161D","E","escape documented in this paper","Chromium-release assay, Longitudinal study, Relative replication capacity assay, Sequence","FV9-specific CTLs showed reduced killing activity against target cells pulsed with the FV9-7D mutant (FPISPIdTV) peptide and failed to kill those infected with the FV9-7D mutant virus; in 2 HLA-B*5401 individuals the mutant appeared during the clinical course, suggesting escape.","Hashimoto2010"
"54623","SL10","259","C","","","Pol","158","167","RT(3-12)","2556..2585","B*8101","SPIETVPVKL","SsIETVPVKL","P2S","P159S","CE","calculated escape","","This variant from an African cohort was more often found in HLA-B*8101 patients, indicating that some favorable HLA alleles induce strong pressure, resulting in escape variants with high fitness cost and low viral loads.","Frater2007"
"54623","SL10","260","C","","","Pol","158","167","RT(3-12)","2556..2585","B*8101","SPIETVPVKL","SPIkTVPVKL","E4K","E161K","CE","calculated escape","","This variant was more often found in HLA-B*8101 patients, indicating that some favorable HLA alleles induce strong pressure, resulting in escape variants with high fitness cost and low viral loads.","Frater2007"
"54623","SL10","262","C","","","Pol","158","167","RT(3-12)","2556..2585","B*8101","SPIETVPVKL","SsIkTVPVKL","P2S, E4K","P159S, E161K","OV","observed variant","","Found in African cohort","Frater2007"
"54623","SL10","263","C","","","Pol","158","167","RT(3-12)","2556..2585","B*8101","SPIETVPVKL","SsIaTVPVKL","P2S, E4A","P159S, E161A","OV","observed variant","","Found in African cohort","Frater2007"
"54623","SL10","264","C","","","Pol","158","167","RT(3-12)","2556..2585","B*8101","SPIETVPVKL","SsIdTVPVKL","P2S, E4D","P159S, E161D","OV","observed variant","","Found in African cohort","Frater2007"
"54623","SL10","265","C","","","Pol","158","167","RT(3-12)","2556..2585","B*8101","SPIETVPVKL","StIETVPVKL","P2T","P159T","OV","observed variant","","Found in African cohort","Frater2007"
"54623","SL10","266","C","","","Pol","158","167","RT(3-12)","2556..2585","B*8101","SPIETVPVKL","SPIETVPVmL","K9M","K166M","OV","observed variant","","Found in African cohort","Frater2007"
"54623","SL10","267","C","","","Pol","158","167","RT(3-12)","2556..2585","B*8101","SPIETVPVKL","SPIaTVPVnL","E4A, K9N","E161A, K166N","OV","observed variant","","Found in African cohort","Frater2007"
"55060","IL8","184","","","","Pol","160","167","RT(5-12)","2562..2585","B*4001","IETVPVKL","IdTVPVKL","E2D","E161D","DR","diminished response","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Immune responses were examined in monozygotic male twins infected simultaneously with the same virus. IdTVPVKL variant arose in one twin; IETVPVrL variant arose in the other. Response to the both variants was diminished.","Draenert2006"
"55060","IL8","185","","","","Pol","160","167","RT(5-12)","2562..2585","B*4001","IETVPVKL","IETVPVrL","K7R","K166R","DR","diminished response","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Immune responses were examined in monozygotic male twins infected simultaneously with the same virus. IdTVPVKL variant arose in one twin; IETVPVrL variant arose in the other. Response to  both variants was diminished.","Draenert2006"
"53751","GL9","778","B","","","Pol","173","181","RT(18-26)","2601..2627","B8","GPKVKQWPL","GPrVKQWPL","K3R","K175R","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","Variant persisted throughout a 5-year period in a patient. The variant was equally well recognized by patient CTLs as the wt form.","Koibuchi2005a"
"53751","GL9","779","B","","","Pol","173","181","RT(18-26)","2601..2627","B8","GPKVKQWPL","GPrVKQgPL","K3R, W7G","K175R, W179G","OV","observed variant","","Variant was found in 1/8 clones at the end of a 5 year period in a patient.","Koibuchi2005a"
"403",,"1238","","","","Pol","173","181","RT(18-26)","2601..2627","B8","GPKVKQWPL","sPKVKQWPL","G1S","G173S","SF","susceptible form","Chromium-release assay","This longitudinally studied natural variant was functional, with normal activity of RT.  Both mutant and wild-type index epitopes showed antagonism, inducing anergy in effector CTL against either epitope form (i.e. index or variant epitope) when previously exposed to the other form.","Menendez-Arias1998, Meier1995"
"404",,"1239","","","","Pol","173","181","RT(18-26)","2601..2627","B8","GPKVKQWPL","sPKVKQWPL","G1S","G173S","SF","susceptible form","Chromium-release assay","This longitudinally studied natural variant was functional, with normal activity of RT.  Both mutant and wild-type index epitopes showed antagonism, inducing anergy in effector CTL against either epitope form (i.e. index or variant epitope) when previously exposed to the other form.","Menendez-Arias1998, Goulder1997c"
"403",,"1240","","","","Pol","173","181","RT(18-26)","2601..2627","B8","GPKVKQWPL","GPrVKQWPL","K3R","K175R","SF","susceptible form","Chromium-release assay","This longitudinally studied natural variant was functional, with normal activity of RT.  Both mutant and wild-type index epitopes showed antagonism, inducing anergy in effector CTL against either form when previously exposed to the other form.","Menendez-Arias1998, Meier1995"
"404",,"1241","","","","Pol","173","181","RT(18-26)","2601..2627","B8","GPKVKQWPL","GPrVKQWPL","K3R","K175R","SF","susceptible form","Chromium-release assay","This longitudinally studied natural variant was functional, with normal activity of RT.  Both mutant and wild-type index epitopes showed antagonism, inducing anergy in effector CTL against either form when previously exposed to the other form.","Menendez-Arias1998, Goulder1997c"
"403",,"2216","","","","Pol","173","181","RT(18-26)","2601..2627","B8","GPKVKQWPL","GPeVKQWPL","K3E","K175E","CHB","calculated diminished HLA binding","Structural prediction","This variant is suggested to have abrogated binding to HLA-B8 based on structural information of closely related species.  The substitution is at an anchor residue.","Menendez-Arias1998, Meier1995"
"404",,"2217","","","","Pol","173","181","RT(18-26)","2601..2627","B8","GPKVKQWPL","GPeVKQWPL","K3E","K175E","CHB","calculated diminished HLA binding","Structural prediction","This variant is suggested to have abrogated binding to HLA-B8 based on structural information of closely related species.  The substitution is at an anchor residue.","Menendez-Arias1998, Goulder1997c"
"54570",,"642","B","","","Pol","188","196","RT(33-41)","2646..2672","A*02","ALVEICTEM","ALiEICTEM","V3I","V190I","DR","diminished response","CD8 T-cell Elispot - IFNy","Weaker responses to this variant. Variant found at the start of infection.","Karlsson2007"
"54570",,"643","B","","","Pol","188","196","RT(33-41)","2646..2672","A*02","ALVEICTEM","ALmEICTEM","V3M","V190M","SF","susceptible form","CD8 T-cell Elispot - IFNy","Strongest responses to this variant that emerged after the first variant. Eventually it reverted back to the wt sequence.","Karlsson2007"
"54570",,"644","B","","","Pol","188","196","RT(33-41)","2646..2672","A*02","ALVEICTEM","ALtEICTEM","V3T","V190T","OV","observed variant","","Variant found in 1/17 clones at week 39.","Karlsson2007"
"54570",,"645","B","","","Pol","188","196","RT(33-41)","2646..2672","A*02","ALVEICTEM","ALiEICTEt","V3I, M9T","V190I, M196T","OV","observed variant","","Variant found in 1/17 clones at week 39.","Karlsson2007"
"54570",,"646","B","","","Pol","188","196","RT(33-41)","2646..2672","A*02","ALVEICTEM","ALiEICTdM","V3I, E8D","V190I, E195D","OV","observed variant","","Variant found in 1/12 clones at week 88.","Karlsson2007"
"54570",,"647","B","","","Pol","188","196","RT(33-41)","2646..2672","A*02","ALVEICTEM","ALmkICTEM","V3M, E4K","V190M, E191K","OV","observed variant","","Variant found in 1/12 clones at week 88.","Karlsson2007"
"54570",,"648","B","","","Pol","188","196","RT(33-41)","2646..2672","A*02","ALVEICTEM","ALmEICaEM","V3M, T7A","V190M, T194A","OV","observed variant","","Variant found in 1/13 clones at week 156.","Karlsson2007"
"53052",,"1083","B","","","Pol","188","196","RT(33-41)","2646..2672","A2, A3","ALVEICTEM","ALVEICTEl","M9L","M196L","DI, SF","drug induced, susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","This M41L  ART-drug (azidothymidine and stavudine) induced variant elicited a greater CTL response than did its wild type epitope.  Cross-recognition between the wild type and variant epitope was seen in 8 patients; but  selective CTL recognition with no cross-reactivity was seen in 10 patients.  Recognition of the wild type and variant peptides was mixed for HLA-A2 subjects, but recognition of the variant predominated in 4 of 5 HLA-A3 subjects.","Mason2004"
"55286",,"1507","B","","","Pol","188","196","RT(33-41)","2646..2672","A2","ALVEICTEM","ALiEICTEM","V3I","V190I","OV","observed variant","Sequence","This index epitope was conserved in the mother's viral strain but mutated in the daughter's isolate.","Reinis2007"
"53440","pol132-140","1612","B","B","A","Pol","188","196","RT(33-41)","2646..2672","A*0201","ALVEICTEM","ALtdICTEM","V3T, E4D","V190T, E191D","SSF","subtype-specific susceptible form","Intracellular cytokine staining","This Clade A peptide-epitope variant was used to stimulate splenocytes from mice immunized with one of 3 kinds of vaccine: wildtype gag-pol plasmid or codon-optimized gag-pol plasmid or an expression library vaccine (ELI) re-engineered to express gag and pol fragments fused to ubiquitin for proteasome targeting.    Priming with plasmids did allow cross-clade-recognition of the variant, but boosting drastically attenuated such a response.  In contrast, the variant was recognized more strongly by ELI vaccine with second immunization boosting this response.","Singh2004"
"53440","pol132-140","1613","B","B","C","Pol","188","196","RT(33-41)","2646..2672","A*0201","ALVEICTEM","ALtaICeEM","V3T, E4A, T7E","V190T, E191A, T194E","SSF","subtype-specific susceptible form","Intracellular cytokine staining","This Clade C peptide-epitope variant was used to stimulate splenocytes from mice immunized with one of 3 kinds of vaccine: wildtype gag-pol plasmid or codon-optimized gag-pol plasmid or an expression library vaccine (ELI) re-engineered to express gag and pol fragments fused to ubiquitin for proteasome targeting.  Priming with plasmids did allow cross-clade-recognition of the variant, but boosting drastically attenuated such a response.  In contrast, the variant was recognized more strongly by ELI vaccine with second immunization boosting this response.","Singh2004"
"53440","pol132-140","1614","B","B","D","Pol","188","196","RT(33-41)","2646..2672","A*0201","ALVEICTEM","ALiEICsEM","V3I, T7S","V190I, T194S","SSF","subtype-specific susceptible form","Intracellular cytokine staining","This Clade D peptide-epitope variant was used to stimulate splenocytes from mice immunized with one of 3 kinds of vaccine: wildtype gag-pol plasmid or codon-optimized gag-pol plasmid or an expression library vaccine (ELI) re-engineered to express gag and pol fragments fused to ubiquitin for proteasome targeting.  Priming with plasmids did allow cross-clade-recognition of the variant, but boosting drastically attenuated such a response.  In contrast, the variant was recognized more strongly by ELI vaccine with second immunization boosting this response.","Singh2004"
"53868",,"1644","","","","Pol","212","220","RT(57-65)","2718..2744","A3 supertype, A*6801","NTPVFAIKK","NTPVFAIrK","K8R","K219R","DI, SF","drug induced, susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Both index epitope and RT drug-induced K65R variant epitope were recognized by the same CTL populations and with similar efficiency.","Stratov2005"
"1467",,"1566","B","","","Pol","228","237","RT(73-82)","2766..2795","A3","KLVDFRELNK","KvVDFRELNK","L2V","L229V","DI, NSF","drug induced, non-susceptible form","CD8 T-cell Elispot - IFNy","Mutation L74V occurs at anchor position 2 and had a predicted  increase in binding to HLA-B*5102.  Patient 252 recognized the index but not mutant epitope after treatment.","Samri2000"
"53053",,"1084","B","","","Pol","262","270","RT(107-115)","2868..2894","B35","TVLDVGDAY","TiLDVGDAY","V2I","V263I","DI, SF","drug induced, susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","Recognition of the wild type epitope and this V108I  ART-drug  (NNRTI and abacavir) induced variant was cross-reactive.","Mason2004"
"53053",,"1085","B","","","Pol","262","270","RT(107-115)","2868..2894","B35","TVLDVGDAY","TVLDVGDAf","Y9F","Y270F","DI, SF","drug induced, susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","Recognition of the wild type epitope and this Y115F ART-drug  (NNRTI and abacavir) induced variant was cross-reactive.","Mason2004"
"53053",,"1086","B","","","Pol","262","270","RT(107-115)","2868..2894","B35","TVLDVGDAY","TiLDVGDAf","V2I, Y9F","V263I, Y270F","DI, SF","drug induced, susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","Recognition of the wild type epitope and this V108I, Y115F ART-drug  (NNRTI and abacavir) induced variant was cross-reactive.","Mason2004"
"421",,"1841","","","","Pol","262","270","RT(107-115)","2868..2894","B35","TVLDVGDAY","TVLDmGDAc","V5M, Y9C","V266M, Y270C","SF","susceptible form","Chromium-release assay","This variant was recognized by a non-transmitting mother.","Wilson1999a"
"57718","TY9","2609","B","B","B","Pol","262","270","RT(107-115)","2868..2894","B*35","TVLDVGDAY","TVLDVGDAf","Y9F","Y270F","A, NSF, SF","HLA association, non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","Variant TVLDVGDAf was recognized by HLA-B*35-Px+ subjects but not by HLA-B*35-Py+ subjects.","Willberg2010"
"57718","TY9","2611","B","B","B","Pol","262","270","RT(107-115)","2868..2894","B*35","TVLDVGDAY","TiLDVGDAY","V2I","V263I","A, NSF, SF","HLA association, non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","Variant TiLDVGDAY was recognized by HLA-B*35-Px+ subjects but not by HLA-B*35-Py+ subjects.","Willberg2010"
"427",,"2191","","","","Pol","268","275","RT(113-120)","2886..2909","A24, B*5101","DAYFSVPL","DrYFSVPL","A2R","A269R","OV","observed variant","Chromium-release assay, HLA binding","1/38 Clade B strain sequences carried this 2R variant.  Challenge epitope elicited CTL response in 1 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.  Variant not tested.","Tomiyama1999"
"57732",,"2632","","","","Pol","272","287","RT(117-132)","2898..2945","","SVPLDKDFRKYTAFTI","SVPLDeDFRKYTAFTI","K6E","K277E","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Escape variant SVPLDeDFRKYTAFTI was seen in patient I13, and suppression of the antigen was accompanied by decline in CD38/PD-1 co-expression on CTL.","Vollbrecht2010"
"430",,"680","","","","Pol","273","282","RT(118-127)","2901..2930","B35","VPLDKDFRKY","VPLDKeFRKY","D6E","D278E","SF","susceptible form","CD8 T-cell Elispot - IFNy","Variant found in 8/10 B35+ individuals and in 3/3 B35- individuals. Equally susceptible to CTLs and binds equally well to B35 as the wt.","Kawana1999"
"429",,"1252","","","","Pol","273","282","RT(118-127)","2901..2930","B*3501","VPLDEDFRKY","VPLDkDFRKY","E5K","E277K","SF","susceptible form","Chromium-release assay, HLA binding","This Lys-122 variant was not recognized by CTL specific to the Glu-122 index epitope though it was recognized by Lys-122-specific CTL.  Glu-122  epitope was also unrecognized by Lys-122-specific CTL.  Both index epitope and variant, however, were able to bind HLA-B35.","Menendez-Arias1998, Tomiyama1997"
"431",,"1253","","","","Pol","273","282","RT(118-127)","2901..2930","B35","VPLDEDFRKY","VPLhEDFRKY","D4H","D276H","NSF","non-susceptible form","Chromium-release assay","This variant was not recognized by CTL generated against the Glu-122 epitope, VPLDEDFRKY.","Sipsas1997"
"431",,"1615","","B","B","Pol","273","282","RT(118-127)","2901..2930","B35","VPLDEDFRKY","VPLDkDFRKY","E5K","E277K","NSF","non-susceptible form","Chromium-release assay","This naturally occurring, strain MN variant, was not recognized by a Patient LWF CTL clone.","Sipsas1997"
"431",,"1616","","B","B","Pol","273","282","RT(118-127)","2901..2930","B35","VPLDEDFRKY","VPhDEDFRKY","L3H","L275H","NSF","non-susceptible form","Chromium-release assay","This naturally occurring, strain YU2 variant, was not recognized by a Patient LWF CTL clone.","Sipsas1997"
"56015","VY10(RT)","1922","B","B","B","Pol","273","282","RT(118-127)","2901..2930","","VPLDKDFRKY","VPLDeDFRKY","K5E","K277E","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B35 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"57720","VY10","2612","B","B","B","Pol","273","282","RT(118-127)","2901..2930","B*35","VPLDEDFRKY","iPLDEDFRKY","V1I","V273I","A, NSF, SF","HLA association, non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","Variant iPLDEDFRKY was recognized by CTL from HLA-B*35-Px+ subjects but not by CTL from HLA-B*35-Py+ subjects.","Willberg2010"
"57720","VY10","2613","B","B","B","Pol","273","282","RT(118-127)","2901..2930","B*35","VPLDEDFRKY","VPLDkDFRKY","E5K","E277K","OV","observed variant","Sequence","Variant VPLDkDFRKY was seen in Subjects 1 &amp; 5, HLA-B*35-Px expressing rapid progressors at 653 and 30 weeks post-infection.","Willberg2010"
"57720","VY10","2614","B","B","B","Pol","273","282","RT(118-127)","2901..2930","B*35","VPLDEDFRKY","VPLDkxFRKY","E5K, D6X","E277K, D278X","OV","observed variant","Sequence","Variant VPLDkxFRKY was seen in Subject 2, an HLA-B*35-Px expressing rapid progressor at 92 weeks post-infection.","Willberg2010"
"57720","VY10","2615","B","B","B","Pol","273","282","RT(118-127)","2901..2930","B*35","VPLDEDFRKY","VPLDEnFRKY","D6N","D278N","OV","observed variant","Sequence","Variant VPLDEnFRKY was seen in Subject 4, an HLA-B*35-Px expressing rapid progressor at 10 and 134 weeks post-infection.","Willberg2010"
"57720","VY10","2616","B","B","B","Pol","273","282","RT(118-127)","2901..2930","B*35","VPLDEDFRKY","VPLDxxFRKY","E5X, D6X","E277X, D278X","OV","observed variant","Sequence","Variant VPLDxxFRKY was seen in Subject 6, an HLA-B*35-Px expressing rapid progressor at 61 weeks post-infection.","Willberg2010"
"55063","YV9","186","","","","Pol","282","290","RT(127-135)","2928..2954","A2","YTAFTIPSV","YTAFTIPSi","V9I","V290I","DR","diminished response","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Immune responses were examined in monozygotic male twins infected simultaneously with the same virus. YTAFTIPSi variant arose in one twin and not the other. Response to the variant was diminished.","Draenert2006"
"53634",,"118","B","","","Pol","283","290","RT(128-135)","2931..2954","B51","TAFTIPSI","TAFTIPSt","I8T","I290T","DR, SF","diminished response, susceptible form","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining","Prior to the initiation of therapy, taftipsT variant was found in 24/24 clones. At week 14 of therapy, this variant was completely replaced with taftipsI. By week 19, a complete replacement occurred again, this time to taftipsM. The change at nucleotide level suggests a stepwise progression from ACA to ATA to ATG. The taftipsT and taftipsM variants had lower avidity than the taftipsI variant, but this wasn't evident at saturating conditions; only careful titrations revealed the difference. HLA-B51 stabilization studies revealed the increased stabilization with the taftipsI form. Also, CD3 down-regulation was larger in response to taftipsI. The viral shift to the taftipsM variant during HAART was predicted to have minimal or undetectable effect on drug sensitivity.","Casazza2005a"
"53634",,"119","B","","","Pol","283","290","RT(128-135)","2931..2954","B51","TAFTIPSI","TAFTIPSm","I8M","I290M","DR, SF","diminished response, susceptible form","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining","Prior to the initiation of therapy, taftipsT variant was found in 24/24 clones. At week 14 of therapy, this variant was completely replaced with taftipsI. By week 19, a complete replacement occurred again, this time to taftipsM. The change at nucleotide level suggests a stepwise progression from ACA to ATA to ATG. The taftipsT and taftipsM variants had lower avidity than the taftipsI variant, but this wasn't evident at saturating conditions; only careful titrations revealed the difference. HLA-B51 stabilization studies revealed the increased stabilization with the taftipsI form. Also, CD3 down-regulation was larger in response to taftipsI. The viral shift to the taftipsM variant during HAART was predicted to have minimal or undetectable effect on drug sensitivity.","Casazza2005a"
"54617","TI8","268","B","","","Pol","283","290","RT(128-135)","2931..2954","B*51","TAFTIPSI","TAFTIPSt","I8T","I290T","CE","calculated escape","","The variant appears very soon after seroconversion, and was present in 7/8 HLA-matched and 21/57 HLA-unmatched patients. Position 8 was under strong positive selection pressure.","Frater2007"
"54617","TI8","269","B","","","Pol","283","290","RT(128-135)","2931..2954","B*51","TAFTIPSI","TAFTIPSm","I8M","I290M","OV","observed variant","","Found in European cohort","Frater2007"
"54617","TI8","270","B","","","Pol","283","290","RT(128-135)","2931..2954","B*51","TAFTIPSI","TAFTIPSr","I8R","I290R","OV","observed variant","","Found in European cohort","Frater2007"
"54617","TI8","271","B","","","Pol","283","290","RT(128-135)","2931..2954","B*51","TAFTIPSI","TAFTvPSt","I5V, I8T","I287V, I290T","OV","observed variant","","Found in European cohort","Frater2007"
"52995",,"306","","","","Pol","283","290","RT(128-135)","2931..2954","B51","TAFTIPSI","TAFTIPSt","I8T","I290T","E","escape documented in this paper","","A dramatic decrease in CTL activity against the epitope occurred as the mutation became fixed. The variant was found at 47 months post-seroconversion.","Geels2003"
"54151","TI8","958","B","","","Pol","283","290","RT(128-135)","2931..2954","B*5101","TAFTIPSI","TAFTIPSt","I8T","I290T","DR","diminished response","CD8 T-cell Elispot - IFNy","Last position (8) of the epitope had potentially experienced positive selection. Wt form of the epitope was >100 times better recognized than the variant, making the variant a partial escape.","Liu2006"
"54151","TI8","959","B","","","Pol","283","290","RT(128-135)","2931..2954","B*5101","TAFTIPSI","TAFTIPSr","I8R","I290R","DR","diminished response","CD8 T-cell Elispot - IFNy","Last position (8) of the epitope had potentially experienced positive selection. Wt form of the epitope was >100 times better recognized than the variant, making the variant a partial escape.","Liu2006"
"54151","TI8","960","B","","","Pol","283","290","RT(128-135)","2931..2954","B*5101","TAFTIPSI","TAFTIPSv","I8V","I290V","DR","diminished response","CD8 T-cell Elispot - IFNy","Last position (8) of the epitope had potentially experienced positive selection. Wt form of the epitope was >100 times better recognized than the variant, making the variant a partial escape.","Liu2006"
"434",,"1254","","","","Pol","283","290","RT(128-135)","2931..2954","B51","TAFTIPSI","TAFTIPSt","I8T","I290T","SF","susceptible form","Chromium-release assay","This variant has slightly altered CTL recognition and lysis, but 100x higher peptide concentration was required for 50% half maximum lysis. [Menendez-Arias1998].","Menendez-Arias1998, Sipsas1997"
"434",,"1255","","","","Pol","283","290","RT(128-135)","2931..2954","B51","TAFTIPSI","TAFTIPSv","I8V","I290V","SF","susceptible form","Chromium-release assay","This variant has slightly altered CTL recognition and lysis, but 10x higher peptide concentration was required for 50% half maximum lysis. [Menendez-Arias1998].","Menendez-Arias1998, Sipsas1997"
"434",,"1256","","","","Pol","283","290","RT(128-135)","2931..2954","B51","TAFTIPSI","TvFTIPSI","A2V","A284V","NSF","non-susceptible form","Chromium-release assay","CTL recognition of this highly conserved Ala-129 is almost abrogated.","Menendez-Arias1998, Sipsas1997"
"52065",,"1315","B","","","Pol","283","290","RT(128-135)","2931..2954","B*5101","TAFTIPSI","TAFTIPSx","I8X","I290X","E","escape documented in this paper","HLA binding, Sequence","98% of subjects in an HLA-B*5101 cohort carried this I135x escape.  It is suggested that it is selected during the acute phase of infection rather than at transmission or at chronic infection.","Moore2002b"
"434",,"1619","","B","B","Pol","283","290","RT(128-135)","2931..2954","B51","TAFTIPSI","TAFTIPSt","I8T","I290T","DR","diminished response","Chromium-release assay","This naturally occurring, strain CAMI variant, was poorly recognized by a Patient LWS CTL clone. [Sipsas1997].","Menendez-Arias1998, Sipsas1997"
"434",,"1620","","B","B","Pol","283","290","RT(128-135)","2931..2954","B51","TAFTIPSI","TAFTIPSv","I8V","I290V","DR","diminished response","Chromium-release assay","This naturally occurring, strain CAMI variant, was not well recognized by a Patient LWS CTL clone. [Sipsas1997].","Menendez-Arias1998, Sipsas1997"
"434",,"1621","","B","B","Pol","283","290","RT(128-135)","2931..2954","B51","TAFTIPSI","TvFTIPSt","A2V, I8T","A284V, I290T","DR","diminished response","Chromium-release assay","This naturally occurring, strain MANC variant, was very poorly recognized by a Patient LWS CTL clone.","Menendez-Arias1998, Sipsas1997"
"437",,"1765","","","","Pol","283","290","RT(128-135)","2931..2954","B*5101","TAFTIPSI","TvFTIPSI","A2V","A284V","OV","observed variant","Chromium-release assay, HLA binding","1/38 Clade B strain sequences carried this 2V variant.  Challenge epitope elicited CTL response in 1 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.  Variant not tested.","Tomiyama1999"
"437",,"1766","","","","Pol","283","290","RT(128-135)","2931..2954","B*5101","TAFTIPSI","TAFTIPSt","I8T","I290T","OV","observed variant","Chromium-release assay, HLA binding","4/38 Clade B strain sequences carried this 8T variant.  Challenge epitope elicited CTL response in 1 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.   Variant not tested.","Tomiyama1999"
"437",,"1767","","","","Pol","283","290","RT(128-135)","2931..2954","B*5101","TAFTIPSI","TAFTIPSv","I8V","I290V","OV","observed variant","Chromium-release assay, HLA binding","4/38 Clade B strain sequences carried this 8V variant.  Challenge epitope elicited CTL response in 1 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.  Variant not tested.","Tomiyama1999"
"52065",,"2218","B","","","Pol","283","290","RT(128-135)","2931..2954","B*5101","TAFTIPSI","TAFTIPSt","I8T","I290T","CHB, OV","calculated diminished HLA binding, observed variant","Sequence","The predominant substitution in  this epitope is I135t.  Binding of this mutant to HLA-B*5101 would be abrogated in vivo as per binding association studies.","Moore2002b"
"57505",,"2522","","","","Pol","283","290","RT(128-135)","2931..2954","B*51","TAFTIPSI","TAFTIPSl","I8L","I290L","E","escape documented in this paper","Sequence","This escape, TAFTIPSl, did not confer significant resistance to NNRTI.  During passages of virus with I135L, however, rare variant E138K also emerged.  I135l, E138K together did confer significant resistance to NVP.  Other variants that occurred with this escape were K103R and V179D, both of which do confer significant NNRTI-resistance.  Variants V108I, V106A, L100I, G190A also arose and are listed as resistance mutations in the IAS-USA table.","Gatanaga2010"
"57505",,"2523","","","","Pol","283","290","RT(128-135)","2931..2954","B*51","TAFTIPSI","TAFTIPSv","I8V","I290V","E","escape documented in this paper","Sequence","This escape, TAFTIPSv, did not confer significant resistance to NNRTI.  During passages of virus with I135L, however, rare variant E138K also emerged.  I135V, E138K together did confer significant resistance to ETR and EFV.  Other variants that occurred with this escape were L100I followed by Y188H, and L100I followed by V108I.","Gatanaga2010"
"57505",,"2524","","","","Pol","283","290","RT(128-135)","2931..2954","B*51","TAFTIPSI","TAFTIPSt","I8T","I290T","E","escape documented in this paper","Sequence","This most frequent escape, TAFTIPSt, did not confer significant resistance to NNRTI.  During passages of virus with I135T, however, rare variant E138K also emerged.  I135T, E138K together did confer significant resistance to EFV, NVP and ETR.  Other variants that occurred with this escape were V108I and K101E.  Variant V106I was followed by V179D which together do confer significant NNRTI-resistance.","Gatanaga2010"
"57505",,"2525","","","","Pol","283","290","RT(128-135)","2931..2954","B*51","TAFTIPSI","TAFTIPSr","I8R","I290R","E","escape documented in this paper","Sequence","This escape, TAFTIPSr, did not confer significant resistance to NNRTI.  During passages of virus with I135L, however, rare variant E138K also emerged.  I135R, E138K together did confer significant resistance to ETR.  Other variants that occurred with this escape were K103R and V179D, both of which do confer significant NNRTI-resistance.  Variants V108I, V106A, L100I, G190A also arose and are listed as resistance mutations in the IAS-USA table.","Gatanaga2010"
"57127",,"2530","","","","Pol","283","290","RT(128-135)","2931..2954","B*51","TAFTIPSI","TAFTIPSt","I8T","I290T","DHB","diminished HLA binding or increased off-rate","Intracellular cytokine staining, Relative replication capacity assay","This variant had greatly reduce binding to HLA-B*51 in vitro.","Kawashima2009"
"57127",,"2531","","","","Pol","283","290","RT(128-135)","2931..2954","B*51","TAFTIPSI","TAFTIPSr","I8R","I290R","DHB","diminished HLA binding or increased off-rate","Intracellular cytokine staining, Relative replication capacity assay","This variant had greatly reduce binding to HLA-B*51 in vitro.","Kawashima2009"
"57636","Pol 283-8","2562","B","B","B","Pol","283","290","RT(128-135)","2931..2954","B*5101","TAFTIPSI","TAFTIPSt","I8T","I290T","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Chromium-release assay, Flow cytometric T-cell cytokine assay, Longitudinal study","Pol 283-8-specific CTL clones failed to kill target cells infected with Pol283-8T mutant. Longitudinal study of one patient showed appearance of the 8T mutant at the same time as increase in viral load.","Kawashima2010"
"57636","Pol 283-8","2563","B","B","B","Pol","283","290","RT(128-135)","2931..2954","B*5101","TAFTIPSI","TAFTIPSr","I8R","I290R","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Chromium-release assay, Flow cytometric T-cell cytokine assay","Pol 283-8-specific CTL clones failed to kill target cells infected with Pol283-8R mutant.","Kawashima2010"
"57636","Pol 283-8","2564","B","B","B","Pol","283","290","RT(128-135)","2931..2954","B*5101","TAFTIPSI","TAFTIPSl","I8L","I290L","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Chromium-release assay, Flow cytometric T-cell cytokine assay","Pol 283-8-specific CTL clones failed to kill target cells infected with Pol283-8L mutant.","Kawashima2010"
"58151","TI8","2739","B","B","B","Pol","283","290","RT(128-135)","2931..2954","B*5101","TAFTIPSI","TAFTIPSv","I8V","I290V","DR","diminished response","CD8 T-cell Elispot - IFNy, Longitudinal study","Variants TAFTIPSv and TAFTIPSr replaced the wild type sequence by 400 days post-infection, while TAFTIPSt became the dominant variant by 800 days post-infection. Sequence changes were associated with decrease, but not loss of EliSpot response to the epitope.","Liu2011a"
"58151","TI8","2740","B","B","B","Pol","283","290","RT(128-135)","2931..2954","B*5101","TAFTIPSI","TAFTIPSr","I8R","I290R","DR","diminished response","CD8 T-cell Elispot - IFNy, Longitudinal study","Variants TAFTIPSv and TAFTIPSr replaced the wild type sequence by 400 days post-infection, while TAFTIPSt became the dominant variant by 800 days post-infection. Sequence changes were associated with decrease, but not loss of EliSpot response to the epitope.","Liu2011a"
"58151","TI8","2741","B","B","B","Pol","283","290","RT(128-135)","2931..2954","B*5101","TAFTIPSI","TAFTIPSt","I8T","I290T","DR","diminished response","CD8 T-cell Elispot - IFNy, Longitudinal study","Variants TAFTIPSv and TAFTIPSr replaced the wild type sequence by 400 days post-infection, while TAFTIPSt became the dominant variant by 800 days post-infection. Sequence changes were associated with decrease, but not loss of EliSpot response to the epitope.","Liu2011a"
"58395","TV8","2933","B","B","B","Pol","283","290","RT(128-135)","2931..2954","B*51","TAFTIPSV","TAFTIPSi","V8I","V290I","","","CD8 T-cell Elispot - IFNy, CTL suppression of replication","0/22 HLA-B51+ and 23/126 HLA-B51- subjects carried this mutation, TAFTIPSi, V8<i><b>I<i><b>.  TAFTIPSi, TI8, was recognized by TI8-specific CTL clones across decreasing concentrations (10-0.625 &micro;M) of peptide.","Zhang2011"
"58395","TV8","2934","B","B","B","Pol","283","290","RT(128-135)","2931..2954","B*51","TAFTIPSV","TAFTIPSl","V8L","V290L","DHB, SF","diminished HLA binding or increased off-rate, susceptible form","CD8 T-cell Elispot - IFNy, CTL suppression of replication","10/22 HLA-B51+ and 5/126 HLA-B51- subjects carried this mutation, TAFTIPSl, V8<i><b>L</i></b>.  The V289L mutation has significant association with HLA-B51.  TAFTIPSl was recognized by TI8-specific CTL clones across decreasing concentrations (10-1.25 M) of peptide.","Zhang2011"
"58395","TV8","2935","B","B","B","Pol","283","290","RT(128-135)","2931..2954","B*51","TAFTIPSV","TAFTIPSt","V8T","V290T","DHB","diminished HLA binding or increased off-rate","CD8 T-cell Elispot - IFNy, CTL suppression of replication","2/22 HLA-B51+ and 0/126 HLA-B51- subjects carried this mutation, TAFTIPSt, V8<i><b>T</i></b>.  The V8<i>T</i> mutation has significant association with HLA-B51.  TAFTIPSt was barely recognized by TI8-specific CTL clones, only at 10 M of peptide.","Zhang2011"
"58395","TV8","2936","B","B","B","Pol","283","290","RT(128-135)","2931..2954","B*51","TAFTIPSV","TAFTIPSr","V8R","V290R","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, CTL suppression of replication","2/22 HLA-B51+ and 0/126 HLA-B51- subjects carried this mutation, TAFTIPSr, V8<i><b>R</i></b>.  The V8<i>R</i> mutation has significant association with HLA-B51.  TAFTIPSr was not recognized by TI8-specific CTL clones.","Zhang2011"
"59083",,"3250","B","B","B","Pol","283","290","RT(128-135)",,"B*5101","TAFTIPSI","TAFTIPSt","I8T","I290T","DR","diminished response","Peptide titration","Ratio of EliSpot peptide titration of this mutant to original epitope EC<sub>50</sub>ratio = >100, suggesting partial escape.","Liu2007a"
"59083",,"3251","B","B","B","Pol","283","290","RT(128-135)",,"B*5101","TAFTIPSI","TAFTIPSr","I8R","I290R","DR","diminished response","Peptide titration","Ratio of EliSpot peptide titration of this mutant to original epitope, EC<sub>50</sub>ratio = >100, suggesting partial escape.","Liu2007a"
"59083",,"3252","B","B","B","Pol","283","290","RT(128-135)",,"B*5101","TAFTIPSI","TAFTIPSv","I8V","I290V","DR","diminished response","Peptide titration","Ratio of EliSpot peptide titration of this mutant to original epitope EC<sub>50</sub>ratio = >100, suggesting partial escape.","Liu2007a"
"59181","TI8","3308","B","B","B","Pol","283","290","RT(128-135)",,"","TAFTIPSI","TAFTIPSv","I8V","I290V","E, RCR, SF","escape documented in this paper, replicative capacity reduced, susceptible form","Chromium-release assay, CTL suppression of replication, Sequence","Mutant 8V, TAFTIPSv, was seen in all 3 subjects under study.  It was selected slowly.  It was seen in subjects KI-021 and KI-124 earlier than it was in subject KI-051 who also carried a different mutation in TI8 (TAFTIPSI).","Kuse2014"
"59181","TI8","3309","B","B","B","Pol","283","290","RT(128-135)",,"","TAFTIPSI","TAFTvPSv","I5V, I8V","I287V, I290V","E, SF","escape documented in this paper, susceptible form","Chromium-release assay, CTL suppression of replication, Sequence","Mutant TAFTvPSv, was seen in 1/3 subjects under study.  It was selected very slowly in subject KI-051 who also carried a different viral mutation in TI8 (TAFTIPSI).","Kuse2014"
"54152","NY9","961","B","","","Pol","291","299","RT(136-144)","2955..2981","B*1801","NNETPGVRY","NNETPGiRY","V7I","V297I","SF","susceptible form","CD8 T-cell Elispot - IFNy","The variant was recognized by CTLs to a similar extent as the wt form of the epitope.","Liu2006"
"54152","NY9","962","B","","","Pol","291","299","RT(136-144)","2955..2981","B*1801","NNETPGVRY","NsETPGVRY","N2S","N292S","SF","susceptible form","CD8 T-cell Elispot - IFNy","The variant was recognized by CTLs to a similar extent as the wt form of the epitope.","Liu2006"
"54152","NY9","963","B","","","Pol","291","299","RT(136-144)","2955..2981","B*1801","NNETPGVRY","NNEiPGVRY","T4I","T294I","SF","susceptible form","CD8 T-cell Elispot - IFNy","The variant was recognized by CTLs to a similar extent as the wt form of the epitope.","Liu2006"
"54152","NY9","964","B","","","Pol","291","299","RT(136-144)","2955..2981","B*1801","NNETPGVRY","NNEiPGiRY","T4I, V7I","T294I, V297I","SF","susceptible form","CD8 T-cell Elispot - IFNy","The variant was recognized by CTLs to a similar extent as the wt form of the epitope.","Liu2006"
"54152","NY9","965","B","","","Pol","291","299","RT(136-144)","2955..2981","B*1801","NNETPGVRY","NNgTPGVRY","E3G","E293G","DR","diminished response","CD8 T-cell Elispot - IFNy","Wt form of the epitope was 22 times better recognized than the variant, making the variant a partial escape.","Liu2006"
"54152","NY9","966","B","","","Pol","291","299","RT(136-144)","2955..2981","B*1801","NNETPGVRY","NNEvPGiRY","T4V, V7I","T294V, V297I","SF","susceptible form","CD8 T-cell Elispot - IFNy","The variant was recognized by CTLs to a similar extent as the wt form of the epitope.","Liu2006"
"58148","NY9","2731","B","B","B","Pol","291","299","RT(136-144)","2955..2981","B*1801","NNETPGVRY","NNEiPGVRY","T4I","T294I","DR","diminished response","CD8 T-cell Elispot - IFNy, Longitudinal study","Variant NNEiPGVRY arose early in infection, and was later replaced by NNETPGiRY and NNgTPGVRY. Sequence changes were associated with loss of EliSpot response to the epitope.","Liu2011a"
"58148","NY9","2732","B","B","B","Pol","291","299","RT(136-144)","2955..2981","B*1801","NNETPGVRY","NNETPGiRY","V7I","V297I","DR","diminished response","CD8 T-cell Elispot - IFNy, Longitudinal study","Variant NNEiPGVRY arose early in infection, and was later replaced by NNETPGiRY and NNgTPGVRY. Sequence changes were associated with loss of EliSpot response to the epitope.","Liu2011a"
"58148","NY9","2733","B","B","B","Pol","291","299","RT(136-144)","2955..2981","B*1801","NNETPGVRY","NNgTPGVRY","E3G","E293G","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Longitudinal study","Variant NNEiPGVRY arose early in infection, and was later replaced by NNETPGiRY and NNgTPGVRY. Sequence changes were associated with loss of EliSpot response to the epitope.","Liu2011a"
"59084",,"3253","B","B","B","Pol","291","299","RT(136-144)",,"B*1801","NNETPGVRY","NNgTPGVRY","E3G","E293G","DR","diminished response","Peptide titration","Ratio of EliSpot peptide titration of this mutant to original epitope EC<sub>50</sub>ratio = 22, suggesting partial escape.","Liu2007a"
"438",,"1768","","","","Pol","306","314","RT(151-159)","3000..3026","B*5101","QGWKGSPAI","QGWKGaPAI","S6A","S311A","OV","observed variant","Chromium-release assay, HLA binding","2/38 Clade B strain sequences carried this 6A variant.  Challenge epitope elicited CTL response in1 of 3 HLA-B51 seropositive individuals,  and bound HLA-B*5101 with low strength.  Variant not tested.","Tomiyama1999"
"57723",,"2623","","","","Pol","306","323","RT(151-168)","3000..3053","","QGWKGSPAIFQSSMTKIL","QGWKGSPAIFQaSMTKIL","S12A","S317A","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Variant QGWKGSPAIFQaSMTKIL was found in patient I11.","Vollbrecht2010"
"55346","SM9","2317","B","","","Pol","311","319","RT(156-164)","3015..3041","B*0702","SPAIFQSSM{TKILE}","SPAIFQSSM{TKILd}","E+5D","E324D","E, P","escape documented in this paper, processing","","The downstream E169D mutation abrogates SM9 recognition by CTL and proteasomal processing.","Zimbwa2007"
"57497","SM9","2497","B, A1","A1, B","A1","Pol","311","319","RT(156-164)","3015..3041","","SPAIFQSSM","SPsIFQSSM","A3S","A313S","SF","susceptible form","CD8 T-cell Elispot - IFNy","SM9 variant, SPsIFQSSM, continued to elicit a response in patients 2632 (African female, experienced some treatment, autologous virus Clade A1) and 3076 (African female, treatment naive, autologous virus Clade A1).","Hoof2010"
"57497","SM9","2498","B, A1","A1, B","A1, B","Pol","311","319","RT(156-164)","3015..3041","","SPAIFQSSM","SPAIFQcSM","S7C","S317C","SF","susceptible form","CD8 T-cell Elispot - IFNy","SM9 variant SPAIFQcSM continued to elicit CTL response from all 3 patients, 2059 (Caucasian male, treated, autologous virus Clade B); 2632 (African female, experienced some treatment, autologous virus Clade A1) and 3076 (African female, treatment naive, autologous virus Clade A1).","Hoof2010"
"57497","SM9","2499","B, A1","A1, B","A1, B","Pol","311","319","RT(156-164)","3015..3041","","SPAIFQSSM","SPAIFQaSM","S7A","S317A","SF","susceptible form","CD8 T-cell Elispot - IFNy","SM9 variant SPAIFQaSM continued to elicit CTL response from all 3 patients, 2059 (Caucasian male, treated, autologous virus Clade B); 2632 (African female, experienced some treatment, autologous virus Clade A1) and 3076 (African female, treatment naive, autologous virus Clade A1).","Hoof2010"
"57497","SM9","2500","B, A1","A1, B","A1, B","Pol","311","319","RT(156-164)","3015..3041","","SPAIFQSSM","SPsIFQcSM","A3S, S7C","A313S, S317C","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","SM9 variant SPsIFQcSM continued to elicit CTL response in patients 2059 (Caucasian male, treated, autologous virus Clade B) and 3076 (African female, treatment naive, autologous virus Clade A1).  No CTL response was seen in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).","Hoof2010"
"57497","SM9","2501","B, A1","A1, B","A1","Pol","311","319","RT(156-164)","3015..3041","","SPAIFQSSM","SPAIFaSSM","Q6A","Q316A","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","SM9 variant SPAIFaSSM continued to elicit CTL response though at a low level, in patient 2632 (African female, experienced some treatment, autologous virus Clade A1).  CTL from patients 2059 (Caucasian male, treated, autologous virus Clade B) and 3076 (African female, treatment naive, autologous virus Clade A1) did not respond to this variant.","Hoof2010"
"57497","SM9","2502","B, A1","A1, B","","Pol","311","319","RT(156-164)","3015..3041","","SPAIFQSSM","SPAaFQSSM","I4A","I314A","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","SM9 variant, SPAaFQSSM did not elicit a response in any patients - 2632 (African female, experienced some treatment, autologous virus Clade A1) and 3076 (African female, treatment naive, autologous virus Clade A1).","Hoof2010"
"57497","SM9","2503","B, A1","A1, B","","Pol","311","319","RT(156-164)","3015..3041","","SPAIFQSSM","SPAIaQSSM","F5A","F315A","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","SM9 variant, SPAIaQSSM did not elicit a response in any patients - 2059 (Caucasian male, treated, autologous virus Clade B); 2632 (African female, experienced some treatment, autologous virus Clade A1) and 3076 (African female, treatment naive, autologous virus Clade A1).","Hoof2010"
"52069",,"1316","B","","","Pol","311","320","RT(156-165)","3015..3044","B7","SPAIFQSSMT","SPAIFQxSMT","S7X","S317X","CE","calculated escape","Sequence","This putative CTL escape is HLA-B7-associated.","Moore2002b"
"1470","P4","1565","B","","","Pol","311","320","RT(156-165)","3015..3044","B35","SPAIFQSSMT","SsPAIFQSSMT","T10M, P2S, A3P, I4A, F5I, Q6F, S7Q, M9S","T320M, P312S, A313P, I314A, F315I, Q316F, S317Q, M319S","LE, NSF","literature escape, non-susceptible form","CD8 T-cell Elispot - IFNy","Patient 252 was unable to recognize the P157S mutant after treatment.","Samri2000"
"52826","A3-AK9 Pol","44","B","","","Pol","313","321","RT(158-166)","3021..3047","A3","AIFQSSMTK","AIFQSSMlK","T8L","T320L","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","Superinfection. The second infecting strain had the variant aifqssmIk. The CTL response to the second variant was zero or low at all timepoints. The CTL response to the first variant was also low, and declined over time.","Altfeld2002a"
"447",,"100","B","B, D","A","Pol","313","321","RT(158-166)","3021..3047","A3","AIFQSSMTK","AIFQaSMTK","S5A","S317A","DR, SSF","diminished response, subtype-specific susceptible form","Chromium-release assay","The consensus peptide of B and D clade viruses is AIFQSSMTK. The consensus peptide of a subset of A clade viruses  is AIFQASMTK, and it is less able to stimulate the CTL clone.","Cao1997a"
"447",,"101","B","B, D","A","Pol","313","321","RT(158-166)","3021..3047","A3","AIFQSSMTK","sIFQSSMTK","A1S","A313S","SSF","subtype-specific susceptible form","Chromium-release assay","The consensus peptide of B and D clade viruses is AIFQSSMTK. The consensus peptide of a  subset of A clade viruses is SIFQSSMTK, and it is as reactive as the originally defined epitope.","Cao1997a"
"53752","AK9","780","B","","","Pol","313","321","RT(158-166)","3021..3047","A11","AIFQSSMTK","AIFQSSMTr","K9R","K321R","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Chromium-release assay","Variant persisted throughout a 5-year period in a patient. The variant was not recognized by patient CTLs.","Koibuchi2005a"
"53752","AK9","781","B","","","Pol","313","321","RT(158-166)","3021..3047","A11","AIFQSSMTK","tIFQSSMTr","A1T, K9R","A313T, K321R","OV","observed variant","","Variant was found in 1/15 clones at the end of a 5 year period in a patient.","Koibuchi2005a"
"53752","AK9","782","B","","","Pol","313","321","RT(158-166)","3021..3047","A11","AIFQSSMTK","AIFQSSMar","T8A, K9R","T320A, K321R","OV","observed variant","","Variant was found in 1/15 clones at the end of a 5 year period in a patient.","Koibuchi2005a"
"446",,"1257","","","","Pol","313","321","RT(158-166)","3021..3047","A*0301, A*1101, A3, A*6801","AIFQSSMTK","AIFQcSMTK","S5C","S317C","SF","susceptible form","","Binding and recognition of this natural variant to HLA-A*0301, -A*1101 and -A*6801-positive CTL was high.","Menendez-Arias1998, Threlkeld1997"
"446",,"1258","","","","Pol","313","321","RT(158-166)","3021..3047","A*0301, A*1101, A3, A*6801","AIFQSSMTK","AIFQSSMTt","K9T","K321T","DHB, NSF","diminished HLA binding or increased off-rate, non-susceptible form","","Binding of this natural variant to HLA-A*0301, -A*1101 and -A*6801-positive CTL was abrogated.","Menendez-Arias1998, Threlkeld1997"
"446",,"1259","","","","Pol","313","321","RT(158-166)","3021..3047","A*0301, A*1101, A3, A*6801","AIFQSSMTK","AIFQrSMTr","S5R, K9R","S317R, K321R","DHB, SF","diminished HLA binding or increased off-rate, susceptible form","","Binding and recognition of this natural variant to HLA-A*0301, -A*1101 and -A*6801-positive CTL was high.","Menendez-Arias1998, Threlkeld1997"
"446",,"1260","","","","Pol","313","321","RT(158-166)","3021..3047","A*0301, A*1101, A3, A*6801","AIFQSSMTK","AIlQSSMTr","F3L, K9R","F315L, K321R","DR, SF","diminished response, susceptible form","","Binding and recognition of this natural variant to HLA-A*0301, and -A*6801-positive CTL was diminished but to HLA-A*1101-CTL was still high.","Menendez-Arias1998, Threlkeld1997"
"446",,"1261","","","","Pol","313","321","RT(158-166)","3021..3047","A*0301, A*1101, A3, A*6801","AIFQSSMTK","AIFQSSMTr","K9R","K321R","SF","susceptible form","","Binding of this K166R natural variant to HLA-A*0301, -A*1101 and -A*6801-positive CTL was high.  CTL recognition and lysis was similar to that elicited by the index epitope sequence.","Menendez-Arias1998, Threlkeld1997"
"446",,"1262","","","","Pol","313","321","RT(158-166)","3021..3047","A*0301, A*1101, A3, A*6801","AIFQSSMTK","sIFQSSMTK","A1S","A313S","SF","susceptible form","","Binding of this A158S natural variant to HLA-A*0301, -A*1101 and -A*6801-positive CTL was high.  CTL recognition and lysis was similar to that elicited by the index epitope sequence.","Menendez-Arias1998, Threlkeld1997"
"52068",,"1317","B","","","Pol","313","321","RT(158-166)","3021..3047","A11","AIFQSSMTK","AIFQSSMTx","K9X","K321X","CE","calculated escape","Sequence","This putative CTL escape is HLA-A11-associated.","Moore2002b"
"452",,"1842","","","","Pol","313","321","RT(158-166)","3021..3047","A3","AIFQSSMTK","AIFQSSMTr","K9R","K321R","SF","susceptible form","Chromium-release assay","This variant was recognized by an infected infant.","Wilson1999a"
"452",,"1844","","","","Pol","313","321","RT(158-166)","3021..3047","A3","AIFQSSMTK","AIFlSSMTK","Q4L","Q316L","E","escape documented in this paper","Chromium-release assay","This variant was not recognized by an infected infant.","Wilson1999a"
"452",,"1845","","","","Pol","313","321","RT(158-166)","3021..3047","A3","AIFQSSMTK","tIsQSSMTK","A1T, F3S","A313T, F315S","E","escape documented in this paper","Chromium-release assay","This variant was not recognized by an infected infant.","Wilson1999a"
"56458","AK9(RT)","1923","B","B","B","Pol","313","321","RT(158-166)","3021..3047","","AIFQCSMTK","AIFQsSMTK","C5S","C317S","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-A11 restricted. No recognition was seen by CTL from HLA-A3 carriers. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"452",,"2266","","","","Pol","313","321","RT(158-166)","3021..3047","A3","AIFQSSMTK","AIlQSSMTK","F3L","F315L","OV","observed variant","Chromium-release assay, Sequence","This variant was not tested for CTL recognition by infant carrying it.","Wilson1999a"
"55328","P","808","A, B, C","","","Pol","314","322","RT(159-167)","3024..3050","H-2K<sup>d</sup>","IFQSSMTKI","IFQaSMTKI","S4A","S317A","SF","susceptible form","CD8 T-cell Elispot - IFNy","After immunization with clade A vaccine containing the wt epitope, T cells responded well both to the index epitope and to this variant.","Larke2007"
"55328","P","809","A, B, C","","","Pol","314","322","RT(159-167)","3024..3050","H-2K<sup>d</sup>","IFQSSMTKI","IFQcSMTKI","S4C","S317C","DR","diminished response","CD8 T-cell Elispot - IFNy","After immunization with clade A vaccine containing the wt epitope, T cells responded to the index epitope but responded poorly to this variant.","Larke2007"
"57934","P","2663","A","A","A","Pol","314","322","RT(159-167)","3024..3050","H-2K<sup>d</sup>","IFQSSMTKI","IFgSSMTKa","Q3G, I9A","Q316G, I322A","DHB","diminished HLA binding or increased off-rate","HLA binding","Artificially-produced mutant IFgSSMTKa was created to abrogate the anchor residues of epitope IFQSSMTKI. Loss of HLA binding was confirmed.","Im2011"
"55348","MR9","1979","","","","Pol","319","327","RT(164-172)","3039..3065","A*0301","MTKILEPFR","MTKILdPFR","E6D","E324D","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","The E169D mutation abolishes MR9 recognition by CTL and reduces HLA binding by 44%.","Zimbwa2007"
"55071",,"215","B","B","C","Pol","328","336","RT(173-181)","3066..3092","B*1503","KQNPDIVIY","KQNPeIVIY","D5E","D332E","SNSF","subtype-specific non-susceptible form","","KQNPDIVIY epitope is found in subtype B, while the variant is found in subtype C. Only subtype B epitope is frequently recognized by B*1503 positive individuals.","Frahm2006"
"1684",,"673","","","","Pol","330","338","RT(175-183)","3072..3098","B35","HPDIVIYQY","nPDIVIYQY","H1N","H330N","SF","susceptible form","CD8 T-cell Elispot - IFNy","This epitope and the variant were recognized by 1/4 HIV infected women and by 2/3 HIV-exposed, persistently seronegative women.  Responses to the epitope and the variant were much higher before HIV-1 seroconversion of previous HEPS.","Kaul2001a"
"457",,"681","","","","Pol","330","338","RT(175-183)","3072..3098","B35","NPDIVIYQY","NPeIVIYQY","D3E","D332E","DHB","diminished HLA binding or increased off-rate","CD8 T-cell Elispot - IFNy","Variant found in 8/10 B35+ individuals and in 2/3 B35- individuals. Reduced binding affinity to B35.","Kawana1999"
"463",,"1263","","B","D","Pol","330","338","RT(175-183)","3072..3098","B35","NPDIVIYQY","NPeIVIYQY","D3E","D332E","DHB, SF","diminished HLA binding or increased off-rate, susceptible form","Chromium-release assay, HLA binding","This D177E natural variant which is the consensus for clade D, displayed CTL cross-reactivity with the consensus, index epitope, NPDIVIYQY.  Binding to HLA-B35 was diminished.","Menendez-Arias1998, RowlandJones1998b"
"463",,"1264","","B","","Pol","330","338","RT(175-183)","3072..3098","B35","NPDIVIYQY","NPDlVIYQY","I4L","I333L","SF","susceptible form","Chromium-release assay","This I178L natural variant displayed CTL cross-reactivity with the consensus, index epitope.","Menendez-Arias1998, RowlandJones1998b"
"463",,"1265","","B","","Pol","330","338","RT(175-183)","3072..3098","B35","NPDIVIYQY","NPDIiIYQY","V5I","V334I","DHB, SF","diminished HLA binding or increased off-rate, susceptible form","Chromium-release assay, HLA binding","This V179I natural variant displayed CTL cross-reactivity with the consensus, index epitope.  Binding to HLA-B35 was diminished.","Menendez-Arias1998, RowlandJones1998b"
"461",,"1266","","B","A","Pol","330","338","RT(175-183)","3072..3098","B35","NPDIVIYQY","hPDIVIYQY","N1H","N330H","SF","susceptible form","","This variant is the HIV-1 Clade A consensus and obtained by a Medline database search in August 1998.","Menendez-Arias1998, Sipsas1997"
"461",,"1267","","B","","Pol","330","338","RT(175-183)","3072..3098","B35","NPDIVIYQY","hPDIlIYQY","N1H, V5L","N330H, V334L","SF","susceptible form","","This HIV-2 homologous epitope is recognized by NPDIVIYQY-specific clones.","Menendez-Arias1998, Sipsas1997"
"52066",,"1318","B","","","Pol","330","338","RT(175-183)","3072..3098","B*3501","NPDIVIYQY","NPxIVIYQY","D3X","D332X","CE, LE","calculated escape, literature escape","HLA binding, Sequence","This escape is an HLA-B*3501-associated polymorphism.","Moore2002b"
"464",,"1547","B","B","A","Pol","330","338","RT(175-183)","3072..3098","B35","NPDIVIYQY","hPDIVIYQY","N1H","N330H","OV","observed variant","Chromium-release assay","One HEPS Kenyan subject cross-reacted to this B clade epitope though it differed from the A clade form, hPDIVIYQY.","Rowland-Jones1998"
"464",,"1548","B","B","D","Pol","330","338","RT(175-183)","3072..3098","B35","NPDIVIYQY","NPeIVIYQY","D3E","D332E","OV","observed variant","Chromium-release assay","One HEPS Kenyan subject cross-reacted to this B clade epitope though it differed from the D clade form, NPeIVIYQY.","Rowland-Jones1998"
"461",,"1629","","B","B","Pol","330","338","RT(175-183)","3072..3098","B35","NPDIVIYQY","NPDIiIYQY","V5I","V334I","SF","susceptible form","Chromium-release assay","This naturally occurring, strain JRCSF variant, was recognized by a Patient LWF CTL clone.","Menendez-Arias1998, Sipsas1997"
"461",,"1630","","B","B","Pol","330","338","RT(175-183)","3072..3098","B35","NPDIVIYQY","NPeIVIYQY","D3E","D332E","SF","susceptible form","Chromium-release assay","This naturally occurring, strain JRU2RF variant, was recognized by a Patient LWF CTL clone.","Menendez-Arias1998, Sipsas1997"
"461",,"1631","","B","B","Pol","330","338","RT(175-183)","3072..3098","B35","NPDIVIYQY","NPDlVIYQY","I4L","I333L","SF","susceptible form","Chromium-release assay","This naturally occurring variant was recognized by a Patient LWF CTL clone.","Menendez-Arias1998, Sipsas1997"
"1468",,"1567","B","","","Pol","330","339","RT(175-184)","3072..3101","B51","NPDIVIYQYM","NPDIVIYQYv","M10V","M339V","DI, SF","drug induced, susceptible form","CD8 T-cell Elispot - IFNy","Mutation M184V had a predicted increase in binding to HLA-B*5101 and -B*5102.  Patient 246 recognized both index and mutant epitopes prior to treatment.","Samri2000"
"477",,"95","","","","Pol","334","342","RT(179-187)","3084..3110","A*0201","VIYQYMDDL","VIYQYvDDL","M6V","M339V","DI, E","drug induced, escape documented in this paper","","CTL recognition was abolished by this M184V amino acid replacement.  This variant confers high-level resistance to lamivudine (3TC).","Brander1998, Menendez-Arias1998"
"53054",,"1087","B","","","Pol","334","342","RT(179-187)","3084..3110","A2","VIYQYMDDL","VIcQYMDDL","Y3C","Y336C","DI, SF","drug induced, susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","This Y181C ART-drug (NNRTI, sustiva) induced mutation was seen in a subject who exclusively recognized that variant.","Mason2004"
"53054",,"1088","B","","","Pol","334","342","RT(179-187)","3084..3110","A2","VIYQYMDDL","VIYQYvDDL","M6V","M339V","DI, SF","drug induced, susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","This M184V ART-drug induced mutation is known to be associated with lamivudine, didanosine, zalcitabine and abacavir. A subject carrying this mutation was able to recognize a double mutant epitope containing M184V and Y181C.","Mason2004"
"53054",,"1089","B","","","Pol","334","342","RT(179-187)","3084..3110","A2","VIYQYMDDL","VIcQYvDDL","Y3C, M6V","Y336C, M339V","DI, SF","drug induced, susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","This Y181C, M184V  ART-drug (NRTI, didanosine, lamivudine, abacavir) induced double mutation in one subject was selectively recognized even though the subject carried only a single M184V mutation himself (having been NNRTI-free for 4 years, the NNRTI being known to induce mutation Y181C).","Mason2004"
"473",,"1242","B","","","Pol","334","342","RT(179-187)","3084..3110","A*0201","VIYQYMDDL","tIYQYMDDL","V1T","V334T","DI, SF","drug induced, susceptible form","","There was no change in CTL-mediated lysis of target cells presenting this RT inhibitor induced-variant.","Menendez-Arias1998, Harrer1996"
"477",,"1243","","","","Pol","334","342","RT(179-187)","3084..3110","A*0201","VIYQYMDDL","tIYQYMDDL","V1T","V334T","DI, SF","drug induced, susceptible form","","There was no change in CTL-mediated lysis of target cells presenting this RT inhibitor induced-variant.","Brander1998, Menendez-Arias1998"
"473",,"1244","B","","","Pol","334","342","RT(179-187)","3084..3110","A*0201","VIYQYMDDL","iIYQYMDDL","V1I","V334I","DI, SF","drug induced, susceptible form","","There was no change in CTL-mediated lysis of target cells presenting this RT inhibitor induced-variant.","Menendez-Arias1998, Harrer1996"
"477",,"1245","","","","Pol","334","342","RT(179-187)","3084..3110","A*0201","VIYQYMDDL","iIYQYMDDL","V1I","V334I","DI, SF","drug induced, susceptible form","","There was no change in CTL-mediated lysis of target cells presenting this RT inhibitor induced-variant.","Brander1998, Menendez-Arias1998"
"473",,"1246","B","","","Pol","334","342","RT(179-187)","3084..3110","A*0201","VIYQYMDDL","eIYQYMDDL","V1E","V334E","DI, E","drug induced, escape documented in this paper","","CTL recognition was abolished by this V179E amino acid replacement.","Menendez-Arias1998, Harrer1996"
"477",,"1247","","","","Pol","334","342","RT(179-187)","3084..3110","A*0201","VIYQYMDDL","eIYQYMDDL","V1E","V334E","DI, E","drug induced, escape documented in this paper","","CTL recognition was abolished by this V179E amino acid replacement.","Brander1998, Menendez-Arias1998"
"473",,"1248","B","","","Pol","334","342","RT(179-187)","3084..3110","A*0201","VIYQYMDDL","VIYQYvDDL","M6V","M339V","DI, E","drug induced, escape documented in this paper","","CTL recognition was abolished by this M184V amino acid replacement.  This variant confers high-level resistance to lamivudine (3TC).","Menendez-Arias1998, Harrer1996"
"473",,"1250","B","","","Pol","334","342","RT(179-187)","3084..3110","A*0201","VIYQYMDDL","VIcQYMDDL","Y3C","Y336C","DI, DR","drug induced, diminished response","","CTL recognition was strongly reduced by this Y181C amino acid replacement.  This variant is associated with resistance to nevirapine and other NNRTIs.","Menendez-Arias1998, Harrer1996"
"477",,"1251","","","","Pol","334","342","RT(179-187)","3084..3110","A*0201","VIYQYMDDL","VIcQYMDDL","Y3C","Y336C","DI, DR","drug induced, diminished response","","CTL recognition was strongly reduced by this Y181C amino acid replacement.  This variant is associated with resistance to nevirapine and other NNRTIs.","Brander1998, Menendez-Arias1998"
"55288",,"1508","B","","","Pol","334","342","RT(179-187)","3084..3110","A*0201, A2","VIYQYMDDL","cIYQYMDDL","V1C","V334C","OV","observed variant","Sequence","This index epitope was conserved in the mother's viral strain but mutated in the daughter's isolate.","Reinis2007"
"472",,"1590","","","","Pol","334","342","RT(179-187)","3084..3110","A2","VIYQYMDDL","VIYQYvDDL","M6V","M339V","DI, SF","drug induced, susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, Peptide titration","1/28 subjects generated CTL that  recognized lamivudine-induced escape mutation M184V but not the index epitope VL9.","Schmitt2000"
"472",,"1591","","","","Pol","334","342","RT(179-187)","3084..3110","A2","VIYQYMDDL","VIYQYiDDL","M6I","M339I","DI, SF","drug induced, susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, Peptide titration","1/28 subjects generated CTL that recognized lamivudine-induced escape mutation M184I but not the index epitope VL9.","Schmitt2000"
"472",,"1592","","","","Pol","334","342","RT(179-187)","3084..3110","A2","VIYQYMDDL","iIYQYvDDL","V1I, M6V","V334I, M339V","OV","observed variant","Sequence","7 years post-infection and 4 years post-treatment in a patient, one double mutant (V179I, M184V) was seen by molecular analysis.","Schmitt2000"
"58378","VL9","2898","B","B","B","Pol","334","342","RT(179-187)","3084..3110","A*02","VIYQYMDDL","VIYQYvDDL","M6V","M339V","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","Variant VL9V, VIYQYvDDL, overlaps the mutant form of the epitope under study, YV9V.  No EliSpot response was detected against VL9V in ART-naive or 3TC HIV-1 infected subjects.","Pacheco2011"
"58850","VV11","3199","B","B","B","Pol","334","344","RT(179-189)","3084..3116","A*0201","VIYQYMDDLYV","VIYQYvDDLYV","M6V","M339V","IE","inferred escape","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Mutant VV11, VIYQYvDDLYV, was optimal for two emtricitabine-lamivudine users who were treatment failures and who carried M184V-virus.  Wt VIYQYMDDLYV-virus was also recognized but at a much lower level.","Vollbrecht2012"
"1469",,"1568","B","","","Pol","336","344","RT(181-189)","3090..3116","A*0201","YQYMDDLYV","YQYvDDLYV","M4V","M339V","DI, SF","drug induced, susceptible form","CD8 T-cell Elispot - IFNy","Patient 250 recognized both index and mutant epitopes robustly.  Patient 201, however,  recognized neither epitope form.","Samri2000"
"58302","YV9","2897","B","B","B","Pol","336","344","RT(181-189)","3090..3116","A*02","YQYMDDLYV","YQYvDDLYV","M4V","M339V","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","9/19 ART-naive patients had EliSpot response to mutant YV9V, however this M184V mutation was not detectable in circulating virus, showing that it was a case of cross-reaction against a variant. 1/4 patients whose YV9-specific CTL were tested as clonal lines, had the same binding avidity to YV9M and YV9V, while the other 3 had lower functional avidity to the mutant, YV9V. In 3TC subjects, 4 responses were detected against YV9V - 2 of these were cross reactive responses where the subjects also reacted to the wt, YV9M; but 2 were CTL responses to the mutant in subjects that did not recognize the wt i.e. they generated a response specific to the 3TC-resistant virus. The presence of mutant YV9V also correlated with the presence of D177E, an upstream polymorphism flanking YV9.","Pacheco2011"
"58847","YV9","3198","B","B","B","Pol","336","344","RT(181-189)","3090..3116","A*0201","YQYMDDLYV","YQYvDDLYV","M4V","M339V","IE","inferred escape","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Mutant YV9, YQYvDDLYV, was optimal for all emtricitabine-lamivudine users who carried M184V-virus.  Wt YQYMDDLYV-virus was also recognized but at a much lower level.","Vollbrecht2012"
"52987",,"307","","","","Pol","347","356","RT(192-201)","3123..3152","A3","DLEIGQHRTK","DLEmGQHRTK","I4M","I350M","OV","observed variant","","The epitope varied over time but the mutations did not become fixed. The variant arose at late timepoints.","Geels2003"
"55059","IL9","187","","","","Pol","357","365","RT(202-210)","3153..3179","B*4001","IEELRQHLL","vEELReHLL","I1V, Q6E","I357V, Q362E","DR","diminished response","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Immune responses were examined in monozygotic male twins infected simultaneously with the same virus. vEELReHLL  variant arose in one twin; IEELReHLL variant arose in the other. Response to  both variants was diminished.","Draenert2006"
"55059","IL9","188","","","","Pol","357","365","RT(202-210)","3153..3179","B*4001","IEELRQHLL","IEELReHLL","Q6E","Q362E","DR","diminished response","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Immune responses were examined in monozygotic male twins infected simultaneously with the same virus. vEELReHLL  variant arose in one twin; IEELReHLL variant arose in the other. Response to  both variants was diminished.","Draenert2006"
"53055",,"2261","B","","","Pol","358","367","RT(203-212)","3156..3185","B44","EELRQHLLRW","EELRQHLwRW","L8W","L365W","DI, SF","drug induced, susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","This L210W  ART-drug induced mutation. Cross-recognition between the wild type and variant epitope was seen in 8 patients; but  selective CTL recognition with no cross-reactivity was seen in 10 patients.    While the variant is less immunogenic than the wild type epitope, HLA-B44 subjects exposed to either stavudine or azidothymidine were able to recognize the variant.","Mason2004"
"54153","EW9","967","B","","","Pol","359","367","RT(204-212)","3159..3185","A*2501","ELRQHLLRW","ELRQHLLkW","R8K","R366K","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","This is a newly defined epitope. Position 8 in the epitope had potentially experienced positive selection. The variant was full escape, as it was not recognized by CTLs.","Liu2006"
"59085",,"3254","B","B","B","Pol","359","367","RT(204-212)",,"A*2501","ELRQHLLRW","ELRQHLLkW","R8K","R366K","E","escape documented in this paper","Peptide titration","EliSpot peptide titration indicated full escape.","Liu2007a"
"55326","RT1","810","A, B, C","A","B","Pol","361","369","RT(206-214)","3165..3191","H-2K<sup>d</sup>","RAHLLSWGF","RqHLLrWGl","A2Q, S6R, F9L","A362Q, S366R, F369L","SF","susceptible form","CD8 T-cell Elispot - IFNy","This variant was recognized by CTLs from both clade B vaccine containing the variant, and clade C vaccine containing the RkHLLkWGF variant.","Larke2007"
"55326","RT1","811","A, B, C","A","C","Pol","361","369","RT(206-214)","3165..3191","H-2K<sup>d</sup>","RAHLLSWGF","RkHLLkWGF","A2K, S6K","A362K, S366K","SF","susceptible form","CD8 T-cell Elispot - IFNy","This variant was recognized by CTLs from both clade B vaccine containing the RqHLLrWGl variant, and clade C vaccine containing this variant.","Larke2007"
"55326","RT1","812","A, B, C","","","Pol","361","369","RT(206-214)","3165..3191","H-2K<sup>d</sup>","RAHLLSWGF","RAHLLrWGF","S6R","S366R","E, SF","escape documented in this paper, susceptible form","CD8 T-cell Elispot - IFNy","This variant was recognized by CTLs from clade B vaccine containing the RqHLLrWGl variant, but not by CTLs from clade C vaccine containing the RkHLLkWGF variant.","Larke2007"
"55326","RT1","813","A, B, C","","","Pol","361","369","RT(206-214)","3165..3191","H-2K<sup>d</sup>","RAHLLSWGF","RqHLLrWGF","A2Q, S6R","A362Q, S366R","E, SF","escape documented in this paper, susceptible form","CD8 T-cell Elispot - IFNy","This variant was recognized by CTLs from clade B vaccine containing the RqHLLrWGl variant, but not by CTLs from clade C vaccine containing the RkHLLkWGF variant.","Larke2007"
"55326","RT1","814","A, B, C","","","Pol","361","369","RT(206-214)","3165..3191","H-2K<sup>d</sup>","RAHLLSWGF","ReHLLkWGF","A2E, S6K","A362E, S366K","DR, E","diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy","This variant was poorly recognized by CTLs from clade B vaccine containing the RqHLLrWGl variant, and not recognized by CTLs from clade C vaccine containing the RkHLLkWGF variant.","Larke2007"
"55326","RT1","815","A, B, C","","","Pol","361","369","RT(206-214)","3165..3191","H-2K<sup>d</sup>","RAHLLSWGF","ReHLLrWGF","A2E, S6R","A362E, S366R","E, SF","escape documented in this paper, susceptible form","CD8 T-cell Elispot - IFNy","This variant was recognized by CTLs from clade B vaccine containing the RqHLLrWGl variant, but not by CTLs from clade C vaccine containing the RkHLLkWGF variant.","Larke2007"
"55326","RT1","816","A, B, C","","","Pol","361","369","RT(206-214)","3165..3191","H-2K<sup>d</sup>","RAHLLSWGF","RgHLLkWGF","A2G, S6K","A362G, S366K","DR, E","diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy","This variant was poorly recognized by CTLs from clade B vaccine containing the RqHLLrWGl variant, and not recognized by CTLs from clade C vaccine containing the RkHLLkWGF variant.","Larke2007"
"55326","RT1","817","A, B, C","","","Pol","361","369","RT(206-214)","3165..3191","H-2K<sup>d</sup>","RAHLLSWGF","RkHLLSWGF","A2K","A362K","SF","susceptible form","CD8 T-cell Elispot - IFNy","This variant was recognized by CTLs from both clade B vaccine containing the variant, and clade C vaccine containing the RkHLLkWGF variant.","Larke2007"
"57724",,"2624","","","","Pol","395","412","RT(240-257)","3267..3320","","TVQPIVLPEKDSWTVNDI","TVQPIqLPEKDSWTVNDI","V6Q","V400Q","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Variant TVQPIqLPEKDSWTVNDI was carried by patient I11.","Vollbrecht2010"
"57724",,"2625","","","","Pol","395","412","RT(240-257)","3267..3320","","TVQPIVLPEKDSWTVNDI","TVQhIqLPEKDiWTVNDI","S12I, P4H, V6Q","S406I, P398H, V400Q","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Variant TVQhIqLPEKDiWTVNDI was carried by patient I11.","Vollbrecht2010"
"487",,"735","B","","","Pol","399","407","RT(244-252)","3279..3305","B*5701, B*5801","IVLPEKDSW","ItLPEKeSW","V2T, D7E","V400T, D405E","E","escape documented in this paper","Chromium-release assay","Variant bound to B*5701 with similar affinity as the index peptide but was not recognized by patient's CTLs.","Klein1998"
"487",,"736","B","","","Pol","399","407","RT(244-252)","3279..3305","B*5701, B*5801","IVLPEKDSW","ImLPEKDSW","V2M","V400M","DHB, SF","diminished HLA binding or increased off-rate, susceptible form","Chromium-release assay","Variant bound to B*5701 with reduced affinity compared to wt epitope but could still be recognized by CTLs.","Klein1998"
"487",,"737","B","","","Pol","399","407","RT(244-252)","3279..3305","B*5701, B*5801","IVLPEKDSW","IeLPEKDSW","V2E","V400E","DR","diminished response","Chromium-release assay","Variant had less affinity for B*5701 than the index peptide and was recognized by CTLs at a lower level compared to the wt epitope.","Klein1998"
"485",,"1268","B","","","Pol","399","407","RT(244-252)","3279..3305","B*5701","IVLPEKDSW","ImLPEKDSW","V2M","V400M","SF","susceptible form","","Cross-recognition of the variant by index epitope-specific CTL is seen even though binding of the variant to HLA-B*5701 is diminished.","Menendez-Arias1998, vanderBurg1997"
"485",,"1269","B","","","Pol","399","407","RT(244-252)","3279..3305","B*5701","IVLPEKDSW","ItLPEKgSW","V2T, D7G","V400T, D405G","NSF","non-susceptible form","","This variant binds HLA-B*5701 with similar affinity as the index peptide does, but it is not recognized by index peptide-specific CTL.","Menendez-Arias1998, vanderBurg1997"
"485",,"1270","B","","","Pol","399","407","RT(244-252)","3279..3305","B*5701","IVLPEKDSW","IeLPEKDSW","V2E","V400E","SF","susceptible form","","This variant binds HLA-B*5701 with reduced affinity, but it is recognized by index peptide-specific CTL.","Menendez-Arias1998, vanderBurg1997"
"57423","IVW9","2384","B","B","B","Pol","399","407","RT(244-252)","3279..3305","B*57","IVLPEKDSW","IkLPEKeSW","V2K, D7E","V400K, D405E","OV","observed variant","Sequence","Variant IkLPEKeSW was seen in one progressor, CH-02 and in one controller, CH-03.","Tang2010"
"57423","IVW9","2385","B","B","B","Pol","399","407","RT(244-252)","3279..3305","B*57","IVLPEKDSW","ImLPEKDSW","V2M","V400M","OV","observed variant","Sequence","Variant ImLPEKDSW was seen in one progressor, subject CH-08.","Tang2010"
"57423","IVW9","2386","B","B","B","Pol","399","407","RT(244-252)","3279..3305","B*57","IVLPEKDSW","IkLPEKDSW","V2K","V400K","OV","observed variant","Sequence","Variant IkLPEKDSW was seen in one progressor, CH-11.","Tang2010"
"57423","IVW9","2387","B","B","B","Pol","399","407","RT(244-252)","3279..3305","B*57","IVLPEKDSW","IeLPEKDSW","V2E","V400E","OV","observed variant","Sequence","Variant IeLPEKDSW  was seen in one progressor, CH-12.","Tang2010"
"59144","ISW9","3307","B","B","B","Pol","399","407","RT(244-252)",,"B*57","IVLPEKDSW","IVkPEKDSW","L3K","L401K","OV","observed variant","Sequence","B*57-restricted variant IVkPEKDSW in the 1999 Berlin patient found circulating 15 years post-end of ART.","Jessen2014"
"52988",,"308","","","","Pol","415","426","RT(260-271)","3327..3362","B15","LVGKLNWASQIY","LVGKxNWASQIY","L5X","L419X","OV","observed variant","","The epitope varied over time but the mutations did not become fixed. The variant arose at late timepoints.","Geels2003"
"53753","LY12","783","B","","","Pol","415","426","RT(260-271)","3327..3362","B62","LVGKLNWASQIY","LVGKLNWASQIh","Y12H","Y426H","OV","observed variant","","Variant was found in 1/6 clones at the beginning of a 5 year period in a patient.","Koibuchi2005a"
"52821","A3-QR9 Pol","45","B","","","Pol","424","432","RT(269-277)","3354..3380","A3","QIYAGIKVK","QIYAGIKVr","K9R","K432R","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","Superinfection. The second infecting strain had the variant qiyagikvR. The initial CTL response to both variants was strong but eventually declined, particularly to the variant in the second strain.","Altfeld2002a"
"52100",,"294","B, CRF01_AE","B","B, CRF01_AE","Pol","424","432","RT(269-277)","3354..3380","A*1101","QIYAGIKVK","QIYAGIKVr","K9R","K432R","DHB, DR","diminished HLA binding or increased off-rate, diminished response","Chromium-release assay, HLA binding","Variant predominantly observed in clades B and E. Variant was recognized by CTLs from clade E patients, suggesting it is a cross-clade epitope variant. Recognition and binding affinity of the variant was 10 times lower than for the wt epitope.","Fukada2002"
"52100",,"295","B, CRF01_AE","B","CRF01_AE","Pol","424","432","RT(269-277)","3354..3380","A*1101","QIYAGIKVK","QIYpGIKVr","A4P, K9R","A427P, K432R","DHB, SNSF","diminished HLA binding or increased off-rate, subtype-specific non-susceptible form","Chromium-release assay, HLA binding","Variant predominantly observed in clades C and D. Variant was not recognized by CTLs from clade E patients, suggesting it is not a cross-clade epitope variant. Binding affinity of the variant was 10 times lower than for the wt epitope. It is suggested that the A/P substitution affects TCR recognition.","Fukada2002"
"56753",,"2526","B","B","B","Pol","424","432","RT(269-277)","3354..3380","A*03","QIYAGIKVK","QIYAGIKVr","K9R","K432R","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Tetramer binding","The variant QIYAGIKVr evolved to dominate the quasispecies, and was recognized less well than the index peptide QIYAGIKVK by the PNMC from time points around the time of response decline, indicating escape.","Turnbull2009"
"493",,"1846","","","","Pol","426","434","RT(271-279)","3360..3386","B42","YPGIKVRQL","YPGIKVkQL","R7K","R432K","SF","susceptible form","Chromium-release assay","This variant was recognized by an HIV-transmitting mother.","Wilson1999a"
"493",,"1847","","","","Pol","426","434","RT(271-279)","3360..3386","B42","YPGIKVRQL","YaGIKVRQL","P2A","P427A","SF","susceptible form","Chromium-release assay","This variant was recognized by an HIV-transmitting mother as well as her infected infant.","Wilson1999a"
"493",,"1848","","","","Pol","426","434","RT(271-279)","3360..3386","B42","YPGIKVRQL","YhGIKVRQL","P2H","P427H","E","escape documented in this paper","Chromium-release assay","This variant was not recognized by an HIV-transmitting mother.","Wilson1999a"
"493",,"2267","","","","Pol","426","434","RT(271-279)","3360..3386","B42","YPGIKVRQL","YhkIKVRQL","P2H, G3K","P427H, G428K","OV","observed variant","Chromium-release assay, Sequence","This variant was not tested for CTL recognition by an HIV-transmitting mother.","Wilson1999a"
"58723","RT-YL9","3119","C","C","C","Pol","426","434","RT(271-279)","3360..3386","B*4201, B*4202","YPGIKVRQL","YaGIKVRQL","P2A","P427A","E","escape documented in this paper","Sequence","RT-YL9 mutation, YaGIKVRQL, is selected in 20% HLA-B*4201 (4% have wt YL9) subjects.  The authors designate mutant YaGIKVRQL as an escape when presented by HLA-B*4201.","Kloverpris2012a"
"58723","RT-YL9","3120","C","C","C","Pol","426","434","RT(271-279)","3360..3386","B*4201, B*4202","YPGIKVRQL","YPGIrVRQL","K5R","K430R","OV","observed variant","Sequence","RT-YL9 mutation, YPGIrVRQL, is selected in 14% HLA-B*4202 (0% have wt YL9) subjects.","Kloverpris2012a"
"58723","RT-YL9","3121","C","C","C","Pol","426","434","RT(271-279)","3360..3386","B*4201, B*4202","YPGIKVRQL","YPGIKVRgL","Q8G","Q433G","E","escape documented in this paper","Sequence","RT-YL9 mutation, YPGIKVRgL, is selected in 14% HLA-B*4202 (0% have wt YL9) subjects.  The authors designate mutant YPGIKVRgL as an escape when presented by HLA-B*4202.","Kloverpris2012a"
"58723","RT-YL9","3122","C","C","C","Pol","426","434","RT(271-279)","3360..3386","B*4201, B*4202","YPGIKVRQL","YPGIKVRrL","Q8R","Q433R","E","escape documented in this paper","Sequence","RT-YL9 mutation, YPGIKVRrL, is selected in 14% HLA-B*4202 (0% have wt YL9) subjects.  The authors designate mutant YPGIKVRrL as an escape when presented by HLA-B*4202.","Kloverpris2012a"
"58723","RT-YL9","3123","C","C","C","Pol","426","434","RT(271-279)","3360..3386","B*4201, B*4202","YPGIKVRQL","YqGIKVRQL","P2Q","P427Q","E","escape documented in this paper","Sequence","RT-YL9 mutation, YqGIKVRQ, is selected in 14% HLA-B*4202 (0% have wt YL9) subjects.  The authors designate mutant YqGIKVRQ as an escape when presented by HLA-B*4202.","Kloverpris2012a"
"58723","RT-YL9","3124","C","C","C","Pol","426","434","RT(271-279)","3360..3386","B*4201, B*4202","YPGIKVRQL","YPkIKVRQL","G3K","G428K","OV","observed variant","Sequence","RT-YL9 mutation, YPkIKVRQL, is selected in 14% HLA-B*4202 (0% have wt YL9) subjects.","Kloverpris2012a"
"58723","RT-YL9","3125","C","C","C","Pol","426","434","RT(271-279)","3360..3386","B*4201, B*4202","YPGIKVRQL","YPGIKVsQL","R7S","R432S","OV","observed variant","Sequence","RT-YL9 mutation, YPGIKVsQL, is selected in 14% HLA-B*4202 (0% have wt YL9) subjects.","Kloverpris2012a"
"58723","RT-YL9","3126","C","C","C","Pol","426","434","RT(271-279)","3360..3386","B*4201, B*4202","YPGIKVRQL","YPGIKVkkL","R7K, Q8K","R432K, Q433K","E","escape documented in this paper","Sequence","RT-YL9 mutation, YPGIKVkkL, is selected in 14% HLA-B*4202 (0% have wt YL9) subjects.  The authors designate mutant YPGIKVkkL as an escape when presented by HLA-B*4202.","Kloverpris2012a"
"53413","IPL","1356","","","","Pol","448","456","RT(293-301)","3426..3452","B7","IPLTEEAEL","IPLTEaAEL","E6A","E453A","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","The variant peptide was less potent at inducing production of IFN-gamma than the index peptide.","Oxenius2004"
"53413","IPL","1357","","","","Pol","448","456","RT(293-301)","3426..3452","B7","IPLTEEAEL","IPLTEEAgL","E8G","E455G","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","The variant peptide was less potent at inducing production of IFN-gamma than the index peptide.","Oxenius2004"
"53413","IPL","1358","","","","Pol","448","456","RT(293-301)","3426..3452","B7","IPLTEEAEL","IPLTEEAgf","E8G, L9F","E455G, L456F","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","The variant peptide was less potent at inducing production of IFN-gamma than the index peptide.","Oxenius2004"
"53413","IPL","1359","","","","Pol","448","456","RT(293-301)","3426..3452","B7","IPLTEEAEL","IPLTgEAEL","E5G","E452G","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","The variant peptide was less potent at inducing production of IFN-gamma than the index peptide.","Oxenius2004"
"53413","IPL","1360","","","","Pol","448","456","RT(293-301)","3426..3452","B7","IPLTEEAEL","IPLTqEAEL","E5Q","E452Q","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","The variant peptide was less potent at inducing production of IFN-gamma than the index peptide.","Oxenius2004"
"53413","IPL","1361","","","","Pol","448","456","RT(293-301)","3426..3452","B7","IPLTEEAEL","IPLTvEAEL","E5V","E452V","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","The variant peptide was less potent at inducing production of IFN-gamma than the index peptide.","Oxenius2004"
"53413","IPL","1362","","","","Pol","448","456","RT(293-301)","3426..3452","B7","IPLTEEAEL","IPLTaEAEL","E5A","E452A","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","The variant peptide was less potent at inducing production of IFN-gamma than the index peptide.","Oxenius2004"
"53424","EAE","1363","","","","Pol","453","467","RT(298-312)","3441..3485","","EAELELAENREILKE","aAELELAENREILKE","E1A","E453A","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 2/11 viral clones contained this variant sequence at the first time point (Day 60) tested after infection.  1/9 clones contained the variant sequence at the second time point (Day 297).","Oxenius2004"
"53424","EAE","1364","","","","Pol","453","467","RT(298-312)","3441..3485","","EAELELAENREILKE","EAgfELAENREILKE","E3G, L4F","E455G, L456F","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/11 viral clones contained this variant sequence at the first time point tested after infection.","Oxenius2004"
"53424","EAE","1365","","","","Pol","453","467","RT(298-312)","3441..3485","","EAELELAENREILKE","EAgLELAENREILKE","E3G","E455G","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/18 viral clones contained this variant sequence at the first time point tested after infection.","Oxenius2004"
"53424","EAE","1366","","","","Pol","453","467","RT(298-312)","3441..3485","","EAELELAENREILKE","EAELELAENREILeE","K14E","K466E","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/15 viral clones contained this variant sequence at the third time point (Day 369) tested after infection.","Oxenius2004"
"53424","EAE","1367","","","","Pol","453","467","RT(298-312)","3441..3485","","EAELELAENREILKE","EAELELAgNREILKE","E8G","E460G","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/14 viral clones contained this variant sequence at the last time point (Day 635) tested after infection.","Oxenius2004"
"56140","IV9","83","B","","","Pol","464","472","RT(309-317)","3474..3500","A2","ILKEPVHGV","ILKdPVHGV","E4D","E467D","DR","diminished response","CD8 T-cell Elispot - IFNy, Chromium-release assay","To identify immunogenically optimized epitopes for use in vaccines, mutants of IV9 were tested in transgenic mice. Mutants of epitope IV9 when tested in transgenic mice, showed that the consensus was strongly immunogenic, but the most common mutant, ILKdPVHGV was not especially immunogenic or cross-reactive. Rare mutant, ILKEPVHrV, was highly immunogenic, and cross-reactive to the consensus. Sequences ILrEPiHGV and ILKEPVHGi were also cross-reactive to the consensus.","Blondelle2008"
"56140","IV9","84","B","","","Pol","464","472","RT(309-317)","3474..3500","A2","ILKEPVHGV","ILKEPVHrV","G8R","G471R","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","To identify immunogenically optimized epitopes for use in vaccines, mutants of IV9 were tested in transgenic mice. Mutants of epitope IV9 when tested in transgenic mice, showed that the consensus was strongly immunogenic, but the most common mutant, ILKdPVHGV was not especially immunogenic or cross-reactive. Rare mutant, ILKEPVHrV, was highly immunogenic, and cross-reactive to the consensus. Sequences ILrEPiHGV and ILKEPVHGi were also cross-reactive to the consensus.","Blondelle2008"
"56140","IV9","85","B","","","Pol","464","472","RT(309-317)","3474..3500","A2","ILKEPVHGV","ILrEPiHGV","K3R, V6I","K466R, V469I","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","To identify immunogenically optimized epitopes for use in vaccines, mutants of IV9 were tested in transgenic mice. Mutants of epitope IV9 when tested in transgenic mice, showed that the consensus was strongly immunogenic, but the most common mutant, ILKdPVHGV was not especially immunogenic or cross-reactive. Rare mutant, ILKEPVHrV, was highly immunogenic, and cross-reactive to the consensus. Sequences ILrEPiHGV and ILKEPVHGi were also cross-reactive to the consensus.","Blondelle2008"
"56140","IV9","86","B","","","Pol","464","472","RT(309-317)","3474..3500","A2","ILKEPVHGV","ILKEPVHGi","V9I","V472I","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","To identify immunogenically optimized epitopes for use in vaccines, mutants of IV9 were tested in transgenic mice. Mutants of epitope IV9 when tested in transgenic mice, showed that the consensus was strongly immunogenic, but the most common mutant, ILKdPVHGV was not especially immunogenic or cross-reactive. Rare mutant, ILKEPVHrV, was highly immunogenic, and cross-reactive to the consensus. Sequences ILrEPiHGV and ILKEPVHGi were also cross-reactive to the consensus.","Blondelle2008"
"518",,"109","","A, B, D","A","Pol","464","472","RT(309-317)","3474..3500","A2","ILKEPVHGV","ILKdPVHGV","E4D","E467D","SNSF","subtype-specific non-susceptible form","Chromium-release assay","The consensus peptides of B and D clade viruses and some As have the sequence ILKEPVHGV. The consensus peptide of a subset of A clade viruses, ILKDPVHGV, is not cross-reactive.","Menendez-Arias1998, Cao1997a"
"53009","IV9","493","","","","Pol","464","472","RT(309-317)","3474..3500","A*0201","ILKEPVHGV","ILKEPVHGa","V9A","V472A","IE","inferred escape","","This variant was found in all three patients, being the initial and the last variant in one of the patients. It preceded loss of the IV9 specific CTLs.","Jamieson2003"
"53009","IV9","494","","","","Pol","464","472","RT(309-317)","3474..3500","A*0201","ILKEPVHGV","ILKEPiHGa","V6I, V9A","V469I, V472A","IE","inferred escape","","This variant was found in one of the patients. It preceded loss of the IV9 specific CTLs.","Jamieson2003"
"53009","IV9","495","","","","Pol","464","472","RT(309-317)","3474..3500","A*0201","ILKEPVHGV","ILrEPVHGV","K3R","K466R","IE","inferred escape","","This variant was found in two of the patients. It preceded loss of the IV9 specific CTLs.","Jamieson2003"
"53009","IV9","496","","","","Pol","464","472","RT(309-317)","3474..3500","A*0201","ILKEPVHGV","ILKEPVHea","G8E, V9A","G471E, V472A","IE","inferred escape","","This variant was found in one of the patients. It preceded loss of the IV9 specific CTLs.","Jamieson2003"
"53009","IV9","497","","","","Pol","464","472","RT(309-317)","3474..3500","A*0201","ILKEPVHGV","ILKgPVHGa","E4G, V9A","E467G, V472A","IE","inferred escape","","This variant was found in one of the patients. It preceded loss of the IV9 specific CTLs.","Jamieson2003"
"53009","IV9","498","","","","Pol","464","472","RT(309-317)","3474..3500","A*0201","ILKEPVHGV","ILeEPVHGa","K3E, V9A","K466E, V472A","IE","inferred escape","","This variant was found in one of the patients. It preceded loss of the IV9 specific CTLs.","Jamieson2003"
"53009","IV9","499","","","","Pol","464","472","RT(309-317)","3474..3500","A*0201","ILKEPVHGV","ILrEPVHGa","K3R, V9A","K466R, V472A","IE","inferred escape","","This variant was found in one of the patients. It preceded loss of the IV9 specific CTLs.","Jamieson2003"
"1648",,"671","","","","Pol","464","472","RT(309-317)","3474..3500","A2","ILKDPVHGV","ILKePVHGV","D4E","D467E","SF","susceptible form","CD8 T-cell Elispot - IFNy","This epitope and the variant were recognized by 14/25 HIV infected women and by 7/10 HIV-exposed, persistently seronegative women.  Responses to the epitope and the variant were much higher before HIV-1 seroconversion of previous HEPS.","Kaul2001a"
"506",,"787","","","","Pol","464","472","RT(309-317)","3474..3500","A2","ILKEPVHGV","ILKEPVHeV","G8E","G471E","SF","susceptible form","CD8 T-cell Elispot - IFNy","CTL clones from three patients all recognized this epitope variant.","Kolowos1999"
"506",,"788","","","","Pol","464","472","RT(309-317)","3474..3500","A2","ILKEPVHGV","ILKdPVHGV","E4D","E467D","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","Variant commonly found in clade A. Variant was not recognized by any of the CTL clones derived from three different patients.","Kolowos1999"
"515",,"1271","","","","Pol","464","472","RT(309-317)","3474..3500","A2","ILKEPVHGV","ILKdPVHGV","E4D","E467D","DR","diminished response","","A large reduction in CTL-mediated lysis is seen in this subtype A U455 isolate.","Menendez-Arias1998, Tsomides1994"
"515",,"1272","","","","Pol","464","472","RT(309-317)","3474..3500","A2","ILKEPVHGV","ILKdPVHeV","E4D, G8E","E467D, G471E","DR","diminished response","","A large reduction in CTL-mediated lysis is seen in this subtype B SF2 isolate.","Menendez-Arias1998, Tsomides1994"
"515",,"1273","","","","Pol","464","472","RT(309-317)","3474..3500","A2","ILKEPVHGV","yLKEPVHGV","I1Y","I464Y","SF","susceptible form","","This variant bound HLA-A2 more stably, strongly stimulating a response by index epitope-specific CTL.","Menendez-Arias1998, Tsomides1994"
"515",,"1274","","","","Pol","464","472","RT(309-317)","3474..3500","A2","ILKEPVHGV","fLKEPVHGV","I1F","I464F","SF","susceptible form","","This variant bound HLA-A2 more stably than the index epitope did.","Menendez-Arias1998, Tsomides1994"
"535",,"1549","B","B","A","Pol","464","472","RT(309-317)","3474..3500","A*0202, A2","ILKEPVHGV","ILKdPVHGV","E4D","E467D","SF","susceptible form","Chromium-release assay","Two HEPS Kenyan subjects cross-reacted to this B clade epitope and one of them elicited a stronger reaction to the A clade form, ILKdPVHGV.","Rowland-Jones1998"
"517",,"1560","","B","A","Pol","464","472","RT(309-317)","3474..3500","A2","ILKEPVHGV","ILKdPVHGV","E4D","E467D","OV","observed variant","Chromium-release assay","5/6 Kenyan HEPS subjects recognized this clade B epitope which differed from the clade A variant, ILKdPVHGV.","RowlandJones1998b"
"55397","Pol 476","1759","","","","Pol","464","472","RT(309-317)","3474..3500","A2","ILKEPVHGV","ILKEPVHGa","V9A","V472A","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt18 carried this variant epitope, and did not recognize the challenge HXB2 ILKEPVHGV.","Thorn2007"
"55397","Pol 476","1760","","","","Pol","464","472","RT(309-317)","3474..3500","A2","ILKEPVHGV","IiKEPVHxx","L2I, G8X, V9X","L465I, G471X, V472X","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt41 carried this variant epitope, and did not recognize the challenge HXB2 ILKEPVHGV.","Thorn2007"
"52787","IV9","1862","B","","","Pol","464","472","RT(309-317)","3474..3500","A2","ILKEPVHGV","ILKElVHGV","P5L","P468L","E","escape documented in this paper","Chromium-release assay, Sequence","After 2 weeks of passaging under selection by IV9-specific clone 68A62, this escape variant that was not recognized emerged.","Yang2003"
"57919","Pol 463-10 or IY10","2654","B","B","B","Pol","464","473","RT(309-318)","3474..3503","Cw*1202","ILKEPVHGVY","ILKEPVHGaY","V9A","V472A","E, R","escape documented in this paper, reversion","CD8 T-cell Elispot - IFNy, Longitudinal study, Relative replication capacity assay",,"Honda2011"
"58695",,"3108","B","B","B","Pol","464","473","RT(309-318)","3474..3503","Cw*0303","ILKEPVHGVY","ILrEPVHGVY","K3R","K466R","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","C-mut ILrEPVHGVY that is a variant of Pol ILKEPVHGVY is restricted by HLA-Cw*0302.","Blais2012"
"55327","RT2","818","A, B, C","","","Pol","472","481","RT(317-326)","3498..3527","H-2K<sup>d</sup>","VYYDPSKDLI","VYYDPSKDLv","I10V","I481V","SF","susceptible form","CD8 T-cell Elispot - IFNy","After immunization with any clade vaccine, index epitope was recognized, as well as this variant.","Larke2007"
"55327","RT2","819","A, B, C","","","Pol","472","481","RT(317-326)","3498..3527","H-2K<sup>d</sup>","VYYDPSKDLI","VYYDPtKDLI","S6T","S477T","SF","susceptible form","CD8 T-cell Elispot - IFNy","After immunization with any clade vaccine, index epitope was recognized, as well as this variant.","Larke2007"
"55327","RT2","820","A, B, C","","","Pol","472","481","RT(317-326)","3498..3527","H-2K<sup>d</sup>","VYYDPSKDLI","VYYDPSKeLI","D8E","D479E","DR, NSF","diminished response, non-susceptible form","CD8 T-cell Elispot - IFNy","After immunization with any clade vaccine, index epitope was recognized, but the variant was not, or was poorly recognized.","Larke2007"
"55327","RT2","821","A, B, C","","","Pol","472","481","RT(317-326)","3498..3527","H-2K<sup>d</sup>","VYYDPSKDLI","aYYDPSKeLI","V1A, D8E","V472A, D479E","DR, NSF","diminished response, non-susceptible form","CD8 T-cell Elispot - IFNy","After immunization with any clade vaccine, index epitope was recognized, but the variant was not, or was poorly recognized.","Larke2007"
"55327","RT2","822","A, B, C","","","Pol","472","481","RT(317-326)","3498..3527","H-2K<sup>d</sup>","VYYDPSKDLI","VYYePSKeLI","D4E, D8E","D475E, D479E","DR, NSF","diminished response, non-susceptible form","CD8 T-cell Elispot - IFNy","After immunization with any clade vaccine, index epitope was recognized, but the variant was not, or was poorly recognized.","Larke2007"
"52822","A3-RK11 Pol","46","B","","","Pol","511","521","RT(356-366)","3615..3647","A3","RTRGAHTNDVK","RTRGAHTNDVr","K11R","K521R","DR","diminished response","CD8 T-cell Elispot - IFNy","Superinfection. The second infecting strain had the variant rtrgahtndvR. The CTL response to both variants declined over time, and the response to the second variant was lower than to the first throughout.","Altfeld2002a"
"547",,"174","A","A","D","Pol","519","527","RT(364-372)","3639..3665","B70","DVKQLTEVV","DVKQLaEaV","T6A, V8A","T524A, V526A","SSF","subtype-specific susceptible form","","CTL responses in three individuals with non-clade B infections were studied, 2 with subtype A infections, 1 with subtype C -- their infections all originated in East Africa. Bulk cultures from subtype A patient gave a CTL response that could recognize the subtype D form of this epitope, with two substitutions (DVKQLAEAV), though a CTL line from these cultures didn't recognize the B clade variant (DVKQLTEAV)","Dorrell1999"
"547",,"175","A","A","B","Pol","519","527","RT(364-372)","3639..3665","B70","DVKQLTEVV","DVKQLTEaV","V8A","V526A","SNSF","subtype-specific non-susceptible form","","CTL responses in three individuals with non-clade B infections were studied, 2 with subtype A infections, 1 with subtype C -- their infections all originated in East Africa. Bulk cultures from subtype A patient gave a CTL response that could recognize the subtype D form of this epitope, with two substitutions (DVKQLAEAV), though a CTL line from these cultures didn't recognize the B clade variant (DVKQLTEAV)","Dorrell1999"
"54648","POL-72","1967","B","B","C","Pol","528","545","RT(373-390)","3666..3719","","QKIATESIVIWGKTPKFK","QKIAmESIVIWGKTPKFr","K18R, T5M","K545R, T532M","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 2 amino acids (11.1%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"56053","IW9(RT)","1924","B","B","B","Pol","530","538","RT(375-383)","3672..3698","","IATESIVIW","IAmESIVIW","T3M","T532M","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B58 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"57424","IAW9","2388","B","B","B","Pol","530","538","RT(375-383)","3672..3698","B*57","IATESIVIW","IsTESIVIW","A2S","A531S","OV","observed variant","Sequence","Controller CH-22 carries this variant, IsTESIVIW.","Tang2010"
"57424","IAW9","2389","B","B","B","Pol","530","538","RT(375-383)","3672..3698","B*57","IATESIVIW","IAlESIVIW","T3L","T532L","OV","observed variant","Sequence","Controller CH-13 carried this variant, IAlESIVIW.","Tang2010"
"57424","IAW9","2390","B","B","B","Pol","530","538","RT(375-383)","3672..3698","B*57","IATESIVIW","IsTEcIVIW","A2S, S5C","A531S, S534C","OV","observed variant","Sequence","Progressor CH-12 carried this variant, IsTEcIVIW.","Tang2010"
"57424","IAW9","2391","B","B","B","Pol","530","538","RT(375-383)","3672..3698","B*57","IATESIVIW","IAkEvIVIW","T3K, S5V","T532K, S534V","OV","observed variant","Sequence","Controller CH-03 carried this variant, IAkEvIVIW.","Tang2010"
"57424","IAW9","2393","B","B","B","Pol","530","538","RT(375-383)","3672..3698","B*57","IATESIVIW","vArEaIVIW","I1V, T3R, S5A","I530V, T532R, S534A","OV","observed variant","Sequence","Progressor CH-02 carries this variant, vArEsIVIW.","Tang2010"
"551",,"1275","B","","","Pol","547","556","RT(392-401)","3723..3752","A*3201","PIQKETWETW","PIQKEaWETW","T6A","T552A","SF","susceptible form","","This variant was detected in a mother-infant transmission study. The variant was recognized by index epitope-specific CTL clones.","Menendez-Arias1998, Harrer1996b"
"55955","PW10(RT)","1925","B","B","B","Pol","547","556","RT(392-401)","3723..3752","","PIQKETWEAW","PIQKETWEtW","A9T","A555T","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be  HLA-A32 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"55375","Pol 571","1672","","","","Pol","571","578","RT(416-423)","3795..3818","A2","FVNTPPLV","FVNTPlLV","P6L","P576L","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt18 carried this variant and was unable to recognize the challenge HXB2 epitope form, FVNTPPLV.","Thorn2007"
"554",,"1276","","","","Pol","587","595","RT(432-440)","3843..3869","B*3501","EPIVGAETF","dPIVGAETF","E1D","E587D","DR","diminished response","","The E432D variant did not affect HLA-B35 binding though CTL-mediated lysis was reduced.","Menendez-Arias1998, Tomiyama1997"
"554",,"1277","","","","Pol","587","595","RT(432-440)","3843..3869","B*3501","EPIVGAETF","EPIiGAETF","V4I","V590I","DR","diminished response","","The V435I variant did not affect HLA-B35 binding though CTL-mediated lysis was reduced.","Menendez-Arias1998, Tomiyama1997"
"561",,"1279","","","","Pol","591","600","RT(436-445)","3855..3884","B45","GAETFYVDGA","GvETFYVDGA","A2V","A592V","SF","susceptible form","","RT-specific CTL clones from an HLA-B45 subject recognized both index epitope and its natural variant.","Menendez-Arias1998"
"59034","Pol-EA8 RT","3214","C","C","C","Pol","593","600","RT(438-445)","3861..3884","A*6802","{A}ETFYVDGA","{v}ETFYVDGA","A-1V","A592V","OV","observed variant","Sequence","The A592V variant of Pol EA8, {v}ETFYVDGA is a flanking region mutation.","Kloverpris2013c"
"59034","Pol-EA8 RT","3215","C","C","C","Pol","593","600","RT(438-445)","3861..3884","A*6802","ETFYVDGA{A}","ETFYVDGA{S}","A+1S","A601S","OV","observed variant","Sequence","The A601S variant of Pol EA8, ETFYVDGA{S} is a flanking region mutation.","Kloverpris2013c"
"59034","Pol-EA8 RT","3216","C","C","C","Pol","593","600","RT(438-445)","3861..3884","A*6802","ETFYVDGA{ANRETKI}","ETFYVDGA{ANRETKk}","I+7K","I607K","OV","observed variant","Sequence","The I607K variant of Pol EA8, ETFYVDGA{ANRETKk} is a flanking region mutation.","Kloverpris2013c"
"564",,"1278","","","","Pol","593","603","RT(438-448)","3861..3893","A26","ETFYVDGAANR","ETyYVDGAANR","F3Y","F595Y","SF","susceptible form","","This natural variant is cross-recognized by index epitope-specific CTL.","Menendez-Arias1998"
"565",,"1850","","","","Pol","593","603","RT(438-448)","3861..3893","A26","ETFYVDGAANR","ETyYVnGAANR","F3Y, D6N","F595Y, D598N","DR","diminished response","Chromium-release assay","This variant showed reduced CTL recognition by a non-transmitting mother.","Wilson1999a"
"56064","Pol606","204","","","","Pol","606","614","RT(451-459)","3900..3926","A2","KLGKAGYVT","rLGKAGYVT","K1R","K606R","OV","observed variant","","One HLA-A2 patient did not respond to the KLGKAGYVT epitope but the variant peptide was observed in the patient.","Fomsgaard2008"
"55376","Pol 606","1694","","","","Pol","606","614","RT(451-459)","3900..3926","A2","KLGKAGYVT","KLGKAGYVv","T9V","T614V","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Though poorly immunogenic in A2 transgenic mice,  anchor-optimization of HXB2 Pol 606(9T) to variant Pol606(9V), KLGKAGYVv, induced cross-reaction and higher immunogenicity.","Thorn2007"
"55376","Pol 606","1695","","","","Pol","606","614","RT(451-459)","3900..3926","A2","KLGKAGYVT","KmGKAGYVT","L2M","L607M","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subjects Pt15 and Pt35 carried this variant, but while Pt15 was unable to cross-recognize the challenge HXB2 sequence KLGKAGYVT, Pt35 did recognize this challenge HXB2 sequence.","Thorn2007"
"55376","Pol 606","1696","","","","Pol","606","614","RT(451-459)","3900..3926","A2","KLGKAGYVT","KtGKAGYVT","L2T","L607T","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt16 carried this variant and was unable to cross-recognize the challenge HXB2 epitope, KLGKAGYVT.","Thorn2007"
"55376","Pol 606","1697","","","","Pol","606","614","RT(451-459)","3900..3926","A2","KLGKAGYVT","KiGKAGYVT","L2I","L607I","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt17 carried this variant and was unable to cross-recognize the challenge HXB2 epitope, KLGKAGYVT.","Thorn2007"
"58246",,"2843","B","B","B","Pol","640","648","RT(485-493)","4002..4028","A*0201","ALQDSGLEV","ALQDSGvEV","L7V","L646V","IE","inferred escape","Sequence","1/27 sequences of epitope ALQDSGLEV varied at 552  DFOSx to ALQDSGvEV.  Position 491 in the epitope is marked as being under selection to vary.","Ferrari2011"
"58246",,"2844","B","B","B","Pol","640","648","RT(485-493)","4002..4028","A*0201","ALQDSGLEV","ALQDSGsEV","L7S","L646S","IE","inferred escape","Sequence","2/27 and 1/15 sequences of epitope ALQDSGLEV varied at 552 and 718 DFOSx to ALQDSGsEV.  Position 491 in the epitope is marked as being under selection to vary.","Ferrari2011"
"58246",,"2845","B","B","B","Pol","640","648","RT(485-493)","4002..4028","A*0201","ALQDSGLEV{NV}","ALQDSGLEV{Ni}","V+2I","V650I","IE","inferred escape","Sequence","12/27 and 12/15 sequences of epitope ALQDSGLEV{NV} varied at 552 and 718 DFOSx to ALQDSGLEV{Ni}.  Position 495 in the epitope is marked as being under selection to vary.","Ferrari2011"
"58246",,"2846","B","B","B","Pol","640","648","RT(485-493)","4002..4028","A*0201","ALQDSGLEV{NV}","ALQDSGLEV{Nx}","V+2I","V650I","IE","inferred escape","Sequence","1/27 (or possibly 13/27) sequences of epitope ALQDSGLEV{NV} varied at 552 DFOSx to ALQDSGLEV{Nx} (as well as possibly 1/15 at 718 DFOSx).  Position 495 in the epitope is marked as being under selection to vary.","Ferrari2011"
"58246",,"2847","B","B","B","Pol","640","648","RT(485-493)","4002..4028","A*0201","ALQDSGLEV{NV}","ALQDSGxEV{Nx}","V+2X, L7X","V650X, L646X","IE","inferred escape","Sequence","2/15 sequences of epitope ALQDSGLEV{NV} varied at 718 DFOSx to ALQDSGxEV{Nx}.  Positions 491 and 495 in the epitope are marked as being under selection to vary.","Ferrari2011"
"52102",,"296","B, CRF01_AE","B","CRF01_AE","Pol","675","683","RT(520-528)","4107..4133","A*1101","QIIEQLIKK","QIIEeLIKK","Q5E","Q679E","SNSF","subtype-specific non-susceptible form","Chromium-release assay, HLA binding","This variant found in clade E patient was not recognized by clade B CTLs while its binding affinity to A*1101 was identical to wild type.","Fukada2002"
"52102",,"297","B, CRF01_AE","B","CRF01_AE","Pol","675","683","RT(520-528)","4107..4133","A*1101","QIIEQLIKK","QIIEkLIeK","Q5K, K8E","Q679K, K682E","SNSF","subtype-specific non-susceptible form","Chromium-release assay, HLA binding","This variant found in clade E patient was not recognized by clade B CTLs while its binding affinity to A*1101 was identical to wild type.","Fukada2002"
"56065","Pol687","205","","","","Pol","687","695","RT(532-540)","4143..4169","A2","YLAWVPAHK","YLsWVPAHK","A3S","A689S","OV","observed variant","","One HLA-A2 patient did not respond to the YLAWVPAHK epitope but the variant peptide was observed in the patient.","Fomsgaard2008"
"55377","Pol 687","1673","","","","Pol","687","695","RT(532-540)","4143..4169","A2","YLAWVPAHK","YLsWVPAHK","A3S","A689S","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt15 carried this variant epitope in a structural protein, and did not recognize the challenge HXB2 epitope form, YLAWVPAHK.  10 other subjects were HXB2 epitope carriers, but of them only Pt16 could recognize that epitope.","Thorn2007"
"57730",,"2630","","","","Pol","702","717","RT(547)-Integrase(2)","4188..4235","","QVDKLVSAGIRKVLFL","QVDKLVSAGIRKiLFL","V13I","V714I","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Escape variant QVDKLVSAGIRKiLFL was seen in patient I04, and this suppression of antigen was accompanied by a decline in CD38/PD-1 co-expression on HIV-1-specific CTL.","Vollbrecht2010"
"56145",,"1533","C","","","Pol","724","734","Integrase(9-19)","4254..4286","B*4403","QEEHEKYHSNW","QaEHEKYHSNW","E2A","E725A","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"56145",,"1534","C","","","Pol","724","734","Integrase(9-19)","4254..4286","B*4403","QEEHEKYHSNW","QdEHEKYHSNW","E2D","E725D","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"56145",,"1535","C","","","Pol","724","734","Integrase(9-19)","4254..4286","B*4403","QEEHEKYHSNW","QgEHEKYHSNW","E2G","E725G","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"56145",,"1536","C","","","Pol","724","734","Integrase(9-19)","4254..4286","B*4403","QEEHEKYHSNW","QvEHEKYHSNW","E2V","E725V","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"57957","QW11","2688","B","B","B","Pol","724","734","Integrase(9-19)","4254..4286","B*4402","QEEHERYHSNW","QEEHEkYHSNW","R6K","R729K","SF","susceptible form","CD8 T-cell Elispot - IFNy","QEEHERYHSNW underwent adaptation to neo-epitope QEEHEkYHSNW. 2 subjects had higher EliSpot responses to the neo-epitope than to the non-adapted form.","Keane2012"
"52989",,"309","","","","Pol","743","751","Integrase(28-36)","4311..4337","B51","LPPVVAKEI","LPPiVAKEI","V4I","V746I","OV","observed variant","","The epitope varied over time but the mutations did not become fixed. The variant arose at intermediate timepoints.","Geels2003"
"577",,"1769","","","","Pol","743","751","Integrase(28-36)","4311..4337","B*5101","LPPVVAKEI","LPPiVAKEI","V4I","V746I","OV","observed variant","Chromium-release assay, HLA binding","2/21 Clade B strain sequences carried this 4I variant.  Challenge epitope elicited CTL response in all of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.  Variant not tested.","Tomiyama1999"
"58381","LI9","2938","B","B","B","Pol","743","751","Integrase(28-36)","4311..4337","B*51","LPPVVAKEI","iPPVVAKEI","L1I","L743I","SF","susceptible form","CD8 T-cell Elispot - IFNy, CTL suppression of replication","iPPVVAKEI, L1<i><b>I</i></b>, was found in 17/22 HLA-B51+ subjects and in 12/126 HLA-B51- subjects.  This mutant, L743I, has significant associations with HLA-B51 and with loss of viral control.  It was well recognized by wt LI9-specific CTL.  Virus containing L743I with no flanking mutations had a 2-fold reduction in antiviral efficacy (SM cohort IDs 55 and 446).","Zhang2011"
"58381","LI9","2939","B","B","B","Pol","743","751","Integrase(28-36)","4311..4337","B*51","LPPVVAKEI{VASCDKCQL}","iPPVVAKEI{VASCDKCQi}","L1I, L19I","L743I, L761I","SF","susceptible form","CD8 T-cell Elispot - IFNy, CTL suppression of replication","iPPVVAKEI, L1<i><b>I</i></b>, was found in 17/22 HLA-B51+ subjects and in 12/126 HLA-B51- subjects.  This flanking mutant, L743I, has significant associations with HLA-B51 and with loss of viral control.  It was well recognized by wt LI9-specific CTL.  Virus containing L743I with an L760I flanking downstream mutation had a 4-fold reduction in antiviral efficacy (SM cohort IDs 8, 64, 209, 215, 342 and 381).  This downstream L760 position was mutated (either to I or V) in 82% of L743I-mutation carrying subjects.","Zhang2011"
"58381","LI9","2940","B","B","B","Pol","743","751","Integrase(28-36)","4311..4337","B*51","LPPVVAKEI{VASCDKCQL}","iPPVVAKEI{VASCDKCQv}","L1I, L19V","L743I, L761V","SF","susceptible form","CD8 T-cell Elispot - IFNy, CTL suppression of replication","iPPVVAKEI, L1<i><b>I</i></b>, was found in 17/22 HLA-B51+ subjects and in 12/126 HLA-B51- subjects.  This mutant, L743I, has significant associations with HLA-B51 and with loss of viral control.  It was well recognized by wt LI9-specific CTL.  Virus containing L743I with an L760V flanking downstream mutation had a reduction in antiviral efficacy (SM cohort IDs 176 and 353).  This downstream L760 position was mutated (either to I or V) in 82% of L743I-mutation carrying subjects.","Zhang2011"
"58381","LI9","2941","B","B","B","Pol","743","751","Integrase(28-36)","4311..4337","B*51","LPPVVAKEI{VASCDKCQL}","iPPVVAKEI{VAcCDKCQi}","L1I, S13C, L19I","L743I, S755C, L761I","SF","susceptible form","CD8 T-cell Elispot - IFNy, CTL suppression of replication","iPPVVAKEI, L1<i><b>I</i></b>, was found in 17/22 HLA-B51+ subjects and in 12/126 HLA-B51- subjects.  This flanking mutant, L743I, has significant associations with HLA-B51 and with loss of viral control.  It was well recognized by wt LI9-specific CTL.  Virus containing L743I with L760I and L754C flanking downstream mutations had an 8-fold reduction in antiviral efficacy (SM cohort IDs 14, 63, 350,429 and 455).  This downstream L754 position was mutated (to C or M) in 41% of L743I-mutation carrying subjects.","Zhang2011"
"58381","LI9","2942","B","B","B","Pol","743","751","Integrase(28-36)","4311..4337","B*51","LPPVVAKEI{VASCDKCQL}","iPPVVAKEI{VAmCDKCQi}","L1I, S13M, L19I","L743I, S755M, L761I","SF","susceptible form","CD8 T-cell Elispot - IFNy, CTL suppression of replication","iPPVVAKEI, L1<i><b>I</i></b>, was found in 17/22 HLA-B51+ subjects and in 12/126 HLA-B51- subjects.  This flanking mutant, L743I, has significant associations with HLA-B51 and with loss of viral control.  It was well recognized by wt LI9-specific CTL.  Virus containing L743I with L760I and L754M flanking downstream mutations had a reduction in antiviral efficacy (SM cohort ID 181).  This downstream L754 position was mutated (to C or M) in 41% of L743I-mutation carrying subjects.","Zhang2011"
"58381","LI9","2943","B","B","B","Pol","743","751","Integrase(28-36)","4311..4337","B*51","LPPVVAKEI{VAS}","iPPVVAKEI{VAc}","L1I, S13C","L743I, S755C","SF","susceptible form","CD8 T-cell Elispot - IFNy, CTL suppression of replication","iPPVVAKEI, L1<i><b>I</i></b>, was found in 17/22 HLA-B51+ subjects and in 12/126 HLA-B51- subjects.  This flanking mutant, L743I, has significant associations with HLA-B51 and with loss of viral control.  It was well recognized by wt LI9-specific CTL.  Virus containing L743I with L754C flanking downstream mutations had a reduction in antiviral efficacy (SM cohort ID 47).  This downstream L754 position was mutated (to C or M) in 41% of L743I-mutation carrying subjects.","Zhang2011"
"53777","LI9","3073","B, C","B, C","B, C","Pol","743","751","Integrase(28-36)","4311..4337","B51","LPPIVAKEI","LPPvVAKEI","I4V","I746V","A, OV","HLA association, observed variant","Sequence","Variant LPPvVAKEI (I31V) is found in both clades B and C.  For Clade C, the consensus 31I form is present in 68% B*51- subjects, but the variant 31V form is present in all 6/6 B*51+ subjects.  The 31V form is stably transmitted from B*51+ donors to B*51- recipients.  In B-clade, where HLA-B*51 is not rare (as in C-clade, South Africa), the 31V form has become the consensus.","Leslie2005a"
"58708","Int-LI9","3117","C","C","C","Pol","743","751","Integrase(28-36)","4311..4337","B*4201","LPPIVAKEI","LPPxVAKEI","I4X","I746X","E","escape documented in this paper","Sequence","Epitope Int-LI9 carries escape mutations at position 4, LPPxVAKEI.  The authors designate it an escape when presented by HLA-B*4201.","Kloverpris2012a"
"58708","Int-LI9","3118","C","C","C","Pol","743","751","Integrase(28-36)","4311..4337","B*4201","LPPIVAKEI","LPPIVAxEI","K7X","K749X","E","escape documented in this paper","Sequence","Epitope Int-LI9 carries escape mutations at position 7, LPPIVAxEI.  The authors designate it an escape when presented by HLA-B*4201.","Kloverpris2012a"
"59051","LI9-Int","3224","B","B","C","Pol","743","751","Integrase(28-36)","4311..4337","B*0702","LPPVVAKEI","LPPiVAKEI","V4I","V746I","SNSF","subtype-specific non-susceptible form","HLA binding","C-clade variant of LI9-Int, LPPiVAKEI, is not recognized by any C-clade infected individuals.  It's binding coefficient for HLA-B*0702 is 2,128 nM..","Kloverpris2014"
"57731",,"2631","","","","Pol","827","844","Integrase(112-129)","4563..4616","","TIHTDNGSNFTSTTVKAA","vIHTDNGgNFTSgaVKAA","T1V, T13G, T14A, S8G","T827V, T839G, T840A, S834G","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Escape variant vIHTDNGgNFTSgaVKAA was seen in patient I09, and suppression of this antigen was accompanied by a decline in CD38/PD-1 co-expression on HIV-1-specific CTL.","Vollbrecht2010"
"58601","HF8","3076","B","B","B","Pol","829","836","Integrase(114-121)","4569..4592","Cw*05","HTDNGSNF","HTDNGrNF","S6R","S834R","A, RCR","HLA association, replicative capacity reduced","CD8 T-cell Elispot - IFNy, Relative replication capacity assay, Sequence","The S119R polymorphism exhibited an &#152;35% lower RC than parental NL4-3 in recombinants carrying mutant, HTDNGrNF.","Brockman2012"
"58601","HF8","3077","B","B","B","Pol","829","836","Integrase(114-121)","4569..4592","Cw*05","{A...}HTDNGSNF","{e...}HTDNGrNF","A-28E, S6R","A806E, S834R","A, RCOK, SF","HLA association, replicative capacity is not abrogated, susceptible form","CD8 T-cell Elispot - IFNy, Relative replication capacity assay, Sequence","Double A91E, S119R mutant recombinants exhibited an RC comparable to wild-type RC, confirming A91E as an upstream secondary compensatory mutation for S119R HF8.  No A91E mutation alone occurred naturally in any patient in this study, as it was always associated with S119R.","Brockman2012"
"58601","HF8","3078","B","B","B","Pol","829","836","Integrase(114-121)","4569..4592","Cw*05","HTDNGSNF","HTDNGpNF","S6P","S834P","OV","observed variant","Sequence","The S119P variant, HTDNGpNF, was seen in some C*05-carrying patients.","Brockman2012"
"57955","SW10","2685","B","B","B","Pol","838","847","Integrase(123-132)","4596..4625","B*5701","STTVKAACWW","STaVKAACWW","T3A","T840A","E, LE","escape documented in this paper, literature escape","CD8 T-cell Elispot - IFNy","STTVKAACWW underwent classical escape, with adapted forms STaVKAACWW and SnTVKAACWW having abrogated EliSpot responses.","Keane2012"
"57955","SW10","2686","B","B","B","Pol","838","847","Integrase(123-132)","4596..4625","B*5701","STTVKAACWW","SnTVKAACWW","T2N","T839N","E, LE","escape documented in this paper, literature escape","CD8 T-cell Elispot - IFNy","STTVKAACWW underwent classical escape, with adapted forms STaVKAACWW and SnTVKAACWW having abrogated EliSpot responses.","Keane2012"
"59140","SW10","3304","B","B","B","Pol","838","847","Integrase(123-132)",,"B*57","STTVKAACWW","SaTVKAACWW","T2A","T839A","OV","observed variant","Sequence","B*57-restricted variant SaTVKAACWW in the 1999 Berlin patient found circulating 15 years post-end of ART.","Jessen2014"
"58650","ER10","3080","B","B","B","Pol","872","881","Integrase(157-166)","4698..4727","A*33","ELKKIIGQVR","ELKKIIeQVR","G7E","G878E","A, RCR","HLA association, replicative capacity reduced","CD8 T-cell Elispot - IFNy, Relative replication capacity assay, Sequence","Variant ELKKIIeQVR is shown to be statistically linked to reduced RC.","Brockman2012"
"52828","A3-AK10 Pol","47","B","","","Pol","894","903","Integrase(179-188)","4764..4793","A3","AVFIHNFKRK","AVFvHNFKRK","I4V","I897V","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","Superinfection. The second infecting strain had the variant avfVhnfkrk. The CTL response to the second variant was zero at all timepoints. The CTL response to the first variant was low and declined over time.","Altfeld2002a"
"57769","KY9","2635","B","B","B","Pol","901","909","Integrase(186-194)","4785..4811","B*2705","KRKGGIGGY","KkKGGIGGY","R2K","R902K","DHB, DR, E","diminished HLA binding or increased off-rate, diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding, Intracellular cytokine staining, Longitudinal study","Mutant R2K was enriched among B*2705-positive individuals. The mutant was associated with reduced recognition and severely reduced binding affinity. Longitudinal analysis showed increase of this mutant over time, 18-months post infection.","Payne2010"
"57769","KY9","2636","B","B","B","Pol","901","909","Integrase(186-194)","4785..4811","B*2705","KRKGGIGGY","KRrGGIGGY","K3R","K903R","DHB, DR, E","diminished HLA binding or increased off-rate, diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding, Intracellular cytokine staining, Longitudinal study","Mutant K3R was enriched among B*2705-positive individuals and absent in B*27- subjects. The mutant was associated with reduced recognition and reduced binding affinity. Longitudinal analysis did not show increase of this mutant over time.","Payne2010"
"57769","KY9","2637","B","B","B","Pol","901","909","Integrase(186-194)","4785..4811","B*2705","KRKGGIGGY","KRKGGIGeY","G8E","G908E","DHB, DR, E","diminished HLA binding or increased off-rate, diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding, Intracellular cytokine staining, Longitudinal study","Mutant G8E was enriched among B*2705-positive individuals. The mutant was associated with reduced recognition and reduced binding affinity. Longitudinal analysis showed increase of this mutant over time, during the first 6 months post-infection.","Payne2010"
"55073",,"216","B, C","B","C","Pol","933","942","Integrase(218-227)","4881..4910","B*1503","TKIQNFRVYY","iKIQNFRVYY","T1I","T933I","SNSF","subtype-specific non-susceptible form","","TKIQNFRVYY epitope is found in subtype B, while the variant is found in subtype C. Subtype B epitope is significantly more frequently recognized by  B*1503 positive individuals than the variant C epitope.","Frahm2006"
"55077",,"217","B, C","B","C","Pol","978","986","Integrase(263-271)","5016..5042","B*1503","RKAKIIRDY","RKAKIIkDY","R7K","R984K","SNSF","subtype-specific non-susceptible form","","RKAKIIRDY epitope is found in subtype B, while the variant is found in subtype C. Subtype B epitope is significantly more frequently recognized by  B*1503 positive individuals than the variant C epitope.","Frahm2006"
"58707","Int-IM9","3116","C","C","C","Pol","982","990","Integrase(267-275)","5028..5054","B*4201","IIKDYGKQM","IIxDYGKQM","K3X","K984X","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","Novel epitope, IM9 does accumulate mutations at position 3, IIxDYGKQM. The authors designate this variant as an escape when presented by HLA-B*4201.","Kloverpris2012a"
"52813","A3-RK10 Vif","48","B","","","Vif","17","26","","5089..5118","A3","RIRTWKSLVK","RIsTWKSLVK","R3S","R19S","SF","susceptible form","CD8 T-cell Elispot - IFNy","Superinfection. The second infecting strain had the variant riStwkslvk. The initial CTL response persisted against both variants after the superinfection was established.","Altfeld2002a"
"52673","Vif23(9V)","123","","","","Vif","23","31","","5107..5133","A2","SLVKHHMYV","SLVKHHMYi","V9I","V31I","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, Flow cytometric T-cell cytokine assay","This peptide was a good A2 binder, and induced CTL and CD8+ T-cell IFN gamma responses in mice. Response was detected in 1/17 HIV+ HLA-A2 subjects. The variant slvkhhmyI was an intermediate A2 binder, and stimulated immune responses in fewer A2 transgenic mice. The same person recognized both variants.","Corbet2003"
"56070","Vif 23 (9I)","206","","","","Vif","23","31","","5107..5133","A2","SLVKHHMYI","SLVKHHMYv","I9V","I31V","OV","observed variant","","One HLA-A2 patient did not respond to the SLVKHHMYI epitope but the variant peptide was observed in the patient.","Fomsgaard2008"
"55386","VIf 23(9I)","1698","","","","Vif","23","31","","5107..5133","A2","SLVKHHMYI","SLVKHHMYv","I9V","I31V","SF","susceptible form","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","This 9I variant and 9V consensus epitope cross-reacted in A2 transgenic mice. Subjects Pt18 and Pt41 carried the HXB2 epitope SLVKHHMYV and were unable to recognize either the HXB2 or 9I variant form. Subjects Pt17, Pt23 and Pt43 carried the 9I variant form, and while Pt17 and Pt23 were unable to recognize either form, Pt 43 was able to recognize both the consensus and 9I variant.","Thorn2007"
"55386","VIf 23(9I)","1699","","","","Vif","23","31","","5107..5133","A2","SLVKHHMYI","SvVKHHMYI","L2V","L24V","SF","susceptible form","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","This 2V variant was the most immunogenic of all epitopes studied and it cross-reacted with the 9I variant, SLVKHHMYi.","Thorn2007"
"56146",,"2276","C","","","Vif","32","40","","5134..5160","B*1503","SKRASGWFY","SgRASGWFY","K2G","K33G","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"56146",,"2277","C","","","Vif","32","40","","5134..5160","B*1503","SKRASGWFY","SqRASGWFY","K2Q","K33Q","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"56146",,"2278","C","","","Vif","32","40","","5134..5160","B*1503","SKRASGWFY","SrRASGWFY","K2R","K33R","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"58683",,"3090","C","C","C","Vif","32","40","","5134..5160","B*1503","SKRASGWFF","SqRASGWFF","K2Q","K33Q","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"58683",,"3091","C","C","C","Vif","32","40","","5134..5160","B*1503","SKRASGWFF","SrRASGWFF","K2R","K33R","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"58683",,"3092","C","C","C","Vif","32","40","","5134..5160","B*1503","SKRASGWFF","SgRASGWFF","K2G","K33G","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"57543","S10EV","2544","","","","Vif","46","55","","5176..5205","B*07","SPHPRISSEV","StHPRISSEV","P2T","P47T","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, HLA binding","Intersubtype variant StHPRISSEV exhibited good cross-recognition in mice immunized with SPHPRISSEV.","Cardinaud2009"
"52823","B7-HM0 Vif","49","B","","","Vif","48","57","","5182..5211","B7","HPRISSEVHI","HPkISSEVHI","R3K","R50K","SF","susceptible form","CD8 T-cell Elispot - IFNy","Superinfection. The second infecting strain had the variant hpKissevhi. The CTL response was equal against both variants, and declined over time.","Altfeld2002a"
"57544","H10HI","2545","","","","Vif","48","57","","5182..5211","B*07","HPRISSEVHI","HPkISSEVHI","R3K","R50K","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, HLA binding","Intersubtype variants HPkISSEVHI and HPRvSSEVHI exhibited low cross-recognition in mice immunized with HPRISSEVHI.","Cardinaud2009"
"57544","H10HI","2546","","","","Vif","48","57","","5182..5211","B*07","HPRISSEVHI","HPRvSSEVHI","I4V","I51V","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, HLA binding","Intersubtype variants HPkISSEVHI and HPRvSSEVHI exhibited low cross-recognition in mice immunized with HPRISSEVHI.","Cardinaud2009"
"59041","HI10-Vif","3221","B","B","C","Vif","48","57","","5182..5211","B*0702","HPRISSEVHI","HPkISSEVHI","R3K","R50K","SNSF","subtype-specific non-susceptible form","HLA binding","C-clade variant of Vif-HI10, HPkISSEVHI, is not recognized by any C-clade infected individuals.  It's binding coefficient for HLA-B*0702 is 178 nM..","Kloverpris2014"
"58709","Vif-HI10","3115","C","C","C","Vif","48","58","","5182..5214","B*4201","HPKVSSEVHIa","xPKVSSEVHIa","H1X","H48X","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","Mutations at position 1, xPKVSSEVHIa, were detected.  The authors designate this variant as an escape when presented by HLA-B*4201.","Kloverpris2012a"
"57545","I10VI","2547","","","","Vif","57","66","","5209..5238","B*07","IPLGDARLVI","IPLGDARLVv","I10V","I66V","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, HLA binding","Intersubtype variant IPLGDARLVv exhibited good cross-recognition in mice immunized with IPLGDARLVI.","Cardinaud2009"
"53597","DY9","61","B","","","Vif","61","69","","5221..5247","B*3501","DAKLIITTY","DAKLIIkTY","T7K","T67K","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Chromium-release assay, Intracellular cytokine staining","The peptide that carries this epitope was recognized early in infection but the response diminished over time. A point mutation of epitope position 7 (T to K, DAKLIIkTY) was detected at high frequency at a chronic infection timepoint, 34 months. The K variant was an escape form, and had low avidity by gamma IFN EliSpot.","Bansal2005a"
"54653","VIF-09","2270","B","B","C","Vif","64","81","","5230..5283","","LVITTYWGLHTGERDWHL","LVIkTYWGLqTGERDWHL","H10Q, T4K","H73Q, T67K","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 3 amino acids (16.7%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"53878",,"1873","B","B","A","Vif","73","81","","5257..5283","B*35","HTGERDWHL","HpGERDWHL","T2P","T74P","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Autologous variant differed from the Strain B consensus, but was recognized.","Yang2005"
"54654","VIF-13","1969","B","B","C","Vif","93","110","","5317..5370","","RYSTQVDPGLADQLIHLY","RYSTQVePGLADQLIHmh","L17M, Y18H, D7E","L109M, Y110H, D99E","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 3 amino acids (16.7%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"52665","Vif101(9L)","124","","","","Vif","101","109","","5341..5367","A2","GLADQLIHL","GLADQLIHm","L9M","L109M","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, Flow cytometric T-cell cytokine assay","This peptide was a good A2 binder that induced CTL and CD8+ T-cell IFN gamma responses in mice. Responses were detected in 3/17 HIV+ HLA-A2 subjects. The variant gladqlihM was an intermediate A2 binder, but still could stimulate a response in HLA-A2 transgenic mice. It was not recognized by the 3 people who recognized GLADQLIHL.","Corbet2003"
"56072","Vif 101 (9L)","207","","","","Vif","101","109","","5341..5367","A2","GLADQLIHL","dLADQLIHL","G1D","G101D","OV","observed variant","","One HLA-A2 patient did not respond to the GLADQLIHL epitope but the variant peptide was observed in the patient.","Fomsgaard2008"
"55387","VIf 101(9L)","1700","","","","Vif","101","109","","5341..5367","A2","GLADQLIHL","nLADQLIHL","G1N","G101N","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subjects Pt16, Pt17 carried this variant and were unable to recognize the 9M variant GLADQLIHL.  Pt 17 also did not recognize the challenge 9L HXB2 epitope, but Pt16 did recognize it.","Thorn2007"
"55387","VIf 101(9L)","1701","","","","Vif","101","109","","5341..5367","A2","GLADQLIHL","dLADhLIHL","G1D, Q5H","G101D, Q105H","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt18 carried this variant and was unable to recognize both the 9L HXB2 epitope GLADQLIHL, as well as the 9M variant GLADQLIHM.","Thorn2007"
"55387","VIf 101(9L)","1702","","","","Vif","101","109","","5341..5367","A2","GLADQLIHL","dLADQLIHL","G1D","G101D","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subjects Pt 21, Pt23, Pt33 carried this variant and were unable to recognize the 9M variant GLADQLIHM.  Pt21 and Pt33 were also unable to recognize the HXB2 epitope GLADQLIHL, but Pt23 was able to recognize it.","Thorn2007"
"55387","VIf 101(9L)","1703","","","","Vif","101","109","","5341..5367","A2","GLADQLIHL","evADQLIHL","G1E, L2V","G101E, L102V","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt30 carried this variant and did not recognize either the challenge HXB2 epitope GLADQLIHL, or the 9M variant GLADQLIHM.","Thorn2007"
"55387","VIf 101(9L)","1704","","","","Vif","101","109","","5341..5367","A2","GLADQLIHL","sLADQLIHL","G1S","G101S","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt35 carried this variant and did not recognize either the challenge HXB2 epitope GLADQLIHL, or the 9M variant GLADQLIHM.","Thorn2007"
"55387","VIf 101(9L)","1705","","","","Vif","101","109","","5341..5367","A2","GLADQLIHL","GLADrLIHL","Q5R","Q105R","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt43 carried this variant and did not recognize either the challenge HXB2 epitope GLADQLIHL, or the 9M variant GLADQLIHM.","Thorn2007"
"55387","VIf 101(9L)","1706","","","","Vif","101","109","","5341..5367","A2","GLADQLIHL","hLADQLIHq","G1H, L9Q","G101H, L109Q","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt41 carried this variant and did not recognize the challenge HXB2 epitope GLADQLIHL, however it did recognize the 9M variant GLADQLIHM.","Thorn2007"
"55387","VIf 101(9L)","1707","","","","Vif","101","109","","5341..5367","A2","GLADQLIHL","GLADQLIHm","L9M","L109M","SF","susceptible form","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt41 carried hLADQLIHq variant and did not recognize the challenge HXB2 epitope GLADQLIHL, however it did recognize the 9M variant GLADQLIHm.","Thorn2007"
"58249",,"2852","B","B","B","Vif","113","130","","5377..5430","","DCFSESAIRGAILGHIVS","DCFSESAIRrAILGHIVS","G10R","G122R","IE","inferred escape","Sequence","Peptide DCFSESAIRGAILGHIVS varied at 101 DFOSx to DCFSESAIRrAILGHIVS.  Position 122 in the peptide is marked as being under selection to vary.","Ferrari2011"
"58249",,"2853","B","B","B","Vif","113","130","","5377..5430","","DCFSESAIRGAILGHIVS","DCFSdSAIRrAILGHIVS","G10R, E5D","G122R, E117D","IE","inferred escape","Sequence","Peptide DCFSESAIRGAILGHIVS varied from 101 DFOSx onwards to DCFSdSAIRrAILGHIVS.  Positions 117 and 122 in the peptide are marked as being under selection to vary.","Ferrari2011"
"56658",,"2083","","","","Vif","119","127","","5395..5421","","AIRKAILGR","AIRKAlLGR","I6L","I124L","IE","inferred escape","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Patient CH40 carried this mutant, and at the same time lost response to the original epitope.","Goonetilleke2009"
"56658",,"2084","","","","Vif","119","127","","5395..5421","","AIRKAILGR","AIRKAIvGR","L7V","L125V","IE","inferred escape","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Patient CH40 carried this mutant, and at the same time lost response to the original epitope.","Goonetilleke2009"
"56658",,"2085","","","","Vif","119","127","","5395..5421","","AIRKAILGR","AIRtAILGR","K4T","K122T","IE","inferred escape","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Patient CH40 carried this mutant, and at the same time lost response to the original epitope.","Goonetilleke2009"
"56658",,"2086","","","","Vif","119","127","","5395..5421","","AIRKAILGR","AIReAILGR","K4E","K122E","IE","inferred escape","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Patient CH40 carried this mutant, and at the same time lost response to the original epitope.","Goonetilleke2009"
"56658",,"2329","","","","Vif","119","127","","5395..5421","","{ES}AIRKAILGR","{dS}AIReAILGR","E-2D, K4E","E117D, K122E","IE, P","inferred escape, processing","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Patient CH40 carried this mutant, and at the same time lost response to the original epitope.","Goonetilleke2009"
"58227",,"2790","B","B","B","Vif","119","127","","5395..5421","A*3101","AIRKAILGR","AIRtAILGR","K4T","K122T","IE","inferred escape","Sequence","4/7 sequences of epitope AIRKAlLGR varied at 181 DFOSx to AIRtAlLGR.  Position 122 is marked as being selected to vary.","Ferrari2011"
"58227",,"2791","B","B","B","Vif","119","127","","5395..5421","A*3101","AIRKAILGR","AIReAILGR","K4E","K122E","IE","inferred escape","Sequence","9/12 sequences of epitope AIRKAlLGR varied at 412 DFOSx to AIReAlLGR.  Position 122 is marked as being selected to vary.","Ferrari2011"
"53534","HY9","38","B","","","Vif","127","135","","5419..5445","A29","HIVSPRCEY","HIgSPRCEY","V3G","V129G","SF","susceptible form","CD8 T-cell Elispot - IFNy","Longitudinal study of four clade B-infected patients studied for up to 5 years after acute infection. This mutation was observed in a CD8 targeted  epitope in subject AC-16 who caries HLA-A29. Response could only be detected with autologous peptide.","Allen2005a"
"56073","Vif 149","208","","","","Vif","149","157","","5485..5511","A2","ALAALITPK","ALkALviPt","A3K, I6V, T7I, K9T","A151K, I154V, T155I, K157T","OV","observed variant","","One HLA-A2 patient did not respond to the ALAALITPK epitope but the variant peptide was observed in the patient.","Fomsgaard2008"
"55388","VIf 149","1679","","","","Vif","149","157","","5485..5511","A2","ALAALITPK","ALtALITPK","A3T","A151T","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subjects Pt18, Pt30 carried this variant and were unable to recognize the challenge HXB2 form, ALAALITPK.","Thorn2007"
"55388","VIf 149","1680","","","","Vif","149","157","","5485..5511","A2","ALAALITPK","ALtALIkPK","A3T, T7K","A151T, T155K","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt15 carried this variant and was unable to recognize the challenge HXB2 form, ALAALITPK.","Thorn2007"
"55388","VIf 149","1681","","","","Vif","149","157","","5485..5511","A2","ALAALITPK","ltAALtkPK","A1L, L2T, I6T, T7K","A149L, L150T, I154T, T155K","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt21 carried this variant and was unable to recognize the challenge HXB2 form, ALAALITPK.","Thorn2007"
"55388","VIf 149","1682","","","","Vif","149","157","","5485..5511","A2","ALAALITPK","ALtALIatK","A3T, T7A, P8T","A151T, T155A, P156T","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt23 carried this variant and was unable to recognize the challenge HXB2 form, ALAALITPK.","Thorn2007"
"55388","VIf 149","1684","","","","Vif","149","157","","5485..5511","A2","ALAALITPK","ALAAvITPK","L5V","L153V","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt43 carried this variant and was unable to recognize the challenge HXB2 form, ALAALITPK.","Thorn2007"
"55388","VIf 149","1685","","","","Vif","149","157","","5485..5511","A2","ALAALITPK","ALAALvTPK","I6V","I154V","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt17 carried this variant and was unable to recognize the challenge HXB2 form, ALAALITPK.","Thorn2007"
"55388","VIf 149","1686","","","","Vif","149","157","","5485..5511","A2","ALAALITPK","ALAALIrPK","T7R","T155R","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt33 carried this variant and cross-recognized the challenge HXB2 form, ALAALITPK.","Thorn2007"
"52675","Vif158(2I)","125","","","","Vif","158","166","","5512..5538","A2","KIKPPLPSV","KtKPPLPSV","I2T","I159T","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, Flow cytometric T-cell cytokine assay","This peptide was a good A2 binder, and induced CD8+ T-cell IFN gamma responses in mice. Responses were detected in 1/17 HIV+ HLA-A2 subjects. The substitution kTkpplpsv was also a good binder, but did not elicit a response in transgenic mice, and no response to this variant was detected among the 17 HIV+ people tested.","Corbet2003"
"56074","Vif 158(2I)","209","","","","Vif","158","166","","5512..5538","A2","KIKPPLPSV","rtKPPLPSV","K1R, I2T","K158R, I159T","OV","observed variant","","One HLA-A2 patient did not respond to the KIKPPLPSV epitope but the variant peptide was observed in the patient.","Fomsgaard2008"
"55389","VIf 158(2I)","1708","","","","Vif","158","166","","5512..5538","A2","KIKPPLPSV","KtKPPLPSV","I2T","I159T","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subjects Pt35 and Pt41 carried this HXB2 epitope and did not recognize it; Subjects Pt16, Pt18, Pt23, Pt33, Pt43 carried the 2T variant and did not recognize either this 2T variant or the challenge HXB2.  Only Subject Pt30 who also carried the 2T variant was able to cross-recognize the HXB2 epitope, KIKPPLPSV.","Thorn2007"
"55389","VIf 158(2I)","1709","","","","Vif","158","166","","5512..5538","A2","KIKPPLPSV","KrKPPLPSV","I2R","I159R","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt15 carried this variant and was unable to recognize both the 2T variant, KtKPPLPSV, as well as the HXB2 form.  Subject Pt17 who carried this variant did not recognize the 2I challenge HXB2 epitope.","Thorn2007"
"55389","VIf 158(2I)","1710","","","","Vif","158","166","","5512..5538","A2","KIKPPLPSV","KriPPLPSV","I2R, K3I","I159R, K160I","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt17 carried this variant and was not able to recognize the 2T, KtKPPLPSV, variant epitope.","Thorn2007"
"55389","VIf 158(2I)","1711","","","","Vif","158","166","","5512..5538","A2","KIKPPLPSV","rttPPLPSi","K1R, I2T, K3T, V9I","K158R, I159T, K160T, V166I","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt21 carried this variant epitope and was not able to recognize the challenge HXB2 form.","Thorn2007"
"55389","VIf 158(2I)","1712","","","","Vif","158","166","","5512..5538","A2","KIKPPLPSV","rItPPLPSi","K1R, K3T, V9I","K158R, K160T, V166I","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt21 carried this variant was not able to recognize the 2T variant form, KTKPPLPSV.","Thorn2007"
"52814",,"50","B","","","Vif","158","168","","5512..5544","A3","RRKPPLPSIAK","RtKPPLPSvtK","A10T, R2T, I9V","A167T, R159T, I166V","SF","susceptible form","CD8 T-cell Elispot - IFNy","Superinfection. The second infecting strain had the variant rTkpplpsVTk. The patient maintained persistent reactive CTL against both variants after the superinfection was established.","Altfeld2002a"
"56038","RL9(Vpr)","1926","B","B","B","Vpr","12","20","","5592..5618","","REPYNEWTL","REPhNEWTL","Y4H","Y15H","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B40 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"53519","TN10","39","B","","","Vpr","19","28","","5613..5642","A3?","TLEILEELKN","aLEILEELKN","T1A","T19A","SF","susceptible form","CD8 T-cell Elispot - IFNy","Longitudinal study of four clade B-infected patients studied for up to 5 years after acute infection. This mutation was observed in a CD8 targeted  partially mapped novel epitope in subject AC-38 who caries HLA-A3. Responses could only be detected with autologous peptide.","Allen2005a"
"54155","EI9","968","B","","","Vpr","29","37","","5643..5669","B*5101","EAVRHFPRI","EAVRHFPRt","I9T","I37T","DR","diminished response","CD8 T-cell Elispot - IFNy","Last position (9)in the epitope had potentially experienced positive selection. Wt form of the epitope was 43 times better recognized than the variant, making the variant a partial escape.","Liu2006"
"54155","EI9","969","B","","","Vpr","29","37","","5643..5669","B*5101","EAVRHFPRI","EAVRHFPRl","I9L","I37L","DR","diminished response","CD8 T-cell Elispot - IFNy","Last position (9)in the epitope had potentially experienced positive selection. Wt form of the epitope was 18 times better recognized than the variant, making the variant a partial escape.","Liu2006"
"58012","EI9","2711","B","B","B","Vpr","29","37","","5643..5669","B*51","EAVRHFPRI","EAVRHFPRt","I9T","I37T","A, P","HLA association, processing","","B51-EI9 has known HLA-associated mutants (I9T, I9A). Both mutants displayed severely reduced half-lives.","Lazaro2011"
"58012","EI9","2712","B","B","B","Vpr","29","37","","5643..5669","B*51","EAVRHFPRI","EAVRHFPRa","I9A","I37A","A, P","HLA association, processing","","B51-EI9 has known HLA-associated mutants (I9T, I9A). Both mutants displayed severely reduced half-lives.","Lazaro2011"
"58147","EI9","2729","B","B","B","Vpr","29","37","","5643..5669","B*5101","EAVRHFPRI","EAVRHFPRt","I9T","I37T","DR","diminished response","CD8 T-cell Elispot - IFNy, Longitudinal study","Variant EAVRHFPRt arose early in infection, then disappeared, while EAVRHFPRl dominated by 200 days post-infection. Sequence changes were associated with loss of EliSpot response to the epitope.","Liu2011a"
"58147","EI9","2730","B","B","B","Vpr","29","37","","5643..5669","B*5101","EAVRHFPRI","EAVRHFPRl","I9L","I37L","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Longitudinal study","Variant EAVRHFPRt arose early in infection, then disappeared, while EAVRHFPRl dominated by 200 days post-infection. Sequence changes were associated with loss of EliSpot response to the epitope.","Liu2011a"
"59086",,"3255","B","B","B","Vpr","29","37","",,"B*5101","EAVRHFPRI","EAVRHFPRt","I9T","I37T","DR","diminished response","Peptide titration","Ratio of EliSpot peptide titration of this mutant to original epitope EC<sub>50</sub>ratio = 43, suggesting partial escape.","Liu2007a"
"59086",,"3256","B","B","B","Vpr","29","37","",,"B*5101","EAVRHFPRI","EAVRHFPRl","I9L","I37L","DR","diminished response","Peptide titration","Ratio of EliSpot peptide titration of this mutant to original epitope EC<sub>50</sub>ratio = 18, suggesting partial escape.","Liu2007a"
"59141","AW9","3303","B","B","B","Vpr","30","38","",,"B*57","AVRHFPRIW","AVRHFPRvW","I8V","I37V","OV","observed variant","Sequence","B*57-restricted variant AVRHFPRvW in the 1999 Berlin patient found circulating 15 years post-end of ART.","Jessen2014"
"52825","B7-FL9 Vpr","51","B","","","Vpr","34","42","","5658..5684","B7","FPRTWLHGL","FPwTWLHGL","R3W","R36W","DR","diminished response","CD8 T-cell Elispot - IFNy","Superinfection. The second infecting strain had the variant fpWtwlhgl. The CTL response declined over time and the response to the second variant was lower than to the first one all the time points.","Altfeld2002a"
"56075","Vpr34","210","","","","Vpr","34","42","","5658..5684","A2","FPRPWLHGL","FPRPWLHsL","G8S","G41S","OV","observed variant","","One HLA-A2 patient did not respond to the FPRPWLHGL epitope but the variant peptide was observed in the patient.","Fomsgaard2008"
"55390","Vpr 34","1713","","","","Vpr","34","42","","5658..5684","A2","FPRPWLHGL","FPRmWLHsL","P4M, G8S","P37M, G41S","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt15 carried this variant epitope in a regulatory/accessory protein, and recognized the HXB2 epitope FPRPWLHGL.","Thorn2007"
"55390","Vpr 34","1714","","","","Vpr","34","42","","5658..5684","A2","FPRPWLHGL","FPRiWLHsL","P4I, G8S","P37I, G41S","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt23 carried this variant epitope in a regulatory/accessory protein, and recognized the HXB2 epitope FPRPWLHGL.","Thorn2007"
"55390","Vpr 34","1715","","","","Vpr","34","42","","5658..5684","A2","FPRPWLHGL","FPPtWLHnL","R3P, P4T, G8N","R36P, P37T, G41N","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt16 carried this variant epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope FPRPWLHGL.","Thorn2007"
"55390","Vpr 34","1716","","","","Vpr","34","42","","5658..5684","A2","FPRPWLHGL","FPRvWLHnL","P4V, G8N","P37V, G41N","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt18 carried this variant epitope in a regulatory/accessory protein, and did not recognize the challenge HXB2 epitope FPRPWLHGL.","Thorn2007"
"55390","Vpr 34","1717","","","","Vpr","34","42","","5658..5684","A2","FPRPWLHGL","FPRvWLHGL","P4V","P37V","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt21 carried this variant epitope in a regulatory/accessory protein, and did not recognize the challenge HXB2 epitope FPRPWLHGL.","Thorn2007"
"55390","Vpr 34","1718","","","","Vpr","34","42","","5658..5684","A2","FPRPWLHGL","FPRiWLHnL","P4I, G8N","P37I, G41N","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subjects Pt30, Pt35 carried this variant epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope FPRPWLHGL.","Thorn2007"
"55390","Vpr 34","1719","","","","Vpr","34","42","","5658..5684","A2","FPRPWLHGL","FPRtWLHsL","P4T, G8S","P37T, G41S","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt41 carried this variant epitope in a regulatory/accessory protein, and did not recognize the challenge HXB2 epitope FPRPWLHGL.","Thorn2007"
"55390","Vpr 34","1720","","","","Vpr","34","42","","5658..5684","A2","FPRPWLHGL","FPRmWLHnL","P4M, G8N","P37M, G41N","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt43 carried this variant epitope in a regulatory/accessory protein, and did not recognize the challenge HXB2 epitope FPRPWLHGL.","Thorn2007"
"55981","FL9(Vpr)","1927","B","B","B","Vpr","34","42","","5658..5684","B7","FPRPWLHGL","FPRiWLHGL","P4I","P37I","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B7 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"57535","F9GL","2539","","","","Vpr","34","42","","5658..5684","B*07","FPRIWLHGL","FPRpWLHGL","I4P","I37P","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, HLA binding","Intersubtype variants FPRpWLHGL and FPRIWLHsL exhibited good cross-recognition in mice immunized with FPRIWLHGL.","Cardinaud2009"
"57535","F9GL","2540","","","","Vpr","34","42","","5658..5684","B*07","FPRIWLHGL","FPRIWLHsL","G8S","G41S","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, HLA binding","Intersubtype variants FPRpWLHGL and FPRIWLHsL exhibited good cross-recognition in mice immunized with FPRIWLHGL.","Cardinaud2009"
"58710","Vpr-FL9","3114","C","C","C","Vpr","34","42","","5658..5684","B*4201, B*4202","FPRPWLHGL","FPRPWLHxL","G8X","G41X","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","Mutations at position 8 in Vpr-FL9, FPRPWLHxL, were detected, but only for HLA-B*4201-positive subjects (75% of B*4201 subjects). The authors designate this variant as an escape when presented by HLA-B*4201.","Kloverpris2012a"
"59052","FL9-Vpr","3225","B","B","C","Vpr","34","42","","5658..5684","B*0702","FPRIWLHSL","FPRpWLHgL","I4P, S8G","I37P, S41G","SSF","subtype-specific susceptible form","HLA binding","Variant FL9, FPRpWLHgL, a C-clade Vpr epitope was targeted by C-clade infected subjects more robustly than the B-clade variant FL9.  The affinity of C-clade FL9 to B*0702 was K<sub>d</sub> = 6 nM.  Clade-C FL9 is contained within OLP281, ELKQEAVRHFPRpWLHgL.","Kloverpris2014"
"55391","Vpr 41","1721","","","","Vpr","41","49","","5679..5705","A2","SLGQHIYET","SLGQHIYnT","E8N","E48N","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt15 carried this variant epitope in a regulatory/accessory protein, and did not recognize the challenge HXB2 epitope SLGQHIYET.","Thorn2007"
"55391","Vpr 41","1722","","","","Vpr","41","49","","5679..5705","A2","SLGQHIYET","nLGQyIYET","S1N, H5Y","S41N, H45Y","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt16, Pt30 carried this variant epitope in a regulatory/accessory protein, and did not recognize the index epitope SLGQHIYET.","Thorn2007"
"55391","Vpr 41","1723","","","","Vpr","41","49","","5679..5705","A2","SLGQHIYET","nLGQHIYET","S1N","S41N","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subjects Pt18, Pt43 carried this variant epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope SLGQHIYET.","Thorn2007"
"55391","Vpr 41","1724","","","","Vpr","41","49","","5679..5705","A2","SLGQHIYET","nLGQfIYET","S1N, H5F","S41N, H45F","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt35 carried this variant epitope in a regulatory/accessory protein, and did not recognize the challenge HXB2 epitope SLGQHIYET.","Thorn2007"
"55391","Vpr 41","1725","","","","Vpr","41","49","","5679..5705","A2","SLGQHIYET","SLGQyIYaT","H5Y, E8A","H45Y, E48A","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt41 carried this variant epitope in a regulatory/accessory protein, and did not recognize the challenge HXB2 epitope SLGQHIYET.","Thorn2007"
"55391","Vpr 41","1726","","","","Vpr","41","49","","5679..5705","A2","SLGQHIYET","gLGQHIYET","S1G","S41G","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subjects Pt17, Pt21, Pt33 carried this variant epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope SLGQHIYET.","Thorn2007"
"55969","EV10(Vpr)","1928","B","B","B","Vpr","48","57","","5700..5729","","ETYGDTWAGV","ETYGDTWtGV","A8T","A55T","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"59035","Vpr-EV10","3217","C","C","C","Vpr","48","57","","5700..5729","A*6802","ETYGDTWTGV","dTYGDTWTGV","E1D","E48D","OV","observed variant","Sequence","The E48D variant of Vpr EV10, dTYGDTWTGV was observed in 53% of A*6802+ subjects as compared to 16% of A*6802- subjects.","Kloverpris2013c"
"53475","AL9","35","B","","","Vpr","59","67","","5733..5759","A2","ALIRILQQL","ALIRsLQQL","I5S","I63S","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Intracellular cytokine staining","Variant resulted in dramatic loss of the original CD8 response.","Allen2005"
"53577",,"53","B","","","Vpr","59","67","","5733..5759","A2","ALIRILQQL","AiIRILQQL","L2I","L60I","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","CD8 T-cell Elispot - IFNy, Chromium-release assay, HLA binding","ALIRILQQL bound substantially better to HLA-A2 superfamily than variant AIIRILQQL.  Either the virus in all of the individuals mounting a Vpr59-67-specific CD8+ T-cell response exhibited very early escape from the I60 to the I60L prior to first sequencing or only individuals infected with the I60L variant were able to develop epitope-specific CD8+ T-cell responses during primary infection.","Altfeld2005a"
"55284",,"1509","B","","","Vpr","59","67","","5733..5759","A*0201","AIIRILQQL","AIlRILQQL","I3L","I61L","OV","observed variant","Sequence","This index epitope was conserved in the mother's viral strain but mutated in the daughter's isolate.","Reinis2007"
"57962","AL9","2693","B","B","B","Vpr","59","67","","5733..5759","A*0201","ALIRILQQL","AiIRILQQL","L2I","L60I","SF","susceptible form","CD8 T-cell Elispot - IFNy","ALIRILQQL underwent adaptation to neo-epitope AiIRILQQL. 1 subject had higher EliSpot responses to the neo-epitope than to the non-adapted form.","Keane2012"
"58011","AL9","2710","B","B","B","Vpr","59","67","","5733..5759","A*02","AIIRILQQL","AIIRtLQQL","I5T","I63T","A, P","HLA association, processing","","A2-AL9 has a known HLA-associated mutant (I5T). The wild type epitope displayed a moderate half-life, and the mutant displayed a reduced half-life.","Lazaro2011"
"53070","Vpr 62","1126","M","B, C","C","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","RlLQQLLFI","I2L","I63L","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This anchor position variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53070","Vpr 62","1127","M","B, C","C","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","RvLQQLLFI","I2V","I63V","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This anchor position variant elicited a CTL response with cells from mice immunized with the index form.","McKinney2004"
"53070","Vpr 62","1128","M","B, C","B, C","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","RtLQQLLFI","I2T","I63T","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This anchor position variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53070","Vpr 62","1129","M","B, C","B, C","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","RmLQQLLFI","I2M","I63M","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This anchor position variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53070","Vpr 62","1130","M","B, C","C","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","RILQQLLFv","I9V","I70V","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This anchor position variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53070","Vpr 62","1131","M","B, C","C","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","RILQQLLFt","I9T","I70T","DHB, SF","diminished HLA binding or increased off-rate, susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This anchor position variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.  Binding to HLA is at a very low level.","McKinney2004"
"53070","Vpr 62","1132","M","B, C","","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","RILQQLLFa","I9A","I70A","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This anchor position variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.  Binding to HLA is at a very low level.","McKinney2004"
"53070","Vpr 62","1133","M","B, C","C","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","kILQQLLFI","R1K","R62K","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This non-anchor position variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53070","Vpr 62","1134","M","","","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","tILQQLLFI","R1T","R62T","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This non-anchor position variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53070","Vpr 62","1135","M","B, C","","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","RILQQmLFI","L6M","L67M","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This non-anchor position variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53070","Vpr 62","1136","M","B, C","B","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","RILQQLLlI","F8L","F69L","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This non-anchor position variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53070","Vpr 62","1137","M","B, C","C","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","RILQQpLFI","L6P","L67P","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This non-anchor position variant did not elicit a cross-CTL response with cells from mice immunized with the index form.","McKinney2004"
"53070","Vpr 62","1138","M","B, C","C","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","RvLQQLLFv","I2V, I9V","I63V, I70V","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited a CTL response with cells from mice immunized with the index form.","McKinney2004"
"53070","Vpr 62","1139","M","B, C","","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","RmLQQLLFv","I2M, I9V","I63M, I70V","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited a CTL response with cells from mice immunized with the index form.  It however, was not well recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53070","Vpr 62","1140","M","B, C","C","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","RmLQQLLFt","I2M, I9T","I63M, I70T","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53070","Vpr 62","1141","M","B, C","B","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","RtLQQLLFa","I2T, I9A","I63T, I70A","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.  Binding to HLA is at a very low level.","McKinney2004"
"53070","Vpr 62","1142","M","B, C","","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","RtLQQLLFt","I2T, I9T","I63T, I70T","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant did not elicit a CTL response with cells from mice immunized with the index form.  It was not recognized by CTL lines derived from HIV-1 uninfected donors.  Binding to HLA is at a very low level.","McKinney2004"
"53070","Vpr 62","1143","M","B, C","C","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","RtLQQLLFv","I2T, I9V","I63T, I70V","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53070","Vpr 62","1144","M","B, C","C","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","RtLQQLmFI","I2T, L7M","I63T, L68M","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53070","Vpr 62","1145","M","B, C","C","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","RmLQhLLFI","I2M, Q5H","I63M, Q66H","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant did not elicit a cross-CTL response with cells from mice immunized with the index form.","McKinney2004"
"53070","Vpr 62","1146","M","B, C","","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","RILQhLLFa","Q5H, I9A","Q66H, I70A","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited a very poor CTL response with cells from mice immunized with the index form.  It was, however, recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53070","Vpr 62","1147","M","B, C","C","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","RILQrLLFv","Q5R, I9V","Q66R, I70V","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53070","Vpr 62","1148","M","B, C","","Vpr","62","70","","5742..5768","A*0201","RILQQLLFI","RtLQlLLFv","I2T, Q5L, I9V","I63T, Q66L, I70V","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited a CTL response with cells from mice immunized with the index form.  It however, was not recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"56636",,"1998","","","","Vpr","73","90","","5775..5828","","RIGCQHSRIGISQRRRAR","RIGCQHSRIGIrQRRRAR","S12R","S84R","R","reversion","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This S84R substitution to the Clade B consensus persisted and was inferred to be a case of reversion.  While there was no ELISpot evidence, there was evidence for positive selection.","Goonetilleke2009"
"56636",,"1999","","","","Vpr","73","90","","5775..5828","","RIGCQHSRIGISQRRRAR","RIGCQrSRIGIrQRRRAR","S12R, H6R","S84R, H78R","CE","calculated escape","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Substitution seen in Patient CH40.  While there was no ELISpot evidence, there was evidence for positive selection.","Goonetilleke2009"
"56636",,"2000","","","","Vpr","73","90","","5775..5828","","RIGCQHSRIGISQRRRAR","RIGCQHSRIGIrhRRRAR","S12R, Q13H","S84R, Q85H","CE","calculated escape","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Substitution seen in Patient CH40.  While there was no ELISpot evidence, there was evidence for positive selection.","Goonetilleke2009"
"56636",,"2001","","","","Vpr","73","90","","5775..5828","","RIGCQHSRIGISQRRRAR","RIGCQHSRIGIgQRRRAR","S12G","S84G","CE","calculated escape","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Substitution seen in Patient CH40.  While there was no ELISpot evidence, there was evidence for positive selection.","Goonetilleke2009"
"56636",,"2002","","","","Vpr","73","90","","5775..5828","","RIGCQHSRIGISQRRRAR","RIGCQHSRIGlgQRRRAR","I11L, S12G","I83L, S84G","CE","calculated escape","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Substitution seen in Patient CH40.  While there was no ELISpot evidence, there was evidence for positive selection.","Goonetilleke2009"
"54158","PW9","970","B","","","Tat","3","11","","5837..5863","A*2501","PVDPRLEPW","PVDPRLdPW","E7D","E9D","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Positions 5 and 7 in the epitope had potentially experienced positive selection. The variant was full escape, as it was not recognized by CTLs.","Liu2006"
"54158","PW9","971","B","","","Tat","3","11","","5837..5863","A*2501","PVDPRLEPW","PVDPsLEPW","R5S","R7S","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Positions 5 and 7 in the epitope had potentially experienced positive selection. The variant was full escape, as it was not recognized by CTLs.","Liu2006"
"54158","PW9","972","B","","","Tat","3","11","","5837..5863","A*2501","PVDPRLEPW","PVDPkLEPW","R5K","R7K","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Positions 5 and 7 in the epitope had potentially experienced positive selection. The variant was full escape, as it was not recognized by CTLs.","Liu2006"
"59088",,"3257","B","B","B","Tat","3","11","",,"A*2501","PVDPRLEPW","PVDPRLdPW","E7D","E9D","E","escape documented in this paper","Peptide titration","EliSpot peptide titration indicated full escape.","Liu2007a"
"59088",,"3258","B","B","B","Tat","3","11","",,"A*2501","PVDPRLEPW","PVDPsLEPW","R5S","R7S","E","escape documented in this paper","Peptide titration","EliSpot peptide titration indicated full escape.","Liu2007a"
"59088",,"3259","B","B","B","Tat","3","11","",,"A*2501","PVDPRLEPW","PVDPkLEPW","R5K","R7K","E","escape documented in this paper","Peptide titration","EliSpot peptide titration indicated full escape.","Liu2007a"
"53225","Tat NY9","527","B","","","Tat","24","32","","5900..5926","A*2902","NCYCKKCCY","kCYCKKCCY","N1K","N24K","E","escape documented in this paper","","Variant appeared by day 31, dramatically reduced CTL recognition.","Jones2004"
"53225","Tat NY9","528","B","","","Tat","24","32","","5900..5926","A*2902","NCYCKKCCY","kCYCKrCCY","N1K, K6R","N24K, K29R","E","escape documented in this paper","","Variant appeared by day 218, dramatically reduced CTL recognition.","Jones2004"
"53225","Tat NY9","529","B","","","Tat","24","32","","5900..5926","A*2902","NCYCKKCCY","kCYCKqCCY","N1K, K6Q","N24K, K29Q","E","escape documented in this paper","","Variant appeared by day 556, dramatically reduced CTL recognition.","Jones2004"
"53225","Tat NY9","530","B","","","Tat","24","32","","5900..5926","A*2902","NCYCKKCCY","NCYCKKyCY","C7Y","C30Y","OV","observed variant","","1/23 clones, transiently present at day 55.","Jones2004"
"53225","Tat NY9","531","B","","","Tat","24","32","","5900..5926","A*2902","NCYCKKCCY","NCYCKKCCc","Y9C","Y32C","OV","observed variant","","2/23 clones, transiently present at day 55.","Jones2004"
"53233","Tat NF9","532","B","","","Tat","24","32","","5900..5926","A*2902","NCYCKRCCF","kCYCKRCCF","N1K","N24K","E","escape documented in this paper","","The CTL response diminished in vivo as this variant appeared. The variant was evident by day 72.","Jones2004"
"53233","Tat NF9","533","B","","","Tat","24","32","","5900..5926","A*2902","NCYCKRCCF","NCYCKkCCF","R6K","R29K","OV","observed variant","","1/7 clones, variant evident in samples taken at day 391.","Jones2004"
"53233","Tat NF9","534","B","","","Tat","24","32","","5900..5926","A*2902","NCYCKRCCF","tCYCKRCCF","N1T","N24T","OV","observed variant","","5/7 clones, variant evident in samples taken at day 772.","Jones2004"
"53233","Tat NF9","535","B","","","Tat","24","32","","5900..5926","A*2902","NCYCKRCCF","kCYCKsCCF","N1K, R6S","N24K, R29S","OV","observed variant","","1/9 clones, variant evident in samples taken at day 772.","Jones2004"
"53233","Tat NF9","536","B","","","Tat","24","32","","5900..5926","A*2902","NCYCKRCCF","kCYCKkCCF","N1K, R6K","N24K, R29K","OV","observed variant","","1/9 clones, variant evident in samples taken at day 772.","Jones2004"
"53476","CC8","36","B","","","Tat","30","37","","5918..5941","Cw*12","CCFHCQVC","CCmHCQVC","F3M","F32M","SF","susceptible form","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Intracellular cytokine staining","Significant cross-recognition was observed between the escape variant and the wildtype epitope.","Allen2005"
"54159","CC8","973","B","","","Tat","30","37","","5918..5941","Cw*1203","CCFHCQVC","CClHCQVC","F3L","F32L","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Position 3 in the epitope had potentially experienced positive selection. The variant was full escape, as it was not recognized by CTLs.","Liu2006"
"54159","CC8","974","B","","","Tat","30","37","","5918..5941","Cw*1203","CCFHCQVC","CCFHCQsC","V7S","V36S","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Position 3 in the epitope had potentially experienced positive selection. The variant was full escape, as it was not recognized by CTLs.","Liu2006"
"58146","CC8","2727","B","B","B","Tat","30","37","","5918..5941","Cw*1203","CCFHCQVC","CCFHCQsC","V7S","V36S","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Longitudinal study","Variant CCFHCQsC arose early in infection, then disappeared, while CClHCQVC dominated by 200 days post-infection. Both variants were associated with loss of EliSpot response to the epitope.","Liu2011a"
"58146","CC8","2728","B","B","B","Tat","30","37","","5918..5941","Cw*1203","CCFHCQVC","CClHCQVC","F3L","F32L","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Longitudinal study","Variant CCFHCQsC arose early in infection, then disappeared, while CClHCQVC dominated by 200 days post-infection. Both variants were associated with loss of EliSpot response to the epitope.","Liu2011a"
"59089",,"3260","B","B","B","Tat","30","37","",,"Cw*1203","CCFHCQVC","CClHCQVC","F3L","F32L","E","escape documented in this paper","Peptide titration","EliSpot peptide titration indicated full escape.","Liu2007a"
"59089",,"3261","B","B","B","Tat","30","37","",,"Cw*1203","CCFHCQVC","CCFHCQsC","V7S","V36S","E","escape documented in this paper","Peptide titration","EliSpot peptide titration indicated full escape.","Liu2007a"
"54209",,"398","B","","","Tat","31","39","","5921..5947","A2","CLHCQVCFI","CfHCQVCFI","L2F","L32F","OV","observed variant","","The variant appeared in the early stages of asymptomatic period. It did not affect the activity of Tat.","Guillon2006"
"53235","Tat FK10","537","B","","","Tat","32","41","","5924..5953","","FHCQVCFMTK","FHCQVCFtTK","M8T","M39T","E","escape documented in this paper","","The variant was evident during acute phase of infection. The substitution abrogated responses to the epitope.","Jones2004"
"53235","Tat FK10","538","B","","","Tat","32","41","","5924..5953","","FHCQVCFMTK","FHCQVCFtTe","K10E, M8T","K41E, M39T","OV","observed variant","","1/20 clones, variant found at time point 20.","Jones2004"
"53235","Tat FK10","539","B","","","Tat","32","41","","5924..5953","","FHCQVCFMTK","lHCQVCFMkK","F1L, T9K","F32L, T40K","E","escape documented in this paper","","The double mutation was evident at day 69 and the variant was not recognized.","Jones2004"
"57437","FK10","2433","B","B","B","Tat","32","41","","5924..5953","","FHCQVCFMTK","FHCQVCFMkK","T9K","T40K","OV","observed variant","Sequence","This variant only appeared at day 41 after onset of symptoms after onset of symptoms.","Fischer2010"
"57437","FK10","2434","B","B","B","Tat","32","41","","5924..5953","","FHCQVCFMTK","FHCQVCFMiK","T9I","T40I","OV","observed variant","Sequence","Relative frequency of this variant was low at day 5 after onset of symptoms and then the variant disappeared by day 20, reappearing at day 41 at minute levels.","Fischer2010"
"57437","FK10","2435","B","B","B","Tat","32","41","","5924..5953","","FHCQVCFMTK","lHCQVCFMkK","F1L, T9K","F32L, T40K","OV","observed variant","Sequence","This variant only appeared at day 41 after onset of symptoms.","Fischer2010"
"57437","FK10","2436","B","B","B","Tat","32","41","","5924..5953","","FHCQVCFMTK","FHCQVCFiTK","M8I","M39I","OV","observed variant","Sequence","Relative frequency of this variant remained unchanged until day 20 after onset of symptoms, and then decreased by day 41.","Fischer2010"
"57437","FK10","2437","B","B","B","Tat","32","41","","5924..5953","","FHCQVCFMTK","lHCQVCFMTK","F1L","F32L","OV","observed variant","Sequence","This uncommon variant only appeared at day 41 after onset of symptoms.","Fischer2010"
"57437","FK10","2438","B","B","B","Tat","32","41","","5924..5953","","FHCQVCFMTK","FnCQVCFMTK","H2N","H33N","OV","observed variant","Sequence","Relative frequency of this variant was low at day 5 after onset of symptoms and then the variant disappeared by day 20, reappearing at day 41 at minute levels.","Fischer2010"
"57437","FK10","2439","B","B","B","Tat","32","41","","5924..5953","","FHCQVCFMTK","FHCQdCFMkK","V5D, T9K","V36D, T40K","OV","observed variant","Sequence","This uncommon variant only appeared at day 41 after onset of symptoms.","Fischer2010"
"57437","FK10","2440","B","B","B","Tat","32","41","","5924..5953","","FHCQVCFMTK","FHCQVyFMTK","C6Y","C37Y","OV","observed variant","Sequence","This variant decreases in relative frequency as infection progresses.","Fischer2010"
"57437","FK10","2459","B","B","B","Tat","32","41","","5924..5953","","FHCQVCFMTK","kHCQVCFMlK","F1K, T9L","F32K, T40L","E","escape documented in this paper","Chromium-release assay, Sequence","Escape documented by authors in Table S2 of supplementary material.","Fischer2010"
"57437","FK10","2462","B","B","B","Tat","32","41","","5924..5953","","FHCQVCFMTK","FHCQVCFtTK","M8T","M39T","E","escape documented in this paper","Chromium-release assay, Sequence","Escape documented by authors in Table S2 of supplementary material.","Fischer2010"
"53236","Tat VI10","540","B","","","Tat","36","45","","5936..5965","B*1501","VCFMTKGLGI","VCFtTKGLGI","M4T","M39T","E","escape documented in this paper","","The variant was evident during acute phase of infection. The substitution abrogated responses to the epitope.","Jones2004"
"53236","Tat VI10","541","B","","","Tat","36","45","","5936..5965","B*1501","VCFMTKGLGI","VCFtTeGLGI","M4T, K6E","M39T, K41E","OV","observed variant","","1/20 clones, variant found at time point 20.","Jones2004"
"53236","Tat VI10","542","B","","","Tat","36","45","","5936..5965","B*1501","VCFMTKGLGI","VCFMkKGLGI","T5K","T40K","E","escape documented in this paper","","The mutation was evident at day 69 and the variant was not recognized.","Jones2004"
"57438","VI10","2441","B","B","B","Tat","36","45","","5936..5965","","VCFMTKGLGI","VCFMkKGLGI","T5K","T40K","OV","observed variant","Sequence","This variant only appeared at day 41 after onset of symptoms.","Fischer2010"
"57438","VI10","2442","B","B","B","Tat","36","45","","5936..5965","","VCFMTKGLGI","VCFMTKGLGv","I10V","I45V","OV","observed variant","Sequence","Relative frequency of this variant remained unchanged until day 20 after onset of symptoms and then the variant disappeared by day 41.","Fischer2010"
"57438","VI10","2443","B","B","B","Tat","36","45","","5936..5965","","VCFMTKGLGI","VCFMTKGLsI","G9S","G44S","OV","observed variant","Sequence","Relative frequency of this variant remained unchanged until day 20 after onset of symptoms and then decreased by day 41.","Fischer2010"
"57438","VI10","2444","B","B","B","Tat","36","45","","5936..5965","","VCFMTKGLGI","dCFMkKGLGI","V1D, T5K","V36D, T40K","OV","observed variant","Sequence","This uncommon variant only appeared at day 41 after onset of symptoms.","Fischer2010"
"57438","VI10","2445","B","B","B","Tat","36","45","","5936..5965","","VCFMTKGLGI","VCFiTKGLGI","M4I","M39I","OV","observed variant","Sequence","Relative frequency of this variant remained unchanged until day 20 after onset of symptoms and then decreased by day 41.","Fischer2010"
"57438","VI10","2446","B","B","B","Tat","36","45","","5936..5965","","VCFMTKGLGI","VyFMTKGLGI","C2Y","C37Y","OV","observed variant","Sequence","This variant decreases in relative frequency as infection progresses.","Fischer2010"
"57438","VI10","2447","B","B","B","Tat","36","45","","5936..5965","","VCFMTKGLGI","VCFMiKGLGI","T5I","T40I","OV","observed variant","Sequence","Relative frequency of this variant was low at day 5 after onset of symptoms and then the variant disappeared by day 20, reappearing at day 41 at minute levels.","Fischer2010"
"57438","VI10","2460","B","B","B","Tat","36","45","","5936..5965","","VCFMTKGLGI","VCFMlKGLGI","T5L","T40L","E","escape documented in this paper","Chromium-release assay, Sequence","Escape documented by authors in Table S2 of supplementary material.","Fischer2010"
"57438","VI10","2461","B","B","B","Tat","36","45","","5936..5965","","VCFMTKGLGI","VCFtTKGLGI","M4T","M39T","E","escape documented in this paper","Chromium-release assay, Sequence","Escape documented by authors in Table S2 of supplementary material.","Fischer2010"
"1281","T38-FY10","1338","C","","","Tat","38","47","","5942..5971","B*1503","FQTKGLGISY","FlnKGLGISY","Q2L, T3N","Q39L, T40N","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","CTL response was detected to the peptide VCFQTKGLGISYGRK containing consensus epitope FQTKGLGISY in subjects that carried the FlnKGLGISY autologous sequence.  24% of subjects carried the Q/L variation and 5% of subjects carried the T/N variation.","Novitsky2001"
"1281","T38-FY10","1339","C","","","Tat","38","47","","5942..5971","B*1503","FQTKGLGISY","FQTKGLGIyY","S9Y","S46Y","IE, OV","inferred escape, observed variant","CD8 T-cell Elispot - IFNy, Sequence","No CTL response was detected to the peptide VCFQTKGLGISYGRK that contained consensus epitope FQTKGLGISY in subjects carrying the FQTKGLGIyY autologous sequence.  10% of subjects carried the S/Y variation.","Novitsky2001"
"1281","T38-FY10","1340","C","","","Tat","38","47","","5942..5971","B*1503","FQTKGLGISY","FlTKGLGISY","Q2L","Q39L","IE, OV","inferred escape, observed variant","CD8 T-cell Elispot - IFNy, Sequence","No CTL response was detected to the peptide VCFQTKGLGISYGRK that contained consensus epitope FQTKGLGISY in 1/16 subjects though response was detected in 3/16 subjects containing the FlTKGLGISY autologous variant.  24% of subjects carried the Q/L variation.","Novitsky2001"
"1281","T38-FY10","1341","C","","","Tat","38","47","","5942..5971","B*1503","FQTKGLGISY","FQTKGLsISY","G7S","G44S","IE, OV","inferred escape, observed variant","CD8 T-cell Elispot - IFNy, Sequence","No CTL response was detected to the peptide VCFQTKGLGISYGRK that contained consensus epitope FQTKGLGISY in subjects carrying the FQTKGLsISY autologous sequence.  2% of subjects carried the G/S variation.","Novitsky2001"
"1281","T38-FY10","1342","C","","","Tat","38","47","","5942..5971","B*1503","FQTKGLGISY","FQrKGLGISY","T3R","T40R","IE, OV","inferred escape, observed variant","CD8 T-cell Elispot - IFNy, Sequence","No CTL response was detected to the peptide VCFQTKGLGISYGRK that contained consensus epitope FQTKGLGISY in subjects carrying the FQrKGLGISY autologous sequence.  2% of subjects carried the T/R variation.","Novitsky2001"
"1281","T38-FY10","1343","C","","","Tat","38","47","","5942..5971","B*1503","FQTKGLGISY","FQkKGLGISY","T3K","T40K","IE, OV","inferred escape, observed variant","CD8 T-cell Elispot - IFNy, Sequence","No CTL response was detected to the peptide VCFQTKGLGISYGRK that contained consensus epitope FQTKGLGISY, in subjects carrying the FQkKGLGISY autologous sequence.  24% of subjects carried the T/K variation.","Novitsky2001"
"55999","FY10(Tat)","1929","B","B","B","Tat","38","47","","5942..5971","","FMKKGLGISY","FqtKGLGISY","M2Q, K3T","M39Q, K40T","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at two positions. It is predicted to be HLA-B15 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"57434","FY10, MY9","2427","B","B","B","Tat","38","47","","5942..5971","B*1501","FMTKGLGISY","FMkKGLGISY","T3K","T40K","OV","observed variant","Sequence","This variant only appeared at day 41 after onset of symptoms.","Fischer2010"
"57434","FY10, MY9","2428","B","B","B","Tat","38","47","","5942..5971","B*1501","FMTKGLGISY","FMiKGLGISY","T3I","T40I","OV","observed variant","Sequence","Relative frequency of this variant was low at day 5 after onset of symptoms and then the variant disappeared by day 20, reappearing at day 41 at minute levels.","Fischer2010"
"57434","FY10, MY9","2429","B","B","B","Tat","38","47","","5942..5971","B*1501","FMTKGLGISY","FiTKGLGISY","M2I","M39I","OV","observed variant","Sequence","Relative frequency of this variant remained unchanged until day 20 after onset of symptoms, and then decreased by day 41.","Fischer2010"
"57434","FY10, MY9","2430","B","B","B","Tat","38","47","","5942..5971","B*1501","FMTKGLGISY","FMTKGLGvSY","I8V","I45V","OV","observed variant","Sequence","Relative frequency of this variant remained unchanged until day 20 after onset of symptoms, and then the variant disappeared by day 41.","Fischer2010"
"57434","FY10, MY9","2431","B","B","B","Tat","38","47","","5942..5971","B*1501","FMTKGLGISY","FMTKGLGIfY","S9F","S46F","OV","observed variant","Sequence","Low levels of this variant were seen only at day 20 after onset of symptoms, followed by a drop at day 41.","Fischer2010"
"57434","FY10, MY9","2432","B","B","B","Tat","38","47","","5942..5971","B*1501","FMTKGLGISY","FMTKGLsISY","G7S","G44S","OV","observed variant","Sequence","Relative frequency of this variant remained unchanged until day 20 after onset of symptoms and then decreased by day 41.","Fischer2010"
"57434","FY10, MY9","2458","B","B","B","Tat","38","47","","5942..5971","B*1501","FMTKGLGISY","FMlKGLGISY","T3L","T40L","E, P","escape documented in this paper, processing","Chromium-release assay, Sequence","Authors mention in Table S2 of supplementary material that this FY10 mutant is recognized in a Chromium release assay, but escape is conferred by processing.","Fischer2010"
"57434","FY10, MY9","2463","B","B","B","Tat","38","47","","5942..5971","B*1501","FMTKGLGISY","FtTKGLGISY","M2T","M39T","SF","susceptible form","Chromium-release assay, Sequence","This variant remained susceptible to CTL response as documented by the authors in Table S2 in supplementary materials.","Fischer2010"
"59055","Tat 38-47","3227","C","C","C","Tat","38","47","","5942..5971","B*1503","FQKKGLGISY","FQtKGLGISY","K3T","K40T","DR, E","diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","Calculated time to escape to FQtKGLGISY was 105 days.","Liu2013a"
"53237","Tat MY9","543","B","","","Tat","39","47","","5945..5971","B*1501","MTKGLGISY","tTKGLGISY","M1T","M39T","SF","susceptible form","","The variant was evident during acute phase of infection. The substitution did not abrogate responses to the epitope.","Jones2004"
"53237","Tat MY9","544","B","","","Tat","39","47","","5945..5971","B*1501","MTKGLGISY","tTeGLGISY","M1T, K3E","M39T, K41E","OV","observed variant","","1/20 clones, variant found at time point 20.","Jones2004"
"53237","Tat MY9","545","B","","","Tat","39","47","","5945..5971","B*1501","MTKGLGISY","MkKGLGISY","T2K","T40K","IE, P","inferred escape, processing","","This mutation was evident at day 69. CTL response was strong to the variant, but the substitution seemed to impact processing of the epitope.","Jones2004"
"53418","ITK","1368","","","","Tat","39","49","","5945..5977","A*6801","ITKGLGISYGR","tTKGLGISYGR","I1T","I39T","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","4/13 viral clones contained this variant sequence at the first time point (Day 60) tested after infection.  While no variant sequence was detected at the second sampling, 2/13 clones contained it at the third time point (Day 369) and the sequence was lost thereafter.","Oxenius2004"
"53418","ITK","1369","","","","Tat","39","49","","5945..5977","A*6801","ITKGLGISYGR","ITKGsGISYGR","L5S","L43S","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/17 viral clones contained this variant sequence at the last time point (Day 635) tested after infection.","Oxenius2004"
"55965","IR11(Tat)","1930","B","B","B","Tat","39","49","","5945..5977","","MKKGLGISYGR","itKGLGISYGR","M1I, K2T","M39I, K40T","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at two positions. It is predicted to be HLA-A68 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"53526","AI12","40","B","","","Tat","58","69","","6002..6037","","APQGHPNNQVSI","APQdHPNNQVSI","G4D","G61D","SF","susceptible form","CD8 T-cell Elispot - IFNy","Longitudinal study of four clade B-infected patients studied for up to 5 years after acute infection. This mutation was observed in a CD8 targeted  novel  epitope in subject AC-59. The mutation, at position 3, CClHCQVC, was found in the most polymorphic residue in the epitope. The response could only be detected with autologous peptide.","Allen2005a"
"57343",,"2050","","","","Rev","9","26","","5994..6045,8379..8380","","DEDLLKTVRLIKRLYQSS","DEnLLKTVRLIKRLYQSS","D3N","D11N","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This variant seen in Patient CH77. Response not measured.","Goonetilleke2009"
"57343",,"2051","","","","Rev","9","26","","5994..6045,8379..8380","","DEDLLKTVRLIKRLYQSS","DEDLLKaVRLIKRLYQSS","T7A","T15A","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This variant seen in Patient CH77. Response not measured.","Goonetilleke2009"
"57343",,"2052","","","","Rev","9","26","","5994..6045,8379..8380","","DEDLLKTVRLIKRLYQSS","DEDLLKiVRLIKRLYQSS","T7I","T15I","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This variant seen in Patient CH77. Response not measured.","Goonetilleke2009"
"57343",,"2053","","","","Rev","9","26","","5994..6045,8379..8380","","DEDLLKTVRLIKRLYQSS","DEDLLKTVgiIKRLYQSS","L10I, R9G","L18I, R17G","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This variant seen in Patient CH77. Response not measured.","Goonetilleke2009"
"57343",,"2054","","","","Rev","9","26","","5994..6045,8379..8380","","DEDLLKTVRLIKRLYQSS","DEDLLKTVRvIKRLYQSS","L10V","L18V","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This variant seen in Patient CH77. Response not measured.","Goonetilleke2009"
"57343",,"2055","","","","Rev","9","26","","5994..6045,8379..8380","","DEDLLKTVRLIKRLYQSS","DEDLLKTVRiIKRLYQSS","L10I","L18I","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This variant seen in Patient CH77. Response not measured.","Goonetilleke2009"
"57343",,"2056","","","","Rev","9","26","","5994..6045,8379..8380","","DEDLLKTVRLIKRLYQSS","DEDLLrTVRLIKRLYQSS","K6R","K14R","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This variant seen in Patient CH77. Response not measured.","Goonetilleke2009"
"58686","EL9","3095","B","B","B","Rev","10","18","","5997..6023","B*4402, B*4403","EELLKTVRL","EdLLqTVRL","E2D, K5Q","E11D, K14Q","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Longitudinal study, Sequence","Variant EdLLqTVRL was first seen 60 weeks post-ART interruption (AI) and persisted for over a year up to at least week 124 post-AI.  It did however decrease in frequency from 40% at week 72- to 20% at week 124-post-AI.  The mutant was unable to elicit any CTL response in EliSpot assays.  Rev complementation assays demonstrated that this mutant virus was not functionally impaired.","Allard2012"
"58686","EL9","3096","B","B","B","Rev","10","18","","5997..6023","B*4402, B*4403","EELLKTVRL","EdLLKTVRL","E2D","E11D","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Longitudinal study, Sequence","Variant EdLLKTVRL was first seen 72 weeks post-ART interruption (AI) and persisted for over a year up to at least week 124 post-AI.  The mutant was unable to elicit any CTL response in EliSpot assays.  Rev complementation assays demonstrated that this mutant virus was not functionally impaired.","Allard2012"
"58686","EL9","3097","B","B","B","Rev","10","18","","5997..6023","B*4402, B*4403","EELLKTVRL","dELLKTVRL","E1D","E10D","DR, E","diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","Variant dELLKTVRL was seen only at 72 weeks post-ART interruption (AI), but formed 53% of all EL9 sequences.  The mutant had decreased CTL response in EliSpot assays.  Rev complementation assays demonstrated that this mutant virus was not functionally impaired.","Allard2012"
"58686","EL9","3098","B","B","B","Rev","10","18","","5997..6023","B*4402, B*4403","EELLKTVRL","EELiKTVRL","L4I","L13I","DR, E","diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","Variant EELiKTVRL was seen only at 124 weeks post-ART interruption (AI), but formed 30% of all EL9 sequences.  The mutant had decreased CTL response in EliSpot assays.  Rev complementation assays demonstrated that this mutant virus was not functionally impaired.","Allard2012"
"58686","EL9","3099","B","B","B","Rev","10","18","","5997..6023","B*4402, B*4403","EELLKTVRL","ddLLqTVRL","E1D, E2D, K5Q","E10D, E11D, K14Q","OV","observed variant","Sequence","Variant ddLLqTVRL was seen only at 72 weeks post-ART interruption (AI).","Allard2012"
"54963","LI9","1014","A, B","","","Rev","13","21","","6006..6032","B*5701, B*5703","LRAVRIIKI","LkAVRIIKI","R2K","R14K","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","Variant LkAVRIIKI is found in Clades A, B and is recognized preferentially.  8-mer kAVRIIKI shows comparable recognition by CTL.","Makadzange2006"
"54963","LI9","1015","A, B","","","Rev","13","21","","6006..6032","B*5701, B*5703","LRAVRIIKI","LRAVRIIKf","I9F","I21F","DR","diminished response","Chromium-release assay","Variant LRAVRIIKf elicits reduced CTL recognition.","Makadzange2006"
"56052","KY10(Rev)","1931","B","B","B","Rev","14","23","","6009..6038","","RTVRLIKLLY","kaVRLIKLLY","R1K, T2A","R14K, T15A","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at two positions. It is predicted to be HLA-B58 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"56147",,"1540","C","","","Rev","15","22","","6012..6035","","AVRIIKIL","AVkIIKIL","R3K","R17K","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"56147",,"1541","C","","","Rev","15","22","","6012..6035","","AVRIIKIL","AVqIIKIL","R3Q","R17Q","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"58682",,"3088","C","C","C","Rev","15","22","","6012..6035","","AVRIIKIM","AVqIIKIM","R3Q","R17Q","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"58682",,"3089","C","C","C","Rev","15","22","","6012..6035","","AVRIIKIM","AVkIIKIM","R3K","R17K","CE","calculated escape","CD8 T-cell Elispot - IFNy, Sequence","This variant is associated with lower viral loads, suggesting a fitness cost to the mutation.","Rousseau2008"
"53879",,"1875","B","B","A","Rev","15","23","","6012..6038","A*03","TVRLIKFLY","TVkiIKFLY","R3K, L4I","R17K, L18I","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Autologous variant differed from the Strain B consensus, but was recognized.","Yang2005"
"56634",,"1990","","","","Rev","47","55","","8441..8467","","QRQRQIQSL","QkQRQIQSL","R2K","R48K","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence","Patient SUMA0874 developed this nonsynonymous substitution that diminished CTL response measured by ELISpot.","Goonetilleke2009"
"56634",,"1991","","","","Rev","47","55","","8441..8467","","QRQRQIQSL","QRQRhIQSL","Q5H","Q51H","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","Patient SUMA0874 developed this nonsynonymous substitution that abrogated ELISpot response.","Goonetilleke2009"
"56634",,"1992","","","","Rev","47","55","","8441..8467","","QRQRQIQSL","QRQRQIrSL","Q7R","Q53R","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence","Patient SUMA0874 developed this nonsynonymous substitution that diminished CTL response measured by ELISpot.","Goonetilleke2009"
"56634",,"1993","","","","Rev","47","55","","8441..8467","","QRQRQIQSL","QRQRQIQSi","L9I","L55I","DR, SF","diminished response, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Patient SUMA0874 developed this nonsynonymous substitution that had a robust EliSpot response, but somewhat diminished.","Goonetilleke2009"
"56634",,"2207","","","","Rev","47","55","","8441..8467","","QRQRQIQSL","QRQRQIQlL","S8L","S54L","DR, E","diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","Patient SUMA0874 developed this nonsynonymous substitution that severely diminished CTL response measured by ELISpot.","Goonetilleke2009"
"57433","QL9","2405","B","B","B","Rev","47","55","","8441..8467","","QRQRQIQSL","QRQRQIQSi","L9I","L54I","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence","QRQRQIQSi appears first in trace amounts by day 20 after onset of symptoms to become the dominant variant (45.73%) by day 41.  It has diminished susceptibility by ELISpot, and an accumulation rate of 0.4.","Fischer2010"
"57433","QL9","2406","B","B","B","Rev","47","55","","8441..8467","","QRQRQIQSL","QRQRQIrSL","Q7R","Q52R","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","QRQRQIrSL is an escape documented by ELISpot that becomes the second most dominant variant by day 41 after onset of symptoms at 29.71%.  It has an accumulation/loss rate of 0.4 and is detectable in trace amounts from day 5 onwards.","Fischer2010"
"57433","QL9","2407","B","B","B","Rev","47","55","","8441..8467","","QRQRQIQSL","QRQRQIkSL","Q7K","Q52K","OV","observed variant","Sequence","QRQRQIkSL is first seen at day 41 after onset of symptoms at a level of 4.46% of all variants in patient SUMA.","Fischer2010"
"57433","QL9","2408","B","B","B","Rev","47","55","","8441..8467","","{R}QRQRQIQSL","{k}QRQRQIQSL","R-1K","R45K","CE, P","calculated escape, processing","","This mutation is adjacent to the Rev QL9 epitope, and is a candidate processing escape.  It was present at trace levels at day 5 after onset of symptoms, absent at day 20 and present again at day 41 in patient SUMA.","Fischer2010"
"57433","QL9","2409","B","B","B","Rev","47","55","","8441..8467","","QRQRQIQSL","QRQRrIQSL","Q5R","Q50R","OV","observed variant","Sequence","Variant QRQRriQSL was present at trace levels at day 5 after onset of symptoms, absent at day 20 and present again at day 41 in patient SUMA.","Fischer2010"
"57433","QL9","2410","B","B","B","Rev","47","55","","8441..8467","","QRQRQIQSL","QRQiQIQSL","R4I","R49I","OV","observed variant","Sequence","QL9 variant QRQiQIQSL appears at day 20 after onset of symptoms, increasing slightly to 1.72% by day 41.","Fischer2010"
"57433","QL9","2411","B","B","B","Rev","47","55","","8441..8467","","QRQRQIQSL","QkQRQIQSL","R2K","R47K","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence","QL9 variant QkQRQIQSLS has diminished susceptibility as determined by ELISpot.  It was present at trace levels at day 5 after onset of symptoms, absent at day 20 and present again at day 41 in patient SUMA.","Fischer2010"
"57433","QL9","2412","B","B","B","Rev","47","55","","8441..8467","","QRQRQIQSL","QRrRQIQSL","Q3R","Q48R","OV","observed variant","Sequence","QL9 variant QRrRQIQSL arises by day 41 after onset of symptoms and is present in trace amounts.","Fischer2010"
"57433","QL9","2413","B","B","B","Rev","47","55","","8441..8467","","QRQRQIQSL","QRQRQIQSv","L9V","L54V","OV","observed variant","Sequence","QL9 variant QRQRQIQSv arises in trace amounts by day 20 after onset of symptoms but increases only marginally by day 41.","Fischer2010"
"57433","QL9","2414","B","B","B","Rev","47","55","","8441..8467","","QRQRQIQSL","QRQRkIQSL","Q5K","Q50K","OV","observed variant","Sequence","QL9 variant QRQRkIQSL is first seen at day 41 after onset of symptoms and in trace amounts.","Fischer2010"
"57433","QL9","2415","B","B","B","Rev","47","55","","8441..8467","","QRQRQIQSL","QRQRQIlSL","Q7L","Q52L","OV","observed variant","Sequence","Variant QEQEQIlSL was present at trace levels at day 5 after onset of symptoms, absent at day 20 and present again at day 41 in patient SUMA.","Fischer2010"
"57433","QL9","2464","B","B","B","Rev","47","55","","8441..8467","","QRQRQIQSL","QRQRQIQlL","S8L","S53L","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","Variant QRQRQIQlLS is a documented escape by ELISpot.","Fischer2010"
"57433","QL9","2465","B","B","B","Rev","47","55","","8441..8467","","QRQRQIQSL","QRQRhIQSL","Q5H","Q50H","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","Variant QRQRhIQSLS is a documented escape from QL9 in patient SUMA.","Fischer2010"
"56659",,"2088","","","","Rev","49","66","","8447..8500","","QRQIRSISERILSTYLER","QRQIRSISERILnTYLER","S13N","S61N","IE","inferred escape","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Patient CH40 responded to the epitope until day 412 when this mutant dominated the sequenced population.","Goonetilleke2009"
"58228",,"2793","B","B","B","Rev","51","60","","8453..8482","A*3101","QIRSISERIL","QIRSISERIf","L10F","L60F","IE","inferred escape","Sequence","1/9, 1/7 and 1/12 sequences of epitope QIRSISERIL varied at 111, 181 and 412 DFOSx to QIRSISERIf.  Position 60 is marked as being selected to vary.","Ferrari2011"
"53824",,"1310","B","","","Rev","55","63","","8465..8491","A*0101","ISERILSTY","ISERILSTf","Y9F","Y63F","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","This anchor residue variant was seen in Donor2 and Recipient2, both of whom carried the restricting HLA-A*0101 allele.  It was not recognized by either subject and binding to HLA was greatly reduced.","Milicic2005"
"55517","RL10","71","A, B, C, D, F, G","B","A1","Rev","66","75","","8498..8527","B*07","RPAEPVPLQL","RsAEPVPLQL","P2S","P67S","SSF","subtype-specific susceptible form","Chromium-release assay","RL10 epitope variants used were RPAEPVPLQL for clades B/C/G, RSAEPVPLQL for clade A1, RPTEPVPLQL for clades A2/F2, RSEEPVPLQL for clade D, and RPEEPVPLQL for clade F1. Clade B-elicited CTLs recognized epitopes from all other clades when tested by Cr-release.","Bennett2008"
"55517","RL10","72","A, B, C, D, F, G","B","A2, F2","Rev","66","75","","8498..8527","B*07","RPAEPVPLQL","RPtEPVPLQL","A3T","A68T","SSF","subtype-specific susceptible form","Chromium-release assay","RL10 epitope variants used were RPAEPVPLQL for clades B/C/G, RSAEPVPLQL for clade A1, RPTEPVPLQL for clades A2/F2, RSEEPVPLQL for clade D, and RPEEPVPLQL for clade F1. Clade B-elicited CTLs recognized epitopes from all other clades when tested by Cr-release.","Bennett2008"
"55517","RL10","73","A, B, C, D, F, G","B","D","Rev","66","75","","8498..8527","B*07","RPAEPVPLQL","RseEPVPLQL","P2S, A3E","P67S, A68E","SSF","subtype-specific susceptible form","Chromium-release assay","RL10 epitope variants used were RPAEPVPLQL for clades B/C/G, RSAEPVPLQL for clade A1, RPTEPVPLQL for clades A2/F2, RSEEPVPLQL for clade D, and RPEEPVPLQL for clade F1. Clade B-elicited CTLs recognized epitopes from all other clades when tested by Cr-release.","Bennett2008"
"55517","RL10","74","A, B, C, D, F, G","B","F1","Rev","66","75","","8498..8527","B*07","RPAEPVPLQL","RPeEPVPLQL","A3E","A68E","SSF","subtype-specific susceptible form","Chromium-release assay","RL10 epitope variants used were RPAEPVPLQL for clades B/C/G, RSAEPVPLQL for clade A1, RPTEPVPLQL for clades A2/F2, RSEEPVPLQL for clade D, and RPEEPVPLQL for clade F1. Clade B-elicited CTLs recognized epitopes from all other clades when tested by Cr-release.","Bennett2008"
"56454","RL10(Rev)","1932","B","B","B","Rev","66","75","","8498..8527","","RSAEPVPLQL","RpAEPVPLQL","S2P","S67P","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B7 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"57556",,"2528","B","B","B","Rev","66","75","","8498..8527","","RPAELVLQL","RstELVLQL","P2S, A3T","P67S, A68T","E","escape documented in this paper","CD4 T-cell Elispot - IFNy","The variants RstELVLQL and RPtAELVLQL evolved to dominate the quasispecies, and were less well recognized than the index peptide by the PBMC from time points around the time of response decline, indicating escape.","Turnbull2009"
"57556",,"2529","B","B","B","Rev","66","75","","8498..8527","","RPAELVLQL","RPtAELVLQL","-2T","-67T","E","escape documented in this paper","CD4 T-cell Elispot - IFNy","The variants RstELVLQL and RPtAELVLQL evolved to dominate the quasispecies, and were less well recognized than the index peptide by the PBMC from time points around the time of response decline, indicating escape.","Turnbull2009"
"53477","SL9","37","B","","","Rev","67","75","","8501..8527","Cw5","SAEPVPLQL","SAEPgPLQL","V5G","V71G","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Intracellular cytokine staining","Variant resulted in dramatic loss of the original CD8 response.","Allen2005"
"1317",,"1604","","","","Rev","67","75","","8501..8527","B14","SAEPVPLQL","SeEPVPLQL","A2E","A68E","E","escape documented in this paper","Chromium-release assay","Macrophage-tropic HIV-1 clone escaped more efficiently from specific cytotoxic T-lymphocyte (CTL) pressure than its non-macrophage-tropic counterpart. This variant was escape in mice as demonstrated by Cr release assay.","Schutten2001"
"1317",,"1605","","","","Rev","67","75","","8501..8527","B14","SAEPVPLQL","SAEhVPLQL","P4H","P70H","E","escape documented in this paper","Chromium-release assay","Macrophage-tropic HIV-1 clone escaped more efficiently from specific cytotoxic T-lymphocyte (CTL) pressure than its non-macrophage-tropic counterpart. This variant was escape in mice as demonstrated by Cr release assay.","Schutten2001"
"1317",,"1606","","","","Rev","67","75","","8501..8527","B14","SAEPVPLQL","SAEsVPLQL","P4S","P70S","E","escape documented in this paper","Chromium-release assay","Macrophage-tropic HIV-1 clone escaped more efficiently from specific cytotoxic T-lymphocyte (CTL) pressure than its non-macrophage-tropic counterpart. This variant was escape in mice as demonstrated by Cr release assay.","Schutten2001"
"1317",,"1607","","","","Rev","67","75","","8501..8527","B14","SAEPVPLQL","SvEPVPLQL","A2V","A68V","E","escape documented in this paper","Chromium-release assay","Macrophage-tropic HIV-1 clone escaped more efficiently from specific cytotoxic T-lymphocyte (CTL) pressure than its non-macrophage-tropic counterpart. This variant was escape in mice as demonstrated by Cr release assay.","Schutten2001"
"1317",,"1608","","","","Rev","67","75","","8501..8527","B14","SAEPVPLQL","SAEPVPfQL","L7F","L73F","E","escape documented in this paper","Chromium-release assay","Macrophage-tropic HIV-1 clone escaped more efficiently from specific cytotoxic T-lymphocyte (CTL) pressure than its non-macrophage-tropic counterpart. This variant was escape in mice as demonstrated by Cr release assay.","Schutten2001"
"1317",,"1609","","","","Rev","67","75","","8501..8527","B14","SAEPVPLQL","SlEPVPLQL","A2L","A68L","E","escape documented in this paper","Chromium-release assay","Macrophage-tropic HIV-1 clone escaped more efficiently from specific cytotoxic T-lymphocyte (CTL) pressure than its non-macrophage-tropic counterpart. This variant was escape in mice as demonstrated by Cr release assay.","Schutten2001"
"54211",,"399","B","","","Rev","70","78","","8510..8536","A2","PVPFQLPPL","PVPlQLPPL","F4L","F73L","OV","observed variant","","The variant appeared in the early stages of asymptomatic period.","Guillon2006"
"55383","Rev 73","1688","","","","Rev","73","81","","8519..8545","A2","LQLPPIERL","fQLPPIERL","L1F","L73F","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subjects Pt15 carried this variant but was unable to cross-recognize the challenge HXB2 sequence, LQLPPIERL.","Thorn2007"
"55383","Rev 73","1689","","","","Rev","73","81","","8519..8545","A2","LQLPPIERL","LQLPPlERL","I6L","I78L","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subjects Pt16, Pt17, Pt18, Pt21, Pt23, Pt30, Pt33, Pt35, Pt41 and Pt43 carried the HXB2 epitope LQLPPLERL; and none were able to cross-recognize the variant LQLPPIERL.","Thorn2007"
"52683","Rev96(2M)","126","","","","Rev","96","104","","8588..8614","A2","GMGSPQILV","GvGSPQILV","M2V","M97V","DHB, E, NSF","diminished HLA binding or increased off-rate, escape documented in this paper, non-susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, Flow cytometric T-cell cytokine assay","This peptide was an intermediate A2 binder, and induced a CD8+ T-cell IFN gamma response in 1/6 mice. Responses were detected in 1/17 HIV+ HLA-A2 subjects. The variant GvGSPQILV did not elicit a CD8+ T-cell IFN gamma response in transgenic mice, and bound to A2 with low affinity.","Corbet2003"
"55384","Rev 96","1727","","","","Rev","96","104","","8588..8614","A2","GMGSPQILV","GvGSPQILV","M2V","M97V","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subjects Pt16, Pt18, Pt35, Pt41 carried this HXB2 consensus epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope GMGSPQILV.","Thorn2007"
"55384","Rev 96","1728","","","","Rev","96","104","","8588..8614","A2","GMGSPQILV","GvGSPQIsg","M2V, L8S, V9G","M97V, L103S, V104G","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt15 carried this variant epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope GMGSPQILV.","Thorn2007"
"55384","Rev 96","1729","","","","Rev","96","104","","8588..8614","A2","GMGSPQILV","GvGSPQIsV","M2V, L8S","M97V, L103S","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt17 carried this variant epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope GMGSPQILV.","Thorn2007"
"55384","Rev 96","1730","","","","Rev","96","104","","8588..8614","A2","GMGSPQILV","GvGSPQILl","M2V, V9L","M97V, V104L","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt21 carried this variant epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope GMGSPQILV.","Thorn2007"
"55384","Rev 96","1731","","","","Rev","96","104","","8588..8614","A2","GMGSPQILV","GvGnPQILV","M2V, S4N","M97V, S99N","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt33 carried this variant epitope in a regulatory/accessory protein, and did not recognize the  HXB2 epitope GMGSPQILV.","Thorn2007"
"55384","Rev 96","1732","","","","Rev","96","104","","8588..8614","A2","GMGSPQILV","GvGnPQvLV","M2V, S4N, I7V","M97V, S99N, I102V","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt23 carried this variant  epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope GMGSPQILV.","Thorn2007"
"55384","Rev 96","1733","","","","Rev","96","104","","8588..8614","A2","GMGSPQILV","GvGSPQvLV","M2V, I7V","M97V, I102V","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt43 carried this variant epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope GMGSPQILV.","Thorn2007"
"55384","Rev 96","1734","","","","Rev","96","104","","8588..8614","A2","GMGSPQILV","GvGSPeILV","M2V, Q6E","M97V, Q101E","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt30 carried this variant epitope in a regulatory/accessory protein, and  cross-recognized the HXB2 epitope GMGSPQILV.","Thorn2007"
"54212",,"400","B","","","Rev","101","109","","8603..8629","A2","QILGEPPTV","QILGEhPpV","P6H, T8P","P106H, T108P","OV","observed variant","","The variant appeared in the early stages of asymptomatic period.","Guillon2006"
"54212",,"401","B","","","Rev","101","109","","8603..8629","A2","QILGEPPTV","QILGghPpV","E5G, P6H, T8P","E105G, P106H, T108P","OV","observed variant","","The variant appeared in the early stages of asymptomatic period.","Guillon2006"
"53532","QL10","41","B","","","Rev","101","110","","8603..8632","","QVLGESPTVL","QVLGkSPTVL","E5K","E105K","SF","susceptible form","CD8 T-cell Elispot - IFNy","Longitudinal study of four clade B-infected patients studied for up to 5 years after acute infection. This mutation was observed in a CD8 targeted  novel  epitope in subject AC-04. Response could only be detected with autologous peptide.","Allen2005a"
"53532","QL10","42","B","","","Rev","101","110","","8603..8632","","QVLGESPTVL","QVLGEStTVL","P7T","P107T","SF","susceptible form","CD8 T-cell Elispot - IFNy","Longitudinal study of four clade B-infected patients studied for up to 5 years after acute infection. This mutation was observed in a CD8 targeted  novel  epitope in subject AC-04. Response could only be detected with autologous peptide.","Allen2005a"
"56069","Rev102","211","","","","Rev","102","110","","8606..8632","A2","ILVESPAVL","IpVESPtVL","L2P, A7T","L103P, A108T","OV","observed variant","","One HLA-A2 patient did not respond to the ILVESPAVL epitope but the variant peptide was observed in the patient.","Fomsgaard2008"
"54215",,"402","B","","","Rev","102","110","","8606..8632","A2","ILGEPPTVL","ILGEhPpVL","P5H, T7P","P106H, T108P","OV","observed variant","","The variant appeared in the early stages of asymptomatic period.","Guillon2006"
"54215",,"403","B","","","Rev","102","110","","8606..8632","A2","ILGEPPTVL","ILGghPpVL","E4G, P5H, T7P","E105G, P106H, T108P","OV","observed variant","","The variant appeared in the early stages of asymptomatic period.","Guillon2006"
"55385","Rev 102","1735","","","","Rev","102","110","","8606..8632","A2","ILVESPAVL","IsgkpcAVL","L2S, V3G, E4K, S5P, P6C","L103S, V104G, E105K, S106P, P107C","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt15 carried this variant epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope ILVESPAVL.","Thorn2007"
"55385","Rev 102","1736","","","","Rev","102","110","","8606..8632","A2","ILVESPAVL","ILVEpstVL","S5P, P6S, A7T","S106P, P107S, A108T","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt16 carried this variant epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope ILVESPAVL.","Thorn2007"
"55385","Rev 102","1737","","","","Rev","102","110","","8606..8632","A2","ILVESPAVL","IsVESPtVL","L2S, A7T","L103S, A108T","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt17 carried this variant epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope ILVESPAVL.","Thorn2007"
"55385","Rev 102","1738","","","","Rev","102","110","","8606..8632","A2","ILVESPAVL","ILVEhPtiL","S5H, A7T, V8I","S106H, A108T, V109I","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt18 carried this variant epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope ILVESPAVL.","Thorn2007"
"55385","Rev 102","1739","","","","Rev","102","110","","8606..8632","A2","ILVESPAVL","ILlESPtVL","V3L, A7T","V104L, A108T","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt21 carried this variant epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope ILVESPAVL.","Thorn2007"
"55385","Rev 102","1740","","","","Rev","102","110","","8606..8632","A2","ILVESPAVL","ILVESPtVL","A7T","A108T","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt33 carried this variant epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope ILVESPAVL.","Thorn2007"
"55385","Rev 102","1741","","","","Rev","102","110","","8606..8632","A2","ILVESPAVL","ILVEpsAVL","S5P, P6S","S106P, P107S","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt35 carried this variant epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope ILVESPAVL.","Thorn2007"
"55385","Rev 102","1742","","","","Rev","102","110","","8606..8632","A2","ILVESPAVL","ILVESPAVi","L9I","L110I","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt41 carried this variant epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope ILVESPAVL.","Thorn2007"
"55385","Rev 102","1743","","","","Rev","102","110","","8606..8632","A2","ILVESPAVL","vLVEpPpVL","I1V, S5P, A7P","I102V, S106P, A108P","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt43 carried this variant epitope in a regulatory/accessory protein, and  recognized the HXB2 epitope ILVESPAVL.","Thorn2007"
"55385","Rev 102","1744","","","","Rev","102","110","","8606..8632","A2","ILVESPAVL","vLVESPAVL","I1V","I102V","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt23 carried this variant epitope in a regulatory/accessory protein, and  recognized the HXB2 epitope ILVESPAVL.","Thorn2007"
"55393","Vpu 66","1745","","","","Vpu","67","75","","6260..6286","","ALVEMGHHA","ALVEMGHHv","A9V","A75V","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","This modified variant, designed to optimize the anchor residue was cross-recognized strongly by index epitope ALVEMGHHA-recognizing CTL.","Thorn2007"
"55393","Vpu 66","1746","","","","Vpu","67","75","","6260..6286","","ALVEMGHHA","tmVdMGnlr","A1T, L2M, E4D, H7N, H8L, A9R","A67T, L68M, E70D, H73N, H74L, A75R","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt15 carried this variant epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope ALVEMGHHA.","Thorn2007"
"55393","Vpu 66","1747","","","","Vpu","67","75","","6260..6286","","ALVEMGHHA","iLVEMGHdA","A1I, H8D","A67I, H74D","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt16 carried this variant epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope ALVEMGHHA.","Thorn2007"
"55393","Vpu 66","1748","","","","Vpu","67","75","","6260..6286","","ALVEMGHHA","gLVEMGHpA","A1G, H8P","A67G, H74P","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt17 carried this variant epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope ALVEMGHHA.","Thorn2007"
"55393","Vpu 66","1749","","","","Vpu","67","75","","6260..6286","","ALVEMGHHA","ALVErGylA","M5R, H7Y, H8L","M71R, H73Y, H74L","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt23 carried this variant epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope ALVEMGHHA.","Thorn2007"
"55393","Vpu 66","1750","","","","Vpu","67","75","","6260..6286","","ALVEMGHHA","iLmEMGHdA","A1I, V3M, H8D","A67I, V69M, H74D","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt35 carried this variant epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope ALVEMGHHA.","Thorn2007"
"55393","Vpu 66","1751","","","","Vpu","67","75","","6260..6286","","ALVEMGHHA","ALmgMGHHA","V3M, E4G","V69M, E70G","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt41 carried this variant epitope in a regulatory/accessory protein, and did not recognize the HXB2 epitope ALVEMGHHA.","Thorn2007"
"54157","HL9","975","B","","","Vpu","74","82","","6281..6307","Cw*0102","HAPWDVNDL","HAPWDVNDm","L9M","L82M","SF","susceptible form","CD8 T-cell Elispot - IFNy","Last position (9) in the epitope had potentially experienced positive selection. The variant was recognized by CTLs to at a better extent than the wt form of the epitope.","Liu2006"
"620",,"1617","","B","B","gp160","2","10","gp120(2-10)","6228..6254","B8","RVKEKYQHL","RVKgirknYQHL","E4G, K5I, Y6R, Q7K, H8N, L9Y","E5G, K6I, Y7R, Q8K, H9N, L10Y","NSF","non-susceptible form","Chromium-release assay","This naturally occurring, strain JRCSF variant, was not recognized by a Patient LWS CTL clone.","Sipsas1997"
"58250",,"2855","B","B","B","gp160","6","20","gp120(6-20)","6240..6284","","NYQHLWRGGIMLLWRGIM","NYQHLWRGGIsLLWRGIM","M11S","M16S","IE","inferred escape","Sequence","Peptide NYQHLWRGGIMLLWRGIM varied at 228 DFOSx to NYQHLWRGGIsLLWRGIM.  Position 16 in the peptide is marked as being under selection to vary.","Ferrari2011"
"58250",,"2856","B","B","B","gp160","6","20","gp120(6-20)","6240..6284","","NYQHLWRGGIMLLWRGIM","NYQHwWRGGIMLLWRGIM","L5W","L10W","IE","inferred escape","Sequence","Peptide NYQHLWRGGIMLLWRGIM varied at 368 DFOSx to NYQHwWRGGIMLLWRGIM.  Position 10 in the peptide is marked as being under selection to vary.","Ferrari2011"
"54650","ENV-05","1970","B","B","C","gp160","30","46","gp120(30-46)","6312..6362","","AAENLWVTVYYGVPVWK","vggNLWVTVYYGVPVWK","A1V, A2G, E3G","A30V, A31G, E32G","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 3 amino acids (17.6%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"53422","ATE","1370","","","","gp160","30","49","gp120(30-49)","6312..6371","","ATEKLWVTVYYGVPVWKEAT","ATEKmWVTVYYGVPVWKEAT","L5M","L34M","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/20 viral clones contained this variant sequence at the first time point (Day60) tested after infection.","Oxenius2004"
"53422","ATE","1371","","","","gp160","30","49","gp120(30-49)","6312..6371","","ATEKLWVTVYYGVPVWKEAT","ATEKLWVTVYYGaPVWKEAT","V13A","V42A","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/20 viral clones contained this variant sequence at the first time point (Day60) tested after infection.","Oxenius2004"
"53422","ATE","1372","","","","gp160","30","49","gp120(30-49)","6312..6371","","ATEKLWVTVYYGVPVWKEAT","ATEKLcVTVYYGVPVWKEAT","W6C","W35C","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/19 viral clones contained this variant sequence at the second time point (Day 369) tested after infection.","Oxenius2004"
"53422","ATE","1373","","","","gp160","30","49","gp120(30-49)","6312..6371","","ATEKLWVTVYYGVPVWKEAT","ATEKLWVTVhYGVPVWKEAT","Y10H","Y39H","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/19 viral clones contained this variant sequence at the second time point (Day 369) tested after infection.","Oxenius2004"
"53422","ATE","1374","","","","gp160","30","49","gp120(30-49)","6312..6371","","ATEKLWVTVYYGVPVWKEAT","ATEKLWVTVYYGVPaWKEAT","V15A","V44A","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/19 viral clones contained this variant sequence at the second time point (Day 369) tested after infection.","Oxenius2004"
"53422","ATE","1375","","","","gp160","30","49","gp120(30-49)","6312..6371","","ATEKLWVTVYYGVPVWKEAT","ATEKLWVTVYhGVPVWKEAT","Y11H","Y40H","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/12 viral clones contained this variant sequence at the last time point (Day 635) tested after infection.","Oxenius2004"
"622",,"91","","B","B","gp160","31","39","gp120(31-39)","6315..6341","B44","AENLWVTVY","tENLWVTVY","A1T","A31T","SF","susceptible form","","The naturally occurring forms of the peptide found in WEAU were tested as targets for early WEAU CTLs -- the form TENLWVTVY was as reactive as the wild type AENLWVTVY -- but the forms AKNLWVTVY, AGNLWVTVY, AANLWVTVY did not serve as targets.","Borrow1998, Borrow1997, Goulder1997e"
"622",,"92","","B","B","gp160","31","39","gp120(31-39)","6315..6341","B44","AENLWVTVY","AkNLWVTVY","E2K","E32K","NSF","non-susceptible form","","The naturally occurring forms of the peptide found in WEAU were tested as targets for early WEAU CTLs -- the form TENLWVTVY was as reactive as the wild type AENLWVTVY -- but the forms AKNLWVTVY, AGNLWVTVY, AANLWVTVY did not serve as targets.","Borrow1998, Borrow1997, Goulder1997e"
"622",,"93","","B","B","gp160","31","39","gp120(31-39)","6315..6341","B44","AENLWVTVY","AgNLWVTVY","E2G","E32G","NSF","non-susceptible form","","The naturally occurring forms of the peptide found in WEAU were tested as targets for early WEAU CTLs -- the form TENLWVTVY was as reactive as the wild type AENLWVTVY -- but the forms AKNLWVTVY, AGNLWVTVY, AANLWVTVY did not serve as targets.","Borrow1998, Borrow1997, Goulder1997e"
"622",,"94","","B","B","gp160","31","39","gp120(31-39)","6315..6341","B44","AENLWVTVY","AaNLWVTVY","E2A","E32A","NSF","non-susceptible form","","The naturally occurring forms of the peptide found in WEAU were tested as targets for early WEAU CTLs -- the form TENLWVTVY was as reactive as the wild type AENLWVTVY -- but the forms AKNLWVTVY, AGNLWVTVY, AANLWVTVY did not serve as targets.","Borrow1998, Borrow1997, Goulder1997e"
"53226","gp160 AY9","546","","","","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","AaNLWVTaY","E2A, V8A","E32A, V38A","DR","diminished response","","Confirmed some degree of escape by reduction of CTL response.","Jones2004"
"53226","gp160 AY9","547","","","","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","AEkLWVTVY","N3K","N33K","DR","diminished response","","Confirmed some degree of escape by reduction of CTL response.","Jones2004"
"53226","gp160 AY9","548","","","","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","AENLgVTVY","W5G","W35G","DR","diminished response","","Confirmed some degree of escape by reduction of CTL response.","Jones2004"
"53226","gp160 AY9","549","","","","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","tENLWVTVY","A1T","A31T","SF","susceptible form","","Variant did not diminish CTL response.","Jones2004"
"53226","gp160 AY9","550","","","","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","vENsWVTVY","A1V, L4S","A31V, L34S","DR","diminished response","","Confirmed some degree of escape by reduction of CTL response.","Jones2004"
"53226","gp160 AY9","551","","","","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","tEkLWVTVY","A1T, N3K","A31T, N33K","DR","diminished response","","Confirmed some degree of escape by reduction of CTL response.","Jones2004"
"53226","gp160 AY9","552","","","","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","AgNLWVTVY","E2G","E32G","DR","diminished response","","Confirmed some degree of escape by reduction of CTL response.","Jones2004"
"53226","gp160 AY9","553","","","","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","AaNLWVTVY","E2A","E32A","E","escape documented in this paper","","Confirmed escape by dramatic decrease in CTL response.","Jones2004"
"53226","gp160 AY9","554","","","","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","AkNLWVTVY","E2K","E32K","E","escape documented in this paper","","Confirmed escape by dramatic decrease in CTL response.","Jones2004"
"53226","gp160 AY9","555","","","","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","tENLWVTiY","A1T, V8I","A31T, V38I","SF","susceptible form","","Elicited strong CTL response","Jones2004"
"54160","AY9","976","B","","","gp160","31","39","gp120(31-39)","6315..6341","B*1801","AENLWVTVY","AdNLWVTVY","E2D","E32D","SF","susceptible form","CD8 T-cell Elispot - IFNy","Position 1 in the epitope had potentially experienced positive selection. The variant was recognized by CTLs to a similar extent as the wt form of the epitope.","Liu2006"
"54160","AY9","977","B","","","gp160","31","39","gp120(31-39)","6315..6341","B*1801","AENLWVTVY","tdNLWVTVY","A1T, E2D","A31T, E32D","SF","susceptible form","CD8 T-cell Elispot - IFNy","Position 1 in the epitope had potentially experienced positive selection. The variant was recognized by CTLs to a similar extent as the wt form of the epitope.","Liu2006"
"54160","AY9","978","B","","","gp160","31","39","gp120(31-39)","6315..6341","B*1801","AENLWVTVY","tEdLWVTVY","A1T, N3D","A31T, N33D","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Position 1 in the epitope had potentially experienced positive selection. The variant was full escape, as it was not recognized by CTLs.","Liu2006"
"54160","AY9","979","B","","","gp160","31","39","gp120(31-39)","6315..6341","B*1801","AENLWVTVY","eEdLWVTVY","A1E, N3D","A31E, N33D","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Position 1 in the epitope had potentially experienced positive selection. The variant was full escape, as it was not recognized by CTLs.","Liu2006"
"54160","AY9","980","B","","","gp160","31","39","gp120(31-39)","6315..6341","B*1801","AENLWVTVY","AEdsWVTVY","N3D, L4S","N33D, L34S","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Position 1 in the epitope had potentially experienced positive selection. The variant was full escape, as it was not recognized by CTLs.","Liu2006"
"57436","AY9","2394","B","B","B","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","AEkLWVTVY","N3K","N33K","E","escape documented in this paper","Chromium-release assay, Sequence","AY9 variant, AEkLWVTVY, is seen from day 10 after onset of symptoms onwards and accumulates to 23.34% of variants by day 30 at a rate of 0.21. This escape is seen by conventional sequencing from day 23 to day 44.","Fischer2010"
"57436","AY9","2395","B","B","B","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","tENLWVTVY","N3K","N33K","SF","susceptible form","Chromium-release assay, Sequence","AY9 variant tENLWVTVY is seen to increase in proportion up to 10.92% on day 30 after onset of symptoms, with an estimated accumulation rate of 0.14. It continues to be sensitive as seen in Chromium release assays from day 15 onwards, even at day 212.","Fischer2010"
"57436","AY9","2396","B","B","B","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","vENLWVTVY","A1V","A31V","IE","inferred escape","Chromium-release assay, Sequence","AY9 variant vENLWVTVY is seen to increase from day 10 after onset of symptoms onwards to 10.61% on day 30, at an estimated accumulation rate of 0.17.  It is seen by conventional sequencing from day 15 to day 44.","Fischer2010"
"57436","AY9","2397","B","B","B","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","AkNLWVTVY","E2K","E32K","E","escape documented in this paper","Chromium-release assay, Sequence","AY9 variant AkNLWVTVY is seen to increase from day 10 after onset of symptoms onwards to 7.55% on day 30, at an estimated accumulation rate of 0.14.  This escape as determined by Chromium release assay, is seen by conventional sequencing from day 23 to day 212.","Fischer2010"
"57436","AY9","2398","B","B","B","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","AgNLWVTVY","E2G","E32G","E","escape documented in this paper","Chromium-release assay, Sequence","AY9 variant AgNLWVTVY was seen from day 20 after onset of symptoms onwards, with a frequency of 4.74% by day 30.  It was also detected by conventional sequencing from day 30 onwards and was an escape as determined by Chromium release assay.","Fischer2010"
"57436","AY9","2399","B","B","B","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","AENLWVTiY","V8I","V38I","OV","observed variant","Sequence","AY9 variant AENLWVTiY was seen all through early infection sampling time points, though at a low level.","Fischer2010"
"57436","AY9","2400","B","B","B","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","AEdLWVTVY","N3D","N33D","OV","observed variant","Sequence","AY9 variant AEdLWVTVY was seen from day 20 after onset of symptoms onwards and was also detected by conventional sequencing on day 44.","Fischer2010"
"57436","AY9","2401","B","B","B","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","AaNLWVTVY","E2A","E32A","E","escape documented in this paper","Chromium-release assay, Sequence","AY9 variant AaNLWVTVY was seen at trace levels from day 20 after onset of symptoms onwards.  It was also detected by conventional sequencing on day 136, when it was determined to be an escape as tested by Chromium release assay.","Fischer2010"
"57436","AY9","2402","B","B","B","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","AEsLWVTVY","N3S","N33S","OV","observed variant","Sequence","AY9 variant AEsLWVTVY was seen from day 10 after onset of symptoms onwards; and also by conventional sequencing at day 44.","Fischer2010"
"57436","AY9","2403","B","B","B","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","AdNLWVTVY","E2D","E32D","OV","observed variant","Sequence","AY9 variant AdNLWVTVY was seen at trace levels by day 20 after onset of symptoms.","Fischer2010"
"57436","AY9","2466","B","B","B","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","AaNLWVTaY","E2A, V8A","E32A, V38A","E","escape documented in this paper","Chromium-release assay, Sequence","AY9 variant AaNLWVTaY was detected by conventional sequencing on day 72 after onset of symptoms, when it was determined to be an escape as tested by Chromium release assay.","Fischer2010"
"57436","AY9","2467","B","B","B","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","AENsWVTVY","L4S","L34S","OV","observed variant","Chromium-release assay","AY9 variant AENsWVTVY was seen at day 23 after onset of symptoms by conventional sequencing.","Fischer2010"
"57436","AY9","2468","B","B","B","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","vENsWVTVY","A1V, L4S","A31V, L34S","E","escape documented in this paper","Chromium-release assay, Sequence","AY9 variant vENsWVTVY is an escape seen at day 30 after onset of symptoms by conventional sequencing.","Fischer2010"
"57436","AY9","2469","B","B","B","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","AEtLWVTVY","N3T","N33T","OV","observed variant","Sequence","AY9 variant AEtLWVTVY is seen at day 44 after onset of symptoms by conventional sequencing.","Fischer2010"
"57436","AY9","2470","B","B","B","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","tENLWVTiY","A1T, V8I","A31T, V38I","SF","susceptible form","Chromium-release assay, Sequence","AY9 variant tENLWVTiY was seen by conventional sequencing on day 72 after onset of symptoms and when tested by Chromium release assay, elicited a CTL response resulting in killing.","Fischer2010"
"57436","AY9","2471","B","B","B","gp160","31","39","gp120(31-39)","6315..6341","B*4403","AENLWVTVY","tEkLWVTVY","A1T, N3K","A31T, N33K","E","escape documented in this paper","Chromium-release assay, Sequence","AY9 variant tEkLWVTVY was seen by conventional sequencing on day 391 after onset of symptoms when it was determined to be an escape by Chromium release assay.","Fischer2010"
"58157","AY9","2745","B","B","B","gp160","31","39","gp120(31-39)","6315..6341","B*1801","AENLWVTVY","AdNLWVTVY","E2D","E32D","SF","susceptible form","CD8 T-cell Elispot - IFNy, Longitudinal study","Variant AdNLWVTVY arose by 400 days post-infection, and was replaced by AEdsWVTVY after 800 days post-infection. The latter variant was associated with loss of EliSpot response to the epitope.","Liu2011a"
"58157","AY9","2746","B","B","B","gp160","31","39","gp120(31-39)","6315..6341","B*1801","AENLWVTVY","AEdsWVTVY","N3D, L4S","N33D, L34S","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Longitudinal study","Variant AdNLWVTVY arose by 400 days post-infection, and was replaced by AEdsWVTVY after 800 days post-infection. The latter variant was associated with loss of EliSpot response to the epitope.","Liu2011a"
"59090",,"3262","B","B","B","gp160","31","39","gp120(31-39)",,"B*1801","AENLWVTVY","TEdLWVTVY","A1T, N3D","A31T, N33D","E","escape documented in this paper","Peptide titration","EliSpot peptide titration indicated full escape.","Liu2007a"
"59090",,"3263","B","B","B","gp160","31","39","gp120(31-39)",,"B*1801","AENLWVTVY","eEDLWVTVY","A1E, N3D","A31E, N33D","E","escape documented in this paper","Peptide titration","EliSpot peptide titration indicated full escape.","Liu2007a"
"59090",,"3264","B","B","B","gp160","31","39","gp120(31-39)",,"B*1801","AENLWVTVY","AEdsWVTVY","N3D, L4S","N33D, L34S","E","escape documented in this paper","Peptide titration","EliSpot peptide titration indicated full escape.","Liu2007a"
"55118",,"1442","","","","gp160","33","42","gp120(33-42)","6321..6350","A2","NLWVTVYYGV","kLWVTVYYGV","N1K","N33K","OV","observed variant","Sequence","This variant was found in 4/10 Brazilian Subtype B and 2/19 Brazilian Subtype B/F recombinant sequences.","Queiroz2007"
"55118",,"1443","","","","gp160","33","42","gp120(33-42)","6321..6350","A2","NLWVTVYYGV","qLWVTVYYGV","N1Q","N33Q","OV","observed variant","Sequence","This variant was found in 3/10 Brazilian Subtype B and 2/19 Brazilian Subtype B/F recombinant sequences.","Queiroz2007"
"55118",,"1444","","","","gp160","33","42","gp120(33-42)","6321..6350","A2","NLWVTVYYGV","dLWVTVYYGV","N1D","N33D","OV","observed variant","Sequence","This variant was found in 2/19 Brazilian Subtype B/F recombinant sequences.","Queiroz2007"
"55290",,"1510","B","","","gp160","33","42","gp120(33-42)","6321..6350","A2, A2.1","KLWVTVYYGV","nwWVTVYYGV","K1N, L2W","K33N, L34W","OV","observed variant","Sequence","This index epitope was conserved in the mother's viral strain but mutated in the daughter's isolate.","Reinis2007"
"55287",,"1511","B","","","gp160","34","55","gp120(34-55)","6324..6389","A2","LWVTVYYGVPVWKEATTTLFCA","wWVTVYYGVPVWKEATnTLFCA","L1W, T17N","L34W, T50N","OV","observed variant","Sequence","This index epitope was conserved in the mother's viral strain but mutated in the daughter's isolate.","Reinis2007"
"53069","Env 47","1218","M","B, C","C","gp160","36","46","gp120(36-46)","6330..6362","A*1101","VTVYYGVPVWK","VTVYYGVPVWr","K11R","K46R","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This anchor position variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53069","Env 47","1219","M","B, C","","gp160","36","46","gp120(36-46)","6330..6362","A*1101","VTVYYGVPVWK","VTiYYGVPVWK","V3I","V38I","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant elicited a CTL response with cells from mice immunized with the index form.  It was also recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53069","Env 47","1220","M","B, C","C","gp160","36","46","gp120(36-46)","6330..6362","A*1101","VTVYYGVPVWK","VTVYdGVPVWK","Y5D","Y40D","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant elicited a CTL response with cells from mice immunized with the index form.  It was however, not recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53069","Env 47","1221","M","B, C","","gp160","36","46","gp120(36-46)","6330..6362","A*1101","VTVYYGVPVWK","VTVYYGVPiWK","V9I","V44I","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant elicited a CTL response with cells from mice immunized with the index form.  It was recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53069","Env 47","1222","M","B, C","","gp160","36","46","gp120(36-46)","6330..6362","A*1101","VTVYYGVPVWK","iTVYYGVPVWr","V1I, K11R","V36I, K46R","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited a CTL response with cells from mice immunized with the index form.  It was recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53069","Env 47","1223","M","B, C","","gp160","36","46","gp120(36-46)","6330..6362","A*1101","VTVYYGVPVWK","VTiYYGVPVWr","K11R, V3I","K46R, V38I","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited a CTL response with cells from mice immunized with the index form.  It was recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53069","Env 47","1224","M","B, C","B","gp160","36","46","gp120(36-46)","6330..6362","A*1101","VTVYYGVPVWK","VTVYdGVPVWr","K11R, Y5D","K46R, Y40D","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited a weak CTL response with cells from mice immunized with the index form.  It was not recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53069","Env 47","1225","M","B, C","","gp160","36","46","gp120(36-46)","6330..6362","A*1101","VTVYYGVPVWK","VTVYYGiPVWr","K11R, V7I","K46R, V42I","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited a CTL response with cells from mice immunized with the index form.  It was weakly recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53069","Env 47","1226","M","B, C","","gp160","36","46","gp120(36-46)","6330..6362","A*1101","VTVYYGVPVWK","VTVYYGVPVrr","W10R, K11R","W45R, K46R","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant elicited a weak CTL response with cells from mice immunized with the index form.  It was not recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"55124",,"1445","","","","gp160","36","46","gp120(36-46)","6330..6362","A*6801","VTVYYGVPVWK","VTVYYGVPVWr","K11R","K46R","OV","observed variant","Sequence","This variant was found in 2/12 Brazilian Subtype C and 2/19 Brazilian Subtype B/F recombinant sequences.","Queiroz2007"
"55125",,"1446","","","","gp160","37","46","gp120(37-46)","6333..6362","A*0301, A*6801","TVYYGVPVWK","TVYYGVPVWr","K10R","K46R","OV","observed variant","Sequence","This variant was found in 2/12 Brazilian Subtype C and 2/19 Brazilian Subtype B/F recombinant sequences.","Queiroz2007"
"57678","EnvTK10","2675","A, B","A, B, C, D","A, B, C, D","gp160","37","46","gp120(37-46)","6333..6362","A3","TVYYGVPVWK","TVYYGVPVWr","K10R","K46R","SF, SSF","susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Variant TVYYGVPVWr was found at a frequency of 36, 6, 19 and 4 in clades A, B, C and D respectively.","Koup2010"
"57678","EnvTK10","2676","A, B","A, B, C, D","C","gp160","37","46","gp120(37-46)","6333..6362","A3","TVYYGVPVWK","TVYYGVPVWt","K10T","K46T","SF, SSF","susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Variant TVYYGVPVWt was found at a frequency of 7 in clade C.","Koup2010"
"57678","EnvTK10","2677","A, B","A, B, C, D","C, D","gp160","37","46","gp120(37-46)","6333..6362","A3","TVYYGVPVWK","aVYYGVPVWK","T1A","T37A","SF, SSF","susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Variant aVYYGVPVWK was found frequencies of 1 and 2 in clades C and D.","Koup2010"
"54651","ENV-06","1971","B","B","C","gp160","37","53","gp120(37-53)","6333..6383","","TVYYGVPVWKEATTTLF","TVYYGVPVWKEAkTTLF","T13K","T49K","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 1 amino acid (5.9%) and was recognized.","Zhao2007"
"55126",,"1447","","","","gp160","38","48","gp120(38-48)","6336..6368","Cw7","VYYGVPVWKEA","VYYGVPVWrEA","K9R","K46R","OV","observed variant","Sequence","This variant was found in 2/12 Brazilian Subtype C and 2/19 Brazilian Subtype B/F recombinant sequences.","Queiroz2007"
"58558","OLP-8","3025","A1","A1","B","gp160","39","53","gp120(39-53)","6339..6383","B*3501, B*5501","YYGVPVWKDAETTLF","YYGVPVWKeAtTTLF","E11T, D9E","E49T, D47E","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Clade B sequence analogous to Clade A1 OLP-8 is YYGVPVWKeAtTTLF, containing Clade B-BDE, VPVWKeAtTT.","McKinnon2009a"
"55127",,"1448","","","","gp160","42","51","gp120(42-51)","6348..6377","B55, B*5501","VPVWKEATTT","VPVWKEAkTT","T8K","T49K","OV","observed variant","Sequence","This variant was found in 10/12 Brazilian Subtype C sequences.","Queiroz2007"
"55127",,"1449","","","","gp160","42","51","gp120(42-51)","6348..6377","B55, B*5501","VPVWKEATTT","VPVWrEAnTT","K5R, T8N","K46R, T49N","OV","observed variant","Sequence","This variant was found in 2/19 Brazilian Subtype B/F recombinant sequences.","Queiroz2007"
"640",,"102","","B, D","C","gp160","42","52","gp120(42-52)","6348..6380","B35","VPVWKEATTTL","VPVWKEAdTTL","T8D","T49D","SSF","subtype-specific susceptible form","Chromium-release assay","VPVWKEATTTL is the consensus sequence for clades B and D.VPVWKEAdTTL is the consensus sequence for clade C and it is cross-reactive.","Cao1997a"
"640",,"103","","B, D","C","gp160","42","52","gp120(42-52)","6348..6380","B35","VPVWKEATTTL","VPVWrdAdTTL","K5R, E6D, T8D","K46R, E47D, T49D","SSF","subtype-specific susceptible form","Chromium-release assay","VPVWKEATTTL is the consensus sequence for clades B and D. VPVWrdAdTTL is the consensus sequence for clade E and even with three substitutions still retains some cross-reactivity.","Cao1997a"
"55128",,"1450","","","","gp160","42","52","gp120(42-52)","6348..6380","B*3501","VPVWKEATTTL","VPVWKEAkTTL","T8K","T49K","OV","observed variant","Sequence","This variant was found in 10/12 Brazilian Subtype C sequences.","Queiroz2007"
"640",,"2932","","B, D","C","gp160","42","52","gp120(42-52)","6348..6380","B35","VPVWKEATTTL","VPVWKdAeTTL","E6D, T8E","E47D, T49E","SSF","subtype-specific susceptible form","Chromium-release assay","VPVWKEATTTL is the consensus sequence for clades B and D. VPVWKdAeTTL is the consensus sequence for clade A and it is cross-reactive.","Cao1997a"
"53423","VPV","1376","","","","gp160","42","61","gp120(42-61)","6348..6407","","VPVWKEATTTLFCASDAKAY","VPVWKEATTTLsrASDAKAY","F12S, C13R","F53S, C54R","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 3/20 viral clones contained this variant sequence at the first time point (Day 60) tested after infection.","Oxenius2004"
"53423","VPV","1377","","","","gp160","42","61","gp120(42-61)","6348..6407","","VPVWKEATTTLFCASDAKAY","aPVWKEATTTLFCASDAKAY","V1A","V42A","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/20 viral clones contained this variant sequence at the first time point (Day60) tested after infection.","Oxenius2004"
"53423","VPV","1378","","","","gp160","42","61","gp120(42-61)","6348..6407","","VPVWKEATTTLFCASDAKAY","VPVWKEATTTLFrASDAKAY","C13R","C54R","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/20 viral clones contained this variant sequence at the first time point (Day60) tested after infection.","Oxenius2004"
"53423","VPV","1379","","","","gp160","42","61","gp120(42-61)","6348..6407","","VPVWKEATTTLFCASDAKAY","VPVWKEATTTLFCvSDAKAY","A14V","A55V","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/20 viral clones contained this variant sequence at the first time point (Day60) tested after infection.","Oxenius2004"
"53423","VPV","1380","","","","gp160","42","61","gp120(42-61)","6348..6407","","VPVWKEATTTLFCASDAKAY","VPVWKEATTTLFCAtDAKAY","S15T","S56T","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/19 viral clones contained this variant sequence at the second time point (Day 369) tested after infection.","Oxenius2004"
"53423","VPV","1381","","","","gp160","42","61","gp120(42-61)","6348..6407","","VPVWKEATTTLFCASDAKAY","VPVWKEATTTLFyASDAKAY","C13Y","C54Y","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/19 viral clones contained this variant sequence at the second time point (Day 369) tested after infection.","Oxenius2004"
"53423","VPV","1382","","","","gp160","42","61","gp120(42-61)","6348..6407","","VPVWKEATTTLFCASDAKAY","VPVWKEATTTpFCASDAKAY","L11P","L52P","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/19 viral clones contained this variant sequence at the second time point (Day 369) tested after infection.","Oxenius2004"
"53423","VPV","1383","","","","gp160","42","61","gp120(42-61)","6348..6407","","VPVWKEATTTLFCASDAKAY","VPaWKEATTTLFCASDAKsY","A19S, V3A","A60S, V44A","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/19 viral clones contained this variant sequence at the second time point (Day 369) tested after infection.","Oxenius2004"
"55129",,"1451","","","","gp160","50","59","gp120(50-59)","6372..6401","A3","TTLFCASDAK","TTLFCASDAr","K10R","K59R","OV","observed variant","Sequence","This variant was found in 2/12 Brazilian Subtype C sequences.","Queiroz2007"
"55130",,"1452","","","","gp160","51","59","gp120(51-59)","6375..6401","A3","TLFCASDAK","TLFCASDAr","K9R","K59R","OV","observed variant","Sequence","This variant was found in 2/12 Brazilian Subtype C sequences.","Queiroz2007"
"57472",,"2454","B","B","B","gp160","55","72","gp120(55-72)","6387..6440","","ASDAKAHDPEVHNVWATH","ASDAKAHDPEVyNVWATH","H12Y","H66Y","DR","diminished response","CD8 T-cell Elispot - IFNy","One patient had a positive response to 18-mer ASDAKAHDPEVHNVWATH and a diminished response to variant ASDAKAHDPEVyNVWATH.","Wood2009"
"56054","KW11(gp120)","1933","B","B","B","gp160","59","69","gp120(59-69)","6399..6431","","KAYDTEVHNVW","KAYeTEVHNVW","D4E","D62E","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B58 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"57471",,"2449","B","B","B","gp160","59","69","gp120(59-69)","6399..6431","B*5801","KAHDPEVHNVW","KAHDPEVyNVW","H8Y","H66Y","DR","diminished response","CD8 T-cell Elispot - IFNy","Documented diminished response to epitope.","Wood2009"
"54161","YW9","981","B","","","gp160","61","69","gp120(61-69)","6405..6431","B*1801","YETEVHNVW","YgTEVHNVW","E2G","E62G","DR","diminished response","CD8 T-cell Elispot - IFNy","Positions 2 and 5 in the epitope had potentially experienced positive selection. Wt form of the epitope was 22 times better recognized than the variant, making the variant a partial escape.","Liu2006"
"54161","YW9","982","B","","","gp160","61","69","gp120(61-69)","6405..6431","B*1801","YETEVHNVW","YdTEVHNVW","E2D","E62D","DR","diminished response","CD8 T-cell Elispot - IFNy","Positions 2 and 5 in the epitope had potentially experienced positive selection. Wt form of the epitope was 13 times better recognized than the variant, making the variant a partial escape.","Liu2006"
"54161","YW9","983","B","","","gp160","61","69","gp120(61-69)","6405..6431","B*1801","YETEVHNVW","YETEaHNVW","V5A","V65A","SF","susceptible form","CD8 T-cell Elispot - IFNy","Positions 2 and 5 in the epitope had potentially experienced positive selection. The variant was recognized by CTLs to a similar extent as the wt form of the epitope.","Liu2006"
"54161","YW9","984","B","","","gp160","61","69","gp120(61-69)","6405..6431","B*1801","YETEVHNVW","YdTEaHNVW","E2D, V5A","E62D, V65A","DR","diminished response","CD8 T-cell Elispot - IFNy","Positions 2 and 5 in the epitope had potentially experienced positive selection. Wt form of the epitope was >83 times better recognized than the variant, making the variant a partial escape.","Liu2006"
"58149","YW9","2734","B","B","B","gp160","61","69","gp120(61-69)","6405..6431","B*1801","YETEVHNVW","YgTEVHNVW","E2G","E62G","DR","diminished response","CD8 T-cell Elispot - IFNy, Longitudinal study","Variants YgTEVHNVW, YETEaHNVW, and YdTEVHNVW replaced the wild type sequence early in infection, while variant YdTEaHNVW dominated by 800 days post-infection. Sequence changes were associated with loss of EliSpot response to the epitope.","Liu2011a"
"58149","YW9","2735","B","B","B","gp160","61","69","gp120(61-69)","6405..6431","B*1801","YETEVHNVW","YETEaHNVW","V5A","V65A","DR","diminished response","CD8 T-cell Elispot - IFNy, Longitudinal study","Variants YgTEVHNVW, YETEaHNVW, and YdTEVHNVW replaced the wild type sequence early in infection, while variant YdTEaHNVW dominated by 800 days post-infection. Sequence changes were associated with loss of EliSpot response to the epitope.","Liu2011a"
"58149","YW9","2736","B","B","B","gp160","61","69","gp120(61-69)","6405..6431","B*1801","YETEVHNVW","YdTEVHNVW","E2D","E62D","DR","diminished response","CD8 T-cell Elispot - IFNy, Longitudinal study","Variants YgTEVHNVW, YETEaHNVW, and YdTEVHNVW replaced the wild type sequence early in infection, while variant YdTEaHNVW dominated by 800 days post-infection. Sequence changes were associated with loss of EliSpot response to the epitope.","Liu2011a"
"58149","YW9","2737","B","B","B","gp160","61","69","gp120(61-69)","6405..6431","B*1801","YETEVHNVW","YdTEaHNVW","E2D, V5A","E62D, V65A","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Longitudinal study","Variants YgTEVHNVW, YETEaHNVW, and YdTEVHNVW replaced the wild type sequence early in infection, while variant YdTEaHNVW dominated by 800 days post-infection. Sequence changes were associated with loss of EliSpot response to the epitope.","Liu2011a"
"59091",,"3265","B","B","B","gp160","61","69","gp120(61-69)",,"B*1801","YETEVHNVW","YgTEVHNVW","E2G","E62G","DR","diminished response","Peptide titration","Ratio of EliSpot peptide titration of this mutant to original epitope EC<sub>50</sub>ratio = 22, suggesting partial escape.","Liu2007a"
"59091",,"3266","B","B","B","gp160","61","69","gp120(61-69)",,"B*1801","YETEVHNVW","YdTEVHNVW","E2D","E62D","DR","diminished response","Peptide titration","Ratio of EliSpot peptide titration of this mutant to original epitope EC<sub>50</sub>ratio = 13, suggesting partial escape.","Liu2007a"
"59091",,"3267","B","B","B","gp160","61","69","gp120(61-69)",,"B*1801","YETEVHNVW","YdTEaHNVW","E2D, V5A","E62D, V65A","DR","diminished response","Peptide titration","Ratio of EliSpot peptide titration of this mutant to original epitope EC<sub>50</sub>ratio = >83, suggesting partial escape.","Liu2007a"
"53746",,"699","A, B, C, CRF01_AE, D","","","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EVHNiWATHA","V5I","V68I","SF","susceptible form","CD8 T-cell Elispot - IFNy","Variant bound to A*2603 with equal affinity as the wt and was efficiently recognized by CTLs.","Kawashima2005"
"53746",,"700","A, B, C, CRF01_AE, D","","","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EiHNVWATHA","V2I","V65I","DHB, SF","diminished HLA binding or increased off-rate, susceptible form","CD8 T-cell Elispot - IFNy","Variant bound to A*2603 with reduced affinity compared to the wt but was efficiently recognized by CTLs.","Kawashima2005"
"53746",,"701","A, B, C, CRF01_AE, D","","","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EaHNVWATHA","V2A","V65A","DHB, SF","diminished HLA binding or increased off-rate, susceptible form","CD8 T-cell Elispot - IFNy","Variant bound to A*2603 with reduced affinity compared to the wt but was efficiently recognized by CTLs.","Kawashima2005"
"53746",,"702","A, B, C, CRF01_AE, D","","","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EmHNVWATHA","V2M","V65M","DHB, IE","diminished HLA binding or increased off-rate, inferred escape","CD8 T-cell Elispot - IFNy","Variant did not bind to A*2603.","Kawashima2005"
"53746",,"703","A, B, C, CRF01_AE, D","A, B, C, CRF01_AE","D","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EaHNiWATHA","V2A, V5I","V65A, V68I","OV","observed variant","","Variant most common in clade D but present in all subtypes in HIV sequence database.","Kawashima2005"
"53746",,"704","A, B, C, CRF01_AE, D","","","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EkHNVWATHA","V2K","V65K","DHB","diminished HLA binding or increased off-rate","CD8 T-cell Elispot - IFNy","Variant did not bind to A*2603.","Kawashima2005"
"53746",,"705","A, B, C, CRF01_AE, D","","B","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","gVHNVWATHA","E1G","E64G","OV","observed variant","","Variant found in clade B from HIV sequence database.","Kawashima2005"
"53746",,"706","A, B, C, CRF01_AE, D","","B","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EVHNmWATHA","V5M","V68M","OV","observed variant","","Variant found in clade B from HIV sequence database.","Kawashima2005"
"53746",,"707","A, B, C, CRF01_AE, D","","A, B","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EVHNVsATHA","W6S","W69S","OV","observed variant","","Variant found in clades A and B from HIV sequence database.","Kawashima2005"
"53746",,"708","A, B, C, CRF01_AE, D","","A, B, D","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EkHNiWATHA","V2K, V5I","V65K, V68I","OV","observed variant","","Variant found in clades A, B and D from HIV sequence database.","Kawashima2005"
"53746",,"709","A, B, C, CRF01_AE, D","","A","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EkHNVsATHA","V2K, W6S","V65K, W69S","OV","observed variant","","Variant found in clade A from HIV sequence database.","Kawashima2005"
"53746",,"710","A, B, C, CRF01_AE, D","","B","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EVHNVWAiHA","T8I","T71I","OV","observed variant","","Variant found in clade B from HIV sequence database.","Kawashima2005"
"53746",,"711","A, B, C, CRF01_AE, D","","B","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EVHNVWATyA","H9Y","H72Y","OV","observed variant","","Variant found in clade B from HIV sequence database.","Kawashima2005"
"53746",,"712","A, B, C, CRF01_AE, D","","B","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EVHNVWAkHA","T8K","T71K","OV","observed variant","","Variant found in clade B from HIV sequence database.","Kawashima2005"
"53746",,"713","A, B, C, CRF01_AE, D","","B","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EVHNVWATqA","H9Q","H72Q","OV","observed variant","","Variant found in clade B from HIV sequence database.","Kawashima2005"
"53746",,"714","A, B, C, CRF01_AE, D","","A, B","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","ErHNVWATHA","V2R","V65R","OV","observed variant","","Variant found in clades A and B from HIV sequence database.","Kawashima2005"
"53746",,"715","A, B, C, CRF01_AE, D","","","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EVyNiWATHA","H3Y, V5I","H66Y, V68I","OV","observed variant","","Variant not found by authors in HIV sequence database.","Kawashima2005"
"53746",,"716","A, B, C, CRF01_AE, D","","A","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EqHNVWATHA","V2Q","V65Q","OV","observed variant","","Variant found in clade A from HIV sequence database.","Kawashima2005"
"53746",,"717","A, B, C, CRF01_AE, D","","A","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EqHiVWATHA","V2Q, N4I","V65Q, N67I","OV","observed variant","","Variant found in clade A from HIV sequence database.","Kawashima2005"
"53746",,"718","A, B, C, CRF01_AE, D","","A","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EaHNVsATHA","V2A, W6S","V65A, W69S","OV","observed variant","","Variant found in clade A from HIV sequence database.","Kawashima2005"
"53746",,"719","A, B, C, CRF01_AE, D","","C","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EgHNVWATHA","V2G","V65G","OV","observed variant","","Variant found in clade C from HIV sequence database.","Kawashima2005"
"53746",,"720","A, B, C, CRF01_AE, D","","C","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EVHNaWATHA","V5A","V68A","OV","observed variant","","Variant found in clade C from HIV sequence database.","Kawashima2005"
"53746",,"721","A, B, C, CRF01_AE, D","","C","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EVHNtWATHA","V5T","V68T","OV","observed variant","","Variant found in clade C from HIV sequence database.","Kawashima2005"
"53746",,"722","A, B, C, CRF01_AE, D","","C","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EVHNVWgTfA","A7G, H9F","A70G, H72F","OV","observed variant","","Variant found in clade C from HIV sequence database.","Kawashima2005"
"53746",,"723","A, B, C, CRF01_AE, D","","D","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","gaHNiWATHA","E1G, V2A, V5I","E64G, V65A, V68I","OV","observed variant","","Variant found in clade D from HIV sequence database.","Kawashima2005"
"53746",,"724","A, B, C, CRF01_AE, D","","D","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EaHNiWAsHA","V2A, V5I, T8S","V65A, V68I, T71S","OV","observed variant","","Variant found in clade D from HIV sequence database.","Kawashima2005"
"53746",,"725","A, B, C, CRF01_AE, D","","D","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EaHdiWATHA","V2A, N4D, V5I","V65A, N67D, V68I","OV","observed variant","","Variant found in clade D from HIV sequence database.","Kawashima2005"
"53746",,"726","A, B, C, CRF01_AE, D","","B, CRF01_AE","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EVHNVWATHv","A10V","A73V","OV","observed variant","","Variant found in clades B and E from HIV sequence database.","Kawashima2005"
"53746",,"727","A, B, C, CRF01_AE, D","","CRF01_AE","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EVHNVWtTHA","A7T","A70T","OV","observed variant","","Variant found in clade E from HIV sequence database.","Kawashima2005"
"53746",,"728","A, B, C, CRF01_AE, D","","CRF01_AE","gp160","64","73","gp120(64-73)","6414..6443","A*2603","EVHNVWATHA","EmrsiWATHA","V2M, H3R, N4S, V5I","V65M, H66R, N67S, V68I","OV","observed variant","","Variant found in clade E from HIV sequence database.","Kawashima2005"
"55379","Env 67(2V)","10","","","","gp160","67","75","gp120(67-75)","6423..6449","A2","NVWATHACV","NiWATHACV","V2I","V68I","SF","susceptible form","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt23 carried the challenge HXB2 epitope, and recognized the 2I variant epitope NIWATRACV, while all other Subjects Pt15, Pt16, Pt17, Pt18, Pt21, Pt33, Pt35, Pt41 and Pt43 did not recognize the 2I variant.  All of the above subjects, however, also did not recognize the consensus HXB2 epitope that they carried.","Thorn2007"
"52677","Env67(2I)","127","","","","gp160","67","75","gp120(67-75)","6423..6449","A2","NIWATHACV","NvWATHACV","I2V","I68V","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, Flow cytometric T-cell cytokine assay","This peptide was a good A2 binder, and induced CTL and CD8+ T-cell IFN gamma responses in mice. Responses were detected in 1/17 HIV+ HLA-A2 subjects. The variant nVwathacv was also immunogenic in transgenic mice, but was not recognized in the 17 people tested.","Corbet2003"
"56066","Env67(2I)","212","","","","gp160","67","75","gp120(67-75)","6423..6449","A2","NIWATHACV","NvWATHACV","I2V","I68V","OV","observed variant","","One HLA-A2 patient did not respond to the NIWATHACV epitope but the variant peptide was observed in the patient.","Fomsgaard2008"
"55379","Env 67(2V)","1752","","","","gp160","67","75","gp120(67-75)","6423..6449","A2","NVWATHACV","NVWATrACV","H6R","H72R","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt30 carried this variant epitope, and did not recognize the challenge HXB2 epitope NIWATRACV.","Thorn2007"
"55379","Env 67(2V)","1753","","","","gp160","67","75","gp120(67-75)","6423..6449","A2","NVWATHACV","NiWATrACV","V2I, H6R","V68I, H72R","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt30 carried this variant epitope, and did not recognize the HXB2  epitope NVWATRACV.","Thorn2007"
"58568","OLP-15","3048","A1","A1","B","gp160","74","88","gp120(74-88)","6444..6488","B*3501","CVPTDPNPQEIYMEN","CVPTDPNPQEvvlEN","I11V, Y12V, M13L","I84V, Y85V, M86L","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Clade B sequence analogous to OLP-15 is CVPTDPNPQEvvlEN and it contains the BDE DPNPQEvvl.","McKinnon2009a"
"53415","DPN","1384","","","","gp160","78","86","gp120(78-86)","6456..6482","B35","DPNPQEVAL","DPNPQEaAL","V7A","V84A","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Positive selection on this epitope resulted in an escape by phylogenetic analysis. The variant peptide was less potent at inducing production of IFN-gamma than the index peptide.","Oxenius2004"
"53415","DPN","1385","","","","gp160","78","86","gp120(78-86)","6456..6482","B35","DPNPQEVAL","DPNPQEtAL","V7T","V84T","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Positive selection on this epitope resulted in an escape by phylogenetic analysis. The variant peptide was less potent at inducing production of IFN-gamma than the index peptide.","Oxenius2004"
"53415","DPN","1386","","","","gp160","78","86","gp120(78-86)","6456..6482","B35","DPNPQEVAL","DlNPQEVAL","P2L","P79L","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Positive selection on this epitope resulted in an escape by phylogenetic analysis. The variant peptide was less potent at inducing production of IFN-gamma than the index peptide.","Oxenius2004"
"53415","DPN","1387","","","","gp160","78","86","gp120(78-86)","6456..6482","B35","DPNPQEVAL","DPNPQEVpL","A8P","A85P","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Positive selection on this epitope resulted in an escape by phylogenetic analysis. The variant peptide was less potent at inducing production of IFN-gamma than the index peptide.","Oxenius2004"
"58597","OLP-16","3040","A1","A1","B","gp160","79","93","gp120(79-93)","6459..6503","","PNPQEIYMENVTEEF","PNPQEvvlENVTEnF","E14N, I6V, Y7V, M8L","E92N, I84V, Y85V, M86L","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Clade B sequence analogous to OLP-16 is PNPQEvvlENVTEnF.","McKinnon2009a"
"54162","NW9","985","B","","","gp160","88","96","gp120(88-96)","6486..6512","A*2501","NVTENFNMW","NVTEdFdMW","N5D, N7D","N92D, N94D","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Positions 5 and 7 in the epitope had potentially experienced positive selection. The variant was full escape, as it was not recognized by CTLs.","Liu2006"
"54162","NW9","986","B","","","gp160","88","96","gp120(88-96)","6486..6512","A*2501","NVTENFNMW","NVTEeFdMW","N5E, N7D","N92E, N94D","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Positions 5 and 7 in the epitope had potentially experienced positive selection. The variant was full escape, as it was not recognized by CTLs.","Liu2006"
"54162","NW9","987","B","","","gp160","88","96","gp120(88-96)","6486..6512","A*2501","NVTENFNMW","NVTEsFdMW","N5S, N7D","N92S, N94D","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Positions 5 and 7 in the epitope had potentially experienced positive selection. The variant was full escape, as it was not recognized by CTLs.","Liu2006"
"58153","NW9","2743","B","B","B","gp160","88","96","gp120(88-96)","6486..6512","A*2501","NVTENFNMW","NVTEdFdMW","N5D, N7D","N92D, N94D","DR","diminished response","CD8 T-cell Elispot - IFNy, Longitudinal study","Variants NVTEdFdMW and NVTEeFdMW replaced the wild type sequence by 400 days post-infection. Sequence changes were associated with decrease in EliSpot response to the epitope.","Liu2011a"
"58153","NW9","2744","B","B","B","gp160","88","96","gp120(88-96)","6486..6512","A*2501","NVTENFNMW","NVTEeFdMW","N5E, N7D","N92E, N94D","DR","diminished response","CD8 T-cell Elispot - IFNy, Longitudinal study","Variants NVTEdFdMW and NVTEeFdMW replaced the wild type sequence by 400 days post-infection. Sequence changes were associated with decrease in EliSpot response to the epitope.","Liu2011a"
"59092",,"3268","B","B","B","gp160","88","96","gp120(88-96)",,"A*2501","NVTENFNMW","NVTEdFdMW","N5D, N7D","N92D, N94D","E","escape documented in this paper","Peptide titration","EliSpot peptide titration indicated full escape.","Liu2007a"
"59092",,"3269","B","B","B","gp160","88","96","gp120(88-96)",,"A*2501","NVTENFNMW","NVTEeFdMW","N5E, N7D","N92E, N94D","E","escape documented in this paper","Peptide titration","EliSpot peptide titration indicated full escape.","Liu2007a"
"59092",,"3270","B","B","B","gp160","88","96","gp120(88-96)",,"A*2501","NVTENFNMW","NVTEsFdMW","N5S, N7D","N92S, N94D","E","escape documented in this paper","Peptide titration","EliSpot peptide titration indicated full escape.","Liu2007a"
"53806",,"1227","A, B, C, D","A","B, D","gp160","89","97","gp120(89-97)","6489..6515","","VTEEFNMWK","VnEEFNMWK","T2N","T90N","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","This Clade B and D variant was recognized by Clade A-specific CTLs.","McKinnon2005"
"53806",,"1228","A, B, C, D","A","C","gp160","89","97","gp120(89-97)","6489..6515","","VTEEFNMWK","VnEEFNMWe","T2N, K9E","T90N, K97E","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","This Clade C variant was recognized by Clade A-specific CTLs.","McKinnon2005"
"58569","OLP-21","3049","A1","A1","B","gp160","104","118","gp120(104-118)","6534..6578","B*3801","MHTDIISLWDQSLKP","MHeDIISLWDQSLKP","T3E","T106E","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Clade B sequence analogous to OLP-21 is MHeDIISLWDQSLKP and it contains the BDE MHeDIISLW.","McKinnon2009a"
"53067","Env 134","1149","","B, C","","gp160","121","129","gp120(121-129)","6585..6611","A*0201","KLTPLCVTL","KiTPLCVTL","L2I","L122I","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This anchor position variant elicited a CTL response with cells from mice immunized with the index form.  It was weakly recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53067","Env 134","1150","","B, C","C","gp160","121","129","gp120(121-129)","6585..6611","A*0201","KLTPLCVTL","KmTPLCVTL","L2M","L122M","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This anchor position variant elicited a CTL response with cells from mice immunized with the index form.","McKinney2004"
"53067","Env 134","1151","","B, C","","gp160","121","129","gp120(121-129)","6585..6611","A*0201","KLTPLCVTL","KLTPLCVTm","L9M","L129M","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This anchor position variant elicited a CTL response with cells from mice immunized with the index form.  It was not recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53067","Env 134","1152","","B, C","C","gp160","121","129","gp120(121-129)","6585..6611","A*0201","KLTPLCVTL","rLTPLCVTL","K1R","K121R","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant elicited a CTL response with cells from mice immunized with the index form.","McKinney2004"
"53067","Env 134","1154","","B, C","B","gp160","121","129","gp120(121-129)","6585..6611","A*0201","KLTPLCVTL","qLTPLCVTL","K1Q","K121Q","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant elicited a CTL response with cells from mice immunized with the  index form.  It was weakly recognized by CTL lines derived from HIV-1 uninfected donors.","McKinney2004"
"53067","Env 134","1155","","B, C","B","gp160","121","129","gp120(121-129)","6585..6611","A*0201","KLTPLCVTL","eLTPLCVTL","K1E","K121E","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant elicited a CTL response with cells from mice immunized with the index form.  It was not recognized by CTL lines derived from HIV-1 uninfected donors.  Binding to HLA is at a very low level.","McKinney2004"
"53067","Env 134","1156","","B, C","C","gp160","121","129","gp120(121-129)","6585..6611","A*0201","KLTPLCVTL","KLTsLCVTL","P4S","P124S","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant elicited a CTL response with cells from mice immunized with the index form.","McKinney2004"
"53067","Env 134","1157","","B, C","C","gp160","121","129","gp120(121-129)","6585..6611","A*0201","KLTPLCVTL","KLTqLCVTL","P4Q","P124Q","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant did not elicit a CTL response with cells from mice immunized with the index form.","McKinney2004"
"53067","Env 134","1158","","B, C","","gp160","121","129","gp120(121-129)","6585..6611","A*0201","KLTPLCVTL","KLTPfCVTL","L5F","L125F","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant did not elicit a CTL response with cells from mice immunized with the index form.   It was not recognized by CTL lines derived from HIV-1","McKinney2004"
"53067","Env 134","1159","","B, C","","gp160","121","129","gp120(121-129)","6585..6611","A*0201","KLTPLCVTL","KLTPrCVTL","L5R","L125R","DHB, NSF","diminished HLA binding or increased off-rate, non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant did not elicit a CTL response with cells from mice immunized with the index form.   It was not recognized by CTL lines derived from HIV-1.  Binding to HLA is at a very low level.","McKinney2004"
"53067","Env 134","1160","","B, C","","gp160","121","129","gp120(121-129)","6585..6611","A*0201","KLTPLCVTL","KLTPLCiTL","V7I","V127I","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant elicited a CTL response with cells from mice immunized with the index form.   It was recognized by CTL lines derived from HIV-1.","McKinney2004"
"53067","Env 134","1161","","B, C","B","gp160","121","129","gp120(121-129)","6585..6611","A*0201","KLTPLCVTL","KLTPLCVpL","T8P","T128P","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant elicited a CTL response with cells from mice immunized with the index form.   It was not recognized by CTL lines derived from HIV-1.","McKinney2004"
"53067","Env 134","1162","","B, C","","gp160","121","129","gp120(121-129)","6585..6611","A*0201","KLTPLCVTL","KLTPLCVsL","T8S","T128S","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant elicited a CTL response with cells from mice immunized with the index form.   It was weakly recognized by CTL lines derived from HIV-1.","McKinney2004"
"53067","Env 134","1163","","B, C","","gp160","121","129","gp120(121-129)","6585..6611","A*0201","KLTPLCVTL","KLTPLCVaL","T8A","T128A","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant elicited a CTL response with cells from mice immunized with the index form.   It was recognized by CTL lines derived from HIV-1.","McKinney2004"
"53067","Env 134","1164","","B, C","","gp160","121","129","gp120(121-129)","6585..6611","A*0201","KLTPLCVTL","KLTPLCViL","T8I","T128I","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This nonanchor position variant elicited a CTL response with cells from mice immunized with the index form.   It was weakly recognized by CTL lines derived from HIV-1.","McKinney2004"
"53067","Env 134","1165","","B, C","","gp160","121","129","gp120(121-129)","6585..6611","A*0201","KLTPLCVTL","qiTPLCVTL","K1Q, L2I","K121Q, L122I","DHB, NSF","diminished HLA binding or increased off-rate, non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant did not elicit a CTL response with cells from mice immunized with the index form.   It was not recognized by CTL lines derived from HIV-1.  Binding to HLA was at a very low level.","McKinney2004"
"53067","Env 134","1166","","B, C","","gp160","121","129","gp120(121-129)","6585..6611","A*0201","KLTPLCVTL","qmTfLCVqm","K1Q, L2M, P4F, T8Q, L9M","K121Q, L122M, P124F, T128Q, L129M","DHB, NSF","diminished HLA binding or increased off-rate, non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant did not elicit a CTL response with cells from mice immunized with the index form.   It was not recognized by CTL lines derived from HIV-1.  Binding to HLA was at a very low level.","McKinney2004"
"53067","Env 134","1167","","B, C","","gp160","121","129","gp120(121-129)","6585..6611","A*0201","KLTPLCVTL","KmTfLCVqm","L2M, P4F, T8Q, L9M","L122M, P124F, T128Q, L129M","DHB, NSF","diminished HLA binding or increased off-rate, non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","This multiple substitution variant did not elicit a CTL response with cells from mice immunized with the index form.   It was not recognized by CTL lines derived from HIV-1.  Binding to HLA was at a very low level.","McKinney2004"
"55398","Env 121","1761","","","","gp160","121","129","gp120(121-129)","6585..6611","A2","KLTPLCVTL","KLTPfCVvL","L5F, T8V","L125F, T128V","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt30 carried this variant epitope, and did not recognize the challenge HXB2 epitope KLTPLCVTL.","Thorn2007"
"55398","Env 121","1762","","","","gp160","121","129","gp120(121-129)","6585..6611","A2","KLTPLCVTL","KLTPLCVsL","T8S","T128S","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt41 carried the HXB2 epitope KLTPLCVsL, and did not recognize the index epitope KLTPLCVTL.","Thorn2007"
"55398","Env 121","1763","","","","gp160","121","129","gp120(121-129)","6585..6611","A2","KLTPLCVTL","KiTPLCVTL","L2I","L122I","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt43 carried this variant epitope, and did not recognize the challenge HXB2 epitope KLTPLCVTL.","Thorn2007"
"53810",,"1229","A, B, C, D","A, C","B","gp160","155","163","gp120(155-163)","6687..6713","","KNCSFNMTT","KNCSFNMis","T8I, T9S","T162I, T163S","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","This Clade B variant was recognized by Clade A and C-specific CTLs.","McKinnon2005"
"53810",,"1230","A, B, C, D","A, C","D","gp160","155","163","gp120(155-163)","6687..6713","","KNCSFNMTT","KNiSFNMTT","C3I","C157I","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","This Clade D variant was recognized by Clade A and Clade C-specific CTLs.","McKinnon2005"
"58593","OLP-26","3037","A1","A1","B","gp160","155","169","gp120(155-169)","6687..6731","","LDCSYNITNNITNSI","knCSfNITsNIrdkv","L1K, T12R, N13D, S14K, I15V, D2N, Y5F, N9S","L155K, T166R, N167D, S168K, I169V, D156N, Y159F, N163S","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Clade B form analogous to this OLP-26 is knCSfNITsNIrdkv.","McKinnon2009a"
"672",,"1618","","B","B","gp160","156","165","gp120(156-165)","6690..6719","Cw8","NCSFNISTSI","NCSFNItTSI","S7T","S162T","NSF","non-susceptible form","Chromium-release assay","This naturally occurring, strain MN variant, was not recognized by a Patient LWF CTL clone.","Sipsas1997"
"59102","KL9, 168-KMQKEYALL","3280","B","B","CRF01_AE","gp160","168","176","gp120(168-176)",,"A*02","KMQKEYALL","KkQKvhALf","M2K, E5V, Y6H, L9F","M169K, E172V, Y173H, L176F","A, OV, SSF","HLA association, observed variant, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Peptide titration","Subtype CRF01_AE-specific variant KMQKvhALf, from either strains 92TH023 or A244, bound HLA-A*0203 with IC<sub>50</sub> = 2281 nM, but did not bind HLAs -A*0201 or -A*0207 appreciably.","Gartland2014"
"59102","KL9, 168-KMQKEYALL","3282","B","B","CRF01_AE","gp160","168","176","gp120(168-176)",,"A*02","KMQKEYALL","KkQqvYALf","M2K, K4Q, E5V, L9F","M169K, K171Q, E172V, L176F","A, DHB, OV, SSF","HLA association, diminished HLA binding or increased off-rate, observed variant, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Peptide titration","Subtype CRF01_AE-specific variant KkQqvYALf, from either strains 92TH023 or A244, bound HLA-A*0203 with IC<sub>50</sub> = 25294 nM, but did not bind HLAs -A*0201 or -A*0207 appreciably. This variant was isolated from both RV144 vaccinated and -placebo CRF01_AE-infected recipients.","Gartland2014"
"59102","KL9, 168-KMQKEYALL","3283","B","B","CRF01_AE","gp160","168","176","gp120(168-176)",,"A*02","KMQKEYALL","KqrKvqALf","M2Q, Q3R, E5V, Y6Q, L9F","M169Q, Q170R, E172V, Y173Q, L176F","A, DHB, OV, SSF","HLA association, diminished HLA binding or increased off-rate, observed variant, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Peptide titration","Subtype CRF01_AE-specific variant KqrKvqALf, from either strains 92TH023 or A244, bound HLA-A*0203 with IC<sub>50</sub> = 25667 nM, but did not bind HLAs -A*0201 or -A*0207 appreciably. This variant was isolated from an RV144-vaccinated CRF01_AE-infected recipient.","Gartland2014"
"59102","KL9, 168-KMQKEYALL","3284","B","B","CRF01_AE","gp160","168","176","gp120(168-176)",,"A*02","KMQKEYALL","KkQKfYALf","M2K, E5F, L9F","M169K, E172F, L176F","DHB, NSF, OV, SSF","diminished HLA binding or increased off-rate, non-susceptible form, observed variant, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Peptide titration","Subtype CRF01_AE-specific variant KkQKfYALf, from either strains 92TH023 or A244, did not bind tested HLAs -A*0203 -A*0201 or -A*0207 appreciably.  This variant was isolated from both RV144-vaccinated and -placebo CRF01_AE-infected recipients.","Gartland2014"
"59102","KL9, 168-KMQKEYALL","3285","B","B","CRF01_AE","gp160","168","176","gp120(168-176)",,"A*02","KMQKEYALL","KrQqvhALf","M2R, K4Q, E5V, Y6H, L9F","M169R, K171Q, E172V, Y173H, L176F","DHB, NSF, OV, SSF","diminished HLA binding or increased off-rate, non-susceptible form, observed variant, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Peptide titration","Subtype CRF01_AE-specific variant KrQqvhALf, from either strains 92TH023 or A244, did not bind tested HLAs -A*0203 -A*0201 or -A*0207 appreciably.  This variant was isolated from an RV144-vaccinated CRF01_AE-infected recipient.","Gartland2014"
"59102","KL9, 168-KMQKEYALL","3286","B","B","CRF01_AE","gp160","168","176","gp120(168-176)",,"A*02","KMQKEYALL","KqQKvYALf","M2Q, E5V, L9F","M169Q, E172V, L176F","DHB, NSF, OV, SSF","diminished HLA binding or increased off-rate, non-susceptible form, observed variant, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Peptide titration","Subtype CRF01_AE-specific variant KqQKvYALf, from either strains 92TH023 or A244, did not bind tested HLAs -A*0203 -A*0201 or -A*0207 appreciably.  This variant was isolated from both RV144-vaccinated and -placebo CRF01_AE-infected recipients.","Gartland2014"
"59102","KL9, 168-KMQKEYALL","3288","B","B","CRF01_AE","gp160","168","176","gp120(168-176)",,"A*02","KMQKEYALL","rkQqiSALf","K1R, M2K, K4Q, E5I, Y6S, L9F","K168R, M169K, K171Q, E172I, Y173S, L176F","A, DHB, OV, SSF","HLA association, diminished HLA binding or increased off-rate, observed variant, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Peptide titration","Subtype CRF01_AE-specific variant rkQqiSALf, from either strains 92TH023 or A244, bound HLA-A*0201 with IC<sub>50</sub> = 34021 nM, but did not bind HLAs -A*0203 or -A*0207 appreciably. This variant was isolated from an RV144-vaccinated CRF01_AE-infected recipient.","Gartland2014"
"59102","KL9, 168-KMQKEYALL","3289","B","B","CRF01_AE","gp160","168","176","gp120(168-176)",,"A*02","KMQKEYALL","KqQnfYALf","M2Q, K4N, E5F, L9F","M169Q, K171N, E172F, L176F","A, DHB, OV, SSF","HLA association, diminished HLA binding or increased off-rate, observed variant, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Peptide titration","Subtype CRF01_AE-specific variant KqQnfYALf, from either strains 92TH023 or A244, bound HLAs -A*0201 and -A*0207 with IC<sub>50</sub> = 1768 nM and 36940 nM respectively, but did not bind HLA -A*0203 appreciably. This variant was isolated from an RV144-vaccinated CRF01_AE-infected recipient.","Gartland2014"
"59102","KL9, 168-KMQKEYALL","3290","B","B","CRF01_AE","gp160","168","176","gp120(168-176)",,"A*02","KMQKEYALL","KqQqihALf","M2Q, K4Q, E5I, Y6H, L9F","M169Q, K171Q, E172I, Y173H, L176F","A, DHB, OV, SSF","HLA association, diminished HLA binding or increased off-rate, observed variant, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Peptide titration","Subtype CRF01_AE-specific variant KqQqihALf, from either strains 92TH023 or A244, bound HLAs -A*0201 and -A*0207 with IC<sub>50</sub> = 16306 nM and 37102 nM respectively, but did not bind HLA -A*0203 appreciably. This variant was isolated from an RV144-placebo CRF01_AE-infected recipient.","Gartland2014"
"58567","OLP-40","3047","A1","A1","B","gp160","196","210","gp120(196-210)","6810..6854","A*1101","CNTSALTQACPKVTF","CNTSviTQACPKVTF","A5V, L6I","A200V, L201I","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Clade B sequence analogous to OLP-40 is CNTSviTQACPKVTF and it contains the BDE SviTQACPK.","McKinnon2009a"
"52105",,"298","B","B","A, C, D","gp160","199","207","gp120(199-207)","6819..6845","A*1101","SVITQACPK","SaITQACPK","V2A","V200A","OV","observed variant","","Variant predominantly found in clades A, C and D.","Fukada2002"
"52105",,"299","B","B","CRF01_AE","gp160","199","207","gp120(199-207)","6819..6845","A*1101","SVITQACPK","SVIkQACPK","T4K","T202K","SF","susceptible form","Chromium-release assay","Variant predominantly found in clade E. There was low CTL activity in PBMC from clade E patients stimulated with this epitope variant.","Fukada2002"
"58572","OLP-42","3051","A1","A1","B","gp160","206","220","gp120(206-220)","6840..6884","A*2902","PKVTFEPIPIRYCAP","PKVsFEPIPIhYCAP","R11H, T4S","R216H, T209S","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Clade B sequence analogous to OLP-42 is PKVsFEPIPIhYCAP and it contains the BDE sFEPIPIhY.","McKinnon2009a"
"1356",,"111","A","A","B","gp160","207","216","gp120(207-216)","6843..6872","A29","KMSFEPIPIH","KvSFEPIPIH","M2V","M208V","DR, SSF","diminished response, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","CTL derived from subtype A clade infection (patient SP 528), recognized the subtype A version of the peptide (KMSFEPIPIH), had a slightly reduced specific lysis using the B clade version of the peptide (KVSFEPIPIH), and no lysis using the D clade version of the epitope (KVTFEPIPIH)","Cao2000"
"1356",,"112","A","A","D","gp160","207","216","gp120(207-216)","6843..6872","A29","KMSFEPIPIH","KvtFEPIPIH","M2V, S3T","M208V, S209T","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay","CTL derived from subtype A clade infection (patient SP 528), recognized the subtype A version of the peptide (KMSFEPIPIH), had a slightly reduced specific lysis using the B clade version of the peptide (KVSFEPIPIH), and no lysis using the D clade version of the epitope (KVTFEPIPIH)","Cao2000"
"53219","gp160 SY9","556","B","","","gp160","209","217","gp120(209-217)","6849..6875","A*2902","SFEPIPIHY","SFdPIPIHY","E3D","E211D","DR","diminished response","","Confirmed some degree of escape by reduction of CTL response.","Jones2004"
"53219","gp160 SY9","557","B","","","gp160","209","217","gp120(209-217)","6849..6875","A*2902","SFEPIPIHY","SFEPIPIHf","Y9F","Y217F","DR","diminished response","","Variant found in two patients, somewhat reduced CTL response.","Jones2004"
"53219","gp160 SY9","558","B","","","gp160","209","217","gp120(209-217)","6849..6875","A*2902","SFEPIPIHY","SiEPIPIHf","F2I, Y9F","F210I, Y217F","DR","diminished response","","Rare form found at day 218. Weakest CTL response.","Jones2004"
"53219","gp160 SY9","559","B","","","gp160","209","217","gp120(209-217)","6849..6875","A*2902","SFEPIPIHY","tFEPIPIHY","S1T","S209T","DR","diminished response","","Confirmed some degree of escape by reduction of CTL response.","Jones2004"
"53219","gp160 SY9","560","B","","","gp160","209","217","gp120(209-217)","6849..6875","A*2902","SFEPIPIHY","SsEPIPIHY","F2S","F210S","OV","observed variant","","1/10 clones present at time point 41.","Jones2004"
"53219","gp160 SY9","561","B","","","gp160","209","217","gp120(209-217)","6849..6875","A*2902","SFEPIPIHY","SFEPIPInY","H8N","H216N","OV","observed variant","","7/34 clones present at time point 212 and 4/14 clones at time point 295.","Jones2004"
"53219","gp160 SY9","562","B","","","gp160","209","217","gp120(209-217)","6849..6875","A*2902","SFEPIPIHY","SFEPIPIdf","H8D, Y9F","H216D, Y217F","OV","observed variant","","1/11 clones present at time point 136.","Jones2004"
"54163","YL10","988","B","","","gp160","217","226","gp120(217-226)","6873..6902","Cw*0102","YCAPAGFAIL","YCAPAGFAIi","L10I","L226I","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Last position (10)in the epitope had potentially experienced positive selection. The variant was full escape, as it was not recognized by CTLs.","Liu2006"
"58152","YL10","2742","B","B","B","gp160","217","226","gp120(217-226)","6873..6902","Cw*0102","YCAPAGFAIL","YCAPAGFAIi","L10I","L226I","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Longitudinal study","Variant YCAPAGFAIi had replaced the wild type sequence by 400 days post-infection. Sequence change was associated with loss of EliSpot response to the epitope.","Liu2011a"
"59093",,"3271","B","B","B","gp160","217","226","gp120(217-226)",,"Cw*0102","YCAPAGFAIL","YCAPAGFAIi","L10I","L226I","E","escape documented in this paper","Peptide titration","EliSpot peptide titration indicated full escape.","Liu2007a"
"55487","CL9","1646","B","","","gp160","218","226","gp120(218-226)","6876..6902","Cw1","CAPAGFAIL","CtPAGFAIL","A2T","A219T","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","At the time of superinfection at day 503, the WT response exhibited the highest magnitude, suggestive of having driven the recombination event to the A217T form. Decline of both the WT and the A217T -specific CL9 response was observed at day 1,034.","Streeck2008a, ZunigaPerCom2008"
"55487","CL9","1647","B","","","gp160","218","226","gp120(218-226)","6876..6902","Cw1","CAPAGFAIL","CtPAGFtIL","A2T, A7T","A219T, A224T","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","This additional mutation A7T abrogated wild type and variant-specific CTL responses.","Streeck2008a, ZunigaPerCom2008"
"55487","CL9","1648","B","","","gp160","218","226","gp120(218-226)","6876..6902","Cw1","CAPAGFAIL","CtPAGFvIL","A2T, A7V","A219T, A224V","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","This additional mutation A7V abrogated wild type and variant-specific CTL responses.","Streeck2008a, ZunigaPerCom2008"
"57651","EnvCL9","2666","A, B, C, D","A, B, C, D","A, B, C","gp160","218","226","gp120(218-226)","6876..6902","","CAPAGFAIL","CtPAGFAIL","A2T","A219T","SF, SSF","susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Variant CtPAGFAIL was found at a frequency of 5, 17 and 1 in clades A, B and C respectively.","Koup2010"
"57651","EnvCL9","2667","A, B, C, D","A, B, C, D","A, B, C, D","gp160","218","226","gp120(218-226)","6876..6902","","CAPAGFAIL","CAPAGyAIL","F6Y","F223Y","SF, SSF","susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Variant CAPAGyAIL was found at a frequency of 3, 1, 82 and 13 in clades A, B, C and D respectively.","Koup2010"
"53220","gp160 CC9","563","B","","","gp160","239","247","gp120(239-247)","6939..6965","Cw*0802","CKNVSTVQC","CeNVSTVQC","K2E","K240E","IE","inferred escape","","4 variants found in the patient. This one and cCeNVSTVhC came up first, at day 6. This variant persisted. Not tested for impact on escape.","Jones2004"
"53220","gp160 CC9","564","B","","","gp160","239","247","gp120(239-247)","6939..6965","Cw*0802","CKNVSTVQC","CeNVSTVhC","K2E, Q8H","K240E, Q246H","IE","inferred escape","","4 variants found in the patient. This one and CeNVSTVQC came up first, at day 6. Not tested for impact on escape.","Jones2004"
"53220","gp160 CC9","565","B","","","gp160","239","247","gp120(239-247)","6939..6965","Cw*0802","CKNVSTVQC","CgNVSTVQC","K2G","K240G","OV","observed variant","","Rare variant present at day 35. Not tested for impact on escape.","Jones2004"
"55294",,"1512","B","","","gp160","239","247","gp120(239-247)","6939..6965","Cw8","CTNVSTVQC","CqNVSTVQC","T2Q","T240Q","OV","observed variant","Sequence","This index epitope was conserved in the mother's viral strain but mutated in the daughter's isolate.","Reinis2007"
"55134",,"1453","","","","gp160","252","261","gp120(252-261)","6978..7007","B7, B8","KPVVSTQLLL","rPVVSTQLLL","K1R","K252R","OV","observed variant","Sequence","This variant was found in 10/14 Brazilian Subtype B and 6/20 Brazilian Subtype B/F recombinant sequences.","Queiroz2007"
"55134",,"1454","","","","gp160","252","261","gp120(252-261)","6978..7007","B7, B8","KPVVSTQLLL","KPViSTQLLL","V4I","V255I","OV","observed variant","Sequence","This variant was found in 3/14 Brazilian Subtype C sequences.","Queiroz2007"
"55134",,"1455","","","","gp160","252","261","gp120(252-261)","6978..7007","B7, B8","KPVVSTQLLL","KPVmSTQLLL","V4M","V255M","OV","observed variant","Sequence","This variant was found in 2/14 Brazilian Subtype C sequences.","Queiroz2007"
"57539","R10LL","2543","","","","gp160","252","261","gp120(252-261)","6978..7007","B*07","RPVVSTQLLL","kPVVSTQLLL","R1K","R252K","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, HLA binding","Intersubtype variant kPVVSTQLLL exhibited low cross-recognition in mice immunized with RPVVSTQLLL.","Cardinaud2009"
"58589","OLP-27","3034","A1","A1","B","gp160","276","292","gp120(276-292)","7050..7100","B*1503","NITNNITNSITNSSV","NITtsIrdkvqkeya","I10V, T11Q, N12K, S13E, S14Y, V15A, N4T, N5S, T7R, N8D, S9K","I285V, T286Q, N287K, S288E, S289Y, V290A, N279T, N280S, T282R, N283D, S284K","OV","observed variant","CD8 T-cell Elispot - IFNy, HLA binding","Clade B sequence analogous to OLP-27, is NITtsIrdkvqkeya.","McKinnon2009a"
"55235",,"803","B, CRF01_AE","","B","gp160","296","305","gp120(296-305)","7110..7139","A3","CTRPNNNTRK","CTRPsNNTRK","N5S","N300S","OV","observed variant","Sequence","Patient was superinfected with three strains, B1, B2 and CRF01_AE. This was the infecting variant  in B1 and B2, and it did not change over time.","Kozaczynska2007"
"55235",,"804","B, CRF01_AE","","CRF01_AE","gp160","296","305","gp120(296-305)","7110..7139","A3","CTRPNNNTRK","CTRPsNNTRt","K10T, N5S","K305T, N300S","OV","observed variant","Sequence","Patient was superinfected with three strains, B1, B2 and CRF01_AE. This was the infecting variant  in CRF01_AE and it did not change over time.","Kozaczynska2007"
"55135",,"1456","","","","gp160","296","305","gp120(296-305)","7110..7139","A2, A3","CTRPNNNTRK","CTRPgNNTRK","N5G","N300G","OV","observed variant","Sequence","This variant was found in 31/392 Brazilian Subtype B and 2/29 Brazilian Subtype C sequences.","Queiroz2007"
"55135",,"1457","","","","gp160","296","305","gp120(296-305)","7110..7139","A2, A3","CTRPNNNTRK","CTRPNNyTRK","N7Y","N302Y","OV","observed variant","Sequence","This variant was found in 2/45 Brazilian Subtype F sequences.","Queiroz2007"
"55135",,"1458","","","","gp160","296","305","gp120(296-305)","7110..7139","A2, A3","CTRPNNNTRK","CTRPNNNTRe","K10E","K305E","OV","observed variant","Sequence","This variant was found in 8/29 Brazilian Subtype C sequences.","Queiroz2007"
"55135",,"1459","","","","gp160","296","305","gp120(296-305)","7110..7139","A2, A3","CTRPNNNTRK","CTRsNNNTRK","P4S","P299S","OV","observed variant","Sequence","This variant was found in 2/49 Brazilian Subtype B/F recombinant sequences.","Queiroz2007"
"58559","OLP-60","3031","A1","A1","B","gp160","296","310","gp120(296-310)","7110..7154","B*0702","CTRPNNNTRKSVRIG","CTRPNNNTRKSiRIG","V12I","V307I","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","OLP-60 contained the BDE RPNNNTRKSi in Clade B that was frequently recognized.  The Clade A1-specific analogous epitope, RPNNNTRKSV was also recognizable.","McKinnon2009a"
"52830","B7-RI10 Env","52","B","","","gp160","298","307","gp120(298-307)","7116..7145","B7","RPNNNTRRGI","RPsNNTRksI","N3S, R8K, G9S","N300S, R305K, G306S","SF","susceptible form","CD8 T-cell Elispot - IFNy","Superinfection. The first infecting strain had the variant rpSnntrKSi, and the CTL response was higher to the second variant, RPNNNTRRGI.","Altfeld2002a"
"707",,"1836","B","","","gp160","298","307","gp120(298-307)","7116..7145","B7","RPNNNTRKSI","RPNNNTRKSv","I10V","I307V","SF","susceptible form","Chromium-release assay, Structural prediction","This epitope is conserved between clades B_LAI and C_92BR025.  The anchor residue substitution in clade A_92UG037 does not abrogate HLA binding.","Wilson1998b"
"707",,"1837","B","","","gp160","298","307","gp120(298-307)","7116..7145","B7","RPNNNTRKSI","RPNyNkRKrI","N4Y, T6K, S9R","N301Y, T303K, S306R","DHB, LE","diminished HLA binding or increased off-rate, literature escape","Chromium-release assay, Structural prediction","This intraclade B_MN epitope sequence does not bind HLA-B7.","Wilson1998b"
"57537","R10SI","2541","","","","gp160","298","307","gp120(298-307)","7116..7145","B*07","RPNNNTRKSI","RPNNNTRKgI","S9G","S306G","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, HLA binding","Intersubtype variant RPNNNTRKgI exhibited good cross-recognition in mice immunized with RPNNNTRKSI.","Cardinaud2009"
"59246",,"3385","B","B","B","gp160","298","307","gp120(298-307)",,"B*0702","RPNNNTRKSI","RPNNNTRRSI","K8R","K282R","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","First variant detected; no Elispot response.","Melhem2014"
"59246",,"3386","B","B","B","gp160","298","307","gp120(298-307)",,"B*0702","RPNNNTRKSI","RPNNNTRKST","I10T","I284T","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Third variant to arise; seen only in late post-seroconversion period; Elispot response about 2000 SFC/10<sup>6</sup>PBMC.","Melhem2014"
"59246",,"3387","B","B","B","gp160","298","307","gp120(298-307)",,"B*0702","RPNNNTRKSI","RPNNSTRKSI","N5S","N279S","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Fourth variant to arise; seen only in late post-seroconversion period; postive Elispot response about 3000 SFC/10<sup>6</sup>PBMC.","Melhem2014"
"59246",,"3388","B","B","B","gp160","298","307","gp120(298-307)",,"B*0702","RPNNNTRKSI","RPNNDTRKSI","N5D","N279D","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Fifth variant to arise; seen only in late post-seroconversion period; positive Elispot response about 2500 SFC/10<sup>6</sup>PBMC","Melhem2014"
"59246",,"3389","B","B","B","gp160","298","307","gp120(298-307)",,"B*0702","RPNNNTRKSI","RSNNNTRKSI","P2S","P276S","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Second variant to arise; no Elispot response.","Melhem2014"
"59246",,"3390","B","B","B","gp160","298","307","gp120(298-307)",,"B*0702","RPNNNTRKSI","RPNNNTRKRI","S9R","S283R","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Sixth variant to arise; seen in late post-SC (seroconversion), early ART, and late ART periods; Elispot response <100 SFC/10<sup>6</sup>PBMC in all 3 periods.","Melhem2014"
"59246",,"3391","B","B","B","gp160","298","307","gp120(298-307)",,"B*0702","RPNNNTRKSI","RPNNNTGKRI","R7G, S9R","R281G, S283R","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Seventh variant to arise; no positive Elispot responses.","Melhem2014"
"59246",,"3392","B","B","B","gp160","298","307","gp120(298-307)",,"B*0702","RPNNNTRKSI","RPSNNTRKRI","N3S, S9R","N277S, S283R","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Eighth variant to arise; no positive Elispot responses.","Melhem2014"
"59246",,"3393","B","B","B","gp160","298","307","gp120(298-307)",,"B*0702","RPNNNTRKSI","RPTNNTRKSI","N3T","N277T","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Nineth variant to arise; seen in early and late ART periods; Elispot response <50/10<sup>6</sup>PBMC in early ART and zero in late ART period.","Melhem2014"
"59246",,"3394","B","B","B","gp160","298","307","gp120(298-307)",,"B*0702","RPNNNTRKSI","RPNNNTRKCI","S9C","S283C","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Tenth variant to arise; no positive Elispot response.","Melhem2014"
"59246",,"3395","B","B","B","gp160","298","307","gp120(298-307)",,"B*0702","RPNNNTRKSI","RPNNNTRKSL","I10L","I284L","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Eleventh variant to arise; seen in early and late ART periods; positive Elispot response <100 SFC/10<sup>6</sup>PBMC in early ART and about 200 SFC/10<sup>6</sup>PBMC in late ART.","Melhem2014"
"58573","OLP-62","3026","A1","A1","B","gp160","306","322","gp120(306-322)","7140..7190","A*0201, A*3002","SVRIGPGQTFYATGD","SVhIGPGraFYATGD","R3H, Q8R, T9A","R308H, Q313R, T314A","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Clade B variant of OLP-62, SVhIGPGraFYATGD, contains a three residue difference in its HLA-A*3002-restricted BDE, hIGPGraFY, from the Clade A epitope, RIGPGQTFY (within Clade A1 OLP-62, SVRIGPGQTFYATGD). OLP-62 was not recognized.","McKinnon2009a"
"58573","OLP-62","3027","A1","A1","B","gp160","306","322","gp120(306-322)","7140..7190","A*0201, A*3002","SVRIGPGQTFYATGD","SVRrGPGraFvtiGD","Y11V, A12T, T13I, I4R, Q8R, T9A","Y316V, A317T, T318I, I309R, Q313R, T314A","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Clade B variant of OLP-62, SVRrGPGraFvtiGD, contains a three residue difference in its HLA-A*0201-restricted BDE, rGPGraFvti, from the Clade A epitope, IGPGQTFYAT (within Clade A1 OLP-62, SVRIGPGQTFYATGD). OLP-62 was not recognized.","McKinnon2009a"
"55322","H","823","A","","","gp160","311","320","gp120(311-320)","7155..7184","H-2D<sup>d</sup>","RGPGRAFVTI","iGPGqAFyat","R1I, I10T, R5Q, V8Y, T9A","R311I, I320T, R315Q, V318Y, T319A","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","There was no cross-reactivity seen with this  epitope variant after immunization with Clade A containing index epitope","Larke2007"
"55322","H","824","A","","","gp160","311","320","gp120(311-320)","7155..7184","H-2D<sup>d</sup>","RGPGRAFVTI","fGPGqAFyTn","R1F, I10N, R5Q, V8Y","R311F, I320N, R315Q, V318Y","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","There was no cross-reactivity seen with this  epitope variant after immunization with Clade A containing index epitope","Larke2007"
"55322","H","825","A","","","gp160","311","320","gp120(311-320)","7155..7184","H-2D<sup>d</sup>","RGPGRAFVTI","iGPGRAFyTt","R1I, I10T, V8Y","R311I, I320T, V318Y","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","There was no cross-reactivity seen with this  epitope variant after immunization with Clade A containing index epitope","Larke2007"
"55322","H","826","A","","","gp160","311","320","gp120(311-320)","7155..7184","H-2D<sup>d</sup>","RGPGRAFVTI","iGPGqtFyat","R1I, I10T, R5Q, A6T, V8Y, T9A","R311I, I320T, R315Q, A316T, V318Y, T319A","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","There was no cross-reactivity seen with this  epitope variant after immunization with Clade A containing index epitope","Larke2007"
"55322","H","827","A","","","gp160","311","320","gp120(311-320)","7155..7184","H-2D<sup>d</sup>","RGPGRAFVTI","iGlGqAlyTt","R1I, I10T, P3L, R5Q, F7L, V8Y","R311I, I320T, P313L, R315Q, F317L, V318Y","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","There was no cross-reactivity seen with this  epitope variant after immunization with Clade A containing index epitope","Larke2007"
"55322","H","828","A","","","gp160","311","320","gp120(311-320)","7155..7184","H-2D<sup>d</sup>","RGPGRAFVTI","lGPGqAFyat","R1L, I10T, R5Q, V8Y, T9A","R311L, I320T, R315Q, V318Y, T319A","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","There was no cross-reactivity seen with this  epitope variant after immunization with Clade A containing index epitope","Larke2007"
"55322","H","829","A","","","gp160","311","320","gp120(311-320)","7155..7184","H-2D<sup>d</sup>","RGPGRAFVTI","iGPGRAFyat","R1I, I10T, V8Y, T9A","R311I, I320T, V318Y, T319A","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","There was no cross-reactivity seen with this  epitope variant after immunization with Clade A containing index epitope","Larke2007"
"55322","H","830","A","","","gp160","311","320","gp120(311-320)","7155..7184","H-2D<sup>d</sup>","RGPGRAFVTI","iGPGqvFyrt","R1I, I10T, R5Q, A6V, V8Y, T9R","R311I, I320T, R315Q, A316V, V318Y, T319R","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","There was no cross-reactivity seen with this  epitope variant after immunization with Clade A containing index epitope","Larke2007"
"55322","H","831","A","","","gp160","311","320","gp120(311-320)","7155..7184","H-2D<sup>d</sup>","RGPGRAFVTI","mGPGRvFyTt","R1M, I10T, A6V, V8Y","R311M, I320T, A316V, V318Y","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","There was no cross-reactivity seen with this  epitope variant after immunization with Clade A containing index epitope","Larke2007"
"55910","RI10(gp120)","1934","B","B","B","gp160","311","320","gp120(311-320)","7155..7184","","LGPGRVWYTT","rGPGRafvTi","L1R, T10I, V6A, W7F, Y8V","L311R, T320I, V316A, W317F, Y318V","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at 5 residues. It is predicted to be HLA-A2 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"54164","EY10","989","B","","","gp160","321","330","gp120(321-330)","7185..7214","A*2501","EIIGDIRQAY","qIIGDIRQAY","E1Q","E321Q","DR","diminished response","CD8 T-cell Elispot - IFNy","Positions 1, 5 and 10 (last)in the epitope had potentially experienced positive selection. Wt form of the epitope was >200 times better recognized than the variant, making the variant a partial escape.","Liu2006"
"54164","EY10","990","B","","","gp160","321","330","gp120(321-330)","7185..7214","A*2501","EIIGDIRQAY","dIIGDIRQAh","E1D, Y10H","E321D, Y330H","DR","diminished response","CD8 T-cell Elispot - IFNy","Positions 1, 5 and 10 (last)in the epitope had potentially experienced positive selection.  Wt form of the epitope was 34 times better recognized than the variant, making the variant a partial escape.","Liu2006"
"54164","EY10","991","B","","","gp160","321","330","gp120(321-330)","7185..7214","A*2501","EIIGDIRQAY","EIIGnIRQAh","Y10H, D5N","Y330H, D325N","DR","diminished response","CD8 T-cell Elispot - IFNy","Positions 1, 5 and 10 (last)in the epitope had potentially experienced positive selection. Wt form of the epitope was 15.9 times better recognized than the variant, making the variant a partial escape.","Liu2006"
"54164","EY10","992","B","","","gp160","321","330","gp120(321-330)","7185..7214","A*2501","EIIGDIRQAY","EIIGDIRQAh","Y10H","Y330H","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Positions 1, 5 and 10 (last)in the epitope had potentially experienced positive selection. The variant was full escape, as it was not recognized by CTLs.","Liu2006"
"59094",,"3272","B","B","B","gp160","321","330","gp120(321-330)",,"A*2501","EIIGDIRQAY","qIIGDIRQAY","E1Q","E321Q","DR","diminished response","Peptide titration","Ratio of EliSpot peptide titration of this mutant to original epitope EC<sub>50</sub>ratio = >200, suggesting partial escape.","Liu2007a"
"59094",,"3273","B","B","B","gp160","321","330","gp120(321-330)",,"A*2501","EIIGDIRQAY","dIIGDIRQAh","E1D, Y10H","E321D, Y330H","DR","diminished response","Peptide titration","Ratio of EliSpot peptide titration of this mutant to original epitope EC<sub>50</sub>ratio = 34, suggesting partial escape.","Liu2007a"
"59094",,"3274","B","B","B","gp160","321","330","gp120(321-330)",,"A*2501","EIIGDIRQAY","EIIGnIRQAh","Y10H, D5N","Y330H, D325N","DR","diminished response","Peptide titration","Ratio of EliSpot peptide titration of this mutant to original epitope EC<sub>50</sub>ratio = 15.9, suggesting partial escape.","Liu2007a"
"59094",,"3275","B","B","B","gp160","321","330","gp120(321-330)",,"A*2501","EIIGDIRQAY","EIIGDIRQAh","Y10H","Y330H","E","escape documented in this paper","Peptide titration","EliSpot peptide titration indicated full escape.","Liu2007a"
"56647",,"2061","","","","gp160","334","351","gp120(334-351)","7224..7277","","SGEDWNKTLSHVVDKLRE","SGEDWNKTLSyVVDKLRE","H11Y","H344Y","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Variant sequence was observed but not documented as an escape mutant.","Goonetilleke2009"
"56647",,"2062","","","","gp160","334","351","gp120(334-351)","7224..7277","","SGEDWNKTLSHVVDKLRE","SGEDWNKTLSHVVnKLRE","D14N","D347N","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Variant sequence was observed but not documented as an escape mutant.","Goonetilleke2009"
"56647",,"2064","","","","gp160","334","351","gp120(334-351)","7224..7277","","SGEDWNKTLSHVVDKLRE","SGEDWNKTLnHVVDKLRE","S10N","S343N","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Variant sequence was observed but not documented as an escape mutant.","Goonetilleke2009"
"56647",,"2065","","","","gp160","334","351","gp120(334-351)","7224..7277","","SGEDWNKTLSHVVDKLRE","SGEDWNKTLSHVVaKLRE","D14A","D347A","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Variant sequence was observed but not documented as an escape mutant.","Goonetilleke2009"
"56647",,"2273","","","","gp160","334","351","gp120(334-351)","7224..7277","","SGEDWNKTLSHVVDKLRE","SGEDWNKTLgHVVDKLRE","S10G","S343G","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Variant sequence was observed but not documented as an escape mutant.","Goonetilleke2009"
"58239",,"2820","B","B","B","gp160","334","351","gp120(334-351)","7224..7277","","SGEDWNKTLSHVVDKLRE","SGEDWNKTLSyVVDKLRE","H11Y","H344Y","IE","inferred escape","Sequence","1/5 and 4/5 sequences of peptide SGEDWNKTLSHVVDKLRE varied at 102 and 592 DFOSx to SGEDWNKTLSyVVDKLRE.  Position 344 in the peptide is marked as being under selection to vary.","Ferrari2011"
"58239",,"2821","B","B","B","gp160","334","351","gp120(334-351)","7224..7277","","SGEDWNKTLSHVVDKLRE","SGEDWNKTLSHVVnKLRE","D14N","D347N","IE","inferred escape","Sequence","6/12 sequences of peptide SGEDWNKTLSHVVDKLRE varied at 159 DFOSx to SGEDWNKTLSHVVnKLRE.","Ferrari2011"
"54165","TL9","993","B","","","gp160","341","349","gp120(341-349)","7245..7271","A*0201","TLSQIVTKL","TLSkIVTKL","Q4K","Q344K","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Position 4 in the epitope had potentially experienced positive selection. The variant was full escape, as it was not recognized by CTLs.","Liu2006"
"59095",,"3276","B","B","B","gp160","341","349","gp120(341-349)",,"A*0201","TLSQIVTKL","TLSkIVTKL","Q4K","Q344K","E","escape documented in this paper","Peptide titration","EliSpot peptide titration indicated full escape.","Liu2007a"
"59248",,"3396","B","B","B","gp160","341","349","gp120(341-349)",,"","TLEQVVKKL","ALEQVVKKL","T1A","T341A","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","First variant to arise; seen in early and late post-seroconversion period; no Elispot response in early post-SC (seroconversion), and response <50 SFC/10<sup>6</sup>PBMC in late post-SC.","Melhem2014"
"59248",,"3397","B","B","B","gp160","341","349","gp120(341-349)",,"","TLEQVVKKL","MLEQVVKKL","T1M","T341M","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Second variant to arise; seen only in the late post-seroconversion period; Elispot response <50 SFC/10<sup>6</sup>PBMC.","Melhem2014"
"59248",,"3398","B","B","B","gp160","341","349","gp120(341-349)",,"","TLEQVVKKL","TLAQVVKKL","E3A","E343A","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Third variant to arise; seen only in the late post-seroconversion period; Elispot response <50 SFC/10<sup>6</sup>PBMC .","Melhem2014"
"59248",,"3399","B","B","B","gp160","341","349","gp120(341-349)",,"","TLEQVVKKL","TLEQVVEKL","K7E","K347E","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Fourth variant to arise;  seen in the late post-seroconversion, early ART and late ART periods; Elispot response <50 SFC/10<sup>6</sup>PBMC  in late post-SC period; about 300 SFC/10<sup>6</sup>PBMC  in early and ART, and about 800 SFC/10<sup>6</sup>PBMC  in late ART period.","Melhem2014"
"59248",,"3400","B","B","B","gp160","341","349","gp120(341-349)",,"","TLEQVVKKL","ILEQVVKKL","T1I","T341I","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Fifth variant to arise; seen only in the late post-seroconversion period;  Elispot response <50 SFC/10<sup>6</sup>PBMC.","Melhem2014"
"59248",,"3401","B","B","B","gp160","341","349","gp120(341-349)",,"","TLEQVVKKL","TLEQVVNKL","K7N","K347N","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Sixth variant to arise; seen only in the late post-seroconversion period; Elispot response <50 SFC/10<sup>6</sup>PBMC .","Melhem2014"
"59248",,"3402","B","B","B","gp160","341","349","gp120(341-349)",,"","TLEQVVKKL","TLDKVVKKL","E3D, Q4K","E343D, Q344K","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Seventh variant to arise; seen in the late post-seroconversion, early ART and late ART periods; Elispot response <50 SFC/10<sup>6</sup>PBMC  in late post-SC (seroconversion) period; about 100 SFC/10<sup>6</sup>PBMC  in early and late ART periods.","Melhem2014"
"59248",,"3403","B","B","B","gp160","341","349","gp120(341-349)",,"","TLEQVVKKL","TLGRVAKKL","E3G, Q4R, V6A","E343G, Q344R, V346A","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Eighth variant to arise; seen only in the late post-seroconversion period; Elispot response <50 SFC/10<sup>6</sup>PBMC .","Melhem2014"
"59248",,"3404","B","B","B","gp160","341","349","gp120(341-349)",,"","TLEQVVKKL","TLGQVVEKL","E3G, K7E","E343G, K347E","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Ninth variant to arise; seen in the late post-seroconversion and late ART periods; Elispot response <50 SFC/10<sup>6</sup>PBMC  during late post-SC period, and about 500 SFC/10<sup>6</sup>PBMC  in late ART period.","Melhem2014"
"59248",,"3405","B","B","B","gp160","341","349","gp120(341-349)",,"","TLEQVVKKL","TLDKVVEKL","E3D, Q4K, K7E","E343D, Q344K, K347E","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Tenth variant to arise; seen in the late post-seroconversion, early ART and late ART periods; Elispot response <50 SFC/10<sup>6</sup>PBMC  in late post-SC (seroconversion) period; about 900 SFC/10<sup>6</sup>PBMC  in early and ART, and about 600 SFC/10<sup>6</sup>PBMC  in late ART period.","Melhem2014"
"59248",,"3406","B","B","B","gp160","341","349","gp120(341-349)",,"","TLEQVVKKL","TLGKVVKKL","E3G, Q4K","E343G, Q344K","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Eleventh variant to arise; no Elispot response.","Melhem2014"
"53234",,"566","B","","","gp160","344","361","gp120(344-361)","7254..7307","","QIVEKLREIKQFKNKTIVF","QIaEKLREIKQFKNKTIVF","V3A","V346A","OV","observed variant","","2/7 clones present at day 16. Not tested for impact on escape.","Jones2004"
"53234",,"567","B","","","gp160","344","361","gp120(344-361)","7254..7307","","QIVEKLREIKQFKNKTIVF","QIVEKLREIeQFKNKTIVF","K10E","K353E","OV","observed variant","","Variant present at every time point. Not tested for impact on escape.","Jones2004"
"53234",,"568","B","","","gp160","344","361","gp120(344-361)","7254..7307","","QIVEKLREIKQFKNKTIVF","QIVkKLREIKQFKNKTIVF","E4K","E347K","OV","observed variant","","Variant present at 4 different time points. Not tested for impact on escape.","Jones2004"
"53234",,"569","B","","","gp160","344","361","gp120(344-361)","7254..7307","","QIVEKLREIKQFKNKTIVF","QIVgKLREIKQFKNKTIVF","E4G","E347G","OV","observed variant","","1/10 clones present at day 72. Not tested for impact on escape.","Jones2004"
"53234",,"570","B","","","gp160","344","361","gp120(344-361)","7254..7307","","QIVEKLREIKQFKNKTIVF","QIVgKLREIeQFKNKTIVF","K10E, E4G","K353E, E347G","OV","observed variant","","Variant present at time points 136, 212. Not tested for impact on escape.","Jones2004"
"53234",,"571","B","","","gp160","344","361","gp120(344-361)","7254..7307","","QIVEKLREIKQFKNKTIVF","QIVEKLREIeQFKNKTIaF","K10E, V18A","K353E, V361A","OV","observed variant","","Variant present at 3 different time points. Not tested for impact on escape.","Jones2004"
"53234",,"572","B","","","gp160","344","361","gp120(344-361)","7254..7307","","QIVEKLREIKQFKNKTIVF","QIVEKLREIeQFKNrTIVF","K10E, K15R","K353E, K358R","OV","observed variant","","1/35 clones present at day 212. Not tested for impact on escape.","Jones2004"
"53234",,"573","B","","","gp160","344","361","gp120(344-361)","7254..7307","","QIVEKLREIKQFKNKTIVF","QIVkKLREIeQFKNKTIVF","K10E, E4K","K353E, E347K","OV","observed variant","","Variant present at 3 different time points. Not tested for impact on escape.","Jones2004"
"53234",,"574","B","","","gp160","344","361","gp120(344-361)","7254..7307","","QIVEKLREIKQFKNKTIVF","QIVEKLREIqQFKNKTIVF","K10Q","K353Q","OV","observed variant","","Variant present at time points 246, 295. Not tested for impact on escape.","Jones2004"
"53234",,"575","B","","","gp160","344","361","gp120(344-361)","7254..7307","","QIVEKLREIKQFKNKTIVF","QIVkKLREmeQFKNKTIVF","K10E, E4K, I9M","K353E, E347K, I352M","OV","observed variant","","1/11 clones present at day 391. Not tested for impact on escape.","Jones2004"
"53234",,"576","B","","","gp160","344","361","gp120(344-361)","7254..7307","","QIVEKLREIKQFKNKTIVF","QIVEKLREIekFKNKTIVF","K10E, Q11K","K353E, Q354K","OV","observed variant","","1/11 clones present at day 391. Not tested for impact on escape.","Jones2004"
"53234",,"577","B","","","gp160","344","361","gp120(344-361)","7254..7307","","QIVEKLREIKQFKNKTIVF","QIVEKLREIKQFKNKkIVF","T16K","T359K","OV","observed variant","","1/11 clones present at day 391. Not tested for impact on escape.","Jones2004"
"56642",,"2033","","","","gp160","352","361","gp120(352-361)","7278..7307","","QFRNKTIVF","QFkNKTIVF","R3K","R354K","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This newly described epitope showed escape early on in Patient CH77.  Known T cell response from the full proteome scan with evidence for variation and escape was seen.","Goonetilleke2009"
"56642",,"2034","","","","gp160","352","361","gp120(352-361)","7278..7307","","QFRNKTIVF","QFsNKTIVF","R3S","R354S","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This newly described epitope showed escape early on in Patient CH77.  Known T cell response from the full proteome scan with evidence for variation and escape was seen.","Goonetilleke2009"
"56642",,"2035","","","","gp160","352","361","gp120(352-361)","7278..7307","","QFRNKTIVF","QFnNKTIVF","R3N","R354N","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This newly described epitope showed escape early on in Patient CH77.  Known T cell response from the full proteome scan with evidence for variation and escape was seen.","Goonetilleke2009"
"56642",,"2036","","","","gp160","352","361","gp120(352-361)","7278..7307","","QFRNKTIVF","QFRNKaIVF","T6A","T357A","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This newly described epitope showed escape early on in Patient CH77.  Known T cell response from the full proteome scan with evidence for variation and escape was seen.","Goonetilleke2009"
"56642",,"2037","","","","gp160","352","361","gp120(352-361)","7278..7307","","QFRNKTIVF","QFkNKaIVF","R3K, T6A","R354K, T357A","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This newly described epitope showed escape early on in Patient CH77. There was no response to the R3K mutant; R3K, T6A was not tested.","Goonetilleke2009"
"56642",,"2038","","","","gp160","352","361","gp120(352-361)","7278..7307","","QFRNKTIVF","QFkdKTIVF","R3K, N4D","R354K, N355D","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This newly described epitope showed escape early on in Patient CH77. There was no response to the R3K mutant; R3K, N4D was not tested.","Goonetilleke2009"
"57473",,"2455","B","B","B","gp160","352","361","gp120(352-361)","7278..7307","Cw*0401","QFRNKTIVF","QFkNKTIVF","R3K","R354K","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","One patient who had positive responses to previously-reported Cw*0401 epitope QFRNKTIVF and to the corresponding 18-mer REQFRNKTIVFNHSSGGD also had negative responses to two common transmitted variant 18-mers, REQFkNKTIVFNHSSGGD and LSHVVDKLREQFkNKTIV.","Wood2009"
"58238",,"2813","B","B","B","gp160","352","361","gp120(352-361)","7278..7307","Cw*0401","QFRNKTIVF","QFkNKTIVF","R3K","R354K","IE","inferred escape","Sequence","11/15, 12/12, 4/5, 10/12 and 3/5 sequences of epitope QFRNKTIVF  varied at 14, 32, 102, 159 and 592 DFOSx to QFkNKTIVF.  Position 354 in the epitope is marked as being under selection to vary.","Ferrari2011"
"58238",,"2815","B","B","B","gp160","352","361","gp120(352-361)","7278..7307","Cw*0401","QFRNKTIVF","QFRNKaIVF","T6A","T357A","OV","observed variant","Sequence","1/15 sequences of epitope QFRNKTIVF  varied at 14 DFOSx to QFRNKaIVF.","Ferrari2011"
"58238",,"2817","B","B","B","gp160","352","361","gp120(352-361)","7278..7307","Cw*0401","QFRNKTIVF","QFnNKTIVF","R3N","R354N","IE","inferred escape","Sequence","1/5 and 2/12 sequences of epitope QFRNKTIVF  varied at 102 and 159 DFOSx to QFnNKTIVF.","Ferrari2011"
"52996",,"310","","","","gp160","375","383","gp120(375-383)","7347..7373","B15","SFNCGGEFF","SFNCrGEFF","G5R","G379R","E","escape documented in this paper","","A dramatic decrease in CTL activity against the epitope occurred as the mutations arose. The variant became fixed in the population 20 months post-seroconversion.","Geels2003"
"55136",,"1460","","","","gp160","375","383","gp120(375-383)","7347..7373","B15, B*1516, B63","SFNCGGEFF","tFNCGGEFF","S1T","S375T","OV","observed variant","Sequence","This variant was found in 24/153 Brazilian Subtype B sequences.","Queiroz2007"
"55136",,"1461","","","","gp160","375","383","gp120(375-383)","7347..7373","B15, B*1516, B63","SFNCGGEFF","SFNCaGEFF","G5A","G379A","OV","observed variant","Sequence","This variant was found in 4/153 Brazilian Subtype B sequences.","Queiroz2007"
"55136",,"1462","","","","gp160","375","383","gp120(375-383)","7347..7373","B15, B*1516, B63","SFNCGGEFF","SFNCGGEFr","F9R","F383R","OV","observed variant","Sequence","This variant was found in 10/14 Brazilian Subtype F sequences.","Queiroz2007"
"55136",,"1463","","","","gp160","375","383","gp120(375-383)","7347..7373","B15, B*1516, B63","SFNCGGEFF","SFNCrGEFF","G5R","G379R","OV","observed variant","Sequence","This variant was found in 2/153 Brazilian Subtype B, 7/9 Brazilian Subtype C, and 18/24 Brazilian Subtype B/F recombinant  sequences.","Queiroz2007"
"55136",,"1464","","","","gp160","375","383","gp120(375-383)","7347..7373","B15, B*1516, B63","SFNCGGEFF","nFNCmGEFF","S1N, G5M","S375N, G379M","OV","observed variant","Sequence","This variant was found in 4/14 Brazilian Subtype F sequences.","Queiroz2007"
"780",,"1851","","","","gp160","375","383","gp120(375-383)","7347..7373","B15","SFTCGGEFF","SsTCGGEFF","F2S","F376S","DR","diminished response","Chromium-release assay","This variant showed reduced CTL recognition by an  HIV-transmitting mother.","Wilson1999a"
"780",,"1852","","","","gp160","375","383","gp120(375-383)","7347..7373","B15","SFTCGGEFF","SFTCGGgvF","E7G, F8V","E381G, F382V","E","escape documented in this paper","Chromium-release assay","This escape was not recognized by an  HIV-transmitting mother.","Wilson1999a"
"780",,"1853","","","","gp160","375","383","gp120(375-383)","7347..7373","B15","SFTCGGEFF","SFTCGGgFF","E7G","E381G","DR","diminished response","Chromium-release assay","This variant showed reduced CTL recognition by an  HIV-transmitting mother.","Wilson1999a"
"57927",,"2656","B","B","B","gp160","375","383","gp120(375-383)","7347..7373","Cw*0401","SFNCGGEFF","SvNCGGEFF","F2V","F376V","IE","inferred escape","CD8 T-cell Elispot - IFNy, Longitudinal study","Founder sequence SFNCGGEFF was replaced by day 68 post-seroconversion by two mutually exclusive variants, SvNCGGEFF and SFNCrGEFF. EliSpot response to the original peptide was not measured a day 7, but was significant by day 127.","Herbeck2011"
"57927",,"2657","B","B","B","gp160","375","383","gp120(375-383)","7347..7373","Cw*0401","SFNCGGEFF","SFNCrGEFF","G5R","G379R","IE","inferred escape","CD8 T-cell Elispot - IFNy, Longitudinal study","Founder sequence SFNCGGEFF was replaced by day 68 post-seroconversion by two mutually exclusive variants, SvNCGGEFF and SFNCrGEFF. EliSpot response to the original peptide was not measured a day 7, but was significant by day 127.","Herbeck2011"
"55137",,"1465","","","","gp160","375","384","gp120(375-384)","7347..7376","A29","SFNCGGEFFY","tFNCGGEFFY","S1T","S375T","OV","observed variant","Sequence","This variant was found in 23/153 Brazilian Subtype B sequences.","Queiroz2007"
"55137",,"1466","","","","gp160","375","384","gp120(375-384)","7347..7376","A29","SFNCGGEFFY","SFNCaGEFFY","G5A","G379A","OV","observed variant","Sequence","This variant was found in 4/153 Brazilian Subtype B sequences.","Queiroz2007"
"55137",,"1467","","","","gp160","375","384","gp120(375-384)","7347..7376","A29","SFNCGGEFFY","SFNCGGEFrY","F9R","F383R","OV","observed variant","Sequence","This variant was found in 10/14 Brazilian Subtype F sequences.","Queiroz2007"
"55137",,"1468","","","","gp160","375","384","gp120(375-384)","7347..7376","A29","SFNCGGEFFY","SFNCrGEFFY","G5R","G379R","OV","observed variant","Sequence","This variant was found in 7/9 Brazilian Subtype C and 18/24 Brazilian Subtype B/F recombinant  sequences.","Queiroz2007"
"55137",,"1469","","","","gp160","375","384","gp120(375-384)","7347..7376","A29","SFNCGGEFFY","nFNCmGEFFY","S1N, G5M","S375N, G379M","OV","observed variant","Sequence","This variant was found in 4/14 Brazilian Subtype F sequences.","Queiroz2007"
"55138",,"1470","","","","gp160","376","383","gp120(376-383)","7350..7373","Cw4","FNCGGEFF","FNCaGEFF","G4A","G379A","OV","observed variant","Sequence","This variant was found in 4/153 Brazilian Subtype B sequences.","Queiroz2007"
"55138",,"1471","","","","gp160","376","383","gp120(376-383)","7350..7373","Cw4","FNCGGEFF","FNCrGEFF","G4R","G379R","OV","observed variant","Sequence","This variant was found in 2/153 Brazilian Subtype B, 7/9 Brazilian Subtype C, and 18/24 Brazilian Subtype B/F recombinant  sequences.","Queiroz2007"
"55138",,"1472","","","","gp160","376","383","gp120(376-383)","7350..7373","Cw4","FNCGGEFF","FNCGGEFr","F8R","F383R","OV","observed variant","Sequence","This variant was found in 10/14 Brazilian Subtype F sequences.","Queiroz2007"
"55138",,"1473","","","","gp160","376","383","gp120(376-383)","7350..7373","Cw4","FNCGGEFF","FNCmGEFF","G4M","G379M","OV","observed variant","Sequence","This variant was found in 4/14 Brazilian Subtype F sequences.","Queiroz2007"
"55121",,"1474","","","","gp160","376","384","gp120(376-384)","7350..7376","A29","FNCGGEFFY","FNCaGEFFY","G4A","G379A","OV","observed variant","Sequence","This variant was found in 4/153 Brazilian Subtype B sequences.","Queiroz2007"
"55121",,"1476","","","","gp160","376","384","gp120(376-384)","7350..7376","A29","FNCGGEFFY","FNCGGEFrY","F8R","F383R","OV","observed variant","Sequence","This variant was found in 10/14 Brazilian Subtype F sequences.","Queiroz2007"
"55121",,"1477","","","","gp160","376","384","gp120(376-384)","7350..7376","A29","FNCGGEFFY","FNCmGEFrY","G4M, F8R","G379M, F383R","OV","observed variant","Sequence","This variant was found in 4/14 Brazilian Subtype F sequences.","Queiroz2007"
"783",,"1854","","","","gp160","376","384","gp120(376-384)","7350..7376","A29","PNCGGEFFY","PNCrGEFFY","G4R","G379R","E","escape documented in this paper","Chromium-release assay","This variant was not recognized by a non-transmitting mother.","Wilson1999a"
"55121",,"2262","","","","gp160","376","384","gp120(376-384)","7350..7376","A29","FNCGGEFFY","FNCrGEFFY","G4R","G379R","OV","observed variant","Sequence","This variant was found in 7/9 Brazilian Subtype C and 18/24 Brazilian Subtype B/F recombinant  sequences.","Queiroz2007"
"55139",,"1478","","","","gp160","377","386","gp120(377-386)","7353..7382","","NCGGEFFYCN","NCGGEFFYCd","N10D","N386D","OV","observed variant","Sequence","This variant was found in 10/153 Brazilian Subtype B sequences.","Queiroz2007"
"55139",,"1479","","","","gp160","377","386","gp120(377-386)","7353..7382","","NCGGEFFYCN","NCaGEFFYCN","G3A","G379A","OV","observed variant","Sequence","This variant was found in 4/153 Brazilian Subtype B sequences.","Queiroz2007"
"55139",,"1480","","","","gp160","377","386","gp120(377-386)","7353..7382","","NCGGEFFYCN","NCGGEFrYCN","F7R","F383R","OV","observed variant","Sequence","This variant was found in 9/14 Brazilian Subtype F sequences.","Queiroz2007"
"55139",,"1481","","","","gp160","377","386","gp120(377-386)","7353..7382","","NCGGEFFYCN","NCmGEFFYCN","G3M","G379M","OV","observed variant","Sequence","This variant was found in 4/14 Brazilian Subtype F sequences.","Queiroz2007"
"55139",,"1482","","","","gp160","377","386","gp120(377-386)","7353..7382","","NCGGEFFYCN","NCrGEFFYCN","G3R","G379R","OV","observed variant","Sequence","This variant was found in 7/9 Brazilian Subtype C and 18/24 Brazilian Subtype B/F recombinant  sequences.","Queiroz2007"
"59059",,"3231","C","C","C","gp160","404","418","gp120(404-418)","7434..7478","","NSTETNSTRTITIHC","NSTETNSTRTIkIHC","T12K","T415K","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Variant T415K abrogated CTL response to Env CD4bs D-loop peptide, NSTETNSTRTITIHC.","Gao2014"
"59060",,"3232","C","C","C","gp160","409","423","gp120(409-423)","7449..7493","","NSTRTITIHCRIKQI","NSTRTIkIHCRIKQI","T7K","T415K","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Variant T415K abrogated CTL response to Env CD4bs D-loop peptide, NSTRTITIHCRIKQI.","Gao2014"
"788",,"1770","","","","gp160","416","424","gp120(416-424)","7470..7496","B*5101","LPCRIKQII","LlCRIKQII","P2L","P417L","OV","observed variant","Chromium-release assay, HLA binding","1/104 Clade B strain sequences carried this 2L variant.  Challenge epitope elicited CTL response in 1 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.  Variant not tested.","Tomiyama1999"
"788",,"1771","","","","gp160","416","424","gp120(416-424)","7470..7496","B*5101","LPCRIKQII","LqCRIKQII","P2Q","P417Q","OV","observed variant","Chromium-release assay, HLA binding","8/104 Clade B strain sequences carried this 2Q variant.  Challenge epitope elicited CTL response in 1 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.  Variant not tested.","Tomiyama1999"
"788",,"1772","","","","gp160","416","424","gp120(416-424)","7470..7496","B*5101","LPCRIKQII","LgCRIKQII","P2G","P417G","OV","observed variant","Chromium-release assay, HLA binding","1/104 Clade B strain sequences carried this 2G variant.  Challenge epitope elicited CTL response in 1 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.  Variant not tested.","Tomiyama1999"
"788",,"1773","","","","gp160","416","424","gp120(416-424)","7470..7496","B*5101","LPCRIKQII","LsCRIKQII","P2S","P417S","OV","observed variant","Chromium-release assay, HLA binding","1/104 Clade B strain sequences carried this 2S variant.  Challenge epitope elicited CTL response in 1 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.  Variant not tested.","Tomiyama1999"
"788",,"1774","","","","gp160","416","424","gp120(416-424)","7470..7496","B*5101","LPCRIKQII","LqCkIKQII","P2Q, R4K","P417Q, R419K","OV","observed variant","Chromium-release assay, HLA binding","1/104 Clade B strain sequences carried this 2Q4K variant.  Index epitope elicited CTL response in 1 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.  Variant not tested.","Tomiyama1999"
"788",,"1775","","","","gp160","416","424","gp120(416-424)","7470..7496","B*5101","LPCRIKQII","LqCkIrQIv","P2Q, R4K, K6R, I9V","P417Q, R419K, K421R, I424V","OV","observed variant","Chromium-release assay, HLA binding","1/104 Clade B strain sequences carried this 2Q4K6R9V variant.  Challenge epitope elicited CTL response in 1 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.  Variant not tested.","Tomiyama1999"
"788",,"1777","","","","gp160","416","424","gp120(416-424)","7470..7496","B*5101","LPCRIKQII","LqCRIKQIv","P2Q, I9V","P417Q, I424V","OV","observed variant","Chromium-release assay, HLA binding","3/104 Clade B strain sequences carried this 2Q9V variant.  Challenge epitope elicited CTL response in 1 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.  Variant not tested.","Tomiyama1999"
"788",,"1778","","","","gp160","416","424","gp120(416-424)","7470..7496","B*5101","LPCRIKQII","LPCkIKQII","R4K","R419K","OV","observed variant","Chromium-release assay, HLA binding","2/104 Clade B strain sequences carried this 4K variant.  Challenge epitope elicited CTL response in 1 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.  Variant not tested.","Tomiyama1999"
"788",,"1779","","","","gp160","416","424","gp120(416-424)","7470..7496","B*5101","LPCRIKQII","LPCRtKQII","I5T","I420T","OV","observed variant","Chromium-release assay, HLA binding","1/104 Clade B strain sequences carried this 5T variant.  Index epitope elicited CTL response in 1 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.","Tomiyama1999"
"788",,"1780","","","","gp160","416","424","gp120(416-424)","7470..7496","B*5101","LPCRIKQII","LPCRIrQII","K6R","K421R","OV","observed variant","Chromium-release assay, HLA binding","2/104 Clade B strain sequences carried this 6R variant.  Challenge epitope elicited CTL response in 1of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.  Variant not tested.","Tomiyama1999"
"788",,"1781","","","","gp160","416","424","gp120(416-424)","7470..7496","B*5101","LPCRIKQII","LPCRIsQII","K6S","K421S","OV","observed variant","Chromium-release assay, HLA binding","1/104 Clade B strain sequences carried this 6S variant.  Challenge epitope elicited CTL response in 1 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.  Variant not tested.","Tomiyama1999"
"788",,"1782","","","","gp160","416","424","gp120(416-424)","7470..7496","B*5101","LPCRIKQII","LPCRIrQfv","K6R, I8F, I9V","K421R, I423F, I424V","OV","observed variant","Chromium-release assay, HLA binding","1/104 Clade B strain sequences carried this 6R8F9V variant.  Challenge epitope elicited CTL response in 1 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.  Variant not tested.","Tomiyama1999"
"788",,"1783","","","","gp160","416","424","gp120(416-424)","7470..7496","B*5101","LPCRIKQII","LPCRIKeII","Q7E","Q422E","OV","observed variant","Chromium-release assay, HLA binding","1/104 Clade B strain sequences carried this 7E variant.  Challenge epitope elicited CTL response in 1 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.","Tomiyama1999"
"788",,"1784","","","","gp160","416","424","gp120(416-424)","7470..7496","B*5101","LPCRIKQII","LPCRIKQfI","I8F","I423F","OV","observed variant","Chromium-release assay, HLA binding","4/104 Clade B strain sequences carried this 8F variant.  Challenge epitope elicited CTL response in 1 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.  Variant not tested.","Tomiyama1999"
"788",,"1785","","","","gp160","416","424","gp120(416-424)","7470..7496","B*5101","LPCRIKQII","LPCRIKQvI","I8V","I423V","OV","observed variant","Chromium-release assay, HLA binding","3/104 Clade B strain sequences carried this 8V variant.  Challenge epitope elicited CTL response in 1 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.  Variant not tested.","Tomiyama1999"
"788",,"1786","","","","gp160","416","424","gp120(416-424)","7470..7496","B*5101","LPCRIKQII","LPCRIKQfv","I8F, I9V","I423F, I424V","OV","observed variant","Chromium-release assay, HLA binding","1/104 Clade B strain sequences carried this 8F9V variant.  Challenge epitope elicited CTL response in 1 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.  Variant not tested.","Tomiyama1999"
"788",,"1787","","","","gp160","416","424","gp120(416-424)","7470..7496","B*5101","LPCRIKQII","LPCRIKQIv","I9V","I424V","OV","observed variant","Chromium-release assay, HLA binding","19/104 Clade B strain sequences carried this 9V variant.  Challenge epitope elicited CTL response in 1 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.  Variant not tested.","Tomiyama1999"
"788",,"1788","","","","gp160","416","424","gp120(416-424)","7470..7496","B*5101","LPCRIKQII","LPCRIKQIl","I9L","I424L","OV","observed variant","Chromium-release assay, HLA binding","1/104 Clade B strain sequences carried this 9L variant.  Challenge epitope elicited CTL response in 1 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.  Variant not tested.","Tomiyama1999"
"788",,"2265","","","","gp160","416","424","gp120(416-424)","7470..7496","B*5101","LPCRIKQII","LqCRIKQfI","P2Q, I8F","P417Q, I423F","OV","observed variant","Chromium-release assay, HLA binding","1/104 Clade B strain sequences carried this 2Q8F variant.  Challenge epitope elicited CTL response in 1 of 3 HLA-B51 seropositive individuals, and bound HLA-B*5101 with high strength.  Variant not tested.","Tomiyama1999"
"57675","EnvRW9","2669","A, B, C, D","A, B, C, D","A, B, C, D","gp160","419","427","gp120(419-427)","7479..7505","","RIKQIINMW","RIKQIvNMW","I6V","I424V","SF, SSF","susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Variant RIKQIvNMW was found at a frequency of 2, 11, 5 and 6 in clades A, B, C and D respectively.","Koup2010"
"57675","EnvRW9","2670","A, B, C, D","A, B, C, D","A, B, C, D","gp160","419","427","gp120(419-427)","7479..7505","","RIKQIINMW","kIKQIINMW","R1K","R419K","SF, SSF","susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Variant kIKQIINMW was found at a frequency of 4, 3, 7 and 2 in clades A, B, C and D respectively.","Koup2010"
"57675","EnvRW9","2671","A, B, C, D","A, B, C, D","A, B, C, D","gp160","419","427","gp120(419-427)","7479..7505","","RIKQIINMW","RIKQIINrW","M8R","M426R","SF, SSF","susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Variant RIKQIINrW was found at a frequency of 11 and 2 in clades B and C respectively.","Koup2010"
"57921","p41A","2754","B","B","C, G, J","gp160","435","443","gp120(435-443)","7527..7553","Mamu-A*01","YAPPISGQI","YAPPIaGnI","S6A, Q8N","S440A, Q442N","A, OV","HLA association, observed variant","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining, Tetramer binding","Variant 1, YAPPIaGnI, binds Mamu-A*01 and is found at a frequency of 15.93% as opposed to 3.9% for HXB2-p41A epitopes in M group viruses.  When used as cold competitor, 23.95 nM was required to inhibit binding of 50% radiolabeled p41A.  Since this peptide has a low IC50 value, it was used for tetramer binding studies that showed cross-recognition with p41A by a small population of CTL from monkey 3096 and a large population of CTL from monkey 8998.","Hulot2011"
"57921","p41A","2755","B","B","B","gp160","435","443","gp120(435-443)","7527..7553","Mamu-A*01","YAPPISGQI","YAPPIrGQI","S6R","S440R","A, OV","HLA association, observed variant","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining, Tetramer binding","Variant 2, YAPPIrGQI, binds Mamu-A*01 and is found at a frequency of 9.69% as opposed to 3.9% for HXB2-p41A epitopes in M group viruses. When used as cold competitor, 563.3 nM was required to inhibit binding of 50% radiolabeled p41A.","Hulot2011"
"57921","p41A","2756","B","B","A, CRF02_AG","gp160","435","443","gp120(435-443)","7527..7553","Mamu-A*01","YAPPISGQI","YAPPIqGvI","S6Q, Q8V","S440Q, Q442V","A, OV","HLA association, observed variant","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining, Tetramer binding","Variant 3, YAPPIqGvI, binds Mamu-A*01 and is found at a frequency of 3.19% as opposed to 3.9% for HXB2-p41A epitopes in M group viruses.  When used as cold competitor, 34.72 nM was required to inhibit binding of 50% radiolabeled p41A.  Since this peptide has a low IC50 value, it was used for tetramer binding studied that showed cross-recognition with p41A by small populations of CTL from monkeys 3096 and 8998.","Hulot2011"
"57921","p41A","2757","B","B","B","gp160","435","443","gp120(435-443)","7527..7553","Mamu-A*01","YAPPISGQI","YAPPIeGnI","S6E, Q8N","S440E, Q442N","A, OV","HLA association, observed variant","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining, Tetramer binding","Variant 4, YAPPIeGnI, binds Mamu-A*01 and is found at a frequency of 5.16% as opposed to 3.9% for HXB2-p41A epitopes in M group viruses.  When used as cold competitor, 573.7 nM was required to inhibit binding of 50% radiolabeled p41A.","Hulot2011"
"57921","p41A","2758","B","B","CRF01_AE","gp160","435","443","gp120(435-443)","7527..7553","Mamu-A*01","YAPPISGQI","YAPPISGrI","Q8R","Q442R","A, OV","HLA association, observed variant","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining, Tetramer binding","Variant 5, YAPPISGrI, binds Mamu-A*01 and is found at a frequency of 1.08% as opposed to 3.9% for HXB2-p41A epitopes in M group viruses.  When used as cold competitor, 7.04 nM was required to inhibit binding of 50% radiolabeled p41A.  Since this peptide has a low IC50 value, it was used for tetramer binding studies that showed cross-recognition with p41A by a small population of CTL from monkey 3096; but no cross-recognition was seen by CTL from monkey 8998.","Hulot2011"
"57921","p41A","2759","B","B","D","gp160","435","443","gp120(435-443)","7527..7553","Mamu-A*01","YAPPISGQI","YAPPIeGlI","S6E, Q8L","S440E, Q442L","A, OV","HLA association, observed variant","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining, Tetramer binding","Variant 6, YAPPIeGlI, binds Mamu-A*01 and is found at a frequency of 1.93% as opposed to 3.9% for HXB2-p41A epitopes in M group viruses.  When used as cold competitor, 19.78 nM was required to inhibit binding of 50% radiolabeled p41A.  Since this peptide has a low IC50 value, it was used for tetramer binding studies that showed no cross-recognition with p41A by CTL from monkeys 3096 and 8998.","Hulot2011"
"57921","p41A","2760","B","B","B","gp160","435","443","gp120(435-443)","7527..7553","Mamu-A*01","YAPPISGQI","YAPPIpGvI","S6P, Q8V","S440P, Q442V","A, OV","HLA association, observed variant","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining, Tetramer binding","Variant 7, YAPPIpGvI, binds Mamu-A*01 and is found at a frequency of 2.06% as opposed to 3.9% for HXB2-p41A epitopes in M group viruses.  When used as cold competitor, 478.3 nM was required to inhibit binding of 50% radiolabeled p41A.","Hulot2011"
"57921","p41A","2761","B","B","D","gp160","435","443","gp120(435-443)","7527..7553","Mamu-A*01","YAPPISGQI","YAPPIaGQI","S6A","S440A","A, OV","HLA association, observed variant","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining, Tetramer binding","Variant 8, YAPPIaGQI, binds Mamu-A*01 and is found at a frequency of 1.3% as opposed to 3.9% for HXB2-p41A epitopes in M group viruses. When used as cold competitor, 11.7 nM was required to inhibit binding of 50% radiolabeled p41A.  Since this peptide has a low IC50 value, it was used for tetramer binding studies that showed cross-recognition with p41A by large populations of CTL from monkeys 3096 and 8998.","Hulot2011"
"57921","p41A","2762","B","B","B","gp160","435","443","gp120(435-443)","7527..7553","Mamu-A*01","YAPPISGQI","YAPPIkGQI","S6K","S440K","A, OV","HLA association, observed variant","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining, Tetramer binding","Variant 9, YAPPIkGQI, binds Mamu-A*01 and is found at a frequency of 2.56% as opposed to 3.9% for HXB2-p41A epitopes in M group viruses.  When used as cold competitor, 643.5 nM was required to inhibit binding of 50% radiolabeled p41A.","Hulot2011"
"57921","p41A","2763","B","B","B","gp160","435","443","gp120(435-443)","7527..7553","Mamu-A*01","YAPPISGQI","YAPPIkGnI","S6K, Q8N","S440K, Q442N","A, OV","HLA association, observed variant","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining, Tetramer binding","Variant 10, YAPPIkGnI, binds Mamu-A*01 and is found at a frequency of 1.75% as opposed to 3.9% for HXB2-p41A epitopes in M group viruses.  When used as cold competitor, 504.1 nM was required to inhibit binding of 50% radiolabeled p41A.","Hulot2011"
"57921","p41A","2765","B","B","B","gp160","435","443","gp120(435-443)","7527..7553","Mamu-A*01","YAPPISGQI","YAPPIeGQI","S6E","S440E","A, OV","HLA association, observed variant","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining, Tetramer binding","Variant 11, YAPPIeGQI, binds Mamu-A*01 and is found at a frequency of 1.7% as opposed to 3.9% for HXB2-p41A epitopes in M group viruses.  When used as cold competitor, 326.6 nM was required to inhibit binding of 50% radiolabeled p41A.","Hulot2011"
"57921","p41A","2766","B","B","A, B, C, CRF02_AG","gp160","435","443","gp120(435-443)","7527..7553","Mamu-A*01","YAPPISGQI","YAPPIqGiI","S6Q, Q8I","S440Q, Q442I","A, OV","HLA association, observed variant","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining, Tetramer binding","Variant 12, YAPPIqGiI, binds Mamu-A*01 and is found at a frequency of 1.08% as opposed to 3.9% for HXB2-p41A epitopes in M group viruses.  When used as cold competitor, 30.58 nM was required to inhibit binding of 50% radiolabeled p41A.  Since this peptide has a low IC50 value, it was used for tetramer binding studies that showed no cross-recognition with p41A by CTL from monkey 3096; but a small population of CTL from monkey 8998 did cross-recognize this Variant 12 with p41A.","Hulot2011"
"57921","p41A","2767","B","B","B","gp160","435","443","gp120(435-443)","7527..7553","Mamu-A*01","YAPPISGQI","YAPPIkGsI","S6K, Q8S","S440K, Q442S","A, OV","HLA association, observed variant","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining, Tetramer binding","Variant 13, YAPPIkGsI, binds Mamu-A*01 and is found at a frequency of 0.36% as opposed to 3.9% for HXB2-p41A epitopes in M group viruses.  When used as cold competitor, 421.5 nM was required to inhibit binding of 50% radiolabeled p41A.","Hulot2011"
"57921","p41A","2768","B","B","B","gp160","435","443","gp120(435-443)","7527..7553","Mamu-A*01","YAPPISGQI","YAPPIrGiI","S6R, Q8I","S440R, Q442I","A, OV","HLA association, observed variant","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining, Tetramer binding","Variant 14, YAPPIrGiI, binds Mamu-A*01 and is found at a frequency of 0.94% as opposed to 3.9% for HXB2-p41A epitopes in M group viruses.  When used as cold competitor, 221.1 nM was required to inhibit binding of 50% radiolabeled p41A.","Hulot2011"
"57921","p41A","2769","B","B","B","gp160","435","443","gp120(435-443)","7527..7553","Mamu-A*01","YAPPISGQI","YAPPIpGiI","S6P, Q8I","S440P, Q442I","A, OV","HLA association, observed variant","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining, Tetramer binding","Variant 15, YAPPIpGiI, binds Mamu-A*01 and is found at a frequency of 1.08% as opposed to 3.9% for HXB2-p41A epitopes in M group viruses.  When used as cold competitor, 493.1 nM was required to inhibit binding of 50% radiolabeled p41A.","Hulot2011"
"57921","p41A","2770","B","B","F2","gp160","435","443","gp120(435-443)","7527..7553","Mamu-A*01","YAPPISGQI","YAPPIaGkI","S6A, Q8K","S440A, Q442K","A, OV","HLA association, observed variant","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining, Tetramer binding","Variant 16, YAPPIaGkI, binds Mamu-A*01 and is found at a frequency of 1.21% as opposed to 3.9% for HXB2-p41A epitopes in M group viruses.  When used as cold competitor, 26.18 nM was required to inhibit binding of 50% radiolabeled p41A.  Since this peptide has a low IC50 value, it was used for tetramer binding studies that showed cross-recognition with p41A by small populations of CTL from monkeys 3096 and 8998.","Hulot2011"
"57921","p41A","2771","B","B","B","gp160","435","443","gp120(435-443)","7527..7553","Mamu-A*01","YAPPISGQI","YAPPIrGvI","S6R, Q8V","S440R, Q442V","A, OV","HLA association, observed variant","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining, Tetramer binding","Variant 17, YAPPIrGvI, binds Mamu-A*01 and is found at a frequency of 0.85% as opposed to 3.9% for HXB2-p41A epitopes in M group viruses.  When used as cold competitor, 143.3 nM was required to inhibit binding of 50% radiolabeled p41A.","Hulot2011"
"57921","p41A","2772","B","B","B","gp160","435","443","gp120(435-443)","7527..7553","Mamu-A*01","YAPPISGQI","YAPPIeGiI","S6E, Q8I","S440E, Q442I","A, OV","HLA association, observed variant","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining, Tetramer binding","Variant 20, YAPPIeGiI, binds Mamu-A*01 and is found at a frequency of 0.85% as opposed to 3.9% for HXB2-p41A epitopes in M group viruses.  When used as cold competitor, 299.7 nM was required to inhibit binding of 50% radiolabeled p41A.","Hulot2011"
"57921","p41A","2773","B","B","B","gp160","435","443","gp120(435-443)","7527..7553","Mamu-A*01","YAPPISGQI","YAPPIpGeI","S6P, Q8E","S440P, Q442E","A, OV","HLA association, observed variant","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining, Tetramer binding","Variant 21, YAPPIpGeI, binds Mamu-A*01 and is found at a frequency of 0.54% as opposed to 3.9% for HXB2-p41A epitopes in M group viruses.  When used as cold competitor, 96.11 nM was required to inhibit binding of 50% radiolabeled p41A.","Hulot2011"
"57921","p41A","2774","B","B","B","gp160","435","443","gp120(435-443)","7527..7553","Mamu-A*01","YAPPISGQI","YAPPIrGnl","S6R, Q8N, I9L","S440R, Q442N, I443L","A, OV","HLA association, observed variant","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining, Tetramer binding","Variant 17, YAPPIrGnl, binds Mamu-A*01 and is found at a frequency of 0.49% as opposed to 3.9% for HXB2-p41A epitopes in M group viruses.  When used as cold competitor, 287.5 nM was required to inhibit binding of 50% radiolabeled p41A.","Hulot2011"
"57921","p41A","2775","B","B","B","gp160","435","443","gp120(435-443)","7527..7553","Mamu-A*01","YAPPISGQI","YAPPIkGnl","S6K, Q8N, I9L","S440K, Q442N, I443L","A, OV","HLA association, observed variant","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining, Tetramer binding","Variant 18, YAPPIkGnl, binds Mamu-A*01 and is found at a frequency of 0.45% as opposed to 3.9% for HXB2-p41A epitopes in M group viruses.  When used as cold competitor, 471.3 nM was required to inhibit binding of 50% radiolabeled p41A.","Hulot2011"
"57921","p41A","2776","B","B","B","gp160","435","443","gp120(435-443)","7527..7553","Mamu-A*01","YAPPISGQI","YAPPISGtI","Q8T","Q442T","A, OV","HLA association, observed variant","Flow cytometric T-cell cytokine assay, Intracellular cytokine staining, Tetramer binding","Variant 22, YAPPISGtI, binds Mamu-A*01 and is found at a frequency of 0.45% as opposed to 3.9% for HXB2-p41A epitopes in M group viruses.","Hulot2011"
"55140",,"1483","","","","gp160","529","537","gp41(18-26)","7809..7835","A2","TMGAASITL","TMGAASlTL","I7L","I535L","OV","observed variant","Sequence","This variant was found in 2/7 Brazilian Subtype B sequences.","Queiroz2007"
"55140",,"1484","","","","gp160","529","537","gp41(18-26)","7809..7835","A2","TMGAASITL","TMGAASvaL","I7V, T8A","I535V, T536A","OV","observed variant","Sequence","This variant was found in 2/7 Brazilian Subtype B sequences.","Queiroz2007"
"55140",,"1485","","","","gp160","529","537","gp41(18-26)","7809..7835","A2","TMGAASITL","TMGAASmTL","I7M","I535M","OV","observed variant","Sequence","This variant was found in 3/19 Brazilian Subtype B/F recombinant  sequences.","Queiroz2007"
"55380","Env 529","1754","","","","gp160","529","537","gp41(18-26)","7809..7835","A2","TMGAASITL","TMGAASmTL","I7M","I535M","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subjects Pt16, Pt21 carried the  HXB2 epitope TMGAASmTL, but cross-recognized the variant TMGAASITL; Pt18, Pt43 also carried the consensus HXB2 sequence but failed to recognize the index TMGAASITL.","Thorn2007"
"55380","Env 529","1755","","","","gp160","529","537","gp41(18-26)","7809..7835","A2","TMGAASITL","TMGAASlTL","I7L","I535L","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt35 carried this variant epitope in a structural protein, and did not recognize the challenge HXB2 epitope TMGAASITL.","Thorn2007"
"55380","Env 529","1756","","","","gp160","529","537","gp41(18-26)","7809..7835","A2","TMGAASITL","TMGAASvTL","I7V","I535V","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt41 carried this variant epitope in a structural protein, and recognized the challenge HXB2 epitope TMGAASITL.","Thorn2007"
"55380","Env 529","1757","","","","gp160","529","537","gp41(18-26)","7809..7835","A2","TMGAASITL","TMGAASmaL","I7M, T8A","I535M, T536A","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt23 carried this variant epitope in a structural protein, and did not recognize the challenge HXB2 epitope TMGAASITL.","Thorn2007"
"55380","Env 529","1758","","","","gp160","529","537","gp41(18-26)","7809..7835","A2","TMGAASITL","TMGAASvaL","I7V, T8A","I535V, T536A","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt17 carried this variant epitope in a structural protein, and did not recognize the challenge HXB2 epitope TMGAASITL.","Thorn2007"
"52331",,"136","B","B","C","gp160","557","565","gp41(46-54)","7893..7919","Cw*0304","RAIEAQQHL","RAIEAQQHm","L9M","L565M","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","CTL from subject US101, infected with a clade B virus, displayed broad cross-reactivity to HIV-1 clade A, B, C, D, CRF01_AE, F G. Clade B and C had an L->M change in the C-terminal position that was tolerated. The H clade Env was not cross-reactive, and had the sequence RAIqArQHm.","Currier2002b"
"52331",,"137","B","B","C","gp160","557","565","gp41(46-54)","7893..7919","Cw*0304","RAIEAQQHL","RAIqArQHm","E4Q, Q6R, L9M","E560Q, Q562R, L565M","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy","CTL from subject US101, infected with a clade B virus, displayed broad cross-reactivity to HIV-1 clade A, B, C, D, CRF01_AE, F G. Clade B and C had a L->M change in the C-terminal position that was tolerated. The H clade Env was not cross-reactive, and had the sequence RAIqArQHm.","Currier2002b"
"53807",,"1231","A, B, C, D","A, B, D","C","gp160","557","565","gp41(46-54)","7893..7919","","RAIEAQQHL","RAIEAQQHm","L9M","L565M","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","This Clade C variant was recognized by Clade A, Clade B and Clade D-specific CTLs.","McKinnon2005"
"806",,"1632","","B","B","gp160","557","565","gp41(46-54)","7893..7919","B51","RAIEAQQHL","kAIEAQQHL","R1K","R557K","SF","susceptible form","Chromium-release assay","This naturally occurring, strain NY5CG variant, was recognized by a Patient LWS CTL clone.","Sipsas1997"
"806",,"1633","","B","B","gp160","557","565","gp41(46-54)","7893..7919","B51","RAIEAQQHL","RAIEAQQHm","L9M","L565M","SF","susceptible form","Chromium-release assay","This naturally occurring, strain JRCSF variant, was recognized by a Patient LWS CTL clone.","Sipsas1997"
"806",,"1634","","B","B","gp160","557","565","gp41(46-54)","7893..7919","B51","RAIEAQQHL","RAIdAQQHL","E4D","E560D","SF","susceptible form","Chromium-release assay","This naturally occurring, strain ETR variant, was recognized by a Patient LWS CTL clone.","Sipsas1997"
"806",,"1635","","B","B","gp160","557","565","gp41(46-54)","7893..7919","B51","RAIEAQQHL","RAIkAQQHL","E4K","E560K","SF","susceptible form","Chromium-release assay","This naturally occurring, strain CDC42 variant, was recognized by a Patient LWS CTL clone.","Sipsas1997"
"58596","OLP-111","3039","A1","A1","B","gp160","558","572","gp41(47-61)","7896..7940","","AIEAQQHLLKLTVWG","AIEAQQHLLqLTVWG","K10Q","K567Q","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","AIEAQQHLLqLTVWG is the Clade B sequence analogous to OLP-111.","McKinnon2009a"
"58595","OLP-112","3038","A1","A1","B","gp160","563","577","gp41(52-66)","7911..7955","","QHLLKLTVWGIKQLQ","QHLLqLTVWGIKQLQ","K5Q","K567Q","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Clade B analogous sequence to OLP-112 is QHLLqLTVWGIKQLQ.","McKinnon2009a"
"55141",,"1486","","","","gp160","565","573","gp41(54-62)","7917..7943","A2","LLQLTVWGI","mLQLTVWGI","L1M","L565M","OV","observed variant","Sequence","This variant was found in 4/7 Brazilian Subtype B sequences.","Queiroz2007"
"55141",,"1487","","","","gp160","565","573","gp41(54-62)","7917..7943","A2","LLQLTVWGI","LLQLTVWGm","I9M","I573M","OV","observed variant","Sequence","This variant was found in 13/13 Brazilian Subtype C and 6/19 Brazilian Subtype B/F recombinant  sequences.","Queiroz2007"
"55381","Env 565","1674","C","","","gp160","565","573","gp41(54-62)","7917..7943","A2","LLQLTVWGI","mLQLTVWGI","L1M","L565M","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subjects Pt15, Pt18, Pt23 and Pt30 were carriers of this variant and were all unable to recognize the challenge HXB2 epitope, LLQLTVWGI.","Thorn2007"
"55381","Env 565","1675","C","","","gp160","565","573","gp41(54-62)","7917..7943","A2","LLQLTVWGI","LLkLTVWGI","Q3K","Q567K","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt41 was a carrier of this variant and was unable to recognize the challenge HXB2 epitope, LLQLTVWGI.","Thorn2007"
"55662","QL11","1331","C","","","gp160","577","587","gp41(66-76)","7953..7985","B*5801, B*5802","QTRVLAIERYL","QaRVLAIERYL","T2A","T578A","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This T2A polymorphism was not statistically associated with HLA-B*5802 expression.  Of 42 HLA-B*5802+ subjects, 5 responders to the index epitope QL11 and 19 nonresponders to QL11, carried the variant.  38/74 (51.4%) B*5802 negative subjects also carried the variant.  Nonresponders to the QL11 did not respond to T2A variant, but responders to QL11 showed broad cross-recognition to the variant indicating lack of functional escape.","Ngumbela2008"
"55662","QL11","1332","C","","","gp160","577","587","gp41(66-76)","7953..7985","B*5801, B*5802","QTRVLAIERYL","QTRVLAmERYL","I7M","I583M","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This polymorphism was not statistically associated with HLA-B*5802 expression.  Of 42 HLA-B*5802+ subjects, no responders to the index epitope QL11 and 3 nonresponders to QL11, carried the variant.  1/74 (1.4%) B*5802 negative subjects also carried the variant.  The nonresponders to the QL11 did not respond to this variant.","Ngumbela2008"
"55662","QL11","1333","C","","","gp160","577","587","gp41(66-76)","7953..7985","B*5801, B*5802","QTRVLAIERYL","QTRVLAlERYL","I7L","I583L","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This I7L polymorphism was not statistically associated with HLA-B*5802 expression.  Of 42 HLA-B*5802+ subjects, 2 responders to the index epitope QL11 and no nonresponders to QL11, carried the variant.  1/74 (1.4%) B*5802 negative subjects also carried the variant.  Nonresponders to the QL11 did not respond to I7L variant, but responders to QL11 showed broad cross-recognition to the variant indicating lack of functional escape.","Ngumbela2008"
"55662","QL11","1334","C","","","gp160","577","587","gp41(66-76)","7953..7985","B*5801, B*5802","QTRVLAIERYL","QTRVLAvERYL","I7V","I583V","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This  polymorphism was not statistically associated with HLA-B*5802 expression.  Of 42 HLA-B*5802+ subjects, 2 responders to the index epitope QL11 and no nonresponders to QL11, carried the variant.  No (0%) B*5802 negative subjects carried the variant.  Nonresponders to QL11 did not respond to this variant, but responders to QL11 showed broad cross-recognition to this variant indicating lack of functional escape.","Ngumbela2008"
"55662","QL11","1336","C","","","gp160","577","587","gp41(66-76)","7953..7985","B*5801, B*5802","QTRVLAIERYL","QaRVLAmERYL","T2A, I7M","T578A, I583M","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This T2A, I7L polymorphism was not statistically associated with HLA-B*5802 expression.  Of 42 HLA-B*5802+ subjects, 2 responders to the index epitope QL11 and 1 nonresponder to QL11, carried double variants at these positions.  5/74 (6.7%) B*5802 negative subjects also carried double variants at these positions.  Nonresponders to the QL11 did not respond to T2A variant, but responders to QL11 showed broad cross-recognition to the variant indicating lack of functional escape.","Ngumbela2008"
"58560","OLP-115","3042","A1","A1","B","gp160","578","592","gp41(67-81)","7956..8000","B*1402","ARVLAVERYLRDQQL","ARVLAVERYLkDQQL","R11K","R588K","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","The Clade B sequence analogous to OLP-115 is ARVLAVERYLkDQQL and it contains BDE ERYLKDQQL.","McKinnon2009a"
"55291",,"1513","B","","","gp160","583","592","gp41(72-81)","7971..8000","B14","VERYLKDQQL","VERYLrDQQL","K6R","K588R","OV","observed variant","Sequence","This index epitope was conserved in the mother's viral strain but mutated in the daughter's isolate.","Reinis2007"
"58563","OLP-116","3044","A1","A1","B","gp160","583","597","gp41(72-86)","7971..8015","A*23, A*2402, B*0801","VERYLRDQQLLGIWG","VERYLkDQQLLGIWG","R6K","R588K","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","The Clade B sequence analogous to OLP-116 is VERYLkDQQLLGIWG and it contains BDE RYLkDQQLL.","McKinnon2009a"
"818",,"104","","B, C, D","A","gp160","584","592","gp41(73-81)","7974..8000","B14","ERYLKDQQL","ERYLrDQQL","K5R","K588R","SSF","subtype-specific susceptible form","Chromium-release assay","The consensus sequence for clades B, C, and D is ERYLKDQQL. The consensus sequence for clade A is ERYLRDQQL and it is equally reactive.","Cao1997a"
"53221","gp160 EL9","578","B","","","gp160","584","592","gp41(73-81)","7974..8000","B*1402","ERYLKDQQL","ERYLKeQQp","D6E, L9P","D589E, L592P","OV","observed variant","","Came up at day 17. Not tested for escape.","Jones2004"
"53221","gp160 EL9","579","B","","","gp160","584","592","gp41(73-81)","7974..8000","B*1402","ERYLKDQQL","ERYLrDQQL","K5R","K588R","SF","susceptible form","","Came up at day 31, did not confer escape.","Jones2004"
"53221","gp160 EL9","580","B","","","gp160","584","592","gp41(73-81)","7974..8000","B*1402","ERYLKDQQL","ERYLtDQQL","K5T","K588T","DR","diminished response","","One of the three variants found at day 218, gave diminished CTL response.","Jones2004"
"53221","gp160 EL9","581","B","","","gp160","584","592","gp41(73-81)","7974..8000","B*1402","ERYLKDQQL","ERYLqDQQL","K5Q","K588Q","DR","diminished response","","One of the three variants found at day 218, gave diminished CTL response. Also found in another patient.","Jones2004"
"53221","gp160 EL9","582","B","","","gp160","584","592","gp41(73-81)","7974..8000","B*1402","ERYLKDQQL","ERYLsDQQL","K5S","K588S","DR","diminished response","","One of the three variants found at day 218, gave diminished CTL response.","Jones2004"
"53221","gp160 EL9","583","B","","","gp160","584","592","gp41(73-81)","7974..8000","B*1402","ERYLKDQQL","ERYLmDQQL","K5M","K588M","DR","diminished response","","Found at day 556, gave a further reduction of CTL response.","Jones2004"
"53221","gp160 EL9","584","B","","","gp160","584","592","gp41(73-81)","7974..8000","B*1402","ERYLKDQQL","ERYLmDQrL","K5M, Q8R","K588M, Q591R","OV","observed variant","","Double mutant found at day 556. Not tested for escape.","Jones2004"
"53221","gp160 EL9","585","B","","","gp160","584","592","gp41(73-81)","7974..8000","B*1402","ERYLKDQQL","ERYLmDrQL","K5M, Q7R","K588M, Q590R","OV","observed variant","","Double mutant found at day 556. Not tested for escape.","Jones2004"
"53221","gp160 EL9","586","B","","","gp160","584","592","gp41(73-81)","7974..8000","B*1402","ERYLKDQQL","ERYLmDQlL","K5M, Q8L","K588M, Q591L","OV","observed variant","","Double mutant found at day 556. Not tested for escape.","Jones2004"
"53221","gp160 EL9","587","B","","","gp160","584","592","gp41(73-81)","7974..8000","B*1402","ERYLKDQQL","ERYLtDQrL","K5T, Q8R","K588T, Q591R","OV","observed variant","","Double mutant found at day 556. Not tested for escape.","Jones2004"
"53221","gp160 EL9","588","B","","","gp160","584","592","gp41(73-81)","7974..8000","B*1402","ERYLKDQQL","ERYrtDQrL","L4R, K5T, Q8R","L587R, K588T, Q591R","OV","observed variant","","Double mutant found at day 556. Not tested for escape.","Jones2004"
"53761","EL9","784","B","","","gp160","584","592","gp41(73-81)","7974..8000","B14","ERYLKDQQL","ERYLqDQQL","K5Q","K588Q","DR","diminished response","CD8 T-cell Elispot - IFNy, Chromium-release assay","This variant was the only form of the epitope detected over a 6-year period in a patient. The variant was much less well recognized by patient CTLs compared to the wt form.","Koibuchi2005a"
"53808",,"1232","A, B, C, D","A","B, C","gp160","584","592","gp41(73-81)","7974..8000","","ERYLRDQQL","ERYLkDQQL","R5K","R588K","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","This Clade B and C variant was recognized by Clade A-specific CTLs.","McKinnon2005"
"53808",,"1233","A, B, C, D","A","D","gp160","584","592","gp41(73-81)","7974..8000","","ERYLRDQQL","ERsLRDQQL","Y3S","Y586S","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","This Clade D variant was recognized by Clade A-specific CTLs.","McKinnon2005"
"55142",,"1488","","","","gp160","584","592","gp41(73-81)","7974..8000","A32, B14","ERYLKDQQL","ERYLrDQQL","K5R","K588R","OV","observed variant","Sequence","This variant was found in 2/7 Brazilian Subtype B and 2/13 Brazilian Subtype C sequences.","Queiroz2007"
"55142",,"1489","","","","gp160","584","592","gp41(73-81)","7974..8000","A32, B14","ERYLKDQQL","ERYLgDQQL","K5G","K588G","OV","observed variant","Sequence","This variant was found in 2/7 Brazilian Subtype B sequences.","Queiroz2007"
"55142",,"1490","","","","gp160","584","592","gp41(73-81)","7974..8000","A32, B14","ERYLKDQQL","ERYLqDQQL","K5Q","K588Q","OV","observed variant","Sequence","This variant was found in 4/7 Brazilian Subtype F and 3/19 Brazilian Subtype B/F recombinant  sequences.","Queiroz2007"
"55292",,"1514","B","","","gp160","584","592","gp41(73-81)","7974..8000","B14, B*1402","ERYLKDQQL","ERYLrDQQL","K5R","K588R","OV","observed variant","Sequence","This index epitope was conserved in the mother's viral strain but mutated in the daughter's isolate.","Reinis2007"
"833",,"1550","B","B","A","gp160","584","592","gp41(73-81)","7974..8000","B14, B*1402","ERYLKDQQL","ERYLrDQQL","K5R","K588R","SF","susceptible form","Chromium-release assay","One HEPS Kenyan subject cross-reacted to this B clade epitope but elicited a stronger reaction to  the  A clade form, ERYLrDQQL.","Rowland-Jones1998"
"56649",,"2066","","","","gp160","584","592","gp41(73-81)","7974..8000","B*1401","ERYLRDQQL","ERYLgDQQL","R5G","R588G","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This variant arose in longitudinal study of Patient CH58, but loss of response not documented.","Goonetilleke2009"
"56649",,"2067","","","","gp160","584","592","gp41(73-81)","7974..8000","B*1401","ERYLRDQQL","ERhLRDQQL","Y3H","Y586H","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Decrease in response to this epitope was documented in Patient CH58.","Goonetilleke2009"
"56649",,"2068","","","","gp160","584","592","gp41(73-81)","7974..8000","B*1401","ERYLRDQQL","ERYLkDQQL","R5K","R588K","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This variant arose in longitudinal study of Patient CH58, but loss of response not documented.","Goonetilleke2009"
"56649",,"2069","","","","gp160","584","592","gp41(73-81)","7974..8000","B*1401","ERYLRDQQL","ERYLsDQQL","R5S","R588S","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Decrease in response to this epitope was documented in Patient CH58.","Goonetilleke2009"
"818",,"2255","","B, C, D","CRF01_AE","gp160","584","592","gp41(73-81)","7974..8000","B14","ERYLKDQQL","ERYLKDQQf","L9F","L592F","SNSF","subtype-specific non-susceptible form","Chromium-release assay","The consensus sequence for clades B, C, and D is ERYLKDQQL. The consensus sequence for clade E is ERYLKDQKF and it is not reactive.","Cao1997a"
"58235",,"2801","B","B","B","gp160","584","592","gp41(73-81)","7974..8000","B*1402","ERYLRDQQL","ERYLgDQQL","R5G","R588G","IE","inferred escape","Sequence","1/7, 2/9 and 1/9 sequences of epitope ERYLRDQQL varied at 9, 45 and 85 DFOSx to ERYLgDQQL.  Position 588 in the epitope is marked as being under selection to vary.","Ferrari2011"
"58235",,"2802","B","B","B","gp160","584","592","gp41(73-81)","7974..8000","B*1402","ERYLRDQQL","ERYLkDQQL","R5K","R588K","IE","inferred escape","Sequence","1/9 and 3/9 sequences of epitope ERYLRDQQL varied at 45 and 85 DFOSx to ERYLkDQQL.","Ferrari2011"
"58235",,"2803","B","B","B","gp160","584","592","gp41(73-81)","7974..8000","B*1402","ERYLRDQQL","ERYLsDQQL","R5S","R588S","IE","inferred escape","Sequence","2/9, 1/9 and 2/2 sequences of epitope ERYLRDQQL varied at 45, 85 and 350 DFOSx to ERYLsDQQL.","Ferrari2011"
"58235",,"2805","B","B","B","gp160","584","592","gp41(73-81)","7974..8000","B*1402","ERYLRDQQL","ERhLRDQQL","Y3H","Y586H","IE","inferred escape","Sequence","1/7, 3/9 and 3/9 sequences of epitope ERYLRDQQL varied at 9, 45 and 85 DFOSx to ERhLRDQQL.  Position 586 in the epitope is marked as being under selection to vary.","Ferrari2011"
"55143",,"1491","","","","gp160","584","594","gp41(73-83)","7974..8006","","ERYLKDQQLLG","ERYLrDQQLLG","K5R","K588R","OV","observed variant","Sequence","This variant was found in 2/7 Brazilian Subtype B and 2/13 Brazilian Subtype C sequences.","Queiroz2007"
"55143",,"1492","","","","gp160","584","594","gp41(73-83)","7974..8006","","ERYLKDQQLLG","ERYLgDQQLLG","K5G","K588G","OV","observed variant","Sequence","This variant was found in 2/7 Brazilian Subtype B sequences.","Queiroz2007"
"55143",,"1493","","","","gp160","584","594","gp41(73-83)","7974..8006","","ERYLKDQQLLG","ERYLqDQQLLG","K5Q","K588Q","OV","observed variant","Sequence","This variant was found in 4/7 Brazilian Subtype F and 3/19 Brazilian Subtype B/F recombinant  sequences.","Queiroz2007"
"55144",,"1494","","","","gp160","585","593","gp41(74-82)","7977..8003","A*23, A24","RYLKDQQLL","RYLrDQQLL","K4R","K588R","OV","observed variant","Sequence","This variant was found in 2/7 Brazilian Subtype B and 2/13 Brazilian Subtype C sequences.","Queiroz2007"
"55144",,"1495","","","","gp160","585","593","gp41(74-82)","7977..8003","A*23, A24","RYLKDQQLL","RYLgDQQLL","K4G","K588G","OV","observed variant","Sequence","This variant was found in 2/7 Brazilian Subtype B sequences.","Queiroz2007"
"55144",,"1496","","","","gp160","585","593","gp41(74-82)","7977..8003","A*23, A24","RYLKDQQLL","RYLqDQQLL","K4Q","K588Q","OV","observed variant","Sequence","This variant was found in 4/7 Brazilian Subtype F and 3/19 Brazilian Subtype B/F recombinant  sequences.","Queiroz2007"
"1757",,"88","CRF01_AE","","","gp160","586","593","gp41(75-82)","7980..8003","A*24","YLKDQQLL","rYLKDQkLL","Y1R, L2Y, K3L, D4K, Q5D, L7K","Y586R, L587Y, K588L, D589K, Q590D, L592K","SNSF","subtype-specific non-susceptible form","Chromium-release assay, HLA binding","The HLA-A24 subjects tested did not recognize the E clade version rYLKDQkLL, which differs from the previously defined B clade version YLKDQQLL by one amino acid, with an additional amino acid added on.","Bond2001"
"1660",,"672","","","","gp160","586","593","gp41(75-82)","7980..8003","A24","YLRDQQLL","YLkDQQLL","R3K","R588K","SF","susceptible form","CD8 T-cell Elispot - IFNy","This epitope and the variant were recognized by 10/10 HIV infected women and by 3/4 HIV-exposed, persistently seronegative women.","Kaul2001a"
"55560","YL8","733","B","","","gp160","586","593","gp41(75-82)","7980..8003","B*08","YLKDQQLL","YLrDQQLL","K3R","K588R","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Emergence of the escape variant occurred between the first 2 samples. Variant emergence was associated with dramatic loss of CTL recognition. By the third time point, neither wt nor variant sequence were able to elicit an immune response.","Kemal2008"
"53754","YL8","785","B","","","gp160","586","593","gp41(75-82)","7980..8003","B8","YLKDQQLL","YLrDQQLL","K3R","K588R","OV","observed variant","","Variant was found in 1/9 clones at the beginning of a 5 year period in a patient.","Koibuchi2005a"
"53754","YL8","786","B","","","gp160","586","593","gp41(75-82)","7980..8003","B8","YLKDQQLL","YLKgQQLL","D4G","D589G","OV","observed variant","","Variant was found in 1/8 clones at the end of a 5 year period in a patient.","Koibuchi2005a"
"53823",,"1311","B","","","gp160","586","593","gp41(75-82)","7980..8003","B*0801","YLKDQQLL","YLqDQQLL","K3Q","K588Q","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","This anchor residue variant was seen in Donor2 and Recipient2, both of whom carried the restricting HLA-B*0801 allele.  It was not recognized by either subject and binding to HLA was greatly reduced.","Milicic2005"
"57344",,"2057","","","","gp160","597","622","gp41(86-111)","8013..8090","B*5701","GCSGRVICTTTVPWNVSWSNKSLNEI","dCSGRVICTTTVPWNVSWSNKSLNEI","G1D","G597D","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","The peptide containing epitope TTVPWNVSW showed this variant in Patient CH77.","Goonetilleke2009"
"57344",,"2058","","","","gp160","597","622","gp41(86-111)","8013..8090","B*5701","GCSGRVICTTTVPWNVSWSNKSLNEI","GCSGRVICTTTVPWNsSWSNKSLNEI","V16S","V612S","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","The peptide containing epitope TTVPWNVSW showed this variant in Patient CH77.","Goonetilleke2009"
"57344",,"2059","","","","gp160","597","622","gp41(86-111)","8013..8090","B*5701","GCSGRVICTTTVPWNVSWSNKSLNEI","GCSGRVICTTTVPWNtSWSNKSLsEI","V16T, N24S","V612T, N620S","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","The peptide containing epitope TTVPWNVSW showed this variant in Patient CH77.","Goonetilleke2009"
"57344",,"2060","","","","gp160","597","622","gp41(86-111)","8013..8090","B*5701","GCSGRVICTTTVPWNVSWSNKSLNEI","GCSGRVICTTTVPWNtSWSNKSLNEI","V16T","V612T","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","The peptide containing epitope TTVPWNVSW showed this variant in Patient CH77.","Goonetilleke2009"
"57475",,"2457","B","B","B","gp160","600","617","gp41(89-106)","8022..8075","","GKLICTTTVPWNISWSNK","GKLICTTTVPWNtSWSNK","I13T","I612T","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","One patient had a positive response to 18-mer GKLICTTTVPWNISWSNK and a negative response to variant GKLICTTTVPWNtSWSNK. The patient had no documented response to embedded A*3201 epitope LICTTTVPW.","Wood2009"
"58575","OLP-120","3052","A1","A1","B","gp160","603","617","gp41(92-106)","8031..8075","B*3501","ICTTNVPWNSSWSNK","ICTTaVPWNaSWSNK","S10A, N5A","S612A, N607A","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Clade B sequence analogous to OLP-120 is ICTTaVPWNaSWSNK and it contains the BDE TaVPWNaSW.","McKinnon2009a"
"58237",,"2810","B","B","B","gp160","605","614","gp41(94-103)","8037..8066","B*5701","TTTVPWNVSW","TTTVPWNtSW","V8T","V612T","IE","inferred escape","Sequence","3/5 sequences of epitope TTTVPWNVSW  varied at 592 DFOSx to TTTVPWNtSW.  Position 612 in the epitope is marked as being under selection to vary.","Ferrari2011"
"58237",,"2812","B","B","B","gp160","605","614","gp41(94-103)","8037..8066","B*5701","TTTVPWNVSW","TTTVPWNsSW","V8S","V612S","IE","inferred escape","Sequence","3/5 sequences of epitope TTTVPWNVSW  varied at 592 DFOSx to TTTVPWNsSW.  Position 612 in the epitope is marked as being under selection to vary.","Ferrari2011"
"55145",,"1497","","","","gp160","678","686","gp41(167-175)","8256..8282","A2","WLWYIKIFI","WLWYIrIFI","K6R","K683R","OV","observed variant","Sequence","This variant was found in 2/19 Brazilian Subtype B/F recombinant sequences.","Queiroz2007"
"55295",,"1515","B","","","gp160","678","686","gp41(167-175)","8256..8282","A2.1","WLWYIKIFI","WLWYIrIFI","K6R","K683R","OV","observed variant","Sequence","This index epitope was unusual in that it was conserved in the daughter's viral strain but mutated in the mother's isolate.","Reinis2007"
"55146",,"1498","","","","gp160","680","688","gp41(169-177)","8262..8288","A*2402","WYIKIFIMI","WYIrIFIMI","K4R","K683R","OV","observed variant","Sequence","This variant was found in 2/19 Brazilian Subtype B/F recombinant sequences.","Queiroz2007"
"55146",,"1499","","","","gp160","680","688","gp41(169-177)","8262..8288","A*2402","WYIKIFIMI","WYIKIFIiI","M8I","M687I","OV","observed variant","Sequence","This variant was found in 2/19 Brazilian Subtype B/F recombinant sequences.","Queiroz2007"
"55119",,"1500","","","","gp160","681","689","gp41(170-178)","8265..8291","A2","YIKIFIMIV","YIrIFIMIV","K3R","K683R","OV","observed variant","Sequence","This variant was found in 2/19 Brazilian Subtype B/F recombinant sequences.","Queiroz2007"
"55119",,"1501","","","","gp160","681","689","gp41(170-178)","8265..8291","A2","YIKIFIMIV","YIKIFIiIV","M7I","M687I","OV","observed variant","Sequence","This variant was found in 2/19 Brazilian Subtype B/F recombinant sequences.","Queiroz2007"
"55382","Env 681","1676","","","","gp160","681","689","gp41(170-178)","8265..8291","A2","YIKIFIMIV","YIKIFIMIi","V9I","V689I","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subjects Pt23 and Pt35 were carriers of this variant. Pt23 was able to cross-recognize the consensus HXB2 epitope tested, YIKIFIMIV, but Pt35 was not.  Of the 7 subjects who carried the challenge HXB2, YIKIFIMIV, only Pt16 could recognize it.","Thorn2007"
"55382","Env 681","1677","","","","gp160","681","689","gp41(170-178)","8265..8291","A2","YIKIFIMIV","YIrlFIMIV","K3R, I4L","K683R, I684L","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt17 was a carrier of this variant and was unable to recognize the challenge HXB2 epitope, YIKIFIMIV.","Thorn2007"
"55382","Env 681","1678","","","","gp160","681","689","gp41(170-178)","8265..8291","A2","YIKIFIMIV","YIrIFIMIV","K3R","K683R","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subject Pt41 was a carrier of this variant and was unable to recognize the challenge HXB2 epitope, YIKIFIMIV.","Thorn2007"
"58571","OLP-138","3050","A1","A1","B","gp160","693","707","gp41(182-196)","8301..8345","A*3303","IGLRIVFAVLSVINR","IGLRIVFAVLSivNR","V12I, I13V","V704I, I705V","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Clade B sequence analogous to OLP-138 is IGLRIVFAVLSivNR and it contains the BDE VFAVLSivN.","McKinnon2009a"
"58561","OLP-139/140","3028","A1","A1","B","gp160","698","712","gp41(187-201)","8316..8360","A*3002","VFAVLSVINRVRQGY","VFAVLSivNRnRQGY","V11N, V7I, I8V","V708N, V704I, I705V","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Clade B sequence analogous to OLP-139 is VFAVLSivNRnRQGY, containing the BDE ivNRnRQGY.  Both the BDE as well as Clade A1-specific epitope VINRVRQGY are recognized by CTL.","McKinnon2009a"
"52998",,"311","","","","gp160","701","719","gp41(190-208)","8325..8381","B15","VLSIVNQVRRQGYSPLSFQT","VLSIVNkVRRQGYSPLSFQT","Q7K","Q707K","E","escape documented in this paper","","A dramatic decrease in CTL activity against the epitope occurred as the mutations arose. The variant became fixed in the population at 47 months post-seroconversion.","Geels2003"
"58590","OLP-141","3035","A1","A1","B","gp160","708","722","gp41(197-211)","8346..8390","","VRQGYSPLSFQTLTP","VRQGYSPLSFQTrlP","L13R, T14L","L720R, T721L","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","HXB2 sequence analogous to OLP-141 is VRQGYSPLSFQTrlP.","McKinnon2009a"
"58591","OLP-17","3036","A1","A1","B","gp160","708","722","gp41(197-211)","8346..8390","","IYMENVTEEFNMWKN","vvlENVTEnFNMWKN","I1V, Y2V, M3L, E9N","I708V, Y709V, M710L, E716N","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","The Clade B HXB-2 form of OLP-17 is vvlENVTEnFNMWKN, and it is associated with HLA-A*11 or -A*68.","McKinnon2009a"
"54167","YL9","994","B","","","gp160","712","720","gp41(201-209)","8358..8384","Cw*0102","YSPLSLQTL","YSPLSLQTr","L9R","L720R","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Last position (9)in the epitope had potentially experienced positive selection.  The variant was full escape, as it was not recognized by CTLs.","Liu2006"
"58150","YL9","2738","B","B","B","gp160","712","720","gp41(201-209)","8358..8384","Cw*0102","YSPLSLQTL","YSPLSLQTr","L9R","L720R","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Longitudinal study","Variant YSPLSLQTr replaced the wild type sequence by 400 days post-infection. Sequence changes were associated with loss of EliSpot response to the epitope.","Liu2011a"
"59096",,"3277","B","B","B","gp160","712","720","gp41(201-209)",,"Cw*0102","YSPLSLQTL","YSPLSLQTr","L9R","L720R","E","escape documented in this paper","Peptide titration","EliSpot peptide titration indicated full escape.","Liu2007a"
"58598","OLP-142","3041","A1","A1","B","gp160","713","727","gp41(202-216)","8361..8405","","SPLSFQTLTPNPRDP","SPLSFQTrlPaPRgP","N11A, D14G, L8R, T9L","N723A, D726G, L720R, T721L","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Clade B sequence analogous to OLP-142 is SPLSFQTrlPaPRgP.","McKinnon2009a"
"58584","OLP-147","3024","A1","A1","B","gp160","739","753","gp41(228-242)","8439..8483","","EQDRGRSIRLVSGFL","ErDRdRSgRLVdGFL","S12D, Q2R, G5D, I8G","S750D, Q740R, G743D, I746G","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","The clade B version of this OLP is ErDRdRSgRLVdGFL.","McKinnon2009a"
"58585","OLP-148","3023","A1","A1","B","gp160","743","757","gp41(232-246)","8451..8495","","GRSIRLVSGFLALAW","dRSgRLVdGFLALiW","G1D, A14I, I4G, S8D","G743D, A756I, I746G, S750D","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","The clade B version of this OLP, dRSgRLVdGFLALiW, contains epitope VdGFLALiW, which would not bind HLA-B*57. B*57 requires A/T/S in the second position to bind.","McKinnon2009a"
"58586","OLP-149","3022","A1","A1","B","gp160","748","762","gp41(237-251)","8466..8510","","LVSGFLALAWDDLRN","LVdGFLALiWDDLRN","S3D, A9I","S750D, A756I","SNSF","subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","The clade B version of this OLP, LVdGFLALiWDDLRN, contains epitope VdGFLALiW, which would not bind HLA-B*57. B*57 requires A/T/S in the second position to bind.","McKinnon2009a"
"53809",,"1234","A, B, C, D","A, C","B, D","gp160","749","757","gp41(238-246)","8469..8495","","VSGFLALAW","VnGsLiLAW","S2N, F4S, A6I","S750N, F752S, A754I","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","This Clade B and D variant was recognized by Clade A and Clade C-specific CTLs.","McKinnon2005"
"53809",,"1235","A, B, C, D","A, C","B, D","gp160","749","757","gp41(238-246)","8469..8495","","VSGFLALAW","VnGlsAiAW","S2N, F4L, L5S, L7I","S750N, F752L, L753S, L755I","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","This Clade B and D variant was recognized by Clade A and Clade C-specific CTLs.","McKinnon2005"
"56657",,"2082","","","","gp160","765","782","gp41(254-271)","8517..8570","","LFSYHRLRDLLLIVTRIV","LFrYHRLRDLLLIVTRIV","S3R","S767R","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This variant in Patient CH40 gave a positive ELISpot from the full proteome scan but was not associated with statistical evidence of positive selection.","Goonetilleke2009"
"55323","E","832","A","A","","gp160","767","775","gp41(256-264)","8523..8549","H-2K<sup>d</sup>","SYHRLRDFI","SYHRLRDFv","I9V","I775V","SF","susceptible form","CD8 T-cell Elispot - IFNy","After immunization with Clade A vaccine containing the wt epitope, T cells were able to respond to this epitope variant.","Larke2007"
"55323","E","833","A","A","","gp160","767","775","gp41(256-264)","8523..8549","H-2K<sup>d</sup>","SYHRLRDFI","SYHRLRDcI","F8C","F774C","DR","diminished response","CD8 T-cell Elispot - IFNy","After immunization with Clade A vaccine containing the wt epitope, T cells were able to respond to this epitope variant at <50% magnitude.","Larke2007"
"55323","E","834","A","A","","gp160","767","775","gp41(256-264)","8523..8549","H-2K<sup>d</sup>","SYHRLRDFI","SYHRLRDll","F8L, I9L","F774L, I775L","DR","diminished response","CD8 T-cell Elispot - IFNy","After immunization with Clade A vaccine containing the wt epitope, T cells were able to respond to this epitope variant at <50% magnitude.","Larke2007"
"55323","E","835","A","A","","gp160","767","775","gp41(256-264)","8523..8549","H-2K<sup>d</sup>","SYHRLRDFI","SYHRLRDlI","F8L","F774L","DR","diminished response","CD8 T-cell Elispot - IFNy","After immunization with Clade A vaccine containing the wt epitope, T cells were able to respond to this epitope variant at <50% magnitude.","Larke2007"
"55323","E","836","A","A","","gp160","767","775","gp41(256-264)","8523..8549","H-2K<sup>d</sup>","SYHRLRDFI","SYrhLRDFI","H3R, R4H","H769R, R770H","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","After immunization with Clade A vaccine containing the wt epitope, T cells did not recognize this epitope variant.","Larke2007"
"55323","E","837","A","A","","gp160","767","775","gp41(256-264)","8523..8549","H-2K<sup>d</sup>","SYHRLRDFI","iYHhLRDll","S1I, R4H, F8L, I9L","S767I, R770H, F774L, I775L","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","After immunization with Clade A vaccine containing the wt epitope, T cells did not recognize this epitope variant.","Larke2007"
"55323","E","838","A","A","","gp160","767","775","gp41(256-264)","8523..8549","H-2K<sup>d</sup>","SYHRLRDFI","SYrlLRDll","H3R, R4L, F8L, I9L","H769R, R770L, F774L, I775L","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","After immunization with Clade A vaccine containing the wt epitope, T cells did not recognize this epitope variant.","Larke2007"
"58576","OLP-153","3030","A1","A1","B","gp160","768","782","gp41(257-271)","8526..8570","A*0301, A*3101","YHQLRDFILIVARTV","YHrLRDFllIVtRTV","A12T, Q3R, I8L","A779T, Q770R, I775L","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","YHrLRDFllIVtRTV, a clade B sequence analogous to OLP-153 contains HLA-A*3101-restricted BDE rLRDFllIVtR.  The amino acid differences between this epitope in Clades A1 and B as well as low frequency of HLA allele in the cohort are cited as reasons for OLP-53 not being recognized in the Clade A1-containing cohort.","McKinnon2009a"
"864",,"106","","B","A, C, CRF01_AE","gp160","770","780","gp41(259-269)","8532..8564","A3","RLRDLLLIVTR","RLRDfiLIVTR","L5F, L6I","L774F, L775I","DR, SSF","diminished response, subtype-specific susceptible form","Chromium-release assay","The consensus peptide of clade B is RLRDLLLIVTR. The consensus peptide of clades A, C and E is RLRDFILIVTR and it is less reactive.","Cao1997a"
"864",,"107","","B","D","gp160","770","780","gp41(259-269)","8532..8564","A3","RLRDLLLIVTR","SLRDLLLIVTR","R1S","R770S","DR, SSF","diminished response, subtype-specific susceptible form","Chromium-release assay","The consensus peptide of clade B is RLRDLLLIVTR. The consensus peptide of clade D is SLRDLLLIVTR and it is less reactive.","Cao1997a"
"52990",,"312","","","","gp160","770","780","gp41(259-269)","8532..8564","A3","RLRDLLLIVTR","RLRDLLLIiTR","V9I","V778I","OV","observed variant","","The epitope varied over time but the mutations did not become fixed. The variant arose at intermediate timepoints.","Geels2003"
"52990",,"313","","","","gp160","770","780","gp41(259-269)","8532..8564","A3","RLRDLLLIVTR","RLRDLLLvVTR","I8V","I777V","OV","observed variant","","The epitope varied over time but the mutations did not become fixed. The variant arose at late timepoints.","Geels2003"
"58577","OLP-154","3053","A1","A1","B","gp160","773","787","gp41(262-276)","8541..8585","A*6802","DFILIVARTVELLGH","DFILIVtRiVELLGH","A7T, T9I","A779T, T781I","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Clade B sequence analogous to OLP-154 is DFILIVtRiVELLGH and it contains the BDE IVtRiVELL.","McKinnon2009a"
"58564","OLP-157","3045","A1","A1","B","gp160","782","795","gp41(271-284)","8568..8609","B*2705","SSLKGLRLGWEGLKY","SSLKGLR-GWEaLKY","G12A, L8-","G793A, L789-","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Clade B sequence analogous to OLP-157 is SSLKGLR-GWEaLKY and it contains the BDE GLR-GWEaLKY.","McKinnon2009a"
"58587","OLP-156","3029","A1","A1","B","gp160","783","797","gp41(272-286)","8571..8615","","ELLGHSSLKGLRLGW","ELLG-------RLGW","G10-, L11-, H5-, S6-, S7-, L8-, K9-","G792-, L793-, H787-, S788-, S789-, L790-, K791-","EL, NSF","epitope loss, non-susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Clade B sequence analogous to OLP-156 is ELLGRLGW, with a 7 amino acid deletion difference from OLP-156, ELLGHSSLKGLRLGW.","McKinnon2009a"
"57823",,"2646","B","B","B","gp160","786","795","gp41(275-284)","8580..8609","B*27","GRRGWEALKY","GqRGWEALKY","R2Q","R787Q","?","unclear","Sequence","Mutation is in anchor position, stated as possible escape mutant from sequence data, carried by 1/18 patients.","Ammaranond2011"
"57823",,"2647","B","B","B","gp160","786","795","gp41(275-284)","8580..8609","B*27","GRRGWEALKY","GhRGWEALKY","R2H","R787H","?","unclear","Sequence","Mutation is in anchor position, stated as possible escape mutant from sequence data, carried by 2/18 patients.","Ammaranond2011"
"57928",,"2658","B","B","B","gp160","787","795","gp41(276-284)","8583..8609","A1","RRGWEVLKY","RRGWEtLKY","V6T","V792T","IE","inferred escape","CD8 T-cell Elispot - IFNy, Longitudinal study","Transmitted sequence RRGWEVLKY was replaced by day 21 post-seroconversion by RRGWEtLKY. The EliSpot response to the transmitted peptide increased from 15 SFC on day 7 to 715 SFC on day 127.","Herbeck2011"
"58562","OLP-159","3043","A1","A1","B","gp160","791","805","gp41(280-294)","8595..8639","A*3002","EGLKYLGNLLLYWGR","EGLKYcwNLLqYWGR","L11Q, L6C, G7W","L801Q, L796C, G797W","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","The Clade B sequence analogous to OLP-159 is EGLKYcwNLLqYWGR and it contains BDE KYcwNLLqY.","McKinnon2009a"
"55951","KY9(gp41)","1935","B","B","B","gp160","794","802","gp41(283-291)","8604..8630","","KYLWNLLQY","KYcWNLLQY","L3C","L796C","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-A30 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"58605","EnvKY9","3059","","","","gp160","794","802","gp41(283-291)","8604..8630","A*3002","KYLGSLVQY","KYLGSLVQc","Y9C","Y802C","E","escape documented in this paper","Cytokine production, Tetramer binding","KY9 variant, KYLGSLVQc, was found in 1/15 (6.7%) sequences in subject 1503.","Mahlokozera2011"
"58605","EnvKY9","3060","","","","gp160","794","802","gp41(283-291)","8604..8630","A*3002","KYLGSLVQY","KYLGgLVQn","S5G, Y9N","S798G, Y802N","E","escape documented in this paper","Cytokine production, Tetramer binding","KY9 variant, KYLGgLVQn, was found in 7/21 (33.3%) sequences in subject 3808.","Mahlokozera2011"
"58605","EnvKY9","3061","","","","gp160","794","802","gp41(283-291)","8604..8630","A*3002","KYLGSLVQY","KhLGSLVQY","Y2H","Y795H","E","escape documented in this paper","Cytokine production, Tetramer binding","KY9 variant, KhLGSLVQY, was found in 3/16 (18.8%) sequences in subject 3902.","Mahlokozera2011"
"58588","OLP-160","3032","A1","A1","B","gp160","796","810","gp41(285-299)","8610..8654","","LGNLLLYWGRELKTS","wwNLLqYWsqELKnS","L1W, R10Q, T14N, G2W, L6Q, G9S","L796W, R805Q, T809N, G797W, L801Q, G804S","SF","susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","wwNLLqYWsqELKnS is the Clade B sequence analogous to OLP-160, containing the BDE LLqYWsqEL.","McKinnon2009a"
"58565","OLP-161","3046","A1","A1","B","gp160","801","815","gp41(290-304)","8625..8669","B*4001","LYWGRELKTSAINLF","LYWGqELKnSAvsLF","I12V, N13S, R5Q, T9N","I812V, N813S, R805Q, T809N","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Clade B sequence analogous to OLP-161 is LYWGqELKnSAvsLF and it contains the BDE qELKnSAvsL.","McKinnon2009a"
"55062","QL10","189","","","","gp160","805","814","gp41(294-303)","8637..8666","B*4001","QELKNSAVSL","QELKkSAVSL","N5K","N809K","DR","diminished response","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Immune responses were examined in monozygotic male twins infected simultaneously with the same virus. QELKkSAVSL variant arose in one twin and not the other. Response to the variant was diminished.","Draenert2006"
"55911","SV10(gp41)","1936","B","B","B","gp160","813","822","gp41(302-311)","8661..8690","","SLLNATAIAV","SLLNATdIAV","A7D","A819D","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-A2 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"55289",,"1516","B","","","gp160","814","822","gp41(303-311)","8664..8690","A*0201, A2","LLNATAIAV","LLNAiAIAV","T5I","T818I","OV","observed variant","Sequence","This index epitope was conserved in the mother's viral strain but mutated in the daughter's isolate.","Reinis2007"
"58646","Env814-823","3074","B","B","B","gp160","814","822","gp41(303-311)","8664..8690","A*0201","SLLNATDIAV","SLLNATaIAV","D7A","D820A","SF","susceptible form","Chromium-release assay, Sequence","This variant was found to be autologous in 2/5 subjects and surprisingly was recognized at lower concentrations [1 log lower] for target lysis.","Dupuis1995"
"58646","Env814-823","3075","B","B","B","gp160","814","822","gp41(303-311)","8664..8690","A*0201","SLLNATDIAV","nLLNtiaIAV","S1N, A5T, T6I, D7A","S814N, A818T, T819I, D820A","DR, NSF","diminished response, non-susceptible form","Chromium-release assay, Sequence","This variant was found to be autologous in 2/5 subjects and abrogated all CTL target lysis.","Dupuis1995"
"56684",,"2130","","","","gp160","822","836","gp41(311-325)","8688..8732","","VAEGTDRVIEELQRA","VAEGTgRVIEgLQRA","E11G, D6G","E832G, D827G","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Patient CH77 carried this variant.","Goonetilleke2009"
"56684",,"2131","","","","gp160","822","836","gp41(311-325)","8688..8732","","VAEGTDRVIEELQRA","VAEGTDRVIEgLQRA","E11G","E832G","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Patient CH77 carried this variant.","Goonetilleke2009"
"56684",,"2132","","","","gp160","822","836","gp41(311-325)","8688..8732","","VAEGTDRVIEELQRA","VAEGTDRVIEEsQRA","L12S","L833S","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Patient CH77 carried this variant.","Goonetilleke2009"
"56684",,"2133","","","","gp160","822","836","gp41(311-325)","8688..8732","","VAEGTDRVIEELQRA","VAEGTDRiIEEsQRA","L12S, V8I","L833S, V829I","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Patient CH77 carried this variant.","Goonetilleke2009"
"56684",,"2134","","","","gp160","822","836","gp41(311-325)","8688..8732","","VAEGTDRVIEELQRA","VAEGTDRVIEaLQRA","E11A","E832A","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Patient CH77 carried this variant.","Goonetilleke2009"
"56684",,"2318","","","","gp160","822","836","gp41(311-325)","8688..8732","","{A}VAEGTDRVIEELQRA","{t}VAEGTDRVIEELQRA","A-1T","A821T","CM, IE, P","compensatory mutation, inferred escape, processing","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Patient CH77 carried this proximal variant (from {LLNTIAIA}VAEGTDRVIEELQRA) that may impact processing or be a compensatory mutation.  Known T cell response from the full proteome scan with evidence for variation and escape was seen.","Goonetilleke2009"
"56684",,"2319","","","","gp160","822","836","gp41(311-325)","8688..8732","","{A}VAEGTDRVIEELQRA","{t}VAEGTDRVIEgLQRA","A-1T, E11G","A821T, E832G","CM, IE, P","compensatory mutation, inferred escape, processing","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Patient CH77 carried this proximal variant (from {LLNTIAIA}VAEGTDRVIEELQRA) that may impact processing or be a compensatory mutation.  Known T cell response from the full proteome scan with evidence for variation and escape was seen.","Goonetilleke2009"
"56684",,"2320","","","","gp160","822","836","gp41(311-325)","8688..8732","","{A}VAEGTDRVIEELQRA","{t}VAEGTDRiIEgLQRA","A-1T, E11G, V8I","A821T, E832G, V829I","CM, IE, P","compensatory mutation, inferred escape, processing","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Patient CH77 carried this proximal variant (from {LLNTIAIA}VAEGTDRVIEELQRA) that may impact processing or be a compensatory mutation.  Known T cell response from the full proteome scan with evidence for variation and escape was seen.","Goonetilleke2009"
"56684",,"2321","","","","gp160","822","836","gp41(311-325)","8688..8732","","{A}VAEGTDRVIEELQRA","{v}VAEGTDRiIEgLQRv","A-1V, E11G, A15V, V8I","A821V, E832G, A836V, V829I","CM, IE, P","compensatory mutation, inferred escape, processing","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Patient CH77 carried this proximal variant (from {LLNTIAIA}VAEGTDRVIEELQRA) that may impact processing or be a compensatory mutation.  Known T cell response from the full proteome scan with evidence for variation and escape was seen.","Goonetilleke2009"
"56684",,"2322","","","","gp160","822","836","gp41(311-325)","8688..8732","","{A}VAEGTDRVIEELQRA","{v}VAEGTDRiIEgLQRA","A-1V, E11G, V8I","A821V, E832G, V829I","CM, IE, P","compensatory mutation, inferred escape, processing","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Patient CH77 carried this proximal variant (from {LLNTIAIA}VAEGTDRVIEELQRA) that may impact processing or be a compensatory mutation .","Goonetilleke2009"
"58570","OLP-166","3033","A1","A1","B","gp160","826","840","gp41(315-329)","8700..8744","A*3303","TDRVIEVGQRLGRAI","TDRVIEVaQRayRAI","L11A, G12Y, G8A","L836A, G837Y, G833A","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, HLA binding","Clade B sequence analogous to OLP-166, TDRVIEVaQRayRAI, contains BDE EVaQRayRA.","McKinnon2009a"
"57474",,"2456","B","B","B","gp160","828","836","gp41(317-325)","8706..8732","A*0201","RVIEVAQRV","RVIkVvQRV","E4K, A6V","E831K, A833V","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence","One patient had positive responses to previously-reported A*0201 epitope RVIEVAQRV and a diminished response to the variant RVIkVvQRV.","Wood2009"
"56661",,"2090","","","","gp160","830","847","gp41(319-336)","8712..8765","","IEVVQRACRAILHIPRRI","IEVVQRACRAILHIPRkI","R17K","R846K","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","The authors suggested this as an escape mutation by statistical evidence, but the variant was transient, infrequent, and there was no loss of EliSpot response to the original epitope.","Goonetilleke2009"
"56661",,"2091","","","","gp160","830","847","gp41(319-336)","8712..8765","","IEVVQRACRAILHIPRRI","IEiVQRACRAILHIPRRI","V3I","V832I","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","The authors suggested this as an escape mutation by statistical evidence, but the variant was transient, infrequent, and there was no loss of EliSpot response to the original epitope.","Goonetilleke2009"
"56661",,"2092","","","","gp160","830","847","gp41(319-336)","8712..8765","","IEVVQRACRAILHIPRRI","IEVVQRACRAIcHIPRRI","L12C","L841C","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","The authors suggested this as an escape mutation by statistical evidence, but the variant was transient, infrequent, and there was no loss of EliSpot response to the original epitope.","Goonetilleke2009"
"56661",,"2093","","","","gp160","830","847","gp41(319-336)","8712..8765","","IEVVQRACRAILHIPRRI","IEVVQRACRAIrHIPRRI","L12R","L841R","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","The authors suggested this as an escape mutation by statistical evidence, but the variant was transient, infrequent, and there was no loss of EliSpot response to the original epitope.","Goonetilleke2009"
"58226",,"2784","B","B","B","gp160","830","847","gp41(319-336)","8712..8765","","IEVVQRACRAILHIPRRI","IEVVQRACRAIfHIPRRI","L12F","L841F","OV","observed variant","Sequence","1/9 sequences of peptide IEVVQRACRAILHIPRRI varied at 111 DFOSx to IEVVQRACRAIfHIPRRI.","Ferrari2011"
"58226",,"2785","B","B","B","gp160","830","847","gp41(319-336)","8712..8765","","IEVVQRACRAILHIPRRI","IEiVQRACRAILHIPRRI","V3I","V832I","OV","observed variant","Sequence","1/9 sequences of peptide IEVVQRACRAILHIPRRI varied at 111 DFOSx to IEiVQRACRAILHIPRRI.","Ferrari2011"
"58226",,"2786","B","B","B","gp160","830","847","gp41(319-336)","8712..8765","","IEVVQRACRAILHIPRRI","IEVVQRACRAILHIPRkI","R17K","R846K","OV","observed variant","Sequence","1/7 sequences of peptide IEVVQRACRAILHIPRRI varied at 181 DFOSx to IEVVQRACRAILHIPRkI.","Ferrari2011"
"58226",,"2787","B","B","B","gp160","830","847","gp41(319-336)","8712..8765","","IEVVQRACRAILHIPRRI","IEVVQRACRAIcHIPRRI","L12C","L841C","OV","observed variant","Sequence","1/12 sequences of peptide IEVVQRACRAILHIPRRI varied at 412 DFOSx to IEVVQRACRAIcHIPRRI.  Position 841 in the peptide is marked as being under selection to vary.","Ferrari2011"
"58226",,"2788","B","B","B","gp160","830","847","gp41(319-336)","8712..8765","","IEVVQRACRAILHIPRRI","IEVVQRACRAIrHIPRRI","L12R","L841R","OV","observed variant","Sequence","1/12 sequences of peptide IEVVQRACRAILHIPRRI varied at 412 DFOSx to IEVVQRACRAIrHIPRRI.  Position 841 in the peptide is marked as being under selection to vary.","Ferrari2011"
"55962","ER8(gp41)","1937","B","B","B","gp160","831","838","gp41(320-327)","8715..8738","","EVVQRAYR","EVaQRAYR","V3A","V833A","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-A33 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"52991",,"314","","","","gp160","835","843","gp41(324-332)","8727..8753","B51","RAYRAILHI","RtfRAILHI","A2T, Y3F","A836T, Y837F","OV","observed variant","","The epitope varied over time but the mutations did not become fixed. The variant arose at early timepoints.","Geels2003"
"52991",,"315","","","","gp160","835","843","gp41(324-332)","8727..8753","B51","RAYRAILHI","RiYRAILHx","A2I, I9X","A836I, I843X","OV","observed variant","","The epitope varied over time but the mutations did not become fixed. The variant arose at intermediate timepoints.","Geels2003"
"56686",,"2135","","","","gp160","838","855","gp41(327-344)","8736..8789","","RAVLNIPTRIRQGLERAL","RAVLNvPTRIRQGLERAL","I6V","I843V","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This transmitted peptide sequence RAVLNIPTRIRQGLERAL was recognized in patient CH77 by week 24.  A mutation was seen at RAVLNvPTRIRQGLERAL.","Goonetilleke2009"
"895",,"108","B","A, B, D, F","C","gp160","843","851","gp41(332-340)","8751..8777","B7","IPRRIRQGL","IPRRIRQGf","L9F","L851F","SSF","subtype-specific susceptible form","Chromium-release assay","The consensus peptide of clades A, B, D, and F is IPRRIRQGL. The consensus peptide of clade C is iprrirqgF, and it is equally reactive.","Cao1997a"
"53805",,"1236","A, B, C, D","A, B","C","gp160","843","851","gp41(332-340)","8751..8777","","IPRRIRQGL","IPRRIRQGf","L9F","L851F","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","This Clade C variant was recognized by Clade A and Clade B-specific CTLs.","McKinnon2005"
"53805",,"1237","A, B, C, D","A, B","D","gp160","843","851","gp41(332-340)","8751..8777","","IPRRIRQGL","IvRRIRQGL","P2V","P844V","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","This Clade D variant was recognized by Clade A and Clade B-specific CTLs.","McKinnon2005"
"53417","IPR","1388","","","","gp160","843","851","gp41(332-340)","8751..8777","B7","IPRRIRQGL","vPRRIRQGL","I1V","I843V","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/11 viral clones contained this variant sequence at the last time point (Day 635) tested after infection.","Oxenius2004"
"53417","IPR","1389","","","","gp160","843","851","gp41(332-340)","8751..8777","B7","IPRRIRQGL","IPgRIRQGL","R3G","R845G","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/11 viral clones contained this variant sequence at the last time point (Day 635) tested after infection.","Oxenius2004"
"53417","IPR","1390","","","","gp160","843","851","gp41(332-340)","8751..8777","B7","IPRRIRQGL","IPRRkRQGL","I5K","I847K","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/10 viral clones contained this variant sequence at the second time point (Day 369) tested after infection.","Oxenius2004"
"53417","IPR","1391","","","","gp160","843","851","gp41(332-340)","8751..8777","B7","IPRRIRQGL","IPRRIRQGf","L9F","L851F","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Only 1/11 viral clones contained this variant sequence at the last time point (Day 635) tested after infection.","Oxenius2004"
"55476",,"1399","B, C, CRF01_AE, A1","A, AE, B, C","A, AE, B, CRF06_cpx","gp160","843","851","gp41(332-340)","8751..8777","","IPRRIRQGL","IPRRIRQGf","L9F","L851F","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","These variants were cross-recognized by subjects infected with Subtypes A1, B, CRF01_AE.  Epitope IPRRIRQGL was recognized by a subject carrying Subtype C and variant IPRRIRQGf was recognized by a Subtype CPX06-infected subject.","Perez2008"
"894",,"1636","","","","gp160","843","851","gp41(332-340)","8751..8777","B7","IPRRIRQGL","IPRRIRQdL","G8D","G850D","NSF","non-susceptible form","Chromium-release assay","This synthetic variant was not recognized by patient CTL.","Soudeyns1999"
"894",,"1637","","","","gp160","843","851","gp41(332-340)","8751..8777","B7","IPRRIRQGL","IPtRIRQGL","R3T","R845T","DR","diminished response","Chromium-release assay","This Env synthetic variant showed greatly reduced recognition by patient CTL.","Soudeyns1999"
"894",,"1638","","","","gp160","843","851","gp41(332-340)","8751..8777","B7","IPRRIRQGL","IPRRlRQGL","I5L","I847L","DR","diminished response","Chromium-release assay","This Env synthetic variant showed reduced recognition by patient CTL.","Soudeyns1999"
"894",,"1639","","","","gp160","843","851","gp41(332-340)","8751..8777","B7","IPRRIRQGL","IPtRIRQGf","R3T, L9F","R845T, L851F","NSF","non-susceptible form","Chromium-release assay","This Env synthetic variant was not recognized by patient CTL.","Soudeyns1999"
"55982","IL9(gp41)","1938","B","B","B","gp160","843","851","gp41(332-340)","8751..8777","","IPTRIRQGL","IPrRIRQGL","T3R","T845R","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B7 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope","Zhai2008"
"896",,"2205","B","","","gp160","843","851","gp41(332-340)","8751..8777","B7","IPRRIRQGL","IPRRIRQGf","L9F","L851F","CHB, OV","calculated diminished HLA binding, observed variant","Chromium-release assay, Structural prediction","This epitope is conserved between clades B_LAI and A_92UG037.  The conservative substitution in clade C_92BR025 may reduce but does not abrogate HLA binding.","Wilson1998b"
"896",,"2220","B","","","gp160","843","851","gp41(332-340)","8751..8777","B7","IPRRIRQGL","IPtRIRQGL","R3T","R845T","CHB, OV","calculated diminished HLA binding, observed variant","Chromium-release assay, Structural prediction","This epitope is conserved between clades B_LAI and A_92UG037.  The non-conservative substitution in clade B_MN potentially reduces HLA binding.","Wilson1998b"
"57378","IL9 wt","2338","","","","gp160","843","851","gp41(332-340)","8751..8777","B*0702","IPRRIRQGL","IPtRIRQGL","R3T","R845T","LE","literature escape","Tetramer binding","Common natural variant IPtRIRQGL had increased binding over wild type IL9 to inhibitory receptor ILT4 on CD14+ monocytes.  In line with prior studies, this was assumed to induce inhibition of antigen presenting and cytokine secretion of myelomonocytic cells.","Yang2010"
"57538","I9GL","2542","","","","gp160","843","851","gp41(332-340)","8751..8777","B*07","IPRRIRQGL","IPRRIRQGf","L9F","L851F","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, HLA binding","Intersubtype variant IPRRIRQGf exhibited good cross-recognition in mice immunized with IPRRIRQGL.","Cardinaud2009"
"59053","IL9-Env","3226","B","B","C","gp160","843","851","gp41(332-340)","8751..8777","B*0702","IPRRIRQGL","IPRRIRQGf","L9F","L851F","SSF","subtype-specific susceptible form","HLA binding","Variant IF9, IPRRIRQGf, a C-clade Env epitope was targeted by B-clade infected subjects more robustly than the C-clade variant IF9.  The affinity of C-clade IF9 to B*0702 was K<sub>d</sub> = 33 nM.  Clade-C IF9 is contained within OLP401, NIPRRIRQGfEaALq.","Kloverpris2014"
"55147",,"1502","","","","gp160","846","854","gp41(335-343)","8760..8786","A*0205","RIRQGLERA","RIRQGfERA","L6F","L851F","OV","observed variant","Sequence","This variant was found in 4/11 Brazilian Subtype F sequences.","Queiroz2007"
"55147",,"1503","","","","gp160","846","854","gp41(335-343)","8760..8786","A*0205","RIRQGLERA","RIRQGLEaA","R8A","R853A","OV","observed variant","Sequence","This variant was found in 3/13 Brazilian Subtype C sequences.","Queiroz2007"
"55147",,"1504","","","","gp160","846","854","gp41(335-343)","8760..8786","A*0205","RIRQGLERA","RIRQGfEaA","L6F, R8A","L851F, R853A","OV","observed variant","Sequence","This variant was found in 7/13 Brazilian Subtype C sequences.","Queiroz2007"
"55147",,"1505","","","","gp160","846","854","gp41(335-343)","8760..8786","A*0205","RIRQGLERA","RIRQGLfRA","E7F","E852F","OV","observed variant","Sequence","This variant was found in 2/19 Brazilian Subtype B/F recombinant sequences.","Queiroz2007"
"57930",,"2659","B","B","B","gp160","848","856","gp41(337-345)","8766..8792","B8","RQGLERALL","RQGLERvLL","A7V","A854V","IE","inferred escape","CD8 T-cell Elispot - IFNy, Longitudinal study","Founder sequence RQGLERALL was replaced by day 44 post-seroconversion by two mutually exclusive variants, RQGLERvLL and RQGLERAfL. EliSpot response to the original peptide increased from 0 at day 7 to 1310 at day 127","Herbeck2011"
"57930",,"2660","B","B","B","gp160","848","856","gp41(337-345)","8766..8792","B8","RQGLERALL","RQGLERAfL","L8F","L855F","IE","inferred escape","CD8 T-cell Elispot - IFNy, Longitudinal study","Founder sequence RQGLERALL was replaced by day 44 post-seroconversion by two mutually exclusive variants, RQGLERvLL and RQGLERAfL. EliSpot response to the original peptide increased from 0 at day 7 to 1310 at day 127","Herbeck2011"
"58289","gp41 IDR","2872","A, C","A, C","A, C","Env",,,"",,"","LNSWGCAFRQVCHT","LNmWGCAFRQVCHT","S3M","S23M","OV","observed variant","Sequence","3/22 HIV-1+ subjects carried this IDR variant, LNmWGCAFRQVCHT, one of whom did not cross-recognize the HIV-2 gp41 IDR, but the other 2 did.","Maueia2011"
"58289","gp41 IDR","2874","A, C","A, C","A, C","Env",,,"",,"","LNSWGCAFRQVCHT","LNlWGCAFRQVCHT","S3L","S23L","OV","observed variant","Sequence","3/22 HIV-1+ subjects carried this IDR variant, LNlWGCAFRQVCHT, all of whom cross-recognized the HIV-2 gp41 IDR.","Maueia2011"
"58289","gp41 IDR","2875","A, C","A, C","A, C","Env",,,"",,"","LNSWGCAFRQVCHT","LNlWGCAaRQVCHT","S3L, F8A","S23L, F28A","OV","observed variant","Sequence","1/22 HIV-1+ subjects carried this IDR variant, LNlWGCAaRQVCHT, and cross-recognized the HIV-2 gp41 IDR.","Maueia2011"
"58289","gp41 IDR","2876","A, C","A, C","A, C","Env",,,"",,"","LNSWGCAFRQVCHT","LNmWGCAFRfVCHT","Q10F, S3M","Q30F, S23M","OV","observed variant","Sequence","1/22 HIV-1+ subjects carried this IDR variant, LNmWGCAFRfVCHT, and cross-recognized the HIV-2 gp41 IDR.","Maueia2011"
"58289","gp41 IDR","2878","A, C","A, C","A, C","Env",,,"",,"","LNSWGCAFRQVCHT","LNvWGCAFRhVCHT","Q10H, S3V","Q30H, S23V","OV","observed variant","Sequence","1/22 HIV-1+ subjects carried this IDR variant, LNvWGCAFRhVCHT, and cross-recognized the HIV-2 gp41 IDR.","Maueia2011"
"58289","gp41 IDR","2879","A, C","A, C","A, C","Env",,,"",,"","LNSWGCAFRQVCHT","LNSWGCAnRQVCHT","F8N","F28N","OV","observed variant","Sequence","1/22 HIV-1+ subjects carried this IDR variant, LNSWGCAnRQVCHT, and cross-recognized the HIV-2 gp41 IDR.","Maueia2011"
"54168","WW9","995","B","","","Nef","5","13","","8809..8835","A*2501","WSKSSIIGW","WSKtSIIGW","S4T","S8T","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Positions 4 and 6 in the epitope had potentially experienced positive selection. The variant was full escape, as it was not recognized by CTLs.","Liu2006"
"54168","WW9","996","B","","","Nef","5","13","","8809..8835","A*2501","WSKSSIIGW","WSKSSmIGW","I6M","I10M","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Positions 4 and 6 in the epitope had potentially experienced positive selection. The variant was full escape, as it was not recognized by CTLs.","Liu2006"
"59097",,"3278","B","B","B","Nef","5","13","",,"A*2501","WSKSSIIGW","WSKtSIIGW","S4T","S8T","E","escape documented in this paper","Peptide titration","EliSpot peptide titration indicated full escape.","Liu2007a"
"59097",,"3279","B","B","B","Nef","5","13","",,"A*2501","WSKSSIIGW","WSKSSmIGW","I6M","I10M","E","escape documented in this paper","Peptide titration","EliSpot peptide titration indicated full escape.","Liu2007a"
"55298","nef-5141","1517","B","","","Nef","9","23","","8821..8865","","SVVGWPTVRERMRRA","SiVGWPaVRdRMRRA","E10D, V2I, T7A","E18D, V10I, T15A","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","CTL from the daughter, who carried this variant Nef sequence, recognized the Clade B consensus peptide.","Reinis2007"
"55858","WM8","1091","B","","","Nef","13","20","","8833..8856","B*08","WPAIRERM","WPAIRaRM","E6A","E18A","DR","diminished response","CD8 T-cell Elispot - IFNy","The patient's autologous WM8 sequence differed from the consensus (WPTVRERM) at 2 positions. A partial escape emerged 6 years post-infection.","Maurer2008"
"53826",,"1312","B","","","Nef","13","20","","8833..8856","B*0801","WPTVRERM","WPaVRERM","T3A","T15A","DHB, E, SF","diminished HLA binding or increased off-rate, escape documented in this paper, susceptible form","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","This variant was found in Donor2 and Recipient2, both of whom carried the restricting HLA-B*0801 allele.  The variant was not recognized by CTL in Donor2, but was recognized in Recipient2.  This variant also had reduced binding to HLA.","Milicic2005"
"53826",,"1313","B","","","Nef","13","20","","8833..8856","B*0801","WPTVRERM","WPaVRkRM","T3A, E6K","T15A, E18K","DHB, E, SF","diminished HLA binding or increased off-rate, escape documented in this paper, susceptible form","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","This variant was found in Donor2 and Recipient2 both of whom carried the restricting HLA-B*0801 allele.  The variant was not recognized by CTL in Donor2, but was recognized in Recipient2 from whom it was driven out de novo in time.  This variant also had reduced binding to HLA.","Milicic2005"
"53846","WM8","1578","","","","Nef","13","20","","8833..8856","B8","WPTVRERM","WnTVRERM","P2N","P14N","OV","observed variant","Sequence","This variant from the HXB2 sequence was present in the restricting HLA-B8 allele carrying mother, M-1001, as well as her non-HLA-B8-carrying infant, P-1024.  The variant was still detected at 15 months of age in infant P-1024.","Sanchez-Merino2005"
"57878",,"2951","C","C","C","Nef","13","20","","8833..8856","B*0801","WPAVRERI","WPdVRERm","A3D, I8M","A15D, I20M","IE","inferred escape","Sequence","Subject 270 carried this mutation in 11/24 sequences 2.9 months post-infection.","Chopera2011"
"57878",,"2952","C","C","C","Nef","13","20","","8833..8856","B*0801","WPAVRERI","WPnVRERm","A3N, I8M","A15N, I20M","IE","inferred escape","Sequence","Subject 270 carried this mutation 1.8 months post-infection (Mo.PI) in 24/24 sequences and in 11/24 sequences 2.9 Mo.PI.","Chopera2011"
"57878",,"2953","C","C","C","Nef","13","20","","8833..8856","B*0801","WPAVRERI","WPeVRERm","A3E, I8M","A15E, I20M","IE","inferred escape","Sequence","Subject 270 carried this mutation in 21/22 sequences 13.3 months post-infection.","Chopera2011"
"57878",,"2954","C","C","C","Nef","13","20","","8833..8856","B*0801","WPAVRERI","WPnVREgm","A3N, R7G, I8M","A15N, R19G, I20M","IE","inferred escape","Sequence","Subject 270 carried this mutation in 1/24 sequences 2.9 months post-infection.","Chopera2011"
"57878",,"2955","C","C","C","Nef","13","20","","8833..8856","B*0801","WPAVRERI","WPdVREkm","A3D, R7K, I8M","A15D, R19K, I20M","IE","inferred escape","Sequence","Subject 270 carried this mutation in 1/22 sequences 13.3 months post-infection.","Chopera2011"
"57878",,"2956","C","C","C","Nef","13","20","","8833..8856","B*0801","WPAVRERI","WPdVgERm","A3D, R5G, I8M","A15D, R17G, I20M","IE","inferred escape","Sequence","Subject 270 carried this mutation in 1/24 sequences 2.9 months post-infection.","Chopera2011"
"55299","nef-5142","1518","B","","","Nef","13","27","","8833..8877","","WPTVRERMRRAEPAA","WPaVRdRMRRAEPAA","T3A, E6D","T15A, E18D","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","CTL from the daughter, who carried this variant Nef sequence, recognized the Clade B consensus peptide.","Reinis2007"
"56640",,"2006","","","","Nef","17","34","","8845..8898","","RERRRRDEPAAVGVGPAS","RERRRRnEPAAVGVGPAS","D7N","D23N","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This newly defined epitope-containing peptide escaped CTL recognition rapidly in Patient 77. Variant occurred at day 14, when pooled mutants were negative for response.","Goonetilleke2009"
"56640",,"2007","","","","Nef","17","34","","8845..8898","","RERRRRDEPAAVGVGPAS","RERRRRnEPAAVGVGsAS","P16S, D7N","P32S, D23N","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This newly defined epitope-containing peptide escaped CTL recognition rapidly in Patient 77. This variant occurred at day 159 when patient had lost EliSpot response.","Goonetilleke2009"
"56640",,"2008","","","","Nef","17","34","","8845..8898","","RERRRRDEPAAVGVGPAS","RERRRkDEPAAVGVGPAS","R6K","R22K","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This newly defined epitope-containing peptide escaped CTL recognition rapidly in Patient 77. This variant occurred at day 14. Loss of response to this specific variant was clearly documented.","Goonetilleke2009"
"56640",,"2009","","","","Nef","17","34","","8845..8898","","RERRRRDEPAAVGVGPAS","RERRRkDEPAAVGVGPvS","A17V, R6K","A33V, R22K","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This newly defined epitope-containing peptide escaped CTL recognition rapidly in Patient 77. This variant occurred at day 159 when patient had lost EliSpot response.","Goonetilleke2009"
"56640",,"2010","","","","Nef","17","34","","8845..8898","","RERRRRDEPAAVGVGPAS","RERRkRDEPAAVGVGPAS","R5K","R21K","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This newly defined epitope-containing peptide escaped CTL recognition rapidly in Patient 77. This variant occurred at several time points, and loss of response was clearly documented.","Goonetilleke2009"
"56640",,"2011","","","","Nef","17","34","","8845..8898","","RERRRRDEPAAVGVGPAS","RERgkRDEPAAVGVGPAS","R4G, R5K","R20G, R21K","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This newly defined epitope-containing peptide escaped CTL recognition rapidly in Patient 77. This variant occurred at day 592.","Goonetilleke2009"
"56640",,"2012","","","","Nef","17","34","","8845..8898","","RERRRRDEPAAVGVGPAS","RERR....PAAVGVGPAS","R5., R6., D7., E8.","R21., R22., D23., E24.","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This newly defined epitope-containing peptide escaped CTL recognition rapidly in Patient 77. This variant occurred at day 32.","Goonetilleke2009"
"56640",,"2013","","","","Nef","17","34","","8845..8898","","RERRRRDEPAAVGVGPAS","RERRRReEPAAVGVGPAS","D7E","D23E","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This newly defined epitope-containing peptide escaped CTL recognition rapidly in Patient 77. This variant occurred at several time points and lack of response to variant was clearly demonstrated.","Goonetilleke2009"
"56640",,"2014","","","","Nef","17","34","","8845..8898","","RERRRRDEPAAVGVGPAS","kERRRReEPAAVGVGPAS","R1K, D7E","R17K, D23E","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This newly defined epitope-containing peptide escaped CTL recognition rapidly in Patient 77.  This variant occurred at day 159, when patient response had been lost.","Goonetilleke2009"
"56640",,"2015","","","","Nef","17","34","","8845..8898","","RERRRRDEPAAVGVGPAS","RERRRReEPAAVGVGPvS","A17V, D7E","A33V, D23E","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This newly defined epitope-containing peptide escaped CTL recognition rapidly in Patient 77. This variant occurred at day 159 when patient had lost EliSpot response.","Goonetilleke2009"
"56640",,"2016","","","","Nef","17","34","","8845..8898","","RERRRRDEPAAVGVGPAS","RERRRgDEPAAVGVGPAS","R6G","R22G","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This newly defined epitope-containing peptide escaped CTL recognition rapidly in Patient 77. This variant occurred at day 159 when patient had lost EliSpot response.","Goonetilleke2009"
"56640",,"2017","","","","Nef","17","34","","8845..8898","","RERRRRDEPAAVGVGPAS","RERRRgDEPAAVGVGtAS","P16T, R6G","P32T, R22G","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This newly defined epitope-containing peptide escaped CTL recognition rapidly in Patient 77. This variant occurred at day 159 when patient had lost EliSpot response.","Goonetilleke2009"
"56640",,"2018","","","","Nef","17","34","","8845..8898","","RERRRRDEPAAVGVGPAS","RERRRtDEPAAVGVGPAS","R6T","R22T","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This newly defined epitope-containing peptide escaped CTL recognition rapidly in Patient 77. This variant occurred at day 159 when patient had lost EliSpot response.","Goonetilleke2009"
"56640",,"2019","","","","Nef","17","34","","8845..8898","","RERRRRDEPAAVGVGPAS","RERRgRDEPAAVGVGPAS","R5G","R21G","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This newly defined epitope-containing peptide escaped CTL recognition rapidly in Patient 77. This variant occurred at day 159.","Goonetilleke2009"
"56640",,"2020","","","","Nef","17","34","","8845..8898","","RERRRRDEPAAVGVGPAS","RERRRRDEsAAVGVGPAS","P9S","P25S","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This newly defined epitope-containing peptide escaped CTL recognition rapidly in Patient 77. This variant occurred at day 32 when patient response was unknown.","Goonetilleke2009"
"56640",,"2021","","","","Nef","17","34","","8845..8898","","RERRRRDEPAAVGVGPAS","REgaRerrPAAVGVGPAS","R3G, R4A, R6E, D7R, E8R","R19G, R20A, R22E, D23R, E24R","OV","observed variant","Sequence","This newly defined epitope-containing peptide varied rapidly in Patient 77. This variant was found at day 32.","Goonetilleke2009"
"56640",,"2024","","","","Nef","17","34","","8845..8898","","RERRRRDEPAAVGVGPAS","RERRgRDEPAAVGVGPAS|r","Q19R, R5G","Q35R, R21G","E","escape documented in this paper","Sequence","This newly defined epitope-containing peptide varied rapidly in Patient 77. This variant occurred at day 159 when patient had lost EliSpot response.","Goonetilleke2009"
"56640",,"2025","","","","Nef","17","34","","8845..8898","","RERRRRDEPAAVGVGPAS","RERRgkDEPAAVGVGPAS|r","Q19R, R5G, R6K","Q35R, R21G, R22K","OV","observed variant","Sequence","This newly defined epitope-containing peptide varied rapidly in Patient 77. This variant occurred at day 592.","Goonetilleke2009"
"56640",,"2026","","","","Nef","17","34","","8845..8898","","RERRRRDEPAAVGVGPAS","RERRRtDEPAAVGVGPAS|r","S18R, R6T","S34R, R22T","E","escape documented in this paper","Sequence","This newly defined epitope-containing peptide varied rapidly in Patient 77. This variant occurred at day 159 when patient had lost EliSpot response.","Goonetilleke2009"
"56640",,"2272","","","","Nef","17","34","","8845..8898","","RERRRRDEPAAVGVGPAS","RERRRReEPAAVGVGPAS","R6E","R22E","OV","observed variant","Sequence","This newly defined epitope-containing peptide varied rapidly in Patient 77. This variant occurred at day 32; escape was not documented.","Goonetilleke2009"
"56640",,"2334","","","","Nef","17","34","","8845..8898","","RERRRRDEPAAVGVGPAS","RERRRgDEPA.......S","A11., V12., G13., V14., G15., P16., A17., R6G","A27., V28., G29., V30., G31., P32., A33., R22G","E","escape documented in this paper","Sequence","This newly defined epitope-containing peptide varied rapidly in Patient 77. This variant occurred at day 159 when patient had lost EliSpot response.","Goonetilleke2009"
"59185",,"3311","B","B","B","Nef","35","43","",,"B*37","RDLEKHGAI","RDLkKHGAI","E4K","E38K","OV","observed variant","Longitudinal study, Sequence","Acute controller, AC01, carried the Nef RDLEKHGAI mutant, RDLkKHGAI (E39K) at 33 days postinfection.","Kuang2014"
"59185",,"3312","B","B","B","Nef","35","43","",,"B*37","RDLEKHGAI","RnLEKHGAI","D2N","D36N","OV","observed variant","Longitudinal study, Sequence","Acute controller, AC01, carried the Nef RDLEKHGAI mutant, RnLEKHGAI (D37N) at 33 days postinfection.","Kuang2014"
"59185",,"3313","B","B","B","Nef","35","43","",,"B*37","RDLEKHGAI","RDLEKrGAI","H6R","H40R","DR, OV","diminished response, observed variant","Longitudinal study, Sequence","Acute controller, AC01, carried the Nef RDLEKHGAI mutant, RDLEKrGAI (H40R) at 383 days postinfection.  Nef-mediated downregulation of MHC Class I were decreased by 19%.","Kuang2014"
"55066","LS9","190","","","","Nef","37","45","","8905..8931","B*4001, B50","LEKHGAITS","LdKHGAITS","E2D","E38D","DR","diminished response","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Immune responses were examined in monozygotic male twins infected simultaneously with the same virus. LdKHGAITS  variant arose in one twin; LEKHGAvTS variant arose in the other. Response to LdKHGAITS  variant was diminished, while response to LEKHGAvTS was as strong as to LEKHGAITS.","Draenert2006"
"55066","LS9","191","","","","Nef","37","45","","8905..8931","B*4001, B50","LEKHGAITS","LEKHGAvTS","I7V","I43V","SF","susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Immune responses were examined in monozygotic male twins infected simultaneously with the same virus. LdKHGAITS  variant arose in one twin; LEKHGAvTS variant arose in the other. Response to LdKHGAITS  variant was diminished, while response to LEKHGAvTS was as strong as to LEKHGAITS","Draenert2006"
"59058","Nef 64-74","3228","C","C","C","Nef","64","74","","8986..9018","B*4501","EEVGFPVKPQV","dEVGFPVKPQV","E1D","E64D","DR, E","diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy","Variant dEVGFPVKPQV had a calculated time to escape of 8 days.","Liu2013a"
"59058","Nef 64-74","3229","C","C","C","Nef","64","74","","8986..9018","B*4501","EEVGFPVKPQV","dEVGFPVrPQV","E1D, K8R","E64D, K71R","DR, E","diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy","Variant dEVGFPVrPQV had a calculated time to escape of 8 days.","Liu2013a"
"59058","Nef 64-74","3230","C","C","C","Nef","64","74","","8986..9018","B*4501","EEVGFPVKPQV","gEVGFPVrPQV","E1G, K8R","E64G, K71R","E, SF","escape documented in this paper, susceptible form","CD8 T-cell Elispot - IFNy","Variant gEVGFPVrPQV had a calculated time to escape of 8 days.","Liu2013a"
"54640","NEF-10","1972","B","B","C","Nef","65","82","","8989..9042","","EVGFPVRPQVPLRPMTYK","EVGFPVRPQVPLRPMTfK","Y17F","Y81F","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 1 amino acid (5.6%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"55974","FL9(Nef)","1939","B","B","B","Nef","68","76","","8998..9024","B7","FPVRPQVPL","FPVtPQVPL","R4T","R71T","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B7 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope","Zhai2008"
"59249",,"3407","B","B","B","Nef","68","76","",,"B*0702","FPVRPQVPL","FSVRPQVPL","P2S","P69S","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","First variant to arise; seen only in early post-seroconversion period; Elispot response &tilde;50 SFC/10<sup>6</sup>PBMC .","Melhem2014"
"59249",,"3408","B","B","B","Nef","68","76","",,"B*0702","FPVRPQVPL","FPARPQVPL","V3A","V70A","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Second variant to arise; seen only in early post-seroconversion period; Elispot response <50 SFC/10<sup>6</sup>PBMC .","Melhem2014"
"59249",,"3409","B","B","B","Nef","68","76","",,"B*0702","FPVRPQVPL","SPVRPQVPL","F1S","F68S","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Third variant to arise; seen only in early post-seroconversion period; Elispot response <50 SFC/10<sup>6</sup>PBMC .","Melhem2014"
"59249",,"3410","B","B","B","Nef","68","76","",,"B*0702","FPVRPQVPL","FPIRPQVPL","V3I","V70I","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Fourth variant to arise; seen only in late post-seroconversion period; no Elispot response.","Melhem2014"
"55973","FR10(Nef)","1940","B","B","B","Nef","68","77","","8998..9027","B7","FPVRPQVPLR","FPVtPQVPLR","R4T","R71T","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B7 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"57532","F10LR","2532","","","","Nef","68","77","","8998..9027","B*07","FPVTPQVPLR","FPVrPQVPLR","T4R","T71R","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, HLA binding","Intersubtype variant FPVrPQVPLR exhibited low cross-recognition in mice immunized with FPVTPQVPLR.","Cardinaud2009"
"52136",,"404","B","","","Nef","68","81","","8998..9039","","FPVTPQVPLRMTY","FPVrPQVPLRMTY","T4R","T71R","OV","observed variant","","The variant was observed in most of the Brazilian population regardless of the infecting subtype.","Guimaraes2002"
"52136",,"405","B","","","Nef","68","81","","8998..9039","","FPVTPQVPLRMTY","FPVkPQVPLRMTY","T4K","T71K","OV","observed variant","","The variant was observed in most of the Brazilian population regardless of the infecting subtype.","Guimaraes2002"
"966",,"589","","B","F","Nef","68","84","","8998..9048","","FPVRPQVPLRPMTYKGA","FPVRPQVPLRPMTYKaA","G16A","G83A","OV","observed variant","","CTL epitope region conserved among HIV-1 M group subtypes. The variant was found in subtype F.","Jubier-Maurin1999"
"55317","nef-5156","1519","B","","","Nef","69","83","","9001..9045","","PVRPQVPLRPMTYKA","PVRPQVPLRPMTfKA","Y13F","Y81F","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","CTL from the daughter, who carried this variant Nef sequence, recognized the Clade B consensus peptide.","Reinis2007"
"54624","RM9","272","C","","","Nef","71","79","","9007..9033","B*8101","RPQVPLRPM","RPQVPvRPM","L6V","L76V","CE","calculated escape","","This variant was more often found in HLA-B*8101 patients, indicating that some favourable HLA alleles induce strong pressure, resulting in escape variants with high fitness cost and low viral loads.","Frater2007"
"54624","RM9","273","C","","","Nef","71","79","","9007..9033","B*8101","RPQVPLRPM","RPQVPtRPM","L6T","L76T","OV","observed variant","","Found in African cohort","Frater2007"
"54624","RM9","274","C","","","Nef","71","79","","9007..9033","B*8101","RPQVPLRPM","RPQVPmRPM","L6M","L76M","OV","observed variant","","Found in African cohort","Frater2007"
"54624","RM9","275","C","","","Nef","71","79","","9007..9033","B*8101","RPQVPLRPM","RPQmPLRPM","V4M","V74M","OV","observed variant","","Found in African cohort","Frater2007"
"54624","RM9","276","C","","","Nef","71","79","","9007..9033","B*8101","RPQVPLRPM","kPQVPvRPM","R1K, L6V","R71K, L76V","OV","observed variant","","Found in African cohort","Frater2007"
"54624","RM9","277","C","","","Nef","71","79","","9007..9033","B*8101","RPQVPLRPM","RPQVPiRPM","L6I","L76I","OV","observed variant","","Found in African cohort","Frater2007"
"54624","RM9","278","C","","","Nef","71","79","","9007..9033","B*8101","RPQVPLRPM","tPQVPIRPM","R1T, L6I","R71T, L76I","OV","observed variant","","Found in African cohort","Frater2007"
"54193","RM9","936","C","","","Nef","71","79","","9007..9033","","RPQVPLRPM","kPQVPLRPM","R1K","R71K","SF","susceptible form","","This variant is found in 7% of B*4201 and 48% of B*0702 positive individuals.","Leslie2006"
"54193","RM9","937","C","","","Nef","71","79","","9007..9033","","RPQVPLRPM","tPQVPLRPM","R1T","R71T","OV","observed variant","","This epitope is found in  5% of B*4201 and 10% of B*0702 positive individuals.","Leslie2006"
"54193","RM9","938","C","","","Nef","71","79","","9007..9033","","RPQVPLRPM","RPQVPvRPM","L6V","L76V","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Variant found in B*4201, B*0702 and B*8101 positive patients. The variant was less well recognized than the wt, or not recognized at all, by CTLs from B*0702 and B*4201 positive individuals.","Leslie2006"
"54193","RM9","939","C","","","Nef","71","79","","9007..9033","","RPQVPLRPM","RPQVPtRPM","L6T","L76T","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Variant found in B*4201 and B*8101 positive patients. The variant was less well recognized than the wt, or not recognized at all, by CTLs from B*0702 and B*4201 positive individuals.","Leslie2006"
"54193","RM9","940","C","","","Nef","71","79","","9007..9033","","RPQVPLRPM","tPQVPLkPM","R1T, R7K","R71T, R77K","OV","observed variant","","This variant is found in  2% of B*4201  positive individuals.","Leslie2006"
"54193","RM9","941","C","","","Nef","71","79","","9007..9033","","RPQVPLRPM","RPQaPLRPM","V4A","V74A","OV","observed variant","","This variant found in  2% of B*4201  positive individuals.","Leslie2006"
"54193","RM9","942","C","","","Nef","71","79","","9007..9033","","RPQVPLRPM","RPQVPmRPM","L6M","L76M","OV","observed variant","","This variant is found in  10% of B*8101  positive individuals.","Leslie2006"
"54193","RM9","943","C","","","Nef","71","79","","9007..9033","","RPQVPLRPM","kPQVPvRPM","R1K, L6V","R71K, L76V","OV","observed variant","","This variant is found in  10% of B*8101  positive individuals.","Leslie2006"
"54193","RM9","944","C","","","Nef","71","79","","9007..9033","","RPQVPLRPM","RPQmPLRPM","V4M","V74M","OV","observed variant","","This variant is found in  10% of B*8101  positive individuals.","Leslie2006"
"54193","RM9","945","C","","","Nef","71","79","","9007..9033","","RPQVPLRPM","RPQVPiRPM","L6I","L76I","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Variant found in B*8101 positive patients. The variant was less well recognized than the wt by CTLs from B*0702 and B*4201 positive individuals.","Leslie2006"
"54193","RM9","946","C","","","Nef","71","79","","9007..9033","","RPQVPLRPM","cPQVPLRPM","R1C","R71C","OV","observed variant","","This variant was found in individuals negative for B*4201, B*0702 and B*8101 alleles.","Leslie2006"
"54193","RM9","947","C","","","Nef","71","79","","9007..9033","","RPQVPLRPM","RPQVrLRPM","P5R","P75R","OV","observed variant","","This variant was found in individuals negative for B*4201, B*0702 and B*8101 alleles.","Leslie2006"
"54193","RM9","948","C","","","Nef","71","79","","9007..9033","","RPQVPLRPM","RPQVlLRPM","P5L","P75L","OV","observed variant","","This variant was found in individuals negative for B*4201, B*0702 and B*8101 alleles.","Leslie2006"
"55975","TM9(Nef)","1941","B","B","B","Nef","71","79","","9007..9033","B7","RPQVPLRPM","tPQVPLRPM","R1T","R71T","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B7 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"57876",,"2950","C","C","C","Nef","71","79","","9007..9033","B*0702","RPQVPLRPM","kPQVPLRPM","R1K","R71K","IE","inferred escape","Sequence","Subject CAP268 carried this mutation as detected by population sequencing 5.5 months post-infection.","Chopera2011"
"57333","Nef75","8","B","B","B","Nef","71","81","","9007..9039","B35","RPQVPLRPMTY","tPQVPLRPMTY","R1T","R71T","E, TCR","escape documented in this paper, TCR related mutation","Cytotoxicity assay, Flow cytometric T-cell cytokine assay, Sequence, TCR binding","Escape variant tPQVPLRPMTY was documented on the basis of sequence frequency in B35-positive patients, abolished TCR binding, flow cytometric assay, and cytotoxicity assay.","Ueno2007"
"52960",,"303","B","","","Nef","71","81","","9007..9039","B7 supertype","TPQVPLRPMTY","rPQVPLRPMTY","T1R","T71R","SF","susceptible form","CD8 T-cell Elispot - IFNy","After vaccination with a lipopeptide vaccine and a boost, both the variant and the wild type epitope were recognized.","Gahery-Segard2003"
"971",,"682","","","","Nef","71","81","","9007..9039","B35","RPQVPLRPMTY","RPQVPLRPMTf","Y11F","Y81F","SF","susceptible form","CD8 T-cell Elispot - IFNy","Variant found in 9/10 B35+ individuals and in 0/3 B35- individuals. Equally susceptible to CTLs and binds equally well to B35 as the wt.","Kawana1999"
"55694","RY11","1826","","","","Nef","71","81","","9007..9039","B*35","RPQVPLRPMTY","RPQVPLRPMTf","Y11F","Y81F","SF","susceptible form","Intracellular cytokine staining, Tetramer binding","Binding of this variant to HLA-B*3501 was unchanged from index epitope binding.  Cytotoxic sensitivity was also preserved.","Ueno2008"
"55694","RY11","1827","","","","Nef","71","81","","9007..9039","B*35","RPQVPLRPMTY","tPQVPLRPMTY","R1T","R71T","E","escape documented in this paper","Intracellular cytokine staining, Tetramer binding","RY11-specific CTL failed to kill CD4 T cells infected with the T75 variant.  Binding to HLA-B*3501 increased 10-fold with this variant, but cytotoxic activity decreased over a 100-fold.","Ueno2008"
"55694","RY11","1828","","","","Nef","71","81","","9007..9039","B*35","RPQVPLRPMTY","tPQVPLRPMTf","R1T, Y11F","R71T, Y81F","OV","observed variant","Intracellular cytokine staining, Tetramer binding","This double mutant is rarely if ever seen naturally, suggesting a high fitness cost.","Ueno2008"
"57672","RY11","2577","B","B","B","Nef","71","81","","9007..9039","B*3501","RPQVPLRPMTY","tPQVPLRPMTY","R1T","R71T","E","escape documented in this paper","Chromium-release assay, Flow cytometric T-cell cytokine assay, Intracellular cytokine staining","RPQVPLRPMTY-specific CTLs did not respond to cells expressing tPQVPLRPMTY and tPQVPLRPMTf variants.","Mwimanzi2010"
"57672","RY11","2578","B","B","B","Nef","71","81","","9007..9039","B*3501","RPQVPLRPMTY","tPQVPLRPMTf","R1T, Y11F","R71T, Y81F","E","escape documented in this paper","Chromium-release assay, Flow cytometric T-cell cytokine assay, Intracellular cytokine staining","RPQVPLRPMTY-specific CTLs did not respond to cells expressing tPQVPLRPMTY and tPQVPLRPMTf variants.","Mwimanzi2010"
"57736","RY11","2634","","","","Nef","71","81","","9007..9039","B*35","RPQVPLRPMTY","tPQVPLRPMTY","R1T","R71T","DR","diminished response","","Variant to RY11, tPQVPLRPMTY, is seen to reduce antiviral CTL activity by a decline in proliferative capacity, Ueno et al., J. Immunol., 178:5513-23 (2007).","Motozono2010"
"58169","RY11","2779","B","B","B","Nef","71","81","","9007..9039","B35","RPQVPLRPMTY","tPQVPLRPMTY","R1T","R71T","E","escape documented in this paper","Cytotoxicity assay, Flow cytometric T-cell cytokine assay, Intracellular cytokine staining","RPQVPLRPMTY-specific CTLs had toxicity toward HIV-infected macrophages, but failed to kill R71T mutant virus-infected cells.","Mwimanzi2011"
"58169","RY11","2780","B","B","B","Nef","71","81","","9007..9039","B35","RPQVPLRPMTY","tPQVPLRPMTf","R1T, Y11F","R71T, Y81F","E","escape documented in this paper","Cytotoxicity assay, Flow cytometric T-cell cytokine assay, Intracellular cytokine staining","RPQVPLRPMTY-specific CTLs had toxicity toward HIV-infected macrophages, but failed to kill R71T/Y81F mutant virus-infected cells.","Mwimanzi2011"
"59228","RY11","3367","B","B","B","Nef","71","81","",,"","RPQVPLRPMTY","RPQVPLRaMTY","P8A","P78A","A","HLA association","HLA binding, Other, Structural prediction","Complex of B*3501 with variant P8A of RY11, RPQVPLRaMTY, is more stable than B*3501-RY11, but specificity to the cognate TCR is maintained.","Yanaka2014"
"57494","QY9","2486","B, C, D","B, C, D","C, D","Nef","73","81","","9013..9039","","QVPLRPMTY","QVPvRPMTY","L4V","L76V","SF","susceptible form","CD8 T-cell Elispot - IFNy","Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C); 2792 (Caucasian male, treatment naive, autologous virus Clade B); 2840 (African female, treated, autologous virus Clade D) all continued to elicit CTL response to variant QVPvRPMTY.","Hoof2010"
"57494","QY9","2487","B, C, D","B, C, D","C, D","Nef","73","81","","9013..9039","","QVPLRPMTY","QaPLRPMTY","V2A","V74A","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C); 2840 (African female, treated, autologous virus Clade D) all continued to elicit CTL response to variant QaPLRPMTY, but CTL from patient 2792 (Caucasian male, treatment naive, autologous virus Clade B) were not susceptible to this variant.","Hoof2010"
"57494","QY9","2488","B, C, D","B, C, D","C, D","Nef","73","81","","9013..9039","","QVPLRPMTY","QVPLRPMTf","Y9F","Y81F","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","Patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C); 2840 (African female, treated, autologous virus Clade D) all continued to elicit CTL response to variant QVPLRPMTf, but CTL from patient 2792 (Caucasian male, treatment naive, autologous virus Clade B) were not susceptible to this variant.","Hoof2010"
"57494","QY9","2489","B, C, D","B, C, D","D","Nef","73","81","","9013..9039","","QVPLRPMTY","QVPaRPMTY","L4A","L76A","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","Patient 2840 (African female, treated, autologous virus Clade D) continued to elicit CTL response to variant QVPaRPMTY, but CTL from patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C); 2792 (Caucasian male, treatment naive, autologous virus Clade B) were not susceptible to this variant.","Hoof2010"
"57494","QY9","2491","B, C, D","B, C, D","D","Nef","73","81","","9013..9039","","QVPLRPMTY","QVPLRaMTY","P6A","P78A","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","Patient 2840 (African female, treated, autologous virus Clade D) continued to elicit CTL response to variant QVPLRaMTY, but CTL from patients 2295 (Caucasian female, experienced some treatment, autologous virus Clade C); 2792 (Caucasian male, treatment naive, autologous virus Clade B) were not susceptible to this variant.","Hoof2010"
"57494","QY9","2492","B, C, D","B, C, D","C","Nef","73","81","","9013..9039","","QVPLRPMTY","QVPLaPMTY","R5A","R77A","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","Patient 2295 (Caucasian female, experienced some treatment, autologous virus Clade C) continued to elicit CTL response to variant QVPLaPMTY, but CTL from patients 2840 (African female, treated, autologous virus Clade D); 2792 (Caucasian male, treatment naive, autologous virus Clade B) were not susceptible to this variant.","Hoof2010"
"981",,"128","B","","","Nef","73","82","","9013..9042","A11","QVPLRPMTYK","QVPLRPMTsr","K10R, Y9S","K82R, Y81S","DHB","diminished HLA binding or increased off-rate","Chromium-release assay, HLA binding","The epitope QVPLRPMTYK was entirely conserved in 9 isolates from the donor who did not recognize this epitope. QVPLRPMTsr substitutions resulted in a very low binding to HLA-A11.","Goulder1997e, Couillin1994"
"53728",,"421","B, CRF02_AG","","","Nef","73","82","","9013..9042","A11, A3","QVPLRPMTYK","QVPvRPMTYK","L4V","L76V","OV","observed variant","","This variant was found in  1/5 subtype B infected patients.","Inwoley2005"
"53728",,"422","B, CRF02_AG","","","Nef","73","82","","9013..9042","A11, A3","QVPLRPMTYK","QVPmRPMTYK","L4M","L76M","OV","observed variant","","This variant was found in  1/9 subtype CRF02_AG infected patients.","Inwoley2005"
"53728",,"423","B, CRF02_AG","","","Nef","73","82","","9013..9042","A11, A3","QVPLRPMTYK","QVPLRPMTfK","Y9F","Y81F","SF","susceptible form","","Mutation may impair T cell recognition, however, the variant was recognized in one patient as well as the wt.","Inwoley2005"
"986",,"739","B","","","Nef","73","82","","9013..9042","A*0301","QVPLRPMTYK","QiPLRPMTYK","V2I","V74I","SF","susceptible form","Chromium-release assay","Variant found in the plasma before CTL infusion in the patient. The variant induced the same amount of lysis as the wt epitope.","Koenig1995"
"986",,"740","B","","","Nef","73","82","","9013..9042","A*0301","QVPLRPMTYK","QVPLaPMTYK","R5A","R77A","DR","diminished response","Chromium-release assay","Artificial variant that required a 10&#136;4 to 10&#136;5 increase in peptide concentration to induce same amount of lysis as the wt epitope.","Koenig1995"
"986",,"741","B","","","Nef","73","82","","9013..9042","A*0301","QVPLRPMTYK","QVPLgPMTYK","R5G","R77G","DR","diminished response","Chromium-release assay","Artificial variant that required an increase in peptide concentration to induce same amount of lysis as the wt epitope.","Koenig1995"
"986",,"742","B","","","Nef","73","82","","9013..9042","A*0301","QVPLRPMTYK","QVPLgPMsYK","R5G, T8S","R77G, T80S","SF","susceptible form","Chromium-release assay","The second mutation restored the ability of this variant to sensitize target cells for lysis.","Koenig1995"
"986",,"743","B","","","Nef","73","82","","9013..9042","A*0301","QVPLRPMTYK","QVPLRPMaYK","T8A","T80A","DR","diminished response","Chromium-release assay","Artificial variant that required a 10&#136;4 to 10&#136;5 increase in peptide concentration to induce same amount of lysis as the wt epitope.","Koenig1995"
"986",,"744","B","","","Nef","73","82","","9013..9042","A*0301","QVPLRPMTYK","QVPLRPaTYK","M7A","M79A","DR","diminished response","Chromium-release assay","Artificial variant that required a 10-100-fold  increase in peptide concentration to induce same amount of lysis as the wt epitope.","Koenig1995"
"986",,"745","B","","","Nef","73","82","","9013..9042","A*0301","QVPLRPMTYK","aVPLRPMTYK","Q1A","Q73A","SF","susceptible form","Chromium-release assay","Artificial variant that induced the same amount of lysis as the wt epitope.","Koenig1995"
"986",,"746","B","","","Nef","73","82","","9013..9042","A*0301","QVPLRPMTYK","QaPLRPMTYK","V2A","V74A","SF","susceptible form","Chromium-release assay","Artificial variant that induced the same amount of lysis as the wt epitope.","Koenig1995"
"986",,"747","B","","","Nef","73","82","","9013..9042","A*0301","QVPLRPMTYK","QVaLRPMTYK","P3A","P75A","SF","susceptible form","Chromium-release assay","Artificial variant that induced the same amount of lysis as the wt epitope.","Koenig1995"
"986",,"748","B","","","Nef","73","82","","9013..9042","A*0301","QVPLRPMTYK","QVPaRPMTYK","L4A","L76A","SF","susceptible form","Chromium-release assay","Artificial variant that induced the same amount of lysis as the wt epitope.","Koenig1995"
"986",,"749","B","","","Nef","73","82","","9013..9042","A*0301","QVPLRPMTYK","QVPLRaMTYK","P6A","P78A","SF","susceptible form","Chromium-release assay","Artificial variant that induced the same amount of lysis as the wt epitope.","Koenig1995"
"986",,"750","B","","","Nef","73","82","","9013..9042","A*0301","QVPLRPMTYK","QVPLRPMTaK","Y9A","Y81A","SF","susceptible form","Chromium-release assay","Artificial variant that induced the same amount of lysis as the wt epitope.","Koenig1995"
"986",,"751","B","","","Nef","73","82","","9013..9042","A*0301","QVPLRPMTYK","QVPLRPMTYa","K10A","K82A","SF","susceptible form","Chromium-release assay","Artificial variant that induced the same amount of lysis as the wt epitope.","Koenig1995"
"53828",,"1419","C","","","Nef","73","82","","9013..9042","A3","QVPLRPMTYK","QVPLRPMTfK","Y9F","Y81F","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant was the autologous, index sequence carried by an HIV-positive, transmitting mother, M3.  Her infant, I3,  carried the variant as its dominant form and it elicited a CTL response.","Pillay2005"
"53828",,"1420","C","","","Nef","73","82","","9013..9042","A3","QVPLRPMTYK","QVPLkPMTfK","R5K, Y9F","R77K, Y81F","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence","This early variant arose in infant I3 and elicited a diminished CTL response.","Pillay2005"
"53828",,"1421","C","","","Nef","73","82","","9013..9042","A3","QVPLRPMTYK","QVPLRPMnYK","T8N","T80N","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence","This early variant arose in infant I3 and elicited a diminished CTL response.","Pillay2005"
"53828",,"1422","C","","","Nef","73","82","","9013..9042","A3","QVPLRPMTYK","QVPvRPMTfK","L4V, Y9F","L76V, Y81F","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","This variant arose by week 80 in infant I3 and no CTL response was detected to it.","Pillay2005"
"53828",,"1423","C","","","Nef","73","82","","9013..9042","A3","QVPLRPMTYK","QVPLRPMsYr","K10R, T8S","K82R, T80S","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","This variant arose by week 80 in infant I3 and no CTL response was detected to it.","Pillay2005"
"53828",,"1424","C","","","Nef","73","82","","9013..9042","A3","QVPLRPMTYK","QVPLRPMsYK","T8S","T80S","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant arose by week 80 in infant I3 and it elicited a CTL response.","Pillay2005"
"55009","QVP","1812","","","","Nef","73","82","","9013..9042","A*0301","QVPLRPMTYK","QVPLRPMTeK","Y9E","Y81E","DR","diminished response","CD8 T-cell Elispot - IFNy, Tetramer binding","All patients tested had response <60% of the response to the index peptide.","Turnbull2006"
"55009","QVP","1813","","","","Nef","73","82","","9013..9042","A*0301","QVPLRPMTYK","QVPvRPMTYK","L4V","L76V","DR","diminished response","CD8 T-cell Elispot - IFNy, Tetramer binding","All patients tested had response less or equal of 60% of the response to the index peptide.","Turnbull2006"
"55009","QVP","1814","","","","Nef","73","82","","9013..9042","A*0301","QVPLRPMTYK","QVPiRPMTYK","L4I","L76I","DR","diminished response","CD8 T-cell Elispot - IFNy, Tetramer binding","All patients tested had response less or equal of 60% of the response to the index peptide.","Turnbull2006"
"55009","QVP","1815","","","","Nef","73","82","","9013..9042","A*0301","QVPLRPMTYK","QVPLRPMTYq","K10Q","K82Q","DR","diminished response","CD8 T-cell Elispot - IFNy, Tetramer binding","All patients tested had response less or equal of 60% of the response to the index peptide.","Turnbull2006"
"55009","QVP","1816","","","","Nef","73","82","","9013..9042","A*0301","QVPLRPMTYK","QVPLRPMTrr","K10R, Y9R","K82R, Y81R","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","All patients tested had response less than  20% of the response to the index peptide.","Turnbull2006"
"55009","QVP","1817","","","","Nef","73","82","","9013..9042","A*0301","QVPLRPMTYK","QVPLRPMTYr","K10R","K82R","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","Some patients tested had response comparable to the response to the index peptide, one patient had reduced response and two patients did not have a response.","Turnbull2006"
"55009","QVP","1818","","","","Nef","73","82","","9013..9042","A*0301","QVPLRPMTYK","hVPLRPMTYK","Q1H","Q73H","DR, SF","diminished response, susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","Some patients tested had response comparable to the response to the index peptide, one patient had reduced response (60%) and one  patients had a response of 20% of the response to the index peptide.","Turnbull2006"
"981",,"2283","B","","","Nef","73","82","","9013..9042","A11","{T*}QVPLRPMTYK{A}","{r*}QVPLRPMTYK{g}","A+1G, T-2R","A83G, T71R","IE, P","inferred escape, processing","Chromium-release assay, HLA binding","The epitope QVPLRPMTYK was entirely conserved in 9 isolates from the donor who did not recognize this epitope, whereas there were flanking mutations T71R and A83G, suggesting a processing escape.","Goulder1997e, Couillin1994"
"975",,"2323","B","","","Nef","73","82","","9013..9042","A3","{T*}QVPLRPMTYK{A}","{k*}QVPLRPMTYK{g}","A+1G, T-2K","A83G, T71K","E, P","escape documented in this paper, processing","","Mutations in Nef that flank this epitope, Thr71Lys and Ala83Gly, may account for an observed loss of CTL reactivity, with escape due to the introduction of proteasome processing defects.","Chassin1999"
"58242",,"2837","B","B","B","Nef","73","82","","9013..9042","A*0301","QVPLRPMTYK{AA}","QVPLRPMTYK{gA}","A+1G","A83G","IE","inferred escape","Sequence","8/14 sequences of peptide QVPLRPMTYK{AA} varied at 639 DFOSx to QVPLRPMTYK{gA}.  Position 83 in the peptide is marked as being under selection to vary.","Ferrari2011"
"58242",,"2839","B","B","B","Nef","73","82","","9013..9042","A*0301","QVPLRPMTYK{AA}","QVPLRPMTfK{gA}","A+1G, Y9F","A83G, Y81F","IE","inferred escape","Sequence","5/14 and 12/13 sequences of peptide QVPLRPMTYK{AA} varied at 639 and 821 DFOSx to QVPLRPMTfK{gA}.  Positions 81 and 83 in the peptide are marked as being under selection to vary.","Ferrari2011"
"59120","QK10","3300","B","B","B","Nef","73","82","",,"A*0301, A*11","QVPLRPMTYK","QiPLRPMTYK","V2I","V74I","DHB, OV","diminished HLA binding or increased off-rate, observed variant","CTL suppression of replication, HLA binding, Sequence","Strain DH12-specific variant of epitope QK10, QiPLRPMTYK, was poorly recognized by a strain LAI QK10-specific CTL clone. Suppression of replication of all DH12 viruses was poor.","Lissina2014"
"55316","nef-5157","1520","B","","","Nef","73","87","","9013..9057","","QVPLRPMTYKAAVDL","QVPLRPMTfKAAVDL","Y9F","Y81F","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","CTL from the daughter, who carried this variant Nef sequence, barely recognized the Clade B consensus peptide.","Reinis2007"
"53599","VY8","62","B","","","Nef","74","81","","9016..9039","B*3501","VPLRPMTY","VPLRPMTf","Y8F","Y81F","DR","diminished response","CD8 T-cell Elispot - IFNy, Chromium-release assay, Intracellular cytokine staining","Point mutation of epitope at position 8 (Y to F,VPLRPMTf) was detected at a chronic infection timepoint. The CTL response was strong in early infection, but diminished by month 13. This mutation had reduced avidity.","Bansal2005a"
"53416","VPL","1392","","","","Nef","74","81","","9016..9039","B35","VPLRPMTY","VPLRPMsY","T7S","T80S","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","This variant was an escape. Response greatly diminished.","Oxenius2004"
"53416","VPL","1393","","","","Nef","74","81","","9016..9039","B35","VPLRPMTY","VPLRPMTf","Y8F","Y81F","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","This variant was an escape. Response diminished.","Oxenius2004"
"57673","VY8","2579","B","B","B","Nef","74","81","","9016..9039","B*3501","VPLRPMTY","VPLRPMTf","Y8F","Y81F","E","escape documented in this paper","Chromium-release assay, Flow cytometric T-cell cytokine assay, Intracellular cytokine staining","VPLRPMTY-specific CTL clones did not recognize the cells expressing VPLRPMTf variant.","Mwimanzi2010"
"57735","VY8","2633","","","","Nef","74","81","","9016..9039","B*35","VPLRPMTY","VPLRPMTf","Y8F","Y81F","LE","literature escape","","This mutation, Y85F, is seen as the cause for loss of early immunodominant Nef epitope VY8-elicited CTL response to the virus, making way for new dominant epitopes in later infection.","Motozono2010"
"58168","VY8","2777","B","B","B","Nef","74","81","","9016..9039","B35","VPLRPMTY","VPLRPMTf","Y8F","Y81F","E","escape documented in this paper","Cytotoxicity assay, Flow cytometric T-cell cytokine assay, Intracellular cytokine staining","VPLRPMTY-specific CTLs had toxicity toward HIV-infected macrophages, but failed to kill Y81F mutant virus-infected cells.","Mwimanzi2011"
"53736",,"424","B, CRF02_AG","B","B","Nef","77","85","","9025..9051","B7","RPMTYKAAV","RPMTYKAAl","V9L","V85L","OV","observed variant","","One of subtype B infected patients that recognized the epitope had this epitope variant. The variant was found in 3/5 clade B-infected patients.","Inwoley2005"
"53736",,"425","B, CRF02_AG","","","Nef","77","85","","9025..9051","B7","RPMTYKAAV","RPMTYKgAi","A7G, V9I","A83G, V85I","NSF, SF","non-susceptible form, susceptible form","","T cells of one patient did not recognize this variant but it was recognized in another patient.","Inwoley2005"
"53736",,"426","B, CRF02_AG","","","Nef","77","85","","9025..9051","B7","RPMTYKAAV","RPMTYKgAl","A7G, V9L","A83G, V85L","OV","observed variant","","The variant was found in 1/5 subtype B infected patients.","Inwoley2005"
"53736",,"427","B, CRF02_AG","","","Nef","77","85","","9025..9051","B7","RPMTYKAAV","RPMTYKgAf","A7G, V9F","A83G, V85F","OV","observed variant","","The variant was found in 2/9 CRF02_AG infected patients.","Inwoley2005"
"53736",,"428","B, CRF02_AG","","","Nef","77","85","","9025..9051","B7","RPMTYKAAV","RPMTfKgAf","Y5F, A7G, V9F","Y81F, A83G, V85F","OV","observed variant","","The variant was found in 1/9 CRF02_AG infected patients.","Inwoley2005"
"53736",,"429","B, CRF02_AG","","","Nef","77","85","","9025..9051","B7","RPMTYKAAV","RPMTfKAAV","Y5F","Y81F","OV","observed variant","","The variant was found in 1/9 CRF02_AG infected patients.","Inwoley2005"
"53736",,"430","B, CRF02_AG","","","Nef","77","85","","9025..9051","B7","RPMTYKAAV","RPMTYKeAV","A7E","A83E","OV","observed variant","","The variant was found in 1/9 CRF02_AG infected patients.","Inwoley2005"
"54544","RL9","1029","B","B","B","Nef","77","85","","9025..9051","B7 supertype","RPMTYKGAL","RPMTYraAr","K6R, G7A, L9R","K82R, G83A, L85R","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant was found by challenge of 23 subjects with a novel Nef potential T-cell epitope panel in Subtype B.","Malhotra2007a"
"53412","RPM","1394","","","","Nef","77","85","","9025..9051","B7","RPMTYKGAL","RPMTYrGAL","K6R","K82R","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","This variant was seen earlier and was proposed to be an escape.","Oxenius2004"
"53412","RPM","1395","","","","Nef","77","85","","9025..9051","B7","RPMTYKGAL","RPMTYKaAL","G7A","G83A","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","This variant was seen earlier and was proposed to be an escape.","Oxenius2004"
"53412","RPM","1396","","","","Nef","77","85","","9025..9051","B7","RPMTYKGAL","RPMTYKGAv","L9V","L85V","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","This variant was seen earlier and was proposed to be an escape.","Oxenius2004"
"53412","RPM","1397","","","","Nef","77","85","","9025..9051","B7","RPMTYKGAL","RPMsYKaAL","T4S, G7A","T80S, G83A","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","This  was one of two most common forms of variants.","Oxenius2004"
"53412","RPM","1398","","","","Nef","77","85","","9025..9051","B7","RPMTYKGAL","RPMTfKGAL","Y5F","Y81F","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","This was one of two most common forms of variants.","Oxenius2004"
"53847","RW9","1579","","","","Nef","77","85","","9025..9051","B7","RPMTYKAAL","RPMThqAAw","Y5H, K6Q, L9W","Y81H, K82Q, L85W","DR, SF","diminished response, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant from the HXB2 sequence was present in the non-HLA-B7 allele carrying mother, M-1003, as well as her restricting-HLA-B7-carrying infant, P-1189.   The variant was still detected at 12 months of age in infant P-1189.  Decreased recognition of the variant was seen relative to index epitope in the mother, but recognition was equivalent to index epitope recognition in the infant.","Sanchez-Merino2005"
"55976","RL9(Nef)","1942","B","B","B","Nef","77","85","","9025..9051","B7","RPMTYKGAL","RPMTYKaAv","G7A, L9V","G83A, L85V","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at two positions. It is predicted to be HLA-B7 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"55976","RL9(Nef)","1943","B","B","B","Nef","77","85","","9025..9051","B7","RPMTYKGAL","RPMTYKaAL","G7A","G83A","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B7 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"57533","R9AL","2533","","","","Nef","77","85","","9025..9051","B*07","RPMTYKAAL","RPMTYKgAL","A7G","A83G","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, HLA binding","Intersubtype variants RPMTYKgAL, RPMTYKAAv, RPMTfKAAL, RPMTYKfAL, and RPMTYKAAf exhibited good cross-recognition in mice immunized with RPMTYKAAL.","Cardinaud2009"
"57533","R9AL","2534","","","","Nef","77","85","","9025..9051","B*07","RPMTYKAAL","RPMTYKAAv","L9V","L85V","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, HLA binding","Intersubtype variants RPMTYKgAL, RPMTYKAAv, RPMTfKAAL, RPMTYKfAL, and RPMTYKAAf exhibited good cross-recognition in mice immunized with RPMTYKAAL.","Cardinaud2009"
"57533","R9AL","2535","","","","Nef","77","85","","9025..9051","B*07","RPMTYKAAL","RPMTfKAAL","Y5F","Y81F","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, HLA binding","Intersubtype variants RPMTYKgAL, RPMTYKAAv, RPMTfKAAL, RPMTYKfAL, and RPMTYKAAf exhibited good cross-recognition in mice immunized with RPMTYKAAL.","Cardinaud2009"
"57533","R9AL","2536","","","","Nef","77","85","","9025..9051","B*07","RPMTYKAAL","RPMTYKfAL","A7F","A83F","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, HLA binding","Intersubtype variants RPMTYKgAL, RPMTYKAAv, RPMTfKAAL, RPMTYKfAL, and RPMTYKAAf exhibited good cross-recognition in mice immunized with RPMTYKAAL.","Cardinaud2009"
"57533","R9AL","2537","","","","Nef","77","85","","9025..9051","B*07","RPMTYKAAL","RPMTYKAAf","L9F","L85F","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, HLA binding","Intersubtype variants RPMTYKgAL, RPMTYKAAv, RPMTfKAAL, RPMTYKfAL, and RPMTYKAAf exhibited good cross-recognition in mice immunized with RPMTYKAAL.","Cardinaud2009"
"59046","RV9-Nef","3222","B","B","C","Nef","77","85","","9025..9051","B*0702","RPMTYKAAV","RPMTYKAAf","V9F","V85F","SSF","subtype-specific susceptible form","HLA binding","Variant RF9, RPMTYKAAf, a C-clade Nef epitope was targeted by C-clade infected subjects more robustly than the B-clade variant RV9.  The affinity of RF9 to B*0702 was K<sub>d</sub> = 7 nM.  Clade-C RF9 is contained within OLP77, QVPLRPMTfKgAfDLSfF.","Kloverpris2014"
"59250",,"3411","B","B","B","Nef","77","85","",,"","RPMTWKGAL","RPMTWKAAL","G7A","G83A","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","First variant detected; seen throughout infection; Elispot responses in early post-seroconversion (&tilde;100 SFC/10<sup>6</sup>PBMC ), last post-SC  (seroconversion) (at &tilde;50 SFC/10<sup>6</sup>PBMC ), and early ART (&tilde;100 SFC) periods.","Melhem2014"
"59250",,"3412","B","B","B","Nef","77","85","",,"","RPMTWKGAL","RPMTYKGAL","W5Y","W81Y","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Second variant detected; seen only in early post-seroconversion; positive Elispot response &tilde;50 SFC/10<sup>6</sup>PBMC .","Melhem2014"
"59250",,"3413","B","B","B","Nef","77","85","",,"","RPMTWKGAL","RPMTRKAAL","W5R, G7A","W81R, G83A","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Third variant detected; seen only in early post-seroconversion; positive Elispot response &tilde;200 SFC/10<sup>6</sup>PBMC .","Melhem2014"
"59250",,"3414","B","B","B","Nef","77","85","",,"","RPMTWKGAL","RPMTCKGAL","W5C","W81C","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Fourth variant detected; seen only in early post-seroconversion; positive Elispot response &tilde;100 SFC/10<sup>6</sup>PBMC .","Melhem2014"
"59250",,"3415","B","B","B","Nef","77","85","",,"","RPMTWKGAL","RPMTYKAAL","W5Y, G7A","W81Y, G83A","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Fifth variant detected; seen only in late post-seroconversion; no Elispot response.","Melhem2014"
"59250",,"3416","B","B","B","Nef","77","85","",,"","RPMTWKGAL","RPITYKAAL","M3I, W5Y, G7A","M79I, W81Y, G83A","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Sixth variant detected; seen in early and late ART periods; Elispot response &tilde;200 SFC/10<sup>6</sup>PBMC  in early ART period and &tilde;150 SFC/10<sup>6</sup>PBMC  in late ART period.","Melhem2014"
"55300","nef-5158","1521","B","","","Nef","77","91","","9025..9069","","RPMTYKAAVDLSHFL","RPMTfKAAVDLSHFL","Y5F","Y81F","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","CTL from the daughter, who carried this variant Nef sequence, recognized the Clade B consensus peptide.","Reinis2007"
"53740",,"431","B, CRF02_AG","AG","AG","Nef","80","87","","9034..9057","A24","TYKAAVDL","TYKgAfDL","A4G, V6F","A83G, V85F","OV","observed variant","","Only one patient recognized the wt epitope, but that patient carried the variant sequence. This epitope was highly variable in CRF02_AG infected patients, while 3/5 subtype B patients had 1 substitution in the epitope.","Inwoley2005"
"53740",,"432","B, CRF02_AG","","","Nef","80","87","","9034..9057","A24","TYKAAVDL","TfKAAVDL","Y2F","Y81F","OV","observed variant","","The variant was found in 2/9 CRF02_AG infected patients.","Inwoley2005"
"53740",,"433","B, CRF02_AG","","","Nef","80","87","","9034..9057","A24","TYKAAVDL","TfKgAfDL","Y2F, A4G, V6F","Y81F, A83G, V85F","OV","observed variant","","The variant was found in 1/9 CRF02_AG infected patients.","Inwoley2005"
"53740",,"434","B, CRF02_AG","","","Nef","80","87","","9034..9057","A24","TYKAAVDL","TYKeAVDL","A4E","A83E","OV","observed variant","","The variant was found in 2/9 CRF02_AG infected patients.","Inwoley2005"
"53740",,"435","B, CRF02_AG","","","Nef","80","87","","9034..9057","A24","TYKAAVDL","TYKgAiDL","A4G, V6I","A83G, V85I","OV","observed variant","","The variant was found in 1/9 CRF02_AG infected patients.","Inwoley2005"
"53740",,"436","B, CRF02_AG","","","Nef","80","87","","9034..9057","A24","TYKAAVDL","TYKgAlDL","A4G, V6L","A83G, V85L","OV","observed variant","","The variant was found in 1/5 subtype B infected patients.","Inwoley2005"
"53740",,"437","B, CRF02_AG","","","Nef","80","87","","9034..9057","A24","TYKAAVDL","TYKAAlDL","V6L","V85L","OV","observed variant","","The variant was found in 2/5 subtype B infected patients.","Inwoley2005"
"58750",,"3139","","","","Nef","81","95","","9037..9081","","FKAALDLSHFLNEKG","FKAAvDLSHFLNEKG","L5V","L85V","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","Variant FKAAvDLSHFLNEKG is seen in CP2 sequence but not recognized.","Buckheit2012"
"54642","NEF-12","1973","B","B","C","Nef","81","97","","9037..9087","","YKGALDLSHFLKEKGGL","fKGAfDLSfFLKEKGGL","Y1F, L5F, H9F","Y81F, L85F, H89F","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 3 amino acids (17.6%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"53775","KF9","915","B","","B","Nef","82","90","","9040..9066","B*57, B*5801","KAAVDLSHF","KgAVDLSHF","A2G","A83G","DHB, E, SF","diminished HLA binding or increased off-rate, escape documented in this paper, susceptible form","","This variant form of the epitope was shown to be an escape variant by virtue of an increased off-rate; however Elispot reactions to both variant and wt are positive. The escape form was shown to be transmitted, and the most common form of the epitope in a B clade infected population in Perth, Australia (52%), though the proportion of HLA-B*57/5801+ population carrying the escape form was 86%.","Leslie2005a"
"53831",,"1425","C","","","Nef","82","90","","9040..9066","B57","KAAFDLSFF","KAAFDLgFF","S7G","S88G","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence","This variant was found in mother M5.  In the infant, I5, it elicited a diminished CTL response","Pillay2005"
"53831",,"1426","C","","","Nef","82","90","","9040..9066","B57","KAAFDLSFF","KgAFDLgFF","A2G, S7G","A83G, S88G","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant was the dominant (only) circulating form by week 33 in infant I5 and elicited CTL response.","Pillay2005"
"56632",,"1981","","","","Nef","82","90","","9040..9066","B*5701","KAALDLSHF","KgALDLSHF","A2G","A83G","DR","diminished response","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Documented reduced response to this variant.","Goonetilleke2009"
"56632",,"1982","","","","Nef","82","90","","9040..9066","B*5701","KAALDLSHF","qAALDLSHF","K1Q","K82Q","DR","diminished response","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Documented reduced response to this variant.","Goonetilleke2009"
"56632",,"1983","","","","Nef","82","90","","9040..9066","B*5701","KAALDLSHF","tAALDLSHF","K1T","K82T","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Variant arose on day 32; response unknown.","Goonetilleke2009"
"56632",,"1984","","","","Nef","82","90","","9040..9066","B*5701","KAALDLSHF","pAALDLSHF","K1P","K82P","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Variant arose on day 32; response unknown.","Goonetilleke2009"
"56632",,"1985","","","","Nef","82","90","","9040..9066","B*5701","KAALDLSHF","KAAhDLSHF","L4H","L85H","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Variant arose on day 32; response unknown.","Goonetilleke2009"
"56632",,"1986","","","","Nef","82","90","","9040..9066","B*5701","KAALDLSHF","KAALDiSHF","L6I","L87I","OV","observed variant","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","Variant arose on day 32; response unknown.","Goonetilleke2009"
"56632",,"2326","","","","Nef","82","90","","9040..9066","B*5701","{V*****}KAALDLSHF","{l*****}qAALDLSHF","K1Q, V-6L","K82Q, V76L","CM, IE, P","compensatory mutation, inferred escape, processing","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This flanking substitution is predicted to be either a processing escape or a compensatory mutation.","Goonetilleke2009"
"56632",,"2327","","","","Nef","82","90","","9040..9066","B*5701","{V*****}KAALDLSHF","{*****}KgALDLSHF","A2G, V-6L","A83G, V76L","CM, IE, P","compensatory mutation, inferred escape, processing","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This flanking substitution is predicted to be either a processing escape or a compensatory mutation.","Goonetilleke2009"
"56632",,"2328","","","","Nef","82","90","","9040..9066","B*5701","{M**}KAALDLSHF","{**}KAALDLSHF","M-3I","M79I","CM, IE, P","compensatory mutation, inferred escape, processing","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This flanking substitution is predicted to be either a processing escape or a compensatory mutation.","Goonetilleke2009"
"57421","KAF9","2376","B","B","B","Nef","82","90","","9040..9066","B*57","KAAVDLSHF","KgAVDLSHF","A2G","A83G","OV","observed variant","Sequence","One progressor, subject CH-08 carried this KAF9 variant, KgAVDLSHF.","Tang2010"
"57421","KAF9","2377","B","B","B","Nef","82","90","","9040..9066","B*57","KAAVDLSHF","KAAlDLSHF","V4L","V85L","OV","observed variant","Sequence","Variant KAAlDLSHF is seen in one progressor, CH-11.","Tang2010"
"57421","KAF9","2378","B","B","B","Nef","82","90","","9040..9066","B*57","KAAVDLSHF","KrAlDLSHF","A2R, V4L","A83R, V85L","OV","observed variant","Sequence","One progressor, subject CH-10 carried this KAF9 variant, KrAlDLSHF.","Tang2010"
"57421","KAF9","2379","B","B","B","Nef","82","90","","9040..9066","B*57","KAAVDLSHF","KgAlDLSHF","A2G, V4L","A83G, V85L","OV","observed variant","Sequence","KAF9 variant KgAlDLSHF is seen in 1/6 progressors, subject CH-12; and in 3/4 controllers, CH-13, CH-04 and CH-03.","Tang2010"
"57421","KAF9","2380","B","B","B","Nef","82","90","","9040..9066","B*57","KAAVDLSHF","agAlnLSHF","K1A, A2G, V4L, D5N","K82A, A83G, V85L, D86N","OV","observed variant","Sequence","This variant, agVlnLSHF is seen in one controller, subject CH-22.","Tang2010"
"57421","KAF9","2381","B","B","B","Nef","82","90","","9040..9066","B*57","KAAVDLSHF","rgAVDLSHF","K1R, A2G","K82R, A83G","OV","observed variant","Sequence","One progressor, subject CH-01 carried this KAF9 variant, rgAVDLSHF.","Tang2010"
"57874","KF9","2651","C","C","C","Nef","82","90","","9040..9066","B*5801","KAAFDLSFF","KeAFDLSFF","A2E","A83E","E","escape documented in this paper","Longitudinal study","This variant, KeAFDLSFF, was seen in subject CAP217. 1/24, 13/24 and 22/22 sequences carried the variant 2.2, 5.2 and 13.8 months post-infection thus the variant reached KeAFDLSFF reached fixation by 14 months in 1/6 patients.","Chopera2011"
"57874","KF9","2652","C","C","C","Nef","82","90","","9040..9066","B*5801","{Y}KAAFDLSFF","{f}KAAFDLgFF","--1F, S7G","-81F, S88G","E","escape documented in this paper","Longitudinal study, Sequence","This variant, from {Y}KAAFDLSFF to {f}KAAFDLgFF, was seen in subject CAP270.  1/24 and 22/22 sequences carried the variant at 2.9 and 13.3 months post-infection, the variant thus reaching fixation by 14 months.","Chopera2011"
"57874","KF9","2653","C","C","C","Nef","82","90","","9040..9066","B*5801","KAAFDLSFF","KgAFDLSFF","A2G","A83G","E","escape documented in this paper","Longitudinal study","This variant, KgAFDLSFF, was seen in 3 subjects.  In subject CAP217 1/24 sequences carried the variant 5.2 months post-infection; subject CAP229 had all 24/24 sequences with the variant 18.4 months post-infection and subject CAP239 carried the variant in 6/23 sequences 18.2 months post-infection. Thus KgAFDLSFF reached fixation by 19 months in 2/6 patients.","Chopera2011"
"57874","KF9","2748","C","C","C","Nef","82","90","","9040..9066","B*5801","KAAFDLSFF","KgAvDLSFF","A2G, F4V","A83G, F85V","E","escape documented in this paper","Longitudinal study","This variant, KgAvDLSFF, was seen in subject CAP239. 22/24 and 27/23 sequences carried the variant 5.1 and 18.2 months post-infection.","Chopera2011"
"57874","KF9","2749","C","C","C","Nef","82","90","","9040..9066","B*5801","KAAFDLSFF","rAAFDLSFF","K1R","K82R","E","escape documented in this paper","Longitudinal study","This variant, rAAFDLSFF, was seen in subject CAP229. 1/24 sequences carried the variant 5.8 months post-infection.","Chopera2011"
"57874","KF9","2750","C","C","C","Nef","82","90","","9040..9066","B*5801","KAAFDLSFF","KAAvDLSFF","F4V","F85V","E","escape documented in this paper","Longitudinal study","This variant, KAAvDLSFF, was seen in 2 subjects.  In subject CAP217 2/24 sequences carried the variant 2.2 months after infection.  In subject CAP239, all (i.e. 24/24 and 23/23) sequences carried the variant at 0.5 and 1.2 months post-infection.","Chopera2011"
"57874","KF9","2751","C","C","C","Nef","82","90","","9040..9066","B*5801","{Y}KAAFDLSFF","{f}KAAFDLSFF","Y-1F","Y81F","E","escape documented in this paper","Longitudinal study","This variant in flanking sequence of KF9, {f}KAAFDLSFF, was seen in subject CAP270. 24/24 and 23/24 sequences carried the variant 1.8 and 2.9 months post-infection.","Chopera2011"
"57874","KF9","2753","C","C","C","Nef","82","90","","9040..9066","B*5801","KAAFDLSFF","-----LSFF","K1-, A2-, A3-, F4-, D5-","K82-, A83-, A84-, F85-, D86-","E","escape documented in this paper","Longitudinal study, Sequence","This deletion variant,-----LSFF, was seen in subject CAP217.  1/24 sequences carried the variant at 2.2 months post-infection.","Chopera2011"
"58635","KF9","3062","C","C","C","Nef","82","90","","9040..9066","B*57, B*5801","KAAFDLSFF","KgAFDLSFF","A2G","A83G","A, DHB, DR, E","HLA association, diminished HLA binding or increased off-rate, diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","The KgAFDLSFF (A83G) form of the epitope was shown to be an escape mutation by virtue of increased off-rate; and diminished CTL recognition in 3 patients, but ablated recognition by ex-vivo EliSpot. Consensus KF9 in a B*57/5801 negative mother quickly mutates to the variant A83G form when transmitted to B*57/5801 positive infants. This variant form was transmitted and persisted from mother to infant in B*57/5801 positive and B*57/5801 negative pairs.","Leslie2005a"
"58635","KF9","3064","C","C","C","Nef","82","90","","9040..9066","B*57, B*5801","KAAFDLSFF","KgAFgLSFF","A2G, D5G","A83G, D86G","A, OV","HLA association, observed variant","Sequence","The KgAFgLSFF (A83G, D86G) form of the epitope was a variant found in an HLA-B*57/5801 positive child, S30. This variant was found at 9 months postpartum and was transmitted initially from its HLA-B*57/5801 negative KAAFgLSFF (D86G)-carrying mother, S30.","Leslie2005a"
"58635","KF9","3065","C","C","C","Nef","82","90","","9040..9066","B*57, B*5801","KAAFDLSFF","KAAFgLSFF","D5G","D86G","OV","observed variant","Sequence","The KAAFgLSFF (D86G) form of the epitope was a variant found in an HLA-B*57/5801 negative mother, S30 from 6-weeks up to 9 months postpartum.","Leslie2005a"
"58635","KF9","3066","C","C","C","Nef","82","90","","9040..9066","B*57, B*5801","KAAFDLSFF","KgAvDLSFF","A2G, F4V","A83G, F85V","OV, SF","observed variant, susceptible form","Sequence","Variant KgAvDLSFF was found in a mother child pair, both of whom were HLA-B*57/5801 negative. It persisted in the child up to 2 years postpartum.","Leslie2005a"
"52939",,"304","B","","","Nef","82","91","","9040..9069","A2","KAALDLSHFL","KAAvDLSHFL","L4V","L85V","SF","susceptible form","CD8 T-cell Elispot - IFNy","After vaccination with a lipopeptide vaccine and a boost, both the variant and the wild type epitope were recognized.","Gahery-Segard2003"
"59211","KL10","3358","B","B","B","Nef","82","91","",,"B*5701","KAALDLSHFL","KAALDLSHlL","F9L","F90L","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant KAALDLSHlL was seen in 1/3 HRP (patient P2) and 2/3 LRP (patients P4, P6) subjects.","Buggert2014"
"59211","KL10","3359","B","B","B","Nef","82","91","",,"B*5701","KAALDLSHFL","rAALDLSHFL","K1R","K82R","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant rAALDLSHlL was seen in 1/3 LRP (patient P6) and no HRP subjects.","Buggert2014"
"59211","KL10","3360","B","B","B","Nef","82","91","",,"B*5701","KAALDLSHFL","rAALDLSHlL","K1R, F9L","K82R, F90L","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant rAALDLSHlL was seen in no HRP and 1/3 LRP (patient P6) subjects.","Buggert2014"
"59211","KL10","3361","B","B","B","Nef","82","91","",,"B*5701","KAALDLSHFL","rAAvDLSHFL","K1R, L4V","K82R, L85V","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant rAAvDLSHFL was seen in no HRP and 1/3 LRP (patient P6) subjects and was the major analogous epitope at later time points.","Buggert2014"
"59211","KL10","3362","B","B","B","Nef","82","91","",,"B*5701","KAALDLSHFL","KgALDLSHFL","A2G","A83G","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant KgALDLSHFL was seen in 1/3 HRP (patient P3) and 1/3 (patient P4) LRP subjects.  It was the autologous epitope of the major viral population in the later time points for the LRP but the only epitope in the HRP.","Buggert2014"
"59211","KL10","3363","B","B","B","Nef","82","91","",,"B*5701","KAALDLSHFL","KAAvDLSHFL","L4V","L85V","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant KAAvDLSHFL was seen in no HRP and 2/3 LRP subjects.  It was the autologous epitope of the major viral population at the first time point for the patient P6 but was then lost.","Buggert2014"
"53767",,"847","B, CRF01_AE","B","CRF01_AE","Nef","83","90","","9043..9066","B*62","AAVDLSHF","gAfDLSfF","A1G, V3F, H7F","A83G, V85F, H89F","OV","observed variant","Computer prediction","This was the most common variant in CRF01 (17/23 patients). It had a higher binding score to HLA than the wt epitope.","Lazaro2005"
"53767",,"848","B, CRF01_AE","B","CRF01_AE","Nef","83","90","","9043..9066","B*62","AAVDLSHF","gvfDLSfF","A1G, A2V, V3F, H7F","A83G, A84V, V85F, H89F","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53767",,"849","B, CRF01_AE","B","CRF01_AE","Nef","83","90","","9043..9066","B*62","AAVDLSHF","ggfDLSfF","A1G, A2G, V3F, H7F","A83G, A84G, V85F, H89F","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53767",,"850","B, CRF01_AE","B","CRF01_AE","Nef","83","90","","9043..9066","B*62","AAVDLSHF","AAfDLSfF","V3F, H7F","V85F, H89F","OV","observed variant","","Variant found in 2/23 patients infected with CRF01_AE.","Lazaro2005"
"55065","AL9","192","","","","Nef","83","91","","9043..9069","Cw3","AALDMSHFL","AALDiSHFL","M5I","M87I","SF","susceptible form","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Immune responses were examined in monozygotic male twins infected simultaneously with the same virus. AALDiSHFL variant arose in one twin; gALDMSHFL variant arose in the other. Response to AALDiSHFL  variant was as strong as to AALDMSHFL, while response to gALDMSHFL was diminished.","Draenert2006"
"55065","AL9","193","","","","Nef","83","91","","9043..9069","Cw3","AALDMSHFL","gALDMSHFL","A1G","A83G","DR","diminished response","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining","Immune responses were examined in monozygotic male twins infected simultaneously with the same virus. AALDiSHFL variant arose in one twin; gALDMSHFL variant arose in the other. Response to AALDiSHFL  variant was as strong as to AALDMSHFL, while response to gALDMSHFL was diminished.","Draenert2006"
"53718",,"438","B, CRF02_AG","AG","AG, B","Nef","83","91","","9043..9069","A2","AAVDLSHFL","gAfDLSHFL","A1G, V3F","A83G, V85F","OV","observed variant","","The one patient that recognized the wt epitope carried this epitope variant. Substitutions were present in 6/8 CRF02_AG, and 3/5 subtype B infected patients.","Inwoley2005"
"53718",,"439","B, CRF02_AG","","","Nef","83","91","","9043..9069","A2","AAVDLSHFL","eAVDLSHFL","A1E","A83E","OV","observed variant","","The variant was found in 2/9 CRF02_AG infected patients.","Inwoley2005"
"53718",,"440","B, CRF02_AG","","","Nef","83","91","","9043..9069","A2","AAVDLSHFL","gAiDLSHFL","A1G, V3I","A83G, V85I","OV","observed variant","","The variant was found in 1/9 CRF02_AG infected patients.","Inwoley2005"
"53718",,"441","B, CRF02_AG","","","Nef","83","91","","9043..9069","A2","AAVDLSHFL","gAlDLSHFL","A1G, V3L","A83G, V85L","OV","observed variant","","The variant was found in 1/5 subtype B infected patients.","Inwoley2005"
"53718",,"442","B, CRF02_AG","","","Nef","83","91","","9043..9069","A2","AAVDLSHFL","AAlDLSHFL","V3L","V85L","OV","observed variant","","The variant was found in 2/5 subtype B infected patients.","Inwoley2005"
"54564","AL9","649","B","","","Nef","83","91","","9043..9069","A*02","AAVDLSHFL","AAVDiSHFL","L5I","L87I","DR","diminished response","CD8 T-cell Elispot - IFNy","Variant found as a minor population at week 10 (5/16 clones) and dominated viral population at later timepoint. A less intense CTL response targeted this variant than the wt epitope and an increase in viral load was observed. Position under positive selection.","Karlsson2007"
"54564","AL9","650","B","","","Nef","83","91","","9043..9069","A*02","AAVDLSHFL","AAVDirHFL","L5I, S6R","L87I, S88R","IE","inferred escape","CD8 T-cell Elispot - IFNy","Author tabulates this variant found at week 61 in 1/14 clones from patient OP177 as viral escape. No CTL response detected against the variant.","Karlsson2007"
"54564","AL9","651","B","","","Nef","83","91","","9043..9069","A*02","AAVDLSHFL","gAlDLSHFL","A1G, V3L","A83G, V85L","DR, E","diminished response, escape documented in this paper","CD8 T-cell Elispot - IFNy","Variant found as a major population at week 158 in one of the patients, and a less prevalent CTL response against it could be detected. Positions under positive selection. Variant was found in many of the HLA-A2 positive and HLA-A2 negative patients at baseline and follow up timepoints. None of the patients were able to generate a CTL response against autologous virus.","Karlsson2007"
"54564","AL9","652","B","","","Nef","83","91","","9043..9069","A*02","AAVDLSHFL","gArDLSHFL","A1G, V3R","A83G, V85R","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Variant was found in one of the HLA-A2 positive patients at baseline and follow up timepoints. The patient was not able to generate a CTL response against autologous virus.","Karlsson2007"
"54564","AL9","653","B","","","Nef","83","91","","9043..9069","A*02","AAVDLSHFL","gAfDLSfFL","A1G, V3F, H7F","A83G, V85F, H89F","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Variant was found in one of the HLA-A2 negative patients at baseline and follow up timepoints. The patient was not able to generate a CTL response against autologous virus.","Karlsson2007"
"54564","AL9","654","B","","","Nef","83","91","","9043..9069","A*02","AAVDLSHFL","AAlDLSHFL","V3L","V85L","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Variant found at week 109 in 1/13 clones in one of the patients. No CTL response detected against the variant. Variant was also found in two HLA-A2 negative patients at baseline and follow up timepoints. None of the patients were able to generate a CTL response against autologous virus.","Karlsson2007"
"54564","AL9","655","B","","","Nef","83","91","","9043..9069","A*02","AAVDLSHFL","AAiDLSHFL","V3I","V85I","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Variant was found in one of the HLA-A2 negative patients at baseline and follow up timepoints. The patient was not able to generate a CTL response against autologous virus.","Karlsson2007"
"54564","AL9","656","B","","","Nef","83","91","","9043..9069","A*02","AAVDLSHFL","AAlDiSHFL","V3L, L5I","V85L, L87I","DR","diminished response","CD8 T-cell Elispot - IFNy","Variant found at weeks 109 and 158. A less intense CTL response targeted this variant than the wt epitope and an increase in viral load was observed.","Karlsson2007"
"54564","AL9","657","B","","","Nef","83","91","","9043..9069","A*02","AAVDLSHFL","AAlDiSHlL","V3L, L5I, F8L","V85L, L87I, F90L","IE","inferred escape","CD8 T-cell Elispot - IFNy","Author tabulates this variant found at week 109 in 1/13 clones in patient OP177 as viral escape. No CTL response detected against the variant.","Karlsson2007"
"54564","AL9","658","B","","","Nef","83","91","","9043..9069","A*02","AAVDLSHFL","kAlDLSHFL","A1K, V3L","A83K, V85L","IE","inferred escape","CD8 T-cell Elispot - IFNy","Author tabulates this variant found at week 109 in 1/13 clones from patient OP177 as viral escape. No CTL response detected against the variant.","Karlsson2007"
"54564","AL9","659","B","","","Nef","83","91","","9043..9069","A*02","AAVDLSHFL","gAVDLSHFL","A1G","A83G","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Variant found in two HLA-A2 positive patients at baseline timepoint and none of the patients were able to generate a CTL response against autologous virus.","Karlsson2007"
"53766",,"851","B, CRF01_AE","B","CRF01_AE","Nef","83","91","","9043..9069","A*02","AAVDLSHFL","gAfDLSfFL","A1G, V3F, H7F","A83G, V85F, H89F","OV","observed variant","Computer prediction","This was the most common variant in CRF01 (17/23 patients). It had a higher binding score to HLA than the wt epitope.","Lazaro2005"
"53766",,"852","B, CRF01_AE","B","CRF01_AE","Nef","83","91","","9043..9069","A*02","AAVDLSHFL","gvfDLSfFL","A1G, A2V, V3F, H7F","A83G, A84V, V85F, H89F","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53766",,"853","B, CRF01_AE","B","CRF01_AE","Nef","83","91","","9043..9069","A*02","AAVDLSHFL","ggfDLSfFL","A1G, A2G, V3F, H7F","A83G, A84G, V85F, H89F","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53766",,"854","B, CRF01_AE","B","CRF01_AE","Nef","83","91","","9043..9069","A*02","AAVDLSHFL","AAfDLSfFL","V3F, H7F","V85F, H89F","OV","observed variant","","Variant found in 2/23 patients infected with CRF01_AE.","Lazaro2005"
"54541","AL9","1030","B","B","B","Nef","83","91","","9043..9069","B62, Cw8","AAVDLSHFL","gAVDLSHFL","A1G","A83G","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant was found by challenge of 23 subjects with a novel Nef potential T-cell epitope panel in Subtype B.  It was recognized by an HLA-B62- (Subject 1212) and an HLA-Cw08-restricted (Subject 1238) response.","Malhotra2007a"
"54541","AL9","1031","B","B","B","Nef","83","91","","9043..9069","B62, Cw8","AAVDLSHFL","AAiDLSHFL","V3I","V85I","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant was found by challenge of 23 subjects with a novel Nef potential T-cell epitope panel in Subtype B.  It was recognized by an HLA-B62- (Subject 1212) and an HLA-Cw08-restricted (Subject 1238) response.","Malhotra2007a"
"54541","AL9","1032","B","B","B","Nef","83","91","","9043..9069","B62, Cw8","AAVDLSHFL","AAlDLSHFL","V3L","V85L","DR, SF","diminished response, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant was found by challenge of 23 subjects with a novel Nef potential T-cell epitope panel in Subtype B.  It was recognized by an HLA-B62- (Subject 1212) response.  HLA-Cw08-restricted CTL response (Subject 1238) was detected, but at 114-fold lower avidity.","Malhotra2007a"
"54541","AL9","1033","B","B","B","Nef","83","91","","9043..9069","B62, Cw8","AAVDLSHFL","gAlDLSHFL","A1G, V3L","A83G, V85L","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence","This variant was found by challenge of 23 subjects with a novel Nef potential T-cell epitope panel in Subtype B.  HLA-B62-restricted CTL response (Subject 1212) was detected but at 92-fold lower avidity.  HLA-Cw08-restricted CTL response (Subject 1238) was detected by at 25-fold lower avidity.","Malhotra2007a"
"54541","AL9","1034","B","B","B","Nef","83","91","","9043..9069","B62, Cw8","AAVDLSHFL","gAfDLSHFL","A1G, V3F","A83G, V85F","DR, NSF","diminished response, non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant was found by challenge of 23 subjects with a novel Nef potential T-cell epitope panel in Subtype B.  HLA-B62-restricted CTL response (Subject 1212) was detected but at 166-fold lower avidity.  HLA-Cw08-restricted CTL response (Subject 1238) was not detected.","Malhotra2007a"
"55468",,"1400","B, C, CRF02_AG, A1","A, AG, B, C","A, AG, B","Nef","83","91","","9043..9069","A2","GALDLSHFL","aAvDLSHFL","G1A, L3V","G83A, L85V","SF, SSF","susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This epitope and variant were cross-recognized by 5 subjects infected with Subtypes A, B, CRF02_AG.  A Subtype C carrying subject recognized GALDLSHFL alone.","Perez2008"
"53848","AL9","1580","","","","Nef","83","91","","9043..9069","A2","AAVDLSHFL","AAVDmSHFL","L5M","L87M","DR, LE","diminished response, literature escape","CD8 T-cell Elispot - IFNy, Sequence","This variant from the HXB2 sequence was present in the non-HLA-A2 allele carrying mother, M-1002, as well as her restricting-HLA-A2-carrying infant, P-1031.   The variant was still detected at 12 months of age in infant P-1031.  Decreased recognition of the variant was seen relative to index epitope, in time.","Sanchez-Merino2005"
"53848","AL9","1581","","","","Nef","83","91","","9043..9069","A2","AAVDLSHFL","gAlDLSHFL","A1G, V3L","A83G, V85L","OV","observed variant","Sequence","This variant from the HXB2 sequence was present in the restricting HLA-A2 allele carrying mother, M-1005, as well as her non-HLA-A2-carrying infant, P-1026.   The variant was still detected at 15 months of age in infant P-1026.","Sanchez-Merino2005"
"55901","GL9(Nef)","1944","B","B","B","Nef","83","91","","9043..9069","","GALDLSFFL","GAfDLSFFL","L3F","L85F","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-A2 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"57250","AL9","2238","B","B","B","Nef","83","91","","9043..9069","Cw*08","AAVDLSHFL","AAiDLSHFL","V3I","V85I","SF","susceptible form","CD8 T-cell Elispot granzyme B, CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Proliferation","This variant was recognized by IFNg EliSpot, Granzyme B EliSpot, and flow cytometry in one newly infected patient and by IFN- EliSpot and T-cell proliferation in another newly infected patient.","Malhotra2009"
"57250","AL9","2239","B","B","B","Nef","83","91","","9043..9069","Cw*08","AAVDLSHFL","gAVDLSHFL","A1G","A83G","SF","susceptible form","CD8 T-cell Elispot granzyme B, CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Proliferation","This variant was recognized by IFNg EliSpot, Granzyme B EliSpot, and flow cytometry in one newly infected patient and by IFN- EliSpot and T-cell proliferation in another newly infected patient.","Malhotra2009"
"57250","AL9","2240","B","B","B","Nef","83","91","","9043..9069","Cw*08","AAVDLSHFL","AAlDLSHFL","V3L","V85L","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot granzyme B, CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Proliferation","This variant had semi-conservative substitution in presumed TCR contact site and was not recognized by IFNg EliSpot, nor by Granzyme B EliSpot, in one newly infected patient. However, it was recognized by IFN-&gamma; EliSpot and T-cell proliferation in another newly infected patient.","Malhotra2009"
"57250","AL9","2241","B","B","B","Nef","83","91","","9043..9069","Cw*08","AAVDLSHFL","gAlDLSHFL","A1G, V3L","A83G, V85L","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot granzyme B, CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Proliferation","This variant had semi-conservative substitution in presumed TCR contact site and was not recognized by IFN&gamma; EliSpot, nor by Granzyme B EliSpot, in one newly infected patient. However, it was recognized by IFN-&gamma;EliSpot and T-cell proliferation in another newly infected patient.","Malhotra2009"
"57250","AL9","2242","B","B","B","Nef","83","91","","9043..9069","Cw*08","AAVDLSHFL","gAfDLSHFL","A1G, V3F","A83G, V85F","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot granzyme B, CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Proliferation","This variant had semi-conservative substitution in presumed TCR contact site and was not recognized by IFNg EliSpot, nor by Granzyme B EliSpot, in one newly infected patient. However, it was recognized by IFN-&gamma; EliSpot and T-cell proliferation in another newly infected patient.","Malhotra2009"
"54546","AK10","1035","B","B","B","Nef","83","92","","9043..9072","A11","AAVDLSHFLK","vAlDLSHFLK","A1V, V3L","A83V, V85L","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant was found by challenge of 23 subjects with a novel Nef potential T-cell epitope panel in Subtype B.","Malhotra2007a"
"53735",,"443","B, CRF02_AG","AG","AG, B","Nef","84","91","","9046..9069","B62","AVDLSHFL","AfDLSHFL","V2F","V85F","OV","observed variant","","The two CRF02_AG subjects that recognized the wt peptide carried this variant sequence. Variant forms were present in 4/8 CRF02_AG and 3/5 subtype B infected patients.","Inwoley2005"
"53735",,"444","B, CRF02_AG","","","Nef","84","91","","9046..9069","B62","AVDLSHFL","AiDLSHFL","V2I","V85I","OV","observed variant","","The variant was found in 1/9 CRF02_AG infected patients.","Inwoley2005"
"53735",,"445","B, CRF02_AG","","","Nef","84","91","","9046..9069","B62","AVDLSHFL","AlDLSHFL","V2L","V85L","OV","observed variant","","The variant was found in 3/5 subtype B infected patients.","Inwoley2005"
"1007",,"129","B","","","Nef","84","92","","9046..9072","A11","AVDLSHFLK","AfDLSHFLr","V2F, K9R","V85F, K92R","DHB","diminished HLA binding or increased off-rate","Chromium-release assay, HLA binding","AfDLSHFLr and ArDLSHFLK mutations abrogated HLA-A11 binding. V to L substitution (AlDLSHFLK) in the second position of the epitope did not influence recognition by HLA-A11 restricted CTL.","Goulder1997e, Couillin1994"
"1007",,"130","B","","","Nef","84","92","","9046..9072","A11","AVDLSHFLK","ArDLSHFLK","V2R","V85R","DHB","diminished HLA binding or increased off-rate","Chromium-release assay, HLA binding","AfDLSHFLr and ArDLSHFLK mutations abrogated HLA-A11 binding. V to L substitution (AlDLSHFLK) in the second position of the epitope did not influence recognition by HLA-A11 restricted CTL.","Goulder1997e, Couillin1994"
"1007",,"131","B","","","Nef","84","92","","9046..9072","A11","AVDLSHFLK","AlDLSHFLK","V2L","V85L","SF","susceptible form","Chromium-release assay, HLA binding","AfDLSHFLr and ArDLSHFLK mutations abrogated HLA-A11 binding. V to L substitution (AlDLSHFLK) in the second position of the epitope did not influence recognition by HLA-A11 restricted CTL.","Goulder1997e, Couillin1994"
"52103",,"300","B, CRF01_AE","B","B, C, CRF01_AE","Nef","84","92","","9046..9072","A*1101","AVDLSHFLK","AfDLSfFLK","V2F, H6F","V85F, H89F","DHB, SNSF","diminished HLA binding or increased off-rate, subtype-specific non-susceptible form","Chromium-release assay, HLA binding","Variant found predominantly in clades C and E. Variant-specific CTL clones from subtype B recognized wildtype but not the V/F, H/F variant. Binding affinity of the variant to A*1101 was 10-50 times lower than that of wildtype and V/L variant.","Fukada2002"
"53729",,"446","B, CRF02_AG","B","AG, B","Nef","84","92","","9046..9072","A11, A3","AVDLSHFLK","AlDLSHFLK","V2L","V85L","OV","observed variant","","One of the two subtype B subjects that recognized the wt peptide carried this variant sequence. This variant was present in 3/5 subtype B infected patients. 4/8 of CRF02_AG infected patients carried a variant of the epitope.","Inwoley2005"
"53729",,"447","B, CRF02_AG","B","B","Nef","84","92","","9046..9072","A11, A3","AVDLSHFLK","AfDLSHFLK","V2F","V85F","DHB","diminished HLA binding or increased off-rate","","Two subtype B subjects that recognized the wt peptide carried this variant sequence. Mutation impaired HLA binding.","Inwoley2005"
"53729",,"448","B, CRF02_AG","","","Nef","84","92","","9046..9072","A11, A3","AVDLSHFLK","AiDLSHFLK","V2I","V85I","OV","observed variant","","The variant was found in 1/9 CRF02_AG infected patients.","Inwoley2005"
"55471",,"1401","B, D, A1","A, B, D","A, B, D","Nef","84","92","","9046..9072","","AVDLSHFLK","AlDLSHFLK","V2L","V85L","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This epitope and variant were recognized by subjects infected with Subtypes A1, B, D.","Perez2008"
"55471",,"1402","B, D, A1","A, B, D","A, AE, C, D","Nef","84","92","","9046..9072","","AVDLSHFLK","AfDLSfFLK","V2F, H6F","V85F, H89F","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Subjects infected with Subtype B cross-recognized these variants.  Variant AfDLSfFLK was recognized by subjects carrying Subtypes C and CRF02_AE.","Perez2008"
"53849","AK9","1582","","","","Nef","84","92","","9046..9072","A3","AVDLSHFLK","AmDLSHFLK","V2M","V85M","OV","observed variant","Sequence","This variant from the HXB2 sequence was present in the restricting HLA-A3 allele carrying mother, M-1001, as well as her HLA-A*31-carrying infant, P-1024.  Infant P-1024 had lost this variant by 15 months of age.","Sanchez-Merino2005"
"55915","AK10(Nef)","1945","B","B","B","Nef","84","92","","9046..9072","","ALDLSHFLK","AvDLSHFLK","L2V","L85V","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-A3 and -A11 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"57495","AK9","2504","B, D, A1","A1, B, D","A1, B, D","Nef","84","92","","9046..9072","","AVDLSHFLK","AlDLSHFLK","V2L","V85L","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","AK9 variant, AlDLSHFLK, was the autologous form for patients 2632 and 2840 who had a CTL response to this peptide.  Patient 2275 did not have a CTL response to this variant.","Hoof2010"
"57495","AK9","2505","B, D, A1","A1, B, D","A1, D","Nef","84","92","","9046..9072","","AVDLSHFLK","AVDLgHFLK","S5G","S88G","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","AK9 variant, AVDLgHFLK elicited CTL response in patients 2632 and 2840.  Patient 2275 did not have a CTL response to this variant.","Hoof2010"
"57495","AK9","2506","B, D, A1","A1, B, D","A1, D","Nef","84","92","","9046..9072","","AVDLSHFLK","AVDLaHFLK","S5A","S88A","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","AK9 variant, AVDLaHFLK, elicited CTL response in patients 2632 and 2840.  Patient 2275 did not have a CTL response to this variant.","Hoof2010"
"57495","AK9","2508","B, D, A1","A1, B, D","","Nef","84","92","","9046..9072","","AVDLSHFLK","AVDLSfFLK","H6F","H89F","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","AK9 variant, AVDLSfFLK, was not able to elicit CTL response in any of the patients tested - 2632, 2840 and 2275.","Hoof2010"
"57495","AK9","2510","B, D, A1","A1, B, D","","Nef","84","92","","9046..9072","","AVDLSHFLK","AVDLSaFLK","H6A","H89A","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","AK9 variant, AVDLSaFLK, was not able to elicit CTL response in any of the patients tested - 2632, 2840 and 2275.","Hoof2010"
"57495","AK9","2511","B, D, A1","A1, B, D","D","Nef","84","92","","9046..9072","","AVDLSHFLK","AVDaSHFLK","V2L","V85L","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","AK9 variant, AVDaSHFLK, elicited a CTL response to this peptide in patient 2840 only.  Patients 2632 and 2275 did not have a CTL response to this variant.","Hoof2010"
"57495","AK9","2512","B, D, A1","A1, B, D","D","Nef","84","92","","9046..9072","","AVDLSHFLK","AfDLSfFLK","V2F, H6F","V85F, H89F","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","AK9 variant, AfDLSfFLK, was the autologous form in patient 2275 in whom it was able to elicit CTL response. Patients 2632 and 2840 did not show any response to this variant.","Hoof2010"
"57647","Nef84","2570","B","B","B","Nef","84","92","","9046..9072","A*1101","AVDLSHFLK","AVDLSHFLr","K9R","K92R","E","escape documented in this paper","Intracellular cytokine staining, Relative replication capacity assay, Tetramer binding","The frequency of the AVDLSHFLr variant was significantly higher in A*1101-positive individuals than A*1101-negative ones. AVDLSHFLK-specific CTLs failed to suppress replication of the mutant.","Koizumi2010"
"57695","Nef84-2L","2588","B","B","B","Nef","84","92","","9046..9072","A*1101","ALDLSHFLK","ALDLSHFLr","K9R","K92R","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding, Intracellular cytokine staining, Relative replication capacity assay, Tetramer binding","9R mutation was significantly enriched in HLA-A*1101-positive individuals.  N84-2L-specific CTL clones could not recognize cells infected with Nef84-2L9R, confirming 9R to be an escape mutation, but 9R mutation did not influence the level of PD-1 on Nef84-specific CD8+ T cells.","Koizumi2010"
"53768",,"855","B, CRF01_AE","B","CRF01_AE","Nef","86","94","","9052..9078","A*03, A*11","DLSHFLKEK","DLSfFLKEK","H4F","H89F","OV","observed variant","Computer prediction","This was the most common variant in CRF01 (18/23 patients). It had the same binding score to HLA as the wt epitope.","Lazaro2005"
"53768",,"856","B, CRF01_AE","B","CRF01_AE","Nef","86","94","","9052..9078","A*03, A*11","DLSHFLKEK","DLSfFLiEK","H4F, K7I","H89F, K92I","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53768",,"857","B, CRF01_AE","B","CRF01_AE","Nef","86","94","","9052..9078","A*03, A*11","DLSHFLKEK","DLSfFLrEK","H4F, K7R","H89F, K92R","OV","observed variant","","Variant found in 2/23 patients infected with CRF01_AE.","Lazaro2005"
"53768",,"858","B, CRF01_AE","B","CRF01_AE","Nef","86","94","","9052..9078","A*03, A*11","DLSHFLKEK","DLSfFLKEq","H4F, K9Q","H89F, K94Q","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53768",,"859","B, CRF01_AE","B","CRF01_AE","Nef","86","94","","9052..9078","A*03, A*11","DLSHFLKEK","DLSfFLrEq","H4F, K7R, K9Q","H89F, K92R, K94Q","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"1013",,"590","","H","A, CRF01_AE, G","Nef","87","102","","9055..9102","","FSHFLKEKGGLEGLIY","lSHFLKEKGGLdGLIY","F1L, E12D","F87L, E98D","OV","observed variant","","CTL epitope region conserved among HIV-1 M group subtypes. The variant was found in subtypes A, E and G.","Jubier-Maurin1999"
"1013",,"591","","H","B","Nef","87","102","","9055..9102","","FSHFLKEKGGLEGLIY","lSHFLKEKGGLEGLIY","F1L","F87L","OV","observed variant","","CTL epitope region conserved among HIV-1 M group subtypes. The variant was found in subtype B, the wt was from subtype H.","Jubier-Maurin1999"
"1013",,"592","","H","D","Nef","87","102","","9055..9102","","FSHFLKEKGGLEGLIY","lSHFLKEKGGLEGLIw","F1L, Y16W","F87L, Y102W","OV","observed variant","","CTL epitope region conserved among HIV-1 M group subtypes. The variant was found in subtype D.","Jubier-Maurin1999"
"1013",,"593","","H","C, CRF01_AE, G","Nef","87","102","","9055..9102","","FSHFLKEKGGLEGLIY","lSfFLKEKGGLEGLIY","F1L, H3F","F87L, H89F","OV","observed variant","","CTL epitope region conserved among HIV-1 M group subtypes. The variant was found in subtypes C, E, and G.","Jubier-Maurin1999"
"52137",,"406","C","B","C","Nef","88","100","","9058..9096","","SHFLKEKGGLEGL","SfFLKEKGGLEGL","H2F","H89F","OV","observed variant","","The variant was observed in most subtype C infected individuals while the regular epitope was found in subtype B.","Guimaraes2002"
"54643","NEF-13","1974","B","B","C","Nef","88","105","","9058..9111","","SHFLKEKGGLEGLIYSQK","SfFLKEKGGLEGLIYSkK","Q17K, H2F","Q104K, H89F","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 2 amino acids (11.1%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"53156",,"145","B","","","Nef","90","97","","9064..9087","B8","FLKEKGGL","FLKEnGGL","K5N","K94N","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","","Immediately after infection the susceptible epitope FLKEKGGL was found in 20/20 viral sequences. Six months later, it was only found in 4/44 sequences. The FLKEnGGL form was most common, 24/44 cases; it bound poorly to HLA B08 and was poorly recognized by CTL.","daSilva2003"
"53156",,"146","B","","","Nef","90","97","","9064..9087","B8","FLKEKGGL","FLKEeGGL","K5E","K94E","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","","Immediately after infection the susceptible epitope FLKEKGGL was found in 20/20 viral sequences. Six months later, it was only found in 4/44 sequences.  Two minor variants were found 3/44 times, FLKEeGGL and FLKEqGGL; both bound poorly to B08, but the K->Q substitution was still well recognized.","daSilva2003"
"53156",,"148","B","","","Nef","90","97","","9064..9087","B8","FLKEKGGL","FLKEqGGL","K5Q","K94Q","SF","susceptible form","","Immediately after infection the susceptible epitope FLKEKGGL was found in 20/20 viral sequences. Six months later, it was only found in 4/44 sequences.  Two minor variants were found 3/44 times, FLKEeGGL and FLKEqGGL; both bound poorly to B08, but the K->Q substitution was still well recognized.","daSilva2003"
"53156",,"149","B","","","Nef","90","97","","9064..9087","B8","FLKEKGGL","FLKdKGGL","E4D","E93D","DR","diminished response","","Immediately after infection the susceptible epitope FLKEKGGL was found in 20/20 viral sequences. Six months later, it was only found in 4/44 sequences. A variant FLKdKGGL was found in 4/44 sequences; it bound B08 moderately well, but was poorly recognized.","daSilva2003"
"53156",,"151","B","","","Nef","90","97","","9064..9087","B8","FLKEKGGL","FLeEnGGL","K3E, K5N","K92E, K94N","NSF","non-susceptible form","","Immediately after infection the susceptible epitope FLKEKGGL was found in 20/20 viral sequences. Six months later, it was only found in 4/44 sequences.  3 double mutants were found once each, and were not recognized by CTL: FLKEnGGL, FLeEnGGL, and FLKgnGGL.","daSilva2003"
"53156",,"152","B","","","Nef","90","97","","9064..9087","B8","FLKEKGGL","FLKgnGGL","E4G, K5N","E93G, K94N","NSF","non-susceptible form","","Immediately after infection the susceptible epitope FLKEKGGL was found in 20/20 viral sequences. Six months later, it was only found in 4/44 sequences.  3 double mutants were found once each, and were not recognized by CTL: FLKEnGGL, FLeEnGGL, and FLKgnGGL.","daSilva2003"
"53190","FL8","166","","","","Nef","90","97","","9064..9087","B*0801","FLKEKGGL","FLKEtGGL","K5T","K94T","E, SF, TCR","escape documented in this paper, susceptible form, TCR related mutation","CD8 T-cell Elispot - IFNy, Chromium-release assay, Flow cytometric T-cell cytokine assay, Tetramer binding","The Q5 variant flkeQggl was rapidly selected in a donor that responded to the FLKEKGGL epitope. The FLKEKGGL peptide and the variant flkeQggl HLA-B8 complexes bound to the Vbeta13.2 FLKEKGGL TCR with equal affinity, while the Vbeta6 FLKEKGGL TCR had reduced affinity for the FLKEKGGL form and did not recognize the Q5 variant. Other variants (T5, N5, and M5 as well as Q5) were recognized by Vbeta13.2 clones from all 4 donors. One clone from donor 046 that was not Vbeta13.2 could only recognize the index variant.","Dong2004"
"53190","FL8","167","","","","Nef","90","97","","9064..9087","B*0801","FLKEKGGL","FLKEnGGL","K5N","K94N","E, SF, TCR","escape documented in this paper, susceptible form, TCR related mutation","CD8 T-cell Elispot - IFNy, Chromium-release assay, Flow cytometric T-cell cytokine assay, Tetramer binding","The Q5 variant flkeQggl was rapidly selected in a donor that responded to the FLKEKGGL epitope. The FLKEKGGL peptide and the variant flkeQggl HLA-B8 complexes bound to the Vbeta13.2 FLKEKGGL TCR with equal affinity, while the Vbeta6 FLKEKGGL TCR had reduced affinity for the FLKEKGGL form and did not recognize the Q5 variant. Other variants (T5, N5, and M5 as well as Q5) were recognized by Vbeta13.2 clones from all 4 donors. One clone from donor 046 that was not Vbeta13.2 could only recognize the index variant.","Dong2004"
"53190","FL8","168","","","","Nef","90","97","","9064..9087","B*0801","FLKEKGGL","FLKEmGGL","K5M","K94M","E, SF, TCR","escape documented in this paper, susceptible form, TCR related mutation","CD8 T-cell Elispot - IFNy, Chromium-release assay, Flow cytometric T-cell cytokine assay, Tetramer binding","The Q5 variant flkeQggl was rapidly selected in a donor that responded to the FLKEKGGL epitope. The FLKEKGGL peptide and the variant flkeQggl HLA-B8 complexes bound to the Vbeta13.2 FLKEKGGL TCR with equal affinity, while the Vbeta6 FLKEKGGL TCR had reduced affinity for the FLKEKGGL form and did not recognize the Q5 variant. Other variants (T5, N5, and M5 as well as Q5) were recognized by Vbeta13.2 clones from all 4 donors. One clone from donor 046 that was not Vbeta13.2 could only recognize the index variant.","Dong2004"
"53190","FL8","169","","","","Nef","90","97","","9064..9087","B*0801","FLKEKGGL","FLKEqGGL","K5Q","K94Q","E, SF, TCR","escape documented in this paper, susceptible form, TCR related mutation","CD8 T-cell Elispot - IFNy, Chromium-release assay, Flow cytometric T-cell cytokine assay, Tetramer binding","The Q5 variant flkeQggl was rapidly selected in a donor that responded to the FLKEKGGL epitope. The FLKEKGGL peptide and the variant flkeQggl HLA-B8 complexes bound to the Vbeta13.2 FLKEKGGL TCR with equal affinity, while the Vbeta6 FLKEKGGL TCR had reduced affinity for the FLKEKGGL form and did not recognize the Q5 variant. Other variants (T5, N5, and M5 as well as Q5) were recognized by Vbeta13.2 clones from all 4 donors. One clone from donor 046 that was not Vbeta13.2 could only recognize the index variant.","Dong2004"
"53722","BRU","449","B, CRF02_AG","AG","AG","Nef","90","97","","9064..9087","A2, B8","FLKEKGGL","FLKEqGGL","K5Q","K94Q","OV","observed variant","","One CRF02_AG subject that recognized the wt peptide carried this variant sequence. The variant was found in 1/9 CRF02_AG infected patients.","Inwoley2005"
"54172","FL8","997","B","","","Nef","90","97","","9064..9087","B8","FLKEKGGL","FLKEeGGL","K5E","K94E","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Presumed escape variant was transmitted from a B8 positive donor to a B8 negative recipient. The variant was not recognized by CTLs.","Liu2006"
"54172","FL8","998","B","","","Nef","90","97","","9064..9087","B8","FLKEKGGL","FLKEgGGL","K5G","K94G","OV","observed variant","","Variant was found in 2/26 clones in the patient at sampling times 76 and 113.","Liu2006"
"54172","FL8","999","B","","","Nef","90","97","","9064..9087","B8","FLKEKGGL","FLKgeGGL","E4G, K5E","E93G, K94E","OV","observed variant","","Variant was found in 1/39 clones in the patient at sampling times 8, 22 and 50.","Liu2006"
"54172","FL8","1001","B","","","Nef","90","97","","9064..9087","B8","FLKEKGGL","FLKveGGL","E4V, K5E","E93V, K94E","OV","observed variant","","Variant was found in 2/10 clones in the patient at sampling time 23.","Liu2006"
"55750","FL8","1092","B","","","Nef","90","97","","9064..9087","B*08","FLKEKGGL","FLrEKGGL","K3R","K92R","DR","diminished response","CD8 T-cell Elispot - IFNy","Partial escape with diminished recognition was seen when CTL were challenged with this synthetic peptide-epitope.","Maurer2008"
"55750","FL8","1093","B","","","Nef","90","97","","9064..9087","B*08","FLKEKGGL","FLrdKGGL","K3R, E4D","K92R, E93D","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","This double mutation synthetic variant was not recognized by CTL.","Maurer2008"
"55750","FL8","1094","B","","","Nef","90","97","","9064..9087","B*08","FLKEKGGL","FLKErGGL","K5R","K94R","DR","diminished response","CD8 T-cell Elispot - IFNy","Partial escape with diminished recognition was seen when CTL were challenged with this synthetic peptide-epitope.","Maurer2008"
"55750","FL8","1095","B","","","Nef","90","97","","9064..9087","B*08","FLKEKGGL","FLrkeGGL","K3R, E4K, K5E","K92R, E93K, K94E","OV","observed variant","CD8 T-cell Elispot - IFNy","Mutation found within B*08-positive patients","Maurer2008"
"55750","FL8","1096","B","","","Nef","90","97","","9064..9087","B*08","FLKEKGGL","FLKEqGGL","K5Q","K94Q","DR, SF","diminished response, susceptible form","CD8 T-cell Elispot - IFNy","Peptide titration indicated that this variant was a partial escape, with a 2-fold decrease in recognition.  This variant was the autologous sequence in 2/5 subjects.","Maurer2008"
"55750","FL8","1097","B","","","Nef","90","97","","9064..9087","B*08","FLKEKGGL","FLKEmGGL","K5M","K94M","DR","diminished response","CD8 T-cell Elispot - IFNy","Partial escape with diminished recognition was seen for this variant that was the autologous sequence in 1/5 subjects.","Maurer2008"
"55750","FL8","1098","B","","","Nef","90","97","","9064..9087","B*08","FLKEKGGL","FLKEnGGL","K5N","K94N","DR","diminished response","CD8 T-cell Elispot - IFNy","Partial escape with diminished recognition was seen for this variant that was the autologous sequence in 1/5 subjects.","Maurer2008"
"55750","FL8","1099","B","","","Nef","90","97","","9064..9087","B*08","FLKEKGGL","FLKEtGGL","K5T","K94T","DR","diminished response","CD8 T-cell Elispot - IFNy","Partial escape with diminished recognition was seen for this variant that was the autologous sequence in 1/5 subjects.","Maurer2008"
"53825",,"1314","B","","","Nef","90","97","","9064..9087","B*0801","FLKEKGGL","FLKEqGGL","K5Q","K94Q","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","This variant was found in Donor2 and Recipient2, both of whom carried the restricting HLA-B*0801 allele.  The variant was not recognized by CTL in Donor2, but was recognized in Recipient2 from whom it was driven out de novo in time.","Milicic2005"
"1375","FLK","1348","","","","Nef","90","97","","9064..9087","B8","FLKEKGGL","FLKEnGGL","K5N","K94N","IE","inferred escape","CD8 T-cell Elispot - IFNy, Sequence, Tetramer binding","Initial immunodominant response for Patient SC2 was against epitope FLK but upon ceasing HAART, recognition of the index epitope was abrogated, concomitant with emergence of the mutant epitope in 8/10 clones sequenced. ELISpot was measured using the index peptide.","Oxenius2000b"
"1015",,"1431","B","","","Nef","90","97","","9064..9087","B*08","FLKEKGGL","FLKEqGGL","K5Q","K94Q","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","Chromium-release assay, HLA binding","Reduced binding and recognition","Goulder1997e, Price1997"
"1015",,"1432","B","","","Nef","90","97","","9064..9087","B*08","FLKEKGGL","FLKEeGGL","K5E","K94E","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","Chromium-release assay, HLA binding","Reduced binding, recognition","Goulder1997e, Price1997"
"1015",,"1433","B","","","Nef","90","97","","9064..9087","B*08","FLKEKGGL","FLKEnGGL","K5N","K94N","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","Chromium-release assay, HLA binding","Reduced binding, recognition","Goulder1997e, Price1997"
"1015",,"1434","B","","","Nef","90","97","","9064..9087","B*08","FLKEKGGL","FLKdKGGL","E4D","E93D","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","Chromium-release assay, HLA binding","Reduced binding, recognition","Goulder1997e, Price1997"
"1015",,"1435","B","","","Nef","90","97","","9064..9087","B*08","FLKEKGGL","sLKEKGGL","F1S","F90S","SF","susceptible form","HLA binding","Variant recognized robustly","Goulder1997e, Price1997"
"1015",,"1436","B","","","Nef","90","97","","9064..9087","B*08","FLKEKGGL","lLKEKGGL","F1L","F90L","SF","susceptible form","HLA binding","Variant recognized robustly","Goulder1997e, Price1997"
"1015",,"1437","B","","","Nef","90","97","","9064..9087","B*08","FLKEKGGL","FiKEnGGL","L2I, K5N","L91I, K94N","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","HLA binding","Escaped recognition completely","Goulder1997e, Price1997"
"1015",,"1438","B","","","Nef","90","97","","9064..9087","B*08","FLKEKGGL","FLeEnGGL","K3E, K5N","K92E, K94N","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","HLA binding","Escaped recognition completely","Goulder1997e, Price1997"
"1015",,"1439","B","","","Nef","90","97","","9064..9087","B*08","FLKEKGGL","FLKgnGGL","E4G, K5N","E93G, K94N","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","HLA binding","Escaped recognition completely","Goulder1997e, Price1997"
"55006","FLK","1819","","","","Nef","90","97","","9064..9087","B*0801","FLKEKGGL","FLKEqGGL","K5Q","K94Q","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","One patient had response comparable to the response to the index peptide, other had reduced or no response.","Turnbull2006"
"55006","FLK","1820","","","","Nef","90","97","","9064..9087","B*0801","FLKEKGGL","FLKEtGGL","K5T","K94T","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","One patient had response comparable to the response to the index peptide, other had reduced or no response.","Turnbull2006"
"55006","FLK","1821","","","","Nef","90","97","","9064..9087","B*0801","FLKEKGGL","FLKEnGGL","K5N","K94N","DR, NSF","diminished response, non-susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","All patients tested had either no response or response &lt; 40% of response to the index peptide.","Turnbull2006"
"55006","FLK","1822","","","","Nef","90","97","","9064..9087","B*0801","FLKEKGGL","FLKEmGGL","K5M","K94M","DR, NSF, SF","diminished response, non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","All patients tested had either no response or response &lt; 70% of response to the index peptide.","Turnbull2006"
"55006","FLK","1823","","","","Nef","90","97","","9064..9087","B*0801","FLKEKGGL","FLKEeGGL","K5E","K94E","DR, NSF","diminished response, non-susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","All patients tested had either no response or response &lt; 40% of response to the index peptide.","Turnbull2006"
"55006","FLK","1824","","","","Nef","90","97","","9064..9087","B*0801","FLKEKGGL","FLrEKGGL","K3R","K92R","DR, NSF","diminished response, non-susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","All patients tested had either no response or response &lt; 60% of response to the index peptide.","Turnbull2006"
"55006","FLK","1825","","","","Nef","90","97","","9064..9087","B*0801","FLKEKGGL","FLKdKGGL","E4D","E93D","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Tetramer binding","One patient responded at the level of the response to the index peptide, Other patients had &lt; 40% of original response.","Turnbull2006"
"54172","FL8","2259","B","","","Nef","90","97","","9064..9087","B8","FLKEKGGL","cLKEKGGL","F1C","F90C","OV","observed variant","","Variant was found in 1/68 clones in the patient at several latter sampling times.","Liu2006"
"54172","FL8","2260","B","","","Nef","90","97","","9064..9087","B8","FLKEKGGL","sLKEKGGL","F1S","F90S","OV","observed variant","","Variant was found in 1/68 clones in the patient at several latter sampling times.","Liu2006"
"54172","FL8","2275","B","","","Nef","90","97","","9064..9087","B8","FLKEKGGL{E}","FLKEeGGL{p}","E+1P, K5E","E98P, K94E","OV","observed variant","","Reversion variant was observed in the patient at several different sampling times.","Liu2006"
"57376","B8-FL8 wt","2335","","","","Nef","90","97","","9064..9087","B*0801","FLKEKGGL","FLrEKGGL","K3R","K92R","LE","literature escape","Tetramer binding","Natural variant FLrEKGGL had increased binding over wild type FL8 to inhibitory receptor ILT4 on CD14+ monocytes.  In line with prior studies, this was assumed to induce inhibition of antigen presenting and cytokine secretion of myelomonocytic cells.","Yang2010"
"57376","B8-FL8 wt","2336","","","","Nef","90","97","","9064..9087","B*0801","FLKEKGGL","FLKEeGGL","K5E","K94E","LE","literature escape","Tetramer binding","Natural variant FLKEeGGL had increased binding over wild type FL8 to inhibitory receptor ILT4 on CD14+ monocytes.  In line with prior studies, this was assumed to induce inhibition of antigen presenting and cytokine secretion of myelomonocytic cells.","Yang2010"
"1015",,"2655","B","B","B","Nef","90","97","","9064..9087","B*08","FLKEKGGL","--------","F1-, L2-, K3-, E4-, K5-, G6-, G7-, L8-","F90-, L91-, K92-, E93-, K94-, G95-, G96-, L97-","EL","epitope loss","Sequence","A single nucleotide deletion within DNA resulted in a premature termination of Nef protein 6 amino acids before the epitope FL8. 2 clones with this truncation of protein and epitope loss were found at separate time points.","Goulder1997e, Price1997"
"57954","FL8","2682","A, B","","","Nef","90","97","","9064..9087","B*0801","FLKEKGGL","FLKEqGGL","K5Q","K94Q","E, LE, NSF","escape documented in this paper, literature escape, non-susceptible form","CD8 T-cell Elispot - IFNy","FLKEKGGL underwent classical escape, with adapted forms FLKEqGGL, FLKEeGGL, and FLKEnGGL having abrogated EliSpot responses.","Keane2012"
"57954","FL8","2683","A, B","B","B","Nef","90","97","","9064..9087","B*0801","FLKEKGGL","FLKEeGGL","K5E","K94E","E, LE, NSF","escape documented in this paper, literature escape, non-susceptible form","CD8 T-cell Elispot - IFNy","FLKEKGGL underwent classical escape, with adapted forms FLKEqGGL, FLKEeGGL, and FLKEnGGL having abrogated EliSpot responses.","Keane2012"
"57954","FL8","2684","A, B","","","Nef","90","97","","9064..9087","B*0801","FLKEKGGL","FLKEnGGL","K5N","K94N","E, LE, NSF, SF","escape documented in this paper, literature escape, non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy","FLKEKGGL underwent classical escape, with adapted forms FLKEqGGL, FLKEeGGL, and FLKEnGGL having abrogated EliSpot responses. Longitudinal study of an acute subtype A infection in a B*08-positive patient revealed early responses to FLKEKGGL and its variant, FLKEnGGL. The patient's sequences were the non-adapted form and remained invariant despite high-magnitude responses.","Keane2012"
"58007","FL8","2694","B","B","B","Nef","90","97","","9064..9087","B*08","FLKEKGGL","FLKEnGGL","K5N","K94N","LE, P","literature escape, processing","","B8-FL8 was selected for analysis based on having known early mutants (K5N and K5M) that were predicted to have reduced intracellular stability. Mutant 5N slightly reduced peptide half-life, while 5M severely reduced half-life.","Lazaro2011"
"58007","FL8","2695","B","B","B","Nef","90","97","","9064..9087","B*08","FLKEKGGL","FLKEmGGL","K5M","K94M","LE, P","literature escape, processing","","B8-FL8 was selected for analysis based on having known early mutants (K5N and K5M) that were predicted to have reduced intracellular stability. Mutant 5N slightly reduced peptide half-life, while 5M severely reduced half-life.","Lazaro2011"
"58277","FL8","2859","B","B","B","Nef","90","97","","9064..9087","B*08","FLKEKGGL","FLrEKGGL","K3R","K92R","LE","literature escape","Intracellular cytokine staining","FLrEKGGL was one of 2 FL8 sequence variants cross-recognized by subdominant clonotypes.","Conrad2011"
"58277","FL8","2860","B","B","B","Nef","90","97","","9064..9087","B*08","FLKEKGGL","FLKdKGGL","E4D","E93D","LE","literature escape","Intracellular cytokine staining","FLKdKGGL was one of 2 FL8 sequence variants cross-recognized by subdominant clonotypes.  It was the only variant used that circulated in patient 10094.","Conrad2011"
"52516",,"21","B","","","Nef","92","100","","9070..9096","B60","KEKGGLEGL","KgKGGLEGL","E2G","E93G","E","escape documented in this paper","Assay for Class I down-regulation by Nef","The molecular clone HIV-1 NL4-3.1 was passaged under selective pressure in the presence of 2  Nef KEKGGLEGL-specific CTL clones (KM3 and STD11) isolated from different individuals, giving rise to rapid selection of escape mutations. This mutation was observed in 3/72 sequences, selected by KM3 clone, and  shown to impair the down regulation of class I MHC by Nef.","Ali2003"
"52516",,"22","B","","","Nef","92","100","","9070..9096","B60","KEKGGLEGL","KkKGGLEGL","E2K","E93K","E","escape documented in this paper","Assay for Class I down-regulation by Nef","The molecular clone HIV-1 NL4-3.1 was passaged under selective pressure in the presence of 2  Nef KEKGGLEGL-specific CTL clones (KM3 and STD11) isolated from different individuals, giving rise to rapid selection of escape mutations. This mutation was observed in 2/72 sequences, selected by STD11 clone, and  shown to impair the down regulation of class I MHC by Nef","Ali2003"
"52516",,"23","B","","","Nef","92","100","","9070..9096","B60","KEKGGLEGL","KEnGGLErL","K3N, G8R","K94N, G99R","IE","inferred escape","Sequence","The molecular clone HIV-1 NL4-3.1 was passaged under selective pressure in the presence of 2  Nef KEKGGLEGL-specific CTL clones (KM3 and STD11) isolated from different individuals, giving rise to rapid selection of escape mutations. This mutation was observed in 1/72 sequences and selected by STD11 clone.  Viral escape from CTL in vitro was commonly associated with functional impairment of MHC-1 down modulation.","Ali2003"
"52516",,"24","B","","","Nef","92","100","","9070..9096","B60","KEKGGLEGL","KEKrGLErL","G4R, G8R","G95R, G99R","IE","inferred escape","Sequence","The molecular clone HIV-1 NL4-3.1 was passaged under selective pressure in the presence of 2  Nef KEKGGLEGL-specific CTL clones (KM3 and STD11) isolated from different individuals, giving rise to rapid selection of escape mutations. This mutation was observed in 1/72 sequences and selected by STD11 clone.  Viral escape from CTL in vitro was commonly associated with functional impairment of MHC-1 down modulation.","Ali2003"
"52516",,"25","B","","","Nef","92","100","","9070..9096","B60","KEKGGLEGL","KEKGGLkGL","E7K","E98K","IE","inferred escape","Sequence","The molecular clone HIV-1 NL4-3.1 was passaged under selective pressure in the presence of 2  Nef KEKGGLEGL-specific CTL clones (KM3 and STD11) isolated from different individuals, giving rise to rapid selection of escape mutations. This mutation was observed in 3/72 sequences and selected by KM3 clone.","Ali2003"
"52516",,"26","B","","","Nef","92","100","","9070..9096","B60","KEKGGLEGL","KEKGGLdGL","E7D","E98D","IE","inferred escape","Sequence","The molecular clone HIV-1 NL4-3.1 was passaged under selective pressure in the presence of 2  Nef KEKGGLEGL-specific CTL clones (KM3 and STD11) isolated from different individuals, giving rise to rapid selection of escape mutations. This mutation was observed in 1/72 sequences and selected by KM3 clone.  Viral escape from CTL in vitro was commonly associated with functional impairment of MHC-1 down modulation.","Ali2003"
"52516",,"27","B","","","Nef","92","100","","9070..9096","B60","KEKGGLEGL","KEKGGLErL","G8R","G99R","IE","inferred escape","Sequence","The molecular clone HIV-1 NL4-3.1 was passaged under selective pressure in the presence of 2  Nef KEKGGLEGL-specific CTL clones (KM3 and STD11) isolated from different individuals, giving rise to rapid selection of escape mutations. This mutation was observed in 2/72 sequences and selected by both KM3 and STD11 clones.  Viral escape from CTL in vitro was commonly associated with functional impairment of MHC-1 down modulation.","Ali2003"
"52516",,"28","B","","","Nef","92","100","","9070..9096","B60","KEKGGLEGL","KEKGGLEeL","G8E","G99E","IE","inferred escape","Sequence","The molecular clone HIV-1 NL4-3.1 was passaged under selective pressure in the presence of 2  Nef KEKGGLEGL-specific CTL clones (KM3 and STD11) isolated from different individuals, giving rise to rapid selection of escape mutations. This mutation was observed in 1/72 sequences and selected by  STD11 clone.  Viral escape from CTL in vitro was commonly associated with functional impairment of MHC-1 down modulation.","Ali2003"
"52516",,"29","B","","","Nef","92","100","","9070..9096","B60","KEKGGLEGL","KEKGGLEGp","L9P","L100P","IE","inferred escape","Sequence","The molecular clone HIV-1 NL4-3.1 was passaged under selective pressure in the presence of 2  Nef KEKGGLEGL-specific CTL clones (KM3 and STD11) isolated from different individuals, giving rise to rapid selection of escape mutations. This mutation was observed in 1/72 sequences and selected by  STD11 clone.  Viral escape from CTL in vitro was commonly associated with functional impairment of MHC-1 down modulation.","Ali2003"
"52516",,"30","B","","","Nef","92","100","","9070..9096","B60","KEKGGLEGL","KEKGGLEGi","L9I","L100I","IE","inferred escape","Sequence","The molecular clone HIV-1 NL4-3.1 was passaged under selective pressure in the presence of 2  Nef KEKGGLEGL-specific CTL clones (KM3 and STD11) isolated from different individuals, giving rise to rapid selection of escape mutations. This mutation was observed in 9/72 sequences and selected by  STD11 clone.  Viral escape from CTL in vitro was commonly associated with functional impairment of MHC-1 down modulation.","Ali2003"
"54578","KL9","660","B","","","Nef","92","100","","9070..9096","B*40","KEKGGLEGL","KEKGGLdGL","E7D","E98D","DR","diminished response","CD8 T-cell Elispot - IFNy","Variant found at weeks 109 and 158. A less intense CTL response targeted this variant than the wt epitope.","Karlsson2007"
"54578","KL9","661","B","","","Nef","92","100","","9070..9096","B*40","KEKGGLEGL","KEKGGLEeL","G8E","G99E","IE","inferred escape","CD8 T-cell Elispot - IFNy","Author tabulates this variant found at week 158 in 1/14 clones as viral escape. No CTL response detected against the variant.","Karlsson2007"
"52790","KL9","1863","B","","","Nef","92","100","","9070..9096","B60","KEKGGLEGL","KEKGGLEGi","L9I","L100I","E","escape documented in this paper","Chromium-release assay, Sequence","After one round of week-long passaging under selection by KL9-specific CTL clone, STD11, this mutation was seen.  It was not recognized.","Yang2003"
"52790","KL9","1864","B","","","Nef","92","100","","9070..9096","B60","KEKGGLEGL","KkKGGLEGL","E2K","E93K","E","escape documented in this paper","Chromium-release assay, Sequence","After one round of week-long passaging under selection by KL9-specific CTL clone, STD11, this mutation was seen.  It was not recognized.","Yang2003"
"52790","KL9","1865","B","","","Nef","92","100","","9070..9096","B60","KEKGGLEGL","KEKGGLEGp","L9P","L100P","E","escape documented in this paper","Chromium-release assay, Sequence","After 2 weeks of passaging under selection by KL9-specific clone STD11, this escape variant that was not recognized emerged.","Yang2003"
"52790","KL9","1866","B","","","Nef","92","100","","9070..9096","B60","KEKGGLEGL","KEKGGLEeL","G8E","G99E","E","escape documented in this paper","Chromium-release assay, Sequence","After 2 weeks of passaging under selection by KL9-specific clone STD11, this escape variant that was not recognized emerged.","Yang2003"
"52790","KL9","1867","B","","","Nef","92","100","","9070..9096","B60","KEKGGLEGL","KEKGGLErL","G8R","G99R","E","escape documented in this paper","Chromium-release assay, Sequence","After 2 weeks of passaging under selection by KL9-specific clone STD11, this escape variant that was not recognized emerged.","Yang2003"
"52790","KL9","1868","B","","","Nef","92","100","","9070..9096","B60","KEKGGLEGL","KEKrGLErL","G4R, G8R","G95R, G99R","E","escape documented in this paper","Chromium-release assay, Sequence","After 2 weeks of passaging under selection by KL9-specific clone STD11, this escape variant that was not recognized emerged.","Yang2003"
"52790","KL9","1869","B","","","Nef","92","100","","9070..9096","B60","KEKGGLEGL","KEnGGLEGL","K3N","K94N","E","escape documented in this paper","Chromium-release assay, Sequence","After 2 weeks of passaging under selection by KL9-specific clone STD11, this escape variant that was not recognized emerged.","Yang2003"
"57501",,"2516","B","B","B","Nef","92","100","","9070..9096","","KEKGGLEGL","KEKGGLEGi","L9I","L100I","A, SF","HLA association, susceptible form","CD8 T-cell Elispot - IFNy","This 'adapted epitope' or variant from the polyallelic peptide set was part of the 13 central Nef adapted epitopes, 7 of which elicited responses in >20% of responders.  Epitope KEKGGLEGi was able to elicit a response in 24% of responding subjects.  It is restricted by HLA B*40.","Almeida2010"
"58245",,"2842","B","B","B","Nef","92","100","","9070..9096","B*4001","KEKGGLEGL","KEKGGLEGm","L9M","L100M","IE","inferred escape","Sequence","16/21 and 8/10  sequences of epitope KEKGGLEGL varied at 552 and 718  DFOSx to KEKGGLEGm.  Position 100 in the epitope is marked as being under selection to vary.","Ferrari2011"
"58806","KL9","3145","A, B, C, CRF01_AE, D, F, G, H","AE, C, D, F","A, B, G, H","Nef","92","100","","9070..9096","B*40","KEKGGLEGL","KEKGGLdGL","E7D","E98D","SNSF, SSF","subtype-specific non-susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy","The same KL9-7D sequence from different subtypes (clades A, B, G and H), was recognized to different extents; just as KL9 from various clades was recognized to varying extents. Both KL9 and KL9-D were found to have the same functional avidity.","Culshaw2012"
"54644","NEF-14","1975","B","B","C","Nef","96","113","","9082..9135","","GLEGLIYSQKRQDILDLW","GLEGLIYSkKRQeILDLW","D13E, Q9K","D108E, Q104K","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 2 amino acids (11.1%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"56302",,"161","B","","","Nef","101","109","","9097..9123","A24","IHSQRRQDI","IySQkRQDI","H2Y, R5K","H102Y, R105K","SF","susceptible form","Flow cytometric T-cell cytokine assay","IHSQRRQDI, elicited a response in 1 patient. Patient autologous sequence was IySQkRQDI, which was exclusively targeted over the consensus form IHSQRRQDI.","Daucher2008"
"58749",,"3138","","","","Nef","101","116","","9097..9144","","IYSQKRQDILDLWVYH","vwSQKRQDILDLWVYn","I1V, H16N, Y2W","I101V, H116N, Y102W","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Variant vwSQKRQDILDLWVYn was seen in both ES38 and CP2 even though it was recognized only by subject ES38.","Buckheit2012"
"53616",,"68","A, D","","","Nef","103","117","","9103..9147","","SKKRQEILDLWVYHT","SKKRQkILDLWVYHT","E6K","E108K","OV","observed variant","CD8 T-cell Elispot - IFNy","The sequence contains a previously-defined epitope (KRQEILDLWVY) of unknown HLA restriction. The viral sequence from the subjects that recognized the peptide was skkrqKildlwvyNt.","Barugahare2005"
"54645","NEF-15","1976","B","B","C","Nef","104","121","","9106..9159","","QKRQDILDLWVYHTQGYF","kKRQeILDLWVYHTQGYF","Q1K, D5E","Q104K, D108E","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 2 amino acids (11.1%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"57824",,"2661","B","B","B","Nef","105","114","","9109..9138","B*27","RRQDILDLWI","RgQDILDLWI","R2G","R106G","?","unclear","CD8 T-cell Elispot - IFNy, Tetramer binding","Mutation is in anchor position, stated as possible escape mutant from sequence data, carried by 1/16 patients.","Ammaranond2011"
"57824",,"2662","B","B","B","Nef","105","114","","9109..9138","B*27","RRQDILDLWI","ReQDILDLWI","R2E","R106E","?","unclear","CD8 T-cell Elispot - IFNy, Tetramer binding","Mutation is in anchor position, stated as possible escape mutant from sequence data, carried by 1/16 patients.","Ammaranond2011"
"54543","KY11","1036","B","B","B","Nef","105","115","","9109..9141","Cw7","KRQDILDLWVY","rRQDILDLWVY","K1R","K105R","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant was found by challenge of 23 subjects with a novel Nef potential T-cell epitope panel in Subtype B.","Malhotra2007a"
"54543","KY11","1037","B","B","B","Nef","105","115","","9109..9141","Cw7","KRQDILDLWVY","KRQeILDLWVY","D4E","D108E","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant was found by challenge of 23 subjects with a novel Nef potential T-cell epitope panel in Subtype B.","Malhotra2007a"
"54543","KY11","1038","B","B","B","Nef","105","115","","9109..9141","Cw7","KRQDILDLWVY","rRQeILDLWVY","K1R, D4E","K105R, D108E","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant was found by challenge of 23 subjects with a novel Nef potential T-cell epitope panel in Subtype B.","Malhotra2007a"
"54543","KY11","1039","B","B","B","Nef","105","115","","9109..9141","Cw7","KRQDILDLWVY","KRQDILDLWiY","V10I","V114I","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant was found by challenge of 23 subjects with a novel Nef potential T-cell epitope panel in Subtype B.  It was found as an autologous sequence in HLA-Cw07-restricted Subject 1188.","Malhotra2007a"
"56652",,"2070","","","","Nef","105","115","","9109..9141","Cw*0701","KRQDILDLWVY","rRQDILDLWVY","K1R","K105R","DR","diminished response","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This nonsynonymous change, K110R showed 50% CTL response compared to index epitope sequence in Patient CH58.  It could also affect processing of the downstream epitope  HTQGYFPDWQ.  Known T cell response from the full proteome scan with evidence for variation and escape was seen.","Goonetilleke2009"
"56652",,"2071","","","","Nef","105","115","","9109..9141","Cw*0701","KRQDILDLWVY","KRQeILDLWVY","D4E","D108E","DR","diminished response","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This nonsynonymous change, K110R showed 50% CTL response compared to wild index epitope in Patient CH58.  It could also affect processing of the downstream epitope  HTQGYFPDWQ.  Known T cell response from the full proteome scan with evidence for variation and escape was seen.","Goonetilleke2009"
"57500",,"2515","B","B","B","Nef","105","115","","9109..9141","","KRQDILDLWVY","KRQeILDLWVY","D4E","D108E","A, SF","HLA association, susceptible form","CD8 T-cell Elispot - IFNy","This 'adapted epitope' or variant from the polyallelic peptide set was part of the 13 central Nef adapted epitopes, 7 of which elicited responses in >20% of responders.  Epitope KRQeILDLWVY was able to elicit a response in 24% of responding subjects.  It is restricted by HLA Cw*07.","Almeida2010"
"57956","KY11","2687","B","B","B","Nef","105","115","","9109..9141","Cw*0702","KRQDILDWVY","KRQeILDWVY","D4E","D108E","SF","susceptible form","CD8 T-cell Elispot - IFNy","KRQDILDWVY underwent adaptation to neo-epitope KRQeILDWVY. 8 subjects had higher EliSpot responses to the neo-epitope than to the non-adapted form.","Keane2012"
"56303",,"162","B","","","Nef","106","114","","9112..9138","B7","RQDILDLWI","RQDILDLWv","I9V","I114V","OV","observed variant","Flow cytometric T-cell cytokine assay","HLA-B7-restricted epitope, RQDILDLWI, elicited a response in 1 patient. Patient autologous sequence was RQDILDLWv.","Daucher2008"
"53706","RI9","415","","","","Nef","106","114","","9112..9138","B13","RQDILDLWI","RQDILDLWv","I9V","I114V","SF","susceptible form","","Equally well recognized as the wt epitope.","Harrer2005b"
"53706","RI9","416","","","","Nef","106","114","","9112..9138","B13","RQDILDLWI","RkDILDLWI","Q2K","Q107K","DR","diminished response","","Variant less well recognized by the CTLs.","Harrer2005b"
"53706","RI9","417","","","","Nef","106","114","","9112..9138","B13","RQDILDLWI","RQeILDLWI","D3E","D108E","DR","diminished response","","Variant less well recognized by the CTLs.","Harrer2005b"
"53706","RI9","418","","","","Nef","106","114","","9112..9138","B13","RQDILDLWI","aQDILDLWI","R1A","R106A","DR","diminished response","","The artificial substitution resulted in dramatic decrease, but not total loss of recognition by the CTLs.","Harrer2005b"
"53706","RI9","419","","","","Nef","106","114","","9112..9138","B13","RQDILDLWI","RQaILDLWI","D3A","D108A","DR","diminished response","","Variant less well recognized by the CTLs.","Harrer2005b"
"53706","RI9","420","","","","Nef","106","114","","9112..9138","B13","RQDILDLWI","RrDILDLWv","Q2R, I9V","Q107R, I114V","DR","diminished response","","Variant less well recognized by the CTLs.","Harrer2005b"
"55988","RV9(Nef)","1946","B","B","B","Nef","106","114","","9112..9138","","RQDILDLWV","RQDILDLWi","V9I","V114I","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B13 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"55978","RY10(Nef)","1947","B","B","B","Nef","106","115","","9112..9141","","RQDILDLWVY","RQDILDLWiY","V9I","V114I","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B7 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"56304",,"163","B","","","Nef","107","115","","9115..9141","B18","QDILDLWIY","QDILDLWvY","I8V","I114V","SF","susceptible form","Flow cytometric T-cell cytokine assay","QDILDLWIY elicited a response in 1 patient. Patient autologous sequence was QDILDLWvY, which was exclusively targeted over the consensus form QDILDLWIY.","Daucher2008"
"57496","QY9","2493","B","B","B","Nef","107","115","","9115..9141","","QEILDLWVY","QdILDLWVY","E2D","E108D","SF","susceptible form","CD8 T-cell Elispot - IFNy","Variant QdILDLWVY continued to elicit CTL response in patient 2255 (Caucasian female, treated, autologous virus Clade B).","Hoof2010"
"57496","QY9","2494","B","B","B","Nef","107","115","","9115..9141","","QEILDLWVY","QEILDLWiY","V8I","V114I","SF","susceptible form","CD8 T-cell Elispot - IFNy","Variant QEILDLWiY continued to elicit CTL response in patient 2255 (Caucasian female, treated, autologous virus Clade B).","Hoof2010"
"57496","QY9","2495","B","B","B","Nef","107","115","","9115..9141","","QEILDLWVY","QEILDaWVY","L6A","L112A","SF","susceptible form","CD8 T-cell Elispot - IFNy","Variant QEILDaWVY continued to elicit CTL response in patient 2255 (Caucasian female, treated, autologous virus Clade B).","Hoof2010"
"57496","QY9","2496","B","B","B","Nef","107","115","","9115..9141","","QEILDLWVY","QEIaDLWVY","L4A","L110A","SF","susceptible form","CD8 T-cell Elispot - IFNy","Variant QEIaDLWVY continued to elicit CTL response though at a low level in patient 2255 (Caucasian female, treated, autologous virus Clade B).","Hoof2010"
"57496","QY9","2513","B","B","B","Nef","107","115","","9115..9141","","QEILDLWVY","QEILDLWVh","Y9H","Y115H","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","Variant QEILDLWVh did not elicit CTL response in patient 2255 (Caucasian female, treated, autologous virus Clade B).","Hoof2010"
"57496","QY9","2514","B","B","B","Nef","107","115","","9115..9141","","QEILDLWVY","QEILaLWVY","D5A","D111A","NSF","non-susceptible form","CD8 T-cell Elispot - IFNy","Variant QEILaLWVY did not elicit CTL response in patient 2255 (Caucasian female, treated, autologous virus Clade B).","Hoof2010"
"56305",,"164","B","","","Nef","108","115","","9118..9141","Cw7","DILDLWIY","DILDLWvY","I7V","I114V","SF","susceptible form","Flow cytometric T-cell cytokine assay","DILDLWIY elicited a response in 1 patient. Patient autologous sequence was DILDLWvY, which was exclusively targeted over the consensus form DILDLWIY.","Daucher2008"
"52138",,"407","C","","","Nef","113","127","","9133..9177","","WIYHTQGYFDPWQNY","WIYnTQGYFDPWQNY","H4N","H116N","OV","observed variant","","Variant found mostly among subtype C, but also in other subtypes.","Guimaraes2002"
"53643","HW9","201","","","","Nef","116","124","","9142..9168","B57, B*5801","HTQGYFPDW","nTQGYFPDW","H1N","H116N","IE","inferred escape","Sequence","ISPRTLNAW was recognized more often in children than in adults, and was the most frequently recognized B57 epitope in children. Longitudinal sequencing of 2 HLA B57 children born to HLA B57-negative mothers and HIV-negative fathers showed  a variant of this epitope: nTQGYFPDW, while the mothers carried HTQGYFPDW, confirming that the mutation arose under selection pressure in the children following vertical transmission. Response to the variant was not studied.","Feeney2005a"
"53734",,"450","B, CRF02_AG","","","Nef","116","124","","9142..9168","B57, B58","HTQGYFPDW","HTQGfFPDW","Y5F","Y120F","OV","observed variant","","The variant was found in 1/9 CRF02_AG infected patients.","Inwoley2005"
"53734",,"451","B, CRF02_AG","","","Nef","116","124","","9142..9168","B57, B58","HTQGYFPDW","nTQGfFPDW","H1N, Y5F","H116N, Y120F","OV","observed variant","","The variant was found in 1/9 CRF02_AG infected patients.","Inwoley2005"
"53734",,"452","B, CRF02_AG","","","Nef","116","124","","9142..9168","B57, B58","HTQGYFPDW","HTQGiFPDW","Y5I","Y120I","OV","observed variant","","The variant was found in 2/9 CRF02_AG infected patients.","Inwoley2005"
"55855","HW9","1330","","","","Nef","116","124","","9142..9168","B57, B*5801","HTQGYFPDW","nTQGYFPDW","H1N","H116N","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Among subjects carrying the restricting HLA, the H116N substitution was seen in 12/13 progressors and 7/9 LTNPs.  Of the 5 progressors and 5 LTNPs studied longitudinally, 1 progressor acquired the variant in time; 1 LTNP acquired it in time; 2 LTNPs never had the substitution; and the remaining 6 subjects had this variant from the earliest time points tested.  Authors suggest that early selection of this mutation may confer a positive effect, but peptide prediction programs did not reveal a difference in processing and presentation compared with the index epitope.  It was found that 4/5 LTNPs and 2/5 progressors responded to index HW9 at earlier times, but lost their responsiveness with time (at a later time 3/5 LTNPs elicited a CTL response against index HW9 and none of the progressors did).  T cell reactivity was present early to the HW9 variant in LTNPs but not to progressors (later, only 1 LTNP was able to respond to the H116N variant and at its highest peptide concentrations - attributed to T cell exhaustion).","Navis2008a"
"53830",,"1427","C","","","Nef","116","124","","9142..9168","B57","HTQGYFPDW","HTQGfFPDW","Y5F","Y120F","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This index epitope in mother M5 generated the Y/F variant which was transmitted to infant I5 where it was recognized.","Pillay2005"
"53830",,"1428","C","","","Nef","116","124","","9142..9168","B57","HTQGYFPDW","nTQGfFPDW","H1N, Y5F","H116N, Y120F","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence","This variant arose in infant I5 by week 33 and elicited a diminished CTL response.","Pillay2005"
"57419","HW9","2374","B","B","B","Nef","116","124","","9142..9168","B*57","HTQGYFPDW","nTQGYFPDW","H1N","H116N","OV","observed variant","Sequence","Variant nTQGYFPDW was seen in all subjects except for progressor CH-02.","Tang2010"
"57419","HW9","2375","B","B","B","Nef","116","124","","9142..9168","B*57","HTQGYFPDW","nTQGfFPDW","H1N, Y5F","H116N, Y120F","OV","observed variant","Sequence","Variant nTQGfFPDW was seen in one subject, controller CH-03.","Tang2010"
"58748",,"3137","","","","Nef","116","124","","9142..9168","","HTQGYFPDW","nTQGYFPDW","H1N","H116N","NSF","non-susceptible form","Sequence","nTQGYFPDW, a variant of epitope HTQGYFPDW was seen in both ES38 and CP2 HIV-1 sequences though neither subject could recognize the variant by EliSpot.","Buckheit2012"
"54620","HQ10","279","B","","","Nef","116","125","","9142..9171","B*57","HTQGYFPDWQ","nTQGYFPDWQ","H1N","H116N","CE","calculated escape","","The variant was found in 100% of HLA-matched and in 28.8% of HLA-unmatched patients, indicating that some favourable HLA alleles induce strong pressure, resulting in escape variants with high fitness cost and low viral loads.","Frater2007"
"59212","HQ10","3364","B","B","B","Nef","116","125","",,"B*5701","HTQGYFPDWQ","nTQGYFPDWQ","H1N","H116N","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant nTQGYFPDWQ was seen in 2/3 HRP and all 3 LRP subjects.  It was the autologous epitope of the major viral population in patients P2, P3 and P6; and it was the only form in patients P4 and P5.","Buggert2014"
"54646","NEF-17","1977","B","B","C","Nef","118","135","","9148..9201","","QGYFPDWQNYTPGPGRF","QGYFPDWQNYTPGPvRy","G15V, F17Y","G132V, F134Y","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 2 amino acids (11.1%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"53725",,"453","B, CRF02_AG","","","Nef","119","127","","9151..9177","A24","GYFPDWQNY","GfFPDWQNY","Y2F","Y120F","OV","observed variant","","The variant was found in 2/9 CRF02_AG infected patients.","Inwoley2005"
"53725",,"454","B, CRF02_AG","","","Nef","119","127","","9151..9177","A24","GYFPDWQNY","GiFPDWQNY","Y2I","Y120I","OV","observed variant","","The variant was found in 2/9 CRF02_AG infected patients.","Inwoley2005"
"57420","YY8","2382","B","B","B","Nef","120","127","","9154..9177","B*57","YFPDWQNY","YFPDWhNY","Q6H","Q125H","OV","observed variant","Sequence","Variant YFPDWhNY was seen in one subject, progressor CH-12.","Tang2010"
"57420","YY8","2383","B","B","B","Nef","120","127","","9154..9177","B*57","YFPDWQNY","fFPDWQNY","Y1F","Y120F","OV","observed variant","Sequence","Variant fFPDWQNY was seen in only one subject, controller CH-03.","Tang2010"
"52997",,"316","","","","Nef","120","128","","9154..9180","B51","FFPDWKNYT","yFPDWqNYT","F1Y, K6Q","F120Y, K125Q","E","escape documented in this paper","","A dramatic decrease in CTL activity against the epitope occurred as the mutations arose. The variant was found at 2 months post-seroconversion.","Geels2003"
"52997",,"317","","","","Nef","120","128","","9154..9180","B51","FFPDWKNYT","yFPDWhNYT","F1Y, K6H","F120Y, K125H","E","escape documented in this paper","","A dramatic decrease in CTL activity against the epitope occurred as the mutations arose. The variant was found at 2 months post-seroconversion.","Geels2003"
"52997",,"318","","","","Nef","120","128","","9154..9180","B51","FFPDWKNYT","yFPDWqsYT","F1Y, K6Q, N7S","F120Y, K125Q, N126S","E","escape documented in this paper","","A dramatic decrease in CTL activity against the epitope occurred as the mutations arose.  The variant was found at 20 and 47 months post-seroconversion.","Geels2003"
"52997",,"319","","","","Nef","120","128","","9154..9180","B51","FFPDWKNYT","ylPDWqsYT","F1Y, F2L, K6Q, N7S","F120Y, F121L, K125Q, N126S","E","escape documented in this paper","","A dramatic decrease in CTL activity against the epitope occurred as the mutations arose.  The variant was found at 20  months post-seroconversion.","Geels2003"
"52997",,"320","","","","Nef","120","128","","9154..9180","B51","FFPDWKNYT","yFPDWdNYT","F1Y, K6D","F120Y, K125D","E","escape documented in this paper","","A dramatic decrease in CTL activity against the epitope occurred as the mutations arose. The variant was found at 20 and 47 months post-seroconversion.","Geels2003"
"1045",,"1855","","","","Nef","120","128","","9154..9180","B15","FFPDWKNYT","lFPDWKNYT","F1L","F120L","E","escape documented in this paper","Chromium-release assay","This escape was not recognized by an infected infant.","Wilson1999a"
"59213","YT9","3365","B","B","B","Nef","120","128","",,"B*5701","YFPDWQNYT","YFPDWQcYT","N7C","N126C","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant YFPDWQcYT was an autologous epitope found in 1/3 HRP (patient P2) and 1/3 LRP (patient P4).","Buggert2014"
"59213","YT9","3366","B","B","B","Nef","120","128","",,"B*5701","YFPDWQNYT","YFPDWQchT","N7C, Y8H","N126C, Y127H","OV","observed variant","HLA binding, Intracellular cytokine staining, Sequence","Variant YFPDWQchT was an autologous epitope found in no HRP  and 1/3 LRP (patient P4).","Buggert2014"
"53769",,"860","B, CRF01_AE","B","CRF01_AE","Nef","121","128","","9157..9180","A*01","FPDWQNYT","FPDWhNYT","Q5H","Q125H","OV","observed variant","Computer prediction","This was the most common variant in CRF01 (12/23 patients). It had similar binding score to HLA as the wt epitope.","Lazaro2005"
"53769",,"861","B, CRF01_AE","B","CRF01_AE","Nef","121","128","","9157..9180","A*01","FPDWQNYT","FPDWQyYT","N6Y","N126Y","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53769",,"862","B, CRF01_AE","B","CRF01_AE","Nef","121","128","","9157..9180","A*01","FPDWQNYT","FPeWgNYT","D3E, Q5G","D123E, Q125G","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"54647","NEF-18","1978","B","B","C","Nef","125","143","","9169..9225","","QNYTPGPGRFPLTFGWCF","QNYTPGPGvRyPLTFGWCF","F10R, P11Y, L12P, T13L, F14T, G15F, W16G, C17W, F18C, R9V","F134R, P135Y, L136P, T137L, F138T, G139F, W140G, C141W, F142C, R133V","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This Clade C consensus synthetic peptide variant from an immunodominant region, differs from the immunodominant Clade B consensus at 2 amino acids (10.5%) and both were recognized by subtype-B-infected subjects.","Zhao2007"
"59203","Nef126-10","3326","B","B","B","Nef","126","135","",,"A*2402","NYTPGPGIRY","NYTPGPGvRY","I8V","I133V","OV","observed variant","Sequence","1/46 subjects carried this sequence, NYTPGPGvRY, in epitope Nef126-10: Nef126-143 sequence, NYTPGPGvRYPLTFGWCF exists in that subject.","Han2014"
"59203","Nef126-10","3327","B","B","B","Nef","126","135","",,"A*2402","NYTPGPGIRY","cYTPGPGtRY","N1C, I8T","N126C, I133T","OV","observed variant","Sequence","1/46 subjects carried this sequence, cYTPGPGtRY, in epitope Nef126-10: Nef126-143 sequence, cYTPGPGtRYPLTFGWCF exists in that subject.","Han2014"
"59203","Nef126-10","3328","B","B","B","Nef","126","135","",,"A*2402","NYTPGPGIRY","NYTPGPGtRY","I8T","I133T","OV","observed variant","Sequence","2/46 subjects carried this sequence, NYTPGPGtRY, in epitope Nef126-10: Nef126-143 sequence, NYTPGPGtRYPLTFGWCF exists in 1 subject and NYTPGPGtRYPLcFGWCF in the other.","Han2014"
"59203","Nef126-10","3329","B","B","B","Nef","126","135","",,"A*2402","NYTPGPGIRY","NYTPGPGIRf","Y10F","Y135F","OV","observed variant","Sequence","2/46 subjects carried this 8I10F variant sequence, NYTPGPGIRf, in epitope Nef126-10: Nef126-143 sequence, NYTPGPGIRfPLTFGWCF exists in those subjects. NYTPGPGIRf(8I10F)-specific CTL responses were inversely correlated with plasma viral load (pVL).","Han2014"
"59203","Nef126-10","3330","B","B","B","Nef","126","135","",,"A*2402","NYTPGPGIRY","NYTPGPGtRf","Y10F, I8T","Y135F, I133T","OV","observed variant","Sequence","23/46 (50%) subjects carried this sequence, NYTPGPGtRf (8T10F), in epitope Nef126-10: Nef126-143 sequence, NYTPGPGtRfPLTFGWCF exists in those subjects. NYTPGPGtRf(8T10F)-specific CTL responses were not inversely correlated with pVL.  The I133T mutation shortly followed the Y135F one.","Han2014"
"59203","Nef126-10","3331","B","B","B","Nef","126","135","",,"A*2402","NYTPGPGIRY","cYTPGPGIRf","N1C, Y10F","N126C, Y135F","OV","observed variant","Sequence","1/46 subjects carried this sequence, cYTPGPGIRf, in epitope Nef126-10: Nef126-143 sequence, cYTPGPGIRfPLTFGWCF exists in that subject.","Han2014"
"59203","Nef126-10","3332","B","B","B","Nef","126","135","",,"A*2402","NYTPGPGIRY","gYTPGPGIRf","N1G, Y10F","N126G, Y135F","OV","observed variant","Sequence","1/46 subjects carried this sequence, gYTPGPGIRf, in epitope Nef126-10: Nef126-143 sequence, gYTPGPGIRfPLTFGWCF exists in that subject.","Han2014"
"59203","Nef126-10","3333","B","B","B","Nef","126","135","",,"A*2402","NYTPGPGIRY","cYTPGPGtRf","N1C, Y10F, I8T","N126C, Y135F, I133T","OV","observed variant","Sequence","1/46 subjects carried this sequence, cYTPGPGtRf, in epitope Nef126-10: Nef126-143 sequence, cYTPGPGtRfPLTFGWCF exists in that subject.","Han2014"
"59203","Nef126-10","3334","B","B","B","Nef","126","135","",,"A*2402","NYTPGPGIRY","gYTPGPGtRf","N1G, Y10F, I8T","N126G, Y135F, I133T","OV","observed variant","Sequence","1/46 subjects carried this sequence, gYTPGPGtRf, in epitope Nef126-10: Nef126-143 sequence, gYTPGPGtRfPLTFGWCF exists in that subject.","Han2014"
"59203","Nef126-10","3335","B","B","B","Nef","126","135","",,"A*2402","NYTPGPGIRY","NYTPGPGvRf","Y10F, I8V","Y135F, I133V","OV","observed variant","Sequence","4/46 subjects carried this sequence, NYTPGPGvRf, in epitope Nef126-10: Nef126-143 sequence, NYTPGPGvRfPLTFGWCF exists in those subjects.","Han2014"
"59203","Nef126-10","3336","B","B","B","Nef","126","135","",,"A*2402","NYTPGPGIRY","NYTPGPGeRf","Y10F, I8E","Y135F, I133E","OV","observed variant","Sequence","1/46 subjects carried this sequence, NYTPGPGeRf, in epitope Nef126-10: Nef126-143 sequence, NYTPGPGeRfPLcFGWCF exists in that subject.","Han2014"
"59203","Nef126-10","3337","B","B","B","Nef","126","135","",,"A*2402","NYTPGPGIRY","NYTPGPGvRl","Y10L, I8V","Y135L, I133V","OV","observed variant","Sequence","2/46 subjects carried this sequence, NYTPGPGvRl, in epitope Nef126-10: Nef126-143 sequence, NYTPGPGvRlPLTFGWCF exists in those subjects.","Han2014"
"59203","Nef126-10","3338","B","B","B","Nef","126","135","",,"A*2402","NYTPGPGIRY","NYTPGPGtRw","Y10W, I8T","Y135W, I133T","OV","observed variant","Sequence","1/46 subjects carried this sequence, NYTPGPGtRw, in epitope Nef126-10: Nef126-143 sequence, NYTPGPGtRwPLTFGWCF exists in that subject.","Han2014"
"1669",,"674","","","","Nef","128","137","","9178..9207","B7","TPGPGVRYPL","TPGPGiRYPL","V6I","V133I","SF","susceptible form","CD8 T-cell Elispot - IFNy","This epitope and the variant were recognized by 5/6 HIV infected women and by 4/5 HIV-exposed, persistently seronegative women.  Responses to the epitope and the variant were much higher after HIV-1 seroconversion of previous HEPS.","Kaul2001a"
"54545","TL10","1040","B","B","B","Nef","128","137","","9178..9207","B35","TPGPGTRYPL","TPGPGvRYPL","T6V","T133V","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant was found by challenge of 23 subjects with a novel Nef potential T-cell epitope panel in Subtype B.","Malhotra2007a"
"53829",,"1429","C","","","Nef","128","137","","9178..9207","B*4201","TPGPGVRYPL","TsGPGVRYPL","P2S","P129S","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","This index epitope from mother, M4 was transmitted to infant, I4 in whom the variant form which had reduced binding to HLA-B*4201 was seen by week 26. The variant was unable to elicit a CTL response.","Pillay2005"
"53829",,"1430","C","","","Nef","128","137","","9178..9207","B*4201","TPGPGVRYPL","TqGPGVRYPL","P2Q","P129Q","DHB, E","diminished HLA binding or increased off-rate, escape documented in this paper","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","This index epitope from mother, M4 was transmitted to infant, I4 in whom the variant form which had reduced binding to HLA-B*4201 was seen by week 26. The variant was unable to elicit a CTL response.","Pillay2005"
"1056",,"1551","B","B","A, D","Nef","128","137","","9178..9207","B7","TPGPGVRYPL","TPGPGiRYPL","V6I","V133I","OV","observed variant","Chromium-release assay","Two HEPS Kenyan subjects cross-reacted to this B clade epitope though it differed from the A and D clade form,  TPGPGiRYPL.","Rowland-Jones1998"
"1054",,"1561","","B","A","Nef","128","137","","9178..9207","B7","TPGPGVRYPL","TPGPGiRYPL","V6I","V133I","OV","observed variant","Chromium-release assay","5/6 Kenyan HEPS subjects recognized this clade B epitope which differed from the clade A variant, TPGPGiRYPL.","RowlandJones1998b"
"55979","TL10(Nef)","1948","B","B","B","Nef","128","137","","9178..9207","","TPGPGRFPL","TPGPGvryPL","R6V, F7R, P8Y, L9P","R133V, F134R, P135Y, L136P","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at 3 residues. It is predicted to be HLA-B7 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"57502",,"2517","B","B","B","Nef","128","137","","9178..9207","","TPGPGIRYPL","TPGPGvRYPL","I6V","I133V","A, SF","HLA association, susceptible form","CD8 T-cell Elispot - IFNy","This 'adapted epitope' or variant from the polyallelic peptide set was part of the 13 central Nef adapted epitopes, 7 of which elicited responses in >20% of responders.  Epitope TPGPGvRYPL was able to elicit a response in 24% of responding subjects.  It is restricted by HLA B*07, B*35 and B*42.","Almeida2010"
"57534","T10PL","2538","","","","Nef","128","137","","9178..9207","B*07","TPGPGVKYPL","TPGPGiKYPL","V6I","V133I","SF","susceptible form","CD8 T-cell Elispot - IFNy, Chromium-release assay, HLA binding","Intersubtype variant TPGPGiKYPL exhibited good cross-recognition in mice immunized with TPGPGVKYPL.","Cardinaud2009"
"57958","TL10","2689","B","B","B","Nef","128","137","","9178..9207","B*0702","TPGPGIRYPL","TPGPGvRYPL","I6V","I133V","SF","susceptible form","CD8 T-cell Elispot - IFNy","TPGPGIRYPL underwent adaptation to neo-epitope TPGPGvRYPL. 6 subjects had higher EliSpot responses to the neo-epitope than to the non-adapted form.","Keane2012"
"59047","TL10-Nef","3223","B","B","C","Nef","128","137","","9178..9207","B*0702","TPGPGIRYPL","TPGPGvRYPL","I6V","I133V","SSF","subtype-specific susceptible form","HLA binding","Variant TL10-Nef, TPGPGvRYPL, a C-clade Nef epitope was targeted by C-clade infected subjects more robustly than the B-clade variant TL10.  The affinity of TL10 to B*0702 was K<sub>d</sub> = 27 nM.  Clade-C TL10 is contained within OLP84, NYTPGPGvRYPLTFGWCF.","Kloverpris2014"
"59251",,"3417","B","B","B","Nef","128","137","",,"","TPGPGTRYPL","TPGPGIRFPL","T6I, Y8F","T133I, Y135F","SF","susceptible form","HLA binding","First variant detected; seen in early and late post-SC periods; positive Elispot responses &tilde;50 SFC/10<sup>6</sup>PBMC  in both periods.","Melhem2014"
"59251",,"3418","B","B","B","Nef","128","137","",,"","TPGPGTRYPL","TPGPGIRYPL","T6I","T133I","SF","susceptible form","HLA binding","Second variant detected; seen in early and late post-SC periods; positive Elispot responses in early post-SC (&tilde;150 SFC/10<sup>6</sup>PBMC ) and late post-SC (<50 SFC/10<sup>6</sup>PBMC ).","Melhem2014"
"59251",,"3419","B","B","B","Nef","128","137","",,"","TPGPGTRYPL","TPGPGIRYPV","L10V, T6I","L137V, T133I","SF","susceptible form","HLA binding","Third variant detected; seen in early and late post-seroconversion periods; positive Elispot responses in early post-SC(seroconversion) (&tilde;50 SFC/10<sup>6</sup>PBMC ) and late post-SC (<50 SFC/10<sup>6</sup>PBMC ).","Melhem2014"
"59251",,"3420","B","B","B","Nef","128","137","",,"","TPGPGTRYPL","TPGPGIRFPI","L10I, T6I, Y8F","L137I, T133I, Y135F","SF","susceptible form","HLA binding","Fourth variant detected; seen in early post-SC (seroconversion) period; positive Elispot response &tilde;50 SFC/10<sup>6</sup>PBMC .","Melhem2014"
"59251",,"3421","B","B","B","Nef","128","137","",,"","TPGPGTRYPL","TSGPGTRFPL","P2S, Y8F","P129S, Y135F","SF","susceptible form","HLA binding","Fifth variant detected; seen in early post-SC period; Elispot response <50 SFC/10<sup>6</sup>PBMC .","Melhem2014"
"59251",,"3422","B","B","B","Nef","128","137","",,"","TPGPGTRYPL","IPGPG-RHPL","T1I, T6-, Y8H","T128I, T133-, Y135H","OV","observed variant","HLA binding","Sixth variant detected; seen in early post-SC (seroconversion) period; Elispot response <20 SFC/10<sup>6</sup>PBMC .","Melhem2014"
"59251",,"3423","B","B","B","Nef","128","137","",,"","TPGPGTRYPL","TPGPGVRYPL","T6V","T133V","OV","observed variant","HLA binding","Seventh variant detected; seen in early post-SC period; no Elispot response.","Melhem2014"
"59251",,"3425","B","B","B","Nef","128","137","",,"","TPGPGTRYPL","TPGPGPRYPL","T6P","T133P","SF","susceptible form","HLA binding","Eighth variant detected; seen at all 4 timepoints in infection; positive Elispot responses in early post-seroconversion (<50 SFC), late post-SC (<50 SFC), early ART (&tilde;250 SFC), and late ART (<50 SFC).","Melhem2014"
"59251",,"3426","B","B","B","Nef","128","137","",,"","TPGPGTRYPL","TPGPGTRFPL","Y8F","Y135F","OV","observed variant","HLA binding","Ninth variant detected; seen in early post-SC period; no Elispot response.","Melhem2014"
"59251",,"3427","B","B","B","Nef","128","137","",,"","TPGPGTRYPL","TPGPGPRFPL","T6P, Y8F","T133P, Y135F","OV","observed variant","HLA binding","Tenth variant detected; seen only in early post-seroconversion period; no Elispot response.","Melhem2014"
"59251",,"3428","B","B","B","Nef","128","137","",,"","TPGPGTRYPL","TPGPGIRYPM","L10M, T6I","L137M, T133I","SF","susceptible form","HLA binding","Eleventh variant detected; seen only in late post-seroconversion period; Elispot response <50 SFC/10<sup>6</sup>PBMC .","Melhem2014"
"59251",,"3429","B","B","B","Nef","128","137","",,"","TPGPGTRYPL","TPGPGPRYPV","L10V, T6P","L137V, T133P","SF","susceptible form","HLA binding","Twelfth variant detected; seen only in late post-seroconversion period; Elispot response <50 SFC/10<sup>6</sup>PBMC .","Melhem2014"
"59251",,"3430","B","B","B","Nef","128","137","",,"","TPGPGTRYPL","TPGPGPRYPM","L10M, T6P","L137M, T133P","SF","susceptible form","HLA binding","Thirteenth variant detected; seen in early and late ART periods; positive Elispot response in early ART (&tilde;100 SFC) and late ART (&tilde;100 SFC).","Melhem2014"
"59251",,"3431","B","B","B","Nef","128","137","",,"","TPGPGTRYPL","TKGPGIRFPL","P2K, T6I, Y8F","P129K, T133I, Y135F","SF","susceptible form","HLA binding","Fourteenth variant detected; seen in early and late ART periods; strongly positive Elispot responses in early ART (&tilde;200 SFC/10<sup>6</sup>PBMC ) and late ART (&tilde;300 SFC/10<sup>6</sup>PBMC ).","Melhem2014"
"59251",,"3456","B","B","B","Nef","128","137","",,"","TPGPGTRYPL","TPGPGPRYPM","L10M, T6P","L137M, T133P","SF","susceptible form","HLA binding","Thirteenth variant detected; seen in early and late ART periods; positive Elispot response in early ART (&tilde;100 SFC/10<sup>6</sup>PBMC ) and late ART (&tilde;100 SFC/10<sup>6</sup>PBMC ).","Melhem2014"
"55303","nef-5171","1522","B","","","Nef","129","143","","9181..9225","","PGPGIRYPLTFGWCF","PGPGtRfPLTFGWCF","I5T, Y7F","I133T, Y135F","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","CTL from the daughter, who carried this variant Nef sequence, recognized the Clade B consensus peptide.","Reinis2007"
"58751",,"3140","","","","Nef","129","143","","9181..9225","","PGPGIRYPLTFGWCF","PGPGpRYPLTFGWCF","I5P","I133P","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Variant PGPGpRYPLTFGWCF is seen in both ES38 and CP2 HIV-1, though the variant epitope is recognized only by subject CP2 and not ES38.","Buckheit2012"
"1060",,"594","","B","C, H","Nef","132","144","","9190..9228","","GIRYPLTFGWCFK","GvRYPLTFGWCFK","I2V","I133V","OV","observed variant","","CTL epitope region conserved among HIV-1 M group subtypes. The variant was found in subtypes C and H.","Jubier-Maurin1999"
"1060",,"595","","B","CRF01_AE","Nef","132","144","","9190..9228","","GIRYPLTFGWCFK","GIRYPLcFGWCFK","T7C","T138C","OV","observed variant","","CTL epitope region conserved among HIV-1 M group subtypes. The variant was found in subtype E.","Jubier-Maurin1999"
"55960","TW9(Nef)","1949","B","B","B","Nef","133","141","","9193..9219","","GRFPLTFGW","tRyPLTFGW","G1T, F3Y","G133T, F135Y","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at 2 residues. It is predicted to be HLA-A33 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"58753",,"3141","","","","Nef","133","147","","9193..9237","","IRYPLTFGWCFKLVP","pRYPLTFGWCFKLVP","I1P","I133P","NSF, SF","non-susceptible form, susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Variant pRYPLTFGWCFKLVP is seen in both ES38 and CP2, though it is recognized only by subject CP2 in EliSpot.","Buckheit2012"
"55930","RW8(Nef)","1950","B","B","B","Nef","134","141","","9196..9219","","RFPLTFGW","RyPLTFGW","F2Y","F135Y","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-A24 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"57249","RW8","2234","B","B","B","Nef","134","141","","9196..9219","A*2402","RYPLTFGW","RfPLTFGW","Y2F","Y134F","SF","susceptible form","CD8 T-cell Elispot granzyme B, CD8 T-cell Elispot - IFNy","This variant was recognized by IFNg EliSpot and Granzyme B EliSpot in a newly-infected patient.","Malhotra2009"
"57249","RW8","2235","B","B","B","Nef","134","141","","9196..9219","A*2402","RYPLTFGW","RYPLTlGW","F6L","F138L","NSF","non-susceptible form","CD8 T-cell Elispot granzyme B, CD8 T-cell Elispot - IFNy","This variant had substitution in presumed TCR contact site and was not recognized neither by IFNg EliSpot nor Granzyme B EliSpot in a newly-infected patient.","Malhotra2009"
"57249","RW8","2236","B","B","B","Nef","134","141","","9196..9219","A*2402","RYPLTFGW","RYPLcFGW","T5C","T137C","NSF","non-susceptible form","CD8 T-cell Elispot granzyme B, CD8 T-cell Elispot - IFNy","This variant had substitution in presumed TCR contact site and was not recognized neither by IFNg EliSpot nor Granzyme B EliSpot in a newly-infected patient.","Malhotra2009"
"57249","RW8","2237","B","B","B","Nef","134","141","","9196..9219","A*2402","RYPLTFGW","RfPLcFGW","Y2F, T5C","Y134F, T137C","NSF","non-susceptible form","CD8 T-cell Elispot granzyme B, CD8 T-cell Elispot - IFNy","This variant had substitution in presumed TCR contact site and was not recognized neither by IFNg EliSpot nor Granzyme B EliSpot in a newly-infected patient.","Malhotra2009"
"57275","Nef138-10","7","B","B","B","Nef","134","143","","9196..9225","A*2402","RYPLTFGWCF","RFPLTFGWCF","Y2F","Y135F","LE, SF, TCR","literature escape, susceptible form, TCR related mutation","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence, Tetramer binding","TCR repertoires against wt epitope RYPLTFGWCF and a previously determined escape variant RfPLTFGWCF were studied in 7 patients. All carried the 2F escape mutation sequence. In most patients, the T-cell populations that responded to the wild-type and 2F variant were not clearly distinct. A diverse TCR repertoire was observed in CTL specific for RYPLTFGWCF, while the TCR repertoire was highly restricted for CTLs dual-positive for the wild-type and 2F variant. Only 1 patient had CTL specific for the 2F mutant. The  variant bound to HLA almost as efficiently as the wild-type epitope, eliciting strong CTL response in all 7 patients.","Miyazaki2009"
"55578","Nef138-10","280","B","B","B","Nef","134","143","","9196..9225","A*2402","RYPLTFGWCY","RfPLTFGWCY","Y2F","Y135F","E","escape documented in this paper","CTL suppression of replication","Confirmed escape variant in A*2402 individuals. Epitope-specific CTLs did not suppress replication of the mutant virus.","Fujiwara2008"
"55577","Nef138-10","281","B","B","B","Nef","134","143","","9196..9225","A*2402","RYPLTFGWCF","RfPLTFGWCF","Y2F","Y135F","E","escape documented in this paper","CTL suppression of replication","Confirmed escape variant in A*2402 individuals. Epitope-specific CTLs did not suppress replication of the mutant virus.","Fujiwara2008"
"55577","Nef138-10","282","B","B","B","Nef","134","143","","9196..9225","A*2402","RYPLTFGWCF","RYPLTFGWCy","F10Y","F143Y","OV","observed variant","","The frequency of this mutant was much lower in the population.","Fujiwara2008"
"55577","Nef138-10","283","B","B","B","Nef","134","143","","9196..9225","A*2402","RYPLTFGWCF","RYPLcFGWCF","T5C","T138C","OV","observed variant","","The frequency of this mutant was much lower in the population.","Fujiwara2008"
"55577","Nef138-10","284","B","B","B","Nef","134","143","","9196..9225","A*2402","RYPLTFGWCF","RfPLcFGWCF","Y2F, T5C","Y135F, T138C","OV","observed variant","","The frequency of this mutant was much lower in the population.","Fujiwara2008"
"55577","Nef138-10","285","B","B","B","Nef","134","143","","9196..9225","A*2402","RYPLTFGWCF","RfPLlFGWCF","Y2F, T5L","Y135F, T138L","OV","observed variant","","Only few variants found in the population","Fujiwara2008"
"55577","Nef138-10","286","B","B","B","Nef","134","143","","9196..9225","A*2402","RYPLTFGWCF","RfPiTFGWCF","Y2F, L4I","Y135F, L137I","OV","observed variant","","Only few variants found in the population","Fujiwara2008"
"55577","Nef138-10","287","B","B","B","Nef","134","143","","9196..9225","A*2402","RYPLTFGWCF","RYPLTFGWpF","C9P","C142P","OV","observed variant","","Only few variants found in the population","Fujiwara2008"
"55577","Nef138-10","288","B","B","B","Nef","134","143","","9196..9225","A*2402","RYPLTFGWCF","RlPLTFGWCF","Y2L","Y135L","OV","observed variant","","Only few variants found in the population","Fujiwara2008"
"55577","Nef138-10","289","B","B","B","Nef","134","143","","9196..9225","A*2402","RYPLTFGWCF","RfPLTFGWsF","Y2F, C9S","Y135F, C142S","OV","observed variant","","Only few variants found in the population","Fujiwara2008"
"52936","Nef138-10","301","B","B","B","Nef","134","143","","9196..9225","A*2402","RYPLTFGWCF","RfPLTFGWCF","Y2F","Y135F","E, P","escape documented in this paper, processing","Chromium-release assay, HLA binding","The variant was positively selected in Japanese HLA A24 positive patients. Escape was experimentally confirmed and suggested as processing and antigen presentation escape. Mutant peptides bound well to the HLA A*2402 heavy chain but were expressed poorly on the cell surface from the native protein and the Y/F substitution virtually abolished the killing by the CTL clones.","Furutsuki2004"
"53726",,"455","B, CRF02_AG","AG, B","AG, B","Nef","134","143","","9196..9225","A24, B35","RYPLTFGWCY","RYPLTFGWCf","Y10F","Y143F","OV","observed variant","","All subjects that had this epitope variant reacted with the wt peptide. This was the most common variant in both subtypes, found in 3/9 CRF02_AG and 3/5 subtype B infected patients.","Inwoley2005"
"53726",,"456","B, CRF02_AG","AG, B","AG, B","Nef","134","143","","9196..9225","A24, B35","RYPLTFGWCY","RfPLTFGWCf","Y10F, Y2F","Y143F, Y135F","OV","observed variant","","One CRF02_AG subject that recognized the wt peptide carried this variant sequence. The variant was found in 3/9 CRF02_AG infected patients.","Inwoley2005"
"53726",,"457","B, CRF02_AG","AG, B","B","Nef","134","143","","9196..9225","A24, B35","RYPLTFGWCY","RYPLTyGWCf","Y10F, F6Y","Y143F, F139Y","OV","observed variant","","The variant was found in 2/5 subtype B infected patients.","Inwoley2005"
"53770",,"863","B, CRF01_AE","B","CRF01_AE","Nef","134","143","","9196..9225","A*24","RYPLTFGWCY","RYPLcFGWCY","T5C","T138C","OV","observed variant","Computer prediction","This variant did not occur in any of the CRF01 patients without an additional Y/F mutation. However, the score was checked and it had the same binding score to HLA as the wt epitope.","Lazaro2005"
"53770",,"864","B, CRF01_AE","B","CRF01_AE","Nef","134","143","","9196..9225","A*24","RYPLTFGWCY","RYPLcFGWCf","Y10F, T5C","Y143F, T138C","OV","observed variant","","Variant was the most common, found in 20/23 patients infected with CRF01_AE.","Lazaro2005"
"53770",,"865","B, CRF01_AE","B","CRF01_AE","Nef","134","143","","9196..9225","A*24","RYPLTFGWCY","RfPLcFGWCf","Y10F, Y2F, T5C","Y143F, Y135F, T138C","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53852",,"1583","","","","Nef","134","143","","9196..9225","A24","RYPLTFGWCF","RfPLTFGWCF","Y2F","Y135F","LE, OV","literature escape, observed variant","CD8 T-cell Elispot - IFNy, Sequence","This variant from the HXB2 sequence was absent in the non-HLA-A24 carrying mother; but was present early in infant P-1026, becoming the predominant form by 13 months.  This Y135F mutation is a previously described  escape in hemophiliacs.","Sanchez-Merino2005"
"53852",,"1584","","","","Nef","134","143","","9196..9225","A24","RYPLTFGWCF","kfPLTFGWCF","R1K, Y2F","R134K, Y135F","OV","observed variant","Sequence","This variant from the HXB2 sequence was absent in the non-HLA-A24 carrying mother; but was present early in infant P-1026 at a very low copy number.","Sanchez-Merino2005"
"53852",,"1585","","","","Nef","134","143","","9196..9225","A24","RYPLTFGWCF","RYPLTlGWCF","F6L","F139L","IE","inferred escape","Sequence","This variant from the HXB2 sequence was absent in the non-HLA-A24 carrying mother; but was present early in infant P-1026.","Sanchez-Merino2005"
"55576","Nef138-10","1653","","","","Nef","134","143","","9196..9225","A*2402","RYPLTFGWCF","RfPLTFGWCF","Y2F","Y135F","IE, LE, RCR","inferred escape, literature escape, replicative capacity reduced","Sequence, Tetramer binding","All 12 subjects developed this previously described Y2F escape variant which correlates with increased viral load and diminished CTL response.   Nef138-WT had a much stronger binding affinity to Nef138-WT-specific CTL clones than to Nef-138-2F-specific CTL clones and vice versa.  Nef-138-WT-specific CTL clones strongly suppressed WT viral replication, but only weakly suppressed 2F mutant replication.  Coupled with longitudinal evidence of positive selection of the Nef138-2F variant under pressure from Nef-138-WT-CTLs, the authors strongly suggest this is an escape.","Tanuma2008"
"55576","Nef138-10","1654","","","","Nef","134","143","","9196..9225","A*2402","RYPLTFGWCF","RYPiTFGWCF","L4I","L137I","OV","observed variant","Sequence, Tetramer binding","1/12 subjects developed this L4I variant.","Tanuma2008"
"55576","Nef138-10","1655","","","","Nef","134","143","","9196..9225","A*2402","RYPLTFGWCF","RfPiTFGWCF","Y2F, L4I","Y135F, L137I","OV","observed variant","Sequence, Tetramer binding","1/12 subjects developed this double mutation variant.","Tanuma2008"
"55576","Nef138-10","1656","","","","Nef","134","143","","9196..9225","A*2402","RYPLTFGWCF","RfPLcFGWCF","Y2F, T5C","Y135F, T138C","OV","observed variant","Sequence, Tetramer binding","1/12 subjects developed this double mutation variant.","Tanuma2008"
"55576","Nef138-10","1657","","","","Nef","134","143","","9196..9225","A*2402","RYPLTFGWCF","RYPLcFGWCF","T5C","T138C","IE, LE","inferred escape, literature escape","Sequence, Tetramer binding","1/12 subjects developed this T5C previously suspected escape variant, which results in decreased viral control.","Tanuma2008"
"53876",,"1874","B","B","B","Nef","134","143","","9196..9225","A*24","RYPLTFGWCF","RYPLcFGWCF","T5C","T138C","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Autologous variant differed from the Strain B consensus, but was recognized.","Yang2005"
"53770",,"2293","B, CRF01_AE","B","CRF01_AE","Nef","134","143","","9196..9225","A*24","RYPLTFGWCY","R(f)YPLcFGWCf","Y10F, -(1.1)F, T5C","Y143F, -(134.1)F, T138C","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53770",,"2294","B, CRF01_AE","B","CRF01_AE","Nef","134","143","","9196..9225","A*24","RYPLTFGWCY","RYPLcF(a)GWCf","Y10F, T5C, -(6.1)A","Y143F, T138C, -(139.1)A","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"57498",,"2518","B","B","B","Nef","134","143","","9196..9225","","RYPLTFGWCF","--PLTFGWCyKL","R1-, F10Y, Y2-","R134-, F143Y, Y135-","A, SF","HLA association, susceptible form","CD8 T-cell Elispot - IFNy","This 'adapted epitope' or variant from the polyallelic peptide set was part of the 13 central Nef adapted epitopes, 7 of which elicited responses in >20% of responders.  Epitope --PLTFGWCyKL was able to elicit a response in 29% of responding subjects.  It is restricted by HLA A*02.","Almeida2010"
"57498",,"2519","B","B","B","Nef","134","143","","9196..9225","","RYPLTFGWCF","-fPLTFGWCG","R1-, F10G, Y2F","R134-, F143G, Y135F","A, SF","HLA association, susceptible form","CD8 T-cell Elispot - IFNy","This 'adapted epitope' or variant from the polyallelic peptide set was part of the 13 central Nef adapted epitopes, 7 of which elicited responses in >20% of responders.  Epitope -fPLTFGWCG was able to elicit a response in 35% of responding subjects.  It is restricted by HLA A*23, A*24 and B*35.","Almeida2010"
"57498",,"2520","B","B","B","Nef","134","143","","9196..9225","","RYPLTFGWCF","-YPLTFGWCy","R1-, F10Y","R134-, F143Y","A, SF","HLA association, susceptible form","CD8 T-cell Elispot - IFNy","This 'adapted epitope' or variant from the polyallelic peptide set was part of the 13 central Nef adapted epitopes, 7 of which elicited responses in >20% of responders.  Epitope -YPLTFGWCy was able to elicit a response in 29% of responding subjects.  It is restricted by HLA B*18 and B*35.","Almeida2010"
"57498",,"2521","B","B","B","Nef","134","143","","9196..9225","","{I}RYPLTFGWCF","{t}RYPLTFGW","I-1T","I133T","A, SF","HLA association, susceptible form","CD8 T-cell Elispot - IFNy","This 'adapted epitope' or variant from the polyallelic peptide set was part of the 13 central Nef adapted epitopes, 7 of which elicited responses in >20% of responders.  Epitope {t}RYPLTFGW was able to elicit a response in 24% of responding subjects.  It is restricted by HLA A*33, B*14 and Cw*04.","Almeida2010"
"59197","Nef134-10","3317","B","B","B","Nef","134","143","",,"A*2402","RYPLTFGWCF","RfPLTFGWCF","Y2F","Y135F","E, OV","escape documented in this paper, observed variant","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","Most (33/46) subjects carried this sequence RfPLTFGWCF, in epitope Nef134-10: Nef126-143 sequence, NYTPGPGIRfPLTFGWCF exists in 2/46 (4.3%), cYTPGPGIRfPLTFGWCF exists in 1/46 (2.2%), gYTPGPGIRfPLTFGWCF exists in 1/46 (2.2%), cYTPGPGtRfPLTFGWCF exists in 1/46 (2.2%), gYTPGPGtRfPLTFGWCF exists in 1/46 (2.2%), NYTPGPGtRfPLTFGWCF exists in 23/46 (50%), gYTPGPGtRfPLTFGWCF exists in 1/46 (2.2%), NYTPGPGvRfPLTFGWCF exists in 4/46 (8.7%).","Han2014"
"59197","Nef134-10","3318","B","B","B","Nef","134","143","",,"A*2402","RYPLTFGWCF","RfPLcFGWCF","Y2F, T5C","Y135F, T138C","E, OV","escape documented in this paper, observed variant","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","2/46 subjects carried this sequence, RfPLcFGWCF, in epitope Nef134-10: Nef126-143 sequence, NYTPGPGIRfPLcFGWCF exists in 1/46 (2.2%)and NYTPGPGeRfPLcFGWCF exists in 1/46 (2.2%).","Han2014"
"59197","Nef134-10","3319","B","B","B","Nef","134","143","",,"A*2402","RYPLTFGWCF","RlPLTFGWCF","Y2L","Y135L","OV","observed variant","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","2/46 subjects carried this sequence, RlPLTFGWCF, in epitope Nef134-10: Nef126-143 sequence, NYTPGPGvRlPLTFGWCF exists in those subjects.","Han2014"
"59197","Nef134-10","3320","B","B","B","Nef","134","143","",,"A*2402","RYPLTFGWCF","RwPLTFGWCF","Y2W","Y135W","OV","observed variant","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","1/46 subjects carried this sequence, RwPLTFGWCF, in epitope Nef134-10: Nef126-143 sequence, NYTPGPGtRwPLTFGWCF exists in that subject.","Han2014"
"59197","Nef134-10","3321","B","B","B","Nef","134","143","",,"A*2402","RYPLTFGWCF","RYPLTFGWCy","F10Y","F143Y","OV","observed variant","CD8 T-cell Elispot - IFNy, HLA binding, Sequence","1/46 subjects carried this sequence, RYPLTFGWCy, in epitope Nef134-10: Nef126-143 sequence, NYTPGPGIRYPLTFGWCy exists in that subject.","Han2014"
"59197","Nef134-10","3322","B","B","B","Nef","134","143","",,"A*2402","RYPLTFGWCF","RYPLTlGWCF","F6L","F139L","OV","observed variant","Sequence","3/46 subjects carried this sequence, RYPLTlGWCF, in epitope Nef134-10: Nef126-143 sequence, NYTPGPGIRYPLTlGWCF exists in 2 subjects and cYTPGPGtRYPLTlGWCF in 1 subject.","Han2014"
"59197","Nef134-10","3323","B","B","B","Nef","134","143","",,"A*2402","RYPLTFGWCF","RYPLTlGWCy","F10Y, F6L","F143Y, F139L","OV","observed variant","Sequence","1/46 subjects carried this sequence, RYPLTlGWCy, in epitope Nef134-10: Nef126-143 sequence, NYTPGPGIRYPLTlGWCy exists in that subject.","Han2014"
"59197","Nef134-10","3324","B","B","B","Nef","134","143","",,"A*2402","RYPLTFGWCF","RYPLTFGWpF","C9P","C142P","OV","observed variant","Sequence","1/46 subjects carried this sequence, RYPLTFGWpF, in epitope Nef134-10: Nef126-143 sequence, NYTPGPGIRYPLTlGWpF exists in that subject.","Han2014"
"59197","Nef134-10","3325","B","B","B","Nef","134","143","",,"A*2402","RYPLTFGWCF","RYPLcFGWCF","T5C","T138C","OV","observed variant","Sequence","1/46 subjects carried this sequence, RYPLcFGWCF, in epitope Nef134-10: Nef126-143 sequence, NYTPGPGIRYPLcFGWCF exists in that subject.","Han2014"
"1066",,"132","B","","","Nef","134","144","","9196..9228","B18","RYPLTFGWCYK","RYPLcFGWCYK","T5C","T138C","E","escape documented in this paper","Chromium-release assay, HLA binding","Mutants with T5C mutation (RYPLcFGWCYK) evade HLA-B18-restricted CTL responses.","Goulder1997e, Couillin1994"
"53628",,"120","B","","","Nef","135","143","","9199..9225","B18, B35, B49, B53, B7","YPLTFGWCY","YPLTFGWCf","Y9F","Y143F","SF","susceptible form","","A predominant sequence of ypltfgwcF was found in 2 patients (in 11/11 and 15/15 sequences) that cross-recognized the peptide used for screening, YPLTFGWCY. In patient B, CD8 T-cell response of 0.95% was found for the dominant variant, while the response for the screening epitope ypltfgwcy was 0.58%. In patient F, the frequency of response did not differ significantly between the 2 variants. Assays for both patients were done immediately prior to the initiation of therapy.","Casazza2005a"
"53737",,"458","B, CRF02_AG","AG, B","AG, B","Nef","135","143","","9199..9225","B18, B53, B7","YPLTFGWCY","YPLTFGWCf","Y9F","Y143F","OV","observed variant","","One of the three CRF02_AG subjects that recognized the wt peptide carried this variant sequence. 3/8 CRF02 patients and 3/5 subtype B patients carried a variant of the epitope.","Inwoley2005"
"53737",,"459","B, CRF02_AG","AG, B","B","Nef","135","143","","9199..9225","B18, B53, B7","YPLTFGWCY","fPLTFGWCf","Y1F, Y9F","Y135F, Y143F","OV","observed variant","","One subtype B subject that recognized the wt peptide carried this variant sequence. The variant was found in 3/5 subtype B infected patients.","Inwoley2005"
"53737",,"460","B, CRF02_AG","AG, B","AG, B","Nef","135","143","","9199..9225","B18, B53, B7","YPLTFGWCY","YPLTyGWCf","F5Y, Y9F","F139Y, Y143F","OV","observed variant","","The variant was found in 3/9 CRF02_AG infected patients.","Inwoley2005"
"1679",,"678","","","","Nef","135","143","","9199..9225","B18, B49","YPLTFGWCY","YPLTFGWCf","Y9F","Y143F","SF","susceptible form","CD8 T-cell Elispot - IFNy","This epitope and the variant were recognized by 8/9 HIV infected women and by 1/4 HIV-exposed, persistently seronegative women.","Kaul2001a"
"54524","YF9","1041","B","A, B, C","A, B, C","Nef","135","143","","9199..9225","B18, B35","YPLTFGWCF","fPLTFGWCF","Y1F","Y135F","SF, SSF","susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant was found by challenge of 23 subjects with a novel Nef potential T-cell epitope panel in Subtype B.   It was the only HLA-B35-restricted autologous variant sequence found.  fPLTFGWCF was recognized by CTL restricted by either HLA-B35 or -B18.","Malhotra2007a"
"54524","YF9","1042","B","A, B, C","B","Nef","135","143","","9199..9225","B18, B35","YPLTFGWCF","YPLcFGWCF","T4C","T138C","SF, SSF","susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant was found by challenge of 23 subjects with a novel Nef potential T-cell epitope panel in Subtype B.   It was not found as an autologous sequence but was recognized by HLA-B35-restricted CTL.","Malhotra2007a"
"54524","YF9","1043","B","A, B, C","CRFs","Nef","135","143","","9199..9225","B18, B35","YPLTFGWCF","fPLcFGWCF","Y1F, T4C","Y135F, T138C","SF, SSF","susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant was found by challenge of 23 subjects with a novel Nef potential T-cell epitope panel in Subtype B.   It was not found as an autologous sequence but was recognized by HLA-B35-restricted CTL.","Malhotra2007a"
"54524","YF9","1044","B","A, B, C","A, C","Nef","135","143","","9199..9225","B18, B35","YPLTFGWCF","YPLTFGWCy","F9Y","F143Y","SF, SSF","susceptible form, subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant was found by challenge of 23 subjects with a novel Nef potential T-cell epitope panel in Subtype B.   It was not found as an autologous sequence but was recognized by HLA-B35- or HLA-B18-restricted CTL.","Malhotra2007a"
"54524","YF9","1045","B","A, B, C","F","Nef","135","143","","9199..9225","B18, B35","YPLTFGWCF","YPLTlGWCF","F5L","F139L","NSF, SF, SNSF","non-susceptible form, susceptible form, subtype-specific non-susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant was found by challenge of 23 subjects with a novel Nef potential T-cell epitope panel in Subtype B.   It was not found as an autologous sequence and was not recognized by HLA-B35- or HLA-B18- (Subject 1362) restricted CTL.","Malhotra2007a"
"1072",,"1552","B","B","D","Nef","135","143","","9199..9225","B49","YLPTFGWCY","YLPTFGWCf","Y9F","Y143F","OV","observed variant","Chromium-release assay","Two HEPS Kenyan subjects cross-reacted to this B clade epitope though it differed from the D clade form, YLPTFGWCf.","Rowland-Jones1998"
"1069",,"1562","","B","D","Nef","135","143","","9199..9225","B49","YPLTFGWCY","YPLTFGWCf","Y9F","Y143F","OV","observed variant","Chromium-release assay","5/6 Kenyan HEPS subjects recognized this clade B epitope which differed from the clade A variant, YPLTFGWCf.","RowlandJones1998b"
"53875",,"1876","B","B","B","Nef","135","143","","9199..9225","B*35","YPLTFGWCF","YPLcFGWCF","T4C","T138C","SSF","subtype-specific susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Autologous variant differed from the Strain B consensus, but was recognized.","Yang2005"
"1754",,"89","CRF01_AE","B","CRF01_AE","Nef","136","145","","9202..9231","A*02","PLTFGWCYKL","PLcFGWCfKL","T3C, Y8F","T138C, Y143F","SNSF","subtype-specific non-susceptible form","Chromium-release assay, HLA binding","0/4 HLA-A2 tested subjects recognized the E clade version PLcFGWCfKL, which differs from the previously defined B clade version (PLTFGWCYKL) by two amino acids.","Bond2001"
"53771",,"866","B, CRF01_AE","B","CRF01_AE","Nef","136","145","","9202..9231","A*02","PLTFGWCYKL","PLcFGWCfKL","T3C, Y8F","T138C, Y143F","OV","observed variant","Computer prediction","This was the most common variant in CRF01 (22/23 patients). It had similar binding score to HLA as the wt epitope.","Lazaro2005"
"55902","PL11(Nef)","1951","B","B","B","Nef","136","145","","9202..9231","","PLTFGWCFKL","PLTFGWCyKL","F8Y","F143Y","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-A2 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"53771",,"2307","B, CRF01_AE","B","CRF01_AE","Nef","136","145","","9202..9231","A*02","PLTFGWCYKL","PLcF(a)GWCfKL","T3C, -(4.1)A, Y8F","T138C, -(139.1)A, Y143F","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"59262",,"3432","B","B","B","Nef","136","145","",,"","PLTFGWCFKL","PLTLGWCFKL","F4L","F139L","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","First variant detected; seen only at early post-seroconversion period; no Elispot response.","Melhem2014"
"59262",,"3433","B","B","B","Nef","136","145","",,"","PLTFGWCFKL","PITFGWCFKL","L2I","L137I","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Second variant detected; seen only at early post-seroconversion period; strongly positive Elispot response &tilde;200 SFC/10<sup>6</sup>PBMC .","Melhem2014"
"59262",,"3434","B","B","B","Nef","136","145","",,"","PLTFGWCFKL","PVTFGWCFKL","L2V","L137V","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Third variant detected; seen in early post-seroconversion period; positive Elispot response &tilde;200 SFC/10<sup>6</sup>PBMC .","Melhem2014"
"59262",,"3435","B","B","B","Nef","136","145","",,"","PLTFGWCFKL","PLCFGWCFKL","T3C","T138C","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Fourth variant detected; seen in the late post-seroconversion, early ART, and late ART periods; positive Elispot response in the late post-seroconversion (<50 SFC/10<sup>6</sup>PBMC ) and early ART (&tilde;50 SFC/10<sup>6</sup>PBMC ) periods; response lost in the late ART period.","Melhem2014"
"59262",,"3436","B","B","B","Nef","136","145","",,"","PLTFGWCFKL","PVCFGWCFKL","L2V, T3C","L137V, T138C","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Fifth variant detected; seen in the late post-seroconversion period; no Elispot response.","Melhem2014"
"59262",,"3437","B","B","B","Nef","136","145","",,"","PLTFGWCFKL","PMCFGWCFKL","L2M, T3C","L137M, T138C","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Sixth variant detected; seen in the late post-seroconversion, early ART and late ART periods; positive Elispot response only in the early ART period (&tilde;100 SFC/10<sup>6</sup>PBMC ).","Melhem2014"
"59262",,"3438","B","B","B","Nef","136","145","",,"","PLTFGWCFKL","PLCFGWCFKP","L10P, T3C","L145P, T138C","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Seventh variant detected; seen in the late post-seroconversion period; Elispot response <50 SFC/10<sup>6</sup>PBMC .","Melhem2014"
"55394","Nef 141","1687","","","","Nef","141","148","","9217..9240","A2","WCFKLVPV","WCyKLVPV","F3Y","F143Y","OV","observed variant","CD8 T-cell Elispot - IFNy, Flow cytometric T-cell cytokine assay, Sequence","Subjects Pt15 and Pt16 carried the HXB2 epitope WCYKLVPV; but while Pt15 was able to cross-recognize the challenge variant sequence WCFKLVPV, Pt 16 was not.","Thorn2007"
"1755",,"90","CRF01_AE","","","Nef","180","189","","9334..9363","A*02","VLEWRFDSRL","VLiWkFDSaL","E3I, R5K, R9A","E182I, R184K, R188A","SNSF","subtype-specific non-susceptible form","","0/4 HLA-A2 tested subjects recognized the E clade version VLiWkFDSa, which differs from the previously defined B clade version (VLEWRFDSRL) by three amino acids.","Bond2001"
"54566","VL10","662","B","","","Nef","180","189","","9334..9363","A*02","VLEWRFDSRL","VLEWRFDSsL","R9S","R188S","IE","inferred escape","CD8 T-cell Elispot - IFNy","Author tabulates this variant found at week 10 in 2/16 clones from patient OP177 as viral escape. No CTL response detected against the variant.","Karlsson2007"
"54566","VL10","663","B","","","Nef","180","189","","9334..9363","A*02","VLEWRFDSRL","VLEWRFgSRL","D7G","D186G","IE","inferred escape","CD8 T-cell Elispot - IFNy","Author tabulates this variant found at week 13 in 1/26 clones from patient OP177 as viral escape. No CTL response detected against the variant.","Karlsson2007"
"54566","VL10","664","B","","","Nef","180","189","","9334..9363","A*02","VLEWRFDSRL","VLEWkFDSRL","R5K","R184K","DR","diminished response","CD8 T-cell Elispot - IFNy","Variant found at week 158 in 4/14 clones. A less intense CTL response targeted this variant than the wt epitope.","Karlsson2007"
"53772",,"867","B, CRF01_AE","B","CRF01_AE","Nef","180","189","","9334..9363","A*02","VLEWRFDSRL","VLmWkFDSaL","E3M, R5K, R9A","E182M, R184K, R188A","OV","observed variant","Computer prediction","This CRF01_AE variant was the most common, 14/23 patients, and it had a higher HLA- binding score than the HXB2 epitope, which isn't predicted to bind to A2.","Lazaro2005"
"53772",,"868","B, CRF01_AE","B","CRF01_AE","Nef","180","189","","9334..9363","A*02","VLEWRFDSRL","VLiWkFDSaL","E3I, R5K, R9A","E182I, R184K, R188A","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53772",,"869","B, CRF01_AE","B","CRF01_AE","Nef","180","189","","9334..9363","A*02","VLEWRFDSRL","VLmWkFDSsL","E3M, R5K, R9S","E182M, R184K, R188S","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53772",,"870","B, CRF01_AE","B","CRF01_AE","Nef","180","189","","9334..9363","A*02","VLEWRFDSRL","limWkFDSaL","V1L, L2I, E3M, R5K, R9A","V180L, L181I, E182M, R184K, R188A","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53772",,"871","B, CRF01_AE","B","CRF01_AE","Nef","180","189","","9334..9363","A*02","VLEWRFDSRL","VLmWkFDtaL","E3M, R5K, S8T, R9A","E182M, R184K, S187T, R188A","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53772",,"872","B, CRF01_AE","B","CRF01_AE","Nef","180","189","","9334..9363","A*02","VLEWRFDSRL","VLmWqFDSaL","E3M, R5Q, R9A","E182M, R184Q, R188A","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"55859",,"1100","B","","","Nef","180","189","","9334..9363","A*02","VLEWRFDSRL","VLkWRFDSRL","E3K","E182K","SF","susceptible form","CD8 T-cell Elispot - IFNy","Appearance of variant with increase in viral load, but it was recognized.","Maurer2008"
"55859",,"1101","B","","","Nef","180","189","","9334..9363","A*02","VLEWRFDSRL","VLEWkFDSRL","R5K","R184K","SF","susceptible form","CD8 T-cell Elispot - IFNy","Appearance of variant with increase in viral load.  Variant recognized by patient.","Maurer2008"
"55903","VL10(Nef)","1952","B","B","B","Nef","180","189","","9334..9363","","VLMWKFDSRL","VLeWrFDSRL","M3E, K5R","M182E, K184R","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at 2 residues. It is predicted to be HLA-A2 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"53772",,"2296","B, CRF01_AE","B","CRF01_AE","Nef","180","189","","9334..9363","A*02","VLEWRFDSRL{*}","VLmWkFDSaL{a}","*+1A, E3M, R5K, R9A","*190A, E182M, R184K, R188A","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53772",,"2297","B, CRF01_AE","B","CRF01_AE","Nef","180","189","","9334..9363","A*02","VLEWRFDSRL","VLmWkFDSa(s)L","E3M, R5K, R9A, -(9.1)S","E182M, R184K, R188A, -(188.1)S","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"59263",,"3439","B","B","B","Nef","180","189","",,"","VLVWRFDSSL","VLVWKFDSSL","R5K","R184K","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","First variant detected; seen in early and late post-seroconversion periods; Elispot response only in late post-SC (seroconversion) period (&tilde;50 SFC/10<sup>6</sup>PBMC ).","Melhem2014"
"59263",,"3440","B","B","B","Nef","180","189","",,"","VLVWRFDSSL","VLVWKSDSSL","R5K, F6S","R184K, F185S","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Second variant detected; Elispot response not tested.","Melhem2014"
"59263",,"3441","B","B","B","Nef","180","189","",,"","VLVWRFDSSL","VLVWKFDSNL","R5K, S9N","R184K, S188N","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Third variant detected; Elispot response not measured.","Melhem2014"
"59263",,"3442","B","B","B","Nef","180","189","",,"","VLVWRFDSSL","VLVWKFDSKL","R5K, S9K","R184K, S188K","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Fourth variant detected; seen in early and late ART periods; Elispot response &tilde;600 SFC/10<sup>6</sup>PBMC  in early ART and &tilde;100 SFC/10<sup>6</sup>PBMC  in late ART.","Melhem2014"
"59263",,"3443","B","B","B","Nef","180","189","",,"","VLVWRFDSSL","VLVWKFDSRL","R5K, S9R","R184K, S188R","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","Fifth variant detected; seen in early and late ART periods; Elispot response increased from early ART (&tilde;200 SFC/10<sup>6</sup>PBMC ) to late ART (&tilde;300 SFC/10<sup>6</sup>PBMC ) periods.","Melhem2014"
"59263",,"3444","B","B","B","Nef","180","189","",,"","VLVWRFDSSL","VLVWKFDSHL","R5K, S9H","R184K, S188H","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","Sixth variant detected; seen in early and late ART periods; no Elispot response.","Melhem2014"
"58248",,"2848","B","B","B","Nef","181","189","","9337..9363","A*0201","LEWRFDITL","LaWRFDITL","E2A","E182A","IE","inferred escape","Sequence","Epitope LEWRFDITL varied at 228 and 368  DFOSx to LaWRFDITL.  Position 182 in the epitope is marked as being under selection to vary.","Ferrari2011"
"58248",,"2849","B","B","B","Nef","181","189","","9337..9363","A*0201","LEWRFDITL","LqWRFDITL","E2Q","E182Q","IE","inferred escape","Sequence","Epitope LEWRFDITL varied at 228, 552 and 718  DFOSx to LqWRFDITL.  Position 182 in the epitope is marked as being under selection to vary.","Ferrari2011"
"58248",,"2850","B","B","B","Nef","181","189","","9337..9363","A*0201","LEWRFDITL","LpWRFDITL","E2P","E182P","IE","inferred escape","Sequence","Epitope LEWRFDITL varied at 228 DFOSx to LpWRFDITL.  Position 182 in the epitope is marked as being under selection to vary.","Ferrari2011"
"58248",,"2851","B","B","B","Nef","181","189","","9337..9363","A*0201","LEWRFDITL","LvWRFDITL","E2P","E182P","IE","inferred escape","Sequence","Epitope LEWRFDITL varied at 552 and 718 DFOSx to LvWRFDITL.  Position 182 in the epitope is marked as being under selection to vary.","Ferrari2011"
"55075",,"218","B, C","B","C","Nef","183","191","","9343..9369","B*1503","WKFDSRLAF","WKFDSqLAF","R6Q","R188Q","SNSF","subtype-specific non-susceptible form","","WKFDSRLAF epitope is found in subtype B, while the variant is found in subtype C, Subtype B epitope is significantly more frequently recognized by  B*1503 positive individuals than the variant C epitope.","Frahm2006"
"54581","WF9","665","B","","","Nef","183","191","","9343..9369","B*15","WRFDSRLAF","WkFDSRLAF","R2K","R184K","SF","susceptible form","CD8 T-cell Elispot - IFNy","Variant found at week 158 in 4/14 clones. Variant elicited a potent HLA-B15 restricted immune response.","Karlsson2007"
"54581","WF9","666","B","","","Nef","183","191","","9343..9369","B*15","WRFDSRLAF","WRFgSRLAF","D4G","D186G","IE","inferred escape","CD8 T-cell Elispot - IFNy","Author tabulates this variant found at week 13 in 1/26 clones from patient OP177 as viral escape. No CTL response detected against the variant.","Karlsson2007"
"54581","WF9","667","B","","","Nef","183","191","","9343..9369","B*15","WRFDSRLAF","WRFDSsLAF","R6S","R188S","IE","inferred escape","CD8 T-cell Elispot - IFNy","Author tabulates this variant found at week 10 in 2/16 clones from patient OP177 as viral escape. No CTL response detected against the variant.","Karlsson2007"
"54581","WF9","668","B","","","Nef","183","191","","9343..9369","B*15","WRFDSRLAF","WRFDSRLAc","F9C","F191C","IE","inferred escape","CD8 T-cell Elispot - IFNy","Author tabulates this variant found at week 13 in 1/26 clones from patient OP177 as viral escape. No CTL response detected against the variant.","Karlsson2007"
"54581","WF9","669","B","","","Nef","183","191","","9343..9369","B*15","WRFDSRLAF","WRFDSRLAl","F9L","F191L","IE","inferred escape","CD8 T-cell Elispot - IFNy","Author tabulates this variant found at week 13 in 1/26 clones from patient OP177 as viral escape. No CTL response detected against the variant.","Karlsson2007"
"54542","WF9","1046","B","B","B","Nef","183","191","","9343..9369","B*1503","WKFDSRLAF","WKFDSRLAl","F9L","F191L","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant was found by challenge of 23 subjects with a novel Nef potential T-cell epitope panel in Subtype B.  It was recognized by HLA-B1503-restricted CTL (Subject 1188).","Malhotra2007a"
"54542","WF9","1047","B","B","B","Nef","183","191","","9343..9369","B*1503","WKFDSRLAF","WrFDSRLAF","K2R","K184R","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant was found by challenge of 23 subjects with a novel Nef potential T-cell epitope panel in Subtype B.   It was recognized by HLA-B1503-restricted CTL (Subject 1188).","Malhotra2007a"
"54542","WF9","1048","B","B","B","Nef","183","191","","9343..9369","B*1503","WKFDSRLAF","WKrDShLAF","F3R, R6H","F185R, R188H","SF","susceptible form","CD8 T-cell Elispot - IFNy, Sequence","This variant was found by challenge of 23 subjects with a novel Nef potential T-cell epitope panel in Subtype B.   It was recognized by HLA-B1503-restricted CTL (Subject 1188).","Malhotra2007a"
"54542","WF9","1049","B","B","B","Nef","183","191","","9343..9369","B*1503","WKFDSRLAF","WKFDSsLAF","R6S","R188S","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence","This variant was found by challenge of 23 subjects with a novel Nef potential T-cell epitope panel in Subtype B.  It was recognized by HLA-B1503-restricted CTL (Subject 1188), though at a 5-fold reduction.","Malhotra2007a"
"54542","WF9","1050","B","B","B","Nef","183","191","","9343..9369","B*1503","WKFDSRLAF","WKFDShLAF","R6H","R188H","DR","diminished response","CD8 T-cell Elispot - IFNy, Sequence","This variant was found by challenge of 23 subjects with a novel Nef potential T-cell epitope panel in Subtype B.  It was recognized by HLA-B1503-restricted CTL (Subject 1188), though at a 10-fold reduction.","Malhotra2007a"
"54542","WF9","1051","B","B","B","Nef","183","191","","9343..9369","B*1503","WKFDSRLAF","WKFaSRLAF","D4A","D186A","OV","observed variant","Sequence","This variant was the only WF9 autologous variant found in 1/12 clones from HLA-B1503-restricted Subject 1188.  It was not tested.","Malhotra2007a"
"55998","WF9(Nef)","1953","B","B","B","Nef","183","191","","9343..9369","","WKFDSRLAF","WrFDSRLAF","K2R","K184R","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B15 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"57248","WF9","2229","B","B","B","Nef","183","191","","9343..9369","B*1503","WKFDSRLAF","WKFDSRLAl","F9L","F190L","SF","susceptible form","CD8 T-cell Elispot granzyme B, CD8 T-cell Elispot - IFNy","The variant was recognized by IFN EliSpot and Granzyme B EliSpot in a newly infected patient.","Malhotra2009"
"57248","WF9","2230","B","B","B","Nef","183","191","","9343..9369","B*1503","WKFDSRLAF","WrFDSRLAF","K2R","K183R","SF","susceptible form","CD8 T-cell Elispot granzyme B, CD8 T-cell Elispot - IFNy","The variant was recognized by IFN EliSpot but not by and Granzyme B EliSpot in a newly infected patient.","Malhotra2009"
"57248","WF9","2231","B","B","B","Nef","183","191","","9343..9369","B*1503","WKFDSRLAF","WKFDShLAF","R6H","R187H","NSF","non-susceptible form","CD8 T-cell Elispot granzyme B, CD8 T-cell Elispot - IFNy","The variant had was had semi-conservative substitutions in presumed TCR contact sites and was not recognized neither by IFN&gamma; nor by EliSpot in a newly infected patient.","Malhotra2009"
"57248","WF9","2232","B","B","B","Nef","183","191","","9343..9369","B*1503","WKFDSRLAF","WrFDShLAF","K2R, R6H","K183R, R187H","NSF","non-susceptible form","CD8 T-cell Elispot granzyme B, CD8 T-cell Elispot - IFNy","The variant had was had semi-conservative substitutions in presumed TCR contact sites and was not recognized neither by IFN&gamma; nor by EliSpot in a newly infected patient.","Malhotra2009"
"57248","WF9","2233","B","B","B","Nef","183","191","","9343..9369","B*1503","WKFDSRLAF","WKFDSsLAF","R6S","R187S","NSF","non-susceptible form","CD8 T-cell Elispot granzyme B, CD8 T-cell Elispot - IFNy","The variant had was had semi-conservative substitutions in presumed TCR contact sites and was not recognized neither by IFN&gamma; nor by EliSpot in a newly infected patient.","Malhotra2009"
"57961","WF9","2692","A, B","B","B","Nef","183","191","","9343..9369","B*1503","WKFDSRLAF","WrFDSRLAF","K2R","K184R","SF","susceptible form","CD8 T-cell Elispot - IFNy, Longitudinal study","WKFDSRLAF underwent adaptation to neo-epitope WrFDSRLAF. 1 subject had higher EliSpot responses to the neo-epitope than to the non-adapted form.","Keane2012"
"55570","WY20","734","B","","","Nef","183","202","","9343..9402","B51","WKFDSRLAFHHMARELHPEY","WKFDSRLAFrHMARELHPEY","H10R","H192R","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","Loss of response to this 20-mer was due to loss of recognition of AL9 epitope contained within it.","Kemal2008"
"53773",,"873","B, CRF01_AE","B","CRF01_AE","Nef","184","191","","9346..9369","A*01","RFDSRLAF","kFDSaLAr","R1K, R5A, F8R","R184K, R188A, F191R","OV","observed variant","Computer prediction","This was the most common variant in CRF01 (14/23 patients). It had similar binding score to HLA as the wt epitope.","Lazaro2005"
"53773",,"874","B, CRF01_AE","B","CRF01_AE","Nef","184","191","","9346..9369","A*01","RFDSRLAF","kFDSaLey","R1K, R5A, A7E, F8Y","R184K, R188A, A190E, F191Y","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53773",,"875","B, CRF01_AE","B","CRF01_AE","Nef","184","191","","9346..9369","A*01","RFDSRLAF","kFDSaLAe","R1K, R5A, F8E","R184K, R188A, F191E","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53773",,"876","B, CRF01_AE","B","CRF01_AE","Nef","184","191","","9346..9369","A*01","RFDSRLAF","kFDSsLAr","R1K, R5S, F8R","R184K, R188S, F191R","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53773",,"877","B, CRF01_AE","B","CRF01_AE","Nef","184","191","","9346..9369","A*01","RFDSRLAF","kFDtaLAr","R1K, S4T, R5A, F8R","R184K, S187T, R188A, F191R","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53773",,"878","B, CRF01_AE","B","CRF01_AE","Nef","184","191","","9346..9369","A*01","RFDSRLAF","qFDSaLAr","R1Q, R5A, F8R","R184Q, R188A, F191R","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53773",,"2298","B, CRF01_AE","B","CRF01_AE","Nef","184","191","","9346..9369","A*01","RFDSRLAF","kFDSa(s)LAr","R1K, R5A, -(5.1)S, F8R","R184K, R188A, -(188.1)S, F191R","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"58241",,"2840","B","B","B","Nef","185","202","","9349..9402","A*0201","FDSRLAFHHIARELHPEY","FDSlLAFHHIARELHPEY","R4L","R188L","IE","inferred escape","Sequence","Peptide FDSRLAFHHIARELHPEY varied from 183 DFOSx onwards to FDSlLAFHHIARELHPEY.  Position 188 in the peptide is marked as being under selection to vary.","Ferrari2011"
"52992",,"321","","","","Nef","186","194","","9352..9378","B51","DSRLAFHHV","DSlLAlrHm","R3L, F6L, H7R, V9M","R188L, F191L, H192R, V194M","OV","observed variant","","The epitope varied over time but the mutations did not become fixed. The variant arose at early timepoints.","Geels2003"
"52992",,"322","","","","Nef","186","194","","9352..9378","B51","DSRLAFHHV","DSRLAvHHV","F6V","F191V","OV","observed variant","","The epitope varied over time but the mutations did not become fixed. The variant arose at intermediate timepoints.","Geels2003"
"53850","DM9","1586","B","","","Nef","186","194","","9352..9378","A24","DSRLAFHHM","DSRLAFqHM","H7Q","H192Q","DR, LE","diminished response, literature escape","CD8 T-cell Elispot - IFNy, Sequence","This variant from the HXB2 sequence was present in the non-HLA-A24 allele carrying mother, M-1001, as well as her restricting HLA-A24-carrying infant, P-1024.  Infant P-1024 had lost this variant by 15 months of age.  Decreased recognition of the variant was seen relative to the index epitope.","Sanchez-Merino2005"
"53850","DM9","1587","B","","","Nef","186","194","","9352..9378","A24","DSRLAFHHM","DStLAFqHk","R3T, H7Q, M9K","R188T, H192Q, M194K","DR, LE","diminished response, literature escape","CD8 T-cell Elispot - IFNy, Sequence","This variant from the HXB2 sequence was present in the restricting HLA-A24 allele carrying mother, M-1003, as well as her restricting HLA-A24-carrying infant, P-1089.   This variant was still detected at 15 months of age.  Decreased recognition of the variant was seen relative to the index epitope.","Sanchez-Merino2005"
"56049","RR9(Nef)","1954","B","B","B","Nef","188","196","","9358..9384","","RLAFHHMAR","RLAFHHvAR","M7V","M194V","OV","observed variant","CD8 T-cell Elispot - IFNy, Sequence","This Asian B Clade optimal epitope differs from the consensus B at one position. It is predicted to be HLA-B52 restricted. Experimentally, B clade consensus peptide was used to challenge CTL response in subjects commonly carrying the Asian B-type epitope.","Zhai2008"
"56635",,"1997","","","","Nef","188","196","","9358..9384","A*3101","SLAFRHVAR","nLAFRHVAR","S1N","S188N","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This S188N substitution was a dominating variant in Patient CH40. The variant was not recognized by EliSpot.","Goonetilleke2009"
"56635",,"2271","","","","Nef","188","196","","9358..9384","A*3101","SLAFRHVAR","SLAFRHVAq","R9Q","R196Q","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Intracellular cytokine staining, Sequence","This R196Q substitution was a dominating variant in Patient CH40. The variant was not recognized by EliSpot.","Goonetilleke2009"
"57431","SR9","2416","B","B","B","Nef","188","196","","9358..9384","","SLAFRHVAR","SLAFRHVAq","R9Q","R196Q","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","Variant SLAFRHVAq was an escape as found by ELISpot and it increased in overall relative frequency with time.  It had a loss/accumulation rate of 0.17.","Fischer2010"
"57431","SR9","2417","B","B","B","Nef","188","196","","9358..9384","","SLAFRHVAR","SLAFhHVAR","R5H","R192H","IE","inferred escape","Sequence","This most common variant at day 16 after onset of symptoms in patient CH40 became subdominant by day 45.  Estimated accumulation or loss rate was -0.04.","Fischer2010"
"57431","SR9","2418","B","B","B","Nef","188","196","","9358..9384","","SLAFRHVAR","nLAFRHVAR","S1N","S188N","E","escape documented in this paper","CD8 T-cell Elispot - IFNy, Sequence","Variant nLAFRHVAR was an escape as found by ELISpot and it had a marginal increase in relative frequency with time.","Fischer2010"
"57431","SR9","2419","B","B","B","Nef","188","196","","9358..9384","","SLAFRHVAR","rLAFRHVAR","S1R","S188R","IE","inferred escape","Sequence","Transient variant rLAFRHVAR was not seen before day 16 after onset of symptoms and was lost by day 45.","Fischer2010"
"57431","SR9","2420","B","B","B","Nef","188","196","","9358..9384","","SLAFRHVAR","SLAFRHmAR","V7M","V194M","OV","observed variant","Sequence","Transient variant SLAFRHmAR was not seen before day 16 after onset of symptoms and was lost by day 45.","Fischer2010"
"57431","SR9","2421","B","B","B","Nef","188","196","","9358..9384","","SLAFRHVAR","SLAFRHeAR","V7E","V194E","OV","observed variant","Sequence","Transient variant SLAFRHeAR was not seen before day 16 after onset of symptoms and was lost by day 45.","Fischer2010"
"57431","SR9","2422","B","B","B","Nef","188","196","","9358..9384","","SLAFRHVAR","SLAFcHVAR","R5C","R192C","OV","observed variant","Sequence","Variant SLAFcHVAR had a marginal increase in relative frequency with time.","Fischer2010"
"57431","SR9","2423","B","B","B","Nef","188","196","","9358..9384","","SLAFRHVAR","iLAFRHVAR","S1I","S188I","OV","observed variant","Sequence","Transient variant iLAFRHVAR was not seen before day 16 after onset of symptoms and was lost by day 45.","Fischer2010"
"57431","SR9","2424","B","B","B","Nef","188","196","","9358..9384","","SLAFRHVAR","gLAFRHVAR","S1G","S188G","OV","observed variant","Sequence","Transient variant gLAFRHVAR was lost by day 45 after onset of symptoms.","Fischer2010"
"57431","SR9","2425","B","B","B","Nef","188","196","","9358..9384","","SLAFRHVAR","SLAFRHaAR","V7A","V194A","OV","observed variant","Sequence","Variant SLAFRHaAR had a marginal increase in relative frequency with time.","Fischer2010"
"57431","SR9","2426","B","B","B","Nef","188","196","","9358..9384","","SLAFRHVAR","SLAvRHVAR","F4V","F191V","OV","observed variant","Sequence","Transient variant SLAvRHVAR was not seen before day 16 after onset of symptoms and after day 45.","Fischer2010"
"59184",,"3310","B","B","B","Nef","188","196","",,"A*31","TLAFHHVAR","TLAFHHaAR","V7A","V194A","DR","diminished response","Longitudinal study, Sequence","Acute controller, AC01, carried the Nef TLAFHHVAR mutant, TLAFHHaAR at V194A, and had a diminished effect, decreasing downregulation of MHC Class I molecules and increasing CD4 levels.","Kuang2014"
"52993",,"323","","","","Nef","190","198","","9364..9390","B51","AFHHVAREK","AlrHmAREK","F2L, H3R, V5M","F191L, H192R, V194M","OV","observed variant","","The epitope varied over time but the mutations did not become fixed. The variant arose at early timepoints.","Geels2003"
"52993",,"324","","","","Nef","190","198","","9364..9390","B51","AFHHVAREK","AvHHVAREK","F2V","F191V","OV","observed variant","","The epitope varied over time but the mutations did not become fixed. The variant arose at intermediate timepoints.","Geels2003"
"52993",,"325","","","","Nef","190","198","","9364..9390","B51","AFHHVAREK","AFHHVAxEi","R7X, K9I","R196X, K198I","OV","observed variant","","The epitope varied over time but the mutations did not become fixed. The variant arose at late timepoints.","Geels2003"
"53774",,"879","B, CRF01_AE","B","CRF01_AE","Nef","190","198","","9364..9390","A*24","AFHHVAREL","ArrHiAREm","F2R, H3R, V5I, L9M","F191R, H192R, V194I, L198M","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53774",,"880","B, CRF01_AE","B","CRF01_AE","Nef","190","198","","9364..9390","A*24","AFHHVAREL","rrtHiAREq","A1R, F2R, H3T, V5I, L9Q","A190R, F191R, H192T, V194I, L198Q","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53774",,"881","B, CRF01_AE","B","CRF01_AE","Nef","190","198","","9364..9390","A*24","AFHHVAREL","ArrHiARaq","F2R, H3R, V5I, E8A, L9Q","F191R, H192R, V194I, E197A, L198Q","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53774",,"882","B, CRF01_AE","B","CRF01_AE","Nef","190","198","","9364..9390","A*24","AFHHVAREL","ArkHiARaL","F2R, H3K, V5I, E8A","F191R, H192K, V194I, E197A","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53774",,"883","B, CRF01_AE","B","CRF01_AE","Nef","190","198","","9364..9390","A*24","AFHHVAREL","ArtHiAREq","F2R, H3T, V5I, L9Q","F191R, H192T, V194I, L198Q","OV","observed variant","","Variant found in 2/23 patients infected with CRF01_AE.","Lazaro2005"
"53774",,"884","B, CRF01_AE","B","CRF01_AE","Nef","190","198","","9364..9390","A*24","AFHHVAREL","ArkHiAREq","F2R, H3K, V5I, L9Q","F191R, H192K, V194I, L198Q","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"53774",,"885","B, CRF01_AE","B","CRF01_AE","Nef","190","198","","9364..9390","A*24","AFHHVAREL","ArrHiAkEL","F2R, H3R, V5I, R7K","F191R, H192R, V194I, R196K","OV","observed variant","","Variant found in 1/23 patients infected with CRF01_AE.","Lazaro2005"
"55860",,"1102","B","","","Nef","190","198","","9364..9390","A*02","AFHHVAREL","AFrHVAREL","H3R","H192R","R, SF","reversion, susceptible form","CD8 T-cell Elispot - IFNy","This variant appeared approx. 6 years post-infection in the patient under longitudinal study, with a reversion 10 months later.  Both forms were susceptible.","Maurer2008"
"55860",,"1103","B","","","Nef","190","198","","9364..9390","A*02","AFHHVAREL","AFHHmAREL","V5M","V194M","SF","susceptible form","CD8 T-cell Elispot - IFNy","This variant of the epitope AFHHVAREL appeared concomitant with reversion of the above variant, but was susceptible.","Maurer2008"
"1097",,"1553","B","B","A","Nef","190","198","","9364..9390","A*0201, A*0202, A2","AFHHVAREL","AlkHrAyEL","F2L, H3K, V5R, R7Y","F191L, H192K, V194R, R196Y","OV","observed variant","Chromium-release assay","Two HEPS Kenyan subjects cross-reacted to this B clade epitope though it differed from the A clade form, AlkHrAyEL.","Rowland-Jones1998"
"1097",,"1554","B","B","D","Nef","190","198","","9364..9390","A*0201, A*0202, A2","AFHHVAREL","AFeHkAREm","H3E, V5K, L9M","H192E, V194K, L198M","OV","observed variant","Chromium-release assay","Two HEPS Kenyan subjects cross-reacted to this B clade epitope though it differed from the D clade form, AFeHkAREm.","Rowland-Jones1998"
"1095",,"1563","B","B","A","Nef","190","198","","9364..9390","A2","AFHHVAREL","AlkHrAyEL","F2L, H3K, V5R, R7Y","F191L, H192K, V194R, R196Y","OV","observed variant","Chromium-release assay","5/6 Kenyan HEPS subjects recognized this clade B epitope which differed from the clade A variant, AlkHrAyEL.","RowlandJones1998b, Hadida1995, Connan1994"
"1095",,"1564","B","B","D","Nef","190","198","","9364..9390","A2","AFHHVAREL","AFeHkAREm","H3E, V5K, L9M","H192E, V194K, L198M","OV","observed variant","Chromium-release assay","5/6 Kenyan HEPS subjects recognized this clade B epitope which differed from the clade D variant, AFeHkAREm.","RowlandJones1998b, Hadida1995, Connan1994"
"53851","AL9","1588","","","","Nef","190","198","","9364..9390","A3","AFHHVAREK","AFqHmAREl","H3Q, V5M, K9L","H192Q, V194M, K198L","OV","observed variant","Sequence","This variant from the HXB2 sequence was present in the restricting HLA-A3 allele carrying mother, M-1001, as well as her HLA-A*31-carrying infant, P-1024.  Infant P-1024 had lost this variant by 15 months of age.","Sanchez-Merino2005"
"52944",,"2189","B","","","Nef","190","198","","9364..9390","A2","ALHHVAREL","AfHHVAREL","L2F","L191F","SF","susceptible form","CD8 T-cell Elispot - IFNy","After vaccination with a lipopeptide vaccine and a boost, both the variant and the wild type epitope were recognized.","Gahery-Segard2003"
"53774",,"2213","B, CRF01_AE","B","CRF01_AE","Nef","190","198","","9364..9390","A*24","AFHHVAREL","ArrHiAREL","F2R, H3R, V5I","F191R, H192R, V194I","CHB, OV","calculated diminished HLA binding, observed variant","Computer prediction","This common CRF01_AE variant was predicted not to bind to A2.","Lazaro2005"
"53774",,"2214","B, CRF01_AE","B","CRF01_AE","Nef","190","198","","9364..9390","A*24","AFHHVAREL","ArtHiAREL","F2R, H3T, V5I","F191R, H192T, V194I","CHB, OV","calculated diminished HLA binding, observed variant","Computer prediction","This common CRF01_AE variant was predicted not to bind to A2.","Lazaro2005"
"53774",,"2215","B, CRF01_AE","B","CRF01_AE","Nef","190","198","","9364..9390","A*24","AFHHVAREL","ArkHiAREL","F2R, H3K, V5I","F191R, H192K, V194I","CHB, OV","calculated diminished HLA binding, observed variant","Computer prediction","This common CRF01_AE variant was predicted not to bind to A2.","Lazaro2005"
"58727","Nef AL9","3127","B","B","B","Nef","190","198","","9364..9390","B*0801","AFHHVAREL","AFHHmAREL","V5M","V194M","SF, TCR","susceptible form, TCR related mutation","CD8 T-cell Elispot - IFNy","This AL9 mutation at position 5 to AFHHmAREL is associated with TCR contact residues.  It elicits a greater response in CTL &gamma;-IFN production than wt AL9 does.","Bronke2013"
"53716",,"461","B, CRF02_AG","","","Nef","195","202","","9379..9402","A1","ARELHPEY","AREmHPEY","L4M","L198M","OV","observed variant","","The one subtype B subject that recognized the wt peptide carried this variant sequence.","Inwoley2005"
"53716",,"462","B, CRF02_AG","","","Nef","195","202","","9379..9402","A1","ARELHPEY","AkEmHPEf","R2K, L4M, Y8F","R196K, L198M, Y202F","OV","observed variant","","The variant was found in 1/9 CRF02_AG infected patients.","Inwoley2005"
"53716",,"463","B, CRF02_AG","","","Nef","195","202","","9379..9402","A1","ARELHPEY","ARvLHPEf","E3V, Y8F","E197V, Y202F","OV","observed variant","","The variant was found in 1/9 CRF02_AG infected patients.","Inwoley2005"
"53716",,"464","B, CRF02_AG","","","Nef","195","202","","9379..9402","A1","ARELHPEY","ARaiHPEf","E3A, L4I, Y8F","E197A, L198I, Y202F","OV","observed variant","","The variant was found in 1/9 CRF02_AG infected patients.","Inwoley2005"
"53716",,"465","B, CRF02_AG","","","Nef","195","202","","9379..9402","A1","ARELHPEY","AkELvPyY","R2K, H5V, E7Y","R196K, H199V, E201Y","OV","observed variant","","The variant was found in 1/9 CRF02_AG infected patients.","Inwoley2005"
"53716",,"466","B, CRF02_AG","","","Nef","195","202","","9379..9402","A1","ARELHPEY","AkELaiEY","R2K, H5A, P6I","R196K, H199A, P200I","OV","observed variant","","The variant was found in 1/9 CRF02_AG infected patients.","Inwoley2005"
"57564","GR17, RR9","2554","B","B","B","Cryptic",,,"","4937..4963","A*03","RTSKASLER","RTSKAaLER","S6A","S241A","A, SF","HLA association, susceptible form","CD8 T-cell Elispot - IFNy","The three variants RTSKAaLER, RTSKApLER and RTSKtSLER to the cryptic epitope RTSKASLER were common in A3-positive subjects. 2/5 A3-positive subjects recognized variant RTSKAaLER, and the authors describe it as &quot;variably associated with escape&quot;.","Berger2010"
"57564","GR17, RR9","2555","B","B","B","Cryptic",,,"","4937..4963","A*03","RTSKASLER","RTSKApLER","S6P","S241P","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","The three variants RTSKAaLER, RTSKApLER and RTSKtSLER to the cryptic epitope RTSKASLER were common in A3-positive subjects. None of 5 A3-positive subjects recognized variant RTSKApLER.","Berger2010"
"57564","GR17, RR9","2556","B","B","B","Cryptic",,,"","4937..4963","A*03","RTSKASLER","RTSKtSLER","A5T","A240T","E","escape documented in this paper","CD8 T-cell Elispot - IFNy","The three variants RTSKAaLER, RTSKApLER and RTSKtSLER to the cryptic epitope RTSKASLER  were common in A3-positive subjects. None of 5 A3-positive subjects recognized variant RTSKtSLER.","Berger2010"
"57783","Q9VF","2639","","","","Cryptic",,,"","1281..1307","B*07","QPRSDTHVF","QPRSNTHVF","D5N","D36N","E, P","escape documented in this paper, processing","CD8 T-cell Elispot - IFNy, Sequence","Cells infected with HIV-1 strains encoding variant 5N (QPRSNTHVF) were not recognized by either 5N nor 5D-specific CTLS. Using in vitro proteasomal digestions, the 5N variant was shown to introduce an aberrant proteasomal cleavage site within the epitope, leading to epitope destruction by proteasomes.","Cardinaud2011"

